[	O	O
Long	O	O
term	O	O
observation	O	O
in	O	O
effects	O	O
of	O	O
potassium	O	O
and	O	O
calcium	O	O
supplementation	O	O
on	O	O
arterial	Physical	O
blood	Physical	O
pressure	Physical	O
and	O	O
sodium	Physical	O
metabolism	Physical	O
in	O	O
adolescents	O	O
with	O	O
higher	O	O
blood	O	O
pressure	O	O
]	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
potassium	O	O
and	O	O
calcium	O	O
supplementation	O	O
in	O	O
table	O	O
salt	O	O
on	O	O
reduction	O	O
of	O	O
arterial	Physical	O
blood	Physical	O
pressure	Physical	O
and	O	O
sodium	Physical	O
metabolism	Physical	O
in	O	O
adolescents	O	O
with	O	O
higher	O	O
blood	O	O
pressure	O	O
.	O	O

METHODS	O	O
A	O	O
single	O	O
blind	O	O
placebo-controlled	O	O
trial	O	O
was	O	O
carried	O	O
out	O	O
for	O	O
two	O	O
years	O	O
in	O	O
220	O	O
adolescents	O	O
with	O	O
higher	O	O
blood	O	O
pressure	O	O
,	O	O
aged	O	O
18	O	O
-	O	O
22	O	O
years	O	O
,	O	O
who	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
supplementary	O	O
group	O	O
(	O	O
n	O	O
=	O	O
110	O	O
)	O	O
and	O	O
control	O	O
group	O	O
(	O	O
n	O	O
=	O	O
110	O	O
)	O	O
.	O	O

Each	O	O
of	O	O
the	O	O
subjects	O	O
in	O	O
the	O	O
supplementary	O	O
group	O	O
and	O	O
their	O	O
family	O	O
members	O	O
was	O	O
given	O	O
10	O	O
mmol	O	O
of	O	O
potassium	O	O
and	O	O
10	O	O
mmol	O	O
of	O	O
calcium	O	O
mixed	O	O
in	O	O
their	O	O
table	O	O
salt	O	O
daily	O	O
for	O	O
24	O	O
months	O	O
.	O	O

RESULTS	O	O
Night	Physical	Physical
urinary	Physical	Physical
sodium	Physical	Physical
and	O	Physical
potassium	Physical	Physical
excretion	Physical	Physical
increased	O	O
(	O	O
urinary	O	O
Na	O	O
(	O	O
+	O	O
)	O	O
,	O	O
P	O	O
<	O	O
0.05	O	O
;	O	O
urinary	O	O
K	O	O
(	O	O
+	O	O
)	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
and	O	O
blood	Physical	O
pressure	Physical	O
lowered	O	O
by	O	O
5.3	O	O
mm	O	O
Hg/1.8	O	O
mm	O	O
Hg	O	O
in	O	O
average	O	O
from	O	O
the	O	O
baseline	O	O
in	O	O
the	O	O
supplementary	O	O
group	O	O
two	O	O
years	O	O
after	O	O
potassium	O	O
and	O	O
calcium	O	O
supplementation	O	O
,	O	O
as	O	O
compared	O	O
with	O	O
that	O	O
in	O	O
the	O	O
control	O	O
group	O	O
increased	O	O
by	O	O
(	O	O
1.3/1.7	O	O
)	O	O
mm	O	O
Hg	O	O
.	O	O

CONCLUSIONS	O	O
Adequate	O	O
supplement	O	O
of	O	O
potassium	O	O
and	O	O
calcium	O	O
in	O	O
daily	O	O
table	O	O
salt	O	O
intake	O	O
was	O	O
an	O	O
effective	O	O
way	O	O
to	O	O
prevent	O	O
form	O	O
hypertension	Physical	O
and	O	O
could	O	O
promote	O	O
their	O	O
urinary	Physical	O
sodium	Physical	O
excretion	Physical	O
and	O	O
reduction	Physical	Physical
of	Physical	Physical
arterial	Physical	Physical
blood	Physical	Physical
pressure	Physical	Physical
in	O	O
adolescents	O	O
with	O	O
higher	O	O
blood	O	O
pressure	O	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
time	Others	O
required	Others	O
to	O	O
administer	O	O
three	O	O
different	O	O
fluke	O	O
and	O	O
worm	O	O
combination	O	O
products	O	O
to	O	O
commercial	O	O
beef	O	O
cattle	O	O
at	O	O
housing	O	O
.	O	O

Larger	O	O
livestock	O	O
units	O	O
,	O	O
a	O	O
decline	O	O
in	O	O
the	O	O
farm	O	O
labor	O	O
force	O	O
,	O	O
animal	O	O
welfare	O	O
concerns	O	O
,	O	O
and	O	O
a	O	O
trend	O	O
toward	O	O
more	O	O
selective	O	O
use	O	O
of	O	O
drugs	O	O
have	O	O
increased	O	O
the	O	O
focus	O	O
on	O	O
animal	O	O
handling	O	O
,	O	O
time	O	O
management	O	O
,	O	O
convenience	O	O
,	O	O
and	O	O
compliance	O	O
in	O	O
administering	O	O
veterinary	O	O
therapeutics	O	O
.	O	O

This	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
quantify	Others	O
and	O	O
compare	Others	O
the	Others	O
time	Others	O
needed	Others	O
to	Others	O
treat	Others	O
commercial	Others	O
beef	Others	O
cattle	Others	O
with	O	O
three	O	O
fluke	O	O
and	O	O
worm	O	O
combination	O	O
products	O	O
with	O	O
different	O	O
administration	O	O
profiles	O	O
.	O	O

Young	O	O
beef	O	O
cattle	O	O
(	O	O
n	O	O
=	O	O
270	O	O
)	O	O
weighing	O	O
approximately	O	O
400	O	O
kg	O	O
were	O	O
allocated	O	O
to	O	O
batches	O	O
of	O	O
five	O	O
,	O	O
which	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
ivermectin	O	O
+	O	O
clorsulon	O	O
injection	O	O
,	O	O
ivermectin	O	O
+	O	O
closantel	O	O
injection	O	O
,	O	O
or	O	O
levamisole	O	O
+	O	O
triclabendazole	O	O
oral	O	O
drench	O	O
.	O	O

The	O	O
mean	Others	O
time	Others	O
needed	Others	O
to	O	O
administer	O	O
ivermectin	O	O
+	O	O
clorsulon	O	O
(	O	O
single	O	O
injection	O	O
)	O	O
to	O	O
five	O	O
cattle	O	O
was	O	O
31	O	O
seconds	O	O
,	O	O
which	O	O
was	O	O
significantly	O	O
less	O	O
than	O	O
the	O	O
100	O	O
seconds	O	O
needed	O	O
for	O	O
ivermectin	O	O
+	O	O
closantel	O	O
(	O	O
two	O	O
injections	O	O
)	O	O
and	O	O
the	O	O
126	O	O
seconds	O	O
needed	O	O
for	O	O
levamisole	O	O
+	O	O
triclabendazole	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

Such	O	O
quantitative	O	O
data	O	O
can	O	O
allow	O	O
for	O	O
better	O	O
planning	O	O
and	O	O
selection	O	O
of	O	O
parasiticide	O	O
treatment	O	O
approaches	O	O
at	O	O
the	O	O
farm	O	O
level	O	O
.	O	O

Does	O	O
temporary	O	O
clamping	O	O
of	O	O
drains	O	O
following	O	O
knee	O	O
arthroplasty	O	O
reduce	O	O
blood	O	O
loss	O	O
?	O	O
A	O	O
randomised	O	O
controlled	O	O
trial	O	O
.	O	O

In	O	O
a	O	O
randomised	O	O
,	O	O
blinded	O	O
study	O	O
76	O	O
patients	O	O
undergoing	O	O
primary	O	O
total	O	O
knee	O	O
arthroplasty	O	O
were	O	O
assigned	O	O
to	O	O
either	O	O
immediate	O	O
drain	O	O
opening	O	O
(	O	O
n	O	O
=	O	O
45	O	O
)	O	O
or	O	O
drains	O	O
opened	O	O
at	O	O
2	O	O
h	O	O
(	O	O
n	O	O
=	O	O
31	O	O
)	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
were	O	O
found	O	O
between	O	O
the	O	O
groups	O	O
for	O	O
the	O	O
volume	Physical	O
of	Physical	O
drained	Physical	O
blood	Physical	O
,	O	O
transfusion	Others	Physical
requirements	Others	Physical
,	O	Physical
knee	Physical	Physical
motion	Physical	Physical
or	O	Physical
wound	Physical	Physical
status	Physical	Physical
.	O	O

The	O	O
authors	O	O
conclude	O	O
that	O	O
the	O	O
practice	O	O
of	O	O
clamping	O	O
drains	O	O
has	O	O
no	O	O
benefit	O	O
in	O	O
routine	O	O
knee	O	O
arthroplasty	O	O
.	O	O

However	O	O
,	O	O
when	O	O
faced	O	O
with	O	O
immediate	O	O
brisk	O	O
blood	Physical	O
loss	Physical	O
,	O	O
the	O	O
results	O	O
suggest	O	O
that	O	O
drains	O	O
can	O	O
be	O	O
clamped	O	O
without	O	O
any	O	O
excess	O	O
morbidity	Adverseeffect	O
.	O	O

0.1	O	O
%	O	O
bupivacaine	O	O
does	O	O
not	O	O
reduce	O	O
the	O	O
requirement	O	O
for	O	O
epidural	O	O
fentanyl	O	O
infusion	O	O
after	O	O
major	O	O
abdominal	O	O
surgery	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
OBJECTIVES	O	O
Although	O	O
local	O	O
anesthesia	O	O
has	O	O
been	O	O
demonstrated	O	O
to	O	O
potentiate	O	O
spinal	O	O
morphine	O	O
analgesia	O	O
in	O	O
animal	O	O
studies	O	O
,	O	O
results	O	O
comparing	O	O
epidural	O	O
local	O	O
anesthesia/opioid	O	O
mixtures	O	O
with	O	O
opioid	O	O
alone	O	O
are	O	O
contradictory	O	O
in	O	O
clinical	O	O
studies	O	O
.	O	O

The	O	O
hypothesis	O	O
was	O	O
that	O	O
,	O	O
although	O	O
the	O	O
concentration	O	O
of	O	O
bupivacaine	O	O
(	O	O
0.1	O	O
%	O	O
)	O	O
was	O	O
low	O	O
to	O	O
minimize	O	O
its	O	O
adverse	O	O
effects	O	O
,	O	O
if	O	O
the	O	O
infusion	O	O
rate	O	O
of	O	O
a	O	O
fentanyl/bupivacaine	O	O
solution	O	O
was	O	O
closely	O	O
adjusted	O	O
according	O	O
to	O	O
need	O	O
,	O	O
the	O	O
presence	O	O
bupivacaine	O	O
would	O	O
reduce	O	O
the	O	O
requirement	O	O
for	O	O
epidural	O	O
fentanyl	O	O
.	O	O

METHODS	O	O
Forty	O	O
patients	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
either	O	O
fentanyl	O	O
(	O	O
10	O	O
micrograms/mL	O	O
)	O	O
or	O	O
a	O	O
fentanyl/bupivacaine	O	O
(	O	O
0.1	O	O
%	O	O
)	O	O
mixture	O	O
epidurally	O	O
corresponding	O	O
to	O	O
the	O	O
dermatome	O	O
of	O	O
the	O	O
surgical	O	O
incision	O	O
in	O	O
a	O	O
double-blind	O	O
fashion	O	O
for	O	O
the	O	O
first	O	O
18	O	O
hours	O	O
after	O	O
major	O	O
abdominal	O	O
surgery	O	O
.	O	O

The	O	O
infusion	O	O
was	O	O
titrated	O	O
for	O	O
each	O	O
patient	O	O
to	O	O
the	O	O
rate	O	O
required	O	O
for	O	O
pain	O	Pain
relief	O	Pain
during	O	Pain
forced	O	Pain
inspiration	O	Pain
(	O	Pain
pain	O	Pain
score	O	Pain
<	O	O
or	O	O
=	O	O
2	O	O
,	O	O
maximum	O	O
10	O	O
)	O	O
.	O	O

Pain	O	Pain
scores	O	Pain
,	O	O
the	O	O
fentanyl	O	O
doses	O	O
required	O	O
,	O	O
plasma	O	O
concentrations	O	O
of	O	O
fentanyl	O	O
at	O	O
18	O	O
hours	O	O
,	O	O
and	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
adverse	Adverseeffect	Adverseeffect
effects	Adverseeffect	Adverseeffect
were	O	O
recorded	O	O
.	O	O

RESULTS	O	O
Patients	O	O
reported	O	O
similar	O	O
median	Pain	Pain
pain	Pain	Pain
scores	Pain	Pain
and	O	O
were	O	O
equally	O	O
satisfied	O	O
with	O	O
pain	Pain	Pain
relief	Pain	Pain
in	O	O
both	O	O
groups	O	O
.	O	O

The	O	O
mean	Others	O
required	Others	O
post-operative	Others	Physical
fentanyl	Others	Physical
infusion	Others	Physical
rate	Others	Physical
(	O	O
57.7	O	O
+/-	O	O
19.5	O	O
micrograms/h	O	O
)	O	O
and	O	O
the	O	O
plasma	Physical	Physical
concentrations	Physical	Physical
(	O	O
0.84	O	O
+/-	O	O
0.36	O	O
ng/mL	O	O
)	O	O
in	O	O
the	O	O
fentanyl	O	O
group	O	O
were	O	O
comparable	O	O
to	O	O
the	O	O
infusion	Others	O
rate	Others	O
(	O	O
54.4	O	O
+/-	O	O
19.2	O	O
micrograms/h	O	O
)	O	O
and	O	O
the	O	O
plasma	Physical	Physical
concentrations	Physical	Physical
(	O	O
0.86	O	O
+/-	O	O
0.36	O	O
ng/mL	O	O
)	O	O
in	O	O
the	O	O
fentanyl/bupivacaine	O	O
group	O	O
.	O	O

Respiratory	Physical	Physical
and	Physical	Physical
cardiovascular	Physical	Physical
functions	Physical	Physical
were	O	O
preserved	O	O
,	O	O
and	O	O
the	O	O
incidence	Physical	Physical
of	Physical	Physical
nausea	Adverseeffect	Physical
,	Physical	O
pruritus	Adverseeffect	O
,	Physical	O
and	Physical	O
periods	Adverseeffect	Physical
of	Adverseeffect	Physical
drowsiness	Adverseeffect	Physical
or	Adverseeffect	Physical
sleep	Adverseeffect	Physical
were	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
In	O	O
low	O	O
concentrations	O	O
(	O	O
0.1	O	O
%	O	O
)	O	O
,	O	O
bupivacaine	O	O
did	O	O
not	O	O
reduce	O	O
the	O	O
titrated	O	O
dose	O	O
of	O	O
epidural	O	O
fentanyl	O	O
required	O	O
for	O	O
adequate	O	O
pain	O	O
relief	O	O
during	O	O
forced	O	O
inspiration	O	O
after	O	O
major	O	O
abdominal	O	O
surgery	O	O
.	O	O

The	O	O
incidence	O	O
and	O	O
severity	O	Adverseeffect
of	O	Adverseeffect
adverse	O	Adverseeffect
effects	O	Adverseeffect
were	O	O
also	O	O
comparable	O	O
whether	O	O
or	O	O
not	O	O
low-dose	O	O
bupivacaine	O	O
infusion	O	O
was	O	O
used	O	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
effect	O	O
of	O	O
gonadotropin-releasing	O	O
hormone	O	O
analog	O	O
(	O	O
Diphereline	O	O
)	O	O
and	O	O
Cabergoline	O	O
(	O	O
Dostinex	O	O
)	O	O
treatment	O	O
on	O	O
uterine	O	O
myoma	O	O
regression	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
investigate	O	O
the	O	O
effect	O	O
of	O	O
cabergoline	O	O
(	O	O
Dostinex	O	O
,	O	O
a	O	O
dopamine	O	O
agonist	O	O
)	O	O
on	O	O
the	O	O
myoma	O	O
growth	O	O
compared	O	O
to	O	O
Diphereline	O	O
(	O	O
a	O	O
gonadotropin-releasing	O	O
hormone	O	O
agonist	O	O
)	O	O
.	O	O

METHODS	O	O
This	O	O
study	O	O
took	O	O
place	O	O
in	O	O
the	O	O
Department	O	O
of	O	O
Obstetrics	O	O
and	O	O
Gynecology	O	O
of	O	O
Tabriz	O	O
University	O	O
of	O	O
Medical	O	O
Sciences	O	O
,	O	O
Tabriz	O	O
,	O	O
Iran	O	O
from	O	O
July	O	O
2004	O	O
to	O	O
December	O	O
2005	O	O
.	O	O

Fifty	O	O
women	O	O
with	O	O
uterine	O	O
myoma	O	O
,	O	O
who	O	O
met	O	O
the	O	O
criteria	O	O
of	O	O
the	O	O
study	O	O
thoroughly	O	O
,	O	O
were	O	O
randomly	O	O
allocated	O	O
into	O	O
2	O	O
equal	O	O
groups	O	O
to	O	O
take	O	O
either	O	O
Diphereline	O	O
or	O	O
Cabergoline	O	O
.	O	O

The	O	O
first	O	O
Group	O	O
took	O	O
3.75	O	O
mg	O	O
of	O	O
Diphereline	O	O
4	O	O
times	O	O
every	O	O
28	O	O
days	O	O
and	O	O
the	O	O
second	O	O
group	O	O
took	O	O
0.5	O	O
mg	O	O
of	O	O
Cabergoline	O	O
once	O	O
a	O	O
week	O	O
for	O	O
6	O	O
weeks	O	O
.	O	O

RESULTS	O	O
The	O	O
Cabergoline	O	O
was	O	O
well	Others	O
tolerated	Others	O
and	O	O
fewer	Adverseeffect	O
adverse	Adverseeffect	Adverseeffect
effects	Adverseeffect	Adverseeffect
were	O	O
noted	O	O
.	O	O

The	O	O
tumor	Physical	O
regressed	Physical	O
significantly	O	O
and	O	O
volume	Physical	O
reduction	Physical	Others
rate	Physical	Others
of	Physical	Others
individual	Physical	Others
tumor	Physical	Others
nodule	Physical	Others
varied	O	O
from	O	O
46-53	O	O
%	O	O
.	O	O

The	O	O
gonadotropin	O	O
releasing	O	O
hormone	O	O
agonist	O	O
group	O	O
all	O	O
responded	O	O
to	O	O
the	O	O
treatment	O	O
,	O	O
and	O	O
volume	O	O
reduction	O	O
rate	O	O
of	O	O
the	O	O
individual	O	O
tumor	O	O
nodule	O	O
varied	O	O
from	O	O
21-97	O	O
%	O	O
.	O	O

The	O	O
extent	O	O
of	O	O
tumor	Physical	O
shrinkage	Physical	O
was	O	O
positively	O	O
correlated	O	O
to	O	O
the	O	O
number	Physical	Physical
of	Physical	Physical
nodules	Physical	Physical
(	O	O
p=0.881	O	O
,	O	O
p	O	O
<	O	O
0.005	O	O
and	O	O
0.701	O	O
,	O	O
p	O	O
<	O	O
0.005	O	O
)	O	O
.	O	O

CONCLUSION	O	O
In	O	O
light	O	O
of	O	O
therapeutic	O	Others
efficacy	O	Others
and	O	O
few	O	O
adverse	O	Adverseeffect
effects	O	Adverseeffect
,	O	O
the	O	O
dopamine	O	O
agonists	O	O
may	O	O
hold	O	O
promise	O	O
as	O	O
novel	O	O
treatment	O	O
modalities	O	O
for	O	O
leiomyoma	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
warranted	O	O
to	O	O
determine	O	O
the	O	O
optimal	O	O
strategy	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
leiomyoma	O	O
through	O	O
these	O	O
agents	O	O
.	O	O

Controlled	O	O
clinical	O	O
trial	O	O
of	O	O
IV	O	O
cyclophosphamide	O	O
versus	O	O
IV	O	O
methylprednisolone	O	O
in	O	O
severe	O	O
neurological	O	O
manifestations	O	O
in	O	O
systemic	O	O
lupus	O	O
erythematosus	O	O
.	O	O

BACKGROUND	O	O
Severe	O	O
neurological	O	O
involvement	O	O
in	O	O
systemic	O	O
lupus	O	O
erythematosus	O	O
(	O	O
NPSLE	O	O
)	O	O
is	O	O
one	O	O
of	O	O
the	O	O
most	O	O
dreadful	O	O
complications	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
identify	O	O
the	O	O
best	O	O
drug	O	O
,	O	O
dose	O	O
,	O	O
and	O	O
treatment	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
The	O	O
study	O	O
was	O	O
a	O	O
controlled	O	O
clinical	O	O
trial	O	O
at	O	O
two	O	O
tertiary	O	O
care	O	O
centres	O	O
of	O	O
patients	O	O
with	O	O
SLE	O	O
according	O	O
to	O	O
the	O	O
ACR	O	O
criteria	O	O
,	O	O
with	O	O
incident	O	O
(	O	O
no	O	O
more	O	O
than	O	O
15	O	O
days	O	O
)	O	O
onset	O	Physical
of	O	Physical
severe	O	Physical
NP	O	Physical
manifestations	O	Physical
such	O	Physical
as	O	Physical
seizures	O	Physical
,	O	O
optic	O	O
neuritis	O	O
,	O	O
peripheral	O	O
or	O	O
cranial	O	O
neuropathy	O	O
,	O	O
coma	O	O
,	O	O
brainstem	O	O
disease	O	O
,	O	O
or	O	O
transverse	O	O
myelitis	O	O
.	O	O

Induction	O	O
treatment	O	O
with	O	O
3	O	O
g	O	O
of	O	O
IV	O	O
methylprednisolone	O	O
(	O	O
MP	O	O
)	O	O
followed	O	O
by	O	O
either	O	O
IV	O	O
monthly	O	O
cyclophosphamide	O	O
(	O	O
Cy	O	O
)	O	O
versus	O	O
IV	O	O
MP	O	O
bimonthly	O	O
every	O	O
4	O	O
months	O	O
for	O	O
1	O	O
year	O	O
and	O	O
then	O	O
IV	O	O
Cy	O	O
or	O	O
IV	O	O
MP	O	O
every	O	O
3	O	O
months	O	O
for	O	O
another	O	O
year	O	O
.	O	O

The	O	O
primary	O	O
end	O	O
point	O	O
was	O	O
response	Physical	O
to	Physical	O
treatment	Physical	O
:	O	O
at	O	O
least	O	O
20	Physical	O
%	Physical	O
improvement	Physical	O
from	Physical	O
basal	Physical	O
conditions	Physical	O
on	O	O
clinical	Physical	O
,	Physical	O
laboratory	Physical	Physical
,	Physical	Physical
or	Physical	Physical
specific	Physical	Physical
neurological	Physical	Physical
testing	Physical	Physical
variables	Physical	Physical
.	O	O

RESULTS	O	O
Overall	O	O
,	O	O
a	O	O
response	Physical	Others
rate	Physical	Others
of	O	O
75	O	O
%	O	O
was	O	O
observed	O	O
.	O	O

Of	O	O
the	O	O
32	O	O
patients	O	O
studied	O	O
,	O	O
18/19	O	O
receiving	O	O
Cy	O	O
and	O	O
7/13	O	O
receiving	O	O
MP	O	O
responded	O	O
to	O	O
treatment	O	O
(	O	O
p	O	O
<	O	O
0.03	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Cy	O	O
seems	O	O
to	O	O
be	O	O
more	O	O
effective	Others	O
than	O	O
MP	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
acute	O	O
,	O	O
severe	O	O
NPSLE	O	O
.	O	O

Co-administration	O	O
of	O	O
pethidine	O	O
and	O	O
clonidine	O	O
:	O	O
a	O	O
spinal	O	O
anaesthetic	O	O
technique	O	O
for	O	O
total	O	O
hip	O	O
replacement	O	O
.	O	O

Co-administration	O	O
of	O	O
pethidine	O	O
0.75	O	O
mg	O	O
kg-1	O	O
and	O	O
clonidine	O	O
75	O	O
micrograms	O	O
intrathecally	O	O
provided	O	O
good	O	O
intraoperative	O	O
anaesthesia	O	O
for	O	O
total	O	O
hip	O	O
replacement	O	O
,	O	O
similar	O	O
to	O	O
that	O	O
obtained	O	O
using	O	O
0.5	O	O
%	O	O
isobaric	O	O
bupivacaine	O	O
.	O	O

Sensory	O	Physical
and	O	Physical
motor	O	Physical
block	O	Physical
were	O	O
of	O	O
shorter	O	O
duration	O	O
than	O	O
that	O	O
after	O	O
0.5	O	O
%	O	O
isobaric	O	O
bupivacaine	O	O
and	O	O
0.5	O	O
%	O	O
isobaric	O	O
bupivacaine	O	O
with	O	O
morphine	O	O
0.5	O	O
mg	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
sensory	O	O
block	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
motor	O	O
block	O	O
)	O	O
.	O	O

Postoperative	Others	O
morphine	Others	O
consumption	Others	O
,	O	O
measured	O	O
using	O	O
a	O	O
patient-controlled	O	O
system	O	O
,	O	O
was	O	O
similar	O	O
to	O	O
that	O	O
in	O	O
patients	O	O
in	O	O
the	O	O
bupivacaine	O	O
only	O	O
group	O	O
(	O	O
pethidine-clonidine	O	O
:	O	O
median	O	O
39	O	O
mg/24	O	O
h	O	O
;	O	O
bupivacaine	O	O
:	O	O
median	O	O
34	O	O
mg/24	O	O
h	O	O
)	O	O
but	O	O
greater	O	O
than	O	O
that	O	O
in	O	O
the	O	O
bupivacaine-morphine	O	O
group	O	O
(	O	O
median	O	O
8	O	O
mg/24	O	O
h	O	O
)	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

Visual	Pain	Others
analogue	Pain	Others
pain	Pain	Others
scores	Pain	Others
after	O	O
operation	O	O
were	O	O
similar	O	O
to	O	O
those	O	O
with	O	O
bupivacaine	O	O
alone	O	O
at	O	O
all	O	O
but	O	O
one	O	O
of	O	O
the	O	O
recording	O	O
times	O	O
but	O	O
were	O	O
greater	O	O
than	O	O
those	O	O
in	O	O
patients	O	O
who	O	O
received	O	O
bupivacaine	O	O
and	O	O
morphine	O	O
at	O	O
4	O	O
,	O	O
6	O	O
and	O	O
10	O	O
h	O	O
after	O	O
operation	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
,	O	O
P	O	O
<	O	O
0.04	O	O
,	O	O
P	O	O
<	O	O
0.02	O	O
)	O	O
.	O	O

The	O	O
combination	O	O
did	O	O
not	O	O
offer	O	O
any	O	O
major	O	O
advantage	O	O
over	O	O
conventional	O	O
agents	O	O
.	O	O

18F-FDG	O	O
PET/CT	O	O
for	O	O
early	O	O
prediction	O	O
of	O	O
response	O	O
to	O	O
neoadjuvant	O	O
lapatinib	O	O
,	O	O
trastuzumab	O	O
,	O	O
and	O	O
their	O	O
combination	O	O
in	O	O
HER2-positive	O	O
breast	O	O
cancer	O	O
:	O	O
results	O	O
from	O	O
Neo-ALTTO	O	O
.	O	O

UNLABELLED	O	O
Molecular	O	O
imaging	O	O
receives	O	O
increased	O	O
attention	O	O
for	O	O
selecting	O	O
patients	O	O
who	O	O
will	O	O
benefit	O	O
from	O	O
targeted	O	O
anticancer	O	O
therapies	O	O
.	O	O

Neo-ALTTO	O	O
(	O	O
Neoadjuvant	O	O
Lapatinib	O	O
and/or	O	O
Trastuzumab	O	O
Treatment	O	O
Optimisation	O	O
)	O	O
enrolled	O	O
455	O	O
women	O	O
with	O	O
invasive	O	O
human	O	O
epidermal	O	O
growth	O	O
factor	O	O
receptor	O	O
2	O	O
(	O	O
HER2	O	O
)	O	O
-positive	O	O
breast	O	O
cancer	O	O
and	O	O
compared	O	O
rates	O	O
of	O	O
pathologic	O	O
complete	O	O
response	O	O
(	O	O
pCR	O	O
)	O	O
to	O	O
neoadjuvant	O	O
lapatinib	O	O
,	O	O
trastuzumab	O	O
,	O	O
and	O	O
their	O	O
combination	O	O
.	O	O

Each	O	O
anti-HER2	O	O
therapy	O	O
was	O	O
given	O	O
alone	O	O
for	O	O
6	O	O
wk	O	O
,	O	O
followed	O	O
by	O	O
12	O	O
wk	O	O
of	O	O
the	O	O
same	O	O
therapy	O	O
plus	O	O
weekly	O	O
paclitaxel	O	O
.	O	O

The	O	O
early	O	O
metabolic	Physical	O
effects	Physical	O
of	O	O
the	O	O
anti-HER2	O	O
therapies	O	O
on	O	O
the	O	O
primary	O	O
tumors	O	O
and	O	O
their	O	O
predictive	O	O
values	O	O
for	O	O
pCR	O	O
were	O	O
assessed	O	O
in	O	O
a	O	O
subset	O	O
of	O	O
patients	O	O
.	O	O

METHODS	O	O
Eighty-six	O	O
patients	O	O
underwent	O	O
(	O	O
18	O	O
)	O	O
F-FDG	O	O
PET/CT	O	O
at	O	O
baseline	O	O
and	O	O
weeks	O	O
2	O	O
and	O	O
6	O	O
of	O	O
anti-HER2	O	O
treatment	O	O
.	O	O

An	O	O
imaging	O	O
core	O	O
laboratory	O	O
provided	O	O
central	O	O
validation	O	O
,	O	O
and	O	O
2	O	O
independent	O	O
reviewers	O	O
,	O	O
masked	O	O
to	O	O
assigned	O	O
treatment	O	O
arm	O	O
and	O	O
clinical	O	O
outcomes	O	O
,	O	O
performed	O	O
consensus	O	O
(	O	O
18	O	O
)	O	O
F-FDG	O	O
PET/CT	O	O
readings	O	O
.	O	O

Maximum	O	O
standardized	Physical	O
uptake	Physical	O
value	Physical	O
(	Physical	O
SUVmax	Physical	O
)	Physical	O
reductions	Physical	O
from	Physical	O
baseline	Physical	O
were	O	O
used	O	O
to	O	O
measure	O	O
metabolic	O	O
response	O	O
.	O	O

RESULTS	O	O
Seventy-seven	O	O
of	O	O
the	O	O
86	O	O
enrolled	O	O
patients	O	O
presented	O	O
an	O	O
evaluable	O	O
baseline	O	O
(	O	O
18	O	O
)	O	O
F-FDG	O	O
PET/CT	O	O
scan	O	O
;	O	O
of	O	O
these	O	O
,	O	O
68	O	O
and	O	O
66	O	O
were	O	O
evaluable	O	O
at	O	O
weeks	O	O
2	O	O
and	O	O
6	O	O
,	O	O
respectively	O	O
.	O	O

Metabolic	Physical	Physical
responses	Physical	Physical
in	O	O
the	O	O
primary	O	O
tumors	O	O
were	O	O
evident	O	O
after	O	O
2	O	O
wk	O	O
of	O	O
targeted	O	O
therapy	O	O
and	O	O
correlated	O	O
highly	O	O
with	O	O
metabolic	O	O
responses	O	O
at	O	O
week	O	O
6	O	O
(	O	O
R	O	O
(	O	O
2	O	O
)	O	O
=	O	O
0.81	O	O
)	O	O
.	O	O

pCRs	O	O
were	O	O
associated	O	O
with	O	O
greater	O	O
SUVmax	O	O
reductions	O	O
at	O	O
both	O	O
time	O	O
points	O	O
.	O	O

Mean	O	Physical
SUVmax	O	Physical
reductions	O	Physical
for	O	Physical
pCR	O	Physical
and	O	O
non-pCR	O	O
,	O	O
respectively	O	O
,	O	O
were	O	O
54.3	O	O
%	O	O
versus	O	O
32.8	O	O
%	O	O
at	O	O
week	O	O
2	O	O
(	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
and	O	O
61.5	O	O
%	O	O
versus	O	O
34.1	O	O
%	O	O
at	O	O
week	O	O
6	O	O
(	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
.	O	O

(	Physical	O
18	Physical	O
)	Physical	O
F-FDG	Physical	O
PET/CT	Physical	O
metabolic	Physical	O
response	Physical	O
rates	Physical	O
at	O	O
weeks	O	O
2	O	O
and	O	O
6	O	O
were	O	O
71.6	O	O
%	O	O
and	O	O
60	O	O
%	O	O
,	O	O
respectively	O	O
using	O	O
European	O	O
Organization	O	O
for	O	O
Research	O	O
and	O	O
Treatment	O	O
of	O	O
Cancer	O	O
criteria	O	O
;	O	O
pCR	O	O
rates	O	O
were	O	O
twice	O	O
as	O	O
high	O	O
for	O	O
(	O	O
18	O	O
)	O	O
F-FDG	O	O
PET/CT	O	O
responders	O	O
than	O	O
nonresponders	O	O
(	O	O
week	O	O
2	O	O
:	O	O
42	O	O
%	O	O
vs.	O	O
21	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.12	O	O
;	O	O
week	O	O
6	O	O
:	O	O
44	O	O
%	O	O
vs.	O	O
19	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.05	O	O
)	O	O
.	O	O

CONCLUSION	O	O
Early	O	O
metabolic	O	O
assessment	O	O
using	O	O
(	O	O
18	O	O
)	O	O
F-FDG	O	O
PET/CT	O	O
can	O	O
identify	O	O
patients	O	O
with	O	O
an	O	O
increased	O	O
likelihood	O	O
of	O	O
pCR	O	O
after	O	O
neoadjuvant	O	O
trastuzumab	O	O
,	O	O
lapatinib	O	O
,	O	O
or	O	O
their	O	O
combination	O	O
when	O	O
given	O	O
with	O	O
chemotherapy	O	O
.	O	O

Comparison	O	O
of	O	O
rectal	O	O
midazolam	O	O
and	O	O
diazepam	O	O
for	O	O
premedication	O	O
in	O	O
pediatric	O	O
dental	O	O
patients	O	O
.	O	O

Rectally	O	O
administered	O	O
midazolam	O	O
(	O	O
0.35	O	O
mg/kg	O	O
)	O	O
and	O	O
diazepam	O	O
(	O	O
0.70	O	O
mg/kg	O	O
)	O	O
were	O	O
compared	O	O
with	O	O
each	O	O
other	O	O
and	O	O
with	O	O
placebo	O	O
for	O	O
preanesthetic	O	O
medication	O	O
in	O	O
children	O	O
undergoing	O	O
dental	O	O
extractions	O	O
.	O	O

All	O	O
rectal	O	O
medications	O	O
were	O	O
very	O	O
well	O	O
accepted	O	O
,	O	O
but	O	O
mask	Mental	O
acceptance	Mental	O
,	O	O
improvement	O	O
in	O	O
anxiety	Mental	Mental
,	O	O
and	O	O
sedation	Mental	O
were	O	O
best	O	O
in	O	O
the	O	O
midazolam	O	O
group	O	O
.	O	O

Improvement	O	O
in	O	O
anxiety	Mental	Mental
and	O	O
sedation	Mental	O
were	O	O
significantly	O	O
better	O	O
in	O	O
the	O	O
two	O	O
drug	O	O
groups	O	O
than	O	O
in	O	O
those	O	O
patients	O	O
who	O	O
had	O	O
received	O	O
placebo	O	O
.	O	O

Thirty	O	O
minutes	O	O
after	O	O
rectal	O	O
administration	O	O
of	O	O
midazolam	O	O
,	O	O
patients	O	O
showed	O	O
a	O	O
decrease	O	O
in	O	O
both	O	O
systolic	Physical	Physical
and	Physical	Physical
diastolic	Physical	Physical
blood	Physical	Physical
pressure	Physical	Physical
and	O	Physical
heart	Physical	Physical
rate	Physical	Physical
.	O	O

Although	O	O
these	O	O
decreases	O	O
differed	O	O
significantly	O	O
from	O	O
the	O	O
premedication	O	O
values	O	O
,	O	O
they	O	O
were	O	O
probably	O	O
of	O	O
little	O	O
clinical	O	O
importance	O	O
.	O	O

Only	O	O
minor	Adverseeffect	O
adverse	Adverseeffect	Adverseeffect
effects	Adverseeffect	Adverseeffect
were	O	O
observed	O	O
in	O	O
this	O	O
study	O	O
.	O	O

Overall	O	O
rectally	O	O
administered	O	O
midazolam	O	O
appeared	O	O
to	O	O
be	O	O
somewhat	O	O
more	O	O
efficacious	O	O
than	O	O
diazepam	O	O
.	O	O

The	O	O
dipeptidyl	O	O
peptidase-4	O	O
inhibitor	O	O
PHX1149	O	O
improves	O	O
blood	Physical	Physical
glucose	Physical	Physical
control	Physical	Physical
in	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
mellitus	O	O
.	O	O

AIM	O	O
To	O	O
determine	O	O
the	O	O
efficacy	Others	Others
and	O	Others
tolerability	Others	Others
of	O	O
PHX1149	O	O
,	O	O
a	O	O
novel	O	O
dipeptidyl	O	O
peptidase-4	O	O
(	O	O
DPP4	O	O
)	O	O
inhibitor	O	O
,	O	O
in	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
.	O	O

METHODS	O	O
This	O	O
is	O	O
a	O	O
multicentre	O	O
,	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
,	O	O
4-week	O	O
study	O	O
in	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
with	O	O
suboptimal	O	O
metabolic	O	O
control	O	O
.	O	O

Patients	O	O
with	O	O
a	O	O
baseline	O	O
haemoglobin	O	Physical
A	O	Physical
(	O	Physical
1c	O	Physical
)	O	Physical
(	O	Physical
HbA	O	Physical
(	O	Physical
1c	O	Physical
)	O	Physical
)	O	Physical
of	O	O
7.3	O	O
to	O	O
11.0	O	O
%	O	O
were	O	O
randomized	O	O
1	O	O
:	O	O
1	O	O
:	O	O
1	O	O
:	O	O
1	O	O
to	O	O
receive	O	O
once-daily	O	O
oral	O	O
therapy	O	O
with	O	O
either	O	O
PHX1149	O	O
(	O	O
100	O	O
,	O	O
200	O	O
or	O	O
400	O	O
mg	O	O
)	O	O
or	O	O
placebo	O	O
;	O	O
patients	O	O
were	O	O
on	O	O
a	O	O
constant	O	O
background	O	O
therapy	O	O
of	O	O
either	O	O
metformin	O	O
alone	O	O
or	O	O
metformin	O	O
plus	O	O
a	O	O
glitazone	O	O
.	O	O

RESULTS	O	O
Treatment	O	O
with	O	O
100	O	O
,	O	O
200	O	O
or	O	O
400	O	O
mg	O	O
of	O	O
PHX1149	O	O
significantly	O	O
decreased	O	O
postprandial	Physical	Physical
glucose	Physical	Physical
area	Physical	Physical
under	Physical	Physical
the	Physical	Physical
curve	Physical	Physical
AUC	Physical	Physical
(	Physical	O
0-2	Physical	O
h	O	O
)	O	O
by	O	O
approximately	O	O
20	O	O
%	O	O
(	O	O
+0.11	O	O
+/-	O	O
0.50	O	O
,	O	O
-2.08	O	O
+/-	O	O
0.51	O	O
,	O	O
-1.73	O	O
+/-	O	O
0.49	O	O
and	O	O
-1.88	O	O
+/-	O	O
0.48	O	O
mmol/l	O	O
x	O	O
h	O	O
,	O	O
respectively	O	O
,	O	O
for	O	O
placebo	O	O
and	O	O
100	O	O
,	O	O
200	O	O
and	O	O
400	O	O
mg	O	O
(	O	O
p	O	O
=	O	O
0.002	O	O
,	O	O
0.008	O	O
and	O	O
0.004	O	O
vs.	O	O
placebo	O	O
)	O	O
.	O	O

Postprandial	Physical	Physical
AUC	Physical	Physical
(	Physical	Physical
0-2	Physical	Physical
h	Physical	Physical
)	Physical	Physical
of	Physical	Physical
intact	Physical	Physical
glucagon-like	Physical	Physical
peptide-1	Physical	Physical
,	O	O
the	O	O
principal	O	O
mediator	O	O
of	O	O
the	O	O
biological	O	O
effects	O	O
of	O	O
DPP4	O	O
inhibitors	O	O
,	O	O
was	O	O
increased	O	O
by	O	O
3.90	O	O
+/-	O	O
2.83	O	O
,	O	O
11.63	O	O
+/-	O	O
2.86	O	O
,	O	O
16.42	O	O
+/-	O	O
2.72	O	O
and	O	O
15.75	O	O
+/-	O	O
2.71	O	O
pmol/l	O	O
x	O	O
h	O	O
,	O	O
respectively	O	O
,	O	O
for	O	O
placebo	O	O
and	O	O
100	O	O
,	O	O
200	O	O
and	O	O
400	O	O
mg	O	O
(	O	O
p	O	O
=	O	O
0.053	O	O
,	O	O
0.001	O	O
and	O	O
0.002	O	O
vs.	O	O
placebo	O	O
)	O	O
.	O	O

Mean	Physical	Physical
HbA	Physical	Physical
(	Physical	Physical
1c	Physical	Physical
)	Physical	Physical
was	O	O
lower	O	O
in	O	O
all	O	O
dose	O	O
groups	O	O
;	O	O
the	O	O
placebo-corrected	O	O
change	O	O
in	O	O
the	O	O
groups	O	O
receiving	O	O
400	O	O
mg	O	O
PHX1149	O	O
was	O	O
-0.28	O	O
%	O	O
(	O	O
p	O	O
=	O	O
0.02	O	O
)	O	O
.	O	O

DPP4	Physical	O
inhibition	Physical	O
on	O	O
day	O	O
28	O	O
was	O	O
53	O	O
,	O	O
73	O	O
and	O	O
78	O	O
%	O	O
at	O	O
24	O	O
h	O	O
postdose	O	O
in	O	O
the	O	O
groups	O	O
receiving	O	O
100	O	O
,	O	O
200	O	O
and	O	O
400	O	O
mg	O	O
PHX1149	O	O
,	O	O
respectively	O	O
.	O	O

There	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
adverse	Adverseeffect	Adverseeffect
events	Adverseeffect	Adverseeffect
between	O	O
PHX1149-treated	O	O
and	O	O
placebo	O	O
subjects	O	O
.	O	O

CONCLUSIONS	O	O
Addition	O	O
of	O	O
the	O	O
DPP4	O	O
inhibitor	O	O
PHX1149	O	O
to	O	O
a	O	O
stable	O	O
regimen	O	O
of	O	O
metformin	O	O
or	O	O
metformin	O	O
plus	O	O
a	O	O
glitazone	O	O
in	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
was	O	O
well	Others	O
tolerated	Others	O
and	O	O
improved	O	O
blood	Physical	Physical
glucose	Physical	Physical
control	Physical	Physical
.	O	O

Ten-year	O	O
incidence	O	O
of	O	O
myocardial	O	O
infarction	O	O
and	O	O
prognosis	O	O
after	O	O
infarction	O	O
.	O	O

Department	O	O
of	O	O
Veterans	O	O
Affairs	O	O
Cooperative	O	O
Study	O	O
of	O	O
Coronary	O	O
Artery	O	O
Bypass	O	O
Surgery	O	O
.	O	O

BACKGROUND	O	O
The	O	O
10-year	O	O
incidence	O	O
of	O	O
myocardial	O	Physical
infarction	O	Physical
(	O	Physical
fatal	O	Physical
and	O	Physical
nonfatal	O	Physical
)	O	Physical
and	O	O
the	O	O
prognosis	O	O
after	O	O
infarction	O	O
were	O	O
evaluated	O	O
in	O	O
686	O	O
patients	O	O
with	O	O
stable	O	O
angina	O	O
who	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
medical	O	O
or	O	O
surgical	O	O
treatment	O	O
in	O	O
the	O	O
Veterans	O	O
Administration	O	O
Cooperative	O	O
Study	O	O
of	O	O
Coronary	O	O
Artery	O	O
Bypass	O	O
Surgery	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
Myocardial	O	O
infarction	O	O
was	O	O
defined	O	O
by	O	O
either	O	O
new	O	O
Q	O	O
wave	O	O
findings	O	O
or	O	O
clinical	O	O
symptoms	O	O
compatible	O	O
with	O	O
myocardial	O	O
infarction	O	O
accompanied	O	O
by	O	O
serum	O	O
enzyme	O	O
elevations	O	O
with	O	O
or	O	O
without	O	O
electrocardiographic	O	O
findings	O	O
.	O	O

Treatment	O	O
comparisons	O	O
were	O	O
made	O	O
according	O	O
to	O	O
original	O	O
treatment	O	O
assignment	O	O
;	O	O
35	O	O
%	O	O
of	O	O
the	O	O
medical	O	O
cohort	O	O
had	O	O
bypass	O	O
surgery	O	O
during	O	O
the	O	O
10-year	O	O
follow-up	O	O
period	O	O
.	O	O

The	O	O
overall	Physical	Others
cumulative	Physical	Others
infarction	Physical	Others
rate	Physical	Others
was	O	O
somewhat	O	O
higher	O	O
in	O	O
patients	O	O
assigned	O	O
to	O	O
surgery	O	O
(	O	O
36	O	O
%	O	O
)	O	O
than	O	O
in	O	O
medical	O	O
patients	O	O
(	O	O
31	O	O
%	O	O
)	O	O
(	O	O
p	O	O
=	O	O
0.13	O	O
)	O	O
due	O	O
to	O	O
perioperative	O	O
infarctions	O	O
(	O	O
13	O	O
%	O	O
)	O	O
and	O	O
an	O	O
accelerated	Physical	O
infarction	Physical	O
rate	Physical	O
after	O	O
the	O	O
fifth	O	O
year	O	O
of	O	O
follow-up	O	O
(	O	O
average	O	O
,	O	O
2.4	O	O
%	O	O
/yr	O	O
in	O	O
the	O	O
surgical	O	O
group	O	O
versus	O	O
1.4	O	O
%	O	O
/yr	O	O
in	O	O
the	O	O
medical	O	O
group	O	O
)	O	O
.	O	O

The	O	O
10-year	Mortality	O
cumulative	Mortality	O
incidence	Mortality	O
of	Mortality	O
death	Mortality	Mortality
or	Adverseeffect	O
myocardial	Physical	Physical
infarction	Physical	Physical
was	O	O
also	O	O
higher	O	O
in	O	O
surgical	O	O
(	O	O
54	O	O
%	O	O
)	O	O
than	O	O
in	O	O
medical	O	O
(	O	O
49	O	O
%	O	O
)	O	O
patients	O	O
(	O	O
p	O	O
=	O	O
0.20	O	O
)	O	O
.	O	O

According	O	O
to	O	O
the	O	O
Cox	O	O
model	O	O
,	O	O
the	O	O
estimated	Mortality	O
risk	Mortality	O
of	Mortality	O
death	Mortality	Mortality
after	Mortality	Mortality
infarction	Mortality	Mortality
was	O	O
59	O	O
%	O	O
lower	O	O
in	O	O
surgical	O	O
than	O	O
in	O	O
medical	O	O
patients	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.0001	O	O
)	O	O
.	O	O

The	O	O
reduction	O	O
in	O	O
postinfarction	Mortality	Mortality
mortality	Mortality	Mortality
with	O	O
surgery	O	O
was	O	O
most	O	O
striking	O	O
in	O	O
the	O	O
first	O	O
month	O	O
after	O	O
the	O	O
event	O	O
:	O	O
99	O	O
%	O	O
in	O	O
the	O	O
first	O	O
month	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.0001	O	O
)	O	O
and	O	O
49	O	O
%	O	O
subsequently	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.0001	O	O
)	O	O
.	O	O

The	O	O
estimated	O	O
risk	Mortality	O
of	Mortality	O
death	Mortality	Mortality
in	Mortality	O
the	Mortality	O
absence	Mortality	O
of	Mortality	O
infarction	Mortality	O
was	O	O
nearly	O	O
identical	O	O
regardless	O	O
of	O	O
treatment	O	O
(	O	O
p	O	O
=	O	O
0.75	O	O
)	O	O
.	O	O

Exclusion	O	O
of	O	O
perioperative	O	O
infarctions	O	O
did	O	O
not	O	O
alter	O	O
the	O	O
findings	O	O
.	O	O

CONCLUSIONS	O	O
Although	O	O
surgery	O	O
does	O	O
not	O	O
reduce	O	O
the	O	O
incidence	O	O
of	O	O
myocardial	Physical	O
infarction	Physical	O
overall	O	O
,	O	O
it	O	O
does	O	O
reduce	O	O
the	O	O
risk	O	O
of	O	O
mortality	Mortality	O
after	O	O
infarction	O	O
,	O	O
particularly	O	O
in	O	O
the	O	O
first	O	O
30	O	O
days	O	O
after	O	O
the	O	O
event	O	O
(	O	O
fatal	O	O
infarctions	O	O
)	O	O
.	O	O

Junctional	Physical	Physical
ectopic	Physical	Physical
tachycardia	Physical	Physical
after	O	O
congenital	O	O
heart	O	O
surgery	O	O
in	O	O
the	O	O
current	O	O
surgical	O	O
era	O	O
.	O	O

To	O	O
determine	O	O
the	O	O
incidence	O	O
of	O	O
postoperative	Physical	O
junctional	Physical	O
ectopic	Physical	O
tachycardia	Physical	O
(	Physical	O
JET	Physical	O
)	Physical	O
in	O	O
a	O	O
modern	O	O
cohort	O	O
of	O	O
pediatric	O	O
patients	O	O
,	O	O
evaluate	O	O
possible	O	O
risk	Physical	O
factors	Physical	O
for	Physical	O
JET	Physical	O
,	O	O
and	O	O
examine	O	O
the	O	O
effects	Physical	O
of	Physical	O
JET	Physical	O
on	O	O
postoperative	Physical	Mortality
morbidity	Physical	Mortality
and	O	Mortality
mortality	Mortality	Mortality
.	O	O

JET	O	O
is	O	O
common	O	O
after	O	O
congenital	O	O
heart	O	O
surgery	O	O
.	O	O

JET-related	O	O
mortality	O	O
has	O	O
been	O	O
a	O	O
rare	O	O
event	O	O
at	O	O
our	O	O
center	O	O
,	O	O
which	O	O
is	O	O
different	O	O
from	O	O
previous	O	O
reports	O	O
.	O	O

We	O	O
reviewed	O	O
records	O	O
for	O	O
pediatric	O	O
patients	O	O
who	O	O
had	O	O
postoperative	O	O
arrhythmias	O	O
between	O	O
January	O	O
2006	O	O
and	O	O
June	O	O
2010	O	O
at	O	O
a	O	O
large	O	O
tertiary-care	O	O
children	O	O
's	O	O
hospital	O	O
.	O	O

We	O	O
performed	O	O
a	O	O
matched	O	O
case-control	O	O
study	O	O
to	O	O
identify	O	O
risk	O	O
factors	O	O
for	O	O
JET	O	O
and	O	O
a	O	O
matched-cohort	O	O
study	O	O
to	O	O
compare	O	O
outcomes	O	O
between	O	O
patients	O	O
and	O	O
controls	O	O
.	O	O

Whenever	O	O
possible	O	O
,	O	O
each	O	O
JET	O	O
case	O	O
was	O	O
randomly	O	O
matched	O	O
to	O	O
two	O	O
controls	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
lesion	O	O
,	O	O
repair	O	O
,	O	O
and	O	O
surgical	O	O
period	O	O
.	O	O

We	O	O
identified	O	O
54	O	O
patients	O	O
with	O	O
JET	O	O
(	O	O
incidence	O	O
=	O	O
1.4	O	O
%	O	O
)	O	O
.	O	O

After	O	O
multivariate	O	O
logistic	O	O
regression	O	O
analysis	O	O
,	O	O
low	Physical	O
operative	Physical	O
weight	Physical	O
,	O	O
cardiopulmonary	Physical	O
bypass	Physical	O
(	Physical	O
CPB	Physical	O
)	Physical	O
duration	Physical	O
>	O	O
100	O	O
min	O	O
,	O	O
and	O	O
immediate	Physical	O
postoperative	Physical	O
serum	Physical	O
lactic	Physical	O
acid	Physical	O
level	Physical	O
>	O	O
20	O	O
mg/dl	O	O
were	O	O
associated	O	O
with	O	O
increased	O	O
odds	O	O
of	O	O
developing	O	O
JET	O	O
.	O	O

Patients	O	O
with	O	O
JET	O	O
had	O	O
longer	O	O
mechanical	Physical	O
ventilation	Physical	O
time	Physical	O
,	O	O
cardiac	Others	O
intensive	Others	O
care	Others	O
unit	Others	O
(	Others	O
CICU	Others	O
)	Others	O
stay	Others	O
,	O	O
and	O	O
hospital	Others	Others
stay	Others	Others
.	O	O

There	O	O
was	O	O
only	O	O
one	O	O
death	Mortality	O
in	O	O
JET	O	O
group	O	O
(	O	O
1.8	O	O
%	O	O
)	O	O
with	O	O
no	O	O
significant	O	O
difference	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
group	O	O
.	O	O

JET	O	O
remains	O	O
a	O	O
relatively	O	O
common	O	O
postoperative	Physical	O
arrhythmia	Physical	O
,	O	O
but	O	O
it	O	O
is	O	O
less	O	O
frequent	O	O
than	O	O
previously	O	O
reported	O	O
.	O	O

JET	O	O
occurs	O	O
more	O	O
commonly	O	O
in	O	O
smaller	O	O
patients	O	O
with	O	O
longer	O	O
CPB	O	O
runs	O	O
and	O	O
significant	O	O
postoperative	Physical	O
lactic	Physical	O
acidosis	Physical	O
levels	Physical	O
.	O	O

Mortality	Mortality	Mortality
associated	O	O
with	O	O
JET	O	O
is	O	O
lower	O	O
than	O	O
historically	O	O
reported	O	O
,	O	O
but	O	O
morbidity	Physical	O
remains	O	O
high	O	O
.	O	O

Effect	O	O
of	O	O
cigarette	O	O
smoking	O	O
on	O	O
gastric	O	Physical
emptying	O	Physical
of	O	O
solids	O	O
in	O	O
Japanese	O	O
smokers	O	O
:	O	O
a	O	O
crossover	O	O
study	O	O
using	O	O
the	O	O
13C-octanoic	O	O
acid	O	O
breath	O	O
test	O	O
.	O	O

BACKGROUND	O	O
Cigarette	O	O
smoking	O	O
is	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
peptic	O	O
ulcer	O	O
and	O	O
gastroesophageal	O	O
reflux	O	O
disease	O	O
.	O	O

Gastric	O	O
emptying	O	O
disorders	O	O
may	O	O
play	O	O
a	O	O
role	O	O
in	O	O
the	O	O
development	O	O
of	O	O
these	O	O
upper	O	O
gastrointestinal	O	O
diseases	O	O
.	O	O

Thus	O	O
,	O	O
studies	O	O
examining	O	O
a	O	O
link	O	O
between	O	O
smoking	O	O
and	O	O
gastric	O	O
emptying	O	O
disorders	O	O
have	O	O
clinical	O	O
relevance	O	O
.	O	O

This	O	O
study	O	O
was	O	O
conducted	O	O
to	O	O
investigate	O	O
the	O	O
effect	Physical	O
of	Physical	O
smoking	Physical	O
on	O	O
gastric	O	Physical
emptying	O	Physical
of	O	O
solids	O	O
in	O	O
Japanese	O	O
smokers	O	O
.	O	O

METHODS	O	O
The	O	O
(	O	O
13	O	O
)	O	O
C-octanoic	O	O
acid	Physical	O
breath	Physical	O
test	Physical	O
was	O	O
performed	O	O
in	O	O
eight	O	O
male	O	O
habitual	O	O
smokers	O	O
on	O	O
two	O	O
randomized	O	O
occasions	O	O
(	O	O
either	O	O
sham	O	O
smoking	O	O
or	O	O
actively	O	O
smoking	O	O
)	O	O
.	O	O

The	O	O
time	O	O
vs	O	O
(	O	O
13	O	O
)	O	O
CO	O	O
(	O	O
2	O	O
)	O	O
excretion	Physical	Physical
rate	Physical	Physical
curve	Physical	Physical
was	O	O
mathematically	O	O
fitted	O	O
to	O	O
a	O	O
conventional	O	O
formula	O	O
of	O	O
y	O	O
(	O	O
t	O	O
)	O	O
=	O	O
m*k*beta*e	O	O
(	O	O
-k*t	O	O
)	O	O
*	O	O
(	O	O
1	O	O
-	O	O
e	O	O
(	O	O
-k*t	O	O
)	O	O
)	O	O
(	O	O
beta-1	O	O
)	O	O
,	O	O
and	O	O
the	O	O
parameters	Others	O
of	Others	O
k	Others	O
and	Others	O
beta	Others	O
were	O	O
determined	O	O
:	O	O
under	O	O
the	O	O
crossover	O	O
protocol	O	O
,	O	O
a	O	O
larger	O	O
(	O	O
smaller	O	O
)	O	O
beta	O	O
indicates	O	O
slower	Physical	O
(	Physical	O
faster	Physical	O
)	Physical	O
emptying	Physical	O
in	O	O
the	O	O
early	O	O
phase	O	O
,	O	O
and	O	O
a	O	O
larger	O	O
(	O	O
smaller	O	O
)	O	O
k	O	O
indicates	O	O
faster	O	O
(	O	O
slower	O	O
)	O	O
emptying	O	O
in	O	O
the	O	O
later	O	O
phase	O	O
.	O	O

The	O	O
half	Physical	O
(	Physical	O
13	Physical	O
)	Physical	O
CO	Physical	O
(	Physical	O
2	Physical	O
)	Physical	O
excretion	Physical	O
time	Physical	O
(	O	O
t	O	O
(	O	O
1/2b	O	O
)	O	O
=	O	O
-	O	O
[	O	O
ln	O	O
(	O	O
1	O	O
-	O	O
2	O	O
(	O	O
-1/beta	O	O
)	O	O
)	O	O
]	O	O
/k	O	O
)	O	O
and	O	O
the	O	O
time	Physical	O
of	Physical	O
maximal	Physical	O
(	Physical	O
13	Physical	O
)	Physical	O
CO	Physical	O
(	Physical	O
2	Physical	O
)	Physical	O
excretion	Physical	O
rate	Physical	O
(	Physical	O
t	Physical	O
(	Physical	O
max	Physical	O
)	Physical	O
=	O	O
[	O	O
lnbeta	O	O
]	O	O
/k	O	O
)	O	O
were	O	O
also	O	O
calculated	O	O
.	O	O

Between	O	O
the	O	O
two	O	O
occasions	O	O
,	O	O
k	O	O
,	O	O
beta	O	O
,	O	O
t	O	O
(	O	O
1/2b	O	O
)	O	O
,	O	O
and	O	O
t	O	O
(	O	O
max	O	O
)	O	O
were	O	O
compared	O	O
by	O	O
the	O	O
Wilcoxon	O	O
signed-rank	O	O
test	O	O
.	O	O

RESULTS	O	O
After	O	O
smoking	O	O
,	O	O
k	O	O
was	O	O
significantly	O	O
increased	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
were	O	O
found	O	O
in	O	O
beta	Others	O
,	Others	O
t	Others	O
(	Others	O
1/2	Others	O
)	Others	O
,	Others	O
and	Others	O
t	Others	O
(	Others	O
max	Others	O
)	Others	O
between	O	O
the	O	O
two	O	O
occasions	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
increase	Others	O
in	Others	O
k	Others	O
suggests	O	O
the	O	O
acceleration	O	Physical
of	O	Physical
gastric	O	Physical
emptying	O	Physical
in	O	O
the	O	O
later	O	O
phase	O	O
.	O	O

For	O	O
the	O	O
first	O	O
time	O	O
,	O	O
this	O	O
study	O	O
has	O	O
revealed	O	O
that	O	O
acute	O	O
smoking	O	O
speeds	O	O
the	O	O
gastric	O	O
emptying	O	O
of	O	O
solids	O	O
in	O	O
Japanese	O	O
habitual	O	O
smokers	O	O
.	O	O

Long	O	O
pediatric	O	O
colonoscope	O	O
versus	O	O
intermediate	O	O
length	O	O
adult	O	O
colonoscope	O	O
for	O	O
colonoscopy	O	O
.	O	O

BACKGROUND	O	O
Controversy	O	O
exists	O	O
on	O	O
how	O	O
the	O	O
length	O	O
and	O	O
diameter	O	O
of	O	O
colonoscopes	O	O
affect	O	O
the	O	O
quality	Others	O
of	Others	O
colonoscopy	Others	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
a	O	O
long	O	O
pediatric	O	O
colonoscope	O	O
with	O	O
an	O	O
intermediate	O	O
length	O	O
adult	O	O
colonoscope	O	O
with	O	O
regards	O	O
to	O	O
completion	Others	O
rate	Others	O
and	O	O
cecal	Others	O
intubation	Others	O
time	Others	O
.	O	O

Whether	O	O
either	O	O
scope	O	O
may	O	O
be	O	O
more	O	O
efficient	Others	O
in	O	O
any	O	O
subgroups	O	O
was	O	O
also	O	O
investigated	O	O
.	O	O

METHODS	O	O
Asymptomatic	O	O
patients	O	O
admitted	O	O
to	O	O
the	O	O
physical	O	O
check-up	O	O
department	O	O
of	O	O
Buddhist	O	O
Dalin	O	O
Tzu	O	O
Chi	O	O
General	O	O
Hospital	O	O
were	O	O
included	O	O
.	O	O

A	O	O
single	O	O
endoscopist	O	O
performed	O	O
all	O	O
of	O	O
the	O	O
colonoscopic	O	O
examinations	O	O
under	O	O
sedation	O	O
.	O	O

Consecutive	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
undergo	O	O
colonoscopy	O	O
with	O	O
either	O	O
intermediate	O	O
length	O	O
adult	O	O
colonoscope	O	O
(	O	O
CF-240I	O	O
)	O	O
or	O	O
long	O	O
pediatric	O	O
colonoscope	O	O
(	O	O
PCF-240L	O	O
)	O	O
.	O	O

The	O	O
success	Others	Others
rate	Others	Others
and	O	Others
time	Others	Others
required	Others	Others
to	Others	Others
reach	Others	Others
cecum	Others	Others
were	O	O
compared	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

RESULTS	O	O
Between	O	O
April	O	O
2005	O	O
and	O	O
February	O	O
2006	O	O
,	O	O
a	O	O
total	O	O
of	O	O
918	O	O
patients	O	O
were	O	O
enrolled	O	O
.	O	O

Incomplete	Others	O
colonoscopy	Others	O
occurred	O	O
in	O	O
21	O	O
(	O	O
2.3	O	O
%	O	O
)	O	O
cases	O	O
(	O	O
14	O	O
in	O	O
the	O	O
CF-240I	O	O
group	O	O
and	O	O
seven	O	O
in	O	O
the	O	O
PCF-240L	O	O
group	O	O
,	O	O
P	O	O
>	O	O
0.1	O	O
)	O	O
.	O	O

The	O	O
overall	Others	Others
cecal	Others	Others
mean	Others	Others
insertion	Others	Others
time	Others	Others
was	O	O
6.00	O	O
+/-	O	O
3.66	O	O
min	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
the	O	O
CF-240I	O	O
and	O	O
PCF	O	O
240L	O	O
groups	O	O
with	O	O
regard	O	O
to	O	O
the	O	O
cecal	Others	O
intubation	Others	O
rate	Others	O
(	O	O
96.9	O	O
%	O	O
vs	O	O
98.5	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.18	O	O
)	O	O
,	O	O
the	O	O
need	O	O
for	O	O
abdominal	Others	Physical
pressure	Others	Physical
(	O	O
71.7	O	O
%	O	O
vs	O	O
73.4	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.55	O	O
)	O	O
and	O	O
change	Others	O
of	Others	O
position	Others	O
(	O	O
13.5	O	O
%	O	O
vs	O	O
11.5	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.37	O	O
)	O	O
.	O	O

However	O	O
,	O	O
the	O	O
cecal	Others	Others
intubation	Others	Others
time	Others	Others
was	O	O
shorter	O	O
in	O	O
the	O	O
CF-240I	O	O
group	O	O
(	O	O
5.75	O	O
+/-	O	O
3.18	O	O
vs	O	O
6.26	O	O
+/-	O	O
3.30	O	O
min	O	O
,	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
.	O	O

Subgroup	O	O
analysis	O	O
by	O	O
sex	O	O
,	O	O
age	O	O
,	O	O
and	O	O
body	O	O
mass	O	O
index	O	O
showed	O	O
comparable	O	O
outcomes	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
except	O	O
that	O	O
the	O	O
cecal	Others	Others
intubation	Others	Others
times	Others	Others
were	O	O
significantly	O	O
shorter	O	O
in	O	O
the	O	O
CF-240I	O	O
group	O	O
when	O	O
only	O	O
men	O	O
(	O	O
4.78	O	O
+/-	O	O
2.57	O	O
vs	O	O
5.50	O	O
+/-	O	O
2.93	O	O
min	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
or	O	O
those	O	O
younger	O	O
than	O	O
50	O	O
years	O	O
(	O	O
5.50	O	O
+/-	O	O
2.90	O	O
vs	O	O
6.25	O	O
+/-	O	O
3.68	O	O
min	O	O
,	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
were	O	O
considered	O	O
.	O	O

CONCLUSION	O	O
Cecal	Others	O
intubation	Others	O
time	Others	O
is	O	O
shorter	O	O
in	O	O
patients	O	O
examined	O	O
with	O	O
an	O	O
intermediate	O	O
length	O	O
adult	O	O
colonoscope	O	O
,	O	O
mainly	O	O
in	O	O
the	O	O
subgroups	O	O
of	O	O
men	O	O
and	O	O
those	O	O
younger	O	O
than	O	O
50	O	O
years	O	O
of	O	O
age	O	O
.	O	O

Direct	O	O
trocar	O	O
insertion	O	O
vs.	O	O
Verres	O	O
needle	O	O
use	O	O
for	O	O
laparoscopic	O	O
sterilization	O	O
.	O	O

A	O	O
randomized	O	O
,	O	O
prospective	O	O
trial	O	O
was	O	O
designed	O	O
to	O	O
compare	O	O
direct	O	O
trocar	O	O
insertion	O	O
with	O	O
prior	O	O
peritoneal	O	O
insufflation	O	O
with	O	O
a	O	O
Verres	O	O
needle	O	O
for	O	O
laparoscopic	O	O
tubal	O	O
sterilization	O	O
.	O	O

Direct	O	O
trocar	O	O
insertion	O	O
resulted	O	O
in	O	O
fewer	O	O
instrument	Others	Others
insertions	Others	Others
(	O	O
21.8	O	O
%	O	O
vs.	O	O
7.8	O	O
%	O	O
)	O	O
and	O	O
use	O	O
of	O	O
smaller	Others	O
volumes	Others	O
of	Others	O
CO2	Others	O
(	O	O
2.67	O	O
vs.	O	O
2.32	O	O
L	O	O
)	O	O
.	O	O

Direct	O	O
trocar	O	O
use	O	O
resulted	O	O
in	O	O
a	O	O
decrease	O	O
in	O	O
operating	Others	Others
time	Others	Others
from	O	O
9	O	O
minutes	O	O
,	O	O
40	O	O
seconds	O	O
in	O	O
the	O	O
needle	O	O
group	O	O
to	O	O
7	O	O
minutes	O	O
,	O	O
30	O	O
seconds	O	O
in	O	O
the	O	O
trocar	O	O
group	O	O
.	O	O

Minor	Adverseeffect	Physical
omental	Adverseeffect	Physical
injuries	Adverseeffect	Physical
occurred	O	O
in	O	O
a	O	O
small	O	O
percentage	O	O
of	O	O
each	O	O
group	O	O
,	O	O
while	O	O
serious	O	Adverseeffect
complications	O	Adverseeffect
occurred	O	O
once	O	O
in	O	O
each	O	O
group	O	O
.	O	O

Psychoeducational	O	O
group	O	O
intervention	O	O
for	O	O
wives	O	O
of	O	O
men	O	O
with	O	O
prostate	O	O
cancer	O	O
.	O	O

OBJECTIVE	O	O
The	O	O
effects	O	O
of	O	O
a	O	O
6-week	O	O
psychoeducational	O	O
group	O	O
intervention	O	O
on	O	O
the	O	O
distress	O	Physical
,	O	Physical
coping	O	Physical
,	O	Physical
personal	O	Physical
growth	O	Physical
,	O	O
and	O	O
marital	O	O
communication	O	O
of	O	O
wives	O	O
of	O	O
men	O	O
diagnosed	O	O
with	O	O
prostate	O	O
cancer	O	O
were	O	O
evaluated	O	O
using	O	O
a	O	O
randomized	O	O
clinical	O	O
trial	O	O
.	O	O

METHODS	O	O
Sixty	O	O
wives	O	O
completed	O	O
measures	O	O
prior	O	O
to	O	O
random	O	O
assignment	O	O
to	O	O
either	O	O
the	O	O
psychoeducational	O	O
group	O	O
intervention	O	O
or	O	O
a	O	O
no-treatment	O	O
control	O	O
group	O	O
,	O	O
and	O	O
1	O	O
month	O	O
after	O	O
completion	O	O
of	O	O
the	O	O
group	O	O
.	O	O

RESULTS	O	O
No	O	O
differences	O	O
with	O	O
regard	O	O
to	O	O
wives	O	O
'	O	O
general	Mental	O
distress	Mental	O
or	Mental	O
cancer-specific	Mental	Physical
distress	Mental	Physical
were	O	O
noted	O	O
.	O	O

In	O	O
comparison	O	O
with	O	O
the	O	O
control	O	O
group	O	O
,	O	O
participants	O	O
receiving	O	O
the	O	O
intervention	O	O
perceived	O	O
that	O	O
having	O	O
a	O	O
spouse	O	O
with	O	O
prostate	O	O
cancer	O	O
had	O	O
made	O	O
positive	O	O
contributions	O	O
to	O	O
their	O	O
lives	O	O
,	O	O
reported	O	O
gains	O	O
in	O	O
the	O	O
use	O	Physical
of	O	Physical
positive	Mental	Physical
reappraisal	Mental	Physical
coping	Mental	Physical
and	O	Physical
reductions	O	Physical
in	O	Physical
denial	Mental	Physical
coping	Mental	Physical
.	Mental	Physical

CONCLUSION	O	O
Although	O	O
the	O	O
psychoeducational	O	O
intervention	O	O
did	O	O
not	O	O
result	O	O
in	O	O
changes	O	O
in	O	O
psychological	Mental	Mental
distress	Mental	Mental
,	O	O
improvements	O	Physical
in	O	Physical
adaptive	Mental	Physical
coping	Mental	Physical
and	Mental	Physical
indicators	Mental	Physical
of	Mental	Physical
psychological	Mental	Physical
growth	Mental	Physical
were	O	O
found	O	O
.	O	O

The	O	O
utility	O	O
of	O	O
group	O	O
interventions	O	O
for	O	O
spouses	O	O
of	O	O
men	O	O
with	O	O
prostate	O	O
cancer	O	O
is	O	O
discussed	O	O
.	O	O

[	O	O
Effect	O	O
of	O	O
liu	O	O
wei	O	O
di	O	O
huang	O	O
or	O	O
jin	O	O
gui	O	O
shen	O	O
qi	O	O
decoction	O	O
as	O	O
on	O	O
adjuvant	O	O
treatment	O	O
in	O	O
small	O	O
cell	O	O
lung	O	O
cancer	O	O
]	O	O
.	O	O

Eighty-three	O	O
patients	O	O
with	O	O
small	O	O
cell	O	O
lung	O	O
cancer	O	O
were	O	O
randomized	O	O
with	O	O
or	O	O
without	O	O
using	O	O
a	O	O
traditional	O	O
Chinese	O	O
Kidney-tonifying	O	O
decoction	O	O
(	O	O
Liu	O	O
Wei	O	O
Di	O	O
Huang	O	O
or	O	O
Jin	O	O
Gui	O	O
Shen	O	O
Qi	O	O
medicinal	O	O
decoction	O	O
)	O	O
in	O	O
chemotherapy	O	O
or	O	O
radiotherapy	O	O
courses	O	O
.	O	O

74	O	O
patients	O	O
were	O	O
availble	O	O
to	O	O
be	O	O
analysis	O	O
.	O	O

The	O	O
two	O	O
treatment	O	O
groups	O	O
were	O	O
well-matched	O	O
in	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
stage	O	O
and	O	O
performance	O	O
status	O	O
.	O	O

There	O	O
was	O	O
a	O	O
statistically	O	O
significant	O	O
difference	O	O
in	O	O
response	Physical	Physical
rate	Physical	Physical
and	O	O
the	O	O
median	Mortality	Mortality
survival	Mortality	Mortality
between	O	O
two	O	O
groups	O	O
.	O	O

The	O	O
overall	Physical	Physical
response	Physical	Physical
rate	Physical	Physical
(	O	Physical
CR+PR	O	Physical
)	O	Physical
was	O	O
91.5	O	O
%	O	O
for	O	O
Chinese	O	O
herb	O	O
group	O	O
and	O	O
46.9	O	O
%	O	O
for	O	O
control	O	O
group	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
.	O	O

The	O	O
median	Mortality	Mortality
survival	Mortality	Mortality
was	O	O
16	O	O
months	O	O
for	O	O
the	O	O
traditional	O	O
Chinese	O	O
Kidney-tonifying	O	O
decoction	O	O
group	O	O
,	O	O
and	O	O
10	O	O
months	O	O
for	O	O
the	O	O
control	O	O
group	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
.	O	O

Survival	Mortality	O
curve	Mortality	O
(	Mortality	O
Kaplan-meire	Mortality	O
's	Mortality	O
)	Mortality	O
of	O	O
the	O	O
Chinese	O	O
herb	O	O
group	O	O
was	O	O
better	O	O
than	O	O
that	O	O
of	O	O
the	O	O
control	O	O
group	O	O
.	O	O

10	O	O
patients	O	O
of	O	O
Chinese	O	O
herb	O	O
group	O	O
was	O	O
alive	O	O
beyond	O	O
more	O	O
than	O	O
2	O	O
years	O	O
.	O	O

Until	O	O
now	O	O
,	O	O
4	O	O
patients	O	O
in	O	O
the	O	O
Chinese	O	O
herb	O	O
group	O	O
,	O	O
one	O	O
in	O	O
the	O	O
control	O	O
group	O	O
are	O	O
still	O	O
enjoying	O	O
their	O	O
disease-free	Others	O
life	Others	O
for	O	O
more	O	O
than	O	O
7	O	O
years	O	O
.	O	O

Hematologic	Adverseeffect	Adverseeffect
toxicities	Adverseeffect	Adverseeffect
were	O	O
observed	O	O
much	O	O
frequently	O	O
in	O	O
the	O	O
patients	O	O
of	O	O
the	O	O
control	O	O
group	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.005	O	O
and	O	O
0.01/WBC	O	O
and	O	O
BPC	O	O
)	O	O
.	O	O

Results	O	O
of	O	O
animal	O	O
experiments	O	O
with	O	O
the	O	O
same	O	O
traditional	O	O
medicinal	O	O
decoctions	O	O
as	O	O
used	O	O
in	O	O
clinic	O	O
have	O	O
showed	O	O
immuno-enhancement	Physical	O
activities	Physical	O
.	O	O

These	O	O
results	O	O
have	O	O
showed	O	O
that	O	O
the	O	O
traditional	O	O
Chinese	O	O
Kidney-tonifying	O	O
decoction	O	O
may	O	O
enhance	O	O
non-specific	O	O
immunology	O	O
activities	O	O
and	O	O
may	O	O
be	O	O
much	O	O
useful	O	O
for	O	O
solid	O	O
cancer	O	O
patients	O	O
as	O	O
an	O	O
adjuvant	O	O
treatment	O	O
.	O	O

Online	O	O
conductivity	O	O
monitoring	O	O
:	O	O
validation	O	O
and	O	O
usefulness	O	O
in	O	O
a	O	O
clinical	O	O
trial	O	O
of	O	O
reduced	O	O
dialysate	O	O
conductivity	O	O
.	O	O

Relatively	O	O
low	O	O
dialysate	O	O
conductivity	O	O
(	O	O
Cndi	O	O
)	O	O
may	O	O
improve	O	O
outcomes	O	O
by	O	O
reducing	O	O
the	O	O
overall	O	Others
sodium	Physical	Others
burden	Physical	Others
in	O	O
dialysis	O	O
patients	O	O
.	O	O

Excess	O	O
sodium	O	O
removal	O	O
,	O	O
however	O	O
,	O	O
could	O	O
lead	O	O
to	O	O
hemodynamic	O	O
instability	O	O
.	O	O

We	O	O
performed	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O
of	O	O
reduction	O	O
of	O	O
Cndi	O	O
.	O	O

For	O	O
the	O	O
study	O	O
,	O	O
28	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
maintenance	O	O
of	O	O
Cndi	O	O
at	O	O
13.6	O	O
mS/cm	O	O
(	O	O
equivalent	O	O
to	O	O
135	O	O
mmol/L	O	O
of	O	O
Na+	O	O
)	O	O
or	O	O
serial	O	O
reduction	O	O
of	O	O
Cndi	O	O
in	O	O
steps	O	O
of	O	O
0.2	O	O
mS/cm	O	O
,	O	O
guided	O	O
by	O	O
symptoms	O	O
and	O	O
blood	O	O
pressure	O	O
.	O	O

Sodium	O	O
removal	O	O
estimated	O	O
from	O	O
pre-	O	O
and	O	O
postplasma	O	O
concentrations	O	O
correlated	O	O
well	O	O
with	O	O
removal	O	O
measured	O	O
by	O	O
conductivity	O	O
monitoring	O	O
as	O	O
ionic	Physical	Physical
mass	Physical	Physical
balance	Physical	Physical
(	O	O
R2	O	O
0.66	O	O
,	O	O
p	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

Of	O	O
the	O	O
16	O	O
patients	O	O
randomized	O	O
to	O	O
reduction	O	O
of	O	O
Cndi	O	O
,	O	O
6	O	O
achieved	O	O
Cndi	O	O
13.4	O	O
mS/cm	O	O
,	O	O
6	O	O
achieved	O	O
13.2	O	O
mS/cm	O	O
,	O	O
and	O	O
4	O	O
achieved	O	O
13.0	O	O
mS/cm	O	O
.	O	O

No	O	O
episodes	O	O
of	O	O
disequilibrium	O	O
occurred	O	O
.	O	O

Interdialytic	Physical	Physical
weight	Physical	Physical
gain	Physical	Physical
was	O	O
reduced	O	O
from	O	O
2.34	O	O
+/-	O	O
0.10	O	O
kg	O	O
to	O	O
1.57	O	O
+/-	O	O
0.11	O	O
kg	O	O
(	O	O
p	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

Predialysis	Physical	Physical
systolic	Physical	Physical
blood	Physical	Physical
pressure	Physical	Physical
fell	O	O
from	O	O
144	O	O
+/-	O	O
3	O	O
mm	O	O
Hg	O	O
to	O	O
137	O	O
+/-	O	O
4	O	O
mm	O	O
Hg	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

The	O	O
reduction	Others	O
in	Others	O
convective	Physical	O
sodium	Physical	O
removal	Physical	O
was	O	O
balanced	O	O
by	O	O
an	O	O
increase	O	O
in	O	O
diffusive	Physical	O
sodium	Physical	O
removal	Physical	O
(	O	O
95	O	O
+/-	O	O
9	O	O
mmol	O	O
cf	O	O
.	O	O

175	O	O
+/-	O	O
14	O	O
mmol	O	O
,	O	O
p	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

Reduction	O	O
in	O	O
Cndi	O	O
monitored	O	O
by	O	O
IMB	O	O
is	O	O
safe	O	O
and	O	O
practical	O	O
and	O	O
leads	O	O
to	O	O
improved	O	O
interdialytic	O	O
weight	O	O
gains	O	O
and	O	O
blood	O	O
pressure	O	O
control	O	O
,	O	O
while	O	O
avoiding	O	O
excessive	O	O
sodium	O	O
removal	O	O
.	O	O

Secretin	O	O
and	O	O
sleep	O	O
in	O	O
children	O	O
with	O	O
autism	O	O
.	O	O

The	O	O
objectives	O	O
of	O	O
this	O	O
pilot	O	O
study	O	O
were	O	O
1	O	O
)	O	O
to	O	O
examine	O	O
possible	O	O
effects	O	O
of	O	O
secretin	O	O
infusions	O	O
on	O	O
sleep-wake	O	O
state	O	O
organization	O	O
in	O	O
children	O	O
with	O	O
autism	O	O
,	O	O
and	O	O
2	O	O
)	O	O
to	O	O
assess	O	O
the	O	O
feasibility	O	O
of	O	O
home	O	O
recordings	O	O
using	O	O
time-lapse	O	O
videosomnography	O	O
in	O	O
children	O	O
with	O	O
autism	O	O
.	O	O

Participants	O	O
were	O	O
a	O	O
subset	O	O
of	O	O
subjects	O	O
from	O	O
two	O	O
double	O	O
blind	O	O
,	O	O
placebo-control	O	O
,	O	O
multi-center	O	O
clinical	O	O
trials	O	O
.	O	O

One	O	O
trial	O	O
,	O	O
the	O	O
UC	O	O
Irvine	O	O
study	O	O
,	O	O
assessed	O	O
the	O	O
effects	O	O
of	O	O
porcine	O	O
secretin	O	O
vs.	O	O
saline	O	O
infusions	O	O
on	O	O
children	O	Mental
's	O	Mental
behavior	Mental	Mental
,	O	Mental
language	Mental	Mental
and	O	Mental
IQ	Mental	Mental
.	O	O

The	O	O
UC	O	O
Davis	O	O
trial	O	O
assessed	O	O
the	O	O
effects	O	O
of	O	O
synthetic	O	O
human	O	O
secretin	O	O
vs.	O	O
saline	O	O
infusions	O	O
on	O	O
behavior	Mental	Mental
,	O	Mental
language	Mental	Mental
and	O	Mental
gastrointestinal	O	Physical
function	O	Physical
.	O	O

The	O	O
sleep	O	O
study	O	O
enrolled	O	O
some	O	O
of	O	O
the	O	O
children	O	O
from	O	O
each	O	O
of	O	O
the	O	O
two	O	O
trials	O	O
to	O	O
observe	O	O
possible	O	O
secretin	O	O
effects	O	O
on	O	O
sleep	O	O
.	O	O

To	O	O
examine	O	O
sleep	O	O
,	O	O
the	O	O
UC	O	O
Irvine	O	O
trial	O	O
used	O	O
the	O	O
Children	Mental	Physical
's	Mental	Physical
Sleep	Mental	Physical
Habits	Mental	Physical
Questionnaire	Mental	Physical
and	O	Physical
daily	Mental	Physical
sleep	Mental	Physical
diaries	Mental	Physical
,	O	O
whereas	O	O
the	O	O
UC	O	O
Davis	O	O
study	O	O
used	O	O
home-recorded	Others	O
time-lapse	Others	O
videosomnography	Others	O
.	O	O

Because	O	O
of	O	O
the	O	O
small	O	O
sample	O	O
size	O	O
,	O	O
the	O	O
results	O	O
from	O	O
both	O	O
trials	O	O
are	O	O
preliminary	O	O
.	O	O

They	O	O
suggest	O	O
that	O	O
secretin	O	O
,	O	O
porcine	O	O
or	O	O
synthetic	O	O
,	O	O
does	O	O
not	O	O
improve	O	O
sleep-wake	Mental	O
state	Mental	O
organization	Mental	O
dramatically	O	O
.	O	O

Hydrogen	O	O
peroxide	O	O
mouth	O	O
rinse	O	O
:	O	O
an	O	O
analgesic	O	O
post-tonsillectomy	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
compare	O	O
the	O	O
analgesic	Others	O
efficacy	Others	O
of	O	O
hydrogen	O	O
peroxide	O	O
(	O	O
H2O2	O	O
)	O	O
mouth	O	O
rinse	O	O
with	O	O
control	O	O
for	O	O
post-tonsillectomy	Pain	O
pain	Pain	O
management	Pain	O
.	O	O

DESIGN	O	O
Double-blinded	O	O
,	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
controlled	O	O
clinical	O	O
trial	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
Thirty-seven	O	O
patients	O	O
from	O	O
5	O	O
to	O	O
14	O	O
years	O	O
old	O	O
undergoing	O	O
electrocautery	O	O
tonsillectomy	O	O
were	O	O
randomized	O	O
to	O	O
either	O	O
the	O	O
H2O2	O	O
mouth	O	O
rinse	O	O
or	O	O
the	O	O
water	O	O
rinse	O	O
(	O	O
control	O	O
)	O	O
group	O	O
.	O	O

For	O	O
14	O	O
days	O	O
,	O	O
patients	O	O
recorded	O	O
pain	Pain	Pain
levels	Pain	Pain
twice	Pain	Pain
daily	Pain	Pain
using	O	O
a	O	O
visual	Pain	O
analogue	Pain	O
scale	Pain	O
.	O	O

Analgesic	O	O
uses	O	O
,	O	O
as	O	O
well	O	O
as	O	O
any	O	O
complications	O	Adverseeffect
,	O	O
were	O	O
also	O	O
noted	O	O
by	O	O
the	O	O
patients	O	O
.	O	O

RESULTS	O	O
Thirty-seven	O	O
patients	O	O
completed	O	O
the	O	O
study	O	O
,	O	O
21	O	O
in	O	O
the	O	O
treatment	O	O
group	O	O
and	O	O
16	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

Mean	Pain	Physical
postoperative	Pain	Physical
days	Pain	Physical
of	Pain	Physical
pain	Pain	Physical
were	O	O
10.3	O	O
and	O	O
8.3	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
differed	O	O
significantly	O	O
(	O	O
p	O	O
=	O	O
.008	O	O
)	O	O
.	O	O

Mean	Others	Physical
postoperative	Others	Physical
days	Others	Physical
of	Others	Physical
analgesic	Others	Physical
use	O	O
were	O	O
9.0	O	O
and	O	O
6.7	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
differed	O	O
significantly	O	O
(	O	O
p	O	O
=	O	O
.005	O	O
)	O	O
.	O	O

Only	O	O
one	O	O
incidence	O	Adverseeffect
of	O	Adverseeffect
postoperative	Adverseeffect	Adverseeffect
hemorrhage	Adverseeffect	Adverseeffect
occurred	O	O
in	O	O
the	O	O
study	O	O
group	O	O
.	O	O

CONCLUSION	O	O
In	O	O
our	O	O
study	O	O
,	O	O
the	O	O
H2O2	O	O
mouth	O	O
rinse	O	O
does	O	O
not	O	O
provide	O	O
a	O	O
better	O	O
analgesic	Others	Physical
effect	Others	Physical
than	O	O
the	O	O
water	O	O
rinse	O	O
for	O	O
post-tonsillectomy	Pain	O
pain	Pain	O
relief	Pain	O
.	O	O

Niacin	O	O
revisited	O	O
.	O	O

A	O	O
randomized	O	O
,	O	O
controlled	O	O
trial	O	O
of	O	O
wax-matrix	O	O
sustained-release	O	O
niacin	O	O
in	O	O
hypercholesterolemia	O	O
.	O	O

Two	O	O
hundred	O	O
one	O	O
male	O	O
and	O	O
female	O	O
subjects	O	O
,	O	O
aged	O	O
20	O	O
to	O	O
70	O	O
years	O	O
,	O	O
with	O	O
elevated	O	O
low-density	O	Physical
lipoprotein	O	Physical
cholesterol	O	Physical
values	O	Physical
(	O	O
in	O	O
the	O	O
75th	O	O
to	O	O
95th	O	O
percentiles	O	O
)	O	O
,	O	O
participated	O	O
in	O	O
a	O	O
randomized	O	O
,	O	O
controlled	O	O
,	O	O
double-blind	O	O
study	O	O
using	O	O
a	O	O
new	O	O
form	O	O
of	O	O
niacin	O	O
(	O	O
Enduracin	O	O
)	O	O
,	O	O
which	O	O
employs	O	O
a	O	O
wax-matrix	O	O
vehicle	O	O
for	O	O
sustained	O	O
release	O	O
.	O	O

Four	O	O
niacin	O	O
treatment	O	O
groups	O	O
(	O	O
daily	O	O
doses	O	O
of	O	O
2000	O	O
,	O	O
1500	O	O
,	O	O
1250	O	O
,	O	O
and	O	O
1000	O	O
mg	O	O
)	O	O
were	O	O
compared	O	O
with	O	O
placebo-	O	O
and	O	O
diet-treated	O	O
controls	O	O
to	O	O
determine	O	O
side-effect	O	Adverseeffect
profile	O	Adverseeffect
and	O	O
optimal	O	O
range	O	O
of	O	O
efficacy	O	O
.	O	O

The	O	O
groups	O	O
given	O	O
2000	O	O
and	O	O
1500	O	O
mg	O	O
demonstrated	O	O
significant	O	O
reductions	O	O
in	O	O
values	O	O
of	O	O
low-density	Physical	Physical
lipoprotein	Physical	Physical
cholesterol	Physical	Physical
(	O	O
-26	O	O
%	O	O
and	O	O
-19.3	O	O
%	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
total	Physical	Physical
cholesterol	Physical	Physical
(	O	O
-18.4	O	O
%	O	O
and	O	O
-13.3	O	O
%	O	O
)	O	O
,	O	O
and	O	O
total	Physical	Physical
cholesterol-high-density	Physical	Physical
lipoprotein	Physical	Physical
cholesterol	Physical	Physical
ratio	Physical	Physical
(	O	O
-20.4	O	O
%	O	O
and	O	O
-19.4	O	O
%	O	O
)	O	O
when	O	O
compared	O	O
with	O	O
diet-	O	O
and	O	O
placebo-treated	O	O
controls	O	O
.	O	O

Smaller	O	O
improvements	O	O
were	O	O
seen	O	O
in	O	O
high-density	Physical	Physical
lipoprotein	Physical	Physical
cholesterol	Physical	Physical
and	Physical	Physical
triglyceride	Physical	Physical
levels	Physical	Physical
.	Physical	O

Blood	O	O
chemistry	O	O
monitoring	O	O
indicated	O	O
that	O	O
reduction	O	O
in	O	O
low-density	Physical	O
lipoprotein	Physical	O
cholesterol	Physical	O
level	Physical	O
strongly	O	O
correlated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
baseline	O	O
levels	O	O
of	O	O
some	O	O
enzymes	O	O
for	O	O
niacin-treated	O	O
subjects	O	O
.	O	O

The	O	O
improved	O	O
side-effect	O	Adverseeffect
profile	O	Adverseeffect
of	O	O
the	O	O
wax-matrix	O	O
form	O	O
of	O	O
niacin	O	O
was	O	O
particularly	O	O
notable	O	O
.	O	O

The	O	O
dropout	Others	O
rate	Others	O
due	O	O
to	O	O
side	Adverseeffect	O
effects	Adverseeffect	O
was	O	O
only	O	O
3.4	O	O
%	O	O
and	O	O
was	O	O
coupled	O	O
with	O	O
good	O	O
medication	O	O
compliance	O	O
.	O	O

Is	O	O
a	O	O
calculated	O	O
total	O	O
hip	O	O
BMD	O	O
of	O	O
clinical	Others	O
use	Others	O
?	O	O
The	O	O
diagnosis	O	O
of	O	O
osteoporosis	O	O
is	O	O
based	O	O
on	O	O
bone	O	O
mass	O	O
measurement	O	O
.	O	O

To	O	O
avoid	O	O
the	O	O
errors	O	O
associated	O	O
with	O	O
the	O	O
measurement	O	O
of	O	O
spinal	O	Physical
bone	O	Physical
density	O	Physical
the	O	O
total	O	O
hip	O	O
has	O	O
been	O	O
accepted	O	O
as	O	O
the	O	O
standard	O	O
measurement	O	O
site	O	O
.	O	O

This	O	O
information	O	O
is	O	O
not	O	O
available	O	O
for	O	O
many	O	O
early	O	O
measurements	O	O
.	O	O

We	O	O
have	O	O
assessed	O	O
whether	O	O
it	O	O
is	O	O
possible	O	O
to	O	O
derive	O	O
clinically	O	O
useful	O	O
information	O	O
about	O	O
total	O	Physical
hip	O	Physical
bone	O	Physical
mineral	O	Physical
density	O	Physical
(	O	Physical
BMD	O	Physical
)	O	Physical
from	O	O
measurements	O	O
at	O	O
other	O	O
hip	O	O
sites	O	O
.	O	O

The	O	O
bone	O	O
mass	O	O
measurements	O	O
of	O	O
46	O	O
patients	O	O
participating	O	O
in	O	O
a	O	O
current	O	O
trial	O	O
of	O	O
therapy	O	O
for	O	O
osteoporosis	O	O
were	O	O
reviewed	O	O
.	O	O

The	O	O
total	Physical	Physical
hip	Physical	Physical
BMD	Physical	Physical
as	O	O
directly	O	O
measured	O	O
was	O	O
compared	O	O
with	O	O
that	O	O
obtained	O	O
from	O	O
the	O	O
formula	O	O
:	O	O
Total	Physical	O
hip	Physical	O
BMD	Physical	O
=	O	O
0.48	O	O
x	O	O
Neck	Physical	O
BMD	Physical	O
+	O	O
0.62	O	O
x	O	O
Trochanteric	Physical	O
BMD	Physical	O
+	O	O
0.03	O	O
.	O	O

In	O	O
30	O	O
patients	O	O
with	O	O
follow-up	O	O
data	O	O
the	O	O
rate	Physical	O
of	Physical	O
change	Physical	O
in	Physical	O
hip	Physical	Physical
BMD	Physical	Physical
over	O	O
a	O	O
year	O	O
was	O	O
also	O	O
determined	O	O
by	O	O
both	O	O
methods	O	O
.	O	O

In	O	O
the	O	O
pretreatment	O	O
state	O	O
there	O	O
was	O	O
good	O	O
agreement	O	O
between	O	O
the	O	O
two	O	O
measures	O	O
(	O	O
r2	O	O
=	O	O
0.96	O	O
,	O	O
SEE	O	O
0.012	O	O
g/cm2	O	O
)	O	O
.	O	O

If	O	O
the	O	O
formula	O	O
was	O	O
used	O	O
to	O	O
compute	O	O
a	O	O
change	Physical	O
in	Physical	O
total	Physical	O
hip	Physical	O
BMD	Physical	O
,	O	O
the	O	O
agreement	O	O
between	O	O
both	O	O
methods	O	O
remained	O	O
good	O	O
.	O	O

However	O	O
,	O	O
the	O	O
standard	O	O
error	O	O
of	O	O
the	O	O
estimate	O	O
of	O	O
the	O	O
change	O	O
represented	O	O
59	O	O
%	O	O
of	O	O
the	O	O
observed	O	O
change	O	O
.	O	O

This	O	O
indicates	O	O
that	O	O
the	O	O
error	Others	O
associated	Others	O
with	Others	O
this	Others	O
estimate	Others	O
is	O	O
too	O	O
great	O	O
to	O	O
allow	O	O
clinically	O	O
meaningful	O	O
conclusions	O	O
to	O	O
be	O	O
drawn	O	O
from	O	O
calculated	Physical	O
total	Physical	O
hip	Physical	O
BMD	Physical	O
.	O	O

We	O	O
conclude	O	O
that	O	O
,	O	O
whilst	O	O
it	O	O
may	O	O
be	O	O
possible	O	O
to	O	O
obtain	O	O
reasonable	O	O
point	O	O
estimates	O	O
of	O	O
total	Physical	Physical
hip	Physical	Physical
BMD	Physical	Physical
from	O	O
other	O	O
measures	O	O
in	O	O
the	O	O
hip	O	O
,	O	O
these	O	O
estimates	O	O
are	O	O
too	O	O
imprecise	O	O
to	O	O
allow	O	O
conclusions	O	O
about	O	O
change	Physical	O
in	Physical	O
BMD	Physical	Physical
to	O	O
be	O	O
made	O	O
.	O	O

Effects	Others	O
of	O	O
three	O	O
oral	O	O
analgesics	O	O
on	O	O
postoperative	O	O
pain	O	O
following	O	O
root	O	O
canal	O	O
preparation	O	O
:	O	O
a	O	O
controlled	O	O
clinical	O	O
trial	O	O
.	O	O

AIM	O	O
To	O	O
compare	O	O
the	O	O
effects	O	O
of	O	O
single	O	O
doses	O	O
of	O	O
three	O	O
oral	O	O
medications	O	O
on	O	O
postoperative	O	O
pain	Pain	O
following	O	O
instrumentation	O	O
of	O	O
root	O	O
canals	O	O
in	O	O
teeth	O	O
with	O	O
irreversible	O	O
pulpitis	O	O
.	O	O

METHODOLOGY	O	O
In	O	O
this	O	O
double-blind	O	O
clinical	O	O
trial	O	O
,	O	O
100	O	O
patients	O	O
who	O	O
had	O	O
anterior	O	O
or	O	O
premolar	O	O
teeth	O	O
with	O	O
irreversible	O	O
pulpitis	O	O
without	O	O
any	O	O
signs	O	O
and	O	O
symptoms	O	O
of	O	O
acute	O	O
or	O	O
chronic	O	O
apical	O	O
periodontitis	O	O
and	O	O
moderate	O	O
to	O	O
severe	O	O
pain	O	O
were	O	O
divided	O	O
by	O	O
balanced	O	O
block	O	O
random	O	O
allocation	O	O
into	O	O
four	O	O
groups	O	O
of	O	O
25	O	O
each	O	O
,	O	O
a	O	O
control	O	O
group	O	O
receiving	O	O
a	O	O
placebo	O	O
medication	O	O
,	O	O
and	O	O
three	O	O
experimental	O	O
groups	O	O
receiving	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
either	O	O
Tramadol	O	O
(	O	O
100	O	O
mg	O	O
)	O	O
,	O	O
Novafen	O	O
(	O	O
325	O	O
mg	O	O
of	O	O
paracetamol	O	O
,	O	O
200	O	O
mg	O	O
ibuprofen	O	O
and	O	O
40	O	O
mg	O	O
caffeine	O	O
anhydrous	O	O
)	O	O
or	O	O
Naproxen	O	O
(	O	O
500	O	O
mg	O	O
)	O	O
immediately	O	O
after	O	O
the	O	O
first	O	O
appointment	O	O
where	O	O
the	O	O
pulp	O	O
was	O	O
removed	O	O
,	O	O
and	O	O
the	O	O
canals	O	O
were	O	O
fully	O	O
prepared	O	O
.	O	O

The	O	O
intensity	O	Pain
of	Pain	Pain
pain	Pain	Pain
was	O	O
scored	O	O
based	O	O
on	O	O
10-point	O	O
VAS	O	O
before	O	O
and	O	O
after	O	O
treatment	O	O
for	O	O
up	O	O
to	O	O
24	O	O
h	O	O
postoperatively	O	O
.	O	O

Data	O	O
were	O	O
submitted	O	O
to	O	O
repeated	O	O
analysis	O	O
of	O	O
variance	O	O
.	O	O

RESULTS	O	O
At	O	O
the	O	O
6	O	O
,	O	O
12	O	O
and	O	O
24	O	O
h	O	O
postoperative	O	O
intervals	O	O
after	O	O
drug	O	O
administration	O	O
,	O	O
the	O	O
intensity	Pain	Pain
of	Pain	Pain
pain	Pain	Pain
was	O	O
significantly	O	O
lower	O	O
in	O	O
the	O	O
experimental	O	O
groups	O	O
than	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

Tramadol	O	O
was	O	O
significantly	O	O
less	O	O
effective	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
than	O	O
Naproxen	O	O
,	O	O
and	O	O
Novafen	O	O
that	O	O
were	O	O
similar	O	O
to	O	O
each	O	O
other	O	O
(	O	O
P	O	O
>	O	O
0.05	O	O
)	O	O
.	O	O

CONCLUSION	O	O
A	O	O
single	O	O
oral	O	O
dose	O	O
of	O	O
Naproxen	O	O
,	O	O
Novafen	O	O
and	O	O
Tramadol	O	O
taken	O	O
immediately	O	O
after	O	O
treatment	O	O
reduced	O	O
postoperative	O	O
pain	O	O
following	O	O
pulpectomy	O	O
and	O	O
root	O	O
canal	O	O
preparation	O	O
of	O	O
teeth	O	O
with	O	O
irreversible	O	O
pulpitis	O	O
.	O	O

Monitoring	O	O
tumour	O	O
cells	O	O
in	O	O
the	O	O
peripheral	O	O
blood	O	O
of	O	O
small	O	O
cell	O	O
lung	O	O
cancer	O	O
patients	O	O
.	O	O

BACKGROUND	O	O
Flow	O	O
cytometry	O	O
was	O	O
used	O	O
to	O	O
enumerate	O	O
tumour	O	O
cells	O	O
in	O	O
longitudinal	O	O
studies	O	O
of	O	O
peripheral	O	O
blood	O	O
from	O	O
small	O	O
cell	O	O
lung	O	O
cancer	O	O
(	O	O
SCLC	O	O
)	O	O
patients	O	O
,	O	O
together	O	O
with	O	O
magnetic	O	O
bead	O	O
selection	O	O
to	O	O
isolate	O	O
and	O	O
identify	O	O
these	O	O
cells	O	O
.	O	O

As	O	O
part	O	O
of	O	O
a	O	O
trial	O	O
,	O	O
11	O	O
patients	O	O
received	O	O
either	O	O
standard	O	O
(	O	O
four	O	O
weekly	O	O
)	O	O
chemotherapy	O	O
with	O	O
ifosfamide	O	O
,	O	O
carboplatin	O	O
,	O	O
and	O	O
etoposide	O	O
(	O	O
ICE	O	O
)	O	O
or	O	O
accelerated	O	O
(	O	O
two	O	O
weekly	O	O
)	O	O
ICE	O	O
with	O	O
filgrastim	O	O
(	O	O
granulocyte	O	O
colony-stimulating	O	O
factor	O	O
[	O	O
G-CSF	O	O
]	O	O
)	O	O
and	O	O
autologous	O	O
stem	O	O
cell	O	O
support	O	O
.	O	O

METHODS	O	O
Fresh	O	O
venous	O	O
blood	O	O
was	O	O
taken	O	O
throughout	O	O
treatment	O	O
and	O	O
follow-up	O	O
.	O	O

Aliquots	O	O
were	O	O
stained	O	O
with	O	O
a	O	O
tumour-specific	O	O
antibody	O	O
against	O	O
epithelial	O	O
tissue	O	O
(	O	O
Ber	O	O
EP4	O	O
)	O	O
,	O	O
verified	O	O
as	O	O
a	O	O
good	O	O
marker	O	O
of	O	O
SCLC	O	O
cells	O	O
by	O	O
immunohistochemistry	O	O
.	O	O

Matched	O	O
samples	O	O
labelled	O	O
with	O	O
Ber	O	O
EP4	O	O
were	O	O
separated	O	O
magnetically	O	O
by	O	O
adding	O	O
a	O	O
secondary	O	O
bead-antibody	O	O
conjugate	O	O
for	O	O
confirmation	O	O
of	O	O
tumour	O	O
cell	O	O
identity	O	O
.	O	O

RESULTS	O	O
Circulating	Physical	O
tumour	Physical	O
cells	Physical	O
were	O	O
detected	O	O
and	O	O
monitored	O	O
throughout	O	O
treatment	O	O
periods	O	O
.	O	O

An	O	O
initial	O	O
rise	O	O
in	O	O
circulating	Physical	O
cells	Physical	O
after	O	O
the	O	O
first	O	O
cycle	O	O
was	O	O
followed	O	O
by	O	O
a	O	O
fall	O	O
in	O	O
both	O	O
treatment	O	O
arms	O	O
to	O	O
baseline	O	O
levels	O	O
set	O	O
by	O	O
normal	O	O
controls	O	O
.	O	O

This	O	O
was	O	O
achieved	O	O
by	O	O
week	O	O
12	O	O
in	O	O
the	O	O
accelerated	O	O
treatment	O	O
arm	O	O
and	O	O
by	O	O
week	O	O
24	O	O
in	O	O
the	O	O
standard	O	O
arm	O	O
.	O	O

CONCLUSIONS	O	O
Flow	O	O
cytometry	O	O
and	O	O
magnetic	O	O
bead	O	O
isolation	O	O
can	O	O
be	O	O
used	O	O
to	O	O
identify	O	O
changes	O	O
in	O	O
numbers	O	O
of	O	O
circulating	O	O
tumour	O	O
cells	O	O
in	O	O
patients	O	O
undergoing	O	O
chemotherapy	O	O
for	O	O
SCLC	O	O
and	O	O
thereafter	O	O
during	O	O
follow-up	O	O
periods	O	O
.	O	O

Absence	O	O
of	O	O
tumour	O	O
cells	O	O
may	O	O
indicate	O	O
a	O	O
more	O	O
favourable	O	O
patient	O	O
group	O	O
who	O	O
would	O	O
benefit	O	O
from	O	O
a	O	O
more	O	O
intense	O	O
course	O	O
of	O	O
treatment	O	O
.	O	O

Effect	O	O
of	O	O
ranolazine	O	O
on	O	O
A1C	O	O
and	O	O
glucose	O	O
levels	O	O
in	O	O
hyperglycemic	O	O
patients	O	O
with	O	O
non-ST	O	O
elevation	O	O
acute	O	O
coronary	O	O
syndrome	O	O
.	O	O

OBJECTIVE	O	O
We	O	O
determined	O	O
the	O	O
relationships	O	O
between	O	O
glycemia	O	O
at	O	O
randomization	O	O
,	O	O
concurrent	O	O
antidiabetic	O	O
therapy	O	O
,	O	O
and	O	O
change	O	Physical
in	O	Physical
A1C	O	Physical
and	O	Physical
fasting	O	Physical
plasma	O	Physical
glucose	O	Physical
(	O	Physical
FPG	O	Physical
)	O	Physical
in	O	O
patients	O	O
with	O	O
diabetes	O	O
receiving	O	O
standard	O	O
treatment	O	O
for	O	O
diabetes	O	O
and	O	O
randomized	O	O
to	O	O
ranolazine	O	O
or	O	O
placebo	O	O
within	O	O
the	O	O
MERLIN-TIMI-36	O	O
(	O	O
MERLIN	O	O
)	O	O
study	O	O
.	O	O

Ranolazine	O	O
is	O	O
a	O	O
novel	O	O
first-in-class	O	O
drug	O	O
approved	O	O
for	O	O
treating	O	O
angina	O	O
pectoris	O	O
.	O	O

RESEARCH	O	O
DESIGN	O	O
AND	O	O
METHODS	O	O
Randomization	O	O
and	O	O
4-month	O	O
glycemic	O	O
and	O	O
antidiabetes	O	O
drug	O	O
usage	O	O
data	O	O
from	O	O
MERLIN	O	O
were	O	O
analyzed	O	O
using	O	O
Spotfire	O	O
and	O	O
SAS	O	O
version	O	O
9.1	O	O
software	O	O
.	O	O

RESULTS	O	O
In	O	O
patients	O	O
with	O	O
diabetes	O	O
and	O	O
A1C	O	O
of	O	O
>	O	O
or=8-10	O	O
%	O	O
at	O	O
randomization	O	O
(	O	O
n	O	O
=	O	O
171	O	O
)	O	O
,	O	O
there	O	O
was	O	O
an	O	O
absolute	O	O
A1C	Physical	O
reduction	Physical	O
in	O	O
the	O	O
ranolazine	O	O
group	O	O
of	O	O
1.2	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
-1.4	O	O
to	O	O
-1.0	O	O
)	O	O
,	O	O
and	O	O
the	O	O
placebo-adjusted	O	O
(	O	O
n	O	O
=	O	O
182	O	O
)	O	O
decrease	O	O
in	O	O
A1C	Physical	Physical
by	O	Physical
ranolazine	O	Physical
was	O	O
0.59	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
-0.99	O	O
to	O	O
-0.20	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

In	O	O
patients	O	O
with	O	O
FPG	O	O
of	O	O
150-400	O	O
mg/dl	O	O
at	O	O
randomization	O	O
,	O	O
ranolazine	O	O
(	O	O
n	O	O
=	O	O
131	O	O
)	O	O
compared	O	O
with	O	O
placebo	O	O
(	O	O
n	O	O
=	O	O
147	O	O
)	O	O
reduced	O	O
FPG	O	O
by	O	O
25.7	O	O
mg/dl	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
-43.3	O	O
to	O	O
-8.1	O	O
,	O	O
P	O	O
=	O	O
0.001	O	O
)	O	O
.	O	O

When	O	O
changes	O	O
in	O	O
either	O	O
A1C	Physical	O
or	O	O
FPG	Physical	O
were	O	O
correlated	O	O
to	O	O
A1C	O	O
or	O	O
FPG	O	O
at	O	O
randomization	O	O
,	O	O
the	O	O
slopes	O	O
were	O	O
significantly	O	O
steeper	O	O
for	O	O
ranolazine	O	O
than	O	O
placebo	O	O
(	O	O
A1C	O	O
,	O	O
P	O	O
=	O	O
0.046	O	O
;	O	O
FPG	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
,	O	O
indicating	O	O
that	O	O
lowering	O	O
of	O	O
A1C	Physical	O
and	O	O
FPG	Physical	O
by	O	O
ranolazine	O	O
is	O	O
related	O	O
to	O	O
hyperglycemia	O	O
at	O	O
randomization	O	O
.	O	O

Ranolazine	O	O
,	O	O
compared	O	O
with	O	O
placebo	O	O
,	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
serious	Adverseeffect	O
hypoglycemic	Adverseeffect	O
events	Adverseeffect	O
,	O	O
associated	O	O
with	O	O
significant	O	O
changes	O	O
in	O	O
concurrent	O	O
antidiabetic	O	O
therapy	O	O
,	O	O
or	O	O
dependent	O	O
on	O	O
a	O	O
history	O	O
of	O	O
angina	O	O
.	O	O

CONCLUSIONS	O	O
Ranolazine	O	O
,	O	O
when	O	O
added	O	O
to	O	O
concurrent	O	O
antidiabetes	O	O
treatment	O	O
,	O	O
lowers	O	O
FPG	Physical	Physical
and	O	Physical
A1C	Physical	Physical
in	O	O
patients	O	O
with	O	O
cardiovascular	O	O
disease	O	O
and	O	O
poorly	O	O
controlled	O	O
diabetes	O	O
.	O	O

Pilot	O	O
comparison	O	O
between	O	O
potassium	O	O
titanyl	O	O
phosphate	O	O
laser	O	O
and	O	O
bipolar	O	O
radiofrequency	O	O
in	O	O
paediatric	O	O
tonsillectomy	O	O
.	O	O

OBJECTIVES	O	O
To	O	O
compare	O	O
the	O	O
advantages	O	O
and	O	O
disadvantages	O	O
of	O	O
potassium	O	O
titanyl	O	O
phosphate	O	O
laser	O	O
with	O	O
those	O	O
of	O	O
bipolar	O	O
radiofrequency	O	O
techniques	O	O
,	O	O
in	O	O
paediatric	O	O
tonsillectomy	O	O
.	O	O

STUDY	O	O
DESIGN	O	O
Prospective	O	O
,	O	O
randomised	O	O
,	O	O
clinical	O	O
study	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
From	O	O
July	O	O
2004	O	O
to	O	O
April	O	O
2006	O	O
,	O	O
80	O	O
patients	O	O
aged	O	O
between	O	O
10	O	O
and	O	O
15	O	O
years	O	O
,	O	O
with	O	O
tonsillectomy	O	O
planned	O	O
for	O	O
chronic	O	O
tonsillitis	O	O
,	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

Children	O	O
were	O	O
prospectively	O	O
randomised	O	O
into	O	O
two	O	O
equal	O	O
groups	O	O
:	O	O
potassium	O	O
titanyl	O	O
phosphate	O	O
laser	O	O
tonsillectomy	O	O
and	O	O
bipolar	O	O
radiofrequency	O	O
tonsillectomy	O	O
.	O	O

Operative	O	Others
time	O	Others
and	O	O
intra-operative	O	O
blood	O	O
loss	O	O
were	O	O
recorded	O	O
.	O	O

Patients	O	O
were	O	O
scheduled	O	O
for	O	O
follow	O	O
up	O	O
during	O	O
the	O	O
first	O	O
,	O	O
second	O	O
and	O	O
fourth	O	O
post-operative	O	O
weeks	O	O
.	O	O

They	O	O
were	O	O
asked	O	O
to	O	O
record	O	O
their	O	O
pain	O	O
and	O	O
discomfort	O	O
on	O	O
a	O	O
standardised	O	O
visual	O	O
analogue	O	O
scale	O	O
,	O	O
from	O	O
zero	O	O
(	O	O
no	O	O
pain	O	O
)	O	O
to	O	O
10	O	O
(	O	O
severe	O	O
pain	O	O
)	O	O
.	O	O

Post-operative	O	Adverseeffect
complications	O	Adverseeffect
were	O	O
also	O	O
recorded	O	O
and	O	O
managed	O	O
.	O	O

RESULTS	O	O
The	O	O
potassium	O	O
titanyl	O	O
phosphate	O	O
laser	O	O
group	O	O
showed	O	O
a	O	O
slightly	O	O
longer	Others	O
operative	Others	Others
time	Others	Others
(	O	O
mean	O	O
12	O	O
minutes	O	O
)	O	O
than	O	O
the	O	O
bipolar	O	O
radiofrequency	O	O
group	O	O
(	O	O
mean	O	O
10	O	O
minutes	O	O
)	O	O
.	O	O

Intra-operative	Physical	Physical
blood	Physical	Physical
loss	Physical	Physical
was	O	O
significantly	O	O
less	O	O
in	O	O
the	O	O
potassium	O	O
titanyl	O	O
phosphate	O	O
laser	O	O
group	O	O
(	O	O
mean	O	O
21	O	O
cm3	O	O
)	O	O
than	O	O
in	O	O
the	O	O
bipolar	O	O
radiofrequency	O	O
group	O	O
(	O	O
mean	O	O
30	O	O
cm3	O	O
)	O	O
.	O	O

In	O	O
the	O	O
first	O	O
week	O	O
,	O	O
post-operative	Pain	Pain
pain	Pain	Pain
scores	Pain	Pain
were	O	O
less	O	O
in	O	O
the	O	O
potassium	O	O
titanyl	O	O
phosphate	O	O
laser	O	O
group	O	O
than	O	O
in	O	O
the	O	O
bipolar	O	O
radiofrequency	O	O
group	O	O
(	O	O
means	O	O
7.5	O	O
and	O	O
8.5	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

However	O	O
,	O	O
in	O	O
the	O	O
second	O	O
week	O	O
pain	Pain	Pain
scores	Pain	Pain
increased	O	O
more	O	O
in	O	O
the	O	O
potassium	O	O
titanyl	O	O
phosphate	O	O
laser	O	O
group	O	O
than	O	O
in	O	O
the	O	O
bipolar	O	O
radiofrequency	O	O
group	O	O
(	O	O
means	O	O
8.5	O	O
and	O	O
6	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

In	O	O
the	O	O
fourth	O	O
week	O	O
,	O	O
both	O	O
groups	O	O
showed	O	O
equal	O	O
and	O	O
nearly	O	Pain
normal	O	Pain
pain	Pain	Pain
scores	Pain	Pain
.	O	Pain

No	O	O
case	O	O
of	O	O
reactionary	Adverseeffect	Physical
post-tonsillectomy	Adverseeffect	Physical
haemorrhage	Adverseeffect	Physical
was	O	O
recorded	O	O
in	O	O
either	O	O
group	O	O
.	O	O

Only	O	O
one	O	O
case	O	O
of	O	O
secondary	Adverseeffect	Physical
post-tonsillectomy	Adverseeffect	Physical
haemorrhage	Adverseeffect	Physical
was	O	O
recorded	O	O
,	O	O
in	O	O
the	O	O
potassium	O	O
titanyl	O	O
phosphate	O	O
laser	O	O
group	O	O
(	O	O
2.5	O	O
per	O	O
cent	O	O
)	O	O
,	O	O
managed	O	O
conservatively	O	O
.	O	O

CONCLUSION	O	O
Both	O	O
the	O	O
potassium	O	O
titanyl	O	O
phosphate	O	O
and	O	O
the	O	O
bipolar	O	O
radiofrequency	O	O
techniques	O	O
were	O	O
safe	Others	O
and	O	O
easy	Others	O
to	Others	O
use	Others	O
for	O	O
tonsillectomy	O	O
,	O	O
with	O	O
reduced	O	O
operative	Others	Others
time	Others	Others
,	O	O
blood	Physical	O
loss	Physical	O
and	O	O
complication	Adverseeffect	Adverseeffect
rates	Adverseeffect	Adverseeffect
and	O	O
better	O	O
post-operative	O	O
general	O	O
patient	O	O
condition	O	O
.	O	O

Potassium	O	O
titanyl	O	O
phosphate	O	O
laser	O	O
resulted	O	O
in	O	O
reduced	O	Physical
operative	Physical	Physical
bleeding	Physical	Physical
and	O	O
immediate	Pain	O
post-operative	Pain	O
pain	Pain	O
,	O	O
compared	O	O
with	O	O
the	O	O
bipolar	O	O
radiofrequency	O	O
technique	O	O
.	O	O

However	O	O
,	O	O
potassium	O	O
titanyl	O	O
phosphate	O	O
laser	O	O
required	O	O
slightly	O	O
more	O	O
operative	Others	Others
time	Others	Others
and	O	O
caused	O	O
more	O	O
late	Pain	O
post-operative	Pain	O
pain	Pain	O
than	O	O
the	O	O
bipolar	O	O
radiofrequency	O	O
technique	O	O
.	O	O

The	O	O
low	O	O
rate	O	O
of	O	O
recorded	O	O
complications	O	O
showed	O	O
that	O	O
both	O	O
techniques	O	O
cause	O	O
little	O	O
damage	O	O
to	O	O
the	O	O
tonsillar	O	O
bed	O	O
during	O	O
dissection	O	O
,	O	O
thus	O	O
minimising	O	O
complications	O	O
.	O	O

Timing	O	O
for	O	O
delivering	O	O
individualized	O	O
patient	O	O
education	O	O
intervention	O	O
to	O	O
Coronary	O	O
Artery	O	O
Bypass	O	O
Graft	O	O
patients	O	O
:	O	O
An	O	O
RCT	O	O
.	O	O

BACKGROUND	O	O
The	O	O
primary	O	O
focus	O	O
of	O	O
this	O	O
study	O	O
is	O	O
on	O	O
the	O	O
timing	O	O
of	O	O
the	O	O
delivery	O	O
of	O	O
education	O	O
to	O	O
patients	O	O
who	O	O
had	O	O
CABG	O	O
surgery	O	O
.	O	O

AIM	O	O
To	O	O
determine	O	O
the	O	O
efficacy	O	O
of	O	O
an	O	O
individualized	O	O
telephone	O	O
patient	O	O
education	O	O
intervention	O	O
,	O	O
delivered	O	O
at	O	O
two	O	O
different	O	O
points	O	O
in	O	O
time	O	O
(	O	O
1-2	O	O
days	O	O
pre-discharge	O	O
versus	O	O
1-2	O	O
days	O	O
post-discharge	O	O
)	O	O
in	O	O
enhancing	O	O
the	O	O
CABG	O	O
patient	O	O
's	O	O
knowledge	O	Mental
of	O	Mental
self-care	O	Mental
behaviours	O	Mental
,	O	Mental
performance	O	Mental
of	O	Mental
self-care	O	Mental
behaviours	O	Mental
,	O	O
and	O	O
symptom	O	Physical
frequency	O	Physical
.	O	O

METHOD	O	O
A	O	O
randomized	O	O
clinical	O	O
trial	O	O
that	O	O
included	O	O
a	O	O
convenience	O	O
sample	O	O
of	O	O
first	O	O
time	O	O
CABG	O	O
patients	O	O
.	O	O

Individuals	O	O
who	O	O
received	O	O
education	O	O
pre-discharge	O	O
were	O	O
compared	O	O
to	O	O
individuals	O	O
who	O	O
received	O	O
education	O	O
post-discharge	O	O
on	O	O
the	O	O
outcomes	O	O
.	O	O

RESULTS	O	O
Results	O	O
indicated	O	O
no	O	O
statistically	O	O
significant	O	O
difference	O	O
in	O	O
outcomes	Others	O
between	Others	O
the	Others	O
two	Others	O
time	Others	O
points	Others	O
.	Others	O

As	O	O
well	O	O
,	O	O
anxiety	Mental	Physical
levels	Mental	Physical
were	O	O
found	O	O
to	O	O
be	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
pre-discharge	O	O
group	O	O
than	O	O
the	O	O
post-discharge	O	O
group	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
individualized	O	O
nature	O	O
of	O	O
the	O	O
educational	O	O
intervention	O	O
may	O	O
have	O	O
accounted	O	O
for	O	O
non-significant	O	O
findings	O	O
reported	O	O
in	O	O
outcomes	O	O
between	O	O
the	O	O
two	O	O
time	O	O
points	O	O
.	O	O

PRACTICE	O	O
IMPLICATIONS	O	O
Nurses	O	O
may	O	O
consider	O	O
assessing	O	O
anxiety	Mental	O
levels	Mental	O
prior	O	O
to	O	O
delivery	O	O
of	O	O
educational	O	O
interventions	O	O
,	O	O
implement	O	O
interventions	O	O
aimed	O	O
at	O	O
reducing	O	O
anxiety	O	Physical
levels	O	Physical
,	O	O
and	O	O
provide	O	O
individualized	O	O
teaching	O	O
.	O	O

Comparative	O	O
efficacy	Others	O
and	O	O
safety	Others	O
of	O	O
twice	O	O
daily	O	O
fluticasone	O	O
propionate	O	O
powder	O	O
versus	O	O
placebo	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
moderate	O	O
asthma	O	O
.	O	O

BACKGROUND	O	O
Fluticasone	O	O
propionate	O	O
,	O	O
an	O	O
inhaled	O	O
corticosteroid	O	O
with	O	O
negligible	O	O
systemic	O	O
bioavailability	O	O
via	O	O
the	O	O
oral	O	O
route	O	O
,	O	O
is	O	O
efficacious	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
asthma	O	O
when	O	O
administered	O	O
via	O	O
metered-dose	O	O
inhaler	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
evaluate	O	O
the	O	O
efficacy	Others	Others
and	O	Others
safety	Others	Others
of	O	O
inhaled	O	O
fluticasone	O	O
propionate	O	O
powder	O	O
in	O	O
patients	O	O
with	O	O
moderate	O	O
asthma	O	O
previously	O	O
treated	O	O
with	O	O
an	O	O
inhaled	O	O
corticosteroid	O	O
.	O	O

METHODS	O	O
This	O	O
was	O	O
a	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
,	O	O
parallel-group	O	O
,	O	O
multicenter	O	O
study	O	O
of	O	O
342	O	O
adolescent	O	O
and	O	O
adult	O	O
patients	O	O
with	O	O
moderate	O	O
asthma	O	O
[	Physical	O
forced	Physical	O
expiratory	Physical	O
volume	Physical	O
in	Physical	O
1	Physical	O
second	Physical	O
(	Physical	O
FEV1	Physical	O
)	Physical	O
between	O	O
50	O	O
%	O	O
and	O	O
80	O	O
%	O	O
of	O	O
predicted	O	O
]	O	O
treated	O	O
previously	O	O
by	O	O
beclomethasone	O	O
dipropionate	O	O
or	O	O
triamcinolone	O	O
acetonide	O	O
.	O	O

Patients	O	O
received	O	O
fluticasone	O	O
propionate	O	O
powder	O	O
50	O	O
micrograms	O	O
,	O	O
100	O	O
micrograms	O	O
,	O	O
250	O	O
micrograms	O	O
,	O	O
or	O	O
placebo	O	O
via	O	O
a	O	O
breath-actuated	O	O
inhalation	O	O
device	O	O
,	O	O
the	O	O
Diskhaler	O	O
,	O	O
twice	O	O
daily	O	O
for	O	O
12	O	O
weeks	O	O
.	O	O

RESULTS	O	O
Patients	O	O
in	O	O
the	O	O
fluticasone	O	O
propionate	O	O
groups	O	O
experienced	O	O
a	O	O
mean	Physical	O
increase	Physical	O
from	Physical	O
baseline	Physical	O
to	Physical	O
endpoint	Physical	O
in	Physical	O
FEV1	Physical	O
ranging	O	O
from	O	O
0.43	O	O
L	O	O
to	O	O
0.47	O	O
L.	O	O
Patients	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
experienced	O	O
a	O	O
mean	O	O
decrease	O	O
from	O	O
baseline	O	O
of	O	O
0.22	O	O
L	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

The	O	O
probability	O	O
of	O	O
patients	O	O
remaining	O	O
in	O	O
the	O	O
study	O	O
over	O	O
time	O	O
without	O	O
developing	O	O
signs	O	O
of	O	O
exacerbating	Physical	O
asthma	Physical	O
was	O	O
significantly	O	O
greater	O	O
in	O	O
the	O	O
fluticasone	O	O
propionate	O	O
groups	O	O
than	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
(	O	O
P	O	O
=	O	O
.001	O	O
)	O	O
.	O	O

Asthma	Physical	O
symptom	Physical	O
scores	Physical	O
,	O	O
supplemental	Others	O
rescue	Others	O
albuterol	Others	O
use	Others	O
,	O	O
and	O	O
number	Physical	O
of	Physical	O
nighttime	Physical	O
awakenings	Physical	O
due	Physical	O
to	Physical	O
asthma	Physical	O
requiring	O	O
treatment	O	O
also	O	O
improved	O	O
significantly	O	O
with	O	O
all	O	O
fluticasone	O	O
propionate	O	O
treatment	O	O
regimens	O	O
compared	O	O
with	O	O
placebo	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
at	O	O
endpoint	O	O
among	O	O
the	O	O
three	O	O
fluticasone	O	O
propionate	O	O
groups	O	O
.	O	O

No	O	O
serious	Adverseeffect	Adverseeffect
drug-related	Adverseeffect	Adverseeffect
adverse	Adverseeffect	Adverseeffect
events	Adverseeffect	Adverseeffect
occurred	O	O
.	O	O

CONCLUSIONS	O	O
Fluticasone	O	O
propionate	O	O
powder	O	O
(	O	O
50	O	O
,	O	O
100	O	O
,	O	O
and	O	O
250	O	O
micrograms	O	O
)	O	O
was	O	O
well-tolerated	Others	Others
and	Physical	O
significantly	Physical	O
improved	Physical	O
lung	Physical	Physical
function	Physical	Physical
in	O	O
patients	O	O
with	O	O
moderate	O	O
asthma	O	O
.	O	O

Effectiveness	O	O
and	O	O
safety	O	O
of	O	O
the	O	O
Levitan	O	O
FPS	O	O
Scope?	O	O
for	O	O
tracheal	O	O
intubation	O	O
under	O	O
general	O	O
anesthesia	O	O
with	O	O
a	O	O
simulated	O	O
difficult	O	O
airway	O	O
.	O	O

PURPOSE	O	O
Studies	O	O
show	O	O
that	O	O
the	O	O
Levitan	O	O
FPS	O	O
(	O	O
first	O	O
pass	O	O
success	O	O
)	O	O
Scope?	O	O
(	O	O
LFS	O	O
)	O	O
is	O	O
analogous	O	O
to	O	O
a	O	O
bougie	O	O
in	O	O
simulated	O	O
difficult	O	O
airways	O	O
with	O	O
comparable	O	O
tracheal	O	O
intubation	O	O
success	O	O
rates	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
tracheal	O	O
intubation	O	O
with	O	O
the	O	O
LFS	O	O
was	O	O
compared	O	O
with	O	O
that	O	O
of	O	O
the	O	O
Macintosh	O	O
laryngoscope	O	O
utilizing	O	O
manual	O	O
in-line	O	O
stabilization	O	O
(	O	O
MILS	O	O
)	O	O
to	O	O
simulate	O	O
difficult	O	O
airways	O	O
.	O	O

METHODS	O	O
Ninety-four	O	O
subjects	O	O
successfully	O	O
completed	O	O
the	O	O
trial	O	O
.	O	O

Manual	O	O
in-line	O	O
stabilization	O	O
of	O	O
the	O	O
cervical	O	O
spine	O	O
was	O	O
applied	O	O
and	O	O
the	O	O
initial	O	O
laryngoscopy	O	O
was	O	O
performed	O	O
using	O	O
either	O	O
the	O	O
Macintosh	O	O
or	O	O
the	O	O
LFS	O	O
in	O	O
conjunction	O	O
with	O	O
the	O	O
Macintosh	O	O
.	O	O

Following	O	O
the	O	O
initial	O	O
grading	O	O
,	O	O
a	O	O
second	O	O
laryngoscopy	O	O
was	O	O
repeated	O	O
using	O	O
the	O	O
second	O	O
randomized	O	O
technique	O	O
.	O	O

Cormack-Lehane	O	O
grades	Physical	O
,	O	O
percentage	Physical	Physical
of	Physical	Physical
glottic	Physical	Physical
opening	Physical	Physical
(	Physical	Physical
POGO	Physical	Physical
)	Physical	Physical
scores	Physical	Physical
,	O	O
time	Others	Others
to	Others	Others
intubate	Others	Others
,	O	O
number	Others	Mental
of	Others	Mental
intubation	Others	Mental
attempts	Others	Mental
,	O	O
and	O	O
the	Others	O
use	Others	O
of	Others	O
alternate	Others	O
techniques	Others	O
were	O	O
recorded	O	O
.	O	O

The	O	O
anesthesiologist	O	O
rated	O	O
the	O	O
subjective	O	O
difficulty	O	O
in	O	O
using	O	O
each	O	O
technique	O	O
with	O	O
a	O	O
numeric	O	Others
rating	O	Others
scale	O	Others
and	O	O
a	O	O
visual	O	O
rating	O	O
scale	O	O
.	O	O

RESULTS	O	O
There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
the	O	O
primary	O	O
outcome	O	O
good	Physical	O
laryngoscopic	Physical	O
views	Physical	O
(	O	O
Cormack-Lehane	Physical	O
grade	Physical	O
1	O	O
and	O	O
2	O	O
)	O	O
compared	O	O
with	O	O
poor	Physical	O
laryngoscopic	Physical	O
views	Physical	O
(	O	O
Cormack-Lehane	Physical	O
grade	Physical	O
3	O	O
and	O	O
4	O	O
)	O	O
between	O	O
the	O	O
LFS	O	O
and	O	O
the	O	O
Macintosh	O	O
.	O	O

There	O	O
were	O	O
higher	O	O
POGO	O	O
scores	O	O
with	O	O
the	O	O
LFS	O	O
compared	O	O
with	O	O
the	O	O
Macintosh	O	O
(	O	O
80	O	O
%	O	O
vs	O	O
20	O	O
%	O	O
,	O	O
respectively	O	O
;	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
,	O	O
but	O	O
this	O	O
did	O	O
not	O	O
translate	O	O
to	O	O
easier	O	O
intubations	O	O
,	O	O
as	O	O
documented	O	O
by	O	O
the	O	O
need	O	Others
for	O	Others
an	O	Others
alternate	O	Others
intubation	O	Others
technique	O	Others
or	O	Others
time	O	Others
to	O	Others
intubate	O	Others
(	O	O
<	O	O
30	O	O
and	O	O
<	O	O
60	O	O
sec	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
incidence	O	Physical
of	Adverseeffect	Physical
mucosal	Adverseeffect	Physical
trauma	Adverseeffect	Physical
,	Adverseeffect	Physical
sore	Adverseeffect	Physical
throat	Adverseeffect	Physical
,	Adverseeffect	Physical
and	Adverseeffect	Physical
hemodynamic	Adverseeffect	Physical
responses	Adverseeffect	Physical
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
the	O	O
two	O	O
techniques	O	O
.	O	O

CONCLUSION	O	O
The	O	O
LFS	O	O
in	O	O
conjunction	O	O
with	O	O
the	O	O
Macintosh	O	O
laryngoscope	O	O
does	O	O
not	O	O
improve	O	O
the	O	O
efficacy	O	O
or	O	O
safety	O	Others
of	O	O
tracheal	O	O
intubation	O	O
in	O	O
a	O	O
simulated	O	O
difficult	O	O
airway	O	O
.	O	O

Genotyping	O	O
of	O	O
CYP21	O	O
,	O	O
linked	O	O
chromosome	O	O
6p	O	O
markers	O	O
,	O	O
and	O	O
a	O	O
sex-specific	O	O
gene	O	O
in	O	O
neonatal	O	O
screening	O	O
for	O	O
congenital	O	O
adrenal	O	O
hyperplasia	O	O
.	O	O

We	O	O
investigated	O	O
the	O	O
feasibility	Others	Others
and	Others	Others
diagnostic	Others	Others
utility	Others	Others
of	O	O
genotyping	O	O
9	O	O
CYP21	O	O
mutations	O	O
,	O	O
linked	O	O
chromosome	O	O
6p	O	O
markers	O	O
,	O	O
and	O	O
a	O	O
dimorphic	O	O
X-Y	O	O
marker	O	O
from	O	O
neonatal	O	O
screening	O	O
samples	O	O
.	O	O

Blood-impregnated	O	O
filter	O	O
papers	O	O
(	O	O
Guthrie	O	O
cards	O	O
)	O	O
from	O	O
603	O	O
randomly	O	O
chosen	O	O
New	O	O
Zealand	O	O
neonates	O	O
were	O	O
genotyped	O	O
blind	O	O
to	O	O
17-hydroxyprogesterone	O	O
(	O	O
17-OHP	O	O
)	O	O
levels	O	O
.	O	O

Another	O	O
50	O	O
samples	O	O
from	O	O
Swiss	O	O
and	O	O
North	O	O
American	O	O
infants	O	O
with	O	O
correlative	O	O
hormonal	O	O
data	O	O
were	O	O
also	O	O
genotyped	O	O
.	O	O

DNA	O	O
was	O	O
extracted	O	O
,	O	O
and	O	O
gene-specific	O	O
PCR	O	O
was	O	O
performed	O	O
.	O	O

CYP21	O	O
PCR	O	O
products	O	O
were	O	O
subjected	O	O
to	O	O
ligase	O	O
detection	O	O
reaction	O	O
,	O	O
simultaneously	O	O
analyzing	O	O
9	O	O
CYP21	O	O
mutations	O	O
;	O	O
PCR	O	O
products	O	O
of	O	O
other	O	O
genes	O	O
were	O	O
subjected	O	O
to	O	O
direct	O	O
gel	O	O
analysis	O	O
.	O	O

CYP21	O	O
genotyping	O	O
indicated	O	O
a	O	O
heterozygote	Physical	O
rate	Physical	O
of	O	O
2.8	O	O
%	O	O
for	O	O
classic	O	O
mutations	O	O
(	O	O
excluding	O	O
CYP21	O	O
deletions	O	O
)	O	O
,	O	O
and	O	O
2.0	O	O
%	O	O
for	O	O
nonclassic	O	O
mutations	O	O
in	O	O
New	O	O
Zealanders	O	O
.	O	O

Ten	O	O
full-term	O	O
affected	O	O
neonates	O	O
showed	O	O
a	O	O
wide	Physical	O
range	Physical	O
of	Physical	O
17-OHP	Physical	O
levels	Physical	O
(	O	O
15-1400	O	O
nmol/L	O	O
)	O	O
.	O	O

Sick	O	O
or	O	O
preterm	O	O
infants	O	O
or	O	O
infants	O	O
screened	O	O
on	O	O
the	O	O
first	O	O
day	O	O
of	O	O
life	O	O
with	O	O
high	O	O
17-OHP	Physical	O
proved	O	O
genetically	O	O
unaffected	O	O
.	O	O

Genetic	Physical	O
linkage	Physical	O
disequilibrium	Physical	O
was	O	O
found	O	O
between	O	O
two	O	O
CYP21	O	O
mutations	O	O
and	O	O
chromosome	O	O
6p	O	O
markers	O	O
.	O	O

Guthrie	O	O
cards	O	O
can	O	O
be	O	O
used	O	O
to	O	O
accurately	O	O
genotype	O	O
CYP21	Physical	O
and	Physical	O
other	Physical	O
relevant	Physical	O
markers	Physical	O
,	O	O
potentially	O	O
enhancing	O	O
the	O	O
specificity	Others	O
and	Others	O
sensitivity	Others	O
of	O	O
congenital	O	O
adrenal	O	O
hyperplasia	O	O
screening	O	O
.	O	O

CYP21	Physical	O
heterozygote	Physical	O
frequency	Physical	O
for	Physical	O
classic	Physical	O
mutations	Physical	O
is	O	O
higher	O	O
than	O	O
expected	O	O
based	O	O
on	O	O
genotype	O	O
compared	O	O
with	O	O
that	O	O
predicted	O	O
by	O	O
hormonal	O	O
newborn	O	O
screening	O	O
.	O	O

Randomized	O	O
trial	O	O
of	O	O
tailored	O	O
skin	O	O
cancer	O	O
prevention	O	O
for	O	O
children	O	O
:	O	O
the	O	O
Project	O	O
SCAPE	O	O
family	O	O
study	O	O
.	O	O

This	O	O
study	O	O
evaluated	O	O
a	O	O
tailored	O	O
intervention	O	O
to	O	O
promote	O	O
sun	O	O
protection	O	O
in	O	O
parents	O	O
and	O	O
their	O	O
children	O	O
,	O	O
hypothesizing	O	O
that	O	O
the	O	O
tailored	O	O
intervention	O	O
would	O	O
lead	O	O
to	O	O
improved	Mental	O
skin	Mental	Physical
cancer	Mental	Physical
prevention	Mental	Physical
behaviors	Mental	Physical
compared	O	O
to	O	O
generic	O	O
materials	O	O
.	O	O

Families	O	O
were	O	O
recruited	O	O
through	O	O
schools	O	O
and	O	O
community	O	O
centers	O	O
and	O	O
were	O	O
included	O	O
if	O	O
there	O	O
was	O	O
1	O	O
child	O	O
in	O	O
Grades	O	O
1-3	O	O
at	O	O
moderate	O	O
to	O	O
high	O	O
risk	O	O
for	O	O
skin	O	O
cancer	O	O
.	O	O

Participants	O	O
were	O	O
randomized	O	O
into	O	O
one	O	O
of	O	O
two	O	O
intervention	O	O
groups	O	O
:	O	O
a	O	O
tailored	O	O
intervention	O	O
,	O	O
in	O	O
which	O	O
they	O	O
received	O	O
personalized	O	O
skin	O	O
cancer	O	O
education	O	O
through	O	O
the	O	O
mail	O	O
;	O	O
or	O	O
a	O	O
control	O	O
group	O	O
who	O	O
received	O	O
generic	O	O
skin	O	O
cancer	O	O
information	O	O
materials	O	O
.	O	O

Before	O	O
and	O	O
after	O	O
intervention	O	O
,	O	O
parents	O	O
completed	O	O
questionnaires	O	O
about	O	O
their	O	O
and	O	O
their	O	O
children	O	O
's	O	O
skin	O	Physical
cancer	O	Physical
risk	O	Physical
and	O	Physical
prevention	O	Mental
knowledge	O	Mental
and	O	Mental
behaviors	O	Mental
.	O	O

Parents	O	O
also	O	O
completed	O	O
4-day	O	O
sun	O	O
exposure	O	O
and	O	O
protection	O	O
diaries	O	O
for	O	O
their	O	O
child	O	O
and	O	O
themselves	O	O
.	O	O

Tailored	O	O
group	O	O
participants	O	O
demonstrated	O	O
significantly	Mental	O
greater	Mental	O
positive	Mental	Mental
changes	Mental	Mental
in	Mental	Mental
prevention	Mental	Mental
behavior	Mental	Mental
after	O	O
the	O	O
intervention	O	O
,	O	O
including	O	O
children	Mental	O
's	Mental	O
use	Mental	O
of	Mental	O
sunscreen	Mental	O
,	Mental	O
shirts	Mental	O
,	Mental	O
and	Mental	O
hats	Mental	O
,	Mental	O
and	Mental	O
parents	Mental	O
'	Mental	O
use	Mental	O
of	Mental	O
shade	Mental	O
,	Mental	O
and	Mental	O
skin	Mental	O
examinations	Mental	O
.	Mental	O

Effect	O	Physical
sizes	O	Physical
were	O	Physical
small	Mental	Physical
and	Mental	O
perceived	Mental	O
benefits	Mental	O
and	Mental	O
social	Mental	O
norms	Mental	O
mediated	Mental	O
intervention	Mental	O
effects	Mental	O
.	Mental	O

Findings	O	O
from	O	O
this	O	O
study	O	O
support	O	O
the	O	O
efficacy	O	O
of	O	O
focusing	O	O
tailored	O	O
communications	O	O
to	O	O
families	O	O
in	O	O
order	O	O
to	O	O
change	O	O
skin	O	O
cancer	O	O
prevention	O	O
practices	O	O
in	O	O
young	O	O
children	O	O
.	O	O

PROCLAIM	O	O
:	O	O
pilot	O	O
study	O	O
to	O	O
examine	O	O
the	O	O
effects	O	O
of	O	O
clopidogrel	O	O
on	O	O
inflammatory	O	O
markers	O	O
in	O	O
patients	O	O
with	O	O
metabolic	O	O
syndrome	O	O
receiving	O	O
low-dose	O	O
aspirin	O	O
.	O	O

Metabolic	O	O
syndrome	O	O
is	O	O
associated	O	O
with	O	O
intravascular	O	O
inflammation	O	O
,	O	O
as	O	O
determined	O	O
by	O	O
increased	O	O
levels	O	O
of	O	O
inflammatory	O	O
biomarkers	O	O
and	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
ischemic	O	O
atherothrombotic	O	O
events	O	O
.	O	O

Evidence	O	O
suggests	O	O
that	O	O
atherothrombosis	O	O
and	O	O
intravascular	O	O
inflammation	O	O
share	O	O
predictive	O	O
biomarkers	O	O
,	O	O
including	O	O
high-sensitivity	O	Physical
C-reactive	O	Physical
protein	O	Physical
,	O	Physical
CD40	O	Physical
ligand	O	Physical
,	O	Physical
P-selectin	O	Physical
,	O	O
and	O	O
N-terminal	O	O
pro-brain	O	O
natriuretic	O	O
peptide	O	O
.	O	O

Patients	O	O
who	O	O
had	O	O
metabolic	O	O
syndrome	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
clopidogrel	O	O
75	O	O
mg/day	O	O
plus	O	O
aspirin	O	O
81	O	O
mg/day	O	O
(	O	O
n	O	O
=	O	O
89	O	O
)	O	O
or	O	O
placebo	O	O
plus	O	O
aspirin	O	O
81	O	O
mg/day	O	O
(	O	O
n	O	O
=	O	O
92	O	O
)	O	O
for	O	O
9	O	O
weeks	O	O
to	O	O
assess	O	O
the	O	O
efficacy	O	O
of	O	O
each	O	O
treatment	O	O
in	O	O
suppression	O	Physical
of	O	Physical
inflammatory	O	Physical
markers	O	Physical
.	O	O

Change	O	O
from	O	O
baseline	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
high-sensitivity	Physical	Physical
C-reactive	Physical	Physical
protein	Physical	Physical
,	O	Physical
CD40	Physical	Physical
ligand	Physical	Physical
,	O	Physical
P-selectin	Physical	Physical
,	O	O
and	O	O
N-terminal	Physical	O
pro-brain	Physical	O
natriuretic	Physical	O
peptide	Physical	O
at	O	O
6	O	O
weeks	O	O
was	O	O
assessed	O	O
to	O	O
evaluate	O	O
each	O	O
treatment	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
at	O	O
Week	O	O
6	O	O
in	O	O
model-adjusted	Physical	O
CD40-ligand	Physical	O
levels	Physical	O
in	O	O
favor	O	O
of	O	O
clopidogrel	O	O
plus	O	O
aspirin	O	O
compared	O	O
with	O	O
placebo	O	O
plus	O	O
aspirin	O	O
in	O	O
both	O	O
the	O	O
intent-to-treat	O	O
population	O	O
(	O	O
difference	O	O
between	O	O
least-squares	O	O
means	O	O
=	O	O
-186.5	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
-342.3	O	O
to	O	O
-30.8	O	O
;	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
and	O	O
the	O	O
per-protocol	O	O
population	O	O
(	O	O
P	O	O
=	O	O
0.05	O	O
)	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
were	O	O
observed	O	O
between	O	O
the	O	O
treatment	O	O
arms	O	O
for	O	O
high-sensitivity	Physical	O
C-reactive	Physical	O
protein	Physical	O
,	O	O
P-selectin	Physical	Physical
,	O	O
and	O	O
N-terminal	Physical	O
pro-brain	Physical	O
natriuretic	Physical	O
peptide	Physical	O
.	O	O

There	O	O
were	O	O
no	O	O
deaths	Mortality	Adverseeffect
or	O	Adverseeffect
serious	Adverseeffect	Adverseeffect
adverse	Adverseeffect	Adverseeffect
events	Adverseeffect	Adverseeffect
in	O	O
either	O	O
treatment	O	O
arm	O	O
.	O	O

Data	O	O
from	O	O
this	O	O
study	O	O
suggest	O	O
that	O	O
clopidogrel	O	O
can	O	O
decrease	O	O
the	O	O
expression	Physical	O
of	Physical	O
the	Physical	O
CD40-ligand	Physical	O
biomarker	Physical	O
.	O	O

Optimization	O	O
of	O	O
acid	O	O
suppression	O	O
for	O	O
patients	O	O
with	O	O
peptic	O	O
ulcer	O	O
bleeding	O	O
:	O	O
an	O	O
intragastric	O	O
pH-metry	O	O
study	O	O
with	O	O
omeprazole	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
study	O	O
whether	O	O
an	O	O
intravenous	O	O
infusion	O	O
dose	O	O
of	O	O
omeprazole	O	O
(	O	O
80	O	O
mg	O	O
+	O	O
8	O	O
mg/h	O	O
)	O	O
during	O	O
24	O	O
h	O	O
can	O	O
be	O	O
subsequently	O	O
reduced	O	O
with	O	O
maintained	O	O
effect	O	O
.	O	O

Second	O	O
,	O	O
to	O	O
study	O	O
the	O	O
effect	O	O
of	O	O
oral	O	O
omeprazole	O	O
20	O	O
mg	O	O
given	O	O
once	O	O
or	O	O
twice	O	O
daily	O	O
up	O	O
to	O	O
day	O	O
10	O	O
,	O	O
after	O	O
cessation	O	O
of	O	O
a	O	O
3-day	O	O
intravenous	O	O
infusion	O	O
(	O	O
80	O	O
mg	O	O
+	O	O
8	O	O
mg/h	O	O
)	O	O
.	O	O

DESIGN	O	O
Prospective	O	O
,	O	O
randomized	O	O
,	O	O
partly	O	O
blinded	O	O
study	O	O
.	O	O

METHODS	O	O
Twelve	O	O
Helicobacter	O	O
pylori	O	O
(	O	O
+	O	O
)	O	O
patients	O	O
and	O	O
12	O	O
H.	O	O
pylori	O	O
(	O	O
-	O	O
)	O	O
subjects	O	O
were	O	O
included	O	O
.	O	O

In	O	O
part	O	O
I	O	O
the	O	O
patients	O	O
received	O	O
omeprazole	O	O
,	O	O
80	O	O
mg	O	O
+	O	O
8	O	O
mg/h	O	O
,	O	O
during	O	O
24	O	O
h	O	O
followed	O	O
by	O	O
8	O	O
,	O	O
4	O	O
or	O	O
2	O	O
mg/h	O	O
.	O	O

In	O	O
part	O	O
II	O	O
the	O	O
subjects	O	O
received	O	O
80	O	O
mg	O	O
+	O	O
8	O	O
mg/h	O	O
during	O	O
3	O	O
days	O	O
followed	O	O
by	O	O
20	O	O
mg	O	O
omeprazole	O	O
orally	O	O
,	O	O
once	O	O
or	O	O
twice	O	O
daily	O	O
until	O	O
day	O	O
10	O	O
.	O	O

Intragastric	Physical	Physical
pH	Physical	Physical
was	O	O
measured	O	O
.	O	O

RESULTS	O	O
All	O	O
H.	O	O
pylori	O	O
(	O	O
+	O	O
)	O	O
patients	O	O
showed	O	O
a	O	O
rapid	O	O
increase	O	O
of	O	O
intragastric	Physical	Physical
pH	Physical	Physical
with	Physical	O
a	Physical	O
mean	Physical	Physical
intragastric	Physical	Physical
pH	Physical	Physical
of	O	O
6.7	O	O
during	O	O
the	O	O
second	O	O
half	O	O
of	O	O
the	O	O
first	O	O
day	O	O
.	O	O

After	O	O
the	O	O
subsequent	O	O
dose	O	O
reduction	O	O
,	O	O
the	O	O
mean	Physical	Physical
pH	Physical	Physical
decreased	O	O
to	O	O
6.1-6.2	O	O
.	O	O

Patients	O	O
continuing	O	O
on	O	O
8	O	O
mg/h	O	O
showed	O	O
the	O	O
best	O	O
results	O	O
.	O	O

Likewise	O	O
,	O	O
all	O	O
H.	O	O
pylori	O	O
(	O	O
-	O	O
)	O	O
subjects	O	O
showed	O	O
a	O	O
rapid	O	O
and	O	O
sustained	O	O
reduction	O	O
of	O	O
intragastric	Physical	O
acidity	Physical	O
during	O	O
the	O	O
infusion	O	O
.	O	O

Subsequent	O	O
dose	O	O
reduction	O	O
to	O	O
20	O	O
mg	O	O
once	O	O
daily	O	O
led	O	O
to	O	O
a	O	O
stable	O	O
fraction	O	O
of	O	O
time	O	O
with	O	O
pH	O	O
>	O	O
3	O	O
of	O	O
72	O	O
%	O	O
.	O	O

CONCLUSIONS	O	O
Omeprazole	O	O
given	O	O
as	O	O
a	O	O
continuous	O	O
infusion	O	O
of	O	O
80	O	O
mg	O	O
+	O	O
8	O	O
mg/h	O	O
for	O	O
72	O	O
h	O	O
followed	O	O
by	O	O
omeprazole	O	O
20	O	O
mg	O	O
once	O	O
daily	O	O
raised	O	O
the	O	O
intragastric	Physical	Physical
pH	Physical	Physical
to	O	O
and	O	O
above	O	O
levels	O	O
alleged	O	O
to	O	O
allow	O	O
haemostasis	O	O
in	O	O
patients	O	O
with	O	O
peptic	O	O
ulcer	O	O
bleeding	O	O
and	O	O
subsequent	O	O
healing	O	O
of	O	O
the	O	O
ulcer	O	O
.	O	O

B-domain	O	O
deleted	O	O
recombinant	O	O
factor	O	O
VIII	O	O
preparations	O	O
are	O	O
bioequivalent	O	O
to	O	O
a	O	O
monoclonal	O	O
antibody	O	O
purified	O	O
plasma-derived	O	O
factor	O	O
VIII	O	O
concentrate	O	O
:	O	O
a	O	O
randomized	O	O
,	O	O
three-way	O	O
crossover	O	O
study	O	O
.	O	O

BACKGROUND	O	O
Deletion	O	O
of	O	O
the	O	O
B-domain	O	O
of	O	O
recombinant	O	O
blood	O	O
coagulation	O	O
factor	O	O
VIII	O	O
(	O	O
BDDrFVIII	O	O
)	O	O
increases	O	O
the	O	O
manufacturing	O	O
yield	O	O
of	O	O
the	O	O
product	O	O
but	O	O
does	O	O
not	O	O
impair	O	O
in	O	O
vitro	O	O
or	O	O
in	O	O
vivo	O	O
functionality	O	O
.	O	O

BDDrFVIII	O	O
(	O	O
ReFacto	O	O
)	O	O
has	O	O
been	O	O
developed	O	O
with	O	O
the	O	O
additional	O	O
benefit	O	O
of	O	O
being	O	O
formulated	O	O
without	O	O
human	O	O
albumin	O	O
.	O	O

OBJECTIVE	O	O
The	O	O
primary	O	O
objective	O	O
of	O	O
this	O	O
three-way	O	O
crossover-design	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
the	O	O
pharmacokinetic	O	O
(	O	O
PK	O	O
)	O	O
parameters	O	O
of	O	O
two	O	O
BDDrFVIII	O	O
formulations	O	O
(	O	O
one	O	O
reconstituted	O	O
with	O	O
5	O	O
mL	O	O
of	O	O
sterile	O	O
water	O	O
,	O	O
the	O	O
other	O	O
reconstituted	O	O
with	O	O
4	O	O
mL	O	O
sodium	O	O
chloride	O	O
0.9	O	O
%	O	O
USP	O	O
)	O	O
with	O	O
those	O	O
of	O	O
a	O	O
plasma-derived	O	O
,	O	O
full-length	O	O
FVIII	O	O
preparation	O	O
(	O	O
Hemofil	O	O
M	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
haemophilia	O	O
A	O	O
to	O	O
determine	O	O
bioequivalence	O	O
.	O	O

METHODS	O	O
A	O	O
series	O	O
of	O	O
blood	Physical	O
samples	Physical	O
were	O	O
collected	O	O
over	O	O
a	O	O
period	O	O
of	O	O
48	O	O
h	O	O
after	O	O
i.v	O	O
.	O	O

administration	O	O
of	O	O
each	O	O
of	O	O
the	O	O
FVIII	O	O
preparations	O	O
.	O	O

Plasma	Physical	O
FVIII	Physical	O
activity	Physical	O
was	O	O
determined	O	O
using	O	O
a	O	O
validated	O	O
chromogenic	O	O
substrate	O	O
assay	O	O
.	O	O

Plasma	Physical	O
FVIII	Physical	O
activity	Physical	O
vs.	O	O
time	Others	O
curves	Others	O
was	O	O
characterized	O	O
for	O	O
a	O	O
standard	O	O
set	O	O
of	O	O
PK	O	O
parameter	O	O
estimates	O	O
.	O	O

Two	O	O
parameter	O	O
estimates	O	O
,	O	O
the	O	O
maximum	Physical	Others
plasma	Physical	Others
concentration	Physical	Others
(	Physical	Others
Cmax	Physical	Others
)	Physical	Others
and	O	O
the	Physical	O
area	Physical	O
under	Physical	O
plasma	Physical	O
concentration	Physical	O
vs.	O	O
time	Physical	O
curves	Physical	O
(	Physical	O
AUCs	Physical	O
)	Physical	O
,	O	O
were	O	O
used	O	O
to	O	O
evaluate	O	O
bioequivalence	O	O
.	O	O

The	O	O
two	O	O
preparations	O	O
were	O	O
considered	O	O
bioequivalent	O	O
if	O	O
the	O	O
90	O	O
%	O	O
confidence	O	O
intervals	O	O
for	O	O
the	O	O
ratio	Physical	O
of	Physical	O
geometric	Physical	O
means	Physical	O
for	Physical	O
Cmax	Physical	O
and	O	O
AUCs	Physical	O
fell	O	O
within	O	O
the	O	O
bioequivalence	O	O
window	O	O
of	O	O
80	O	O
%	O	O
to	O	O
125	O	O
%	O	O
.	O	O

RESULTS/CONCLUSION	O	O
Results	O	O
show	O	O
that	O	O
each	O	O
BDDrFVIII	O	O
formulation	O	O
is	O	O
bioequivalent	Physical	O
to	O	O
Hemofil	O	O
M	O	O
and	O	O
the	O	O
two	O	O
formulations	O	O
of	O	O
BDDrFVIII	O	O
are	O	O
bioequivalent	O	O
to	O	O
each	O	O
other	O	O
.	O	O

Information	O	O
source	O	O
affects	O	O
peers	O	Mental
'	O	Mental
initial	O	Mental
attitudes	O	Mental
toward	O	Mental
autism	Physical	Mental
.	O	O

Authors	O	O
examined	O	O
the	O	O
effects	O	O
of	O	O
information	O	O
source	O	O
on	O	O
peers	O	Mental
'	O	Mental
cognitive	Mental	Mental
and	Mental	Mental
behavioral	Mental	Mental
attitudes	Mental	Mental
toward	O	O
an	O	O
unfamiliar	O	O
child	O	O
with	O	O
autism	O	O
.	O	O

Children	O	O
(	O	O
N=296	O	O
;	O	O
M	O	O
age=10.21	O	O
years	O	O
)	O	O
received	O	O
information	O	O
about	O	O
an	O	O
unfamiliar	O	O
child	O	O
with	O	O
autism	O	O
from	O	O
one	O	O
of	O	O
the	O	O
following	O	O
sources	O	O
:	O	O
(	O	O
a	O	O
)	O	O
videotape	O	O
,	O	O
(	O	O
b	O	O
)	O	O
teacher	O	O
,	O	O
(	O	O
c	O	O
)	O	O
hypothetical	O	O
mother	O	O
,	O	O
(	O	O
d	O	O
)	O	O
hypothetical	O	O
father	O	O
,	O	O
or	O	O
(	O	O
e	O	O
)	O	O
hypothetical	O	O
doctor	O	O
.	O	O

Interactive	O	O
effects	O	O
between	O	O
source	O	O
,	O	O
and	O	O
sex	O	O
and	O	O
grade	O	O
were	O	O
found	O	O
for	O	O
cognitive	O	O
and	O	O
behavioral	O	Mental
attitudes	O	Mental
.	O	O

Fifth-graders	O	O
reported	O	O
more	O	O
favorable	O	Mental
cognitive	Mental	Mental
and	Mental	Mental
behavioral	Mental	Mental
attitudes	Mental	Mental
when	O	O
information	O	O
was	O	O
provided	O	O
by	O	O
extra-familial	O	O
sources	O	O
(	O	O
i.e.	O	O
,	O	O
doctor	O	O
)	O	O
versus	O	O
parent	O	O
sources	O	O
.	O	O

Mother	O	O
yielded	O	O
more	O	O
persuasive	Mental	O
effects	Mental	O
on	Mental	O
behavioral	Mental	Mental
attitudes	Mental	Mental
for	O	O
third-graders	O	O
versus	O	O
fifth-graders	O	O
.	O	O

Attitudes	O	O
toward	O	O
autism	O	O
differ	O	O
depending	O	O
on	O	O
who	O	O
provides	O	O
information	O	O
about	O	O
the	O	O
disability	O	O
.	O	O

Persuasion	O	O
theory	O	O
appears	O	O
useful	O	O
to	O	O
guide	O	O
evaluation	O	O
of	O	O
educational	O	O
interventions	O	O
to	O	O
improve	O	O
attitudes	O	O
towards	O	O
autism	Mental	O
.	O	O

Implications	O	O
of	O	O
the	O	O
findings	O	O
,	O	O
study	O	O
limitations	O	O
,	O	O
and	O	O
recommendations	O	O
for	O	O
future	O	O
research	O	O
are	O	O
discussed	O	O
.	O	O

Efficacy	O	O
of	O	O
a	O	O
family	O	O
practice-based	O	O
lifestyle	O	O
intervention	O	O
program	O	O
to	O	O
increase	O	O
physical	Others	O
activity	Others	O
and	O	O
reduce	O	O
clinical	O	Physical
and	O	Physical
physiological	O	Physical
markers	O	Physical
of	O	Physical
vascular	O	Physical
health	O	Physical
in	O	O
patients	O	O
with	O	O
high	O	O
normal	O	O
blood	O	O
pressure	O	O
and/or	O	O
high	O	O
normal	O	O
blood	O	O
glucose	O	O
(	O	O
SNAC	O	O
)	O	O
:	O	O
study	O	O
protocol	O	O
for	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
Previous	O	O
interventions	O	O
to	O	O
increase	O	O
physical	Physical	O
activity	Physical	O
and	O	O
reduce	O	O
cardiovascular	O	O
risk	O	O
factors	O	O
have	O	O
been	O	O
targeted	O	O
at	O	O
individuals	O	O
with	O	O
established	O	O
disease	O	O
;	O	O
less	O	O
attention	O	O
has	O	O
been	O	O
given	O	O
to	O	O
intervention	O	O
among	O	O
individuals	O	O
with	O	O
high	O	O
risk	O	O
for	O	O
disease	O	O
nor	O	O
has	O	O
there	O	O
been	O	O
determination	O	O
of	O	O
the	O	O
influence	O	O
of	O	O
setting	O	O
in	O	O
which	O	O
the	O	O
intervention	O	O
is	O	O
provided	O	O
.	O	O

In	O	O
particular	O	O
,	O	O
family	O	O
practice	O	O
represents	O	O
an	O	O
ideal	O	O
setting	O	O
for	O	O
the	O	O
provision	O	O
and	O	O
long-term	O	O
maintenance	O	O
of	O	O
lifestyle	O	O
interventions	O	O
for	O	O
patients	O	O
at	O	O
risk	O	O
(	O	O
ie	O	O
high-normal	O	O
blood	O	O
pressure	O	O
or	O	O
impaired	O	O
glucose	O	O
tolerance	O	O
)	O	O
.	O	O

METHODS/DESIGN	O	O
The	O	O
Staged	O	O
Nutrition	O	O
and	O	O
Activity	O	O
Counseling	O	O
(	O	O
SNAC	O	O
)	O	O
study	O	O
is	O	O
a	O	O
randomized	O	O
clustered	O	O
design	O	O
clinical	O	O
trial	O	O
that	O	O
will	O	O
investigate	O	O
the	O	O
effectiveness	O	Others
and	O	Others
efficacy	O	Others
of	O	O
a	O	O
multi-component	O	O
lifestyle	O	O
intervention	O	O
on	O	O
cardiovascular	O	O
disease	O	O
risk	O	O
factors	O	O
and	O	O
vascular	O	O
function	O	O
in	O	O
patients	O	O
at	O	O
risk	O	O
in	O	O
primary	O	O
care	O	O
.	O	O

Patients	O	O
will	O	O
be	O	O
randomized	O	O
by	O	O
practice	O	O
to	O	O
either	O	O
a	O	O
standard	O	O
of	O	O
care	O	O
lifestyle	O	O
intervention	O	O
or	O	O
a	O	O
behaviourally-based	O	O
,	O	O
matched	O	O
prescriptive	O	O
physical	O	O
activity	O	O
and	O	O
diet	O	O
change	O	O
program	O	O
.	O	O

The	O	O
primary	O	O
goal	O	O
is	O	O
to	O	O
increase	O	O
physical	Others	O
activity	Others	O
and	O	O
improve	O	O
dietary	Mental	O
intake	Mental	O
according	O	O
to	O	O
Canada	O	O
's	O	O
Guides	O	O
to	O	O
Physical	Mental	O
Activity	Mental	O
Healthy	Mental	O
Eating	Mental	O
over	O	O
24	O	O
months	O	O
.	O	O

The	O	O
primary	O	O
intention	O	O
to	O	O
treat	O	O
analysis	O	O
will	O	O
compare	O	O
behavioral	O	O
,	O	O
physiological	O	Physical
and	O	Physical
metabolic	O	Physical
outcomes	O	Physical
at	O	O
6	O	O
,	O	O
12	O	O
and	O	O
24	O	O
months	O	O
post-randomization	O	O
including	O	O
estimation	O	O
of	O	O
incident	O	O
hypertension	Physical	O
and/or	O	O
diabetes	Physical	O
.	O	O

DISCUSSION	O	O
The	O	O
design	O	O
features	O	O
of	O	O
our	O	O
trial	O	O
,	O	O
and	O	O
the	O	O
practical	O	O
problems	O	O
(	O	O
and	O	O
solutions	O	O
)	O	O
associated	O	O
with	O	O
implementing	O	O
these	O	O
design	O	O
features	O	O
,	O	O
particularly	O	O
those	O	O
that	O	O
result	O	O
in	O	O
potential	O	O
delay	O	O
between	O	O
recruitment	O	O
,	O	O
baseline	O	O
data	O	O
collection	O	O
,	O	O
randomization	O	O
,	O	O
intervention	O	O
,	O	O
and	O	O
assessment	O	O
will	O	O
be	O	O
discussed	O	O
.	O	O

Results	O	O
of	O	O
the	O	O
SNAC	O	O
trial	O	O
will	O	O
provide	O	O
scientific	O	O
rationale	O	O
for	O	O
the	O	O
implementation	O	O
of	O	O
this	O	O
lifestyle	O	O
intervention	O	O
in	O	O
primary	O	O
care	O	O
.	O	O

TRIAL	O	O
REGISTRATION	O	O
ISRCTN	O	O
:	O	O
ISRCTN:42921300	O	O
.	O	O

Perioperative	O	O
myocardial	O	O
infarctions	O	O
are	O	O
common	O	O
and	O	O
often	O	O
unrecognized	O	O
in	O	O
patients	O	O
undergoing	O	O
hip	O	O
fracture	O	O
surgery	O	O
.	O	O

BACKGROUND	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
prospective	O	O
cohort	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
incidence	O	O
and	O	O
characteristics	O	O
of	O	O
acute	O	O
myocardial	O	O
infarction	O	O
in	O	O
patients	O	O
undergoing	O	O
surgery	O	O
for	O	O
acute	O	O
hip	O	O
fracture	O	O
.	O	O

METHODS	O	O
A	O	O
consecutive	O	O
cohort	O	O
of	O	O
patients	O	O
(	O	O
n	O	O
=	O	O
200	O	O
,	O	O
68	O	O
men	O	O
)	O	O
referred	O	O
to	O	O
acute	O	O
surgical	O	O
correction	O	O
of	O	O
hip	O	O
fracture	O	O
was	O	O
studied	O	O
.	O	O

Troponin	O	Physical
T	O	Physical
(	O	Physical
TnT	O	Physical
)	O	Physical
measurements	O	Physical
and	O	Physical
electrocardiographic	O	Physical
(	O	Physical
ECG	O	Physical
)	O	Physical
recordings	O	Physical
were	O	O
performed	O	O
at	O	O
admission	O	O
,	O	O
before	O	O
operation	O	O
,	O	O
and	O	O
on	O	O
the	O	O
first	O	O
and	O	O
2nd	O	O
postoperative	O	O
days	O	O
,	O	O
which	O	O
were	O	O
used	O	O
for	O	O
diagnosis	O	O
.	O	O

RESULTS	O	O
The	O	O
age	O	O
of	O	O
the	O	O
patients	O	O
ranged	O	O
from	O	O
32	O	O
to	O	O
98	O	O
years	O	O
(	O	O
mean	O	O
,	O	O
80.8	O	O
years	O	O
)	O	O
,	O	O
and	O	O
65	O	O
patients	O	O
had	O	O
a	O	O
history	O	O
of	O	O
coronary	O	O
artery	O	O
disease	O	O
.	O	O

A	O	O
significant	O	O
rise	Physical	O
in	Physical	O
TnT	Physical	O
as	O	O
a	O	O
sign	O	O
of	O	O
myocardial	O	O
infarction	O	O
was	O	O
observed	O	O
in	O	O
71	O	O
patients	O	O
(	O	O
35.5	O	O
%	O	O
)	O	O
,	O	O
and	O	O
25	O	O
of	O	O
them	O	O
had	O	O
a	O	O
TnT	Physical	O
elevation	Physical	O
exceeding	O	O
five	O	O
times	O	O
the	O	O
upper	O	O
normal	O	O
limit	O	O
.	O	O

TnT	Physical	O
elevation	Physical	O
was	O	O
observed	O	O
in	O	O
36	O	O
patients	O	O
(	O	O
51	O	O
%	O	O
)	O	O
already	O	O
before	O	O
surgery	O	O
.	O	O

Seven	O	O
patients	O	O
(	O	O
10	O	O
%	O	O
)	O	O
had	O	O
ST	O	O
elevation	O	O
myocardial	O	O
infarction	O	O
,	O	O
23	O	O
patients	O	O
(	O	O
32	O	O
%	O	O
)	O	O
had	O	O
new	Physical	Physical
ST	Physical	Physical
depressions	Physical	Physical
,	O	O
and	O	O
21	O	O
patients	O	O
(	O	O
30	O	O
%	O	O
)	O	O
had	O	O
no	O	O
new	O	O
ST	O	O
segment	O	O
changes	O	O
in	O	O
the	O	O
serial	O	Others
electrocardiographic	O	Others
recordings	O	Others
.	O	O

In	O	O
40	O	O
patients	O	O
(	O	O
56	O	O
%	O	O
)	O	O
,	O	O
the	O	O
perioperative	O	Physical
myocardial	O	Physical
infarction	O	Physical
was	O	O
the	O	O
first	O	O
manifestation	O	O
of	O	O
coronary	O	O
artery	O	O
disease	O	O
.	O	O

Multivariate	O	O
logistic	O	O
regression	O	O
revealed	O	O
that	O	O
old	O	O
age	O	O
(	O	O
odds	O	O
ratio	O	O
[	O	O
OR	O	O
]	O	O
,	O	O
1.06	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
,	O	O
1.02-1.10	O	O
;	O	O
p	O	O
=	O	O
0.002	O	O
)	O	O
,	O	O
earlier	O	O
revascularization	O	O
(	O	O
OR	O	O
,	O	O
3.29	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
1.12-9.73	O	O
;	O	O
p	O	O
=	O	O
0.03	O	O
)	O	O
,	O	O
and	O	O
heart	O	Physical
failure	O	Physical
(	O	O
OR	O	O
,	O	O
2.42	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
1.04-5.61	O	O
;	O	O
p	O	O
=	O	O
0.04	O	O
)	O	O
were	O	O
independent	O	O
predictors	O	O
of	O	O
TnT	O	O
elevation	O	O
.	O	O

Majority	O	O
of	O	O
myocardial	Physical	O
infarctions	Physical	O
were	O	O
asymptomatic	O	O
or	O	O
unrecognized	O	O
.	O	O

Evidence-based	O	O
medications	O	O
of	O	O
myocardial	O	O
infarction	O	O
were	O	O
seldom	O	O
started	O	O
and	O	O
cardiologist	O	O
was	O	O
consulted	O	O
in	O	O
12	O	O
patients	O	O
(	O	O
16.9	O	O
%	O	O
)	O	O
.	O	O

CONCLUSION	O	O
Patients	O	O
with	O	O
hip	O	O
fracture	O	O
often	O	O
develop	O	O
asymptomatic	O	O
and	O	O
clinically	O	O
unrecognized	O	O
perioperative	O	O
myocardial	O	O
infarctions	O	O
.	O	O

Earlier	O	O
diagnosis	O	O
and	O	O
appropriate	O	O
treatment	O	O
of	O	O
cardiac	O	O
infarction	O	O
may	O	O
improve	O	O
survival	O	O
of	O	O
hip	O	O
fracture	O	O
patients	O	O
.	O	O

LEVEL	O	O
OF	O	O
EVIDENCE	O	O
Epidemiologic	O	O
study	O	O
,	O	O
level	O	O
III	O	O
.	O	O

Dose	O	O
response	O	O
effect	O	O
of	O	O
cyclical	O	O
medroxyprogesterone	O	O
on	O	O
blood	Physical	Physical
pressure	Physical	Physical
in	O	O
postmenopausal	O	O
women	O	O
.	O	O

OBJECTIVE	O	O
This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
compare	O	O
with	O	O
placebo	O	O
the	O	O
dose-response	O	O
effect	O	O
of	O	O
cyclical	O	O
doses	O	O
of	O	O
the	O	O
C21	O	O
progestogen	O	O
,	O	O
medroxyprogesterone	O	O
acetate	O	O
(	O	O
MPA	O	O
)	O	O
on	O	O
blood	O	Physical
pressure	O	Physical
(	O	Physical
BP	O	Physical
)	O	Physical
when	O	O
administered	O	O
to	O	O
normotensive	O	O
postmenopausal	O	O
women	O	O
receiving	O	O
a	O	O
fixed	O	O
mid-range	O	O
daily	O	O
dose	O	O
of	O	O
conjugated	O	O
equine	O	O
oestrogen	O	O
(	O	O
CEE	O	O
)	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
Twenty	O	O
normotensive	O	O
postmenopausal	O	O
women	O	O
(	O	O
median	O	O
age	O	O
53	O	O
years	O	O
)	O	O
participated	O	O
in	O	O
the	O	O
study	O	O
which	O	O
used	O	O
a	O	O
double-blind	O	O
crossover	O	O
design	O	O
.	O	O

There	O	O
were	O	O
four	O	O
randomised	O	O
treatment	O	O
phases	O	O
,	O	O
each	O	O
of	O	O
4	O	O
weeks	O	O
duration	O	O
.	O	O

The	O	O
four	O	O
blinded	O	O
treatments	O	O
were	O	O
MPA	O	O
2.5	O	O
mg	O	O
,	O	O
MPA	O	O
5	O	O
mg	O	O
,	O	O
MPA	O	O
10	O	O
mg	O	O
and	O	O
matching	O	O
placebo	O	O
,	O	O
taken	O	O
for	O	O
the	O	O
last	O	O
14	O	O
days	O	O
of	O	O
each	O	O
28	O	O
day	O	O
treatment	O	O
cycle	O	O
.	O	O

CEE	O	O
0.625	O	O
mg	O	O
was	O	O
also	O	O
administered	O	O
once	O	O
daily	O	O
as	O	O
open	O	O
labelled	O	O
tablets	O	O
to	O	O
all	O	O
subjects	O	O
throughout	O	O
the	O	O
study	O	O
.	O	O

Clinic	Physical	Physical
BP	Physical	Physical
was	O	O
measured	O	O
weekly	O	O
with	O	O
the	O	O
mean	O	O
values	O	O
of	O	O
weeks	O	O
3	O	O
and	O	O
4	O	O
of	O	O
each	O	O
phase	O	O
used	O	O
for	O	O
analysis	O	O
.	O	O

Ambulatory	Physical	Mental
BP	Physical	Mental
was	O	O
performed	O	O
in	O	O
the	O	O
final	O	O
week	O	O
of	O	O
each	O	O
phase	O	O
.	O	O

RESULTS	O	O
Compared	O	O
with	O	O
the	O	O
placebo	O	O
phase	O	O
,	O	O
end	O	O
of	O	O
phase	O	Physical
clinic	Physical	Physical
BP	Physical	Physical
was	O	O
unchanged	O	O
by	O	O
any	O	O
of	O	O
the	O	O
progestogen	O	O
treatments	O	O
.	O	O

There	O	O
was	O	O
a	O	O
dose-dependent	O	O
decrease	Physical	O
in	Physical	O
ambulatory	Physical	Physical
daytime	Physical	Physical
diastolic	Physical	Physical
and	Physical	Physical
mean	Physical	Physical
arterial	Physical	Physical
BP	Physical	Physical
with	O	O
the	O	O
progestogen	O	O
treatments	O	O
compared	O	O
with	O	O
placebo	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

CONCLUSION	O	O
In	O	O
a	O	O
regimen	O	O
of	O	O
postmenopausal	O	O
hormone	O	O
replacement	O	O
therapy	O	O
with	O	O
a	O	O
fixed	O	O
mid-range	O	O
daily	O	O
dose	O	O
of	O	O
CEE	O	O
combined	O	O
with	O	O
a	O	O
cyclical	O	O
regimen	O	O
of	O	O
a	O	O
C21	O	O
progestogen	O	O
spanning	O	O
the	O	O
current	O	O
clinical	O	O
dose	O	O
range	O	O
,	O	O
the	O	O
progestogen	O	O
has	O	O
either	O	O
no	O	O
effect	O	O
or	O	O
a	O	O
small	O	O
dose-dependent	O	O
reduction	O	O
in	O	O
clinic	Physical	Physical
and	Physical	Physical
ambulatory	Physical	Physical
BPs	Physical	Physical
over	O	O
one	O	O
treatment	O	O
cycle	O	O
.	O	O

Moderate	O	O
sodium	O	O
restriction	O	O
,	O	O
angiotensin	O	Physical
converting	O	Physical
enzyme	O	Physical
inhibition	O	Physical
,	O	O
and	O	O
thiazide	O	O
diuretic	O	O
in	O	O
the	O	O
management	O	O
of	O	O
essential	O	O
hypertension	O	O
.	O	O

Dietary	O	O
sodium	O	O
restriction	O	O
alone	O	O
is	O	O
effective	O	O
in	O	O
lowering	O	O
blood	Physical	Physical
pressure	Physical	Physical
in	O	O
some	O	O
,	O	O
but	O	O
not	O	O
all	O	O
,	O	O
patients	O	O
with	O	O
essential	O	O
hypertension	O	O
.	O	O

Homeostatic	O	O
mechanisms	O	O
,	O	O
including	O	O
activation	O	O
of	O	O
the	O	O
renin-aldosterone	O	O
system	O	O
,	O	O
may	O	O
counteract	O	O
the	O	O
effects	O	O
of	O	O
sodium	O	O
restriction	O	O
.	O	O

Angiotensin	O	O
converting	O	O
enzyme	O	O
(	O	O
ACE	O	O
)	O	O
inhibitors	O	O
are	O	O
also	O	O
effective	Others	Others
as	O	O
sole	O	O
therapy	O	O
in	O	O
many	O	O
patients	O	O
with	O	O
essential	O	O
hypertension	O	O
,	O	O
but	O	O
may	O	O
be	O	O
less	O	O
effective	O	O
in	O	O
those	O	O
with	O	O
low-renin	O	O
hypertension	O	O
.	O	O

The	O	O
combination	O	O
of	O	O
dietary	O	O
sodium	O	O
restriction	O	O
with	O	O
blockade	O	O
of	O	O
the	O	O
renin	O	O
system	O	O
by	O	O
an	O	O
ACE	O	O
inhibitor	O	O
is	O	O
a	O	O
particularly	O	O
effective	O	O
way	O	O
to	O	O
improve	O	O
blood	Physical	Physical
pressure	Physical	Physical
control	Physical	Physical
.	Physical	O

Addition	O	O
of	O	O
a	O	O
thiazide	O	O
diuretic	O	O
will	O	O
reduce	O	O
pressure	O	O
further	O	O
.	O	O

Long-term	O	O
evaluation	O	O
of	O	O
tamsulosin	O	O
in	O	O
benign	O	O
prostatic	O	O
hyperplasia	O	O
:	O	O
placebo-controlled	O	O
,	O	O
double-blind	O	O
extension	O	O
of	O	O
phase	O	O
III	O	O
trial	O	O
.	O	O

Tamsulosin	O	O
Investigator	O	O
Group	O	O
.	O	O

OBJECTIVES	O	O
To	O	O
evaluate	O	O
the	O	O
long-term	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
once-daily	O	O
tamsulosin	O	O
(	O	O
0.4	O	O
and	O	O
0.8	O	O
mg	O	O
)	O	O
,	O	O
a	O	O
unique	O	O
selective	O	O
alpha1A-adrenoceptor	O	O
antagonist	O	O
in	O	O
patients	O	O
with	O	O
benign	O	O
prostatic	O	O
hyperplasia	O	O
(	O	O
BPH	O	O
)	O	O
.	O	O

METHODS	O	O
This	O	O
trial	O	O
extended	O	O
a	O	O
13-week	O	O
,	O	O
Phase	O	O
III	O	O
multicenter	O	O
placebo-controlled	O	O
,	O	O
double-blind	O	O
outpatient	O	O
trial	O	O
for	O	O
an	O	O
additional	O	O
40	O	O
weeks	O	O
.	O	O

Of	O	O
618	O	O
patients	O	O
,	O	O
418	O	O
(	O	O
68	O	O
%	O	O
)	O	O
continued	O	O
into	O	O
the	O	O
extension	O	O
phase	O	O
on	O	O
the	O	O
same	O	O
double-blind	O	O
medication	O	O
and	O	O
dose	O	O
.	O	O

The	O	O
primary	O	O
efficacy	O	O
parameters	O	O
were	O	O
total	Physical	Physical
American	Physical	Physical
Urological	Physical	Physical
Association	Physical	Physical
(	Physical	Physical
AUA	Physical	Physical
)	Physical	Physical
symptom	Physical	Physical
score	Physical	Physical
and	O	Physical
maximum	Physical	Physical
urinary	Physical	Physical
flow	Physical	Physical
(	Physical	Physical
Qmax	Physical	Physical
)	Physical	Physical
.	O	O

RESULTS	O	O
The	O	O
mean	O	Physical
changes	O	Physical
in	O	Physical
AUA	Physical	Physical
symptom	Physical	Physical
score	Physical	Physical
from	O	O
baseline	O	O
to	O	O
end	O	O
point	O	O
were	O	O
statistically	O	O
significant	O	O
in	O	O
all	O	O
groups	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

Significant	O	O
improvements	O	O
were	O	O
observed	O	O
in	O	O
Qmax	Physical	O
for	O	O
both	O	O
tamsulosin	O	O
groups	O	O
but	O	O
not	O	O
for	O	O
the	O	O
placebo	O	O
group	O	O
.	O	O

The	O	O
statistically	O	O
significant	Physical	O
improvements	Others	O
from	O	O
baseline	O	O
in	O	O
efficacy	O	O
parameters	O	O
observed	O	O
for	O	O
each	O	O
tamsulosin	O	O
group	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
13-week	O	O
Phase	O	O
III	O	O
trial	O	O
were	O	O
maintained	O	O
during	O	O
the	O	O
long-term	O	O
extension	O	O
phase	O	O
.	O	O

Tamsulosin	O	O
at	O	O
both	O	O
dosages	O	O
was	O	O
well	O	O
tolerated	Others	Others
as	O	O
maintenance	O	O
therapy	O	O
.	O	O

Clinically	O	O
significant	O	O
orthostatic	Physical	O
hypotension	Physical	O
was	O	O
not	O	O
observed	O	O
.	O	O

Vital	Physical	O
sign	Physical	O
changes	Physical	O
in	O	O
either	O	O
hypertensive	O	O
or	O	O
normotensive	O	O
patients	O	O
were	O	O
not	O	O
clinically	O	O
significantly	O	O
different	O	O
across	O	O
the	O	O
three	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
Tamsulosin	O	O
once-daily	O	O
at	O	O
0.4	O	O
or	O	O
0.8	O	O
mg	O	O
was	O	O
shown	O	O
to	O	O
be	O	O
effective	O	O
,	O	O
safe	O	O
,	O	O
and	O	O
well	O	O
tolerated	O	O
in	O	O
the	O	O
target	O	O
BPH	O	O
population	O	O
during	O	O
long-term	O	O
use	O	O
.	O	O

Effect	O	O
of	O	O
upper	O	O
arm	O	O
brachial	O	O
basilic	O	O
and	O	O
prosthetic	O	O
forearm	O	O
arteriovenous	O	O
fistula	O	O
on	O	O
left	Physical	O
ventricular	Physical	O
hypertrophy	Physical	O
.	O	O

BACKGROUND	O	O
Creation	O	O
of	O	O
an	O	O
arteriovenous	O	O
fistula	O	O
(	O	O
AVF	O	O
)	O	O
may	O	O
increase	O	O
left	Physical	O
ventricular	Physical	O
hypertrophy	Physical	O
in	O	O
the	O	O
hemodialysis	O	O
population	O	O
.	O	O

Aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
the	O	O
effects	O	O
of	O	O
a	O	O
brachial-basilic	O	O
(	O	O
BB	O	O
)	O	O
AVF	O	O
and	O	O
the	O	O
prosthetic	O	O
brachial-antecubital	O	O
forearm	O	O
loop	O	O
access	O	O
(	O	O
PTFE	O	O
)	O	O
on	O	O
cardiac	Physical	O
performance	Physical	O
.	Physical	O

METHODS	O	O
Patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
BB-AVF	O	O
or	O	O
prosthetic	O	O
brachial-antecubital	O	O
forearm	O	O
loop	O	O
access	O	O
.	O	O

Before	O	O
and	O	O
three	O	O
months	O	O
after	O	O
AVF	O	O
creation	O	O
patients	O	O
underwent	O	O
an	O	O
echocardiographic	O	O
examination	O	O
.	O	O

Mann-Whitney	Physical	O
U-test	Physical	O
was	O	O
used	O	O
to	O	O
compare	O	O
relative	O	O
increase	O	O
between	O	O
the	O	O
measured	Physical	O
cardiac	Physical	O
parameters	Physical	O
for	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

RESULTS	O	O
Twenty-seven	O	O
patients	O	O
participated	O	O
in	O	O
the	O	O
study	O	O
.	O	O

The	O	O
relative	O	O
increase	O	O
in	O	O
left	Physical	Physical
ventricular	Physical	Physical
parameters	Physical	Physical
was	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

Only	O	O
left	Physical	O
ventricular	Physical	O
end-diastolic	Physical	O
diameter	Physical	O
tended	O	O
to	O	O
be	O	O
of	O	O
significance	O	O
.	O	O

Mean	Physical	Physical
blood	Physical	Physical
flow	Physical	Physical
through	O	Physical
the	O	Physical
brachial	O	Physical
artery	O	Physical
was	O	O
1680+/-156	O	O
and	O	O
1450+/-221	O	O
mL/min	O	O
three	O	O
months	O	O
after	O	O
surgery	O	O
for	O	O
the	O	O
PTFE	O	O
and	O	O
the	O	O
BB-AVF	O	O
group	O	O
,	O	O
respectively	O	O
.	O	O

CONCLUSION	O	O
After	O	O
three	O	O
months	O	O
of	O	O
follow-up	O	O
,	O	O
changes	Physical	O
in	Physical	O
cardiac	Physical	Physical
structure	Physical	Physical
were	O	O
comparable	O	O
between	O	O
patients	O	O
with	O	O
BB	O	O
and	O	O
PTFE	O	O
AVFs	O	O
.	O	O

Also	O	O
access	Physical	O
flow	Physical	O
was	O	O
comparable	O	O
at	O	O
this	O	O
time	O	O
.	O	O

In	O	O
general	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
creation	O	O
of	O	O
a	O	O
fistula	O	O
on	O	O
LV	O	O
structure	O	O
were	O	O
limited	O	O
.	O	O

Longer	O	O
follow	O	O
up	O	O
time	O	O
may	O	O
be	O	O
needed	O	O
to	O	O
explore	O	O
the	O	O
long	O	O
term	O	O
effects	O	O
of	O	O
different	O	O
vascular	O	O
accesses	O	O
on	O	O
cardiac	Physical	O
function	Physical	O
.	Physical	O

Low-dose	O	O
aspirin	O	O
and	O	O
incidence	O	O
of	O	O
colorectal	O	O
tumors	O	O
in	O	O
a	O	O
randomized	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
Laboratory	O	O
,	O	O
clinical	O	O
,	O	O
and	O	O
epidemiologic	O	O
studies	O	O
have	O	O
recently	O	O
suggested	O	O
that	O	O
regular	O	O
use	O	O
of	O	O
aspirin	O	O
can	O	O
reduce	O	O
colorectal	O	O
cancer	O	O
incidence	O	O
or	O	O
mortality	O	O
.	O	O

However	O	O
,	O	O
observational	O	O
epidemiologic	O	O
analyses	O	O
have	O	O
had	O	O
limited	O	O
opportunity	O	O
to	O	O
control	O	O
for	O	O
confounding	O	O
bias	O	O
or	O	O
to	O	O
specify	O	O
aspirin	O	O
doses	O	O
used	O	O
.	O	O

PURPOSE	O	O
Our	O	O
purpose	O	O
was	O	O
to	O	O
examine	O	O
the	O	O
relationship	O	O
between	O	O
regular	O	O
use	O	O
of	O	O
low-dose	O	O
aspirin	O	O
and	O	O
incidence	O	Physical
of	O	Physical
invasive	O	Physical
and	O	Physical
noninvasive	O	Physical
colorectal	O	Physical
tumors	O	Physical
by	O	O
utilizing	O	O
data	O	O
from	O	O
the	O	O
Physicians	O	O
'	O	O
Health	O	O
Study	O	O
,	O	O
a	O	O
randomized	O	O
,	O	O
double-blinded	O	O
,	O	O
placebo-controlled	O	O
trial	O	O
of	O	O
aspirin	O	O
and	O	O
beta	O	O
carotene	O	O
.	O	O

We	O	O
also	O	O
attempted	O	O
to	O	O
determine	O	O
whether	O	O
invasive	O	O
cancers	O	O
among	O	O
aspirin	O	O
users	O	O
were	O	O
associated	O	O
with	O	O
rectal	O	O
bleeding	O	O
and	O	O
early	O	O
stage	O	O
at	O	O
diagnosis	O	O
.	O	O

METHODS	O	O
The	O	O
Physicians	O	O
'	O	O
Health	O	O
Study	O	O
includes	O	O
22071	O	O
U.S.	O	O
male	O	O
physicians	O	O
.	O	O

The	O	O
aspirin	O	O
arm	O	O
was	O	O
terminated	O	O
in	O	O
1988	O	O
after	O	O
a	O	O
mean	O	O
follow-up	O	O
of	O	O
5	O	O
years	O	O
.	O	O

Stage	O	O
at	O	O
diagnosis	O	O
and	O	O
signs	O	O
and/or	O	O
symptoms	O	O
during	O	O
presentation	O	O
were	O	O
abstracted	O	O
from	O	O
medical	O	O
records	O	O
.	O	O

Cox	O	O
proportional	O	O
hazards	O	O
models	O	O
were	O	O
used	O	O
to	O	O
estimate	O	O
relative	Physical	O
risk	Physical	O
(	O	O
RR	O	O
)	O	O
,	O	O
95	O	O
%	O	O
confidence	Physical	O
intervals	Physical	O
(	O	O
CIs	O	O
)	O	O
,	O	O
and	O	O
the	O	O
association	O	O
between	O	O
aspirin	O	O
and	O	O
bleeding	O	O
.	O	O

Differences	O	O
between	O	O
aspirin	O	O
and	O	O
placebo	O	O
groups	O	O
in	O	O
tumor	O	O
risk	O	O
over	O	O
time	O	O
were	O	O
visualized	O	O
with	O	O
Kaplan-Meier	O	O
curves	O	O
.	O	O

We	O	O
assessed	O	O
the	O	O
association	O	O
between	O	O
aspirin	O	O
and	O	O
stage	O	O
at	O	O
diagnosis	O	O
with	O	O
a	O	O
Mann-Whitney	O	O
rank	O	O
sum	O	O
statistic	O	O
for	O	O
non-parametric	O	O
comparison	O	O
of	O	O
two	O	O
ordinal	O	O
distributions	O	O
.	O	O

RESULTS	O	O
The	O	O
RR	O	Physical
of	O	Physical
developing	O	Physical
colorectal	O	Physical
cancer	O	Physical
for	O	O
aspirin	O	O
compared	O	O
with	O	O
placebo	O	O
was	O	O
1.15	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
=	O	O
0.80-1.65	O	O
)	O	O
.	O	O

For	O	O
in	O	O
situ	O	O
cancers	O	O
and	O	O
polyps	O	O
,	O	O
the	O	O
RR	O	O
was	O	O
0.86	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
=	O	O
0.68-1.10	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
trend	O	O
for	O	O
decreasing	O	O
RR	Physical	Physical
by	O	O
year	O	O
of	O	O
follow-up	O	O
for	O	O
invasive	O	O
cancers	O	O
(	O	O
P	O	O
=	O	O
.09	O	O
)	O	O
or	O	O
noninvasive	O	O
tumors	O	O
(	O	O
P	O	O
=	O	O
.96	O	O
)	O	O
.	O	O

Aspirin	O	O
and	O	O
placebo	O	O
groups	O	O
did	O	O
not	O	O
differ	O	O
in	O	O
stage	O	O
or	O	O
prevalence	O	O
of	O	O
rectal	Physical	O
bleeding	Physical	O
at	O	O
diagnosis	O	O
.	O	O

CONCLUSIONS	O	O
Regular	O	O
aspirin	O	O
use	O	O
,	O	O
at	O	O
a	O	O
dose	O	O
adequate	O	O
for	O	O
preventing	O	O
myocardial	O	O
infarction	O	O
,	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
a	O	O
substantial	O	O
reduction	O	O
in	O	O
the	O	O
incidence	O	O
of	O	O
colorectal	Physical	O
cancer	Physical	O
during	O	O
5	O	O
years	O	O
of	O	O
randomized	O	O
treatment	O	O
and	O	O
follow-up	O	O
.	O	O

A	O	O
small	O	O
decrease	O	O
in	O	O
polyps	O	O
in	O	O
the	O	O
aspirin	O	O
group	O	O
could	O	O
not	O	O
be	O	O
reliably	O	O
distinguished	O	O
from	O	O
a	O	O
chance	O	O
association	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
among	O	O
low-dose	O	O
aspirin	O	O
users	O	O
,	O	O
(	O	O
a	O	O
)	O	O
colorectal	O	Mortality
cancer	O	Mortality
mortality	O	Mortality
is	O	O
not	O	O
likely	O	O
to	O	O
be	O	O
reduced	O	O
by	O	O
earlier	O	O
detection	O	O
and	O	O
(	O	O
b	O	O
)	O	O
incidence	O	O
is	O	O
not	O	O
likely	O	O
to	O	O
be	O	O
increased	O	O
due	O	O
to	O	O
aspirin-induced	O	O
gastrointestinal	O	O
bleeding	O	O
.	O	O

IMPLICATIONS	O	O
The	O	O
potential	O	O
for	O	O
a	O	O
benefit	O	O
from	O	O
higher	O	O
doses	O	O
of	O	O
aspirin	O	O
or	O	O
longer	O	O
duration	O	O
of	O	O
use	O	O
should	O	O
be	O	O
addressed	O	O
by	O	O
more	O	O
detailed	O	O
observational	O	O
epidemiologic	O	O
studies	O	O
and	O	O
prevention	O	O
trials	O	O
with	O	O
longer	O	O
follow-up	O	O
of	O	O
randomized	O	O
participants	O	O
.	O	O

Effects	O	O
of	O	O
interaction	O	O
of	O	O
RRR-alpha-tocopheryl	O	O
acetate	O	O
and	O	O
fish	O	O
oil	O	O
on	O	O
low-density-lipoprotein	O	O
oxidation	O	O
in	O	O
postmenopausal	O	O
women	O	O
with	O	O
and	O	O
without	O	O
hormone-replacement	O	O
therapy	O	O
.	O	O

We	O	O
evaluated	O	O
the	O	O
effects	O	O
of	O	O
RRR-alpha-tocpheryl	O	O
acetate	O	O
(	O	O
alpha-tocopheryl	O	O
acetate	O	O
)	O	O
and	O	O
hormone-replacement	O	O
therapy	O	O
(	O	O
HRT	O	O
)	O	O
on	O	O
the	O	O
oxidative	O	Physical
susceptibility	O	Physical
of	O	Physical
low-density	O	Physical
lipoprotein	O	Physical
(	O	Physical
LDL	O	Physical
)	O	Physical
in	O	O
postmenopausal	O	O
women	O	O
consuming	O	O
a	O	O
fish	O	O
oil	O	O
supplement	O	O
.	O	O

The	O	O
independent	O	O
effect	Physical	O
of	O	O
fish	O	O
oil	O	O
was	O	O
also	O	O
assessed	O	O
.	O	O

Forty-eight	O	O
women	O	O
,	O	O
equally	O	O
divided	O	O
between	O	O
women	O	O
using	O	O
and	O	O
not	O	O
using	O	O
HRT	O	O
,	O	O
participated	O	O
in	O	O
a	O	O
double-blind	O	O
crossover	O	O
trial	O	O
.	O	O

Each	O	O
of	O	O
the	O	O
four	O	O
periods	O	O
lasted	O	O
5	O	O
wk	O	O
and	O	O
was	O	O
followed	O	O
by	O	O
a	O	O
4-wk	O	O
washout	O	O
interval	O	O
.	O	O

During	O	O
each	O	O
period	O	O
all	O	O
subjects	O	O
were	O	O
given	O	O
a	O	O
15-g	O	O
supplement	O	O
of	O	O
fish	O	O
oil	O	O
and	O	O
either	O	O
0	O	O
(	O	O
placebo	O	O
)	O	O
,	O	O
100	O	O
,	O	O
200	O	O
,	O	O
or	O	O
400	O	O
mg	O	O
alpha-tocopheryl	O	O
acetate	O	O
daily	O	O
.	O	O

LDL	Physical	O
resistance	Physical	O
to	Physical	O
oxidative	Physical	O
modification	Physical	O
was	O	O
assessed	O	O
by	O	O
calculating	Physical	Others
lag	Physical	Others
time	Physical	Others
,	O	Others
propagation	Physical	Others
rate	Physical	Others
,	O	Physical
and	O	Physical
maximum	Physical	Physical
production	Physical	Physical
of	Physical	Physical
conjugated	Physical	Physical
dienes	Physical	Physical
.	O	O

Supplementation	O	O
with	O	O
fish	O	O
oil	O	O
and	O	O
placebo	O	O
shortened	O	O
lag	Physical	O
time	Physical	O
and	O	O
slowed	Physical	Others
propagation	Physical	Others
rate	Physical	Others
in	O	O
women	O	O
both	O	O
using	O	O
and	O	O
not	O	O
using	O	O
HRT	O	O
.	O	O

After	O	O
subjects	O	O
consumed	O	O
fish	O	O
oil	O	O
,	O	O
supplementation	O	O
with	O	O
alpha-tocopheryl	O	O
acetate	O	O
increased	O	O
plasma	Physical	O
and	Physical	O
LDL	Physical	O
alpha-tocopherol	Physical	O
contents	Physical	O
significantly	O	O
and	O	O
lengthened	Physical	Others
lag	Physical	Others
time	Physical	Others
(	O	O
at	O	O
even	O	O
the	O	O
lowest	O	O
concentration	O	O
)	O	O
but	O	O
had	O	O
no	O	O
significant	O	O
effect	O	O
on	O	O
propagation	Physical	O
rate	Physical	O
or	O	O
maximum	Physical	O
production	Physical	O
compared	O	O
with	O	O
values	O	O
measured	O	O
after	O	O
consumption	O	O
of	O	O
fish	O	O
oil	O	O
alone	O	O
.	O	O

Women	O	O
not	O	O
using	O	O
HRT	O	O
had	O	O
faster	O	O
propagation	Physical	O
rates	Physical	O
and	O	O
higher	O	O
maximum	Physical	O
production	Physical	O
than	O	O
women	O	O
using	O	O
HRT	O	O
;	O	O
after	O	O
supplementation	O	O
with	O	O
fish	O	O
oil	O	O
and	O	O
alpha-tocopheryl	O	O
acetate	O	O
these	O	O
differences	O	O
prevailed	O	O
.	O	O

Supplements	O	O
as	O	O
low	O	O
as	O	O
100	O	O
mg	O	O
alpha-tocopheryl	O	O
acetate/d	O	O
increase	O	O
the	O	O
resistance	Physical	O
of	Physical	O
LDL	Physical	O
to	Physical	O
oxidation	Physical	O
when	O	O
fish	O	O
oil	O	O
supplements	O	O
are	O	O
used	O	O
.	O	O

HRT	O	O
and	O	O
fish	O	O
oil	O	O
supplements	O	O
may	O	O
independently	O	O
affect	O	O
LDL	Physical	Physical
oxidative	Physical	Physical
susceptibility	Physical	Physical
.	O	O

Nutritional	O	O
orientation	O	O
,	O	O
knowledge	O	Mental
and	O	Mental
quality	O	Mental
of	O	Mental
diet	O	Mental
in	O	O
heart	O	O
failure	O	O
:	O	O
randomized	O	O
clinical	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
Non-pharmacological	O	O
measures	O	O
are	O	O
recommended	O	O
for	O	O
heart	O	O
failure	O	O
patients	O	O
.	O	O

However	O	O
,	O	O
most	O	O
studies	O	O
evaluate	O	O
low	O	O
sodium	O	O
diet	O	O
,	O	O
while	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
effects	O	O
of	O	O
interventions	O	O
to	O	O
improve	O	O
adherence	O	Mental
and	O	Mental
knowledge	O	Mental
of	O	Mental
patients	O	Mental
about	O	Mental
diet	O	Mental
content	O	Mental
.	O	O

OBJECTIVE	O	O
To	O	O
evaluate	O	O
if	O	O
a	O	O
global	O	O
nutritional	O	O
orientation	O	O
could	O	O
affect	O	O
nutritional	Others	O
knowledge	Others	O
,	O	O
adherence	Others	Mental
to	Others	Mental
food	Others	Mental
guidelines	Others	Mental
,	O	O
anthropometrics	Physical	O
and	O	O
quality	Others	Others
of	Others	Others
life	Others	Others
in	O	O
heart	O	O
failure	O	O
patients	O	O
.	O	O

METHODS	O	O
Forty	O	O
six	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
intervention	O	O
or	O	O
control	O	O
group	O	O
.	O	O

Both	O	O
groups	O	O
received	O	O
usual	O	O
care	O	O
with	O	O
medical	O	O
and	O	O
nursing	O	O
staff	O	O
;	O	O
the	O	O
intervention	O	O
group	O	O
received	O	O
additional	O	O
nutritional	O	O
guidance	O	O
about	O	O
diet	O	O
and	O	O
its	O	O
relationship	O	O
with	O	O
disease	O	O
,	O	O
sources	O	O
of	O	O
nutrients	O	O
,	O	O
and	O	O
reduction	O	O
of	O	O
dietary	O	O
sodium	O	O
and	O	O
fats	O	O
.	O	O

Enforcement	O	O
of	O	O
the	O	O
nutritional	O	O
guidance	O	O
was	O	O
performed	O	O
after	O	O
4	O	O
weeks	O	O
.	O	O

Both	O	O
groups	O	O
were	O	O
evaluated	O	O
at	O	O
baseline	O	O
,	O	O
and	O	O
after	O	O
6	O	O
weeks	O	O
and	O	O
6	O	O
months	O	O
.	O	O

Evaluations	O	O
included	O	O
anthropometric	Physical	Physical
parameters	Physical	Physical
,	O	Physical
sodium	Physical	Physical
excretion	Physical	Physical
in	Physical	Physical
24-hour	Physical	Physical
urine	Physical	Physical
,	O	Physical
dietary	Mental	Physical
recall	Mental	Physical
,	O	O
nutrition	Mental	O
knowledge	Mental	O
and	O	O
quality	Others	Others
of	Others	Others
life	Others	Others
questionnaires	Physical	Others
.	O	O

RESULTS	O	O
Mean	O	O
age	O	O
of	O	O
included	O	O
patients	O	O
was	O	O
58	O	O
?	O	O
10	O	O
years	O	O
and	O	O
70	O	O
%	O	O
were	O	O
male	O	O
.	O	O

After	O	O
6	O	O
months	O	O
of	O	O
follow-up	O	O
,	O	O
the	O	O
nutritional	Others	O
knowledge	Others	O
of	O	O
intervention	O	O
group	O	O
increased	O	O
compared	O	O
to	O	O
control	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

Caloric	O	O
,	O	O
fat	O	Physical
and	O	Physical
sodium	O	Mental
intake	O	Mental
decreased	O	O
in	O	O
the	O	O
intervention	O	O
group	O	O
compared	O	O
to	O	O
control	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
were	O	O
seen	O	O
in	O	O
quality	Others	Physical
of	Others	Physical
life	Others	Physical
or	O	Physical
anthropometric	Physical	Physical
parameters	Physical	Physical
.	O	O

CONCLUSIONS	O	O
Nutritional	O	O
orientation	O	O
was	O	O
effective	O	O
to	O	O
modify	O	O
1	O	O
)	O	O
knowledge	Others	O
about	O	O
food	O	O
and	O	O
nutrition	O	O
,	O	O
and	O	O
2	O	O
)	O	O
quality	Others	Others
of	Others	Others
diet	Others	Others
in	O	O
outpatients	O	O
with	O	O
heart	O	O
failure	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
necessary	O	O
to	O	O
evaluate	O	O
the	O	O
benefits	O	O
on	O	O
quality	O	Others
of	O	Others
life	O	Others
and	O	O
prognosis	O	O
.	O	O

Effects	O	O
of	O	O
long-term	O	O
vitamin	O	O
E	O	O
supplementation	O	O
on	O	O
cardiovascular	Physical	Physical
events	Physical	Physical
and	O	O
cancer	Physical	O
:	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

CONTEXT	O	O
Experimental	O	O
and	O	O
epidemiological	O	O
data	O	O
suggest	O	O
that	O	O
vitamin	O	O
E	O	O
supplementation	O	O
may	O	O
prevent	O	O
cancer	O	O
and	O	O
cardiovascular	O	Physical
events	O	Physical
.	O	O

Clinical	O	O
trials	O	O
have	O	O
generally	O	O
failed	O	O
to	O	O
confirm	O	O
benefits	O	O
,	O	O
possibly	O	O
due	O	O
to	O	O
their	O	O
relatively	O	O
short	O	O
duration	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
evaluate	O	O
whether	O	O
long-term	O	O
supplementation	O	O
with	O	O
vitamin	O	O
E	O	O
decreases	O	O
the	O	O
risk	Physical	O
of	Physical	O
cancer	Physical	O
,	O	O
cancer	Adverseeffect	Mortality
death	Adverseeffect	Mortality
,	O	O
and	O	O
major	Physical	O
cardiovascular	Physical	O
events	Physical	O
.	O	O

DESIGN	O	O
,	O	O
SETTING	O	O
,	O	O
AND	O	O
PATIENTS	O	O
A	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
international	O	O
trial	O	O
(	O	O
the	O	O
initial	O	O
Heart	O	O
Outcomes	O	O
Prevention	O	O
Evaluation	O	O
[	O	O
HOPE	O	O
]	O	O
trial	O	O
conducted	O	O
between	O	O
December	O	O
21	O	O
,	O	O
1993	O	O
,	O	O
and	O	O
April	O	O
15	O	O
,	O	O
1999	O	O
)	O	O
of	O	O
patients	O	O
at	O	O
least	O	O
55	O	O
years	O	O
old	O	O
with	O	O
vascular	O	O
disease	O	O
or	O	O
diabetes	O	O
mellitus	O	O
was	O	O
extended	O	O
(	O	O
HOPE-The	O	O
Ongoing	O	O
Outcomes	O	O
[	O	O
HOPE-TOO	O	O
]	O	O
)	O	O
between	O	O
April	O	O
16	O	O
,	O	O
1999	O	O
,	O	O
and	O	O
May	O	O
26	O	O
,	O	O
2003	O	O
.	O	O

Of	O	O
the	O	O
initial	O	O
267	O	O
HOPE	O	O
centers	O	O
that	O	O
had	O	O
enrolled	O	O
9541	O	O
patients	O	O
,	O	O
174	O	O
centers	O	O
participated	O	O
in	O	O
the	O	O
HOPE-TOO	O	O
trial	O	O
.	O	O

Of	O	O
7030	O	O
patients	O	O
enrolled	O	O
at	O	O
these	O	O
centers	O	O
,	O	O
916	O	O
were	O	O
deceased	O	O
at	O	O
the	O	O
beginning	O	O
of	O	O
the	O	O
extension	O	O
,	O	O
1382	O	O
refused	O	O
participation	O	O
,	O	O
3994	O	O
continued	O	O
to	O	O
take	O	O
the	O	O
study	O	O
intervention	O	O
,	O	O
and	O	O
738	O	O
agreed	O	O
to	O	O
passive	O	O
follow-up	O	O
.	O	O

Median	O	O
duration	O	O
of	O	O
follow-up	O	O
was	O	O
7.0	O	O
years	O	O
.	O	O

INTERVENTION	O	O
Daily	O	O
dose	O	O
of	O	O
natural	O	O
source	O	O
vitamin	O	O
E	O	O
(	O	O
400	O	O
IU	O	O
)	O	O
or	O	O
matching	O	O
placebo	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
Primary	O	O
outcomes	O	O
included	O	O
cancer	Physical	Physical
incidence	Physical	Physical
,	O	Physical
cancer	Adverseeffect	Physical
deaths	Adverseeffect	Physical
,	O	Physical
and	O	Physical
major	Physical	Physical
cardiovascular	Physical	Physical
events	Physical	Physical
(	Physical	O
myocardial	Physical	O
infarction	Physical	O
,	Physical	O
stroke	Physical	Physical
,	Physical	O
and	Physical	O
cardiovascular	Adverseeffect	O
death	Adverseeffect	O
)	Physical	O
.	O	O

Secondary	O	O
outcomes	O	O
included	O	O
heart	Physical	Physical
failure	Physical	Physical
,	O	Physical
unstable	Physical	Physical
angina	Physical	Physical
,	O	O
and	O	O
revascularizations	Physical	O
.	O	O

RESULTS	O	O
Among	O	O
all	O	O
HOPE	O	O
patients	O	O
,	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
primary	O	O
analysis	O	O
:	O	O
for	O	O
cancer	Physical	O
incidence	Physical	O
,	O	O
there	O	O
were	O	O
552	O	O
patients	O	O
(	O	O
11.6	O	O
%	O	O
)	O	O
in	O	O
the	O	O
vitamin	O	O
E	O	O
group	O	O
vs	O	O
586	O	O
(	O	O
12.3	O	O
%	O	O
)	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
(	O	O
relative	O	O
risk	O	O
[	O	O
RR	O	O
]	O	O
,	O	O
0.94	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
,	O	O
0.84-1.06	O	O
;	O	O
P	O	O
=	O	O
.30	O	O
)	O	O
;	O	O
for	O	O
cancer	Adverseeffect	O
deaths	Adverseeffect	O
,	O	O
156	O	O
(	O	O
3.3	O	O
%	O	O
)	O	O
vs	O	O
178	O	O
(	O	O
3.7	O	O
%	O	O
)	O	O
,	O	O
respectively	O	O
(	O	O
RR	O	O
,	O	O
0.88	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
0.71-1.09	O	O
;	O	O
P	O	O
=	O	O
.24	O	O
)	O	O
;	O	O
and	O	O
for	O	O
major	Physical	O
cardiovascular	Physical	O
events	Physical	O
,	O	O
1022	O	O
(	O	O
21.5	O	O
%	O	O
)	O	O
vs	O	O
985	O	O
(	O	O
20.6	O	O
%	O	O
)	O	O
,	O	O
respectively	O	O
(	O	O
RR	O	O
,	O	O
1.04	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
0.96-1.14	O	O
;	O	O
P	O	O
=	O	O
.34	O	O
)	O	O
.	O	O

Patients	O	O
in	O	O
the	O	O
vitamin	O	O
E	O	O
group	O	O
had	O	O
a	O	O
higher	O	O
risk	Physical	O
of	Physical	O
heart	Physical	Physical
failure	Physical	Physical
(	O	Physical
RR	O	Physical
,	O	O
1.13	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.01-1.26	O	O
;	O	O
P	O	O
=	O	O
.03	O	O
)	O	O
and	O	O
hospitalization	Adverseeffect	O
for	Adverseeffect	O
heart	Adverseeffect	O
failure	Adverseeffect	O
(	O	O
RR	O	O
,	O	O
1.21	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.00-1.47	O	O
;	O	O
P	O	O
=	O	O
.045	O	O
)	O	O
.	O	O

Similarly	O	O
,	O	O
among	O	O
patients	O	O
enrolled	O	O
at	O	O
the	O	O
centers	O	O
participating	O	O
in	O	O
the	O	O
HOPE-TOO	O	O
trial	O	O
,	O	O
there	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
cancer	Physical	O
incidence	Physical	O
,	O	O
cancer	Adverseeffect	Physical
deaths	Adverseeffect	Physical
,	O	Physical
and	O	Physical
major	Physical	Physical
cardiovascular	Physical	Physical
events	Physical	Physical
,	O	O
but	O	O
higher	O	O
rates	Physical	O
of	Physical	O
heart	Physical	O
failure	Physical	O
and	O	O
hospitalizations	Adverseeffect	O
for	Adverseeffect	O
heart	Adverseeffect	O
failure	Adverseeffect	O
.	O	O

CONCLUSION	O	O
In	O	O
patients	O	O
with	O	O
vascular	O	O
disease	O	O
or	O	O
diabetes	O	O
mellitus	O	O
,	O	O
long-term	O	O
vitamin	O	O
E	O	O
supplementation	O	O
does	O	O
not	O	O
prevent	O	O
cancer	Physical	O
or	O	O
major	Physical	O
cardiovascular	Physical	O
events	Physical	O
and	O	O
may	O	O
increase	O	O
the	O	O
risk	Physical	O
for	Physical	O
heart	Physical	O
failure	Physical	O
.	O	O

Intravenous	O	O
or	O	O
intramuscular	O	O
teicoplanin	O	O
once	O	O
daily	O	O
for	O	O
skin	O	O
and	O	O
soft-tissue	O	O
infections	O	O
.	O	O

Teicoplanin	O	O
is	O	O
a	O	O
new	O	O
glycopeptide	O	O
antibiotic	O	O
with	O	O
potent	O	O
activity	O	O
against	O	O
gram-positive	O	O
bacteria	O	O
and	O	O
pharmacokinetics	O	O
that	O	O
allow	O	O
once	O	O
daily	O	O
administration	O	O
.	O	O

To	O	O
study	O	O
the	O	O
efficacy	Others	Others
and	O	Others
safety	Others	Others
of	O	O
teicoplanin	O	O
for	O	O
skin	O	O
and	O	O
soft-tissue	O	O
infections	O	O
,	O	O
75	O	O
patients	O	O
received	O	O
teicoplanin	O	O
intravenously	O	O
(	O	O
38	O	O
)	O	O
or	O	O
intramuscularly	O	O
(	O	O
37	O	O
,	O	O
of	O	O
which	O	O
16	O	O
were	O	O
outpatients	O	O
)	O	O
.	O	O

Of	O	O
62	O	O
clinically	O	O
evaluable	O	O
patients	O	O
,	O	O
97	O	O
percent	O	O
of	O	O
teicoplanin	O	O
iv	O	O
and	O	O
93	O	O
percent	O	O
of	O	O
teicoplanin	O	O
im	O	O
patients	O	O
were	O	O
cured	O	Physical
or	O	O
improved	O	O
.	O	O

All	O	O
teicoplanin	O	O
iv	O	O
patients	O	O
and	O	O
64	O	O
percent	O	O
of	O	O
teicoplanin	O	O
im	O	O
patients	O	O
were	O	O
cured	O	O
microbiologically	O	O
at	O	O
24-48	O	O
hours	O	O
posttherapy	O	O
.	O	O

Persistence	O	O
of	O	O
organisms	O	O
frequently	O	O
was	O	O
associated	O	O
with	O	O
skin	Physical	Physical
ulcers	Physical	Physical
or	Physical	O
abscess	Physical	O
cavities	Physical	O
and	O	O
usually	O	O
had	O	O
no	O	O
bearing	O	O
on	O	O
clinical	O	O
outcome	O	O
.	O	O

Possible	O	O
adverse	Adverseeffect	O
clinical	Adverseeffect	O
and	Adverseeffect	O
laboratory	Adverseeffect	O
reactions	Adverseeffect	O
caused	O	O
by	O	O
teicoplanin	O	O
occurred	O	O
in	O	O
4	O	O
of	O	O
38	O	O
teicoplanin	O	O
iv	O	O
patients	O	O
(	O	O
11	O	O
percent	O	O
)	O	O
and	O	O
in	O	O
8	O	O
of	O	O
37	O	O
teicoplanin	O	O
im	O	O
patients	O	O
(	O	O
22	O	O
percent	O	O
)	O	O
.	O	O

Reactions	O	O
were	O	O
mild	Physical	O
and	O	O
resolved	O	O
with	O	O
discontinuation	O	O
of	O	O
teicoplanin	O	O
in	O	O
most	O	O
cases	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
teicoplanin	O	O
appeared	O	O
to	O	O
be	O	O
safe	Others	O
,	O	O
efficacious	Others	O
,	O	O
and	O	O
convenient	Others	O
for	O	O
both	O	O
hospital	O	O
staff	O	O
and	O	O
patients	O	O
,	O	O
and	O	O
potentially	O	O
cost-effective	Others	Others
for	O	O
the	O	O
treatment	O	O
of	O	O
skin	O	O
and	O	O
soft-tissue	O	O
infections	O	O
.	O	O

In	O	O
particular	O	O
,	O	O
teicoplanin	O	O
appears	O	O
to	O	O
be	O	O
appropriate	O	O
for	O	O
outpatient	O	O
parenteral	O	O
therapy	O	O
.	O	O

Comparison	O	O
of	O	O
neodymium-doped	O	O
yttrium	O	O
aluminum	O	O
garnet	O	O
laser	O	O
treatment	O	O
with	O	O
cold	O	O
knife	O	O
endoscopic	O	O
incision	O	O
of	O	O
urethral	O	O
strictures	O	O
in	O	O
male	O	O
patients	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
assess	O	O
the	O	O
effectiveness	Others	O
of	O	O
visual	O	O
laser	O	O
ablation	O	O
treatment	O	O
with	O	O
neodymium-doped	O	O
yttrium	O	O
aluminum	O	O
garnet	O	O
(	O	O
Nd	O	O
:	O	O
YAG	O	O
)	O	O
laser	O	O
in	O	O
male	O	O
patients	O	O
with	O	O
urethral	O	O
strictures	O	O
and	O	O
to	O	O
compare	O	O
the	O	O
effects	O	O
with	O	O
those	O	O
obtained	O	O
in	O	O
patients	O	O
treated	O	O
with	O	O
Sachse	O	O
's	O	O
optical	O	O
urethrotomy	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
Fifty	O	O
patients	O	O
aged	O	O
22	O	O
to	O	O
83	O	O
(	O	O
mean	O	O
age	O	O
61.8	O	O
)	O	O
with	O	O
primary	O	O
(	O	O
n	O	O
=	O	O
26	O	O
,	O	O
52	O	O
%	O	O
)	O	O
and	O	O
recurrent	O	O
(	O	O
n	O	O
=	O	O
24	O	O
,	O	O
48	O	O
%	O	O
)	O	O
urethral	O	O
strictures	O	O
0.3	O	O
to	O	O
2.4	O	O
cm	O	O
long	O	O
qualified	O	O
for	O	O
the	O	O
study	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
randomized	O	O
into	O	O
two	O	O
groups	O	O
:	O	O
30	O	O
men	O	O
treated	O	O
using	O	O
visual	O	O
laser	O	O
ablation	O	O
of	O	O
urethral	O	O
strictures	O	O
(	O	O
VLASU	O	O
)	O	O
with	O	O
Nd	O	O
:	O	O
YAGlaser	O	O
and	O	O
20	O	O
men	O	O
treated	O	O
by	O	O
correction	O	O
of	O	O
urethral	O	O
strictures	O	O
using	O	O
Sachse	O	O
's	O	O
optical	O	O
urethrotomy	O	O
.	O	O

RESULTS	O	O
At	O	O
12-month	O	O
follow-up	O	O
,	O	O
seven	O	O
(	O	O
35	O	O
%	O	O
)	O	O
patients	O	O
who	O	O
underwent	O	O
optical	O	O
urethrotomy	O	O
and	O	O
21	O	O
(	O	O
70	O	O
%	O	O
)	O	O
in	O	O
the	O	O
VLASU	O	O
group	O	O
did	O	O
not	O	O
require	O	O
repetition	Others	O
of	Others	O
the	Others	O
procedure	Others	O
.	Others	O

The	O	O
choice	O	O
of	O	O
VLASU	O	O
as	O	O
a	O	O
method	O	O
of	O	O
treatment	O	O
significantly	O	O
decreased	O	O
the	O	O
probability	Others	O
of	Others	O
therapeutic	Others	Others
failure	Others	Others
and	O	Others
recurrence	Physical	Others
of	Physical	Others
urethral	Physical	Others
strictures	Physical	Others
(	O	O
p	O	O
=	O	O
0.02	O	O
)	O	O
.	O	O

CONCLUSION	O	O
VLASU	O	O
can	O	O
be	O	O
used	O	O
as	O	O
a	O	O
method	O	O
of	O	O
treatment	O	O
of	O	O
this	O	O
disorder	O	O
.	O	O

It	O	O
is	O	O
an	O	O
effective	O	O
,	O	O
modern	O	O
,	O	O
low-invasive	O	O
,	O	O
and	O	O
repeatable	O	O
technique	O	O
and	O	O
is	O	O
technically	O	O
simple	O	O
and	O	O
easy	O	O
to	O	O
master	O	O
.	O	O

It	O	O
can	O	O
be	O	O
used	O	O
in	O	O
cases	O	O
in	O	O
which	O	O
introduction	O	O
of	O	O
a	O	O
22	O	O
Char	O	O
optical	O	O
urethrotome	O	O
into	O	O
the	O	O
stricture	O	O
site	O	O
is	O	O
impossible	O	O
,	O	O
as	O	O
well	O	O
as	O	O
for	O	O
treatment	O	O
of	O	O
multiple	O	O
strictures	O	O
during	O	O
one	O	O
procedure	O	O
.	O	O

Transdermal	O	O
scopolamine	O	O
patch	O	O
in	O	O
addition	O	O
to	O	O
ondansetron	O	O
for	O	O
postoperative	O	O
nausea	O	O
and	O	O
vomiting	O	O
prophylaxis	O	O
in	O	O
patients	O	O
undergoing	O	O
ambulatory	O	O
cosmetic	O	O
surgery	O	O
.	O	O

STUDY	O	O
OBJECTIVE	O	O
To	O	O
determine	O	O
the	O	O
efficacy	O	O
of	O	O
transdermal	O	O
scopolamine	O	O
in	O	O
addition	O	O
to	O	O
ondansetron	O	O
in	O	O
decreasing	O	O
the	O	O
incidence	O	Adverseeffect
of	O	Adverseeffect
postoperative	Physical	Adverseeffect
nausea	Physical	Adverseeffect
and	Physical	O
vomiting	Physical	O
(	O	O
PONV	O	O
)	O	O
.	O	O

DESIGN	O	O
Randomized	O	O
controlled	O	O
trial	O	O
.	O	O

SETTING	O	O
Academic	O	O
hospital	O	O
.	O	O

PATIENTS	O	O
126	O	O
ASA	O	O
physical	O	O
status	O	O
I	O	O
and	O	O
II	O	O
patients	O	O
undergoing	O	O
outpatient	O	O
plastic	O	O
surgery	O	O
with	O	O
three	O	O
or	O	O
more	O	O
risk	O	O
factors	O	O
for	O	O
PONV	O	O
.	O	O

INTERVENTIONS	O	O
Patients	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
two	O	O
groups	O	O
to	O	O
receive	O	O
(	O	O
Group	O	O
1	O	O
)	O	O
a	O	O
transdermal	O	O
scopolamine	O	O
(	O	O
TDS	O	O
)	O	O
patch	O	O
or	O	O
(	O	O
Group	O	O
2	O	O
)	O	O
,	O	O
a	O	O
placebo	O	O
patch	O	O
two	O	O
hours	O	O
before	O	O
surgery	O	O
.	O	O

MEASUREMENTS	O	O
Occurrence	Physical	Physical
of	Physical	Physical
vomiting	Physical	Physical
,	O	Physical
severity	Physical	Physical
of	Physical	Physical
nausea	Physical	Physical
using	Physical	O
a	Physical	O
visual	Physical	O
analog	Physical	O
scale	Physical	O
(	Physical	O
VAS	Physical	O
)	Physical	O
,	O	O
rescue	Others	O
medication	Others	O
,	O	O
pain	Pain	Pain
intensity	Pain	Pain
and	Physical	Pain
pain	Others	Pain
medications	Others	Pain
,	O	O
and	O	O
side	Adverseeffect	Adverseeffect
effects	Adverseeffect	Adverseeffect
were	O	O
recorded	O	O
every	O	O
hour	O	O
until	O	O
discharge	O	O
from	O	O
hospital	O	O
,	O	O
then	O	O
every	O	O
4	O	O
hours	O	O
thereafter	O	O
for	O	O
a	O	O
total	O	O
of	O	O
24	O	O
hours	O	O
.	O	O

MAIN	O	O
RESULTS	O	O
A	O	O
statistically	O	O
significant	O	O
reduction	O	O
in	O	O
postoperative	Physical	Physical
nausea	Physical	Physical
between	O	O
8	O	O
and	O	O
24	O	O
hours	O	O
in	O	O
patients	O	O
receiving	O	O
TDS	O	O
was	O	O
noted	O	O
.	O	O

CONCLUSIONS	O	O
Transdermal	O	O
scopolamine	O	O
in	O	O
addition	O	O
to	O	O
ondansetron	O	O
benefits	O	O
patients	O	O
at	O	O
high	O	O
risk	O	O
for	O	O
PONV	O	O
undergoing	O	O
outpatient	O	O
plastic	O	O
surgery	O	O
for	O	O
up	O	O
to	O	O
20	O	O
hours	O	O
after	O	O
surgery	O	O
.	O	O

The	O	O
costs	Others	Others
and	O	O
effects	Others	O
of	O	O
a	O	O
nutritional	O	O
education	O	O
program	O	O
following	O	O
work-site	O	O
cholesterol	O	O
screening	O	O
.	O	O

OBJECTIVES	O	O
The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
costs	Others	Others
and	O	O
impact	Others	O
of	O	O
a	O	O
nutrition	O	O
education	O	O
program	O	O
following	O	O
a	O	O
cholesterol	O	O
screening	O	O
.	O	O

METHODS	O	O
Forty	O	O
work-sites	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
two	O	O
educational	O	O
interventions	O	O
:	O	O
a	O	O
usual	O	O
intervention	O	O
of	O	O
5	O	O
minutes	O	O
of	O	O
counseling	O	O
,	O	O
or	O	O
a	O	O
special	O	O
intervention	O	O
of	O	O
2	O	O
hours	O	O
of	O	O
behaviorally	O	O
based	O	O
education	O	O
on	O	O
dietary	O	O
changes	O	O
to	O	O
lower	O	O
serum	O	O
cholesterol	O	O
.	O	O

Costs	Others	O
were	O	O
monitored	O	O
,	O	O
and	O	O
cholesterol	Physical	Physical
levels	Physical	Physical
were	O	O
retested	O	O
6	O	O
and	O	O
12	O	O
months	O	O
later	O	O
.	O	O

RESULTS	O	O
The	O	O
total	Others	Others
per-person	Others	Others
cost	Others	Others
for	O	O
screening	O	O
and	O	O
the	O	O
educational	O	O
intervention	O	O
was	O	O
about	O	O
$	O	O
50	O	O
.	O	O

Cholesterol	Physical	O
levels	Physical	O
differed	O	O
little	O	O
between	O	O
the	O	O
two	O	O
intervention	O	O
groups	O	O
6	O	O
months	O	O
after	O	O
screening	O	O
,	O	O
but	O	O
after	O	O
12	O	O
months	O	O
those	O	O
in	O	O
the	O	O
special	O	O
intervention	O	O
worksites	O	O
showed	O	O
a	O	O
6.5	O	O
%	O	O
drop	O	O
in	O	O
cholesterol	Physical	Physical
,	O	O
whereas	O	O
those	O	O
at	O	O
the	O	O
usual	O	O
intervention	O	O
worksites	O	O
showed	O	O
a	O	O
drop	O	O
of	O	O
only	O	O
3.0	O	O
%	O	O
.	O	O

Hence	O	O
a	O	O
3.5	O	O
%	O	O
cholesterol	Physical	O
reduction	Physical	O
was	O	O
attributable	O	O
to	O	O
the	O	O
special	O	O
intervention	O	O
.	O	O

CONCLUSIONS	O	O
A	O	O
behaviorally	O	O
based	O	O
nutrition	O	O
education	O	O
program	O	O
following	O	O
cholesterol	O	O
screening	O	O
can	O	O
have	O	O
a	O	O
meaningful	O	O
impact	O	O
on	O	O
long-term	O	O
cholesterol	O	O
levels	O	O
at	O	O
a	O	O
low	O	O
cost	O	O
.	O	O

Nutrition	O	O
education	O	O
in	O	O
work-sites	O	O
may	O	O
therefore	O	O
be	O	O
a	O	O
useful	O	O
way	O	O
to	O	O
lower	O	O
the	O	O
risk	O	O
of	O	O
heart	O	O
disease	O	O
in	O	O
communities	O	O
.	O	O

Echocardiographic	O	O
evaluation	O	O
of	O	O
children	O	O
with	O	O
systemic	O	O
ventricular	O	O
dysfunction	O	O
treated	O	O
with	O	O
carvedilol	O	O
.	O	O

Echocardiography	O	O
is	O	O
used	O	O
to	O	O
measure	O	O
the	O	O
therapeutic	O	O
effectiveness	O	O
of	O	O
heart	O	O
failure	O	O
therapy	O	O
in	O	O
adults	O	O
and	O	O
children	O	O
.	O	O

The	O	O
purposes	O	O
of	O	O
this	O	O
study	O	O
were	O	O
(	O	O
1	O	O
)	O	O
to	O	O
assess	O	O
baseline	O	O
echocardiographic	O	O
predictors	O	O
of	O	O
clinical	O	O
outcome	O	O
,	O	O
(	O	O
2	O	O
)	O	O
to	O	O
investigate	O	O
changes	O	O
in	O	O
echocardiographic	O	O
parameters	O	O
,	O	O
and	O	O
(	O	O
3	O	O
)	O	O
to	O	O
compare	O	O
these	O	O
echocardiographic	O	O
changes	O	O
with	O	O
changes	O	O
in	O	O
plasma	O	Physical
levels	O	Physical
of	O	Physical
b-type	O	Physical
natriuretic	O	Physical
peptide	O	Physical
(	O	Physical
BNP	O	Physical
)	O	Physical
in	O	O
a	O	O
population	O	O
of	O	O
children	O	O
with	O	O
systemic	O	O
ventricular	O	O
dysfunction	O	O
and	O	O
symptomatic	O	O
heart	O	O
failure	O	O
treated	O	O
with	O	O
carvedilol	O	O
or	O	O
placebo	O	O
.	O	O

All	O	O
available	O	O
baseline	O	O
and	O	O
6-month	O	O
echocardiograms	O	O
from	O	O
Pediatric	O	O
Carvedilol	O	O
Trial	O	O
(	O	O
PCT	O	O
)	O	O
participants	O	O
(	O	O
carvedilol	O	O
n	O	O
=	O	O
161	O	O
;	O	O
placebo	O	O
n	O	O
=	O	O
55	O	O
)	O	O
were	O	O
reviewed	O	O
.	O	O

Systolic	Physical	O
and	O	O
diastolic	Physical	O
sphericity	Physical	O
index	Physical	O
(	O	O
SI	O	O
;	O	O
n	O	O
=	O	O
110	O	O
)	O	O
,	O	O
TEI	O	O
index	O	O
(	O	O
n	O	O
=	O	O
145	O	O
)	O	O
,	O	O
and	O	O
systemic	O	O
ventricular	O	O
dP/dt	O	O
(	O	O
n	O	O
=	O	O
70	O	O
)	O	O
were	O	O
measured	O	O
.	O	O

The	O	O
PCT	O	O
composite	O	O
definition	O	O
of	O	O
clinical	O	O
outcome	O	O
(	O	O
i.e.	O	O
,	O	O
worsened	O	O
,	O	O
improved	O	O
,	O	O
or	O	O
unchanged	O	O
)	O	O
was	O	O
used	O	O
.	O	O

For	O	O
all	O	O
patients	O	O
,	O	O
baseline	O	O
TEI	O	O
index	O	O
was	O	O
a	O	O
predictor	O	O
of	O	O
worsened	Physical	O
outcome	Physical	O
.	O	O

Only	O	O
children	O	O
treated	O	O
with	O	O
carvedilol	O	O
showed	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
systolic	Physical	Physical
SI	Physical	Physical
(	O	O
P	O	O
B	O	O
0.0001	O	O
)	O	O
,	O	O
diastolic	Physical	O
SI	Physical	O
(	O	O
P	O	O
B	O	O
0.0001	O	O
)	O	O
,	O	O
and	O	O
TEI	Physical	Physical
index	Physical	Physical
(	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
.	O	O

An	O	O
inverse	O	O
correlation	O	O
between	O	O
changes	Physical	O
in	Physical	O
BNP	Physical	Physical
and	O	Physical
changes	Physical	Physical
in	Physical	Physical
dP/dt	Physical	Physical
(	O	O
r	O	O
=	O	O
-0.45	O	O
,	O	O
P	O	O
=	O	O
0.04	O	O
)	O	O
was	O	O
found	O	O
only	O	O
in	O	O
the	O	O
carvedilol	O	O
group	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
TEI	O	O
index	O	O
predicted	O	O
outcome	O	O
in	O	O
children	O	O
with	O	O
systemic	O	O
ventricular	O	O
dysfunction	O	O
and	O	O
heart	O	O
failure	O	O
.	O	O

Carvedilol	O	O
may	O	O
have	O	O
a	O	O
beneficial	O	O
effect	O	O
on	O	O
reversal	O	O
of	O	O
left	O	Physical
ventricular	O	Physical
remodeling	O	Physical
and	O	O
global	O	Physical
ventricular	O	Physical
function	O	Physical
in	O	O
pediatric	O	O
heart	O	O
failure	O	O
.	O	O

[	O	O
Dose-reduced	O	O
antihypertensive	O	O
agents	O	O
--	O	O
use	O	O
in	O	O
complex	O	O
nonmedicamentous	O	O
therapy	O	O
of	O	O
hypertension	O	O
]	O	O
.	O	O

In	O	O
order	O	O
to	O	O
estimate	O	O
the	O	O
influence	O	O
of	O	O
a	O	O
non-medicamentous	O	O
therapy	O	O
(	O	O
CNT	O	O
)	O	O
on	O	O
the	O	O
consumption	O	O
of	O	O
medicaments	O	O
and	O	O
coronary	O	O
risk	O	O
in	O	O
high	O	O
blood	O	O
pressure	O	O
73	O	O
hypertensives	O	O
of	O	O
a	O	O
medicamentously	O	O
stabilized	O	O
CNT-group	O	O
were	O	O
examined	O	O
in	O	O
comparison	O	O
to	O	O
a	O	O
group	O	O
of	O	O
the	O	O
same	O	O
size	O	O
of	O	O
patients	O	O
with	O	O
hypertension	O	O
who	O	O
were	O	O
managed	O	O
exclusively	O	O
medicamentously	O	O
for	O	O
behaviour	O	O
of	O	O
blood	O	O
pressure	O	O
,	O	O
need	O	Others
of	O	Others
antihypertensive	O	Others
drugs	O	Others
and	O	O
changes	O	O
of	O	O
hypertension-associated	O	O
risk	O	O
factors	O	O
.	O	O

After	O	O
an	O	O
exactly	O	O
controlled	O	O
6-month	O	O
treatment	O	O
hypertensives	O	O
with	O	O
additionally	O	O
recommended	O	O
far-reaching	O	O
CNT	O	O
showed	O	O
an	O	O
economization	O	O
of	O	O
medicaments	O	O
by	O	O
scarcely	O	O
the	O	O
half	O	O
in	O	O
comparison	O	O
to	O	O
the	O	O
reference	O	O
group	O	O
.	O	O

By	O	O
means	O	O
of	O	O
suitable	O	O
control	O	O
methods	O	O
a	O	O
causal	O	O
non-medicamentously	O	O
conditioned	O	O
decrease	O	O
of	O	O
blood	Physical	O
pressure	Physical	O
could	O	O
be	O	O
excluded	O	O
.	O	O

A	O	O
different	O	O
need	O	O
of	O	O
antihypertensive	O	O
drugs	O	O
was	O	O
simulated	O	O
by	O	O
the	O	O
exacter	O	O
intake	O	O
of	O	O
medicaments	O	O
in	O	O
the	O	O
index-patients	O	O
.	O	O

Notwithstanding	O	O
the	O	O
metabolic	O	O
effects	O	O
of	O	O
the	O	O
additional	O	O
therapy	O	O
have	O	O
induced	O	O
a	O	O
positive	O	O
change	O	O
of	O	O
atherogenic	Physical	O
lipids	Physical	O
.	Physical	O

The	O	O
examinations	O	O
indicate	O	O
in	O	O
general	O	O
the	O	O
difficulty	O	O
of	O	O
the	O	O
judgement	O	O
of	O	O
efficacy	O	O
of	O	O
non-medicamentous	O	O
therapeutic	O	O
measures	O	O
in	O	O
connection	O	O
with	O	O
a	O	O
rational	O	O
dose-reduced	O	O
long-term	O	O
therapy	O	O
with	O	O
antihypertensive	O	O
drugs	O	O
.	O	O

Bitewing	O	O
film	O	O
quality	O	O
:	O	O
a	O	O
clinical	O	O
comparison	O	O
of	O	O
the	O	O
loop	O	O
vs.	O	O
holder	O	O
techniques	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
compare	O	O
in	O	O
vivo	O	O
bitewing	O	O
film	O	O
quality	O	O
using	O	O
the	O	O
holder	O	O
versus	O	O
the	O	O
paper	O	O
loop	O	O
technique	O	O
.	O	O

METHOD	O	O
AND	O	O
MATERIALS	O	O
Four	O	O
bitewing	O	O
films	O	O
were	O	O
taken	O	O
from	O	O
the	O	O
right	O	O
and	O	O
left	O	O
premolar	O	O
and	O	O
molar	O	O
regions	O	O
of	O	O
45	O	O
dental	O	O
students	O	O
using	O	O
both	O	O
the	O	O
bitewing	O	O
holder	O	O
and	O	O
paper	O	O
loop	O	O
techniques	O	O
.	O	O

A	O	O
total	O	O
of	O	O
360	O	O
films	O	O
were	O	O
taken	O	O
and	O	O
assessed	O	O
by	O	O
an	O	O
experienced	O	O
practitioner	O	O
not	O	O
apprised	O	O
of	O	O
the	O	O
bitewing	O	O
technique	O	O
used	O	O
.	O	O

Of	O	O
interest	O	O
were	O	O
:	O	O
(	O	O
1	O	O
)	O	O
the	O	O
number	O	O
of	O	O
overlaps	O	O
and	O	O
the	O	O
percentage	O	O
of	O	O
teeth	O	O
showing	O	O
the	O	O
alveolar	O	O
crest	O	O
;	O	O
(	O	O
2	O	O
)	O	O
proper	O	O
film	O	O
positioning	O	O
;	O	O
and	O	O
(	O	O
3	O	O
)	O	O
the	O	O
percentage	O	O
of	O	O
cone	O	O
cutting	O	O
.	O	O

A	O	O
Poisson	O	O
regression	O	O
using	O	O
generalized	O	O
estimating	O	O
equations	O	O
(	O	O
GEEs	O	O
)	O	O
was	O	O
used	O	O
to	O	O
estimate	O	O
the	O	O
difference	O	O
in	O	O
overlap	O	O
between	O	O
the	O	O
two	O	O
techniques	O	O
.	O	O

For	O	O
proper	O	O
positioning	O	O
and	O	O
cone	O	O
cutting	O	O
,	O	O
logistic	O	O
regressions	O	O
using	O	O
GEEs	O	O
were	O	O
used	O	O
.	O	O

RESULTS	O	O
The	O	O
average	Others	O
number	Others	O
of	Others	O
horizontal	Others	O
overlaps	Others	O
for	Others	O
the	Others	O
loop	Others	O
and	Others	O
holder	Others	O
techniques	Others	O
at	O	O
the	O	O
right	O	O
premolar	O	O
,	O	O
right	O	O
molar	O	O
,	O	O
left	O	O
premolar	O	O
,	O	O
and	O	O
left	O	O
molar	O	O
were	O	O
1.64	O	O
,	O	O
2.11	O	O
,	O	O
2.16	O	O
,	O	O
2.78	O	O
,	O	O
and	O	O
1.64	O	O
,	O	O
2.00	O	O
,	O	O
2.00	O	O
,	O	O
2.18	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
loop	O	O
technique	O	O
was	O	O
1.11	O	O
times	O	O
more	O	O
likely	O	O
to	O	O
cause	O	O
overlapping	Others	O
than	O	O
the	O	O
holder	O	O
technique	O	O
.	O	O

The	O	O
highest	Others	O
percentage	Others	O
of	Others	O
teeth	Others	O
showing	Others	O
the	Others	O
alveolar	Others	O
crest	Others	O
by	Others	O
the	Others	O
loop	Others	O
technique	Others	O
was	O	O
97.8	O	O
%	O	O
in	O	O
the	O	O
mandibular	O	O
second	O	O
premolar	O	O
and	O	O
first	O	O
molar	O	O
.	O	O

With	O	O
respect	O	O
to	O	O
film	O	O
positioning	O	O
,	O	O
the	O	O
loop	O	O
technique	O	O
was	O	O
1.12	O	O
times	O	O
more	O	O
likely	O	O
to	O	O
cause	O	O
improper	Others	O
positioning	Others	O
than	O	O
the	O	O
holder	O	O
technique	O	O
.	O	O

Both	O	O
techniques	O	O
demonstrated	O	O
minimal	Others	O
cone	Others	O
cutting	Others	O
(	O	O
1	O	O
in	O	O
the	O	O
loop	O	O
versus	O	O
0	O	O
in	O	O
the	O	O
holder	O	O
)	O	O
.	O	O

CONCLUSION	O	O
The	O	O
quality	O	O
of	O	O
bitewing	O	O
films	O	O
taken	O	O
by	O	O
the	O	O
loop	O	O
and	O	O
holder	O	O
techniques	O	O
was	O	O
not	O	O
significantly	O	O
different	O	O
.	O	O

A	O	O
comparative	O	O
study	O	O
of	O	O
methyldopa	O	O
and	O	O
labetalol	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
hypertension	O	O
.	O	O

1	O	O
Twenty	O	O
patients	O	O
with	O	O
essential	O	O
hypertension	O	O
completed	O	O
a	O	O
double-blind	O	O
,	O	O
dose-tritrated	O	O
,	O	O
cross-over	O	O
comparison	O	O
of	O	O
methyldopa	O	O
and	O	O
labetalol	O	O
.	O	O

2	O	O
Average	Physical	O
lying	Physical	O
BPs	Physical	Physical
(	Physical	Physical
systolic/diastolic	Physical	Physical
)	Physical	Physical
were	O	O
reduced	O	O
by	O	O
28/15	O	O
mmHg	O	O
with	O	O
methyldopa	O	O
and	O	O
by	O	O
23/15	O	O
mmHg	O	O
with	O	O
labetalol	O	O
.	O	O

3	O	O
Average	Physical	O
standing	Physical	O
BPs	Physical	Physical
(	Physical	Physical
systolic/diastolic	Physical	Physical
)	Physical	Physical
were	O	O
reduced	O	O
by	O	O
29/14	O	O
mmHg	O	O
with	O	O
methyldopa	O	O
and	O	O
by	O	O
29/15	O	O
mmHg	O	O
with	O	O
labetalol	O	O
.	O	O

4	O	O
Both	O	O
lying	Physical	O
and	Physical	O
standing	Physical	Physical
heart	Physical	Physical
rates	Physical	Physical
were	O	O
reduced	O	O
with	O	O
labetalol	O	O
.	O	O

5	O	O
It	O	O
is	O	O
concluded	O	O
that	O	O
the	O	O
antihypertensive	Others	O
properties	Others	O
of	O	O
labetalol	O	O
and	O	O
methyldopa	O	O
are	O	O
similar	O	O
but	O	O
that	O	O
larger	O	O
patient	O	O
populations	O	O
are	O	O
needed	O	O
to	O	O
study	O	O
the	O	O
relative	O	O
incidence	O	O
of	O	O
subjective	O	O
adverse	O	O
effects	O	O
.	O	O

Clonidine	O	O
increases	O	O
the	O	O
sweating	Physical	O
threshold	Physical	O
,	O	O
but	O	O
does	O	O
not	O	O
reduce	O	O
the	O	O
gain	Physical	Physical
of	Physical	Physical
sweating	Physical	Physical
.	O	O

We	O	O
tested	O	O
the	O	O
hypothesis	O	O
that	O	O
clonidine	O	O
produces	O	O
a	O	O
dose-dependent	O	O
increase	Physical	O
in	Physical	O
the	Physical	O
sweating	Physical	Physical
threshold	Physical	Physical
but	O	O
does	O	O
not	O	O
reduce	Physical	O
the	Physical	O
gain	Physical	Physical
of	Physical	Physical
sweating	Physical	Physical
.	O	O

Six	O	O
healthy	O	O
male	O	O
volunteers	O	O
were	O	O
evaluated	O	O
,	O	O
each	O	O
on	O	O
three	O	O
separate	O	O
days	O	O
in	O	O
random	O	O
order	O	O
.	O	O

In	O	O
one	O	O
,	O	O
saline	O	O
was	O	O
administered	O	O
;	O	O
in	O	O
another	O	O
,	O	O
a	O	O
2-micrograms/kg	O	O
bolus	O	O
of	O	O
clonidine	O	O
was	O	O
followed	O	O
by	O	O
an	O	O
infusion	O	O
at	O	O
2	O	O
micrograms.kg-1.h-1	O	O
,	O	O
and	O	O
on	O	O
a	O	O
third	O	O
day	O	O
,	O	O
a	O	O
4-micrograms/kg	O	O
bolus	O	O
was	O	O
followed	O	O
by	O	O
an	O	O
infusion	O	O
at	O	O
4	O	O
micrograms.kg-1.h-1	O	O
.	O	O

Core	Physical	Physical
temperature	Physical	Physical
was	O	O
measured	O	O
at	O	O
the	O	O
tympanic	O	O
membrane	O	O
and	O	O
mean	Physical	Physical
skin	Physical	Physical
temperature	Physical	Physical
was	O	O
determined	O	O
from	O	O
four	O	O
sites	O	O
.	O	O

A	O	O
chest	Physical	O
sweating	Physical	O
rate	Physical	O
of	O	O
40	O	O
g.m-2.h-1	O	O
was	O	O
considered	O	O
significant	O	O
.	O	O

The	O	O
core	O	Physical
temperature	O	Physical
triggering	O	Physical
sweating	Physical	Physical
,	O	O
adjusted	O	O
to	O	O
a	O	O
designated	O	O
mean	O	O
skin	O	O
temperature	O	O
of	O	O
34	O	O
degrees	O	O
C	O	O
,	O	O
identified	O	O
the	O	O
threshold	O	O
for	O	O
this	O	O
response	O	O
.	O	O

Gain	O	O
was	O	O
defined	O	O
by	O	O
the	O	O
adjusted	O	O
core	Physical	O
temperature	Physical	O
increase	O	O
required	O	O
to	O	O
augment	O	O
sweating	O	O
from	O	O
100	O	O
to	O	O
300	O	O
g.m-2.h-1	O	O
.	O	O

degree	O	O
C-1	O	O
.	O	O

Plasma	Physical	Physical
clonidine	Physical	Physical
concentrations	Physical	Physical
were	O	O
0.8	O	O
+/-	O	O
0.1	O	O
and	O	O
1.6	O	O
+/-	O	O
0.2	O	O
ng/mL	O	O
on	O	O
the	O	O
small-	O	O
and	O	O
large-dose	O	O
days	O	O
,	O	O
respectively	O	O
.	O	O

Clonidine	O	O
administration	O	O
increased	O	O
the	O	O
sweating	O	O
threshold	O	O
approximately	O	O
0.4	O	O
degree	O	O
C	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
,	O	O
but	O	O
the	O	O
increase	O	O
was	O	O
comparable	O	O
at	O	O
each	O	O
dose	O	O
.	O	O

The	O	O
gain	Physical	Physical
of	Physical	Physical
sweating	Physical	Physical
was	O	O
approximately	O	O
0.2	O	O
degree	O	O
C	O	O
and	O	O
was	O	O
not	O	O
influenced	O	O
by	O	O
clonidine	O	O
administration	O	O
.	O	O

The	O	O
thermoregulatory	Physical	O
effects	Physical	O
of	O	O
clonidine	O	O
thus	O	O
resemble	O	O
those	O	O
of	O	O
volatile	O	O
anesthetics	O	O
,	O	O
opioids	O	O
,	O	O
and	O	O
propofol	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
antishivering	O	O
effect	O	O
of	O	O
clonidine	O	O
results	O	O
from	O	O
central	O	O
thermoregulatory	O	O
inhibition	O	O
rather	O	O
than	O	O
a	O	O
specific	O	O
peripheral	O	O
action	O	O
on	O	O
thermogenic	O	O
muscular	O	O
activity	O	O
.	O	O

Unlike	O	O
other	O	O
sedatives	O	O
and	O	O
anesthetics	O	O
,	O	O
the	O	O
concentration-dependence	O	O
of	O	O
clonidine	O	O
demonstrates	O	O
a	O	O
ceiling	O	O
beyond	O	O
which	O	O
the	O	O
administration	O	O
of	O	O
an	O	O
additional	O	O
drug	O	O
fails	O	O
to	O	O
enhance	O	O
the	O	O
effect	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
thermoregulatory	O	O
effect	O	O
of	O	O
clonidine	O	O
may	O	O
be	O	O
limited	O	O
,	O	O
even	O	O
at	O	O
high	O	O
plasma	O	O
concentrations	O	O
.	O	O

The	O	O
gain	O	Physical
of	O	Physical
sweating	O	Physical
was	O	O
well	O	O
preserved	O	O
indicating	O	O
that	O	O
this	O	O
response	O	O
remains	O	O
effective	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
sedatives	O	O
and	O	O
anesthetics	O	O
.	O	O

Combined	O	O
typhoid	O	O
fever	O	O
and	O	O
hepatitis	O	O
A	O	O
vaccine	O	O
:	O	O
comparison	O	O
of	O	O
immunogenicity	Others	O
and	O	O
safety	Others	O
to	O	O
concomitant	O	O
monovalent	O	O
vaccine	O	O
over	O	O
3	O	O
years	O	O
.	O	O

BACKGROUND	O	O
The	O	O
safety	Others	O
and	O	O
immunogenicity	Others	O
of	O	O
Viatim	O	O
,	O	O
a	O	O
combined	O	O
hepatitis	O	O
A	O	O
(	O	O
HA	O	O
)	O	O
and	O	O
typhoid	O	O
fever	O	O
(	O	O
Vi	O	O
)	O	O
vaccine	O	O
,	O	O
were	O	O
compared	O	O
with	O	O
the	O	O
monovalent	O	O
component	O	O
vaccines	O	O
up	O	O
to	O	O
and	O	O
1	O	O
month	O	O
after	O	O
a	O	O
booster	O	O
dose	O	O
at	O	O
3	O	O
years	O	O
.	O	O

METHODS	O	O
Healthy	O	O
,	O	O
adult	O	O
volunteers	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
Viatim	O	O
(	O	O
group	O	O
A	O	O
,	O	O
n	O	O
=	O	O
179	O	O
)	O	O
or	O	O
separate	O	O
HA	O	O
and	O	O
Vi	O	O
vaccines	O	O
(	O	O
group	O	O
B	O	O
,	O	O
n	O	O
=	O	O
181	O	O
)	O	O
;	O	O
subgroups	O	O
were	O	O
boosted	O	O
after	O	O
3	O	O
years	O	O
with	O	O
Viatim	O	O
(	O	O
groups	O	O
C	O	O
and	O	O
D	O	O
,	O	O
n	O	O
=	O	O
56	O	O
and	O	O
46	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Local	O	Physical
and	O	Physical
systemic	O	Physical
reactions	O	Physical
were	O	O
recorded	O	O
for	O	O
28	O	O
days	O	O
postvaccination	O	O
.	O	O

Seroconversion	Physical	O
and	O	O
seroprotection	Physical	O
rates	Physical	O
and	O	O
geometric	Physical	Physical
mean	Physical	Physical
antibody	Physical	Physical
concentrations	Physical	Physical
were	O	O
measured	O	O
at	O	O
14	O	O
and	O	O
28	O	O
days	O	O
,	O	O
1	O	O
,	O	O
2	O	O
,	O	O
and	O	O
3	O	O
years	O	O
postvaccination	O	O
,	O	O
and	O	O
28	O	O
days	O	O
after	O	O
the	O	O
booster	O	O
dose	O	O
.	O	O

RESULTS	O	O
Local	Others	O
and	Others	O
systemic	Others	O
safety	Others	O
profiles	Others	O
were	O	O
equivalent	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

Immediate	Physical	Physical
local	Physical	Physical
reactions	Physical	Physical
were	O	O
infrequent	O	O
(	O	O
1	O	O
in	O	O
group	O	O
A	O	O
and	O	O
2	O	O
in	O	O
group	O	O
B	O	O
)	O	O
.	O	O

Local	Physical	Physical
reactions	Physical	Physical
,	O	O
consisting	Pain	O
mostly	Pain	O
of	Pain	O
mild	Pain	O
or	Pain	O
moderate	Pain	O
pain	Pain	O
,	O	O
were	O	O
least	O	O
frequent	O	O
with	O	O
monovalent	O	O
HA	O	O
.	O	O

Antibody	Physical	O
concentrations	Physical	O
to	O	O
both	O	O
antigens	O	O
were	O	O
similar	O	O
in	O	O
groups	O	O
A	O	O
and	O	O
B	O	O
,	O	O
in	O	O
which	O	O
HA	Physical	O
seroprotection	Physical	O
rates	Physical	O
(	O	O
>	O	O
or	O	O
=	O	O
20	O	O
mIU/mL	O	O
)	O	O
were	O	O
respectively	O	O
,	O	O
98.7	O	O
%	O	O
and	O	O
100	O	O
%	O	O
at	O	O
day	O	O
28	O	O
,	O	O
and	O	O
99.1	O	O
%	O	O
and	O	O
99.0	O	O
%	O	O
after	O	O
3	O	O
years	O	O
,	O	O
achieving	O	O
100	O	O
%	O	O
after	O	O
the	O	O
booster	O	O
.	O	O

Vi	Physical	O
seroprotection	Physical	O
rates	Physical	O
(	O	O
>	O	O
or	O	O
=	O	O
1	O	O
microg/mL	O	O
)	O	O
of	O	O
85.2	O	O
%	O	O
and	O	O
84.9	O	O
%	O	O
after	O	O
28	O	O
days	O	O
fell	O	O
to	O	O
32.1	O	O
%	O	O
and	O	O
35.6	O	O
%	O	O
after	O	O
3	O	O
years	O	O
,	O	O
increasing	O	O
to	O	O
67.3	O	O
%	O	O
and	O	O
69.8	O	O
%	O	O
after	O	O
the	O	O
booster	O	O
dose	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
combined	O	O
HA/Vi	O	O
vaccine	O	O
,	O	O
Viatim	O	O
,	O	O
had	O	O
equivalent	O	O
tolerability	Others	Others
and	O	Others
safety	Others	Others
and	O	O
was	O	O
as	O	O
rapidly	Physical	O
immunogenic	Others	O
as	O	O
its	O	O
component	O	O
monovalent	O	O
vaccines	O	O
when	O	O
given	O	O
concurrently	O	O
.	O	O

A	O	O
booster	O	O
dose	O	O
after	O	O
3	O	O
years	O	O
significantly	O	O
increased	O	O
antibody	Physical	O
levels	Physical	O
with	O	O
some	O	O
evidence	O	O
of	O	O
relative	O	O
hyporesponsiveness	Physical	O
of	Physical	O
the	Physical	O
typhoid	Physical	O
response	Physical	O
.	O	O

Acute	O	O
exposure	O	O
to	O	O
acid	O	O
fog	O	O
:	O	O
influence	O	O
of	O	O
breathing	O	O
pattern	O	O
on	O	O
effective	Physical	O
dose	Physical	O
.	O	O

Concern	O	O
about	O	O
the	O	O
possible	O	O
adverse	Adverseeffect	O
health	Adverseeffect	O
effects	Adverseeffect	O
of	O	O
acid	O	O
fog	O	O
has	O	O
been	O	O
fed	O	O
by	O	O
two	O	O
observations	O	O
:	O	O
air	O	O
pollution	O	O
disasters	O	O
earlier	O	O
in	O	O
this	O	O
century	O	O
were	O	O
typically	O	O
associated	O	O
with	O	O
fog	O	O
,	O	O
and	O	O
current	O	O
samples	O	O
of	O	O
fog	O	O
water	O	O
can	O	O
be	O	O
strongly	O	O
acid	O	O
.	O	O

To	O	O
study	O	O
the	O	O
acute	O	O
effects	O	O
of	O	O
acid	O	O
fog	O	O
on	O	O
the	O	O
lung	O	O
,	O	O
the	O	O
authors	O	O
generated	O	O
a	O	O
monodisperse	O	O
10	O	O
microM	O	O
MMAD	O	O
aerosol	O	O
of	O	O
H2SO4	O	O
with	O	O
a	O	O
pH	O	O
of	O	O
2.0	O	O
and	O	O
a	O	O
nominal	O	O
concentration	O	O
of	O	O
500	O	O
micrograms/m3	O	O
.	O	O

They	O	O
exposed	O	O
seven	O	O
healthy	O	O
young	O	O
men	O	O
on	O	O
alternate	O	O
days	O	O
to	O	O
acid	O	O
or	O	O
control	O	O
equiosmolar	O	O
NaCl	O	O
aerosol	O	O
during	O	O
40	O	O
min	O	O
of	O	O
resting	O	O
ventilation	O	O
and	O	O
20	O	O
min	O	O
of	O	O
exercise	O	O
;	O	O
the	O	O
latter	O	O
was	O	O
sufficiently	O	O
intense	O	O
to	O	O
induce	O	O
oronasal	Physical	O
breathing	Physical	O
.	O	O

Exposure	O	O
was	O	O
by	O	O
means	O	O
of	O	O
a	O	O
head	O	O
dome	O	O
,	O	O
a	O	O
head-only	O	O
exposure	O	O
device	O	O
that	O	O
permitted	O	O
continuous	O	O
measurement	O	O
(	O	O
unfettered	O	O
breathing	O	O
)	O	O
of	O	O
Vr	O	O
,	O	O
f	O	O
,	O	O
VE	O	Physical
,	O	O
and	O	O
the	O	O
onset	O	O
and	O	O
persistence	O	O
of	O	O
oronasal	Physical	O
breathing	Physical	O
.	O	O

In	O	O
this	O	O
article	O	O
the	O	O
authors	O	O
compare	O	O
the	O	O
relative	O	O
importance	O	O
of	O	O
parameters	O	O
contributing	O	O
to	O	O
the	O	O
between-subject	O	O
variability	O	O
in	O	O
estimated	O	O
hydrogen	O	O
ion	O	O
dose	O	O
to	O	O
the	O	O
lower	O	O
airways	O	O
(	O	O
H+LAW	O	O
)	O	O
,	O	O
based	O	O
on	O	O
analysis	O	O
of	O	O
variance	O	O
.	O	O

Physiologic	O	O
parameters	O	O
accounted	O	O
for	O	O
70	O	O
%	O	O
of	O	O
the	O	O
variability	O	O
,	O	O
of	O	O
which	O	O
34	O	O
%	O	O
was	O	O
due	O	O
to	O	O
differences	O	O
in	O	O
duration	Physical	O
of	Physical	O
oronasal	Physical	O
breathing	Physical	O
(	Physical	O
tON	Physical	O
)	Physical	O
and	O	O
36	O	O
%	O	O
to	O	O
differences	O	O
in	O	O
ventilation	Physical	O
rate	Physical	O
during	Physical	O
oronasal	Physical	O
breathing	Physical	O
(	Physical	O
VE	Physical	O
(	Physical	O
ON	Physical	O
)	Physical	O
)	Physical	O
;	O	O
inhaled	Physical	O
hydrogen	Physical	O
ion	Physical	O
concentration	Physical	O
[	Physical	O
H+	Physical	O
]	Physical	O
,	O	O
the	O	O
environmental	O	O
parameter	O	O
,	O	O
contributed	O	O
only	O	O
30	O	O
%	O	O
.	O	O

Minute	O	O
ventilation	O	O
at	O	O
the	O	O
time	O	O
of	O	O
transition	O	O
from	O	O
nasal	O	O
to	O	O
oronasal	O	O
breathing	O	O
varied	O	O
significantly	O	O
among	O	O
subjects	O	O
even	O	O
if	O	O
normalized	O	O
to	O	O
FVC	O	Physical
,	O	Physical
an	O	Physical
index	O	Physical
of	O	Physical
lung	O	Physical
size	O	Physical
.	O	O

B-type	O	O
natriuretic	O	O
peptide	O	O
in	O	O
the	O	O
evaluation	O	O
and	O	O
management	O	O
of	O	O
dyspnoea	O	O
in	O	O
primary	O	O
care	O	O
.	O	O

OBJECTIVES	O	O
The	O	O
rapid	O	O
and	O	O
accurate	O	O
diagnosis	O	O
of	O	O
heart	O	O
failure	O	O
in	O	O
primary	O	O
care	O	O
is	O	O
a	O	O
major	O	O
unmet	O	O
clinical	O	O
need	O	O
.	O	O

We	O	O
evaluated	O	O
the	O	O
additional	O	O
use	O	O
of	O	O
B-type	Physical	O
natriuretic	Physical	O
peptide	Physical	O
(	Physical	O
BNP	Physical	O
)	Physical	O
levels	Physical	O
.	O	O

DESIGN	O	O
A	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

SETTING	O	O
Twenty-nine	O	O
primary	O	O
care	O	O
physicians	O	O
in	O	O
Switzerland	O	O
and	O	O
Germany	O	O
coordinated	O	O
by	O	O
the	O	O
University	O	O
Hospital	O	O
Basel	O	O
,	O	O
Switzerland	O	O
.	O	O

SUBJECTS	O	O
A	O	O
total	O	O
of	O	O
323	O	O
consecutive	O	O
patients	O	O
presenting	O	O
with	O	O
dyspnoea	O	O
.	O	O

INTERVENTIONS	O	O
Assignment	O	O
in	O	O
a	O	O
1	O	O
:	O	O
1	O	O
ratio	O	O
to	O	O
a	O	O
diagnostic	O	O
strategy	O	O
including	O	O
point-of-care	O	O
measurement	O	O
of	O	O
BNP	O	O
(	O	O
n	O	O
=	O	O
163	O	O
)	O	O
or	O	O
standard	O	O
assessment	O	O
without	O	O
BNP	O	O
(	O	O
n	O	O
=	O	O
160	O	O
)	O	O
.	O	O

The	O	O
total	Others	Others
medical	Others	Others
cost	Others	Others
at	Others	O
3	Others	O
months	Others	O
was	O	O
the	O	O
primary	O	O
end-point	O	O
.	O	O

Secondary	O	O
end-points	O	O
were	O	O
diagnostic	Others	O
certainty	Others	O
,	O	O
time	Others	O
to	Others	O
appropriate	Others	O
therapy	Others	O
,	O	O
functional	Others	Physical
capacity	Others	Physical
,	O	O
hospitalization	Adverseeffect	O
and	O	O
mortality	Mortality	O
.	O	O

The	O	O
final	O	O
diagnosis	O	O
was	O	O
adjudicated	O	O
by	O	O
a	O	O
physician	O	O
blinded	O	O
to	O	O
the	O	O
BNP	O	Physical
levels	O	Physical
.	O	O

RESULTS	O	O
Heart	Physical	O
failure	Physical	O
was	O	O
the	O	O
final	O	O
diagnosis	O	O
in	O	O
34	O	O
%	O	O
of	O	O
patients	O	O
.	O	O

The	O	O
number	Others	Physical
of	Others	Physical
hospitalizations	Others	Physical
,	O	O
functional	Others	Physical
status	Others	Physical
and	O	O
total	Others	Others
medical	Others	Others
cost	Others	Others
at	Others	O
3	Others	O
months	Others	O
[	O	O
median	O	O
$	O	O
1655	O	O
,	O	O
interquartile	O	O
range	O	O
(	O	O
IQR	O	O
)	O	O
,	O	O
850-3331	O	O
vs.	O	O
$	O	O
1541	O	O
,	O	O
IQR	O	O
859-2827	O	O
;	O	O
P	O	O
=	O	O
0.68	O	O
]	O	O
were	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

BNP	Physical	O
increased	O	O
diagnostic	Others	O
certainty	Others	O
as	O	O
defined	O	O
by	O	O
the	O	O
need	O	O
for	O	O
further	O	O
diagnostic	O	O
work-up	O	O
(	O	O
33	O	O
%	O	O
vs.	O	O
45	O	O
%	O	O
;	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
and	O	O
accelerated	O	O
the	O	O
initiation	O	O
of	O	O
the	O	O
appropriate	O	O
treatment	O	O
(	O	O
13	O	O
days	O	O
vs.	O	O
25	O	O
days	O	O
;	O	O
P	O	O
=	O	O
0.01	O	O
)	O	O
.	O	O

The	O	O
area	O	O
under	O	O
the	O	O
receiver-operating	O	O
characteristics	O	O
curve	O	O
for	O	O
BNP	O	O
to	O	O
identify	O	O
heart	O	O
failure	O	O
was	O	O
0.87	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
0.81-0.93	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
use	O	O
of	O	O
BNP	O	O
levels	O	O
in	O	O
primary	O	O
care	O	O
did	O	O
not	O	O
reduce	O	Others
total	O	Others
medical	O	Others
cost	O	Others
,	O	O
but	O	O
improved	O	O
some	O	O
of	O	O
the	O	O
secondary	O	O
end-points	O	O
including	O	O
diagnostic	O	O
certainty	O	O
and	O	O
time	O	O
to	O	O
initiation	O	O
of	O	O
appropriate	O	O
treatment	O	O
.	O	O

Anxiety	O	Mental
sensitivity	O	Mental
as	O	O
an	O	O
incremental	O	O
predictor	O	O
of	O	O
later	O	O
anxiety	O	Mental
symptoms	O	Mental
and	O	O
syndromes	O	O
.	O	O

Although	O	O
anxiety	O	O
sensitivity	O	O
(	O	O
AS	O	O
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
predict	O	O
anxiety	O	O
symptoms	O	O
and	O	O
panic	O	O
,	O	O
this	O	O
literature	O	O
is	O	O
limited	O	O
in	O	O
regard	O	O
to	O	O
evaluating	O	O
AS	O	O
as	O	O
an	O	O
incremental	O	O
predictor	O	O
of	O	O
anxiety	O	O
psychopathology	O	O
relative	O	O
to	O	O
other	O	O
established	O	O
risk	O	O
factors	O	O
including	O	O
sex	O	O
and	O	O
negative	O	O
affect	O	O
.	O	O

The	O	O
present	O	O
report	O	O
prospectively	O	O
evaluated	O	O
whether	O	O
AS	O	O
was	O	O
predictive	O	O
of	O	O
later	O	O
changes	O	O
in	O	O
anxiety	Mental	Mental
symptoms	Mental	Mental
after	O	O
controlling	O	O
for	O	O
potential	O	O
confounding	O	O
factors	O	O
.	O	O

Consistent	O	O
with	O	O
hypothesis	O	O
,	O	O
AS	O	O
was	O	O
found	O	O
to	O	O
be	O	O
a	O	O
significant	O	O
,	O	O
incremental	O	O
predictor	O	O
of	O	O
anxiety	Mental	Mental
symptoms	Mental	Mental
over	O	O
time	O	O
,	O	O
even	O	O
after	O	O
controlling	O	O
for	O	O
sex	O	O
and	O	O
negative	O	O
affectivity	O	O
.	O	O

These	O	O
data	O	O
provide	O	O
novel	O	O
evidence	O	O
for	O	O
the	O	O
unique	O	O
association	O	O
between	O	O
AS	O	O
of	O	O
the	O	O
development	O	O
of	O	O
anxiety	O	Mental
symptoms	O	Mental
.	O	O

Behavioral	Mental	O
effects	Mental	O
of	O	O
Org	O	O
2766	O	O
,	O	O
a	O	O
synthetic	O	O
analog	O	O
of	O	O
the	O	O
adrenocorticotrophic	O	O
hormone	O	O
(	O	O
4-9	O	O
)	O	O
,	O	O
in	O	O
14	O	O
outpatient	O	O
autistic	O	O
children	O	O
.	O	O

Fourteen	O	O
children	O	O
(	O	O
12	O	O
infantile	O	O
autism	O	O
full	O	O
syndrome	O	O
present	O	O
,	O	O
2	O	O
atypical	O	O
pervasive	O	O
developmental	O	O
disorder	O	O
)	O	O
between	O	O
5	O	O
and	O	O
13	O	O
years	O	O
of	O	O
age	O	O
participated	O	O
in	O	O
a	O	O
double-blind	O	O
placebo-controlled	O	O
cross-over	O	O
trial	O	O
.	O	O

Each	O	O
child	O	O
received	O	O
20	O	O
mg	O	O
Org	O	O
2766	O	O
(	O	O
synthetic	O	O
analog	O	O
of	O	O
ACTH	O	O
4-9	O	O
)	O	O
/day	O	O
during	O	O
4	O	O
weeks	O	O
,	O	O
or	O	O
placebo	O	O
in	O	O
a	O	O
randomly	O	O
assigned	O	O
sequence	O	O
.	O	O

Drug	Mental	O
effects	Mental	O
were	O	O
monitored	O	O
by	O	O
ethological	Mental	O
playroom	Mental	O
observation	Mental	O
and	O	O
by	O	O
Aberrant	Mental	O
Behavior	Mental	O
Checklist	Mental	O
ratings	Mental	O
by	O	O
parents	O	O
and	O	O
teachers	O	O
.	O	O

Data	O	O
of	O	O
the	O	O
playroom	O	O
observation	O	O
pointed	O	O
to	O	O
an	O	O
activating	Mental	O
influence	Mental	O
of	O	O
Org	O	O
2766	O	O
,	O	O
as	O	O
revealed	O	O
by	O	O
a	O	O
significant	O	O
decrease	O	O
of	O	O
stereotypic	Mental	Mental
behavior	Mental	Mental
and	O	O
significant	O	O
increases	O	O
in	O	O
change	Mental	O
toys	Mental	O
,	Mental	O
locomote	Mental	O
,	Mental	O
and	Mental	O
talk	Mental	O
.	Mental	O

Checklist	O	Others
ratings	O	Others
did	O	O
not	O	O
show	O	O
significant	O	O
changes	O	O
.	O	O

The	O	O
clinical	O	O
implications	O	O
of	O	O
these	O	O
findings	O	O
are	O	O
discussed	O	O
.	O	O

Social	O	O
support	O	O
and	O	O
abstinence	Mental	O
from	O	O
opiates	O	O
and	O	O
cocaine	O	O
during	O	O
opioid	O	O
maintenance	O	O
treatment	O	O
.	O	O

Social	O	O
support	O	O
may	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
helping	O	O
drug	O	O
users	O	O
achieve	O	O
abstinence	Mental	O
;	Mental	O
however	O	O
these	O	O
benefits	O	O
may	O	O
depend	O	O
on	O	O
the	O	O
type	O	O
of	O	O
support	O	O
experienced	O	O
.	O	O

In	O	O
this	O	O
prospective	O	O
observational	O	O
study	O	O
,	O	O
we	O	O
examined	O	O
the	O	O
extent	O	O
to	O	O
which	O	O
general	O	O
and	O	O
abstinence-specific	O	O
support	O	O
,	O	O
both	O	O
structural	O	O
and	O	O
functional	O	O
,	O	O
predicted	O	O
opiate	O	O
and	O	O
cocaine	O	Mental
abstinence	O	Mental
in	O	O
128	O	O
opioid	O	O
maintenance	O	O
patients	O	O
receiving	O	O
either	O	O
methadone	O	O
or	O	O
LAAM	O	O
.	O	O

A	O	O
new	O	O
multidimensional	O	O
self-report	O	O
instrument	O	O
assessing	O	O
abstinence-specific	O	O
functional	O	O
support	O	O
was	O	O
developed	O	O
for	O	O
the	O	O
study	O	O
.	O	O

Previously	O	O
validated	O	O
measures	O	O
were	O	O
used	O	O
to	O	O
assess	O	O
the	O	O
remaining	O	O
types	O	O
of	O	O
support	O	O
.	O	O

With	O	O
baseline	O	O
abstinence	O	O
and	O	O
other	O	O
statistically	O	O
important	O	O
covariates	O	O
adjusted	O	O
,	O	O
hierarchical	O	O
logistic	O	O
regression	O	O
analyses	O	O
demonstrated	O	O
that	O	O
the	O	O
associations	O	O
between	O	O
social	O	O
support	O	O
at	O	O
study	O	O
baseline	O	O
and	O	O
biochemically	O	O
confirmed	O	O
abstinence	O	O
3	O	O
months	O	O
later	O	O
varied	O	O
by	O	O
type	O	O
of	O	O
support	O	O
and	O	O
by	O	O
drug	O	O
.	O	O

Greater	O	O
abstinence-specific	Mental	O
structural	Mental	O
support	Mental	O
(	O	O
operationalized	O	O
as	O	O
fewer	O	O
drug	O	O
users	O	O
in	O	O
the	O	O
social	O	O
network	O	O
)	O	O
and	O	O
decreases	O	O
in	O	O
three	O	O
types	O	O
of	O	O
negative	Mental	O
abstinence-specific	Mental	O
functional	Mental	O
support	Mental	O
(	Mental	O
Complaints	Mental	O
about	Mental	O
Drug	Mental	O
Use	Mental	O
,	Mental	O
Drug	Mental	O
Exposure	Mental	O
,	Mental	O
and	Mental	O
Demoralization	Mental	O
)	Mental	O
predicted	Mental	O
cocaine	Mental	O
,	O	O
but	O	O
not	O	O
opiate	Mental	O
abstinence	Mental	O
.	Mental	O

There	O	O
were	O	O
no	O	O
effects	O	O
for	O	O
general	O	O
support	O	O
,	O	O
whether	O	O
structural	O	O
or	O	O
functional	O	O
,	O	O
on	O	O
abstinence	Mental	O
from	O	O
either	O	O
drug	O	O
.	O	O

Interventions	O	O
that	O	O
focus	O	O
on	O	O
modifying	O	O
patients	O	O
'	O	O
abstinence-specific	O	O
support	O	O
may	O	O
be	O	O
helpful	O	O
in	O	O
reducing	O	O
the	O	O
high	O	O
rates	Mental	O
of	Mental	O
cocaine	Mental	O
use	Mental	O
disorders	Mental	O
in	O	O
this	O	O
population	O	O
.	O	O

Creon	O	O
10,000	O	O
Minimicrospheres	O	O
vs.	O	O
Creon	O	O
8,000	O	O
microspheres	O	O
--	O	O
an	O	O
open	O	O
randomised	O	O
crossover	O	O
preference	O	O
study	O	O
.	O	O

Creon	O	O
10,000	O	O
Minimicrospherestrade	O	O
mark	O	O
(	O	O
Creon	O	O
)	O	O
10,000	O	O
MMS	O	O
)	O	O
is	O	O
a	O	O
pancreatic	O	O
enzyme	O	O
formulation	O	O
that	O	O
contains	O	O
smaller	O	O
spheres	O	O
of	O	O
pancreatin	O	O
in	O	O
a	O	O
50	O	O
%	O	O
smaller	O	O
capsule	O	O
than	O	O
conventional	O	O
microspheres	O	O
(	O	O
Creon	O	O
)	O	O
8,000	O	O
)	O	O
.	O	O

This	O	O
three-centre	O	O
study	O	O
investigated	O	O
the	O	O
preference	O	O
of	O	O
cystic	O	O
fibrosis	O	O
(	O	O
CF	O	O
)	O	O
patients	O	O
for	O	O
these	O	O
products	O	O
.	O	O

In	O	O
one	O	O
centre	O	O
,	O	O
72	O	O
h	O	O
stool	Physical	O
fat	Physical	O
excretion	Physical	O
and	O	O
coefficient	Physical	O
of	Physical	O
fat	Physical	O
absorption	Physical	O
(	Physical	O
CFA	Physical	O
)	Physical	O
were	O	O
also	O	O
compared	O	O
.	O	O

Fifty-nine	O	O
patients	O	O
with	O	O
a	O	O
mean	O	O
age	O	O
10	O	O
years	O	O
(	O	O
range	O	O
3-17	O	O
)	O	O
took	O	O
Creon	O	O
8,000	O	O
ms	O	O
for	O	O
14	O	O
days	O	O
and	O	O
were	O	O
then	O	O
randomised	O	O
to	O	O
28	O	O
days	O	O
of	O	O
Creon	O	O
8,000	O	O
ms	O	O
followed	O	O
by	O	O
28	O	O
days	O	O
of	O	O
Creon	O	O
10,000	O	O
MMS	O	O
,	O	O
or	O	O
vice	O	O
versa	O	O
.	O	O

Dosing	O	O
was	O	O
lipase	O	O
for	O	O
lipase	O	O
according	O	O
to	O	O
the	O	O
labelled	O	O
declaration	O	O
.	O	O

At	O	O
the	O	O
end	O	O
of	O	O
the	O	O
second	O	O
treatment	O	O
period	O	O
,	O	O
51	O	O
of	O	O
54	O	O
patients	O	O
who	O	O
completed	O	O
the	O	O
study	O	O
expressed	O	O
a	O	O
preference	O	O
,	O	O
with	O	O
a	O	O
statistically	O	O
significant	O	O
preference	O	O
in	O	O
favour	O	O
of	O	O
Creon	O	O
10,000	O	O
MMS	O	O
(	O	O
47/51	O	O
;	O	O
87	O	O
%	O	O
)	O	O
vs.	O	O
Creon	O	O
8,000	O	O
ms	O	O
(	O	O
4/51	O	O
;	O	O
7.4	O	O
%	O	O
;	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

Stool	Physical	O
fat	Physical	O
(	Physical	O
g/day	Physical	O
)	Physical	O
and	O	O
CFA	Physical	O
(	O	O
%	O	O
)	O	O
were	O	O
measured	O	O
in	O	O
24	O	O
patients	O	O
at	O	O
the	O	O
end	O	O
of	O	O
each	O	O
treatment	O	O
period	O	O
:	O	O
the	O	O
products	O	O
were	O	O
therapeutically	O	O
equivalent	O	O
(	O	O
Creon	O	O
10,000	O	O
:	O	O
8.4	O	O
g/day	O	O
,	O	O
91.3	O	O
%	O	O
CFA	O	O
;	O	O
Creon	O	O
8,000	O	O
:	O	O
6.7	O	O
g/day	O	O
,	O	O
93.5	O	O
%	O	O
CFA	O	O
)	O	O
.	O	O

Both	O	O
products	O	O
were	O	O
well	O	O
tolerated	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
in	O	O
CF	O	O
children	O	O
we	O	O
found	O	O
a	O	O
clear	O	O
preference	O	O
for	O	O
Creon	O	O
10,000	O	O
MMS	O	O
compared	O	O
with	O	O
Creon	O	O
8,000	O	O
ms	O	O
with	O	O
no	O	O
difference	O	O
in	O	O
fat	Physical	Physical
absorption	Physical	Physical
between	O	O
the	O	O
two	O	O
products	O	O
.	O	O

Creon	O	O
10,000s	O	O
smaller	O	O
capsules	O	O
are	O	O
easier	O	O
to	O	O
take	O	O
and	O	O
should	O	O
aid	O	O
patient	O	O
compliance	O	O
.	O	O

Whole-body	O	O
CT	O	O
screening	O	O
:	O	O
scan	O	O
delay	O	O
and	O	O
contrast	O	O
injection	O	O
duration	O	O
for	O	O
optimal	Others	O
enhancement	Others	O
of	Others	O
abdominal	Others	O
organs	Others	O
and	O	O
deep	Others	O
vessels	Others	O
.	O	O

PURPOSE	O	O
To	O	O
assess	O	O
the	O	O
optimal	O	O
scan	O	O
delays	O	O
and	O	O
contrast	O	O
injection	O	O
durations	O	O
for	O	O
contrast-enhanced	O	O
whole-body	O	O
computed	O	O
tomography	O	O
(	O	O
CT	O	O
)	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
One	O	O
hundred	O	O
forty-two	O	O
patients	O	O
were	O	O
randomized	O	O
into	O	O
three	O	O
groups	O	O
:	O	O
protocol	O	O
A-scan	O	O
delay	O	O
of	O	O
65	O	O
s	O	O
after	O	O
starting	O	O
contrast	O	O
injection	O	O
over	O	O
30	O	O
s	O	O
;	O	O
protocol	O	O
B-105	O	O
and	O	O
70	O	O
s	O	O
;	O	O
and	O	O
protocol	O	O
C-145	O	O
and	O	O
110	O	O
s	O	O
,	O	O
respectively	O	O
.	O	O

Contrast	Others	O
enhancement	Others	O
and	O	O
diagnostic	Others	Others
acceptability	Others	Others
were	O	O
assessed	O	O
.	O	O

RESULTS	O	O
Qualitative	Others	O
assessment	Others	O
was	O	O
subtle	O	O
among	O	O
the	O	O
three	O	O
protocols	O	O
.	O	O

Homogenous	Others	O
enhancement	Others	O
of	Others	O
deep	Others	O
veins	Others	O
was	O	O
more	O	O
assuredly	O	O
achieved	O	O
with	O	O
protocol	O	O
C.	O	O
CONCLUSION	O	O
With	O	O
protocol	O	O
C	O	O
,	O	O
qualitatively	O	O
acceptable	O	O
enhancement	O	O
can	O	O
be	O	O
obtained	O	O
in	O	O
whole-body	O	O
CT	O	O
.	O	O

[	O	O
Effects	O	O
of	O	O
small	O	O
needle-knife	O	O
comprehensive	O	O
therapy	O	O
on	O	O
pain	O	Pain
and	O	O
lumbar	O	O
flexion	O	O
range	O	O
in	O	O
the	O	O
chronic	O	O
nonspecific	O	O
low	O	O
back	O	O
pain	O	O
patient	O	O
]	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
observe	O	O
therapeutic	O	O
effect	O	O
of	O	O
small	O	O
needle-knife	O	O
comprehensive	O	O
therapy	O	O
on	O	O
pain	Pain	Pain
and	O	O
lumbar	Physical	O
flexion	Physical	O
range	Physical	O
in	O	O
the	O	O
chronic	O	O
nonspecific	O	O
low	O	O
back	O	O
pain	O	O
patient	O	O
.	O	O

METHODS	O	O
Three	O	O
hundred	O	O
and	O	O
five	O	O
cases	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
a	O	O
needle-knife	O	O
group	O	O
of	O	O
153	O	O
cases	O	O
and	O	O
a	O	O
physiotherapy	O	O
group	O	O
of	O	O
152	O	O
cases	O	O
.	O	O

The	O	O
needle-knife	O	O
group	O	O
were	O	O
treated	O	O
with	O	O
small	O	O
needle-knife	O	O
releasing	O	O
therapy	O	O
,	O	O
blocking	O	O
and	O	O
functional	O	O
training	O	O
.	O	O

The	O	O
physiotherapy	O	O
group	O	O
were	O	O
treated	O	O
with	O	O
ultra-short	O	O
wave	O	O
,	O	O
modulated	O	O
medium	O	Physical
frequency	O	Physical
current	O	Physical
,	O	O
massage	O	O
and	O	O
functional	O	O
training	O	O
.	O	O

Pain	Pain	Pain
was	O	O
assessed	O	O
by	O	O
visual	Pain	Others
analogue	Pain	Others
scale	Pain	Others
(	Pain	Others
VAS	Pain	Others
)	Pain	Others
and	O	O
the	O	O
lumbar	Physical	O
flexion	Physical	O
range	Physical	O
was	O	O
determined	O	O
before	O	O
and	O	O
after	O	O
treatment	O	O
.	O	O

RESULTS	O	O
After	O	O
treatment	O	O
,	O	O
the	O	O
pain	Pain	Pain
and	O	O
the	O	O
lumbar	Physical	O
flexion	Physical	O
range	Physical	O
were	O	O
significantly	O	O
improved	O	O
in	O	O
the	O	O
two	O	O
groups	O	O
;	O	O
and	O	O
after	O	O
treatment	O	O
,	O	O
the	O	O
VAS	Pain	Others
score	Pain	Others
and	O	Physical
the	O	Physical
lumbar	Physical	Physical
flexion	Physical	Physical
range	Physical	Physical
were	O	O
(	O	O
1.60	O	O
+/-	O	O
0.38	O	O
)	O	O
points	O	O
and	O	O
(	O	O
65.76	O	O
+/-	O	O
15.11	O	O
)	O	O
cm	O	O
in	O	O
the	O	O
needle-knife	O	O
group	O	O
and	O	O
(	O	O
4.59	O	O
+/-	O	O
1.09	O	O
)	O	O
points	O	O
and	O	O
(	O	O
53.74	O	O
+/-	O	O
15.13	O	O
)	O	O
cm	O	O
in	O	O
the	O	O
physiotherapy	O	O
group	O	O
,	O	O
respectively	O	O
,	O	O
the	O	O
needle-knife	O	O
group	O	O
being	O	O
significantly	O	O
better	O	O
than	O	O
the	O	O
physiotherapy	O	O
group	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

Follow-up	O	O
survey	O	O
of	O	O
6-36	O	O
months	O	O
showed	O	O
that	O	O
the	O	O
VAS	Pain	Others
score	Pain	Others
and	O	O
the	O	O
lumbar	Physical	O
flexion	Physical	O
range	Physical	O
in	O	O
the	O	O
needle-knife	O	O
group	O	O
were	O	O
superior	O	O
to	O	O
those	O	O
in	O	O
the	O	O
physiotherapy	O	O
group	O	O
.	O	O

CONCLUSION	O	O
Small	O	O
needle-knife	O	O
comprehensive	O	O
therapy	O	O
can	O	O
significantly	O	O
improve	O	O
pain	Pain	Pain
and	O	O
lumbar	Physical	O
flexion	Physical	O
range	Physical	O
in	O	O
the	O	O
chronic	O	O
nonspecific	O	O
low	O	O
back	O	O
pain	O	O
patient	O	O
,	O	O
with	O	O
a	O	O
stable	O	O
long-term	O	O
therapeutic	O	O
effect	O	O
.	O	O

Salbutamol	O	O
or	O	O
mist	O	O
in	O	O
acute	O	O
bronchiolitis	O	O
.	O	O

BACKGROUND	O	O
The	O	O
role	O	O
of	O	O
bronchodilators	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
bronchiolitis	O	O
remains	O	O
controversial	O	O
.	O	O

METHODS	O	O
A	O	O
double-blind	O	O
,	O	O
placebo	O	O
controlled	O	O
trial	O	O
was	O	O
performed	O	O
to	O	O
evaluate	O	O
the	O	O
clinical	O	O
response	O	O
to	O	O
nebulized	O	O
salbutamol	O	O
.	O	O

One	O	O
hundred	O	O
and	O	O
fifty-six	O	O
infants	O	O
aged	O	O
between	O	O
7	O	O
weeks	O	O
and	O	O
24	O	O
months	O	O
who	O	O
had	O	O
had	O	O
an	O	O
episode	O	O
of	O	O
wheezing	O	O
and	O	O
other	O	O
signs	O	O
and	O	O
symptoms	O	O
of	O	O
bronchiolitis	O	O
were	O	O
randomized	O	O
to	O	O
three	O	O
groups	O	O
as	O	O
follows	O	O
:	O	O
(	O	O
i	O	O
)	O	O
nebulized	O	O
salbutamol	O	O
was	O	O
administered	O	O
to	O	O
52	O	O
patients	O	O
in	O	O
group	O	O
I	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
0.15	O	O
mg/kg	O	O
in	O	O
2	O	O
mL	O	O
saline	O	O
;	O	O
(	O	O
ii	O	O
)	O	O
saline	O	O
was	O	O
nebulized	O	O
to	O	O
52	O	O
patients	O	O
in	O	O
group	O	O
II	O	O
and	O	O
(	O	O
iii	O	O
)	O	O
in	O	O
group	O	O
III	O	O
52	O	O
patients	O	O
received	O	O
mist	O	O
in	O	O
a	O	O
tent	O	O
.	O	O

All	O	O
three	O	O
groups	O	O
were	O	O
administered	O	O
oxygen	O	O
during	O	O
the	O	O
procedures	O	O
.	O	O

Treatment	O	O
was	O	O
repeated	O	O
with	O	O
the	O	O
same	O	O
agent	O	O
after	O	O
30	O	O
min	O	O
if	O	O
the	O	O
respiratory	O	O
score	O	O
was	O	O
5	O	O
or	O	O
more	O	O
.	O	O

Respiratory	Physical	Physical
rate	Physical	Physical
,	O	Physical
heart	Physical	Physical
rate	Physical	Physical
,	O	Physical
oxygen	Physical	Physical
saturation	Physical	Physical
and	O	O
presence	Physical	O
of	Physical	O
cyanosis	Physical	O
,	Physical	O
wheezing	Physical	O
,	Physical	O
retractions	Physical	O
were	O	O
recorded	O	O
before	O	O
and	O	O
after	O	O
each	O	O
treatment	O	O
.	O	O

RESULTS	O	O
The	O	O
decrease	O	Physical
in	O	Physical
the	O	Physical
respiratory	Physical	Physical
score	Physical	Physical
was	O	O
5.2	O	O
+/-	O	O
1.8	O	O
,	O	O
0.82	O	O
+/-	O	O
2.4	O	O
and	O	O
1.7	O	O
+/-	O	O
1.3	O	O
in	O	O
group	O	O
I	O	O
,	O	O
II	O	O
and	O	O
III	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
decrease	O	O
in	O	O
group	O	O
I	O	O
was	O	O
significantly	O	O
higher	O	O
than	O	O
in	O	O
the	O	O
other	O	O
groups	O	O
.	O	O

Heart	Physical	Physical
rate	Physical	Physical
was	O	O
similar	O	O
between	O	O
groups	O	O
.	O	O

Oxygen	Physical	Physical
saturation	Physical	Physical
decreased	O	O
in	O	O
group	O	O
I	O	O
without	O	O
reaching	O	O
statistical	O	O
significance	O	O
.	O	O

CONCLUSIONS	O	O
Salbutamol	O	O
was	O	O
shown	O	O
to	O	O
be	O	O
effective	Others	O
and	O	O
safe	Others	O
in	O	O
the	O	O
treatment	O	O
of	O	O
acute	O	O
bronchiolitis	O	O
.	O	O

Computer-navigated	O	O
versus	O	O
conventional	O	O
total	O	O
knee	O	O
arthroplasty	O	O
a	O	O
prospective	O	O
randomized	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
The	O	O
literature	O	O
lacks	O	O
studies	O	O
that	O	O
confirm	O	O
whether	O	O
the	O	O
improved	O	O
radiographic	O	O
alignment	O	O
that	O	O
can	O	O
be	O	O
achieved	O	O
with	O	O
computer-navigated	O	O
total	O	O
knee	O	O
arthroplasty	O	O
improves	O	O
patients?	O	O
activities	O	O
of	O	O
daily	O	O
living	O	O
or	O	O
the	O	O
durability	O	O
of	O	O
total	O	O
knee	O	O
prostheses	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
computer-navigated	O	O
total	O	O
knee	O	O
arthroplasty	O	O
improves	O	O
the	O	O
clinical	O	O
function	O	O
,	O	O
alignment	O	O
,	O	O
and	O	O
survivorship	O	O
of	O	O
the	O	O
components	O	O
.	O	O

METHODS	O	O
We	O	O
prospectively	O	O
compared	O	O
the	O	O
results	O	O
of	O	O
520	O	O
patients	O	O
with	O	O
osteoarthritis	O	O
who	O	O
underwent	O	O
computer-navigated	O	O
total	O	O
knee	O	O
arthroplasty	O	O
for	O	O
one	O	O
knee	O	O
and	O	O
conventional	O	O
total	O	O
knee	O	O
arthroplasty	O	O
for	O	O
the	O	O
other	O	O
.	O	O

The	O	O
assignment	O	O
of	O	O
the	O	O
knee	O	O
to	O	O
navigation	O	O
or	O	O
not	O	O
was	O	O
done	O	O
randomly	O	O
.	O	O

There	O	O
were	O	O
452	O	O
women	O	O
(	O	O
904	O	O
knees	O	O
)	O	O
and	O	O
sixty-eight	O	O
men	O	O
(	O	O
136	O	O
knees	O	O
)	O	O
with	O	O
a	O	O
mean	O	O
age	O	O
of	O	O
sixty-eight	O	O
years	O	O
(	O	O
range	O	O
,	O	O
forty-nine	O	O
to	O	O
eighty-eight	O	O
years	O	O
)	O	O
at	O	O
the	O	O
time	O	O
of	O	O
the	O	O
index	O	O
arthroplasty	O	O
.	O	O

The	O	O
mean	O	O
follow-up	O	O
period	O	O
was	O	O
10.8	O	O
years	O	O
(	O	O
range	O	O
,	O	O
ten	O	O
to	O	O
twelve	O	O
years	O	O
)	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
assessed	O	O
clinically	O	O
and	O	O
radiographically	O	O
with	O	O
the	O	O
rating	O	O
system	O	O
of	O	O
the	O	O
Knee	Physical	O
Society	Physical	O
and	O	O
with	O	O
the	O	O
Western	Physical	Physical
Ontario	Physical	Physical
and	Physical	Physical
McMaster	Physical	Physical
Universities	Physical	Physical
Osteoarthritis	Physical	Physical
Index	Physical	Physical
(	Physical	Physical
WOMAC	Physical	Physical
)	Physical	Physical
score	Physical	Physical
at	O	O
three	O	O
months	O	O
,	O	O
one	O	O
year	O	O
,	O	O
and	O	O
annually	O	O
thereafter	O	O
.	O	O

RESULTS	O	O
Total	Physical	Physical
knee	Physical	Physical
scores	Physical	Physical
,	O	Physical
knee	Physical	Physical
function	Physical	Physical
scores	Physical	Physical
,	O	O
pain	Pain	Pain
scores	Pain	Pain
,	O	O
WOMAC	Physical	Physical
scores	Physical	Physical
,	O	O
knee	Physical	O
motion	Physical	O
,	O	O
and	O	O
activity	Physical	Physical
scores	Physical	Physical
did	O	O
not	O	O
show	O	O
statistically	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
preoperatively	O	O
or	O	O
at	O	O
the	O	O
time	O	O
of	O	O
the	O	O
final	O	O
follow-up	O	O
.	O	O

Alignment	O	O
and	O	O
the	O	O
survivorship	O	O
of	O	O
the	O	O
components	O	O
were	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

The	O	O
Kaplan-Meier	O	O
survivorship	O	O
with	O	O
revision	O	O
as	O	O
the	O	O
end	O	O
point	O	O
at	O	O
10.8	O	O
years	O	O
was	O	O
98.8	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
,	O	O
0.96	O	O
to	O	O
1.00	O	O
)	O	O
in	O	O
the	O	O
computernavigated	O	O
total	O	O
knee	O	O
arthroplasty	O	O
group	O	O
and	O	O
99.2	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
0.96	O	O
to	O	O
1.00	O	O
)	O	O
in	O	O
the	O	O
conventional	O	O
total	O	O
knee	O	O
arthroplasty	O	O
group	O	O
.	O	O

CONCLUSIONS	O	O
Our	O	O
data	O	O
demonstrated	O	O
no	O	O
difference	O	O
in	O	O
clinical	O	O
function	O	O
or	O	O
alignment	O	O
and	O	O
survivorship	O	O
of	O	O
the	O	O
components	O	O
between	O	O
the	O	O
knees	O	O
that	O	O
underwent	O	O
computer-navigated	O	O
total	O	O
knee	O	O
arthroplasty	O	O
and	O	O
those	O	O
that	O	O
underwent	O	O
conventional	O	O
total	O	O
knee	O	O
arthroplasty	O	O
.	O	O

Autism-Spectrum	O	O
Quotient-Japanese	O	O
version	O	O
and	O	O
its	O	O
short	O	O
forms	O	O
for	O	O
screening	O	O
normally	O	O
intelligent	O	O
persons	O	O
with	O	O
pervasive	O	O
developmental	O	O
disorders	O	O
.	O	O

A	O	O
Japanese	O	O
version	O	O
of	O	O
the	O	O
Autism	O	O
Spectrum	O	O
Quotient	O	O
(	O	O
AQ	O	O
)	O	O
,	O	O
AQ-J	O	O
was	O	O
administered	O	O
to	O	O
25	O	O
normally	O	O
intelligent	O	O
high-functioning	O	O
pervasive	O	O
developmental	O	O
disorder	O	O
(	O	O
HPDD	O	O
)	O	O
patients	O	O
(	O	O
mean	O	O
age	O	O
,	O	O
24.2	O	O
years	O	O
;	O	O
24	O	O
male	O	O
,	O	O
one	O	O
female	O	O
)	O	O
and	O	O
215	O	O
controls	O	O
(	O	O
mean	O	O
age	O	O
,	O	O
30.4	O	O
years	O	O
;	O	O
86	O	O
male	O	O
,	O	O
129	O	O
female	O	O
)	O	O
randomly	O	O
selected	O	O
from	O	O
the	O	O
general	O	O
population	O	O
.	O	O

The	O	O
AQ-J	O	O
had	O	O
satisfactory	Others	O
internal	Others	O
consistency	Others	O
reliability	Others	O
(	O	O
Cronbach	O	O
's	O	O
alpha	O	O
>	O	O
0.70	O	O
in	O	O
the	O	O
two	O	O
groups	O	O
)	O	O
,	O	O
test-retest	Others	Others
reliability	Others	Others
,	O	O
and	O	O
discriminant	Others	O
validity	Others	O
[	O	O
i.e	O	O
.	O	O

the	O	O
AQ-J	O	Physical
score	O	Physical
was	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
HPDD	O	O
(	O	O
mean	O	O
,	O	O
29.6	O	O
)	O	O
than	O	O
controls	O	O
(	O	O
mean	O	O
,	O	O
22.2	O	O
)	O	O
]	O	O
.	O	O

At	O	O
a	O	O
cut-off	O	O
of	O	O
26	O	O
,	O	O
the	O	O
AQ-J	Physical	O
had	O	O
satisfactory	Others	O
sensitivity	Others	O
,	O	O
specificity	Others	O
,	O	O
and	O	O
negative	Others	O
predictive	Others	O
value	Others	O
,	O	O
but	O	O
it	O	O
had	O	O
low	Others	O
positive	Others	O
predictive	Others	O
value	Others	O
(	O	O
0.24	O	O
)	O	O
possibly	O	O
due	O	O
to	O	O
the	O	O
facts	O	O
that	O	O
the	O	O
25	O	O
mild	O	O
HPDD	O	O
patients	O	O
scored	O	O
lower	O	O
and	O	O
the	O	O
controls	O	O
scored	O	O
higher	O	O
on	O	O
the	O	O
AQ-J	O	O
than	O	O
British	O	O
counterparts	O	O
on	O	O
the	O	O
AQ	O	O
.	O	O

The	O	O
AQ-J-21	Physical	O
(	Physical	O
consisting	Physical	O
of	Physical	O
21	Physical	O
items	Physical	O
significantly	Physical	O
associated	Physical	O
with	Physical	O
HPDD	Physical	O
diagnosis	Physical	O
)	Physical	O
and	O	O
the	O	O
AQ-J-10	Physical	O
(	Physical	O
consisting	Physical	O
of	Physical	O
10	Physical	O
of	Physical	O
the	Physical	O
21	Physical	O
items	Physical	O
with	Physical	O
an	Physical	O
effect	Physical	O
size	Physical	O
>	Physical	O
0.17	Physical	O
)	Physical	O
had	O	O
higher	O	O
,	O	O
although	O	O
not	Physical	O
satisfactory	Physical	O
,	O	O
positive	Others	O
predictive	Others	O
values	Others	O
of	O	O
0.35	O	O
and	O	O
0.46	O	O
at	O	O
cut-offs	O	O
of	O	O
12	O	O
and	O	O
7	O	O
,	O	O
respectively	O	O
,	O	O
than	O	O
the	O	O
AQ-J	O	O
.	O	O

The	O	O
AQ-J	O	O
and	O	O
two	O	O
short	O	O
forms	O	O
are	O	O
useful	O	O
not	O	O
to	O	O
predict	O	O
but	O	O
to	O	O
rule	O	O
out	O	O
mild	Physical	O
HPDD	Physical	O
,	O	O
the	O	O
most	O	O
difficult	O	O
part	O	O
of	O	O
HPDD	O	O
to	O	O
be	O	O
distinguished	O	O
from	O	O
non-PDD	O	O
conditions	O	O
,	O	O
in	O	O
persons	O	O
scoring	O	O
under	O	O
the	O	O
cut-offs	O	O
and	O	O
to	O	O
consider	O	O
professionals	O	O
'	O	O
examination	O	O
of	O	O
HPDD	O	O
in	O	O
persons	O	O
scoring	O	O
over	O	O
them	O	O
,	O	O
because	O	O
their	O	O
negative	O	O
predictive	O	O
values	O	O
were	O	O
satisfactory	O	O
.	O	O

The	O	O
aging	O	O
motor	O	O
system	O	O
as	O	O
a	O	O
model	O	O
for	O	O
plastic	O	O
changes	O	O
of	O	O
GABA-mediated	O	O
intracortical	O	O
inhibition	O	O
and	O	O
their	O	O
behavioral	O	O
relevance	O	O
.	O	O

Since	O	O
GABAA-mediated	O	O
intracortical	O	O
inhibition	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
underlie	O	O
plastic	O	O
changes	O	O
throughout	O	O
the	O	O
lifespan	O	O
from	O	O
development	O	O
to	O	O
aging	O	O
,	O	O
here	O	O
,	O	O
the	O	O
aging	O	O
motor	O	O
system	O	O
was	O	O
used	O	O
as	O	O
a	O	O
model	O	O
to	O	O
analyze	O	O
the	O	O
interdependence	O	O
of	O	O
plastic	O	O
alterations	O	O
within	O	O
the	O	O
inhibitory	O	O
motorcortical	O	O
network	O	O
and	O	O
level	O	O
of	O	O
behavioral	O	Mental
performance	O	Mental
.	O	O

Double-pulse	O	O
transcranial	O	O
magnetic	O	O
stimulation	O	O
(	O	O
dpTMS	O	O
)	O	O
was	O	O
used	O	O
to	O	O
examine	O	O
inhibition	O	O
by	O	O
means	O	O
of	O	O
short-interval	O	Physical
intracortical	O	Physical
inhibition	O	Physical
(	O	Physical
SICI	O	Physical
)	O	Physical
of	O	O
the	O	O
contralateral	O	O
primary	O	O
motor	O	O
cortex	O	O
in	O	O
a	O	O
sample	O	O
of	O	O
64	O	O
healthy	O	O
right-handed	O	O
human	O	O
subjects	O	O
covering	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
the	O	O
adult	O	O
lifespan	O	O
(	O	O
age	O	O
range	O	O
20-88	O	O
years	O	O
,	O	O
mean	O	O
47.6	O	O
?	O	O
20.7	O	O
,	O	O
34	O	O
female	O	O
)	O	O
.	O	O

SICI	O	Physical
was	O	O
evaluated	O	O
during	O	O
resting	O	O
state	O	O
and	O	O
in	O	O
an	O	O
event-related	O	O
condition	O	O
during	O	O
movement	O	O
preparation	O	O
in	O	O
a	O	O
visually	O	O
triggered	O	O
simple	O	O
reaction	O	O
time	O	O
task	O	O
.	O	O

In	O	O
a	O	O
subgroup	O	O
(	O	O
N	O	O
=	O	O
23	O	O
)	O	O
,	O	O
manual	O	Physical
motor	Physical	Physical
performance	Physical	Physical
was	O	O
tested	O	O
with	O	O
tasks	O	O
of	O	O
graded	O	O
dexterous	O	O
demand	O	O
.	O	O

Weak	O	O
resting-state	O	O
inhibition	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
overall	O	O
lower	O	O
manual	O	O
motor	O	O
performance	O	O
.	O	O

Better	O	O
event-related	O	O
modulation	O	O
of	O	O
inhibition	O	O
correlated	O	O
with	O	O
better	O	O
performance	O	O
in	O	O
more	O	O
demanding	O	O
tasks	O	O
,	O	O
in	O	O
which	O	O
fast	O	O
alternating	O	O
activation	O	O
of	O	O
cortical	O	O
representations	O	O
are	O	O
necessary	O	O
.	O	O

Declining	O	O
resting-state	O	O
inhibition	O	O
was	O	O
associated	O	O
with	O	O
weakened	O	O
event-related	O	O
modulation	O	O
of	O	O
inhibition	O	O
.	O	O

Therefore	O	O
,	O	O
reduced	O	O
resting-state	O	O
inhibition	O	O
might	O	O
lead	O	O
to	O	O
a	O	O
subsequent	O	O
loss	O	O
of	O	O
modulatory	O	O
capacity	O	O
,	O	O
possibly	O	O
reflecting	O	O
malfunctioning	O	O
precision	O	O
in	O	O
GABAAergic	O	O
neurotransmission	O	O
;	O	O
the	O	O
consequence	O	O
is	O	O
an	O	O
inevitable	O	O
decline	O	O
in	O	O
motor	O	O
function	O	O
.	O	O

Transurethral	O	O
prostate	O	O
resection	O	O
and	O	O
bleeding	O	O
:	O	O
a	O	O
randomized	O	O
,	O	O
placebo	O	O
controlled	O	O
trial	O	O
of	O	O
role	O	O
of	O	O
finasteride	O	O
for	O	O
decreasing	O	O
operative	O	O
blood	O	O
loss	O	O
.	O	O

PURPOSE	O	O
Bleeding	O	O
associated	O	O
with	O	O
transurethral	O	O
prostate	O	O
resection	O	O
can	O	O
often	O	O
be	O	O
significant	O	O
and	O	O
lead	O	O
to	O	O
increased	O	O
morbidity	O	O
and	O	O
occasionally	O	O
mortality	O	O
.	O	O

It	O	O
has	O	O
been	O	O
shown	O	O
that	O	O
finasteride	O	O
decreases	O	O
bleeding	O	O
in	O	O
patients	O	O
with	O	O
hematuria	O	O
of	O	O
prostatic	O	O
origin	O	O
.	O	O

We	O	O
hypothesized	O	O
that	O	O
bleeding	O	O
in	O	O
patients	O	O
undergoing	O	O
transurethral	O	O
prostate	O	O
resection	O	O
could	O	O
be	O	O
decreased	O	O
by	O	O
giving	O	O
finasteride	O	O
for	O	O
2	O	O
weeks	O	O
before	O	O
surgery	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
A	O	O
total	O	O
70	O	O
patients	O	O
scheduled	O	O
to	O	O
undergo	O	O
elective	O	O
transurethral	O	O
prostate	O	O
resection	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
5	O	O
mg.	O	O
finasteride	O	O
daily	O	O
or	O	O
placebo	O	O
for	O	O
2	O	O
weeks	O	O
before	O	O
surgery	O	O
.	O	O

Serum	Physical	Physical
hemoglobin	Physical	Physical
was	O	O
measured	O	O
before	O	O
and	O	O
after	O	O
surgery	O	O
,	O	O
and	O	O
the	O	O
following	O	O
day	O	O
.	O	O

The	O	O
volume	Others	O
of	Others	O
irrigation	Others	O
fluid	Others	O
used	O	O
and	O	O
its	O	O
hemoglobin	O	O
concentration	O	O
as	O	O
well	O	O
as	O	O
resected	O	O
prostate	O	O
weight	O	O
were	O	O
recorded	O	O
.	O	O

RESULTS	O	O
Of	O	O
the	O	O
68	O	O
patients	O	O
who	O	O
underwent	O	O
transurethral	O	O
prostate	O	O
resection	O	O
2	O	O
were	O	O
withdrawn	O	O
before	O	O
surgery	O	O
,	O	O
and	O	O
so	O	O
32	O	O
received	O	O
finasteride	O	O
and	O	O
36	O	O
received	O	O
placebo	O	O
.	O	O

There	O	O
was	O	O
significantly	O	O
less	O	O
mean	Physical	Physical
blood	Physical	Physical
loss	Physical	Physical
in	Physical	O
irrigation	Physical	O
fluid	Physical	O
in	O	O
the	O	O
finasteride	O	O
group	O	O
than	O	O
in	O	O
the	O	O
control	O	O
group	O	O
(	O	O
43.6	O	O
versus	O	O
69.3	O	O
gm	O	O
.	O	O

hemoglobin	O	O
,	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
difference	O	O
was	O	O
more	O	O
significant	O	O
when	O	O
blood	Physical	O
loss	Physical	O
per	O	O
gm	O	O
.	O	O

resected	O	O
prostate	O	O
was	O	O
calculated	O	O
(	O	O
2.65	O	O
versus	O	O
4.65	O	O
gm	O	O
.	O	O

hemoglobin	O	O
per	O	O
gm	O	O
.	O	O

prostate	O	O
,	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
This	O	O
study	O	O
shows	O	O
that	O	O
finasteride	O	O
given	O	O
for	O	O
2	O	O
weeks	O	O
preoperatively	O	O
decreases	O	O
bleeding	Physical	O
in	O	O
patients	O	O
undergoing	O	O
transurethral	O	O
prostate	O	O
resection	O	O
.	O	O

Further	O	O
study	O	O
is	O	O
required	O	O
to	O	O
determine	O	O
the	O	O
optimal	O	O
timing	O	O
and	O	O
dose	O	O
duration	O	O
to	O	O
minimize	O	O
blood	Physical	O
loss	Physical	O
and	O	O
identify	O	O
how	O	O
relevant	O	O
such	O	O
a	O	O
decrease	O	O
in	O	O
bleeding	O	O
is	O	O
in	O	O
clinical	O	O
practice	O	O
.	O	O

Effect	O	O
of	O	O
acute	O	O
exercise	O	O
on	O	O
executive	Mental	O
function	Mental	O
in	O	O
children	O	O
with	O	O
attention	O	Mental
deficit	O	Mental
hyperactivity	O	Mental
disorder	O	Mental
.	O	Mental

This	O	O
study	O	O
was	O	O
conducted	O	O
to	O	O
determine	O	O
the	O	O
effect	O	O
of	O	O
acute	O	O
aerobic	O	O
exercise	O	O
on	O	O
executive	Mental	O
function	Mental	O
in	O	O
children	O	O
with	O	O
attention	O	Mental
deficit	O	Mental
hyperactivity	O	Mental
disorder	O	Mental
(	O	Mental
ADHD	O	Mental
)	O	Mental
.	O	O

Forty	O	O
children	O	O
with	O	O
ADHD	O	O
were	O	O
randomly	O	O
assigned	O	O
into	O	O
exercise	O	O
or	O	O
control	O	O
groups	O	O
.	O	O

Participants	O	O
in	O	O
the	O	O
exercise	O	O
group	O	O
performed	O	O
a	O	O
moderate	O	O
intensity	O	O
aerobic	O	O
exercise	O	O
for	O	O
30	O	O
min	O	O
,	O	O
whereas	O	O
the	O	O
control	O	O
group	O	O
watched	O	O
a	O	O
running/exercise-related	O	O
video	O	O
.	O	O

Neuropsychological	Others	O
tasks	Others	O
,	Others	O
the	Others	O
Stroop	Others	O
Test	Others	O
and	Others	O
the	Others	O
Wisconsin	Others	O
Card	Others	O
Sorting	Others	O
Test	Others	O
(	Others	O
WCST	Others	O
)	Others	O
,	O	O
were	O	O
assessed	O	O
before	O	O
and	O	O
after	O	O
each	O	O
treatment	O	O
.	O	O

The	O	O
results	O	O
indicated	O	O
that	O	O
acute	O	O
exercise	O	O
facilitated	O	O
performance	O	O
in	O	O
the	O	O
Stroop	O	O
Test	O	O
,	O	O
particularly	O	O
in	O	O
the	O	O
Stroop	Others	O
Color-Word	Others	O
condition	Others	O
.	Others	O

Additionally	O	O
,	O	O
children	O	O
in	O	O
the	O	O
exercise	O	O
group	O	O
demonstrated	O	O
improvement	O	O
in	O	O
specific	O	O
WCST	Mental	O
performances	Mental	O
in	O	O
Non-perseverative	Mental	O
Errors	Mental	O
and	Mental	O
Categories	Mental	O
Completed	Mental	O
,	O	O
whereas	O	O
no	O	O
influences	O	O
were	O	O
found	O	O
in	O	O
those	O	O
performances	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

Tentative	O	O
explanations	O	O
for	O	O
the	O	O
exercise	O	O
effect	O	O
postulate	O	O
that	O	O
exercise	O	O
allocates	O	O
attention	O	O
resources	O	O
,	O	O
influences	O	O
the	O	O
dorsolateral	O	O
prefrontal	O	O
cortex	O	O
,	O	O
and	O	O
is	O	O
implicated	O	O
in	O	O
exercise-induced	O	O
dopamine	O	O
release	O	O
.	O	O

These	O	O
findings	O	O
are	O	O
promising	O	O
and	O	O
additional	O	O
investigations	O	O
to	O	O
explore	O	O
the	O	O
efficacy	Others	O
of	O	O
exercise	O	O
on	O	O
executive	O	O
function	O	O
in	O	O
children	O	O
with	O	O
ADHD	O	O
are	O	O
encouraged	O	O
.	O	O

Mechanisms	O	O
underlying	O	O
the	O	O
lack	O	O
of	O	O
effect	O	O
of	O	O
implantable	O	O
cardioverter-defibrillator	O	O
therapy	O	O
on	O	O
mortality	Mortality	Mortality
in	O	O
high-risk	O	O
patients	O	O
with	O	O
recent	O	O
myocardial	O	O
infarction	O	O
:	O	O
insights	O	O
from	O	O
the	O	O
Defibrillation	O	O
in	O	O
Acute	O	O
Myocardial	O	O
Infarction	O	O
Trial	O	O
(	O	O
DINAMIT	O	O
)	O	O
.	O	O

BACKGROUND	O	O
although	O	O
implantable	O	O
cardioverter-defibrillators	O	O
(	O	O
ICDs	O	O
)	O	O
lower	O	O
mortality	O	O
in	O	O
stable	O	O
patients	O	O
with	O	O
low	O	O
ejection	O	O
fraction	O	O
late	O	O
after	O	O
myocardial	O	O
infarction	O	O
,	O	O
randomized	O	O
trials	O	O
of	O	O
ICD	O	O
versus	O	O
control	O	O
subjects	O	O
implanted	O	O
early	O	O
after	O	O
myocardial	O	O
infarction	O	O
do	O	O
not	O	O
show	O	O
mortality	O	O
benefit	O	O
.	O	O

Our	O	O
objective	O	O
was	O	O
to	O	O
investigate	O	O
possible	O	O
mechanisms	O	O
underlying	O	O
the	O	O
lack	O	O
of	O	O
mortality	Mortality	O
benefit	O	O
in	O	O
the	O	O
Defibrillation	O	O
in	O	O
Acute	O	O
Myocardial	O	O
Infarction	O	O
Trial	O	O
(	O	O
DINAMIT	O	O
)	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
this	O	O
is	O	O
a	O	O
secondary	O	O
analysis	O	O
of	O	O
the	O	O
prospective	O	O
randomized	O	O
clinical	O	O
trial	O	O
.	O	O

Outpatients	O	O
with	O	O
recent	O	O
(	O	O
6	O	O
to	O	O
40	O	O
days	O	O
)	O	O
acute	O	O
myocardial	O	O
infarction	O	O
,	O	O
left	O	Physical
ventricular	O	Physical
dysfunction	O	Physical
(	O	O
ejection	O	O
fraction	O	O
<	O	O
35	O	O
%	O	O
)	O	O
,	O	O
and	O	O
low	O	O
heart	O	O
rate	O	O
variability	O	O
were	O	O
randomized	O	O
to	O	O
ICD	O	O
(	O	O
n=311	O	O
)	O	O
or	O	O
to	O	O
standard	O	O
medical	O	O
therapy	O	O
(	O	O
n=342	O	O
)	O	O
.	O	O

In	O	O
a	O	O
competing-risks	O	O
analysis	O	O
,	O	O
those	O	O
factors	O	O
that	O	O
increased	O	O
the	O	O
risk	Mortality	Physical
of	Mortality	Physical
arrhythmic	Mortality	Physical
death	Mortality	Physical
also	O	O
increased	O	O
the	O	O
risk	Mortality	O
of	Mortality	O
nonarrhythmic	Mortality	O
deaths	Mortality	O
.	O	O

After	O	O
adjustment	O	O
for	O	O
these	O	O
factors	O	O
,	O	O
receiving	O	O
an	O	O
ICD	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
decreased	O	O
risk	Mortality	Mortality
of	Mortality	Mortality
arrhythmic	Mortality	Mortality
death	Mortality	Mortality
(	O	O
hazard	O	O
ratio	O	O
,	O	O
0.33	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
0.15	O	O
to	O	O
0.71	O	O
)	O	O
but	O	O
an	O	O
increase	O	O
in	O	O
nonarrhythmic	Mortality	O
death	Mortality	O
(	O	O
hazard	O	O
ratio	O	O
,	O	O
1.70	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
1.00	O	O
to	O	O
2.80	O	O
)	O	O
.	O	O

In	O	O
an	O	O
adjusted	O	O
time-dependent	O	O
analysis	O	O
,	O	O
patients	O	O
receiving	O	O
an	O	O
ICD	O	O
and	O	O
having	O	O
appropriate	O	O
ICD	O	O
therapy	O	O
had	O	O
a	O	O
15.1	O	O
%	O	O
yearly	Mortality	O
hazard	Mortality	O
of	Mortality	O
mortality	Mortality	O
compared	O	O
with	O	O
5.2	O	O
%	O	O
in	O	O
ICD	O	O
patients	O	O
with	O	O
no	O	O
appropriate	O	O
therapy	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

The	O	O
reduction	O	O
in	O	O
sudden	Mortality	Mortality
death	Mortality	Mortality
in	O	O
ICD	O	O
patients	O	O
was	O	O
completely	O	O
offset	O	O
by	O	O
increased	O	O
nonarrhythmic	Mortality	O
deaths	Mortality	O
,	O	O
which	O	O
were	O	O
greatest	O	O
in	O	O
patients	O	O
receiving	O	O
ICD	O	O
shock	O	O
therapy	O	O
(	O	O
hazard	O	O
ratio	O	O
,	O	O
6.0	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
2.8	O	O
to	O	O
12.7	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
in	O	O
patients	O	O
receiving	O	O
ICDs	O	O
early	O	O
after	O	O
myocardial	O	O
infarction	O	O
,	O	O
those	O	O
factors	O	O
that	O	O
are	O	O
associated	O	O
with	O	O
arrhythmia	O	O
requiring	O	O
ICD	O	O
therapy	O	O
are	O	O
also	O	O
associated	O	O
with	O	O
a	O	O
high	O	O
risk	O	O
of	O	O
nonsudden	Mortality	O
death	Mortality	O
,	O	O
negating	O	O
the	O	O
benefit	O	O
of	O	O
ICDs	O	O
in	O	O
this	O	O
setting	O	O
.	O	O

Double-blind	O	O
randomized	O	O
evaluation	O	O
of	O	O
intercostal	O	O
nerve	O	O
blocks	O	O
as	O	O
an	O	O
adjuvant	O	O
to	O	O
subarachnoid	O	O
administered	O	O
morphine	O	O
for	O	O
post-thoracotomy	O	O
analgesia	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
OBJECTIVES	O	O
Thoracotomy	O	O
is	O	O
associated	O	O
with	O	O
pain	O	Pain
and	O	O
compromised	O	O
pulmonary	O	O
function	O	O
.	O	O

Intercostal	O	O
nerve	O	O
blocks	O	O
(	O	O
INB	O	O
)	O	O
and	O	O
subarachnoid	O	O
morphine	O	O
(	O	O
SM	O	O
)	O	O
act	O	O
on	O	O
different	O	O
portions	O	O
of	O	O
the	O	O
pain	O	O
pathway	O	O
.	O	O

Each	O	O
is	O	O
effective	O	O
for	O	O
post-thoracotomy	O	O
pain	Pain	O
relief	O	O
.	O	O

The	O	O
combination	O	O
of	O	O
these	O	O
two	O	O
modalities	O	O
in	O	O
relieving	O	O
post-thoracotomy	Pain	O
pain	Pain	O
and	O	O
improving	O	O
postoperative	Physical	O
pulmonary	Physical	O
function	Physical	O
has	O	O
not	O	O
been	O	O
investigated	O	O
.	O	O

METHODS	O	O
In	O	O
a	O	O
double-blind	O	O
study	O	O
,	O	O
20	O	O
patients	O	O
undergoing	O	O
lateral	O	O
thoracotomy	O	O
for	O	O
lung	O	O
resection	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
0.5	O	O
mg	O	O
SM	O	O
preoperatively	O	O
and	O	O
INB	O	O
with	O	O
bupivacaine	O	O
(	O	O
INB+	O	O
)	O	O
prior	O	O
to	O	O
wound	O	O
closure	O	O
or	O	O
0.5	O	O
mg	O	O
SM	O	O
with	O	O
INB	O	O
using	O	O
saline	O	O
(	O	O
INB-	O	O
)	O	O
.	O	O

Visual	Pain	Pain
analog	Pain	Pain
scale	Pain	Pain
pain	Pain	Pain
scores	Pain	Pain
at	O	Pain
rest	O	Pain
,	O	O
with	Physical	O
cough	Physical	O
,	Physical	O
and	Physical	O
with	Physical	O
movement	Physical	O
of	Physical	O
the	Physical	O
ipsilateral	Physical	O
arm	Physical	O
,	Physical	O
forced	Physical	O
expiratory	Physical	O
volume	Physical	O
in	Physical	O
1	Physical	O
second	Physical	O
(	Physical	O
FEV1	Physical	O
)	Physical	O
,	O	O
and	O	O
forced	Physical	Physical
vital	Physical	Physical
capacity	Physical	Physical
(	Physical	Physical
FVC	Physical	Physical
)	Physical	Physical
were	O	O
measured	O	O
at	O	O
4	O	O
,	O	O
24	O	O
,	O	O
48	O	O
,	O	O
and	O	O
72	O	O
hours	O	O
after	O	O
the	O	O
operation	O	O
.	O	O

Opioid	Others	O
use	Others	O
was	O	O
measured	O	O
during	O	O
the	O	O
initial	O	O
24	O	O
hours	O	O
after	O	O
the	O	O
operation	O	O
.	O	O

RESULTS	O	O
At	O	O
4	O	O
hours	O	O
,	O	O
the	O	O
INB+	O	O
group	O	O
demonstrated	O	O
better	O	O
FEV1	Physical	Physical
(	O	O
56.6	O	O
%	O	O
vs.	O	O
40.4	O	O
%	O	O
of	O	O
baseline	O	O
,	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
and	O	O
FVC	Physical	Physical
values	O	Physical
(	O	O
54.6	O	O
%	O	O
vs.	O	O
39.6	O	O
%	O	O
of	O	O
baseline	O	O
,	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
and	O	O
less	O	O
resting	O	O
and	O	O
cough	O	Pain
pain	O	Pain
(	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
.	O	O

However	O	O
,	O	O
FEV1	Physical	O
continued	O	O
to	O	O
decline	O	O
in	O	O
the	O	O
INB+	O	O
group	O	O
at	O	O
24	O	O
hours	O	O
to	O	O
lower	O	O
than	O	O
the	O	O
INB-	O	O
group	O	O
although	O	O
pain	Pain	Others
scores	Pain	Others
were	O	O
similar	O	O
beyond	O	O
4	O	O
hours	O	O
.	O	O

Opioid	Others	O
usage	Others	O
during	O	O
the	O	O
first	O	O
24	O	O
hours	O	O
was	O	O
similar	O	O
(	O	O
INB-	O	O
,	O	O
16.7	O	O
mg	O	O
vs.	O	O
INB+	O	O
,	O	O
13.2	O	O
mg	O	O
,	O	O
P	O	O
=	O	O
.7	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Although	O	O
postoperative	O	O
INB	O	O
provided	O	O
modest	O	O
improvements	O	O
in	O	O
pain	O	Pain
and	O	O
pulmonary	O	Physical
function	O	Physical
when	O	O
used	O	O
as	O	O
an	O	O
adjuvant	O	O
to	O	O
0.5	O	O
mg	O	O
SM	O	O
for	O	O
post-thoracotomy	O	O
analgesia	O	O
,	O	O
the	O	O
benefits	O	O
were	O	O
transient	O	O
.	O	O

The	O	O
authors	O	O
do	O	O
not	O	O
recommend	O	O
adding	O	O
INB	O	O
for	O	O
patients	O	O
undergoing	O	O
lateral	O	O
thoracotomy	O	O
who	O	O
receive	O	O
0.5	O	O
mg	O	O
SM	O	O
.	O	O

Randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
trial	O	O
of	O	O
oral	O	O
sirolimus	O	O
for	O	O
restenosis	Physical	O
prevention	O	O
in	O	O
patients	O	O
with	O	O
in-stent	O	O
restenosis	O	O
:	O	O
the	O	O
Oral	O	O
Sirolimus	O	O
to	O	O
Inhibit	O	O
Recurrent	O	O
In-stent	O	O
Stenosis	O	O
(	O	O
OSIRIS	O	O
)	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
Despite	O	O
recent	O	O
advances	O	O
in	O	O
interventional	O	O
cardiology	O	O
,	O	O
including	O	O
the	O	O
introduction	O	O
of	O	O
drug-eluting	O	O
stents	O	O
for	O	O
de	O	O
novo	O	O
coronary	O	O
lesions	O	O
,	O	O
the	O	O
treatment	O	O
of	O	O
in-stent	O	O
restenosis	O	O
(	O	O
ISR	O	O
)	O	O
remains	O	O
a	O	O
challenging	O	O
clinical	O	O
issue	O	O
.	O	O

Given	O	O
the	O	O
efficacy	O	O
of	O	O
systemic	O	O
sirolimus	O	O
administration	O	O
to	O	O
prevent	O	O
neointimal	Physical	O
hyperplasia	Physical	O
in	O	O
animal	O	O
models	O	O
and	O	O
to	O	O
halt	O	O
and	O	O
even	O	O
reverse	O	O
the	O	O
progression	O	O
of	O	O
allograft	O	O
vasculopathy	O	O
,	O	O
the	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
efficacy	O	O
of	O	O
a	O	O
10-day	O	O
oral	O	O
sirolimus	O	O
treatment	O	O
with	O	O
2	O	O
different	O	O
loading	O	O
regimens	O	O
for	O	O
the	O	O
prevention	O	O
of	O	O
recurrent	O	Physical
restenosis	O	Physical
in	O	O
patients	O	O
with	O	O
ISR	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
Three	O	O
hundred	O	O
symptomatic	O	O
patients	O	O
with	O	O
ISR	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
1	O	O
of	O	O
3	O	O
treatment	O	O
arms	O	O
:	O	O
placebo	O	O
or	O	O
usual-dose	O	O
or	O	O
high-dose	O	O
sirolimus	O	O
.	O	O

Patients	O	O
received	O	O
a	O	O
cumulative	O	O
loading	O	O
dose	O	O
of	O	O
0	O	O
,	O	O
8	O	O
,	O	O
or	O	O
24	O	O
mg	O	O
of	O	O
sirolimus	O	O
2	O	O
days	O	O
before	O	O
and	O	O
the	O	O
day	O	O
of	O	O
repeat	O	O
intervention	O	O
followed	O	O
by	O	O
maintenance	O	O
therapy	O	O
of	O	O
2	O	O
mg/d	O	O
for	O	O
7	O	O
days	O	O
.	O	O

Angiographic	Physical	O
restenosis	Physical	O
at	Physical	O
6-month	Physical	O
angiography	Physical	O
was	O	O
the	O	O
primary	O	O
end	O	O
point	O	O
of	O	O
the	O	O
study	O	O
.	O	O

Restenosis	Physical	Physical
was	O	O
significantly	O	O
reduced	O	O
from	O	O
42.2	O	O
%	O	O
to	O	O
38.6	O	O
%	O	O
and	O	O
to	O	O
22.1	O	O
%	O	O
in	O	O
the	O	O
placebo	O	O
,	O	O
usual-dose	O	O
,	O	O
and	O	O
high-dose	O	O
sirolimus	O	O
groups	O	O
,	O	O
respectively	O	O
(	O	O
P=0.005	O	O
)	O	O
.	O	O

Similarly	O	O
,	O	O
the	O	O
need	Others	Physical
for	Others	Physical
target	Others	Physical
vessel	Others	Physical
revascularization	Others	Physical
was	O	O
reduced	O	O
from	O	O
25.5	O	O
%	O	O
to	O	O
24.2	O	O
%	O	O
and	O	O
to	O	O
15.2	O	O
%	O	O
in	O	O
the	O	O
placebo	O	O
,	O	O
usual-dose	O	O
,	O	O
and	O	O
high-dose	O	O
groups	O	O
,	O	O
respectively	O	O
(	O	O
P=0.08	O	O
)	O	O
.	O	O

The	Physical	O
sirolimus	Physical	O
blood	Physical	O
concentration	Physical	O
on	O	O
the	O	O
day	O	O
of	O	O
the	O	O
procedure	O	O
correlated	O	O
significantly	O	O
with	O	O
the	O	O
late	O	Physical
lumen	O	Physical
loss	O	Physical
at	O	O
follow-up	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
In	O	O
patients	O	O
with	O	O
ISR	O	O
,	O	O
an	O	O
oral	O	O
adjunctive	O	O
sirolimus	O	O
treatment	O	O
with	O	O
an	O	O
intensified	O	O
loading	O	O
regimen	O	O
before	O	O
coronary	O	O
intervention	O	O
resulted	O	O
in	O	O
a	O	O
significant	O	O
improvement	O	O
in	O	O
the	O	O
angiographic	Physical	Physical
parameters	Physical	Physical
of	Physical	O
restenosis	Physical	O
.	Physical	O

Step-down	O	O
approach	O	O
using	O	O
either	O	O
cyclosporin	O	O
A	O	O
or	O	O
methotrexate	O	O
as	O	O
maintenance	O	O
therapy	O	O
in	O	O
early	O	O
rheumatoid	O	O
arthritis	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
evaluate	O	O
the	O	O
feasibility	Others	O
and	O	O
outcome	Others	O
of	O	O
the	O	O
step-down	O	O
approach	O	O
using	O	O
either	O	O
cyclosporin	O	O
A	O	O
(	O	O
CSA	O	O
)	O	O
or	O	O
methotrexate	O	O
(	O	O
MTX	O	O
)	O	O
as	O	O
maintenance	O	O
therapy	O	O
following	O	O
6	O	O
months	O	O
treatment	O	O
with	O	O
these	O	O
2	O	O
agents	O	O
in	O	O
combination	O	O
in	O	O
early	O	O
,	O	O
nonerosive	O	O
rheumatoid	O	O
arthritis	O	O
(	O	O
RA	O	O
)	O	O
.	O	O

METHODS	O	O
Fifty-seven	O	O
patients	O	O
younger	O	O
than	O	O
65	O	O
years	O	O
with	O	O
early	O	O
,	O	O
nonerosive	O	O
RA	O	O
were	O	O
first	O	O
treated	O	O
with	O	O
CSA	O	O
and	O	O
MTX	O	O
in	O	O
combination	O	O
for	O	O
6	O	O
months	O	O
.	O	O

They	O	O
were	O	O
then	O	O
randomly	O	O
stepped	O	O
down	O	O
to	O	O
single-agent	O	O
maintenance	O	O
treatment	O	O
for	O	O
another	O	O
18	O	O
months	O	O
.	O	O

Safety	Others	Others
,	O	Others
clinical	Others	Others
efficacy	Others	Others
,	O	O
survival	Others	O
on	Others	O
treatment	Others	O
,	O	O
and	O	O
radiographic	Physical	Physical
progression	Physical	Physical
were	O	O
evaluated	O	O
.	O	O

RESULTS	O	O
When	O	O
being	O	O
treated	O	O
with	O	O
combination	O	O
therapy	O	O
,	O	O
7	O	O
of	O	O
the	O	O
57	O	O
patients	O	O
(	O	O
12.3	O	O
%	O	O
)	O	O
withdrew	O	O
because	O	O
of	O	O
adverse	Adverseeffect	O
events	Adverseeffect	O
.	O	O

Of	O	O
the	O	O
remaining	O	O
50	O	O
patients	O	O
,	O	O
42	O	O
(	O	O
84.0	O	O
%	O	O
)	O	O
were	O	O
American	O	O
College	O	O
of	O	O
Rheumatology	O	O
(	O	O
ACR	O	O
)	O	O
20	O	O
%	O	O
responders	O	O
,	O	O
30	O	O
(	O	O
60.0	O	O
%	O	O
)	O	O
were	O	O
ACR	O	O
50	O	O
%	O	O
responders	O	O
,	O	O
and	O	O
23	O	O
(	O	O
46.0	O	O
%	O	O
)	O	O
were	O	O
ACR	O	O
70	O	O
%	O	O
responders	O	O
.	O	O

At	O	O
month	O	O
6	O	O
,	O	O
22	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
CSA	O	O
and	O	O
27	O	O
to	O	O
MTX	O	O
.	O	O

During	O	O
this	O	O
trial	O	O
period	O	O
,	O	O
the	O	O
treatment	O	O
was	O	O
discontinued	O	O
by	O	O
16	O	O
patients	O	O
taking	O	O
CSA	O	O
(	O	O
mainly	O	O
because	O	O
of	O	O
loss	O	O
of	O	O
efficacy	Others	O
)	O	O
and	O	O
by	O	O
4	O	O
taking	O	O
MTX	O	O
.	O	O

At	O	O
month	O	O
24	O	O
,	O	O
the	O	O
probability	O	O
(	O	O
+/-	O	O
SEM	O	O
)	O	O
of	O	O
survival	Mortality	O
on	O	O
treatment	O	O
was	O	O
0.273	O	O
+/-	O	O
0.09	O	O
for	O	O
CSA	O	O
and	O	O
0.852	O	O
+/-	O	O
0.07	O	O
for	O	O
MTX	O	O
.	O	O

Of	O	O
the	O	O
6	O	O
CSA	O	O
patients	O	O
who	O	O
completed	O	O
the	O	O
trial	O	O
,	O	O
4	O	O
(	O	O
66.7	O	O
%	O	O
)	O	O
were	O	O
ACR	O	O
20	O	O
%	O	O
responders	O	O
,	O	O
and	O	O
3	O	O
(	O	O
50	O	O
%	O	O
)	O	O
were	O	O
both	O	O
ACR	O	O
50	O	O
%	O	O
and	O	O
ACR	O	O
70	O	O
%	O	O
responders	O	O
.	O	O

Of	O	O
the	O	O
23	O	O
completers	O	O
in	O	O
the	O	O
MTX	O	O
arm	O	O
,	O	O
21	O	O
(	O	O
91.3	O	O
%	O	O
)	O	O
were	O	O
ACR	O	O
20	O	O
%	O	O
responders	O	O
,	O	O
18	O	O
(	O	O
78.3	O	O
%	O	O
)	O	O
were	O	O
ACR	O	O
50	O	O
%	O	O
,	O	O
and	O	O
10	O	O
(	O	O
43.5	O	O
%	O	O
)	O	O
were	O	O
ACR	O	O
70	O	O
%	O	O
responders	O	O
.	O	O

The	O	O
treatment	O	O
was	O	O
not	O	O
responsible	O	O
for	O	O
severe	O	O
adverse	Adverseeffect	O
events	Adverseeffect	O
.	O	O

Radiography	O	O
showed	O	O
a	O	O
slow	O	O
progression	O	Physical
in	O	Physical
the	O	Physical
damage	Physical	Physical
score	Physical	Physical
and	O	Physical
number	Physical	Physical
of	Physical	Physical
eroded	Physical	Physical
joints	Physical	Physical
in	O	O
both	O	O
treatment	O	O
groups	O	O
.	O	O

CONCLUSION	O	O
Stepping	O	O
down	O	O
to	O	O
single	O	O
agent	O	O
maintenance	O	O
therapy	O	O
following	O	O
6	O	O
months	O	O
of	O	O
combination	O	O
treatment	O	O
with	O	O
CSA	O	O
and	O	O
MTX	O	O
in	O	O
early	O	O
RA	O	O
was	O	O
only	O	O
successful	O	O
with	O	O
MTX	O	O
.	O	O

Because	O	O
this	O	O
treatment	O	O
did	O	O
not	O	O
prevent	O	O
some	O	O
radiographic	Physical	O
progression	Physical	O
,	O	O
other	O	O
approaches	O	O
(	O	O
e.g.	O	O
,	O	O
step-up	O	O
approach	O	O
)	O	O
may	O	O
be	O	O
more	O	O
appropriate	O	O
in	O	O
early	O	O
RA	O	O
.	O	O

Acute	O	O
effects	O	O
of	O	O
decaffeinated	O	O
coffee	O	O
and	O	O
the	O	O
major	O	O
coffee	O	O
components	O	O
chlorogenic	O	O
acid	O	O
and	O	O
trigonelline	O	O
on	O	O
glucose	Physical	O
tolerance	Physical	O
.	Physical	O

OBJECTIVE	O	O
Coffee	O	O
consumption	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
lower	O	O
risk	O	O
of	O	O
type	O	O
2	O	O
diabetes	O	O
.	O	O

We	O	O
evaluated	O	O
the	O	O
acute	O	O
effects	O	O
of	O	O
decaffeinated	O	O
coffee	O	O
and	O	O
the	O	O
major	O	O
coffee	O	O
components	O	O
chlorogenic	O	O
acid	O	O
and	O	O
trigonelline	O	O
on	O	O
glucose	O	O
tolerance	O	O
.	O	O

RESEARCH	O	O
DESIGN	O	O
AND	O	O
METHODS	O	O
We	O	O
conducted	O	O
a	O	O
randomized	O	O
crossover	O	O
trial	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
12	O	O
g	O	O
decaffeinated	O	O
coffee	O	O
,	O	O
1	O	O
g	O	O
chlorogenic	O	O
acid	O	O
,	O	O
500	O	O
mg	O	O
trigonelline	O	O
,	O	O
and	O	O
placebo	O	O
(	O	O
1	O	O
g	O	O
mannitol	O	O
)	O	O
on	O	O
glucose	O	O
and	O	O
insulin	O	Physical
concentrations	O	Physical
during	O	O
a	O	O
2-h	O	O
oral	O	O
glucose	O	O
tolerance	O	O
test	O	O
(	O	O
OGTT	O	O
)	O	O
in	O	O
15	O	O
overweight	O	O
men	O	O
.	O	O

RESULTS	O	O
Chlorogenic	O	O
acid	O	O
and	O	O
trigonelline	O	O
ingestion	O	O
significantly	O	O
reduced	O	O
glucose	Physical	O
(	O	O
-0.7	O	O
mmol/l	O	O
,	O	O
P	O	O
=	O	O
0.007	O	O
,	O	O
and	O	O
-0.5	O	O
mmol/l	O	O
,	O	O
P	O	O
=	O	O
0.024	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
insulin	Physical	Physical
(	O	O
-73	O	O
pmol/l	O	O
,	O	O
P	O	O
=	O	O
0.038	O	O
,	O	O
and	O	O
-117	O	O
pmol/l	O	O
,	O	O
P	O	O
=	O	O
0.007	O	O
)	O	O
concentrations	O	O
15	O	O
min	O	O
following	O	O
an	O	O
OGTT	O	O
compared	O	O
with	O	O
placebo	O	O
.	O	O

None	O	O
of	O	O
the	O	O
treatments	O	O
affected	O	O
insulin	Physical	Physical
or	Physical	Physical
glucose	Physical	Physical
area	Physical	Physical
under	Physical	Physical
the	Physical	Physical
curve	Physical	Physical
values	Physical	Physical
during	O	O
the	O	O
OGTT	O	O
compared	O	O
with	O	O
placebo	O	O
.	O	O

CONCLUSIONS	O	O
Chlorogenic	O	O
acid	O	O
and	O	O
trigonelline	O	O
reduced	O	O
early	O	O
glucose	Physical	O
and	Physical	O
insulin	Physical	Physical
responses	Physical	Physical
during	O	O
an	O	O
OGTT	O	O
.	O	O

Smoking	Mental	O
cessation	Mental	O
with	O	O
smokeless	O	O
tobacco	O	O
and	O	O
group	O	O
therapy	O	O
:	O	O
an	O	O
open	O	O
,	O	O
randomized	O	O
,	O	O
controlled	O	O
trial	O	O
.	O	O

Smokeless	O	O
tobacco	O	O
might	O	O
be	O	O
effective	O	O
as	O	O
an	O	O
adjunct	O	O
for	O	O
smoking	Mental	O
cessation	Mental	O
.	O	O

We	O	O
evaluated	O	O
the	O	O
efficacy	O	O
of	O	O
smokeless	O	O
tobacco	O	O
and	O	O
group	O	O
support	O	O
for	O	O
smoking	Mental	Mental
cessation	Mental	Mental
in	O	O
an	O	O
open	O	O
,	O	O
randomized	O	O
study	O	O
that	O	O
compared	O	O
smokeless	O	O
tobacco	O	O
plus	O	O
group	O	O
support	O	O
versus	O	O
group	O	O
support	O	O
only	O	O
.	O	O

The	O	O
study	O	O
enrolled	O	O
263	O	O
healthy	O	O
smokers	O	O
(	O	O
M	O	O
(	O	O
age	O	O
)	O	O
=	O	O
49	O	O
years	O	O
)	O	O
who	O	O
smoked	O	O
a	O	O
mean	O	O
of	O	O
24	O	O
cigarettes/day	O	O
,	O	O
with	O	O
a	O	O
mean	O	O
of	O	O
31	O	O
pack-years	O	O
.	O	O

Smokeless	O	O
tobacco	O	O
was	O	O
provided	O	O
for	O	O
7	O	O
weeks	O	O
(	O	O
or	O	O
up	O	O
to	O	O
12	O	O
)	O	O
,	O	O
combined	O	O
with	O	O
eight	O	O
group	O	O
support	O	O
visits	O	O
provided	O	O
by	O	O
nurses	O	O
.	O	O

The	O	O
control	O	O
group	O	O
received	O	O
group	O	O
support	O	O
only	O	O
.	O	O

Smoking	Others	Physical
cessation	Others	Physical
rates	Others	Physical
were	O	O
statistically	O	O
significantly	O	O
better	O	O
in	O	O
the	O	O
smokeless	O	O
tobacco	O	O
group	O	O
than	O	O
in	O	O
the	O	O
control	O	O
group	O	O
during	O	O
the	O	O
first	O	O
7	O	O
weeks	O	O
.	O	O

Point-prevalence	Others	O
abstinence	Others	O
rates	Others	O
at	O	O
7	O	O
weeks	O	O
were	O	O
36.4	O	O
%	O	O
versus	O	O
20.8	O	O
%	O	O
(	O	O
OR	O	O
=	O	O
2.52	O	O
,	O	O
p	O	O
=	O	O
.001	O	O
)	O	O
,	O	O
respectively	O	O
;	O	O
and	O	O
continuous	Others	O
abstinence	Others	O
rates	Others	O
from	O	O
weeks	O	O
4	O	O
to	O	O
7	O	O
were	O	O
31.5	O	O
%	O	O
versus	O	O
19.2	O	O
%	O	O
(	O	O
OR	O	O
=	O	O
1.94	O	O
,	O	O
p	O	O
=	O	O
.023	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
primary	O	O
outcomes	O	O
(	O	O
i.e.	O	O
,	O	O
6-month	Others	O
point	Others	O
prevalence	Others	O
)	O	O
were	O	O
23.1	O	O
%	O	O
versus	O	O
20.8	O	O
%	O	O
,	O	O
respectively	O	O
(	O	O
OR	O	O
=	O	O
1.31	O	O
,	O	O
ns	O	O
)	O	O
.	O	O

Smokeless	O	O
tobacco	O	O
was	O	O
relatively	O	O
well	O	O
tolerated	Others	O
,	O	O
although	O	O
15	O	O
subjects	O	O
(	O	O
11.2	O	O
%	O	O
)	O	O
stopped	O	O
use	O	O
due	O	O
to	O	O
adverse	Adverseeffect	O
events	Adverseeffect	O
.	O	O

A	O	O
total	O	O
of	O	O
25	O	O
subjects	O	O
(	O	O
17.5	O	O
%	O	O
)	O	O
were	O	O
still	O	O
using	O	O
smokeless	O	O
tobacco	O	O
after	O	O
6	O	O
months	O	O
.	O	O

This	O	O
trial	O	O
demonstrated	O	O
short-term	Others	O
efficacy	Others	O
of	Others	O
smokeless	Others	O
tobacco	Others	O
in	O	O
combination	O	O
with	O	O
group	O	O
support	O	O
for	O	O
smoking	O	O
cessation	O	O
but	O	O
no	O	O
long-term	Others	O
efficacy	Others	O
.	O	O

Comparison	O	O
of	O	O
patient-controlled	O	O
and	O	O
nurse-administered	O	O
analgesia	O	O
using	O	O
intravenous	O	O
fentanyl	O	O
during	O	O
labor	O	O
.	O	O

Preliminary	O	O
observations	O	O
have	O	O
shown	O	O
that	O	O
fentanyl	O	O
citrate	O	O
,	O	O
a	O	O
potent	O	O
narcotic	O	O
,	O	O
is	O	O
helpful	O	O
during	O	O
labor	O	O
without	O	O
undue	O	O
side	O	O
effects	O	O
.	O	O

This	O	O
randomized	O	O
prospective	O	O
investigation	O	O
compared	O	O
the	O	O
patient-controlled	O	O
administration	O	O
of	O	O
fentanyl	O	O
with	O	O
that	O	O
of	O	O
administration	O	O
by	O	O
nurses	O	O
on	O	O
request	O	O
.	O	O

Eighty	O	O
healthy	O	O
women	O	O
beginning	O	O
active	O	O
labor	O	O
(	O	O
cervical	O	O
dilation	O	O
4	O	O
cm	O	O
)	O	O
at	O	O
term	O	O
were	O	O
assigned	O	O
to	O	O
receive	O	O
fentanyl	O	O
intravenously	O	O
by	O	O
either	O	O
patient-controlled	O	O
administration	O	O
(	O	O
n=37	O	O
)	O	O
or	O	O
nurse	O	O
administration	O	O
on	O	O
demand	O	O
(	O	O
n=43	O	O
)	O	O
.	O	O

Pain	Pain	Pain
intensity	Pain	Pain
measurements	Pain	Pain
during	O	O
early	O	O
and	O	O
late	O	O
labor	O	O
revealed	O	O
the	O	O
degree	Pain	O
of	Pain	O
analgesia	Pain	O
to	O	O
be	O	O
the	O	O
same	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

The	O	O
delay	O	O
in	O	O
setting	Others	O
up	Others	O
the	Others	O
infusion	Others	O
system	Others	O
and	O	O
the	O	O
short	O	O
time	Others	O
between	Others	O
requesting	Others	O
analgesia	Others	O
and	Others	O
vaginal	Others	O
delivery	Others	O
were	O	O
limitations	O	O
with	O	O
self-administration	O	O
.	O	O

Maternal	Adverseeffect	Physical
oversedation	Adverseeffect	Physical
and	Adverseeffect	Physical
vomiting	Adverseeffect	Physical
did	O	O
not	O	O
occur	O	O
.	O	O

Neonatal	Others	O
naloxone	Others	O
therapy	Others	O
was	O	O
used	O	O
infrequently	O	O
,	O	O
umbilical	Others	O
serum	Others	O
levels	Others	O
of	Others	O
fentanyl	Others	O
were	O	O
the	O	O
same	O	O
in	O	O
both	O	O
groups	O	O
,	O	O
and	O	O
postnatal	Physical	O
neuroadaptive	Physical	O
testing	Physical	O
revealed	O	O
comparable	O	O
results	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Despite	O	O
the	O	O
usefulness	O	O
of	O	O
fentanyl	O	O
during	O	O
labor	O	O
,	O	O
administration	O	O
by	O	O
the	O	O
patient	O	O
had	O	O
no	O	O
advantages	O	O
over	O	O
administration	O	O
by	O	O
the	O	O
nurses	O	O
in	O	O
significantly	O	O
reducing	O	O
drug	Others	O
use	Others	O
,	O	O
improving	Pain	O
pain	Pain	O
relief	Pain	O
,	O	O
or	O	O
avoiding	Physical	O
drowsiness	Adverseeffect	O
.	O	O

Immunological	Physical	Physical
changes	Physical	Physical
after	O	O
minimally	O	O
invasive	O	O
or	O	O
conventional	O	O
esophageal	O	O
resection	O	O
for	O	O
cancer	O	O
:	O	O
a	O	O
randomized	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
This	O	O
study	O	O
was	O	O
performed	O	O
as	O	O
a	O	O
substudy	O	O
analysis	O	O
of	O	O
a	O	O
randomized	O	O
trial	O	O
comparing	O	O
conventional	O	O
open	O	O
esophagectomy	O	O
[	O	O
open	O	O
surgical	O	O
technique	O	O
(	O	O
OE	O	O
)	O	O
]	O	O
by	O	O
thoracotomy	O	O
and	O	O
laparotomy	O	O
with	O	O
minimally	O	O
invasive	O	O
esophagectomy	O	O
[	O	O
minimally	O	O
invasive	O	O
procedure	O	O
(	O	O
MIE	O	O
)	O	O
]	O	O
by	O	O
thoracoscopy	O	O
and	O	O
laparoscopy	O	O
.	O	O

This	O	O
additional	O	O
analysis	O	O
focuses	O	O
on	O	O
the	O	O
immunological	Physical	Physical
changes	Physical	Physical
and	O	Physical
surgical	Physical	Physical
stress	Physical	Physical
response	Physical	Physical
in	O	O
these	O	O
two	O	O
randomized	O	O
groups	O	O
of	O	O
a	O	O
single	O	O
center	O	O
.	O	O

METHODS	O	O
Patients	O	O
with	O	O
a	O	O
resectable	O	O
esophageal	O	O
cancer	O	O
were	O	O
randomized	O	O
to	O	O
OE	O	O
(	O	O
n	O	O
=	O	O
13	O	O
)	O	O
or	O	O
MIE	O	O
(	O	O
n	O	O
=	O	O
14	O	O
)	O	O
.	O	O

All	O	O
patients	O	O
received	O	O
neoadjuvant	O	O
chemoradiotherapy	O	O
.	O	O

The	O	O
immunological	Physical	Physical
response	Physical	Physical
was	O	O
measured	O	O
by	O	O
means	O	O
of	O	O
leukocyte	Physical	Physical
counts	Physical	Physical
,	Physical	O
HLA-DR	Physical	O
expression	Physical	O
on	Physical	O
monocytes	Physical	O
,	O	O
the	Physical	O
acute-phase	Physical	O
response	Physical	O
by	Physical	O
means	Physical	O
of	Physical	O
C-reactive	Physical	O
protein	Physical	O
(	Physical	O
CRP	Physical	O
)	Physical	O
,	O	O
interleukin-6	Physical	Physical
(	Physical	Physical
IL-6	Physical	Physical
)	Physical	Physical
,	O	Physical
and	O	Physical
interleukin-8	Physical	Physical
(	Physical	Physical
IL-8	Physical	Physical
)	Physical	Physical
,	O	O
and	O	O
the	O	O
stress	Physical	Physical
response	Physical	Physical
was	Physical	O
measured	Physical	O
by	Physical	O
cortisol	Physical	O
,	Physical	O
growth	Physical	Physical
hormone	Physical	Physical
,	Physical	Physical
and	Physical	Physical
prolactin	Physical	Physical
.	O	Physical

All	O	O
parameters	O	O
were	O	O
determined	O	O
at	O	O
baseline	O	O
(	O	O
preoperatively	O	O
)	O	O
and	O	O
24	O	O
,	O	O
72	O	O
,	O	O
96	O	O
,	O	O
and	O	O
168	O	O
h	O	O
postoperatively	O	O
.	O	O

RESULTS	O	O
Significant	O	O
differences	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
were	O	O
seen	O	O
in	O	O
favor	O	O
of	O	O
the	O	O
MIE	O	O
group	O	O
with	O	O
regard	O	O
to	O	O
leukocyte	Physical	Physical
counts	Physical	Physical
,	Physical	O
IL-8	Physical	O
,	Physical	O
and	Physical	O
prolactin	Physical	O
at	O	O
168	O	O
h	O	O
(	O	O
1	O	O
week	O	O
)	O	O
postoperatively	O	O
.	O	O

For	O	O
HLA-DR	Physical	O
expression	Physical	O
,	Physical	O
IL-6	Physical	O
,	Physical	O
and	Physical	O
CRP	Physical	Physical
levels	Physical	Physical
,	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
,	O	O
although	O	O
there	O	O
was	O	O
a	O	O
clear	O	O
rise	O	O
in	O	O
levels	O	O
upon	O	O
operation	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

CONCLUSION	O	O
In	O	O
this	O	O
substudy	O	O
of	O	O
a	O	O
randomized	O	O
trial	O	O
comparing	O	O
minimally	O	O
invasive	O	O
and	O	O
conventional	O	O
open	O	O
esophagectomies	O	O
for	O	O
cancer	O	O
,	O	O
significantly	O	O
better	O	O
preserved	O	Physical
leukocyte	Physical	Physical
counts	Physical	Physical
and	Physical	O
IL-8	Physical	Physical
levels	Physical	Physical
were	O	O
observed	O	O
in	O	O
the	O	O
MIE	O	O
group	O	O
compared	O	O
to	O	O
the	O	O
open	O	O
group	O	O
.	O	O

Both	O	O
findings	O	O
can	O	O
be	O	O
related	O	O
to	O	O
fewer	Adverseeffect	O
respiratory	Adverseeffect	Physical
infections	Adverseeffect	Physical
found	O	O
postoperatively	O	O
in	O	O
the	O	O
MIE	O	O
group	O	O
.	O	O

Moreover	O	O
,	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
prolactin	Physical	Physical
levels	Physical	Physical
at	O	O
168	O	O
h	O	O
after	O	O
surgery	O	O
imply	O	O
that	O	O
the	O	O
stress	Physical	O
response	Physical	O
is	O	O
better	O	O
preserved	O	O
in	O	O
the	O	O
MIE	O	O
group	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
less	O	O
surgical	O	O
trauma	O	O
could	O	O
lead	O	O
to	O	O
better	O	O
preserved	O	O
acute-phase	O	O
and	O	O
stress	O	Physical
responses	O	Physical
and	O	Physical
fewer	O	Physical
clinical	O	Physical
manifestations	O	Physical
of	O	Physical
respiratory	O	Physical
infections	O	Physical
.	O	O

Treatment	O	O
of	O	O
stable	O	O
angina	O	O
of	O	O
effort	O	O
with	O	O
verapamil	O	O
:	O	O
a	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
randomized	O	O
crossover	O	O
study	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
verapamil	O	O
were	O	O
assessed	O	O
in	O	O
26	O	O
patients	O	O
with	O	O
stable	O	O
exertional	O	O
angina	O	O
pectoris	O	O
in	O	O
a	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
,	O	O
randomized	O	O
crossover	O	O
protocol	O	O
using	O	O
serial	O	O
treadmill	O	O
tests	O	O
.	O	O

Verapamil	O	O
,	O	O
480	O	O
mg/day	O	O
,	O	O
reduced	O	O
anginal	Physical	Physical
frequency	Physical	Physical
from	O	O
5.6	O	O
+/-	O	O
7.3	O	O
to	O	O
2.2	O	O
+/-	O	O
3.9	O	O
attacks	O	O
per	O	O
week	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
and	O	O
nitroglycerin	Others	O
consumption	Others	O
from	O	O
3.4	O	O
+/-	O	O
4.9	O	O
to	O	O
1.2	O	O
+/-	O	O
2.5	O	O
tablets	O	O
per	O	O
week	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
compared	O	O
with	O	O
placebo	O	O
.	O	O

Treadmill	Physical	O
time	Physical	O
increased	O	O
from	O	O
6.4	O	O
+/-	O	O
2.1	O	O
minutes	O	O
during	O	O
the	O	O
placebo	O	O
phase	O	O
to	O	O
7.5	O	O
+/-	O	O
1.8	O	O
minutes	O	O
during	O	O
the	O	O
verapamil	O	O
phase	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
.	O	O

Verapamil	O	O
's	O	O
beneficial	O	O
effect	O	O
appeared	O	O
to	O	O
be	O	O
related	O	O
,	O	O
in	O	O
part	O	O
,	O	O
to	O	O
a	O	O
10	O	O
%	O	O
reduction	O	O
of	O	O
the	O	O
rate-pressure	Physical	Physical
product	Physical	Physical
at	O	Physical
rest	O	Physical
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
and	O	O
a	O	O
12	O	O
%	O	O
reduction	O	O
during	O	O
submaximal	O	O
exercise	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
.	O	O

Verapamil	O	O
also	O	O
caused	O	O
less	O	O
marked	O	Physical
ST-segment	Physical	Physical
depressions	Physical	Physical
at	Physical	Physical
peak	Physical	Physical
exercise	Physical	Physical
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
at	O	O
a	O	O
similar	O	O
rate-pressure	O	O
product	O	O
,	O	O
suggesting	O	O
a	O	O
favorable	O	O
redistribution	O	O
of	O	O
coronary	Physical	O
blood	Physical	O
flow	Physical	O
to	O	O
the	O	O
ischemic	O	O
zone	O	O
.	O	O

Side	O	O
effects	O	O
from	O	O
verapamil	O	O
were	O	O
minimal	O	O
,	O	O
consisting	O	O
mainly	O	O
of	O	O
constipation	Adverseeffect	O
(	O	O
six	O	O
patients	O	O
)	O	O
.	O	O

Verapamil	O	O
appears	O	O
to	O	O
be	O	O
a	O	O
safe	Others	O
and	Others	O
effective	Others	O
drug	O	O
for	O	O
treating	O	O
angina	O	O
of	O	O
effort	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
on	O	O
adherence	O	O
to	O	O
a	O	O
low-fat	O	O
dietary	O	O
pattern	O	O
in	O	O
the	O	O
Women	O	O
's	O	O
Health	O	O
Initiative	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
examine	O	O
whether	O	O
the	O	O
effects	O	O
of	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
on	O	O
adherance	O	O
to	O	O
a	O	O
low-fat	O	O
(	O	O
20	O	O
%	O	O
energy	O	O
)	O	O
dietary	O	O
pattern	O	O
are	O	O
mediated	O	O
by	O	O
participation	O	O
in	O	O
an	O	O
intervention	O	O
program	O	O
(	O	O
attending	O	O
sessions	O	O
and	O	O
self-monitoring	O	O
)	O	O
.	O	O

DESIGN	O	O
The	O	O
Baron	O	O
and	O	O
Kenny	O	O
mediator	O	O
model	O	O
,	O	O
a	O	O
series	O	O
of	O	O
4	O	O
regression	O	O
analyses	O	O
,	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
whether	O	O
:	O	O
a	O	O
)	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
predicted	O	O
program	O	O
participation	O	O
,	O	O
b	O	O
)	O	O
program	O	O
participation	O	O
predicted	O	O
dietary	O	O
adherence	O	O
,	O	O
c	O	O
)	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
factors	O	O
predicted	O	O
dietary	O	O
adherence	O	O
,	O	O
and	O	O
,	O	O
ultimately	O	O
d	O	O
)	O	O
the	O	O
effects	O	O
of	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
on	O	O
dietary	O	O
adherence	O	O
were	O	O
mediated	O	O
by	O	O
program	O	O
participation	O	O
.	O	O

SUBJECTS/SETTING	O	O
Data	O	O
from	O	O
13,277	O	O
postmenopausal	O	O
women	O	O
randomly	O	O
assigned	O	O
to	O	O
the	O	O
low-fat	O	O
intervention	O	O
arm	O	O
of	O	O
the	O	O
Women	O	O
's	O	O
Health	O	O
Initiative	O	O
Dietary	O	O
Modification	O	O
Trial	O	O
.	O	O

INTERVENTION	O	O
The	O	O
nutrition	O	O
goals	O	O
for	O	O
women	O	O
randomly	O	O
assigned	O	O
to	O	O
the	O	O
low-fat	O	O
intervention	O	O
were	O	O
to	O	O
reduce	O	O
total	O	O
fat	O	O
intake	O	O
to	O	O
20	O	O
%	O	O
or	O	O
less	O	O
of	O	O
energy	O	O
from	O	O
fat	O	O
and	O	O
to	O	O
consume	O	O
5	O	O
or	O	O
more	O	O
fruit/vegetable	O	O
servings	O	O
daily	O	O
and	O	O
6	O	O
or	O	O
more	O	O
grain	O	O
servings	O	O
daily	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
Year	Mental	O
1	Mental	O
program	Mental	O
participation	Mental	O
(	Mental	O
degree	Mental	O
of	Mental	O
attending	Mental	O
group	Mental	O
sessions	Mental	O
and	Mental	O
submitting	Mental	O
fat	Mental	O
scores	Mental	O
)	Mental	O
and	O	O
adherence	Mental	O
to	Mental	O
the	Mental	O
low-fat	Mental	O
dietary	Mental	O
pattern	Mental	O
(	Mental	O
percent	Mental	O
energy	Mental	O
from	Mental	O
fat	Mental	O
)	Mental	O
as	O	O
predicted	O	O
by	O	O
baseline	O	Physical
physical	O	Physical
and	O	Physical
emotional	O	Physical
status	O	Physical
(	O	O
eight	O	O
SF-36	O	O
Health	O	O
Survey	O	O
subscales	O	O
)	O	O
.	O	O

RESULTS	O	O
Participating	O	O
in	O	O
the	O	O
dietary	O	O
intervention	O	O
program	O	O
reduced	O	O
(	O	O
mediated	O	O
)	O	O
the	O	O
negative	O	O
effect	Mental	O
of	Mental	O
poorer	Mental	O
mental	Mental	O
health	Mental	O
on	O	O
dietary	Mental	O
adherence	Mental	O
by	O	O
15	O	O
%	O	O
.	O	O

Additional	O	O
findings	O	O
included	O	O
that	O	O
a	O	O
10	O	O
%	O	O
increase	O	O
in	O	O
physical	Physical	Physical
functioning	Physical	Physical
increased	O	Physical
session	Mental	Physical
attendance	Mental	Physical
by	O	O
0.4	O	O
%	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
and	O	O
a	O	O
10	O	O
%	O	O
increase	O	O
in	O	O
mental	Mental	O
health	Mental	O
predicted	O	O
a	O	O
decrease	O	O
in	O	O
percent	O	O
energy	O	O
from	O	O
fat	O	O
of	O	O
0.3	O	O
%	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

Program	O	O
participation	O	O
had	O	O
a	O	O
marked	O	O
effect	O	O
on	O	O
dietary	Mental	O
adherence	Mental	O
:	O	O
a	O	O
10	O	O
%	O	O
increase	O	O
in	O	O
session	Mental	O
attendance	Mental	O
predicted	O	O
a	O	O
1.2	O	O
%	O	O
decrease	O	O
in	O	O
percent	O	Physical
energy	O	Physical
from	O	Physical
fat	O	Physical
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

APPLICATIONS/CONCLUSIONS	O	O
Understanding	O	O
and	O	O
using	O	O
instruments	O	O
to	O	O
assess	O	O
the	O	O
physical	O	Physical
and	O	O
emotional	O	O
status	O	O
of	O	O
a	O	O
target	O	O
population	O	O
will	O	O
help	O	O
dietetic	O	O
professionals	O	O
promote	O	O
healthful	O	O
dietary	O	O
change	O	O
and	O	O
maintenance	O	O
.	O	O

Menopausal	Others	O
quality	Others	O
of	Others	O
life	Others	O
:	O	O
RCT	O	O
of	O	O
yoga	O	O
,	O	O
exercise	O	O
,	O	O
and	O	O
omega-3	O	O
supplements	O	O
.	O	O

OBJECTIVE	O	O
The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
efficacy	O	O
of	O	O
3	O	O
nonhormonal	O	O
therapies	O	O
for	O	O
the	O	O
improvement	O	O
of	O	O
menopause-related	Others	Physical
quality	Others	Physical
of	Others	Physical
life	Others	Physical
in	O	O
women	O	O
with	O	O
vasomotor	O	O
symptoms	O	O
.	O	O

STUDY	O	O
DESIGN	O	O
We	O	O
conducted	O	O
a	O	O
12-week	O	O
3	O	O
?	O	O
2	O	O
randomized	O	O
,	O	O
controlled	O	O
,	O	O
factorial	O	O
design	O	O
trial	O	O
.	O	O

Peri-	O	O
and	O	O
postmenopausal	O	O
women	O	O
,	O	O
40-62	O	O
years	O	O
old	O	O
,	O	O
were	O	O
assigned	O	O
randomly	O	O
to	O	O
yoga	O	O
(	O	O
n	O	O
=	O	O
107	O	O
)	O	O
,	O	O
exercise	O	O
(	O	O
n	O	O
=	O	O
106	O	O
)	O	O
,	O	O
or	O	O
usual	O	O
activity	O	O
(	O	O
n	O	O
=	O	O
142	O	O
)	O	O
and	O	O
also	O	O
assigned	O	O
randomly	O	O
to	O	O
a	O	O
double-blind	O	O
comparison	O	O
of	O	O
omega-3	O	O
(	O	O
n	O	O
=	O	O
177	O	O
)	O	O
or	O	O
placebo	O	O
(	O	O
n	O	O
=	O	O
178	O	O
)	O	O
capsules	O	O
.	O	O

We	O	O
performed	O	O
the	O	O
following	O	O
interventions	O	O
:	O	O
(	O	O
1	O	O
)	O	O
weekly	O	O
90-minute	O	O
yoga	O	O
classes	O	O
with	O	O
daily	O	O
at-home	O	O
practice	O	O
,	O	O
(	O	O
2	O	O
)	O	O
individualized	O	O
facility-based	O	O
aerobic	O	O
exercise	O	O
training	O	O
3	O	O
times/week	O	O
,	O	O
and	O	O
(	O	O
3	O	O
)	O	O
0.615	O	O
g	O	O
omega-3	O	O
supplement	O	O
,	O	O
3	O	O
times/day	O	O
.	O	O

The	O	O
outcomes	O	O
were	O	O
assessed	O	O
with	O	O
the	O	O
following	O	O
scores	O	O
:	O	O
Menopausal	O	Physical
Quality	O	Physical
of	O	Physical
Life	O	Physical
Questionnaire	O	Physical
(	O	Physical
MENQOL	O	Physical
)	O	Physical
total	O	Physical
and	O	Physical
domain	O	Physical
(	O	Physical
vasomotor	O	Physical
symptoms	O	Physical
,	O	Physical
psychosocial	O	Physical
,	O	Physical
physical	O	Physical
and	O	Physical
sexual	O	Physical
)	O	Physical
.	O	O

RESULTS	O	O
Among	O	O
355	O	O
randomly	O	O
assigned	O	O
women	O	O
who	O	O
average	O	O
age	O	O
was	O	O
54.7	O	O
years	O	O
,	O	O
338	O	O
women	O	O
(	O	O
95	O	O
%	O	O
)	O	O
completed	O	O
12-week	O	O
assessments	O	O
.	O	O

Mean	O	Physical
baseline	O	Physical
vasomotor	O	Physical
symptoms	O	Physical
frequency	O	Physical
was	O	O
7.6/day	O	O
,	O	O
and	O	O
the	O	O
mean	O	Physical
baseline	O	Physical
total	O	Physical
MENQOL	O	Physical
score	O	Physical
was	O	O
3.8	O	O
(	O	O
range	O	O
,	O	O
1-8	O	O
from	O	O
better	O	O
to	O	O
worse	O	O
)	O	O
with	O	O
no	O	O
between-group	O	O
differences	O	O
.	O	O

For	O	O
yoga	O	O
compared	O	O
to	O	O
usual	O	O
activity	O	O
,	O	O
baseline	O	O
to	O	O
12-week	O	O
improvements	O	O
were	O	O
seen	O	O
for	O	O
MENQOL	O	O
total	O	O
-0.3	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
-0.6	O	O
to	O	O
0	O	O
;	O	O
P	O	O
=	O	O
.02	O	O
)	O	O
,	O	O
vasomotor	O	Physical
symptom	O	Physical
domain	O	Physical
(	O	O
P	O	O
=	O	O
.02	O	O
)	O	O
,	O	O
and	O	O
sexuality	O	O
domain	O	O
(	O	O
P	O	O
=	O	O
.03	O	O
)	O	O
scores	O	O
.	O	O

For	O	O
women	O	O
who	O	O
underwent	O	O
exercise	O	O
and	O	O
omega-3	O	O
therapy	O	O
compared	O	O
with	O	O
control	O	O
subjects	O	O
,	O	O
improvements	O	O
in	O	O
baseline	O	O
to	O	O
12-week	O	O
total	O	O
MENQOL	O	O
scores	O	O
were	O	O
not	O	O
observed	O	O
.	O	O

Exercise	O	O
showed	O	O
benefit	O	O
in	O	O
the	O	O
MENQOL	O	Physical
physical	O	Physical
domain	O	Physical
score	O	Physical
at	O	O
12	O	O
weeks	O	O
(	O	O
P	O	O
=	O	O
.02	O	O
)	O	O
.	O	O

CONCLUSION	O	O
All	O	O
women	O	O
become	O	O
menopausal	O	O
,	O	O
and	O	O
many	O	O
of	O	O
them	O	O
seek	O	O
medical	O	O
advice	O	O
on	O	O
ways	O	O
to	O	O
improve	O	O
quality	O	O
of	O	O
life	O	O
;	O	O
little	O	O
evidence-based	O	O
information	O	O
exists	O	O
.	O	O

We	O	O
found	O	O
that	O	O
,	O	O
among	O	O
healthy	O	O
sedentary	O	O
menopausal	O	O
women	O	O
,	O	O
yoga	O	O
appears	O	O
to	O	O
improve	O	O
menopausal	O	Physical
quality	O	Physical
of	O	Physical
life	O	Physical
;	O	O
the	O	O
clinical	O	O
significance	O	O
of	O	O
our	O	O
finding	O	O
is	O	O
uncertain	O	O
because	O	O
of	O	O
the	O	O
modest	O	O
effect	O	O
.	O	O

Short-	Physical	O
and	Physical	O
long-term	Physical	O
effects	Physical	O
of	O	O
tactile	O	O
massage	O	O
on	O	O
salivary	Physical	Physical
cortisol	Physical	Physical
concentrations	Physical	Physical
in	O	O
Parkinson	O	O
's	O	O
disease	O	O
:	O	O
a	O	O
randomised	O	O
controlled	O	O
pilot	O	O
study	O	O
.	O	O

BACKGROUND	O	O
Parkinson	O	O
's	O	O
disease	O	O
(	O	O
PD	O	O
)	O	O
is	O	O
a	O	O
chronic	O	O
neurodegenerative	O	O
disorder	O	O
with	O	O
limited	O	O
knowledge	O	O
about	O	O
the	O	O
normal	O	O
function	O	O
and	O	O
effects	O	O
of	O	O
non-pharmacological	O	O
therapies	O	O
on	O	O
the	O	O
hypothalamic-pituitary-adrenal	Physical	O
(	Physical	O
HPA	Physical	O
)	Physical	O
axis	Physical	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
analyse	O	O
the	O	O
basal	Physical	Physical
diurnal	Physical	Physical
and	Physical	Physical
total	Physical	Physical
secretion	Physical	Physical
of	Physical	Physical
salivary	Physical	Physical
cortisol	Physical	Physical
in	O	O
short-	O	O
and	O	O
long-term	O	O
aspects	O	O
of	O	O
tactile	O	O
massage	O	O
(	O	O
TM	O	O
)	O	O
.	O	O

METHODS	O	O
DESIGN	O	O
Prospective	O	O
,	O	O
Controlled	O	O
and	O	O
Randomised	O	O
Multicentre	O	O
Trial	O	O
.	O	O

SETTING	O	O
AND	O	O
INTERVENTIONS	O	O
Forty-five	O	O
women	O	O
and	O	O
men	O	O
,	O	O
aged	O	O
50-79	O	O
years	O	O
,	O	O
were	O	O
recruited	O	O
.	O	O

Twenty-nine	O	O
of	O	O
them	O	O
were	O	O
blindly	O	O
randomised	O	O
to	O	O
tactile	O	O
massage	O	O
(	O	O
TM	O	O
)	O	O
and	O	O
16	O	O
of	O	O
them	O	O
to	O	O
the	O	O
control	O	O
group	O	O
,	O	O
rest	O	O
to	O	O
music	O	O
(	O	O
RTM	O	O
)	O	O
.	O	O

Ten	O	O
interventions	O	O
were	O	O
given	O	O
during	O	O
8	O	O
weeks	O	O
followed	O	O
by	O	O
a	O	O
26	O	O
weeks	O	O
of	O	O
follow	O	O
up	O	O
.	O	O

Salivary	Physical	O
cortisol	Physical	O
was	O	O
collected	O	O
at	O	O
8	O	O
am	O	O
,	O	O
1	O	O
pm	O	O
,	O	O
8	O	O
pm	O	O
,	O	O
and	O	O
8	O	O
am	O	O
the	O	O
next	O	O
day	O	O
,	O	O
on	O	O
five	O	O
occasions	O	O
.	O	O

With	O	O
the	O	O
first	O	O
and	O	O
eighth	O	O
interventions	O	O
,	O	O
it	O	O
was	O	O
collected	O	O
immediately	O	O
before	O	O
and	O	O
after	O	O
intervention	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
The	O	O
primary	O	O
aim	O	O
was	O	O
to	O	O
assess	Physical	O
and	Physical	O
compare	Physical	Physical
cortisol	Physical	Physical
concentrations	Physical	Physical
before	O	O
and	O	O
immediately	O	O
after	O	O
intervention	O	O
and	O	O
also	O	O
during	O	O
the	O	O
follow-up	O	O
period	O	O
.	O	O

The	O	O
secondary	O	O
aim	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
impact	Physical	O
of	Physical	O
age	Physical	O
,	Physical	O
gender	Physical	O
,	Physical	O
body	Physical	Physical
mass	Physical	Physical
index	Physical	Physical
(	Physical	Physical
BMI	Physical	Physical
)	Physical	Physical
,	O	Physical
duration	Physical	Physical
and	Physical	Physical
severity	Physical	Physical
of	Physical	Physical
PD	Physical	Physical
,	O	O
effects	Physical	O
of	Physical	O
interventional	Physical	O
time-point	Physical	O
of	Physical	O
the	Physical	O
day	Physical	O
,	O	O
and	O	O
levodopa	Physical	O
doses	Physical	O
on	Physical	O
cortisol	Physical	O
concentration	Physical	O
.	O	O

RESULTS	O	O
The	O	O
median	Physical	Physical
cortisol	Physical	Physical
concentrations	Physical	Physical
for	O	O
all	O	O
participants	O	O
were	O	O
16.0	O	O
,	O	O
5.8	O	O
,	O	O
2.8	O	O
,	O	O
and	O	O
14.0	O	O
nmol/L	O	O
at	O	O
baseline	O	O
,	O	O
later	O	O
reproduced	O	O
four	O	O
times	O	O
without	O	O
significant	O	O
differences	O	O
.	O	O

Cortisol	Physical	Physical
concentrations	Physical	Physical
decreased	O	O
significantly	O	O
after	O	O
TM	O	O
intervention	O	O
but	O	O
no	O	O
change	O	O
in	O	O
diurnal	O	Physical
salivary	O	Physical
cortisol	O	Physical
pattern	O	Physical
was	O	O
found	O	O
.	O	O

The	O	O
findings	O	O
of	O	O
reduced	O	O
salivary	Physical	Physical
cortisol	Physical	Physical
concentrations	Physical	Physical
immediately	O	O
after	O	O
the	O	O
interventions	O	O
are	O	O
in	O	O
agreement	O	O
with	O	O
previous	O	O
studies	O	O
.	O	O

However	O	O
,	O	O
there	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
the	O	O
TM	O	O
and	O	O
control	O	O
groups	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
correlations	O	O
between	O	O
cortisol	Physical	Physical
concentrations	Physical	Physical
and	O	O
age	Physical	O
,	Physical	O
gender	Physical	O
,	Physical	O
BMI	Physical	O
,	O	O
time-point	Physical	O
for	Physical	O
intervention	Physical	O
,	O	O
time	Physical	O
interval	Physical	O
between	Physical	O
anti-parkinson	Physical	O
pharmacy	Physical	O
intake	Physical	O
and	Physical	O
sampling	Physical	O
,	O	O
levodopa	Physical	O
doses	Physical	O
,	Physical	O
duration	Physical	O
,	Physical	O
or	Physical	O
severity	Physical	Physical
of	Physical	Physical
PD	Physical	Physical
.	O	O

CONCLUSIONS	O	O
Diurnal	Physical	O
salivary	Physical	O
cortisol	Physical	O
rhythm	Physical	O
was	O	O
normal	O	O
.	O	O

Salivary	Physical	Physical
cortisol	Physical	Physical
concentrations	Physical	Physical
were	O	O
significantly	O	O
reduced	O	O
after	O	O
the	O	O
TM	O	O
intervention	O	O
and	O	O
after	O	O
RTM	O	O
,	O	O
but	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
groups	O	O
and	O	O
no	O	O
sustained	O	O
long-term	O	O
effect	O	O
.	O	O

No	O	O
associations	O	O
were	O	O
seen	O	O
between	O	O
salivary	Physical	Physical
cortisol	Physical	Physical
concentration	Physical	Physical
and	O	O
clinical	O	O
and/or	O	O
pharmacological	O	O
characteristics	O	O
.	O	O

TRIAL	O	O
REGISTRATION	O	O
ClinicalTrial.gov	O	O
,	O	O
NCT01734876	O	O
and	O	O
FoU	O	O
Sweden	O	O
108881	O	O
.	O	O

Relation	O	O
of	O	O
total	O	O
homocysteine	O	O
and	O	O
lipid	O	O
levels	O	O
in	O	O
children	O	O
to	O	O
premature	O	Physical
cardiovascular	O	Physical
death	O	Physical
in	O	O
male	O	O
relatives	O	O
.	O	O

We	O	O
assessed	O	O
the	O	O
relative	Others	O
importance	Others	O
of	O	O
lipid	Physical	O
,	Physical	O
apo	Physical	O
B	Physical	O
,	Physical	O
lipoprotein	Physical	O
(	Physical	O
a	Physical	O
)	Physical	O
[	Physical	O
Lp	Physical	O
(	Physical	O
a	Physical	O
)	Physical	O
]	Physical	O
,	Physical	O
and	Physical	O
total	Physical	Physical
homocysteine	Physical	Physical
(	Physical	Physical
tHcy	Physical	Physical
)	Physical	Physical
levels	Physical	Physical
in	O	O
children	O	O
in	O	O
relation	O	O
to	O	O
premature	O	O
cardiovascular	O	O
disease	O	O
in	O	O
family	O	O
members	O	O
.	O	O

Parents	O	O
of	O	O
381	O	O
girls	O	O
and	O	O
375	O	O
boys	O	O
age	O	O
8-12	O	O
y	O	O
completed	O	O
family	O	O
history	O	O
questionnaires	O	O
.	O	O

Nonfasting	Physical	Physical
serum	Physical	Physical
lipid	Physical	Physical
and	Physical	Physical
lipoproteins	Physical	Physical
and	Physical	O
plasma	Physical	Physical
tHcy	Physical	Physical
and	Physical	Physical
cysteine	Physical	Physical
levels	Physical	Physical
were	O	O
measured	O	O
in	O	O
the	O	O
children	O	O
.	O	O

Serum	Physical	Physical
folate	Physical	Physical
and	Physical	Physical
vitamin	Physical	Physical
B12	Physical	Physical
levels	Physical	Physical
were	O	O
determined	O	O
in	O	O
a	O	O
random	O	O
subsample	O	O
of	O	O
23	O	O
%	O	O
of	O	O
the	O	O
children	O	O
,	O	O
who	O	O
participated	O	O
in	O	O
a	O	O
food	O	O
frequency	O	O
interview	O	O
.	O	O

Children	O	O
whose	O	O
parents	O	O
reported	O	O
hypercholesterolemia	O	O
had	O	O
higher	O	O
total	Physical	Physical
and	Physical	Physical
non-HDL	Physical	Physical
cholesterol	Physical	Physical
and	Physical	Physical
apo	Physical	Physical
B	Physical	Physical
levels	Physical	Physical
than	O	O
the	O	O
rest	O	O
,	O	O
but	O	O
these	O	O
levels	O	O
were	O	O
not	O	O
associated	O	O
with	O	O
cardiovascular	O	O
disease	O	O
.	O	O

tHcy	Physical	Physical
levels	Physical	Physical
were	O	O
similar	O	O
in	O	O
girls	O	O
and	O	O
boys	O	O
.	O	O

tHcy	Physical	O
was	O	O
higher	O	O
in	O	O
children	O	O
whose	O	O
father	O	O
,	O	O
grandfather	O	O
,	O	O
or	O	O
uncle	O	O
died	O	O
at	O	O
age	O	O
<	O	O
or	O	O
=	O	O
55	O	O
y	O	O
of	O	O
myocardial	O	O
infarction	O	O
or	O	O
sudden	O	O
cardiac	O	O
arrest	O	O
(	O	O
n	O	O
=	O	O
42	O	O
)	O	O
than	O	O
in	O	O
control	O	O
children	O	O
[	O	O
5.92	O	O
mumol/L	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
of	O	O
5.47-6.36	O	O
)	O	O
versus	O	O
5.25	O	O
mumol/L	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
5.16-5.34	O	O
)	O	O
]	O	O
,	O	O
also	O	O
after	O	O
adjustment	O	O
for	O	O
socioeconomic	O	O
group	O	O
.	O	O

Intake	Physical	O
and	Physical	O
serum	Physical	O
levels	Physical	O
of	Physical	O
vitamin	Physical	O
B12	Physical	O
and	Physical	O
folate	Physical	O
were	O	O
within	O	O
recommended	O	O
or	O	O
reference	O	O
ranges	O	O
.	O	O

In	O	O
a	O	O
stepwise	O	O
multiple	O	O
regression	O	O
analysis	O	O
,	O	O
serum	Physical	Physical
folate	Physical	Physical
(	Physical	O
negative	Physical	O
correlation	Physical	O
)	Physical	O
,	Physical	O
plasma	Physical	Physical
creatinine	Physical	Physical
,	Physical	O
and	Physical	O
sugar	Physical	O
intake	Physical	O
as	O	O
percent	O	O
of	O	O
dietary	O	O
energy	O	O
(	O	O
positive	O	O
correlations	O	O
)	O	O
were	O	O
significantly	O	O
associated	O	O
with	O	O
tHcy	Physical	O
(	O	O
multiple	O	O
r	O	O
=	O	O
0.44	O	O
,	O	O
adjusted	O	O
r2	O	O
=	O	O
18	O	O
%	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
5-30	O	O
%	O	O
)	O	O
.	O	O

Our	O	O
data	O	O
show	O	O
that	O	O
a	O	O
modest	O	O
elevation	O	O
in	O	O
tHcy	Physical	O
in	O	O
children	O	O
was	O	O
related	O	O
to	O	O
premature	Mortality	Mortality
cardiovascular	Mortality	Mortality
death	Mortality	Mortality
in	O	O
their	O	O
male	O	O
relatives	O	O
and	O	O
may	O	O
partly	O	O
account	O	O
for	O	O
the	O	O
contribution	O	O
of	O	O
family	O	O
history	O	O
to	O	O
risk	O	O
of	O	O
cardiovascular	O	O
disease	O	O
.	O	O

tHcy	Physical	O
may	O	O
be	O	O
modifiable	O	O
through	O	O
the	O	O
diet	O	O
,	O	O
even	O	O
in	O	O
children	O	O
with	O	O
apparently	O	O
adequate	O	O
vitamin	O	O
nutriture	O	O
.	O	O

Mechanical	Physical	O
efficiency	Physical	O
and	O	O
propulsion	Physical	O
technique	Physical	O
after	O	O
7	O	O
weeks	O	O
of	O	O
low-intensity	O	O
wheelchair	O	O
training	O	O
.	O	O

BACKGROUND	O	O
To	O	O
evaluate	O	O
the	O	O
effect	O	O
of	O	O
a	O	O
7-week	O	O
low-intensity	O	O
hand	O	O
rim	O	O
wheelchair	O	O
training	O	O
on	O	O
the	O	O
submaximal	O	Physical
metabolic	O	Physical
cost	O	Physical
,	O	O
mechanical	Physical	Others
efficiency	Physical	Others
and	O	O
propulsion	O	O
technique	O	O
in	O	O
able-bodied	O	O
participants	O	O
.	O	O

METHODS	O	O
Participants	O	O
were	O	O
randomly	O	O
divided	O	O
over	O	O
an	O	O
experimental	O	O
group	O	O
(	O	O
n=14	O	O
)	O	O
and	O	O
a	O	O
control	O	O
group	O	O
(	O	O
n=7	O	O
)	O	O
.	O	O

The	O	O
experimental	O	O
group	O	O
received	O	O
7	O	O
weeks	O	O
wheelchair	O	O
training	O	O
(	O	O
3	O	O
week	O	O
(	O	O
-1	O	O
)	O	O
,	O	O
70	O	O
min	O	O
)	O	O
at	O	O
a	O	O
low	O	O
intensity	O	O
(	O	O
30	O	O
%	O	O
of	O	O
the	O	O
heart	O	O
rate	O	O
reserve	O	O
)	O	O
,	O	O
whereas	O	O
the	O	O
control	O	O
group	O	O
did	O	O
not	O	O
receive	O	O
training	O	O
.	O	O

During	O	O
pre-	O	O
and	O	O
post-tests	O	O
,	O	O
submaximal	O	O
exercise	O	O
was	O	O
performed	O	O
on	O	O
a	O	O
stationary	O	O
wheelchair	O	O
ergometer	O	O
at	O	O
fixed	O	O
levels	O	O
of	O	O
power	O	O
output	O	O
.	O	O

Mechanical	Physical	O
efficiency	Physical	O
,	O	O
oxygen	Physical	Physical
uptake	Physical	Physical
,	O	O
heart	Physical	O
rate	Physical	O
,	O	O
timing	Others	O
parameters	Others	O
and	O	O
stroke	Physical	O
angles	Physical	O
were	O	O
measured	O	O
.	O	O

Video	O	O
recordings	O	O
were	O	O
made	O	O
to	O	O
determine	O	O
the	O	O
stroke	Physical	O
pattern	Physical	O
.	O	O

FINDINGS	O	O
Mechanical	Physical	O
efficiency	Physical	O
increased	O	O
and	O	O
metabolic	Physical	Physical
cost	Physical	Physical
decreased	O	O
significantly	O	O
in	O	O
the	O	O
experimental	O	O
group	O	O
compared	O	O
to	O	O
the	O	O
control	O	O
group	O	O
.	O	O

Push	Others	O
time	Others	O
increased	O	O
and	O	O
cycle	Others	Physical
frequency	Others	Physical
decreased	O	O
as	O	O
a	O	O
result	O	O
of	O	O
training	O	O
.	O	O

The	O	O
stroke	Physical	O
angle	Physical	O
increased	O	O
in	O	O
the	O	O
experimental	O	O
group	O	O
during	O	O
the	O	O
training	O	O
period	O	O
.	O	O

The	O	O
experimental	O	O
group	O	O
preferred	O	O
double-looping	O	O
over	O	O
propulsion	O	O
,	O	O
while	O	O
the	O	O
control	O	O
group	O	O
mainly	O	O
used	O	O
single-looping	Others	O
over	Others	O
propulsion	Others	O
patterns	O	O
during	O	O
the	O	O
post-test	O	O
.	O	O

INTERPRETATION	O	O
A	O	O
low-intensity	O	O
,	O	O
7-week	O	O
training	O	O
protocol	O	O
has	O	O
a	O	O
beneficial	O	O
effect	O	O
on	O	O
the	O	O
mechanical	Physical	O
efficiency	Physical	O
and	O	O
metabolic	Physical	O
cost	Physical	O
of	O	O
wheelchair	O	O
propulsion	O	O
in	O	O
able-bodied	O	O
participants	O	O
.	O	O

The	O	O
improved	O	Others
mechanical	O	Others
efficiency	O	Others
seems	O	O
to	O	O
be	O	O
the	O	O
result	O	O
of	O	O
changes	O	O
in	O	O
propulsion	O	O
technique	O	O
that	O	O
were	O	O
found	O	O
.	O	O

Comparing	O	O
the	O	O
effectiveness	Others	O
of	O	O
peer	O	O
mentoring	O	O
and	O	O
student	O	O
mentoring	O	O
in	O	O
a	O	O
35-week	O	O
fitness	O	O
program	O	O
for	O	O
older	O	O
adults	O	O
.	O	O

To	O	O
investigate	O	O
the	O	O
applicability	Others	O
and	O	O
effectiveness	Others	O
of	O	O
a	O	O
peer-mentored	O	O
exercise	O	O
program	O	O
,	O	O
this	O	O
study	O	O
compared	O	O
the	O	O
retention	Others	Others
and	Others	Others
participation	Others	Others
rates	Others	Others
,	O	O
and	O	O
physical	Physical	O
improvements	Physical	O
of	O	O
older	O	O
adults	O	O
trained	O	O
by	O	O
peer	O	O
mentors	O	O
(	O	O
PM	O	O
)	O	O
to	O	O
a	O	O
group	O	O
trained	O	O
by	O	O
young	O	O
qualified	O	O
student	O	O
mentors	O	O
(	O	O
SM	O	O
)	O	O
.	O	O

A	O	O
group	O	O
of	O	O
older	O	O
adults	O	O
were	O	O
prepared	O	O
as	O	O
peer	O	O
mentors	O	O
through	O	O
a	O	O
30-week	O	O
preparation	O	O
program	O	O
.	O	O

Later	O	O
,	O	O
60	O	O
older	O	O
adults	O	O
(	O	O
mean	O	O
?	O	O
SD	O	O
age	O	O
:	O	O
68.7	O	O
?	O	O
6.1	O	O
years	O	O
)	O	O
were	O	O
recruited	O	O
and	O	O
randomly	O	O
assigned	O	O
to	O	O
either	O	O
the	O	O
PM	O	O
or	O	O
SM	O	O
group	O	O
.	O	O

Both	O	O
groups	O	O
completed	O	O
an	O	O
identical	O	O
35-week	O	O
fitness	O	O
program	O	O
.	O	O

Pre-	O	O
,	O	O
midterm-	O	O
and	O	O
post-training	O	O
assessments	O	O
of	O	O
fitness	O	O
were	O	O
completed	O	O
and	O	O
rates	O	Mental
of	O	Mental
participation	O	Mental
and	O	Mental
retention	O	Mental
were	O	O
documented	O	O
.	O	O

The	O	O
same	O	O
retention	O	Others
rates	O	Others
were	O	O
observed	O	O
in	O	O
the	O	O
two	O	O
groups	O	O
,	O	O
but	O	O
SM	O	O
group	O	O
had	O	O
higher	O	O
participation	O	O
.	O	O

Both	O	O
groups	O	O
improved	O	O
significantly	O	O
in	O	O
all	O	O
measures	O	O
of	O	O
fitness	O	O
and	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
post-test	O	O
differences	O	O
between	O	O
the	O	O
groups	O	O
in	O	O
the	O	O
fitness	O	O
measures	O	O
.	O	O

Findings	O	O
suggest	O	O
that	O	O
the	O	O
peer	O	O
mentor	O	O
model	O	O
is	O	O
applicable	O	O
in	O	O
an	O	O
older	O	O
adult	O	O
exercise	O	O
program	O	O
and	O	O
may	O	O
be	O	O
as	O	O
effective	O	O
as	O	O
a	O	O
program	O	O
mentored	O	O
by	O	O
young	O	O
professionals	O	O
.	O	O

Comparison	O	O
of	O	O
thiopentone/guaifenesin	O	O
,	O	O
ketamine/guaifenesin	O	O
and	O	O
ketamine/midazolam	O	O
for	O	O
the	O	O
induction	O	O
of	O	O
horses	O	O
to	O	O
be	O	O
anaesthetised	O	O
with	O	O
isoflurane	O	O
.	O	O

Forty-eight	O	O
horses	O	O
subjected	O	O
to	O	O
elective	O	O
surgery	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
three	O	O
groups	O	O
of	O	O
16	O	O
horses	O	O
.	O	O

After	O	O
premedication	O	O
with	O	O
0.1	O	O
mg/kg	O	O
acepromazine	O	O
intramuscularly	O	O
and	O	O
0.6	O	O
mg/kg	O	O
xylazine	O	O
intravenously	O	O
,	O	O
anaesthesia	O	O
was	O	O
induced	O	O
either	O	O
with	O	O
2	O	O
g	O	O
thiopentone	O	O
in	O	O
500	O	O
ml	O	O
of	O	O
a	O	O
10	O	O
per	O	O
cent	O	O
guaifenesin	O	O
solution	O	O
,	O	O
given	O	O
intravenously	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
1	O	O
ml/kg	O	O
(	O	O
group	O	O
TG	O	O
)	O	O
,	O	O
or	O	O
with	O	O
100	O	O
mg/kg	O	O
guaifenesin	O	O
and	O	O
2.2	O	O
mg/kg	O	O
ketamine	O	O
given	O	O
intravenously	O	O
(	O	O
group	O	O
KG	O	O
)	O	O
,	O	O
or	O	O
with	O	O
0.06	O	O
mg/kg	O	O
midazolam	O	O
,	O	O
and	O	O
2.2	O	O
mg/kg	O	O
ketamine	O	O
given	O	O
intravenously	O	O
(	O	O
group	O	O
KM	O	O
)	O	O
.	O	O

Anaesthesia	Others	O
was	O	O
maintained	O	O
with	O	O
isoflurane	O	O
.	O	O

The	O	O
mean	Others	O
(	Others	O
sd	Others	O
)	Others	O
end	Others	O
tidal	Others	O
isoflurane	Others	O
concentration	Others	O
(	Others	O
per	Others	O
cent	Others	O
)	Others	O
needed	O	O
to	O	O
maintain	O	O
a	O	O
light	Others	O
surgical	Others	O
anaesthesia	Others	O
(	O	O
stage	O	O
III	O	O
,	O	O
plane	O	O
2	O	O
)	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
group	O	O
KM	O	O
(	O	O
0.91	O	O
[	O	O
0.03	O	O
]	O	O
)	O	O
than	O	O
in	O	O
groups	O	O
TG	O	O
(	O	O
1.11	O	O
[	O	O
0.03	O	O
]	O	O
)	O	O
and	O	O
KG	O	O
(	O	O
1.14	O	O
[	O	O
0.03	O	O
]	O	O
)	O	O
.	O	O

The	O	O
mean	Physical	Physical
(	Physical	Physical
sd	Physical	Physical
)	Physical	Physical
arterial	Physical	Physical
pressure	Physical	Physical
(	Physical	Physical
mmHg	Physical	Physical
)	Physical	Physical
was	O	O
significantly	O	O
lower	O	O
in	O	O
group	O	O
KG	O	O
(	O	O
67.4	O	O
[	O	O
2.07	O	O
]	O	O
)	O	O
than	O	O
in	O	O
groups	O	O
TC	O	O
(	O	O
75.6	O	O
[	O	O
2.23	O	O
]	O	O
)	O	O
and	O	O
KM	O	O
(	O	O
81.0	O	O
[	O	O
2.16	O	O
]	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
logarithm	O	O
of	O	O
the	O	O
heart	Physical	O
rate	Physical	O
,	Others	O
recovery	Physical	Others
time	Physical	Others
or	Others	Others
quality	Physical	Others
of	Physical	Others
recovery	Physical	Others
between	O	O
the	O	O
three	O	O
induction	O	O
groups	O	O
.	O	O

However	O	O
,	O	O
pronounced	O	O
ataxia	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
horses	O	O
of	O	O
group	O	O
KM	O	O
,	O	O
especially	O	O
after	O	O
periods	O	O
of	O	O
anaesthesia	Others	O
lasting	O	O
less	O	O
than	O	O
75	O	O
minutes	O	O
.	O	O

Extracorporeal	O	O
shock	O	O
wave	O	O
therapy	O	O
(	O	O
ESWT	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
chronic	O	O
proximal	O	O
plantar	O	O
fasciitis	O	O
:	O	O
a	O	O
2-year	O	O
follow-up	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
the	O	O
effect	O	O
of	O	O
extracorporeal	O	O
shock	O	O
wave	O	O
therapy	O	O
(	O	O
ESWT	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
chronically	O	O
painful	O	O
proximal	O	O
plantar	O	O
fasciitis	O	O
with	O	O
a	O	O
further	O	O
conventional	O	O
conservative	O	O
treatment	O	O
.	O	O

Forty-seven	O	O
patients	O	O
(	O	O
49	O	O
feet	O	O
)	O	O
with	O	O
a	O	O
previously	O	O
unsuccessful	O	O
nonsurgical	O	O
treatment	O	O
of	O	O
at	O	O
least	O	O
6	O	O
months	O	O
were	O	O
randomized	O	O
to	O	O
two	O	O
groups	O	O
.	O	O

Heel	O	O
cups	O	O
had	O	O
to	O	O
be	O	O
worn	O	O
throughout	O	O
the	O	O
study	O	O
.	O	O

Group	O	O
1	O	O
(	O	O
25	O	O
heels	O	O
)	O	O
was	O	O
treated	O	O
immediately	O	O
with	O	O
three	O	O
sessions	O	O
of	O	O
ESWT	O	O
(	O	O
3000	O	O
shock	O	O
waves/session	O	O
of	O	O
0.2	O	O
mJ/mm2	O	O
)	O	O
at	O	O
weekly	O	O
intervals	O	O
.	O	O

The	O	O
patients	O	O
of	O	O
group	O	O
2	O	O
(	O	O
24	O	O
heels	O	O
)	O	O
continued	O	O
nonsurgical	O	O
treatment	O	O
(	O	O
iontophoresis	O	O
with	O	O
diclofenac	O	O
and	O	O
an	O	O
oral	O	O
nonsteroidal	O	O
anti-inflammatory	O	O
drug	O	O
)	O	O
for	O	O
12	O	O
weeks	O	O
.	O	O

After	O	O
this	O	O
period	O	O
they	O	O
were	O	O
treated	O	O
using	O	O
the	O	O
protocol	O	O
of	O	O
group	O	O
1	O	O
.	O	O

No	O	O
significant	O	O
difference	O	Pain
of	O	Pain
pain	Pain	Pain
and	O	O
walking	Physical	Physical
time	Physical	Physical
after	O	O
further	O	O
nonsurgical	O	O
treatment	O	O
(	O	O
3	O	O
months	O	O
)	O	O
was	O	O
seen	O	O
in	O	O
group	O	O
2	O	O
.	O	O

At	O	O
12	O	O
weeks	O	O
after	O	O
ESWT	O	O
,	O	O
the	O	O
pain	Pain	Pain
estimation	Pain	Pain
on	Pain	Pain
the	Pain	Pain
visual	Pain	Pain
analogue	Pain	Pain
scale	Pain	Pain
(	Pain	Pain
VAS	Pain	Pain
)	Pain	Pain
for	Pain	O
activities	Pain	Physical
of	Pain	Physical
daily	Pain	Physical
living	Pain	Physical
diminished	O	O
significantly	O	O
by	O	O
62.9	O	O
%	O	O
in	O	O
group	O	O
1	O	O
and	O	O
by	O	O
63.0	O	O
%	O	O
in	O	O
group	O	O
2	O	O
.	O	O

The	O	O
comfortable	Physical	O
walking	Physical	O
time	Physical	O
had	O	O
increased	O	O
significantly	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Two	O	O
years	O	O
after	O	O
ESWT	O	O
,	O	O
pain	Pain	Pain
during	Pain	Pain
activities	Pain	Pain
of	Pain	Pain
daily	Pain	Pain
living	Pain	Pain
decreased	O	O
by	O	O
94	O	O
%	O	O
in	O	O
group	O	O
1	O	O
and	O	O
by	O	O
90	O	O
%	O	O
in	O	O
group	O	O
2	O	O
on	O	O
the	O	O
VAS	O	Others
and	O	O
the	O	O
comfortable	Physical	O
walking	Physical	O
time	Physical	O
had	O	O
increased	O	O
significantly	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Lactobacillus	O	O
plantarum	O	O
CECT7315	O	O
and	O	O
CECT7316	O	O
stimulate	O	O
immunoglobulin	Physical	Physical
production	Physical	Physical
after	O	O
influenza	O	O
vaccination	O	O
in	O	O
elderly	O	O
.	O	O

OBJECTIVE	O	O
The	O	O
effectiveness	O	O
of	O	O
influenza	O	O
vaccination	O	O
in	O	O
preventing	O	O
illness	O	O
is	O	O
lower	O	O
in	O	O
the	O	O
elderly	O	O
;	O	O
this	O	O
is	O	O
why	O	O
the	O	O
ability	O	O
of	O	O
Lactobacillus	O	O
plantarum	O	O
CECT	O	O
7315/7316	O	O
to	O	O
stimulate	Physical	O
the	Physical	O
response	Physical	O
to	Physical	O
influenza	Physical	O
vaccination	Physical	O
in	O	O
elderly	O	O
was	O	O
evaluated	O	O
.	O	O

RESEARCH	O	O
METHODS	O	O
AND	O	O
PROCEDURES	O	O
A	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
human	O	O
trial	O	O
including	O	O
60	O	O
institutionalized	O	O
volunteers	O	O
aged	O	O
65-85	O	O
years	O	O
was	O	O
performed	O	O
.	O	O

All	O	O
the	O	O
volunteers	O	O
were	O	O
vaccinated	O	O
with	O	O
a	O	O
trivalent	O	O
influenza	O	O
vaccine	O	O
(	O	O
A/Wisconsin/67/2005	O	O
NYMC	O	O
X-161B	O	O
(	O	O
H3N2	O	O
)	O	O
,	O	O
A/Solomon	O	O
Islands/3/2006	O	O
(	O	O
H1N1	O	O
)	O	O
and	O	O
B/Malaysia/2506/2004	O	O
)	O	O
for	O	O
the	O	O
Spanish	O	O
vaccine	O	O
campaign	O	O
2006/2007	O	O
.	O	O

The	O	O
consumption	O	O
of	O	O
the	O	O
probiotic	O	O
began	O	O
between	O	O
three	O	O
and	O	O
four	O	O
months	O	O
after	O	O
the	O	O
vaccination	O	O
.	O	O

Volunteers	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
three	O	O
following	O	O
groups	O	O
:	O	O
group	O	O
A	O	O
(	O	O
receiving	O	O
5*10	O	O
(	O	O
9	O	O
)	O	O
cfu/day	O	O
of	O	O
L.	O	O
plantarum	O	O
CECT	O	O
7315/7316	O	O
in	O	O
20	O	O
g	O	O
powdered	O	O
skim	O	O
milk	O	O
)	O	O
,	O	O
group	O	O
B	O	O
(	O	O
receiving	O	O
5*10	O	O
(	O	O
8	O	O
)	O	O
cfu/day	O	O
of	O	O
L.	O	O
plantarum	O	O
CECT	O	O
7315/7316	O	O
in	O	O
20	O	O
g	O	O
powdered	O	O
skim	O	O
milk	O	O
)	O	O
and	O	O
group	O	O
C	O	O
or	O	O
placebo	O	O
(	O	O
20	O	O
g	O	O
powered	O	O
skim	O	O
milk	O	O
)	O	O
.	O	O

The	O	O
participants	O	O
consumed	O	O
the	O	O
probiotic	O	O
during	O	O
3	O	O
months	O	O
.	O	O

RESULTS	O	O
The	O	O
consumption	O	O
of	O	O
L.	O	O
plantarum	O	O
CECT	O	O
7315/7316	O	O
during	O	O
3	O	O
months	O	O
after	O	O
influenza	O	O
vaccination	O	O
increased	O	O
the	O	O
levels	Physical	O
of	Physical	O
influenza-specific	Physical	Physical
IgA	Physical	Physical
and	Physical	Physical
IgG	Physical	Physical
antibodies	Physical	Physical
.	Physical	O

Moreover	O	O
,	O	O
a	O	O
trend	O	O
towards	O	O
an	O	O
increase	O	O
in	O	O
influenza-specific	Physical	Physical
IgM	Physical	Physical
antibodies	Physical	Physical
was	O	O
also	O	O
observed	O	O
.	O	O

CONCLUSION	O	O
L.	O	O
plantarum	O	O
CECT7315/7316	O	O
has	O	O
an	O	O
immunostimulating	O	O
effect	O	O
and	O	O
could	O	O
be	O	O
used	O	O
to	O	O
improve	O	O
the	O	O
response	O	Others
to	O	Others
influenza	O	Others
vaccination	O	Others
in	O	O
elderly	O	O
.	O	O

The	O	O
prophylactic	Others	O
effect	Others	O
of	O	O
valproate	O	O
on	O	O
glyceryltrinitrate	Physical	O
induced	Physical	O
migraine	Physical	O
.	Physical	O

In	O	O
this	O	O
study	O	O
the	O	O
human	O	O
glyceryltrinitrate	O	O
(	O	O
GTN	O	O
)	O	O
model	O	O
of	O	O
migraine	O	O
was	O	O
for	O	O
the	O	O
first	O	O
time	O	O
used	O	O
to	O	O
test	O	O
the	O	O
effect	O	O
of	O	O
a	O	O
prophylactic	O	O
drug	O	O
.	O	O

We	O	O
chose	O	O
to	O	O
test	O	O
valproate	O	O
due	O	O
to	O	O
its	O	O
well	O	O
documented	O	O
effect	O	O
as	O	O
a	O	O
migraine	O	O
prophylactic	O	O
drug	O	O
.	O	O

Efficacy	Others	Others
of	O	O
this	O	O
compound	O	O
would	O	O
support	O	O
the	O	O
usefulness	O	O
of	O	O
the	O	O
model	O	O
in	O	O
prophylactic	O	O
antimigraine	O	O
drug	O	O
development	O	O
.	O	O

Twelve	O	O
patients	O	O
with	O	O
migraine	O	O
without	O	O
aura	O	O
were	O	O
included	O	O
in	O	O
a	O	O
randomized	O	O
double	O	O
blind	O	O
crossover	O	O
study	O	O
.	O	O

Valproate	O	O
1000	O	O
mg	O	O
or	O	O
placebo	O	O
was	O	O
given	O	O
daily	O	O
,	O	O
each	O	O
for	O	O
a	O	O
minimum	O	O
of	O	O
13	O	O
days	O	O
.	O	O

On	O	O
the	O	O
last	O	O
treatment	O	O
day	O	O
of	O	O
each	O	O
arm	O	O
a	O	O
20	O	O
min	O	O
intravenous	O	O
infusion	O	O
of	O	O
GTN	O	O
(	O	O
0.25	O	O
microg/kg/min	O	O
)	O	O
was	O	O
given	O	O
.	O	O

Headache	Adverseeffect	O
was	O	O
registered	O	O
for	O	O
12	O	O
h	O	O
after	O	O
the	O	O
infusion	O	O
and	O	O
headache	Adverseeffect	O
intensity	Adverseeffect	O
was	O	O
scored	O	O
on	O	O
a	O	O
scale	O	O
from	O	O
0	O	O
to	O	O
10	O	O
.	O	O

Fulfillment	O	O
of	O	O
IHS	O	O
criteria	O	O
was	O	O
recorded	O	O
for	O	O
24	O	O
h.	O	O
The	O	O
middle	Physical	Physical
cerebral	Physical	Physical
arteries	Physical	Physical
were	O	O
evaluated	O	O
by	O	O
transcranial	Physical	O
Doppler	Physical	O
and	O	O
the	O	O
diameter	Physical	O
of	Physical	O
the	Physical	O
superficial	Physical	O
temporal	Physical	O
and	Physical	O
radial	Physical	O
arteries	Physical	O
were	O	O
measured	O	O
with	O	O
high	Physical	O
frequency	Physical	O
ultrasound	Physical	O
.	Others	O

GTN	Physical	O
evoked	Physical	O
migraine	Pain	O
fulfilling	Pain	O
IHS	Pain	O
criteria	Pain	O
1.1	O	O
in	O	O
6	O	O
patients	O	O
after	O	O
placebo	O	O
and	O	O
in	O	O
2	O	O
patients	O	O
after	O	O
valproate	O	O
(	O	O
P	O	O
=	O	O
0.125	O	O
)	O	O
.	O	O

Including	O	O
additionally	O	O
3	O	O
patients	O	O
on	O	O
placebo	O	O
and	O	O
1	O	O
patient	O	O
on	O	O
valproate	O	O
who	O	O
felt	O	O
they	O	O
had	O	O
suffered	O	O
a	O	O
migraine	Adverseeffect	O
attack	Adverseeffect	O
,	O	O
but	O	O
who	O	O
had	O	O
as	O	O
associated	O	O
symptoms	O	O
only	O	O
photophobia	Physical	O
or	O	O
phonophobia	Physical	O
,	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
the	O	O
number	Others	O
of	Others	O
patients	Others	O
with	Others	O
induced	Others	O
migraine	Others	O
after	O	O
valproate	O	O
was	O	O
seen	O	O
(	O	O
P	O	O
=	O	O
0.031	O	O
)	O	O
.	O	O

Median	Physical	O
peak	Physical	O
headache	Physical	O
intensity	Physical	O
was	O	O
1	O	O
(	O	O
range	O	O
0-9	O	O
)	O	O
after	O	O
valproate	O	O
compared	O	O
to	O	O
4.5	O	O
(	O	O
range	O	O
0-8	O	O
)	O	O
after	O	O
placebo	O	O
(	O	O
P	O	O
=	O	O
0.120	O	O
)	O	O
.	O	O

Pretreatment	O	O
with	O	O
valproate	O	O
as	O	O
compared	O	O
to	O	O
placebo	O	O
reduced	O	O
the	O	O
velocity	Physical	O
in	O	O
both	O	O
middle	Others	O
cerebral	Others	O
arteries	Others	O
after	O	O
GTN	O	O
(	O	O
left	O	O
P	O	O
=	O	O
0.021	O	O
,	O	O
right	O	O
P	O	O
=	O	O
0.031	O	O
)	O	O
.	O	O

No	O	O
effect	O	O
of	O	O
valproate	O	O
was	O	O
seen	O	O
in	O	O
the	O	O
diameter	Physical	O
of	Physical	O
the	Physical	O
superficial	Physical	O
temporal	Physical	O
artery	Physical	O
(	O	O
P	O	O
=	O	O
0.781	O	O
)	O	O
or	O	O
the	O	O
radial	O	O
artery	O	O
(	O	O
P	O	O
=	O	O
0.367	O	O
)	O	O
before	O	O
or	O	O
after	O	O
GTN	O	O
.	O	O

The	O	O
study	O	O
indicates	O	O
that	O	O
a	O	O
prophylactic	O	O
effect	O	O
of	O	O
valproate	O	O
may	O	O
be	O	O
demonstrated	O	O
using	O	O
the	O	O
GTN	Physical	O
human	Physical	O
migraine	Physical	O
model	O	O
.	O	O

Although	O	O
,	O	O
all	O	O
headache	Adverseeffect	O
parameters	Adverseeffect	O
were	O	O
reduced	O	O
after	O	O
valproate	O	O
compared	O	O
to	O	O
placebo	O	O
,	O	O
only	O	O
one	O	O
parameter	O	O
was	O	O
statistically	O	O
significantly	O	O
reduced	O	O
probably	O	O
because	O	O
of	O	O
the	O	O
small	O	O
number	O	O
of	O	O
patients	O	O
.	O	O

The	O	O
size	O	O
of	O	O
the	O	O
effect	O	O
was	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
valproate	O	O
in	O	O
clinical	O	O
trials	O	O
.	O	O

The	O	O
GTN	O	O
model	O	O
may	O	O
therefore	O	O
be	O	O
a	O	O
valid	O	O
tool	O	O
for	O	O
testing	O	O
new	O	O
prophylactic	O	O
antimigraine	O	O
drugs	O	O
.	O	O

Effect	Others	O
of	O	O
a	O	O
multi-faceted	O	O
intervention	O	O
on	O	O
gingival	Physical	Physical
health	Physical	Physical
among	O	O
adults	O	O
with	O	O
systemic	O	O
sclerosis	O	O
.	O	O

OBJECTIVES	O	O
To	O	O
evaluate	Others	O
the	Others	O
effect	Others	O
of	O	O
adaptive	O	O
oral	O	O
hygiene	O	O
devices	O	O
and	O	O
orofacial	O	O
exercise	O	O
to	O	O
improve	O	O
gingival	Physical	Physical
health	Physical	Physical
among	O	O
adults	O	O
with	O	O
systemic	O	O
sclerosis	O	O
(	O	O
SSc	O	O
)	O	O
.	O	O

METHODS	O	O
Forty-eight	O	O
patients	O	O
with	O	O
SSc	O	O
were	O	O
assigned	O	O
randomly	O	O
to	O	O
the	O	O
multifaceted	O	O
oral	O	O
health	O	O
intervention	O	O
or	O	O
usual	O	O
dental	O	O
care	O	O
control	O	O
group	O	O
.	O	O

Participants	O	O
in	O	O
the	O	O
intervention	O	O
group	O	O
received	O	O
a	O	O
rechargeable	O	O
,	O	O
powered	O	O
Oral-B?	O	O
oscillating-rotating-pulsating	O	O
toothbrush	O	O
and	O	O
a	O	O
Reach?	O	O
Access?	O	O
Flosser	O	O
that	O	O
has	O	O
a	O	O
toothbrush-like	O	O
handle	O	O
.	O	O

For	O	O
those	O	O
with	O	O
an	O	O
oral	O	O
aperture	O	O
of	O	O
less	O	O
than	O	O
40	O	O
mm	O	O
,	O	O
orofacial	O	O
exercises	O	O
were	O	O
taught	O	O
.	O	O

Participants	O	O
in	O	O
the	O	O
control	O	O
group	O	O
were	O	O
each	O	O
given	O	O
a	O	O
manual	O	O
toothbrush	O	O
and	O	O
dental	O	O
floss	O	O
.	O	O

Participants	O	O
in	O	O
both	O	O
groups	O	O
received	O	O
instructions	O	O
and	O	O
demonstration	O	O
on	O	O
the	O	O
use	O	O
of	O	O
the	O	O
devices	O	O
,	O	O
and	O	O
were	O	O
requested	O	O
to	O	O
perform	O	O
the	O	O
respective	O	O
intervention	O	O
twice	O	O
a	O	O
day	O	O
for	O	O
6	O	O
months	O	O
.	O	O

Evaluations	O	O
were	O	O
at	O	O
baseline	O	O
,	O	O
3-	O	O
,	O	O
and	O	O
6-months	O	O
.	O	O

The	O	O
main	O	O
outcome	O	O
was	O	O
gingival	Physical	Physical
index	Physical	Physical
(	Physical	Physical
GI	Physical	Physical
)	Physical	Physical
,	O	Physical
an	O	Physical
indicator	O	Physical
of	O	Physical
gingival	O	Physical
inflammation	O	Physical
.	O	O

RESULTS	O	O
Both	O	O
groups	O	O
showed	O	O
significant	O	O
reduction	O	O
in	O	O
GI	O	Physical
scores	O	Physical
at	O	O
6	O	O
months	O	O
(	O	O
ps	O	O
<	O	O
0.005	O	O
)	O	O
.	O	O

Reduction	O	O
in	O	O
GI	O	O
scores	O	O
of	O	O
the	O	O
intervention	O	O
group	O	O
at	O	O
6	O	O
months	O	O
was	O	O
20.8	O	O
%	O	O
which	O	O
is	O	O
considered	O	O
to	O	O
be	O	O
clinically	O	O
significant	O	O
.	O	O

Compared	O	O
to	O	O
the	O	O
control	O	O
group	O	O
,	O	O
the	O	O
intervention	O	O
group	O	O
showed	O	O
a	O	O
significant	O	O
and	O	O
larger	O	Physical
reduction	O	Physical
in	O	Physical
GI	O	Physical
score	O	Physical
by	O	O
8	O	O
%	O	O
at	O	O
6	O	O
months	O	O
(	O	O
p=0.0007	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Results	O	O
support	O	O
the	O	O
use	O	O
of	O	O
adaptive	O	O
devices	O	O
and	O	O
orofacial	O	O
exercise	O	O
to	O	O
improve	O	O
gingival	Physical	Physical
health	Physical	Physical
in	O	O
adults	O	O
with	O	O
SSc	O	O
when	O	O
compared	O	O
to	O	O
use	O	O
of	O	O
manual	O	O
toothbrushing	O	O
and	O	O
finger-held	O	O
flossing	O	O
.	O	O

Recommending	O	O
and	O	O
educating	O	O
patients	O	O
with	O	O
SSc	O	O
to	O	O
use	O	O
adaptive	O	O
devices	O	O
to	O	O
clean	O	O
the	O	O
tooth	O	O
surfaces	O	O
looks	O	O
promising	O	O
for	O	O
long-term	O	O
oral	O	O
health	O	O
improvement	O	O
.	O	O

Prophylactic	O	O
vs	O	O
therapeutic	O	O
blood	O	O
patch	O	O
for	O	O
obstetric	O	O
patients	O	O
with	O	O
accidental	O	O
dural	O	O
puncture	O	O
--	O	O
a	O	O
randomised	O	O
controlled	O	O
trial	O	O
.	O	O

Epidural	O	O
blood	O	O
patch	O	O
is	O	O
a	O	O
standard	O	O
treatment	O	O
for	O	O
obstetric	O	O
patients	O	O
experiencing	O	O
a	O	O
severe	O	O
post-dural	O	Physical
puncture	O	Physical
headache	O	Physical
.	O	O

Patients	O	O
who	O	O
sustained	O	O
an	O	O
accidental	O	O
dural	O	O
puncture	O	O
during	O	O
establishment	O	O
of	O	O
epidural	O	O
analgesia	O	O
during	O	O
labour	O	O
or	O	O
at	O	O
caesarean	O	O
delivery	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
a	O	O
prophylactic	O	O
epidural	O	O
blood	O	O
patch	O	O
or	O	O
conservative	O	O
treatment	O	O
with	O	O
a	O	O
therapeutic	O	O
epidural	O	O
blood	O	O
patch	O	O
if	O	O
required	O	O
.	O	O

Eleven	O	O
of	O	O
60	O	O
(	O	O
18.3	O	O
%	O	O
)	O	O
patients	O	O
in	O	O
the	O	O
prophylactic	O	O
epidural	O	O
blood	O	O
patch	O	O
group	O	O
developed	O	O
a	O	O
post-dural	Adverseeffect	Physical
puncture	Adverseeffect	Physical
headache	Adverseeffect	Physical
compared	O	O
with	O	O
39	O	O
of	O	O
49	O	O
(	O	O
79.6	O	O
%	O	O
)	O	O
in	O	O
the	O	O
therapeutic	O	O
epidural	O	O
blood	O	O
patch	O	O
group	O	O
(	O	O
p	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

A	O	O
blood	O	O
patch	O	O
was	O	O
performed	O	O
in	O	O
36	O	O
(	O	O
73.4	O	O
%	O	O
)	O	O
of	O	O
patients	O	O
in	O	O
the	O	O
therapeutic	O	O
group	O	O
.	O	O

The	O	O
number	Others	O
of	Others	O
patients	Others	O
who	Others	O
needed	Others	O
a	Others	O
second	Others	O
blood	Others	O
patch	Others	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
:	O	O
6	O	O
(	O	O
10.0	O	O
%	O	O
)	O	O
for	O	O
prophylactic	O	O
epidural	O	O
blood	O	O
patch	O	O
and	O	O
4	O	O
(	O	O
11.1	O	O
%	O	O
)	O	O
for	O	O
therapeutic	O	O
epidural	O	O
blood	O	O
patch	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
prophylactic	O	O
epidural	O	O
blood	O	O
patch	O	O
is	O	O
an	O	O
effective	Others	O
method	O	O
to	O	O
reduce	O	O
the	O	O
development	O	O
of	O	O
post-dural	O	Physical
puncture	O	Physical
headache	O	Physical
in	O	O
obstetric	O	O
patients	O	O
.	O	O

A	O	O
randomized	O	O
,	O	O
evaluator-blind	O	O
,	O	O
multicenter	O	O
comparison	O	O
of	O	O
the	O	O
efficacy	O	Others
and	O	Others
tolerability	O	Others
of	O	O
Perlane	O	O
versus	O	O
Zyplast	O	O
in	O	O
the	O	O
correction	O	O
of	O	O
nasolabial	O	O
folds	O	O
.	O	O

Bovine	O	O
collagen	O	O
is	O	O
widely	O	O
used	O	O
as	O	O
a	O	O
dermal	O	O
filler	O	O
for	O	O
facial	O	O
soft-tissue	O	O
augmentation	O	O
,	O	O
but	O	O
it	O	O
provides	O	O
only	O	O
temporary	O	O
cosmetic	O	O
improvement	O	O
.	O	O

Nonanimal	O	O
stabilized	O	O
hyaluronic	O	O
acid	O	O
has	O	O
reduced	O	O
potential	O	O
for	O	O
immunogenicity	O	O
and	O	O
hypersensitivity	O	O
and	O	O
may	O	O
provide	O	O
a	O	O
more	O	O
durable	O	O
aesthetic	O	O
result	O	O
.	O	O

Sixty-eight	O	O
patients	O	O
with	O	O
prominent	O	O
nasolabial	O	O
folds	O	O
were	O	O
randomized	O	O
to	O	O
intradermal	O	O
treatment	O	O
with	O	O
nonanimal	O	O
stabilized	O	O
hyaluronic	O	O
acid	O	O
gel	O	O
(	O	O
Perlane	O	O
)	O	O
and	O	O
bovine	O	O
collagen	O	O
(	O	O
Zyplast	O	O
)	O	O
on	O	O
contralateral	O	O
sides	O	O
of	O	O
the	O	O
face	O	O
.	O	O

On	O	O
achievement	O	O
of	O	O
optimal	Physical	O
cosmetic	Physical	O
result	Physical	O
(	O	O
baseline	O	O
)	O	O
,	O	O
patients	O	O
were	O	O
followed	O	O
up	O	O
for	O	O
6	O	O
months	O	O
;	O	O
bilateral	O	O
retreatment	O	O
with	O	O
Perlane	O	O
was	O	O
offered	O	O
at	O	O
6	O	O
or	O	O
9	O	O
months	O	O
after	O	O
baseline	O	O
.	O	O

Responses	O	O
were	O	O
evaluated	O	O
at	O	O
2	O	O
,	O	O
4	O	O
,	O	O
6	O	O
,	O	O
9	O	O
,	O	O
and	O	O
12	O	O
months	O	O
after	O	O
baseline	O	O
.	O	O

Investigator-based	Others	O
and	Others	O
patient-based	Others	O
ratings	Others	O
indicated	O	O
that	O	O
Perlane	O	O
was	O	O
more	O	O
effective	O	O
than	O	O
Zyplast	O	O
in	O	O
maintaining	O	O
cosmetic	O	O
correction	O	O
.	O	O

According	O	O
to	O	O
investigator-based	Physical	Mental
Wrinkle	Physical	Mental
Severity	Physical	Mental
Rating	Physical	Mental
Scale	Physical	Mental
assessments	Physical	Mental
at	O	O
6	O	O
and	O	O
9	O	O
months	O	O
after	O	O
baseline	O	O
,	O	O
Perlane	O	O
was	O	O
superior	Others	O
in	O	O
50.0	O	O
percent	O	O
and	O	O
48.8	O	O
percent	O	O
of	O	O
patients	O	O
,	O	O
respectively	O	O
,	O	O
whereas	O	O
Zyplast	O	O
was	O	O
superior	Others	O
in	O	O
10.3	O	O
percent	O	O
and	O	O
14.0	O	O
percent	O	O
of	O	O
patients	O	O
,	O	O
respectively	O	O
(	O	O
p	O	O
<	O	O
0.0004	O	O
)	O	O
.	O	O

Investigator-based	O	Mental
Global	Physical	Mental
Aesthetic	Physical	Mental
Improvement	Physical	Mental
Scale	Physical	Mental
assessment	Physical	Mental
at	O	O
9	O	O
months	O	O
after	O	O
baseline	O	O
indicated	O	O
that	O	O
Perlane	O	O
was	O	O
superior	Others	O
in	O	O
48.8	O	O
percent	O	O
of	O	O
patients	O	O
,	O	O
whereas	O	O
Zyplast	O	O
was	O	O
superior	Others	O
in	O	O
14.0	O	O
percent	O	O
of	O	O
patients	O	O
(	O	O
p	O	O
=	O	O
0.0025	O	O
)	O	O
.	O	O

Optimal	Physical	O
cosmetic	Physical	O
result	Physical	O
was	O	O
achieved	O	O
with	O	O
a	O	O
smaller	O	O
volume	O	O
of	O	O
Perlane	O	O
than	O	O
Zyplast	O	O
(	O	O
mean	O	O
,	O	O
1.2	O	O
ml	O	O
versus	O	O
2.1	O	O
ml	O	O
)	O	O
.	O	O

Local	O	Physical
injection-site	O	Physical
reactions	Adverseeffect	Physical
(	Adverseeffect	Physical
redness	Adverseeffect	Physical
,	Adverseeffect	Physical
swelling	Adverseeffect	Physical
,	Adverseeffect	O
pruritus	Adverseeffect	O
,	Adverseeffect	O
and	Adverseeffect	O
induration	Adverseeffect	O
)	Adverseeffect	O
were	O	O
less	O	O
frequent	O	O
with	O	O
Perlane	O	O
than	O	O
with	O	O
Zyplast	O	O
.	O	O

Delayed-onset	O	O
reactions	O	O
were	O	O
rare	O	O
and	O	O
did	O	O
not	O	O
reoccur	O	O
after	O	O
Perlane	O	O
retreatment	O	O
.	O	O

Perlane	O	O
has	O	O
acceptable	O	O
long-term	Others	O
safety	Others	O
and	O	O
offers	O	O
a	O	O
longer-lasting	O	O
aesthetic	O	O
improvement	O	O
than	O	O
Zyplast	O	O
.	O	O

Motion	O	O
style	O	O
acupuncture	O	O
treatment	O	O
(	O	O
MSAT	O	O
)	O	O
for	O	O
acute	O	O
low	O	O
back	O	O
pain	O	O
with	O	O
severe	O	O
disability	O	O
:	O	O
a	O	O
multicenter	O	O
,	O	O
randomized	O	O
,	O	O
controlled	O	O
trial	O	O
protocol	O	O
.	O	O

BACKGROUND	O	O
Acupuncture	O	O
is	O	O
widely-used	O	O
to	O	O
treat	O	O
patients	O	O
with	O	O
low	O	O
back	O	O
pain	O	O
,	O	O
despite	O	O
insufficient	O	O
evidence	O	O
of	O	O
the	O	O
technique	O	O
's	O	O
efficacy	O	O
for	O	O
acute	O	O
back	O	O
pain	O	O
.	O	O

Motion	O	O
style	O	O
acupuncture	O	O
treatment	O	O
(	O	O
MSAT	O	O
)	O	O
is	O	O
a	O	O
non-traditional	O	O
acupuncture	O	O
treatment	O	O
requiring	O	O
a	O	O
patient	O	O
to	O	O
exercise	O	O
while	O	O
receiving	O	O
acupuncture	O	O
.	O	O

In	O	O
Korea	O	O
,	O	O
MSAT	O	O
is	O	O
used	O	O
to	O	O
reduce	O	O
musculoskeletal	O	O
pain	O	O
and	O	O
improve	O	O
functional	O	O
status	O	O
.	O	O

The	O	O
study	O	O
aims	O	O
to	O	O
evaluate	O	O
the	O	O
effect	O	O
of	O	O
MSAT	O	O
on	O	O
acute	O	O
low	O	O
back	O	O
pain	O	O
with	O	O
severe	O	O
disability	O	O
.	O	O

METHODS/DESIGN	O	O
This	O	O
study	O	O
is	O	O
a	O	O
multicenter	O	O
,	O	O
randomized	O	O
,	O	O
active-controlled	O	O
trial	O	O
with	O	O
two	O	O
parallel	O	O
arms	O	O
.	O	O

Participants	O	O
with	O	O
acute	O	O
low	O	O
back	O	O
pain	O	O
and	O	O
severe	O	Physical
functional	O	Physical
disability	O	Physical
,	O	O
defined	O	O
as	O	O
an	O	O
Oswestry	O	O
Disability	O	O
Index	O	O
(	O	O
ODI	O	O
)	O	O
value	O	O
>	O	O
60	O	O
%	O	O
,	O	O
will	O	O
be	O	O
randomly	O	O
allocated	O	O
to	O	O
the	O	O
acupuncture	O	O
group	O	O
and	O	O
the	O	O
nonsteroidal	O	O
anti-inflammatory	O	O
drug	O	O
(	O	O
NSAID	O	O
)	O	O
injection	O	O
group	O	O
.	O	O

The	O	O
acupuncture	O	O
group	O	O
will	O	O
receive	O	O
MSAT	O	O
and	O	O
the	O	O
NSAID	O	O
injection	O	O
group	O	O
will	O	O
receive	O	O
an	O	O
intramuscular	O	O
injection	O	O
of	O	O
diclofenac	O	O
.	O	O

All	O	O
procedures	O	O
will	O	O
be	O	O
limited	O	O
to	O	O
one	O	O
session	O	O
and	O	O
the	O	O
symptoms	O	O
before	O	O
and	O	O
after	O	O
treatment	O	O
will	O	O
be	O	O
measured	O	O
by	O	O
assessors	O	O
blinded	O	O
to	O	O
treatment	O	O
allocation	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
will	O	O
be	O	O
measured	O	O
at	O	O
30	O	O
minutes	O	O
after	O	O
treatment	O	O
using	O	O
the	O	O
numerical	Pain	O
rating	Pain	O
scale	Pain	O
(	Pain	O
NRS	Pain	O
)	Pain	O
of	Pain	O
low	Pain	O
back	Pain	O
pain	Pain	O
while	O	O
the	O	O
patient	O	O
is	O	O
moving	O	O
.	O	O

Secondary	O	O
outcomes	O	O
will	O	O
be	O	O
measured	O	O
at	O	O
30	O	O
minutes	O	O
after	O	O
treatment	O	O
using	O	O
the	O	O
NRS	Pain	Pain
of	Pain	Pain
leg	Pain	Pain
pain	Pain	Pain
,	O	O
ODI	Physical	O
,	O	O
patient	Others	O
global	Others	O
impression	Others	O
of	Others	O
change	Others	O
,	O	O
range	Physical	Physical
of	Physical	Physical
motion	Physical	Physical
(	Physical	Physical
ROM	Physical	Physical
)	Physical	Physical
of	Physical	Physical
the	Physical	Physical
lumbar	Physical	Physical
spine	Physical	Physical
,	O	Physical
and	O	Physical
degrees	Physical	Physical
of	Physical	Physical
straight	Physical	Physical
leg	Physical	Physical
raising	Physical	Physical
(	Physical	O
SLR	Physical	O
)	Physical	O
.	O	O

Post-treatment	O	O
follow-up	O	O
will	O	O
be	O	O
performed	O	O
to	O	O
measure	O	O
primary	O	O
and	O	O
secondary	O	O
outcomes	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
ROM	Physical	O
and	O	O
SLR	Physical	O
at	O	O
2	O	O
,	O	O
4	O	O
,	O	O
and	O	O
24	O	O
weeks	O	O
after	O	O
treatment	O	O
.	O	O

DISCUSSION	O	O
The	O	O
results	O	O
of	O	O
this	O	O
trial	O	O
will	O	O
be	O	O
discussed	O	O
.	O	O

TRIAL	O	O
REGISTRATION	O	O
ClinicalTrial.gov	O	O
NCT01315561	O	O
.	O	O

Brief	O	O
report	O	O
:	O	O
imitation	O	Mental
effects	O	Mental
on	O	O
children	O	O
with	O	O
autism	O	O
.	O	O

Twenty	O	O
children	O	O
with	O	O
autism	O	O
(	O	O
mean	O	O
age	O	O
,	O	O
5	O	O
years	O	O
)	O	O
were	O	O
recruited	O	O
for	O	O
the	O	O
study	O	O
from	O	O
a	O	O
school	O	O
for	O	O
children	O	O
with	O	O
autism	O	O
.	O	O

The	O	O
children	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
an	O	O
imitation	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
or	O	O
contingently	O	O
responsive	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
interaction	O	O
group	O	O
based	O	O
on	O	O
a	O	O
stratification	O	O
table	O	O
for	O	O
gender	O	O
and	O	O
developmental	O	O
and	O	O
chronological	O	O
age	O	O
.	O	O

The	O	O
sessions	O	O
consisted	O	O
of	O	O
four	O	O
phases	O	O
,	O	O
with	O	O
each	O	O
phase	O	O
lasting	O	O
3	O	O
minutes	O	O
.	O	O

In	O	O
the	O	O
first	O	O
phase	O	O
,	O	O
the	O	O
child	O	O
walked	O	O
into	O	O
a	O	O
room	O	O
that	O	O
was	O	O
furnished	O	O
with	O	O
a	O	O
sofa	O	O
,	O	O
a	O	O
table	O	O
,	O	O
chairs	O	O
,	O	O
and	O	O
two	O	O
sets	O	O
of	O	O
identical	O	O
toys	O	O
.	O	O

An	O	O
adult	O	O
was	O	O
in	O	O
the	O	O
room	O	O
sitting	O	O
very	O	O
still	O	O
like	O	O
a	O	O
statue	O	O
(	O	O
first	O	O
still-face	O	O
condition	O	O
)	O	O
.	O	O

In	O	O
the	O	O
second	O	O
phase	O	O
,	O	O
the	O	O
adult	O	O
either	O	O
imitated	O	O
the	O	O
child	O	O
or	O	O
was	O	O
contingently	O	O
responsive	O	O
to	O	O
the	O	O
child	O	O
.	O	O

In	O	O
the	O	O
third	O	O
phase	O	O
,	O	O
the	O	O
adult	O	O
sat	O	O
still	O	O
again	O	O
(	O	O
second	O	O
still-face	O	O
condition	O	O
)	O	O
,	O	O
and	O	O
in	O	O
the	O	O
fourth	O	O
phase	O	O
,	O	O
the	O	O
adult	O	O
engaged	O	O
in	O	O
a	O	O
spontaneous	O	O
interaction	O	O
.	O	O

During	O	O
the	O	O
third	O	O
phase	O	O
(	O	O
the	O	O
second	O	O
still-face	O	O
condition	O	O
)	O	O
,	O	O
the	O	O
children	O	O
in	O	O
the	O	O
imitation	O	O
group	O	O
spent	O	O
less	O	O
time	O	O
in	O	O
gross	O	Physical
motor	O	Physical
activity	O	Physical
and	O	O
more	Others	O
time	Others	O
touching	Others	O
the	Others	O
adult	Others	O
,	O	O
as	O	O
if	O	O
attempting	O	O
to	O	O
initiate	O	O
an	O	O
interaction	O	O
.	O	O

The	O	O
contingency	O	O
condition	O	O
appeared	O	O
to	O	O
be	O	O
a	O	O
more	Others	O
effective	Others	O
way	O	O
to	O	O
facilitate	O	O
a	O	O
distal	Mental	O
social	Mental	O
behavior	Mental	O
(	Mental	O
attention	Mental	O
)	Mental	O
,	O	O
whereas	O	O
the	O	O
imitative	O	O
condition	O	O
was	O	O
a	O	O
more	Others	O
effective	Others	O
way	O	O
to	O	O
facilitate	O	O
a	O	O
proximal	Mental	O
social	Mental	O
behavior	Mental	O
(	Mental	O
touching	Mental	O
)	Mental	O
.	O	O

Effects	O	O
of	O	O
sibutramine	O	O
on	O	O
thermogenesis	O	O
in	O	O
obese	O	O
patients	O	O
assessed	O	O
via	O	O
immersion	O	O
calorimetry	O	O
.	O	O

Glucose	O	O
utilization	O	O
studies	O	O
show	O	O
that	O	O
sibutramine-induced	O	O
thermogenesis	O	O
is	O	O
mediated	O	O
via	O	O
selective	O	O
sympathetic	O	O
activation	O	O
of	O	O
brown	O	O
adipose	O	O
tissue	O	O
.	O	O

The	O	O
goal	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
use	O	O
a	O	O
new	O	O
calorimetry	O	O
method	O	O
in	O	O
which	O	O
resting	O	O
metabolic	O	O
rate	O	O
is	O	O
enhanced	O	O
to	O	O
evaluate	O	O
the	O	O
effects	O	O
of	O	O
sibutramine	O	O
treatment	O	O
on	O	O
thermogenesis	O	O
.	O	O

Sixty	O	O
obese	O	O
women	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

Subjects	O	O
were	O	O
divided	O	O
into	O	O
2	O	O
equal	O	O
groups-the	O	O
placebo	O	O
and	O	O
sibutramine	O	O
treatment	O	O
groups	O	O
.	O	O

The	O	O
sibutramine	O	O
group	O	O
was	O	O
given	O	O
sibutramine	O	O
10	O	O
mg	O	O
daily	O	O
for	O	O
12	O	O
wk	O	O
.	O	O

At	O	O
baseline	O	O
and	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
12-wk	O	O
treatment	O	O
period	O	O
,	O	O
thermogenic	O	O
measurements	O	O
were	O	O
taken	O	O
with	O	O
the	O	O
use	O	O
of	O	O
water	Physical	O
immersion	Physical	O
calorimetry	Physical	O
.	O	O

Subjects	O	O
were	O	O
examined	O	O
at	O	O
weeks	O	O
4	O	O
,	O	O
8	O	O
,	O	O
and	O	O
12	O	O
of	O	O
treatment	O	O
to	O	O
identify	O	O
adverse	O	O
effects	O	O
.	O	O

Body	Physical	Physical
mass	Physical	Physical
index	Physical	Physical
,	O	O
measured	O	O
at	O	O
31.5+/-2.05	O	O
kg/m2	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
,	O	O
decreased	O	O
to	O	O
30.4+/-2.94	O	O
kg/m	O	O
(	O	O
2	O	O
)	O	O
after	O	O
12	O	O
wk	O	O
(	O	O
P=.07	O	O
)	O	O
.	O	O

In	O	O
the	O	O
sibutramine	O	O
group	O	O
,	O	O
it	O	O
decreased	O	O
from	O	O
33.5+/-4.1	O	O
kg/m	O	O
(	O	O
2	O	O
)	O	O
to	O	O
30.9+/-4.8	O	O
kg/m	O	O
(	O	O
2	O	O
)	O	O
(	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
.	O	O

In	O	O
the	O	O
sibutramine	O	O
group	O	O
,	O	O
mean	Physical	Physical
thermogenic	Physical	Physical
response	Physical	Physical
changed	O	O
from	O	O
a	O	O
baseline	O	O
value	O	O
of	O	O
1.27+/-0.29	O	O
kcal/kg/h	O	O
to	O	O
1.44+/-0.13	O	O
kcal/kg/h	O	O
after	O	O
12	O	O
wk	O	O
of	O	O
treatment	O	O
.	O	O

In	O	O
the	O	O
placebo	O	O
group	O	O
,	O	O
the	O	O
baseline	O	O
value	O	O
was	O	O
1.56+/-0.27	O	O
kcal/kg/h	O	O
;	O	O
it	O	O
changed	O	O
to	O	O
1.33+/-0.36	O	O
kcal/kg/h	O	O
at	O	O
the	O	O
end	O	O
of	O	O
12	O	O
wk	O	O
.	O	O

The	O	O
findings	O	O
of	O	O
this	O	O
study	O	O
suggest	O	O
that	O	O
sibutramine	O	O
treatment	O	O
promotes	O	O
thermogenesis	Physical	O
,	O	O
thus	O	O
facilitating	O	O
weight	Physical	O
loss	Physical	O
.	O	O

Calorimetry	O	O
enhances	O	O
resting	Physical	O
metabolism	Physical	O
through	O	O
more	O	O
efficient	O	O
heat	O	O
transfer	O	O
from	O	O
the	O	O
body	O	O
.	O	O

[	O	O
Effects	O	O
of	O	O
transcutaneous	O	O
electrical	O	O
stimulation	O	O
of	O	O
auricular	O	O
Shenmen	O	O
point	O	O
on	O	O
postoperative	O	Adverseeffect
nausea	O	Adverseeffect
and	O	Adverseeffect
vomiting	O	Adverseeffect
and	O	O
patient-controlled	O	O
epidural	O	O
analgesia	O	O
in	O	O
cesarean	O	O
section	O	O
]	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
transcutaneous	O	O
electrical	O	O
stimulation	O	O
of	O	O
auricular	O	O
Shenmen	O	O
point	O	O
on	O	O
postoperative	O	Adverseeffect
nausea	O	Adverseeffect
and	O	Adverseeffect
vomiting	O	Adverseeffect
and	O	O
patient-controlled	O	O
epidural	O	O
analgesia	O	O
in	O	O
cesarean	O	O
section	O	O
.	O	O

METHODS	O	O
After	O	O
IRB	O	O
approval	O	O
and	O	O
informed	O	O
consent	O	O
,	O	O
one	O	O
hundred	O	O
and	O	O
eighty	O	O
singleton	O	O
primiparas	O	O
undergoing	O	O
elective	O	O
cesarean	O	O
section	O	O
,	O	O
in	O	O
Qingdao	O	O
Municipal	O	O
Hospital	O	O
,	O	O
and	O	O
Qingdao	O	O
Hiser	O	O
Medical	O	O
Center	O	O
,	O	O
from	O	O
November	O	O
2011	O	O
to	O	O
March	O	O
2012	O	O
,	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
three	O	O
groups	O	O
:	O	O
transcutaneous	O	O
electrical	O	O
stimulation	O	O
of	O	O
auricular	O	O
Shenmen	O	O
point	O	O
group	O	O
(	O	O
group	O	O
A	O	O
,	O	O
n	O	O
=	O	O
60	O	O
)	O	O
,	O	O
transcutaneous	O	O
electrical	O	O
stimulation	O	O
of	O	O
auricular	O	O
Eye	O	O
point	O	O
group	O	O
(	O	O
group	O	O
B	O	O
,	O	O
n	O	O
=	O	O
60	O	O
)	O	O
and	O	O
control	O	O
group	O	O
(	O	O
group	O	O
C	O	O
,	O	O
n	O	O
=	O	O
60	O	O
)	O	O
.	O	O

Women	O	O
of	O	O
group	O	O
A	O	O
received	O	O
transcutaneous	O	O
electrical	O	O
stimulation	O	O
of	O	O
auricular	O	O
Shenmen	O	O
point	O	O
(	O	O
frequency	O	O
1.5	O	O
HZ	O	O
)	O	O
at	O	O
the	O	O
time	O	O
of	O	O
preoperation	O	O
,	O	O
4	O	O
,	O	O
10	O	O
and	O	O
22	O	O
hours	O	O
of	O	O
postoperation	O	O
for	O	O
30	O	O
minutes	O	O
.	O	O

The	O	O
strength	O	O
was	O	O
controlled	O	O
by	O	O
themselves	O	O
.	O	O

Women	O	O
of	O	O
group	O	O
B	O	O
received	O	O
stimulation	O	O
of	O	O
auricular	O	O
Eye	O	O
point	O	O
as	O	O
group	O	O
A	O	O
.	O	O

Women	O	O
of	O	O
group	O	O
C	O	O
received	O	O
pressurization	O	O
and	O	O
connected	O	O
line	O	O
were	O	O
the	O	O
same	O	O
with	O	O
group	O	O
A	O	O
,	O	O
but	O	O
without	O	O
electrical	O	O
stimulation	O	O
.	O	O

The	O	O
following	O	O
indexes	O	O
was	O	O
observed	O	O
:	O	O
the	O	O
incidence	O	O
of	O	O
postoperative	O	O
nausea	O	O
and	O	O
vomiting	O	O
(	O	O
PONV	O	O
)	O	O
for	O	O
48	O	O
hours	O	O
;	O	O
the	O	O
rate	O	O
of	O	O
metoclopramide	O	O
;	O	O
the	O	O
visual	Pain	Pain
analogue	Pain	Pain
scale	Pain	Pain
(	Pain	Pain
VAS	Pain	Pain
)	Pain	Pain
score	Pain	Pain
of	Pain	Pain
rest	Pain	Pain
pain	Pain	Pain
,	Pain	Pain
uterine	Pain	Pain
contration	Pain	Pain
pain	Pain	Pain
and	Pain	Pain
dynamic	Pain	Pain
pain	Pain	Pain
at	O	O
the	O	O
time	O	O
of	O	O
postoperation	O	O
for	O	O
6	O	O
,	O	O
12	O	O
,	O	O
24	O	O
and	O	O
48	O	O
hours	O	O
(	O	O
T	O	O
(	O	O
1	O	O
)	O	O
-T	O	O
(	O	O
4	O	O
)	O	O
)	O	O
;	O	O
the	O	O
total	O	O
number	O	O
and	O	O
effective	O	Pain
compressions	O	Pain
number	O	Pain
of	O	Pain
patient-controlled	Physical	Pain
epidural	Physical	Pain
analgesia	Physical	Pain
(	Physical	O
PCEA	Physical	O
)	Physical	O
;	O	O
the	O	O
dose	Others	O
of	Others	O
analgesia	Others	O
mixture	Others	O
;	O	O
the	O	O
anal	Physical	O
exhaust	Physical	O
time	Physical	O
;	O	O
the	O	O
volume	Physical	O
of	Physical	O
postoperative	Physical	O
bleeding	Physical	O
for	Physical	O
6	Physical	O
hours	Physical	O
of	Physical	O
postoperation	Physical	O
and	O	O
the	O	O
other	Adverseeffect	O
side	Adverseeffect	O
effects	Adverseeffect	O
.	O	O

RESULTS	O	O
Compared	O	O
with	O	O
group	O	O
B	O	O
and	O	O
group	O	O
C	O	O
,	O	O
the	O	O
incidence	Physical	O
of	Physical	O
PONV	Physical	O
,	O	O
the	O	O
rate	Others	O
of	Others	O
metoclopramide	Others	O
,	O	O
the	O	O
VAS	Physical	Others
score	Physical	Others
at	O	O
the	O	O
time	O	O
T	O	O
(	O	O
1	O	O
)	O	O
-T	O	O
(	O	O
4	O	O
)	O	O
,	O	O
the	O	O
total	Physical	Physical
number	Physical	Physical
and	Physical	Physical
effective	Physical	Physical
compressions	Physical	Physical
number	Physical	Physical
of	Physical	Physical
PCEA	Physical	Physical
,	O	O
the	O	O
ratio	Physical	O
of	Physical	O
the	Physical	O
total	Physical	O
number	Physical	O
with	Physical	O
effective	Physical	O
compressions	Physical	O
number	Physical	O
and	O	O
the	O	O
dose	Physical	O
of	Physical	O
analgesia	Physical	O
mixture	Physical	O
were	O	O
decreased	O	O
in	O	O
group	O	O
A	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
,	O	O
but	O	O
no	O	O
difference	O	O
compared	O	O
group	O	O
B	O	O
with	O	O
group	O	O
C	O	O
(	O	O
P	O	O
>	O	O
0.05	O	O
)	O	O
.	O	O

The	O	O
anal	Physical	O
exhaust	Physical	O
time	Physical	O
and	O	O
the	Adverseeffect	O
volume	Physical	O
of	Physical	O
postoperative	Physical	O
bleeding	Physical	O
for	O	O
6	O	O
hours	O	O
of	O	O
postoperation	O	O
were	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
three	O	O
groups	O	O
(	O	O
P	O	O
>	O	O
0.05	O	O
)	O	O
.	O	O

No	O	O
other	O	Adverseeffect
side	Adverseeffect	Adverseeffect
effects	Adverseeffect	Adverseeffect
were	O	O
observed	O	O
.	O	O

CONCLUSION	O	O
Transcutaneous	O	O
electrical	O	O
stimulation	O	O
of	O	O
auricular	O	O
Shenmen	O	O
point	O	O
can	O	O
reduce	O	O
the	O	O
incidence	Physical	O
of	Physical	O
PONV	Physical	O
and	O	O
improves	O	O
analgesia	Pain	O
effect	Pain	O
of	Pain	O
PCEA	Pain	O
in	O	O
postoperation	O	O
of	O	O
cesarean	O	O
section	O	O
.	O	O

Use	Others	O
and	Others	O
limitations	Others	O
of	O	O
Holter	O	O
electrocardiography	O	O
in	O	O
assessing	O	O
drug	O	O
therapy	O	O
of	O	O
myocardial	O	O
ischemia	O	O
during	O	O
the	O	O
peri-PTCA	O	O
period	O	O
.	O	O

Incidence	O	O
and	O	O
pattern	O	O
of	O	O
myocardial	O	O
ischemia	O	O
during	O	O
the	O	O
peri-PTCA	O	O
(	O	O
percutaneous	O	O
transluminal	O	O
coronary	O	O
angioplasty	O	O
)	O	O
period	O	O
and	O	O
the	O	O
possible	O	O
role	O	O
of	O	O
continuous	O	O
intravenous	O	O
isosorbide	O	O
dinitrate	O	O
in	O	O
its	O	O
prevention	O	O
were	O	O
examined	O	O
prospectively	O	O
in	O	O
30	O	O
patients	O	O
.	O	O

Holter	O	Others
electrocardiographic	O	Others
monitoring	O	Others
was	O	O
performed	O	O
for	O	O
21	O	O
+/-	O	O
3	O	O
h	O	O
before	O	O
PTCA	O	O
and	O	O
continued	O	O
during	O	O
and	O	O
for	O	O
41	O	O
+/-	O	O
8	O	O
h	O	O
after	O	O
the	O	O
procedure	O	O
.	O	O

Before	O	O
PTCA	O	O
,	O	O
19	O	O
ischemic	O	O
episodes	O	O
were	O	O
present	O	O
in	O	O
10	O	O
(	O	O
33	O	O
%	O	O
)	O	O
of	O	O
30	O	O
patients	O	O
.	O	O

PTCA	O	O
produced	O	O
an	O	O
abrupt	O	O
decrease	O	O
in	O	O
number	O	O
(	O	O
p	O	O
=	O	O
0.015	O	O
)	O	O
and	O	O
duration	O	O
(	O	O
p	O	O
=	O	O
0.03	O	O
)	O	O
of	O	O
spontaneous	Physical	O
ischemic	Physical	O
episodes	Physical	O
.	Physical	O

The	O	O
rarity	O	O
of	O	O
recurrent	Physical	O
myocardial	Physical	O
ischemic	Physical	O
events	Physical	O
by	O	O
Holter	O	O
monitoring	O	O
after	O	O
PTCA	O	O
negated	O	O
any	O	O
attempt	O	O
at	O	O
assessing	O	O
the	O	O
efficacy	O	O
of	O	O
intravenous	O	O
isosorbide	O	O
dinitrate	O	O
in	O	O
their	O	O
prevention	O	O
.	O	O

Holter	O	O
monitoring	O	O
could	O	O
not	O	O
be	O	O
used	O	O
as	O	O
an	O	O
early	O	O
predictor	O	O
of	O	O
late	O	O
coronary	O	O
restenosis	O	O
.	O	O

Effects	O	O
of	O	O
tonabersat	O	O
on	O	O
migraine	O	O
with	O	O
aura	O	O
:	O	O
a	O	O
randomised	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
crossover	O	O
study	O	O
.	O	O

BACKGROUND	O	O
Migraine	O	O
with	O	O
aura	O	O
is	O	O
thought	O	O
likely	O	O
to	O	O
be	O	O
caused	O	O
by	O	O
cortical	O	O
spreading	O	O
depression	O	O
(	O	O
CSD	O	O
)	O	O
.	O	O

Tonabersat	O	O
inhibits	O	O
CSD	O	O
,	O	O
and	O	O
we	O	O
therefore	O	O
investigated	O	O
whether	O	O
tonabersat	O	O
has	O	O
a	O	O
preventive	O	O
effect	O	O
in	O	O
migraine	O	O
with	O	O
aura	O	O
.	O	O

METHODS	O	O
In	O	O
this	O	O
randomised	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
crossover	O	O
trial	O	O
,	O	O
40	O	O
mg	O	O
tonabersat	O	O
once	O	O
daily	O	O
was	O	O
compared	O	O
with	O	O
matched	O	O
placebo	O	O
in	O	O
patients	O	O
who	O	O
had	O	O
at	O	O
least	O	O
one	O	O
aura	O	O
attack	O	O
per	O	O
month	O	O
during	O	O
the	O	O
past	O	O
3	O	O
months	O	O
.	O	O

Randomisation	O	O
was	O	O
by	O	O
computer-generated	O	O
list	O	O
.	O	O

Patients	O	O
kept	O	O
a	O	O
detailed	O	O
diary	O	O
to	O	O
enable	O	O
objective	O	O
diagnosis	O	O
of	O	O
each	O	O
attack	O	O
as	O	O
migraine	O	O
with	O	O
aura	O	O
,	O	O
migraine	O	O
without	O	O
aura	O	O
,	O	O
or	O	O
other	O	Adverseeffect
type	O	Adverseeffect
of	O	Adverseeffect
headache	O	Adverseeffect
.	O	O

Primary	O	O
endpoints	O	O
were	O	O
a	O	O
reduction	Physical	Physical
in	Physical	Physical
aura	Physical	Physical
attacks	Physical	Physical
with	Physical	Physical
or	Physical	Physical
without	Physical	Physical
headache	Physical	Physical
and	O	O
a	O	O
reduction	Physical	O
in	Physical	O
migraine	Physical	Physical
headache	Physical	Physical
days	Physical	O
with	Physical	O
or	Physical	O
without	Physical	O
an	Physical	O
aura	Physical	O
.	O	O

Analysis	O	O
was	O	O
per	O	O
protocol	O	O
.	O	O

This	O	O
trial	O	O
is	O	O
registered	O	O
,	O	O
number	O	O
NCT00332007	O	O
.	O	O

FINDINGS	O	O
39	O	O
patients	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
,	O	O
of	O	O
whom	O	O
31	O	O
were	O	O
included	O	O
in	O	O
the	O	O
statistical	O	O
analysis	O	O
of	O	O
efficacy	O	O
.	O	O

Median	Physical	Physical
(	Physical	Physical
IQR	Physical	Physical
)	Physical	Physical
attacks	Physical	Physical
of	Physical	Physical
aura	Physical	Physical
were	O	O
reduced	O	O
from	O	O
3.2	O	O
(	O	O
1.0-5.0	O	O
)	O	O
per	O	O
12	O	O
weeks	O	O
on	O	O
placebo	O	O
to	O	O
1.0	O	O
(	O	O
0-3.0	O	O
)	O	O
on	O	O
tonabersat	O	Physical
(	O	Physical
p=0.01	O	Physical
)	O	Physical
,	O	O
whereas	O	O
the	O	O
other	O	O
primary	O	O
outcome	O	O
measure	O	O
,	O	O
median	Physical	Physical
migraine	Physical	Physical
headache	Physical	Physical
days	Physical	Physical
with	Physical	Physical
or	Physical	Physical
without	Physical	Physical
aura	Physical	Physical
,	O	O
was	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
placebo	O	O
and	O	O
tonabersat	O	O
groups	O	O
(	O	O
3.0	O	O
days	O	O
in	O	O
each	O	O
group	O	O
;	O	O
p=0.09	O	O
)	O	O
.	O	O

Tonabersat	O	O
was	O	O
well	O	O
tolerated	Others	Others
but	O	O
overall	O	O
had	O	O
more	O	O
side-effects	O	O
than	O	O
placebo	O	O
.	O	O

INTERPRETATION	O	O
Tonabersat	O	O
showed	O	O
a	O	O
preventive	O	O
effect	O	O
on	O	O
attacks	O	O
of	O	O
migraine	O	O
aura	O	O
but	O	O
no	O	O
efficacy	O	O
on	O	O
non-aura	O	O
attacks	O	O
,	O	O
in	O	O
keeping	O	O
with	O	O
its	O	O
known	O	O
inhibitory	O	O
effect	O	O
on	O	O
CSD	O	O
.	O	O

The	O	O
results	O	O
support	O	O
the	O	O
theory	O	O
that	O	O
auras	O	O
are	O	O
caused	O	O
by	O	O
CSD	O	O
and	O	O
that	O	O
this	O	O
phenomenon	O	O
is	O	O
not	O	O
involved	O	O
in	O	O
attacks	O	O
without	O	O
aura	O	O
.	O	O

FUNDING	O	O
Minster	O	O
Pharmaceuticals	O	O
;	O	O
Lundbeck	O	O
Foundation	O	O
.	O	O

Hyperbaric	O	O
oxygen	O	O
attenuation	O	O
of	O	O
lipopolysaccharide-induced	O	O
acute	O	O
lung	O	O
injury	O	O
involves	O	O
heme	O	O
oxygenase-1	O	O
.	O	O

BACKGROUND	O	O
Hyperbaric	O	O
oxygen	O	O
(	O	O
HBO	O	O
)	O	O
attenuates	O	O
lipopolysaccharide	O	O
(	O	O
LPS	O	O
)	O	O
-induced	O	O
acute	O	O
lung	O	O
injury	O	O
.	O	O

This	O	O
beneficial	O	O
effect	O	O
of	O	O
HBO	O	O
involves	O	O
inhibition	O	O
of	O	O
inducible	O	O
nitric	O	O
oxide	O	O
synthase	O	O
(	O	O
iNOS	O	O
)	O	O
expression	O	O
and	O	O
subsequent	O	Physical
nitric	O	Physical
oxide	O	Physical
(	O	Physical
NO	O	Physical
)	O	Physical
biosynthesis	O	Physical
.	O	O

We	O	O
sought	O	O
to	O	O
investigate	O	O
the	O	O
role	O	O
of	O	O
heme	O	O
oxygenase-1	O	O
(	O	O
HO-1	O	O
)	O	O
on	O	O
this	O	O
HBO	O	O
inhibition	O	O
of	O	O
iNOS	O	O
induction	O	O
and	O	O
acute	O	O
lung	O	O
injury	O	O
in	O	O
septic	O	O
rat	O	O
lungs	O	O
.	O	O

METHODS	O	O
Before	O	O
the	O	O
experiment	O	O
,	O	O
72	O	O
rats	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
receive	O	O
HBO	O	O
or	O	O
air	O	O
treatment	O	O
.	O	O

With	O	O
or	O	O
without	O	O
HBO	O	O
pre-treatment	O	O
,	O	O
the	O	O
rats	O	O
were	O	O
further	O	O
divided	O	O
into	O	O
the	O	O
following	O	O
subgroups	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
:	O	O
(	O	O
i	O	O
)	O	O
LPS	O	O
injection	O	O
,	O	O
(	O	O
ii	O	O
)	O	O
normal	O	O
saline	O	O
(	O	O
N/S	O	O
)	O	O
injection	O	O
,	O	O
(	O	O
iii	O	O
)	O	O
hemin	O	O
(	O	O
a	O	O
HO-1	O	O
inducer	O	O
)	O	O
plus	O	O
LPS	O	O
,	O	O
(	O	O
iv	O	O
)	O	O
hemin	O	O
alone	O	O
,	O	O
(	O	O
v	O	O
)	O	O
tin	O	O
protoporphyrin	O	O
(	O	O
SnPP	O	O
;	O	O
a	O	O
HO-1	O	O
inhibitor	O	O
)	O	O
plus	O	O
LPS	O	O
,	O	O
and	O	O
(	O	O
vi	O	O
)	O	O
SnPP	O	O
alone	O	O
.	O	O

All	O	O
rats	O	O
were	O	O
maintained	O	O
for	O	O
6	O	O
h	O	O
and	O	O
then	O	O
sacrificed	O	O
with	O	O
a	O	O
high-dose	O	O
pentobarbital	O	O
injection	O	O
.	O	O

Lung	O	O
injuries	O	O
and	O	O
relevant	O	O
enzymes	O	O
expression	O	O
were	O	O
thus	O	O
assayed	O	O
.	O	O

RESULTS	O	O
Histological	Physical	O
analysis	Physical	O
,	Others	O
PMNs/alveoli	Physical	O
ratio	Physical	O
,	Others	O
and	Others	O
wet/dry	Physical	O
weight	Physical	O
ratio	Physical	O
measurements	Others	O
demonstrated	O	O
that	O	O
LPS	O	O
caused	O	O
significant	O	O
lung	O	O
injury	O	O
and	O	O
HBO	O	O
and/or	O	O
hemin	O	O
significantly	O	O
attenuated	O	O
this	O	O
LPS-induced	O	O
lung	O	O
injury	O	O
.	O	O

Increased	O	O
pulmonary	O	O
iNOS	Physical	O
expression	Physical	O
and	Physical	O
NO	Physical	O
production	Physical	O
were	O	O
associated	O	O
with	O	O
lung	O	O
injury	O	O
.	O	O

Induction	O	O
of	O	O
HO-1	O	O
,	O	O
by	O	O
HBO	O	O
and/or	O	O
hemin	O	O
,	O	O
significantly	O	O
attenuated	O	O
this	O	O
LPS-induced	O	Physical
iNOS	O	Physical
expression	O	Physical
and	O	O
acute	O	O
lung	O	O
injury	O	O
.	O	O

SnPP	O	O
,	O	O
on	O	O
the	O	O
contrary	O	O
,	O	O
offset	O	O
the	O	O
effects	O	O
of	O	O
HBO	O	O
and	O	O
worsened	O	O
the	O	O
LPS-induced	O	O
lung	O	O
injury	O	O
.	O	O

CONCLUSIONS	O	O
HBO	O	O
may	O	O
act	O	O
through	O	O
inhibiting	O	O
pulmonary	O	O
iNOS	O	O
expression	O	O
to	O	O
attenuate	O	O
LPS-induced	O	O
acute	O	O
lung	O	O
injury	O	O
in	O	O
septic	O	O
rats	O	O
.	O	O

Furthermore	O	O
,	O	O
this	O	O
HBO	O	O
attenuation	O	O
of	O	O
iNOS	O	O
expression	O	O
involves	O	O
HO-1	O	O
induction	O	O
.	O	O

Long-term	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
controlled	O	O
study	O	O
using	O	O
repetitive	O	O
education	O	O
at	O	O
six-month	O	O
intervals	O	O
and	O	O
monitoring	O	O
for	O	O
adherence	O	O
in	O	O
heart	O	O
failure	O	O
outpatients	O	O
:	O	O
the	O	O
REMADHE	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
The	O	O
effectiveness	O	O
of	O	O
heart	O	O
failure	O	O
disease	O	O
management	O	O
programs	O	O
in	O	O
patients	O	O
under	O	O
cardiologists	O	O
'	O	O
care	O	O
over	O	O
long-term	O	O
follow-up	O	O
is	O	O
not	O	O
established	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
We	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
a	O	O
disease	O	O
management	O	O
program	O	O
with	O	O
repetitive	O	O
education	O	O
and	O	O
telephone	O	O
monitoring	O	O
on	O	O
primary	O	O
(	O	O
combined	Physical	O
death	Others	O
or	Physical	O
unplanned	Others	Physical
first	Others	Physical
hospitalization	Others	Physical
and	Physical	O
quality-of-life	Others	Others
changes	Others	Others
)	O	Others
and	O	O
secondary	O	O
end	O	O
points	O	O
(	O	O
hospitalization	Others	O
,	Physical	O
death	Others	Mortality
,	Physical	O
and	Physical	O
adherence	Mental	O
)	O	O
.	O	O

The	O	O
REMADHE	O	O
[	O	O
Repetitive	O	O
Education	O	O
and	O	O
Monitoring	O	O
for	O	O
ADherence	O	O
for	O	O
Heart	O	O
Failure	O	O
]	O	O
trial	O	O
is	O	O
a	O	O
long-term	O	O
randomized	O	O
,	O	O
prospective	O	O
,	O	O
parallel	O	O
trial	O	O
designed	O	O
to	O	O
compare	O	O
intervention	O	O
with	O	O
control	O	O
.	O	O

One	O	O
hundred	O	O
seventeen	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
usual	O	O
care	O	O
,	O	O
and	O	O
233	O	O
to	O	O
additional	O	O
intervention	O	O
.	O	O

The	O	O
mean	O	O
follow-up	O	O
was	O	O
2.47+/-1.75	O	O
years	O	O
,	O	O
with	O	O
54	O	O
%	O	O
adherence	O	O
to	O	O
the	O	O
program	O	O
.	O	O

In	O	O
the	O	O
intervention	O	O
group	O	O
,	O	O
the	O	O
primary	O	O
end	O	O
point	O	O
composite	Mortality	O
of	Mortality	O
death	Mortality	Mortality
or	Physical	O
unplanned	Mortality	Physical
hospitalization	Mortality	Physical
was	O	O
reduced	O	O
(	O	O
hazard	O	O
ratio	O	O
,	O	O
0.64	O	O
;	O	O
confidence	O	O
interval	O	O
,	O	O
0.43	O	O
to	O	O
0.88	O	O
;	O	O
P=0.008	O	O
)	O	O
,	O	O
driven	O	O
by	O	O
reduction	O	O
in	O	O
hospitalization	Others	O
.	Physical	O

The	O	O
quality-of-life	Others	Others
questionnaire	Others	Others
score	Others	Others
improved	O	O
only	O	O
in	O	O
the	O	O
intervention	O	O
group	O	O
(	O	O
P	O	O
<	O	O
0.003	O	O
)	O	O
.	O	O

Mortality	Mortality	Mortality
was	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Number	Adverseeffect	O
of	Adverseeffect	O
hospitalizations	Adverseeffect	O
(	O	O
1.3+/-1.7	O	O
versus	O	O
0.8+/-1.3	O	O
,	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
,	O	O
total	Others	Physical
hospital	Others	Physical
days	Others	Physical
during	Others	O
the	Others	O
follow-up	Others	O
(	O	O
19.9+/-51	O	O
versus	O	O
11.1+/-24	O	O
days	O	O
,	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
,	O	O
and	O	O
the	O	O
need	Others	O
for	Others	O
emergency	Others	O
visits	Others	O
(	O	O
4.5+/-10.6	O	O
versus	O	O
1.6+/-2.4	O	O
,	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
were	O	O
lower	O	O
in	O	O
the	O	O
intervention	O	O
group	O	O
.	O	O

Beneficial	Others	O
effects	Others	O
were	O	O
homogeneous	O	O
for	O	O
sex	O	O
,	O	O
race	O	O
,	O	O
diabetes	O	O
and	O	O
no	O	O
diabetes	O	O
,	O	O
age	O	O
,	O	O
functional	O	O
class	O	O
,	O	O
and	O	O
etiology	O	O
.	O	O

CONCLUSIONS	O	O
For	O	O
a	O	O
longer	O	O
follow-up	O	O
period	O	O
than	O	O
in	O	O
previous	O	O
studies	O	O
,	O	O
this	O	O
heart	O	O
failure	O	O
disease	O	O
management	O	O
program	O	O
model	O	O
of	O	O
patients	O	O
under	O	O
the	O	O
supervision	O	O
of	O	O
a	O	O
cardiologist	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
reduction	O	O
in	O	O
unplanned	Others	Physical
hospitalization	Others	Physical
,	O	O
a	O	O
reduction	O	Others
of	O	Others
total	Others	Others
hospital	Others	Others
days	Others	Others
,	O	O
and	O	O
a	O	O
reduced	O	O
need	Others	Others
for	Others	Others
emergency	Others	Others
care	Others	Others
,	O	O
as	O	O
well	O	O
as	O	O
improved	Physical	Physical
quality	Others	Physical
of	Others	Physical
life	Others	Physical
,	O	O
despite	O	O
modest	O	O
program	Mental	O
adherence	Mental	O
over	O	O
time	O	O
.	O	O

Induction	O	O
chemotherapy	O	O
in	O	O
head	O	O
and	O	O
neck	O	O
cancer	O	O
:	O	O
results	O	O
of	O	O
a	O	O
phase	O	O
III	O	O
trial	O	O
.	O	O

Between	O	O
December	O	O
1982	O	O
and	O	O
October	O	O
1986	O	O
,	O	O
131	O	O
patients	O	O
with	O	O
stage	O	O
II-III-IV	O	O
squamous	O	O
cell	O	O
carcinoma	O	O
of	O	O
the	O	O
oropharynx	O	O
or	O	O
oral	O	O
cavity	O	O
were	O	O
randomized	O	O
to	O	O
induction	O	O
chemotherapy	O	O
,	O	O
consisting	O	O
of	O	O
bleomycin	O	O
(	O	O
10	O	O
mg/m2/day	O	O
in	O	O
continuous	O	O
infusion	O	O
from	O	O
day	O	O
1	O	O
to	O	O
day	O	O
5	O	O
)	O	O
,	O	O
methotrexate	O	O
(	O	O
120	O	O
mg/m2	O	O
on	O	O
day	O	O
2	O	O
)	O	O
followed	O	O
by	O	O
folinic	O	O
acid	O	O
,	O	O
5-fluorouracil	O	O
(	O	O
5	O	O
FU	O	O
)	O	O
(	O	O
600	O	O
mg/m2	O	O
on	O	O
day	O	O
2	O	O
)	O	O
,	O	O
and	O	O
cisplatin	O	O
(	O	O
120	O	O
mg/m2	O	O
on	O	O
day	O	O
4	O	O
)	O	O
every	O	O
4	O	O
weeks	O	O
for	O	O
a	O	O
total	O	O
of	O	O
three	O	O
cycles	O	O
followed	O	O
by	O	O
definitive	O	O
locoregional	O	O
treatment	O	O
versus	O	O
locoregional	O	O
treatment	O	O
alone	O	O
.	O	O

The	O	O
modalities	O	O
of	O	O
definitive	O	O
treatment	O	O
(	O	O
radiotherapy	O	O
+/-	O	O
surgery	O	O
)	O	O
were	O	O
chosen	O	O
prior	O	O
to	O	O
randomization	O	O
.	O	O

A	O	O
total	O	O
of	O	O
116	O	O
patients	O	O
were	O	O
evaluable	O	O
.	O	O

Of	O	O
55	O	O
patients	O	O
in	O	O
the	O	O
chemotherapy	O	O
arm	O	O
,	O	O
four	O	O
(	O	O
7	O	O
%	O	O
)	O	O
had	O	O
a	O	O
complete	O	Others
response	O	Others
(	O	Others
CR	O	Others
)	O	Others
and	O	O
23	O	O
(	O	O
42	O	O
%	O	O
)	O	O
a	O	O
partial	O	Others
response	O	Others
(	O	Others
PR	O	Others
)	O	Others
following	O	O
the	O	O
induction	O	O
regimen	O	O
.	O	O

At	O	O
the	O	O
completion	O	O
of	O	O
locoregional	O	O
treatment	O	O
,	O	O
76	O	O
%	O	O
(	O	O
42	O	O
of	O	O
55	O	O
)	O	O
of	O	O
patients	O	O
in	O	O
the	O	O
experimental	O	O
group	O	O
were	O	O
in	O	O
CR	O	O
compared	O	O
to	O	O
89	O	O
%	O	O
(	O	O
54	O	O
of	O	O
61	O	O
)	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
survival	Others	Mortality
,	O	O
cause-specific	Others	Mortality
survival	Others	Mortality
,	O	O
and	O	O
pattern	Physical	O
of	Physical	O
relapse	Physical	O
between	O	O
both	O	O
groups	O	O
.	O	O

The	O	O
median	Others	Mortality
survival	Others	Mortality
was	O	O
22	O	O
months	O	O
in	O	O
the	O	O
chemotherapy	O	O
group	O	O
and	O	O
29	O	O
months	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

Responders	O	O
to	O	O
chemotherapy	O	O
did	O	O
not	O	O
fare	O	O
better	O	O
than	O	O
nonresponders	O	O
.	O	O

Chemotherapy-related	Adverseeffect	Adverseeffect
toxicities	Adverseeffect	Adverseeffect
were	O	O
few	O	O
and	O	O
most	O	O
of	O	O
them	O	O
related	O	O
to	O	O
cisplatin	O	O
which	O	O
was	O	O
reduced	O	O
to	O	O
100	O	O
mg/m2	O	O
for	O	O
35	O	O
patients	O	O
.	O	O

There	O	O
were	O	O
no	O	O
treatment-related	O	Mortality
deaths	Mortality	Mortality
and	O	O
,	O	O
in	O	O
the	O	O
experimental	O	O
arm	O	O
of	O	O
the	O	O
trial	O	O
,	O	O
no	O	O
increased	O	O
morbidity	Adverseeffect	O
from	O	O
locoregional	O	O
treatment	O	O
.	O	O

This	O	O
induction	O	O
regimen	O	O
does	O	O
not	O	O
offer	O	O
any	O	O
advantages	O	O
over	O	O
standard	O	O
treatment	O	O
.	O	O

Learning	O	O
about	O	O
the	O	O
equal	O	O
sign	O	O
:	O	O
does	O	O
comparing	O	O
with	O	O
inequality	O	O
symbols	O	O
help	O	O
?	O	O
This	O	O
study	O	O
investigated	O	O
whether	O	O
instruction	O	O
that	O	O
involves	O	O
comparing	O	O
the	O	O
equal	O	O
sign	O	O
with	O	O
other	O	O
relational	O	O
symbols	O	O
is	O	O
more	O	O
effective	O	O
at	O	O
imparting	O	O
a	O	O
relational	Mental	O
interpretation	Mental	O
of	Mental	O
the	Mental	O
equal	Mental	O
sign	Mental	O
than	O	O
instruction	O	O
about	O	O
the	O	O
equal	O	O
sign	O	O
alone	O	O
.	O	O

Third-	O	O
and	O	O
fourth-grade	O	O
students	O	O
in	O	O
a	O	O
comparing	O	O
symbols	O	O
group	O	O
learned	O	O
about	O	O
the	O	O
greater	O	O
than	O	O
,	O	O
less	O	O
than	O	O
,	O	O
and	O	O
equal	O	O
signs	O	O
and	O	O
had	O	O
the	O	O
opportunity	O	O
to	O	O
compare	O	O
the	O	O
inequality	O	O
symbols	O	O
with	O	O
the	O	O
equal	O	O
sign	O	O
.	O	O

Students	O	O
in	O	O
an	O	O
equal	O	O
sign	O	O
group	O	O
learned	O	O
about	O	O
the	O	O
equal	O	O
sign	O	O
only	O	O
.	O	O

A	O	O
third	O	O
group	O	O
of	O	O
students	O	O
served	O	O
as	O	O
a	O	O
control	O	O
group	O	O
.	O	O

Three	O	O
aspects	O	O
of	O	O
students	O	O
'	O	O
knowledge	O	O
were	O	O
assessed	O	O
before	O	O
and	O	O
after	O	O
the	O	O
lesson	O	O
:	O	O
(	O	O
a	O	O
)	O	O
conceptual	Mental	O
understanding	Mental	O
of	Mental	O
the	Mental	O
equal	Mental	O
sign	Mental	O
,	O	O
(	O	O
b	O	O
)	O	O
equation	Mental	O
encoding	Mental	O
,	O	O
and	O	O
(	O	O
c	O	O
)	O	O
problem	Mental	O
solving	Mental	O
.	O	O

Students	O	O
in	O	O
the	O	O
comparing	O	O
symbols	O	O
group	O	O
showed	O	O
greater	O	O
gains	O	O
in	O	O
conceptual	Mental	O
understanding	Mental	O
from	O	O
pretest	O	O
to	O	O
posttest	O	O
than	O	O
students	O	O
in	O	O
the	O	O
other	O	O
two	O	O
groups	O	O
,	O	O
and	O	O
students	O	O
in	O	O
the	O	O
comparing	O	O
symbols	O	O
group	O	O
also	O	O
scored	O	O
higher	O	O
on	O	O
a	O	O
posttest	O	O
that	O	O
assessed	O	O
knowledge	Mental	O
about	Mental	O
inequality	Mental	O
symbols	Mental	O
and	O	O
inequality	Mental	O
problem	Mental	O
solving	Mental	O
.	O	O

Thus	O	O
,	O	O
they	O	O
learned	O	O
about	O	O
three	O	O
symbols	O	O
in	O	O
the	O	O
same	O	O
amount	O	O
of	O	O
time	O	O
as	O	O
other	O	O
students	O	O
learned	O	O
about	O	O
the	O	O
equal	O	O
sign	O	O
alone	O	O
or	O	O
not	O	O
at	O	O
all	O	O
.	O	O

Therefore	O	O
,	O	O
an	O	O
instructional	O	O
approach	O	O
involving	O	O
comparison	O	O
can	O	O
be	O	O
an	O	O
effective	O	O
tool	O	O
for	O	O
learning	O	O
about	O	O
concepts	O	O
in	O	O
mathematics	O	O
.	O	O

Differential	O	O
effects	O	O
of	O	O
amino	O	O
acid	O	O
and	O	O
ketoacid	O	O
on	O	O
protein	O	O
metabolism	O	O
in	O	O
humans	O	O
.	O	O

We	O	O
examined	O	O
the	O	O
effects	O	Physical
of	O	Physical
insulin	O	Physical
,	O	O
amino	O	O
acid	O	O
(	O	O
AA	O	O
)	O	O
,	O	O
and	O	O
branched-chain	O	O
ketoacid	O	O
(	O	O
KA	O	O
)	O	O
availability	O	O
on	O	O
leucine	O	O
kinetics	O	O
in	O	O
eight	O	O
healthy	O	O
volunteers	O	O
(	O	O
age	O	O
=	O	O
22	O	O
+/-	O	O
2	O	O
y	O	O
,	O	O
body	O	O
mass	O	O
index	O	O
=	O	O
24	O	O
+/-	O	O
1	O	O
kg	O	O
)	O	O
by	O	O
using	O	O
the	O	O
euglycemic	O	O
insulin	O	O
clamp	O	O
and	O	O
[	O	O
1-14C	O	O
]	O	O
leucine	O	O
turnover	O	O
techniques	O	O
.	O	O

Four	O	O
experimental	O	O
conditions	O	O
were	O	O
studied	O	O
:	O	O
study	O	O
I	O	O
,	O	O
hyperinsulinemia	O	O
;	O	O
study	O	O
II	O	O
,	O	O
hyperinsulinemia	O	O
with	O	O
maintenance	O	O
of	O	O
basal	O	O
plasma	O	O
AA	O	O
and	O	O
branched-chain	O	O
KA	O	O
concentrations	O	O
;	O	O
study	O	O
III	O	O
,	O	O
hyperinsulinemia	O	O
with	O	O
hyperaminoacidemia	O	O
and	O	O
basal	O	O
plasma	O	O
branched-chain	O	O
KA	O	O
concentrations	O	O
;	O	O
and	O	O
study	O	O
IV	O	O
,	O	O
hyperinsulinemia	O	O
plus	O	O
basal	O	O
plasma	O	O
AA	O	O
concentrations	O	O
and	O	O
elevated	O	O
branched-chain	O	O
KA	O	O
levels	O	O
.	O	O

Basal	O	Physical
endogenous	Physical	Physical
leucine	Physical	Physical
flux	Physical	Physical
(	Physical	Physical
ELF	Physical	Physical
)	Physical	Physical
averaged	O	O
1.20	O	O
+/-	O	O
0.05	O	O
(	O	O
mumol.kg-1.min-1	O	O
,	O	O
mean	O	O
+/-	O	O
SE	O	O
)	O	O
;	O	O
basal	O	Physical
leucine	Physical	Physical
oxidation	Physical	Physical
(	Physical	Physical
LOX	Physical	Physical
)	Physical	Physical
was	O	O
0.25	O	O
+/-	O	O
0.01	O	O
;	O	O
and	O	O
basal	O	Physical
non-oxidative	Physical	Physical
leucine	Physical	Physical
disposal	Physical	Physical
(	Physical	Physical
NOLD	Physical	Physical
)	Physical	Physical
was	O	O
0.95	O	O
+/-	O	O
0.04	O	O
.	O	O

ELF	Physical	O
significantly	O	O
decreased	O	O
in	O	O
study	O	O
I	O	O
(	O	O
0.77	O	O
+/-	O	O
0.06	O	O
mumol.kg-1.min-1	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
)	O	O
.	O	O

When	O	O
plasma	Physical	O
AA	Physical	O
and	Physical	O
branched-chain	Physical	O
KA	Physical	O
were	O	O
either	O	O
maintained	O	O
at	O	O
their	O	O
basal	O	O
levels	O	O
(	O	O
study	O	O
II	O	O
)	O	O
or	O	O
increased	O	O
above	O	O
baseline	O	O
values	O	O
(	O	O
studies	O	O
III	O	O
and	O	O
IV	O	O
)	O	O
,	O	O
ELF	O	O
declined	O	O
further	O	O
(	O	O
0.64	O	O
+/-	O	O
0.05	O	O
,	O	O
0.66	O	O
+/-	O	O
0.02	O	O
,	O	O
and	O	O
0.66	O	O
+/-	O	O
0.03	O	O
mumol.kg-1.min-1	O	O
,	O	O
respectively	O	O
;	O	O
all	O	O
Ps	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
and	O	O
P	O	O
<	O	O
0.01	O	O
versus	O	O
study	O	O
I	O	O
)	O	O
.	O	O

LOX	Physical	O
declined	O	O
in	O	O
study	O	O
I	O	O
(	O	O
0.12	O	O
+/-	O	O
0.02	O	O
mumol.kg-1.min-1	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
)	O	O
but	O	O
increased	O	O
significantly	O	O
in	O	O
studies	O	O
II	O	O
,	O	O
III	O	O
,	O	O
and	O	O
IV	O	O
(	O	O
0.31	O	O
+/-	O	O
0.04	O	O
,	O	O
0.37	O	O
+/-	O	O
0.03	O	O
,	O	O
and	O	O
0.40	O	O
+/-	O	O
0.03	O	O
mumol.kg-1.min-1	O	O
,	O	O
respectively	O	O
,	O	O
all	O	O
Ps	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
,	O	O
P	O	O
<	O	O
0.05	O	O
study	O	O
IV	O	O
versus	O	O
study	O	O
II	O	O
,	O	O
and	O	O
P	O	O
<	O	O
0.05	O	O
study	O	O
III	O	O
versus	O	O
study	O	O
II	O	O
)	O	O
.	O	O

NOLD	Physical	Physical
declined	O	O
in	O	O
study	O	O
I	O	O
(	O	O
0.65	O	O
+/-	O	O
0.05	O	O
mumol/kg.min	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
)	O	O
,	O	O
whereas	O	O
neither	O	O
the	O	O
maintenance	O	Physical
of	O	Physical
basal	Physical	Physical
plasma	Physical	Physical
AA/branched-chain	Physical	Physical
KA	Physical	Physical
levels	Physical	Physical
(	O	O
study	O	O
II	O	O
;	O	O
0.89	O	O
+/-	O	O
0.2	O	O
mumol.kg-1.min-1	O	O
)	O	O
nor	O	O
the	O	O
elevation	O	O
of	O	O
plasma	Physical	O
branched-chain	Physical	O
KA	Physical	O
concentration	Physical	O
(	O	O
study	O	O
IV	O	O
;	O	O
0.96	O	O
+/-	O	O
0.1	O	O
mumol.kg-1.min-1	O	O
)	O	O
increased	O	O
NOLD	Physical	O
above	O	O
baseline	O	O
level	O	O
.	O	O

A	O	O
stimulation	O	O
of	O	O
NOLD	Physical	O
was	O	O
observed	O	O
only	O	O
when	O	O
plasma	Physical	O
AA	Physical	O
levels	Physical	O
were	O	O
increased	O	O
(	O	O
study	O	O
III	O	O
;	O	O
1.23	O	O
+/-	O	O
0.03	O	O
mumol/kg.min	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
)	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
the	O	O
present	O	O
data	O	O
do	O	O
not	O	O
support	O	O
the	O	O
concept	O	O
of	O	O
a	O	O
direct	O	O
anabolic	O	O
action	O	O
of	O	O
ketoanalogs	O	O
but	O	O
do	O	O
provide	O	O
additional	O	O
evidence	O	O
for	O	O
the	O	O
pivotal	O	O
role	O	O
of	O	O
AA	O	O
availability	O	O
in	O	O
the	O	O
stimulation	O	O
of	O	O
whole-body	O	O
protein	O	O
synthesis	O	O
.	O	O

A	O	O
description	O	O
of	O	O
the	O	O
clinical	O	O
characteristics	O	O
at	O	O
baseline	O	O
of	O	O
patients	O	O
recruited	O	O
into	O	O
the	O	O
Carvedilol	O	O
or	O	O
Metoprolol	O	O
European	O	O
Trial	O	O
(	O	O
COMET	O	O
)	O	O
.	O	O

BACKGROUND	O	O
&	O	O
AIMS	O	O
The	O	O
COMET	O	O
trial	O	O
was	O	O
a	O	O
prospective	O	O
,	O	O
double-blind	O	O
,	O	O
randomised	O	O
trial	O	O
comparing	O	O
carvedilol	O	O
,	O	O
a	O	O
comprehensive	O	O
adrenergic	O	O
receptor	O	O
antagonist	O	O
,	O	O
with	O	O
metoprolol	O	O
,	O	O
a	O	O
beta-1-selective	O	O
agent	O	O
in	O	O
patients	O	O
with	O	O
heart	O	O
failure	O	O
and	O	O
left	O	O
ventricular	O	O
systolic	O	O
dysfunction	O	O
.	O	O

The	O	O
trial	O	O
showed	O	O
a	O	O
reduction	O	O
in	O	O
mortality	Mortality	O
with	O	O
carvedilol	O	O
that	O	O
was	O	O
consistent	O	O
across	O	O
subgroups	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
report	O	O
is	O	O
to	O	O
describe	O	O
in	O	O
greater	O	O
detail	O	O
the	O	O
heterogeneity	O	O
of	O	O
this	O	O
population	O	O
at	O	O
baseline	O	O
with	O	O
particular	O	O
reference	O	O
to	O	O
the	O	O
impact	O	O
of	O	O
symptomatic	O	O
severity	O	O
,	O	O
age	O	O
and	O	O
gender	O	O
on	O	O
patient	O	O
characteristics	O	O
.	O	O

METHODS	O	O
A	O	O
descriptive	O	O
report	O	O
using	O	O
data	O	O
entered	O	O
in	O	O
the	O	O
COMET	O	O
study	O	O
data-base	O	O
.	O	O

RESULTS	O	O
The	O	O
characteristics	O	O
of	O	O
the	O	O
population	O	O
studied	O	O
were	O	O
similar	O	O
to	O	O
those	O	O
reported	O	O
in	O	O
previous	O	O
trials	O	O
of	O	O
beta-blockers	O	O
.	O	O

Almost	O	O
all	O	O
patients	O	O
were	O	O
receiving	O	O
diuretics	O	O
and	O	O
ACE	O	O
inhibitors	O	O
with	O	O
few	O	O
patients	O	O
taking	O	O
angiotensin	O	O
receptor	O	O
blockers	O	O
.	O	O

As	O	O
expected	O	O
,	O	O
older	O	O
patients	O	O
had	O	O
more	O	O
co-morbidity	Physical	O
.	Physical	O

Older	O	O
patients	O	O
and	O	O
women	O	O
reported	O	O
worse	O	O
symptoms	Physical	O
and	Physical	O
poorer	Physical	O
well-being	Physical	O
despite	O	O
similar	O	O
ventricular	Physical	O
dimensions	Physical	O
and	Physical	O
systolic	Physical	O
dysfunction	Physical	O
.	Physical	O

NT-proBNP	Physical	O
was	O	O
higher	O	O
in	O	O
patients	O	O
with	O	O
more	O	O
severe	O	O
symptoms	O	O
and	O	O
older	O	O
patients	O	O
but	O	O
not	O	O
in	O	O
women	O	O
,	O	O
although	O	O
differences	O	O
in	O	O
NT-proBNP	O	O
may	O	O
have	O	O
been	O	O
confounded	O	O
by	O	O
differences	O	O
in	O	O
renal	Physical	O
function	Physical	O
.	Physical	O

CONCLUSION	O	O
Age	O	O
and	O	O
gender	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
severity	O	Physical
of	O	Physical
cardiac	O	Physical
dysfunction	O	Physical
,	O	O
appear	O	O
to	O	O
have	O	O
an	O	O
important	O	O
effect	O	O
on	O	O
the	O	O
severity	O	O
of	O	O
heart	Physical	Physical
failure	Physical	Physical
symptoms	Physical	Physical
and	O	O
patient	Physical	O
'well-being	Physical	O
'	Physical	O
.	Physical	O

This	O	O
could	O	O
have	O	O
important	O	O
implications	O	O
for	O	O
the	O	O
relationship	O	O
between	O	O
symptoms	O	O
and	O	O
prognosis	O	O
and	O	O
therefore	O	O
the	O	O
way	O	O
in	O	O
which	O	O
patients	O	O
are	O	O
selected	O	O
for	O	O
clinical	O	O
trials	O	O
and	O	O
the	O	O
goals	O	O
of	O	O
treatment	O	O
.	O	O

This	O	O
will	O	O
be	O	O
the	O	O
subject	O	O
of	O	O
further	O	O
analyses	O	O
.	O	O

Concurrent	O	O
alcohol	O	O
dependence	O	O
among	O	O
methadone-maintained	O	O
cocaine	O	O
abusers	O	O
is	O	O
associated	O	O
with	O	O
greater	O	O
abstinence	Mental	O
.	Physical	O

Concurrent	O	O
alcohol	O	O
dependence	O	O
(	O	O
AD	O	O
)	O	O
among	O	O
polysubstance	O	O
abusers	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
negative	O	O
consequences	O	O
,	O	O
although	O	O
it	O	O
may	O	O
not	O	O
necessarily	O	O
lead	O	O
to	O	O
poor	O	O
treatment	O	O
outcomes	O	O
.	O	O

One	O	O
of	O	O
the	O	O
most	O	O
efficacious	O	O
treatments	O	O
for	O	O
cocaine	O	O
abuse	O	O
is	O	O
contingency	O	O
management	O	O
(	O	O
CM	O	O
)	O	O
,	O	O
but	O	O
little	O	O
research	O	O
has	O	O
explored	O	O
the	O	O
impact	O	O
of	O	O
AD	O	O
on	O	O
abstinence	Mental	O
outcomes	Mental	O
,	O	O
particularly	O	O
among	O	O
patients	O	O
in	O	O
methadone	O	O
maintenance	O	O
.	O	O

Using	O	O
data	O	O
from	O	O
three	O	O
trials	O	O
of	O	O
CM	O	O
for	O	O
cocaine	O	O
use	O	O
,	O	O
we	O	O
compared	O	O
baseline	Physical	O
characteristics	Physical	O
and	Physical	O
posttreatment	Physical	O
and	Physical	O
follow-up	Physical	O
cocaine	Physical	O
outcomes	Physical	O
between	O	O
methadone-maintained	O	O
,	O	O
cocaine-dependent	O	O
patients	O	O
(	O	O
N	O	O
=	O	O
193	O	O
)	O	O
with	O	O
and	O	O
without	O	O
concurrent	O	O
AD	O	O
,	O	O
randomized	O	O
to	O	O
standard	O	O
care	O	O
(	O	O
SC	O	O
)	O	O
with	O	O
or	O	O
without	O	O
CM	O	O
.	O	O

Patients	O	O
with	O	O
and	O	O
without	O	O
concurrent	O	O
AD	O	O
had	O	O
similar	O	O
baseline	O	O
characteristics	O	O
,	O	O
with	O	O
the	O	O
exception	O	O
that	O	O
AD	O	O
patients	O	O
reported	O	O
more	O	O
alcohol	O	O
use	O	O
.	O	O

AD	O	O
patients	O	O
achieved	O	O
longer	O	O
durations	Mental	O
of	Mental	O
cocaine	Mental	Mental
abstinence	Mental	Mental
and	O	O
were	O	O
more	O	O
likely	O	O
to	O	O
submit	O	O
a	O	O
cocaine-negative	Mental	O
sample	Mental	O
at	O	O
follow-up	O	O
than	O	O
non-AD	O	O
patients	O	O
.	O	O

Patients	O	O
randomized	O	O
to	O	O
CM	O	O
achieved	O	O
better	O	O
outcomes	O	O
than	O	O
those	O	O
randomized	O	O
to	O	O
SC	O	O
,	O	O
but	O	O
there	O	O
was	O	O
no	O	O
interaction	O	O
between	O	O
treatment	O	O
condition	O	O
and	O	O
AD	O	O
status	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
cocaine-using	O	O
methadone	O	O
patients	O	O
with	O	O
AD	O	O
achieve	O	O
greater	O	O
cocaine	Mental	Mental
abstinence	Mental	Mental
than	O	O
their	O	O
non-AD	O	O
counterparts	O	O
and	O	O
should	O	O
not	O	O
necessarily	O	O
be	O	O
viewed	O	O
as	O	O
more	O	O
difficult	O	O
to	O	O
treat	O	O
.	O	O

The	O	O
effects	O	Physical
of	O	Physical
hypoxemia	O	Physical
on	O	Physical
cardiac	O	Physical
output	O	Physical
.	O	Physical

A	O	O
dose-response	O	O
curve	O	O
.	O	O

To	O	O
establish	O	O
a	O	O
dose-response	O	O
curve	O	O
for	O	O
the	O	O
effects	O	Physical
of	O	Physical
isocapnic	O	Physical
hypoxemia	O	Physical
on	O	Physical
cardiac	Physical	Physical
output	Physical	Physical
(	Physical	Physical
CO	Physical	Physical
)	Physical	Physical
,	O	O
we	O	O
studied	O	O
20	O	O
healthy	O	O
men	O	O
,	O	O
aged	O	O
20	O	O
to	O	O
34	O	O
years	O	O
,	O	O
using	O	O
a	O	O
tight-fitting	O	O
face	O	O
mask	O	O
and	O	O
an	O	O
isocapnic	O	O
partial	O	O
rebreathing	O	O
system	O	O
(	O	O
a	O	O
modified	O	O
anesthesia	O	O
machine	O	O
)	O	O
.	O	O

We	O	O
blended	O	O
oxygen	O	O
and	O	O
hypoxic	O	O
gas	O	O
to	O	O
achieve	O	O
arterial	O	O
oxygen	O	O
saturations	O	O
(	O	O
SaO2	O	O
)	O	O
of	O	O
80	O	O
,	O	O
85	O	O
,	O	O
and	O	O
90	O	O
percent	O	O
;	O	O
subjects	O	O
also	O	O
breathed	O	O
100	O	O
percent	O	O
oxygen	O	O
and	O	O
room	O	O
air	O	O
(	O	O
RA	O	O
)	O	O
.	O	O

Target	O	O
SaO2	O	O
and	O	O
end-tidal	O	O
carbon	O	O
dioxide	O	O
were	O	O
continuously	O	O
monitored	O	O
using	O	O
an	O	O
ear	O	O
oximeter	O	O
and	O	O
CO2	O	O
gas	O	O
analyzer	O	O
.	O	O

Subjects	O	O
experienced	O	O
the	O	O
five	O	O
SaO2	O	O
measurements	O	O
in	O	O
random	O	O
order	O	O
.	O	O

CO	Physical	Physical
was	O	O
measured	O	O
noninvasively	O	O
at	O	O
approximately	O	O
two-minute	O	O
intervals	O	O
,	O	O
using	O	O
continuous-wave	O	O
Doppler	O	O
echocardiography	O	O
.	O	O

Mean	Physical	Physical
cardiac	Physical	Physical
output	Physical	Physical
increased	O	O
with	O	O
increasing	O	O
hypoxemia	Physical	O
from	O	O
6.84	O	O
L/min	O	O
at	O	O
FIo2	O	O
1.0	O	O
to	O	O
8.44	O	O
L/min	O	O
at	O	O
SaO2	O	O
80	O	O
percent	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.0005	O	O
)	O	O
;	O	O
the	O	O
increase	O	O
was	O	O
entirely	O	O
due	O	O
to	O	O
increased	O	O
heart	Physical	O
rate	Physical	O
.	O	O

We	O	O
concluded	O	O
that	O	O
cardiac	Physical	O
output	Physical	O
increases	O	O
significantly	O	O
in	O	O
a	O	O
dose-response	O	O
manner	O	O
in	O	O
response	O	Physical
to	O	Physical
acute	O	Physical
isocapnic	O	Physical
hypoxemia	O	Physical
in	O	O
normal	O	O
persons	O	O
.	O	O

Transcutaneous	O	O
electrical	O	O
nerve	O	O
stimulation	O	O
following	O	O
appendicectomy	O	O
:	O	O
the	O	O
placebo	O	O
effect	O	O
.	O	O

A	O	O
controlled	O	O
trial	O	O
was	O	O
undertaken	O	O
to	O	O
compare	O	O
the	O	O
efficacy	O	O
of	O	O
transcutaneous	O	O
electrical	O	O
nerve	O	O
stimulation	O	O
(	O	O
TENS	O	O
)	O	O
with	O	O
standard	O	O
intramuscular	O	O
opiate	O	O
analgesia	O	O
in	O	O
the	O	O
management	O	O
of	O	O
postoperative	O	O
pain	O	O
following	O	O
appendicectomy	O	O
.	O	O

Consecutive	O	O
patients	O	O
undergoing	O	O
emergency	O	O
appendicectomy	O	O
were	O	O
randomised	O	O
into	O	O
control	O	O
,	O	O
sham	O	O
TENS	O	O
and	O	O
active	O	O
TENS	O	O
groups	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
pain	Pain	Pain
severity	Pain	Pain
and	O	Pain
analgesic	Others	Pain
intake	Others	Pain
in	O	O
both	O	O
active	O	O
and	O	O
sham	O	O
TENS	O	O
groups	O	O
when	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
group	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.01	O	O
)	O	O
.	O	O

No	O	O
difference	O	O
was	O	O
demonstrated	O	O
in	O	O
pain	Pain	Pain
severity	Pain	Pain
between	O	O
active	O	O
and	O	O
sham	O	O
TENS	O	O
groups	O	O
but	O	O
the	O	O
active	O	O
TENS	O	O
group	O	O
required	O	O
slightly	O	O
less	O	O
analgesia	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
major	O	O
benefit	O	O
of	O	O
TENS	O	O
in	O	O
the	O	O
postappendicectomy	O	O
patient	O	O
is	O	O
due	O	O
to	O	O
its	O	O
'placebo	O	O
effect	O	O
'	O	O
and	O	O
its	O	O
use	O	O
in	O	O
this	O	O
situation	O	O
can	O	O
not	O	O
be	O	O
recommended	O	O
.	O	O

[	O	O
Radiotherapy	O	O
of	O	O
malignant	O	O
brain	O	O
gliomas	O	O
using	O	O
teniposide	O	O
]	O	O
.	O	O

Efficacy	Others	O
of	O	O
radiochemotherapy	O	O
of	O	O
malignantly-converted	O	O
brain	O	O
gliomas	O	O
using	O	O
teniposide	O	O
was	O	O
evaluated	O	O
in	O	O
a	O	O
randomized	O	O
prospective	O	O
study	O	O
.	O	O

Combined	O	O
use	O	O
of	O	O
cytostatics	O	O
and	O	O
irradiation	O	O
appeared	O	O
safe	O	Others
,	O	Others
tolerable	O	Others
and	O	Others
significantly	O	Others
more	O	Others
effective	O	Others
than	O	O
radiotherapy	O	O
alone	O	O
as	O	O
assessed	O	O
by	O	O
local	Physical	O
control	Physical	O
of	Physical	O
tumor	Physical	O
and	O	O
survival	Mortality	O
.	O	O

In-hospital	Others	O
costs	Others	O
of	O	O
self-expanding	O	O
nitinol	O	O
stent	O	O
implantation	O	O
versus	O	O
balloon	O	O
angioplasty	O	O
in	O	O
the	O	O
femoropopliteal	O	O
artery	O	O
(	O	O
the	O	O
VascuCoil	O	O
Trial	O	O
)	O	O
.	O	O

PURPOSE	O	O
Although	O	O
several	O	O
prospective	O	O
studies	O	O
have	O	O
examined	O	O
the	O	O
safety	Others	O
and	O	O
efficacy	Others	O
of	O	O
stent	O	O
placement	O	O
for	O	O
femoropopliteal	O	O
arterial	O	O
disease	O	O
,	O	O
the	O	O
current	O	O
cost	O	O
of	O	O
these	O	O
procedures	O	O
is	O	O
unknown	O	O
.	O	O

To	O	O
estimate	O	Others
and	O	Others
compare	O	Others
hospital	Others	Others
costs	Others	Others
associated	O	O
with	O	O
conventional	O	O
balloon	O	O
angioplasty	O	O
(	O	O
percutaneous	O	O
transluminal	O	O
angioplasty	O	O
[	O	O
PTA	O	O
]	O	O
)	O	O
and	O	O
stent	O	O
placement	O	O
for	O	O
patients	O	O
with	O	O
symptomatic	O	O
peripheral	O	O
arterial	O	O
disease	O	O
,	O	O
the	O	O
authors	O	O
performed	O	O
a	O	O
prospective	O	O
economic	O	O
evaluation	O	O
in	O	O
conjunction	O	O
with	O	O
the	O	O
Intracoil	O	O
Femoropopliteal	O	O
Stent	O	O
Trial	O	O
(	O	O
VascuCoil	O	O
)	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
Between	O	O
May	O	O
1997	O	O
and	O	O
December	O	O
1999	O	O
,	O	O
266	O	O
patients	O	O
with	O	O
stenotic	O	O
or	O	O
occluded	O	O
superficial	O	O
femoral	O	O
or	O	O
popliteal	O	O
arteries	O	O
were	O	O
prospectively	O	O
randomized	O	O
to	O	O
treatment	O	O
with	O	O
the	O	O
IntraCoil	O	O
stent	O	O
or	O	O
PTA	O	O
.	O	O

Detailed	O	O
resource	Others	O
use	Others	O
and	O	O
cost	Others	Others
data	Others	Others
for	O	O
each	O	O
patient	O	O
's	O	O
initial	O	O
revascularization	O	O
procedure	O	O
and	O	O
ensuing	O	O
hospitalization	O	O
were	O	O
collected	O	O
and	O	O
analyzed	O	O
on	O	O
an	O	O
intention-to-treat	O	O
basis	O	O
.	O	O

RESULTS	O	O
Compared	O	O
with	O	O
conventional	O	O
balloon	O	O
angioplasty	O	O
,	O	O
stent	O	O
placement	O	O
did	O	O
not	O	O
improve	O	O
clinical	Physical	O
outcomes	Physical	O
but	O	O
increased	O	O
procedure	Others	Others
duration	Others	Others
,	O	O
equipment	Others	Others
costs	Others	Others
,	O	O
and	O	O
physician	Others	O
services	Others	O
.	O	O

As	O	O
a	O	O
result	O	O
,	O	O
initial	Others	Others
hospital	Others	Others
costs	Others	Others
were	O	O
approximately	O	O
3,500	O	O
dollars	O	O
higher	O	O
for	O	O
patients	O	O
randomized	O	O
to	O	O
the	O	O
IntraCoil	O	O
stent	O	O
,	O	O
compared	O	O
with	O	O
PTA	O	O
(	O	O
8,435	O	O
dollars	O	O
vs	O	O
4,980	O	O
dollars	O	O
;	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
As	O	O
performed	O	O
in	O	O
the	O	O
VascuCoil	O	O
trial	O	O
,	O	O
primary	O	O
stent	O	O
placement	O	O
for	O	O
femoropopliteal	O	O
disease	O	O
did	O	O
not	O	O
improve	O	O
clinical	Physical	O
outcomes	Physical	O
but	O	O
increased	O	O
initial	Others	O
treatment	Others	O
costs	Others	O
by	O	O
more	O	O
than	O	O
3,000	O	O
dollars	O	O
.	O	O

Because	O	O
there	O	O
were	O	O
no	O	O
substantial	O	O
differences	O	O
in	O	O
subsequent	O	O
clinical	Physical	O
outcomes	Physical	O
between	O	O
the	O	O
two	O	O
treatments	O	O
,	O	O
it	O	O
is	O	O
unlikely	O	O
that	O	O
these	O	O
increased	O	O
initial	Others	O
costs	Others	O
would	O	O
be	O	O
offset	O	O
by	O	O
savings	O	O
in	O	O
follow-up	Others	O
costs	Others	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
a	O	O
strategy	O	O
of	O	O
routine	O	O
stent	O	O
implantation	O	O
for	O	O
patients	O	O
undergoing	O	O
femoropopliteal	O	O
PTA	O	O
is	O	O
not	O	O
optimal	O	O
on	O	O
economic	O	O
grounds	O	O
and	O	O
that	O	O
PTA	O	O
with	O	O
provisional	O	O
stent	O	O
implantation	O	O
is	O	O
preferred	O	O
.	O	O

[	O	O
Methodologic	O	O
comparison	O	O
of	O	O
the	O	O
polyfrequency	O	O
oscillation	O	O
method	O	O
,	O	O
transcutaneous	O	Physical
oxygen	O	Physical
pressure	O	Physical
measurement	O	Physical
and	O	Physical
body	O	Physical
plethysmography	O	Physical
in	O	O
bronchial	O	O
provocation	O	O
with	O	O
methacholine	O	O
]	O	O
.	O	O

A	O	O
bronchial	O	O
provocation	O	O
challenge	O	O
test	O	O
was	O	O
conducted	O	O
with	O	O
30	O	O
subjects	O	O
using	O	O
metacholin	O	O
.	O	O

In	O	O
randomised	O	O
sequence	O	O
lung	O	O
function	O	O
analysis	O	O
tests	O	O
were	O	O
carried	O	O
out	O	O
with	O	O
the	O	O
bodyplethysmograph	O	O
(	O	O
Raw	O	O
,	O	O
FEV1	O	Physical
)	O	Physical
and	O	O
the	O	O
polyfrequent	O	O
oscillation	O	O
method	O	O
(	O	O
resistance	O	O
,	O	O
reactance	O	Physical
between	O	Physical
2	O	Physical
and	O	Physical
52	O	Others
Hz	O	Others
)	O	Others
,	O	O
whereas	O	O
the	O	O
transcutaneous	O	Physical
oxygen	O	Physical
pressure	O	Physical
(	O	Physical
tc-PO2	O	Physical
)	O	Physical
was	O	O
measured	O	O
continuously	O	O
.	O	O

Correlations	O	O
between	O	O
the	O	O
various	O	O
parameters	O	O
,	O	O
the	O	O
change	O	O
of	O	O
the	O	O
values	O	O
at	O	O
PD60	O	O
sGaw	O	O
in	O	O
relation	O	O
to	O	O
the	O	O
initial	O	O
values	O	O
,	O	O
the	O	O
interindividual	O	O
variability	O	O
and	O	O
the	O	O
reactivity	O	O
were	O	O
determined	O	O
.	O	O

Medium	O	O
correlations	O	O
were	O	O
found	O	O
for	O	O
the	O	O
oscillatory	Physical	O
parameters	Physical	O
and	Others	O
Raw	Physical	O
,	O	O
whereas	O	O
for	O	O
tc-PO2	Physical	O
and	Others	O
Raw	Physical	O
the	O	O
correlation	O	O
was	O	O
markedly	O	O
lower	O	O
.	O	O

In	O	O
terms	O	O
of	O	O
percentage	O	O
the	O	O
greatest	O	O
change	O	O
was	O	O
found	O	O
in	O	O
reactance	O	O
,	O	O
in	O	O
relation	O	O
to	O	O
the	O	O
initial	O	O
value	O	O
,	O	O
followed	O	O
by	O	O
Raw	Physical	O
and	Others	O
FEV1	Physical	Physical
.	Others	O

The	O	O
interindividual	O	O
variability	O	O
resulted	O	O
in	O	O
the	O	O
highest	O	O
values	O	O
for	O	O
the	O	O
reactance	O	O
,	O	O
followed	O	O
by	O	O
Raw	Physical	O
and	O	O
FEV1	Physical	Physical
.	Others	O

Interindividual	O	O
variability	O	O
showed	O	O
the	O	O
highest	O	O
values	O	O
for	O	O
the	O	O
reactance	O	O
before	O	O
oscillatory	Physical	O
resistance	Physical	O
and	Others	O
Raw	Physical	O
.	Others	O

In	O	O
respect	O	O
of	O	O
reactivity	O	O
,	O	O
reactance	O	O
also	O	O
had	O	O
the	O	O
highest	O	O
values	O	O
.	O	O

Overall	O	O
evaluation	O	O
showed	O	O
that	O	O
bodyplethysmography	O	O
and	O	O
the	O	O
polyfrequent	O	O
oscillation	O	O
method	O	O
(	O	O
reactance	O	O
or	O	O
resonance	O	Physical
frequency	O	Physical
)	O	Physical
are	O	O
comparably	O	O
sensitive	O	O
.	O	O

The	O	O
relationship	O	O
between	O	O
repetitive	Mental	O
behaviors	Mental	O
and	O	O
growth	Physical	Physical
hormone	Physical	Physical
response	Physical	Physical
to	O	O
sumatriptan	O	O
challenge	O	O
in	O	O
adult	O	O
autistic	O	O
disorder	O	O
.	O	O

Autism	O	O
is	O	O
heterogeneous	O	O
with	O	O
respect	O	O
to	O	O
clinical	O	O
symptoms	O	O
and	O	O
etiology	O	O
.	O	O

To	O	O
sort	O	O
out	O	O
this	O	O
heterogeneity	O	O
in	O	O
autism	O	O
,	O	O
we	O	O
investigated	O	O
whether	O	O
specific	Physical	O
neurobiological	Physical	O
markers	Physical	O
vary	O	O
in	O	O
parallel	O	O
to	O	O
core	Physical	O
symptomatology	Physical	O
.	O	O

Specifically	O	O
,	O	O
we	O	O
assessed	O	O
growth	Physical	Physical
hormone	Physical	Physical
response	Physical	Physical
to	O	O
the	O	O
5-HT	O	O
1d	O	O
agonist	O	O
,	O	O
sumatriptan	O	O
,	O	O
and	O	O
linked	Physical	O
this	Physical	O
measure	Physical	O
of	Physical	O
serotonergic	Physical	O
function	Physical	O
to	O	O
the	Mental	O
severity	Mental	O
of	Mental	O
repetitive	Mental	O
behaviors	Mental	O
in	O	O
adult	O	O
autistic	O	O
patients	O	O
.	O	O

Eleven	O	O
adult	O	O
patients	O	O
with	O	O
autism	O	O
or	O	O
Asperger	O	O
's	O	O
disorder	O	O
were	O	O
randomized	O	O
to	O	O
single	O	O
dose	O	O
sumatriptan	O	O
(	O	O
6	O	O
mg	O	O
SQ	O	O
)	O	O
and	O	O
placebo	O	O
challenges	O	O
,	O	O
separated	O	O
by	O	O
a	O	O
one-week	O	O
interval	O	O
.	O	O

In	O	O
adult	O	O
autistic	O	O
disorders	O	O
,	O	O
severity	Mental	O
of	Mental	O
repetitive	Mental	Mental
behaviors	Mental	Mental
at	Mental	O
baseline	Mental	O
,	O	O
as	O	O
measured	O	O
by	O	O
YBOCS-compulsion	Mental	Physical
score	Mental	Physical
,	O	O
significantly	O	O
positively	O	O
correlated	O	O
with	O	O
both	O	O
peak	Physical	Physical
delta	Physical	Physical
growth	Physical	Physical
hormone	Physical	Physical
response	Physical	Physical
and	O	Physical
area	Physical	Physical
under	Physical	Physical
the	Physical	Physical
curve	Physical	Physical
growth	Physical	Physical
hormone	Physical	Physical
response	Physical	Physical
to	O	O
sumatriptan	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
severity	Mental	O
of	Mental	O
a	Mental	O
specific	Mental	O
behavioral	Mental	O
dimension	Mental	O
in	O	O
autism	O	O
(	Mental	O
repetitive	Mental	O
behaviors	Mental	O
)	Mental	O
parallels	Mental	O
the	Mental	O
sensitivity	Mental	O
of	O	O
the	O	O
5-HT	O	O
1d	O	O
receptor	O	O
,	O	O
as	O	O
manifest	O	O
by	O	O
sumatriptan	Physical	O
elicited	Physical	O
GH	Physical	O
response	Physical	O
.	O	O

Physostigmine	O	O
reverses	O	O
propofol-induced	O	O
unconsciousness	O	O
and	O	O
attenuation	O	O
of	O	O
the	O	O
auditory	O	Physical
steady	O	Physical
state	O	Physical
response	O	Physical
and	O	O
bispectral	O	Physical
index	O	Physical
in	O	O
human	O	O
volunteers	O	O
.	O	O

BACKGROUND	O	O
It	O	O
is	O	O
postulated	O	O
that	O	O
alteration	O	O
of	O	O
central	O	O
cholinergic	O	O
transmission	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
mechanism	O	O
by	O	O
which	O	O
anesthetics	O	O
produce	O	O
unconsciousness	O	O
.	O	O

The	O	O
authors	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
altering	O	O
central	O	O
cholinergic	O	O
transmission	O	O
,	O	O
by	O	O
physostigmine	O	O
and	O	O
scopolamine	O	O
,	O	O
on	O	O
unconsciousness	O	O
produced	O	O
by	O	O
propofol	O	O
.	O	O

METHODS	O	O
Propofol	O	O
was	O	O
administered	O	O
to	O	O
American	O	O
Society	O	O
of	O	O
Anesthesiologists	O	O
physical	O	O
status	O	O
1	O	O
(	O	O
n	O	O
=	O	O
17	O	O
)	O	O
volunteers	O	O
with	O	O
use	O	O
of	O	O
a	O	O
computer-controlled	O	O
infusion	O	O
pump	O	O
at	O	O
increasing	O	O
concentrations	O	O
until	O	O
unconsciousness	O	O
resulted	O	O
(	O	O
inability	O	O
to	O	O
respond	O	O
to	O	O
verbal	O	O
commands	O	O
,	O	O
abolition	O	O
of	O	O
spontaneous	O	O
movement	O	O
)	O	O
.	O	O

Central	Physical	O
nervous	Physical	O
system	Physical	O
function	Physical	O
was	O	O
assessed	O	O
by	O	O
use	O	Others
of	O	Others
the	O	Others
Auditory	Physical	Others
Steady	Physical	Others
State	Physical	Others
Response	Physical	Others
(	Physical	Others
ASSR	Physical	Others
)	Physical	Others
and	O	O
Bispectral	Physical	O
Index	Physical	O
(	Physical	O
BIS	Physical	O
)	Physical	O
analysis	Physical	O
of	Physical	O
electrooculogram	Physical	O
.	O	O

During	O	O
continuous	O	O
administration	O	O
of	O	O
propofol	O	O
,	O	O
reversal	Physical	O
of	Physical	O
unconsciousness	Physical	O
produced	O	O
by	O	O
physostigmine	O	O
(	O	O
28	O	O
microgram/kg	O	O
)	O	O
and	O	O
block	Physical	O
of	Physical	O
this	Physical	O
reversal	Physical	O
by	O	O
scopolamine	O	O
(	O	O
8.6	O	O
microgram/kg	O	O
)	O	O
were	O	O
evaluated	O	O
.	O	O

RESULTS	O	O
Propofol	O	O
produced	O	O
unconsciousness	Physical	O
at	O	O
a	O	O
plasma	O	Physical
concentration	O	Physical
of	O	O
3.2	O	O
+/-	O	O
0.8	O	O
(	O	O
+/-	O	O
SD	O	O
)	O	O
microgram/ml	O	O
(	O	O
n	O	O
=	O	O
17	O	O
)	O	O
.	O	O

Unconsciousness	Physical	O
was	O	O
associated	O	O
with	O	O
reductions	O	O
in	O	O
ASSR	Physical	O
(	O	O
0.10	O	O
+/-	O	O
0.08	O	O
microV	O	O
[	O	O
awake	O	O
baseline	O	O
0.32	O	O
+/-	O	O
0.18	O	O
microV	O	O
]	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
and	O	O
BIS	Physical	O
(	O	O
55.7	O	O
+/-	O	O
8.8	O	O
[	O	O
awake	O	O
baseline	O	O
92.4	O	O
+/-	O	O
3.9	O	O
]	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

Physostigmine	O	O
restored	Physical	O
consciousness	Physical	O
in	O	O
9	O	O
of	O	O
11	O	O
subjects	O	O
,	O	O
with	O	O
concomitant	O	O
increases	O	O
in	O	O
ASSR	Physical	O
(	O	O
0.38	O	O
+/-	O	O
0.17	O	O
microV	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
and	O	O
BIS	Physical	O
(	O	O
75.3	O	O
+/-	O	O
8.3	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

In	O	O
all	O	O
subjects	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
scopolamine	O	O
blocked	O	O
the	O	O
physostigmine-induced	Physical	O
reversal	Physical	O
of	Physical	O
unconsciousness	Physical	O
and	O	O
the	O	O
increase	O	O
of	O	O
the	O	O
ASSR	Physical	O
and	O	O
BIS	Physical	O
(	O	O
ASSR	Physical	O
and	O	O
BIS	Physical	O
during	O	O
propofol-induced	O	O
unconsciousness	O	O
:	O	O
0.09	O	O
+/-	O	O
0.09	O	O
microV	O	O
and	O	O
58.2	O	O
+/-	O	O
7.5	O	O
,	O	O
respectively	O	O
;	O	O
ASSR	Physical	O
and	O	O
BIS	Physical	O
after	O	O
physostigmine	O	O
administration	O	O
:	O	O
0.08	O	O
+/-	O	O
0.06	O	O
microV	O	O
and	O	O
56.8	O	O
+/-	O	O
6.7	O	O
,	O	O
respectively	O	O
,	O	O
NS	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
These	O	O
findings	O	O
suggest	O	O
that	O	O
the	O	O
unconsciousness	O	O
produced	O	O
by	O	O
propofol	O	O
is	O	O
mediated	O	O
at	O	O
least	O	O
in	O	O
part	O	O
via	O	O
interruption	O	O
of	O	O
central	O	O
cholinergic	O	O
muscarinic	O	O
transmission	O	O
.	O	O

A	O	O
prospective	O	O
randomised	O	O
comparison	O	O
of	O	O
sublingual	O	O
and	O	O
vaginal	O	O
misoprostol	O	O
in	O	O
second	O	O
trimester	O	O
termination	O	O
of	O	O
pregnancy	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
compare	O	O
the	O	O
efficacy	Others	O
,	O	O
side	Adverseeffect	O
effects	Adverseeffect	O
and	O	O
acceptability	Others	O
of	O	O
sublingual	O	O
and	O	O
vaginal	O	O
misoprostol	O	O
for	O	O
second	O	O
trimester	O	O
medical	O	O
abortion	O	O
.	O	O

DESIGN	O	O
Prospective	O	O
randomised	O	O
controlled	O	O
trial	O	O
.	O	O

SETTING	O	O
Tertiary	O	O
referral	O	O
unit	O	O
and	O	O
a	O	O
teaching	O	O
hospital	O	O
.	O	O

POPULATION	O	O
Two	O	O
hundred	O	O
and	O	O
twenty-four	O	O
women	O	O
at	O	O
12	O	O
to	O	O
20	O	O
weeks	O	O
of	O	O
gestation	O	O
.	O	O

METHODS	O	O
The	O	O
women	O	O
were	O	O
randomised	O	O
to	O	O
receive	O	O
either	O	O
sublingual	O	O
or	O	O
vaginal	O	O
misoprostol	O	O
400	O	O
microg	O	O
every	O	O
3	O	O
hours	O	O
for	O	O
a	O	O
maximum	O	O
of	O	O
five	O	O
doses	O	O
.	O	O

The	O	O
course	O	O
of	O	O
misoprostol	O	O
was	O	O
repeated	O	O
if	O	O
the	O	O
woman	O	O
did	O	O
not	O	O
abort	O	O
within	O	O
24	O	O
hours	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
The	O	O
success	Others	Others
rate	Others	Others
at	Others	O
48	Others	O
hours	Others	O
,	O	O
induction-to-abortion	Others	O
interval	Others	O
and	O	O
the	O	O
side	Physical	O
effects	Physical	O
.	Physical	O

RESULTS	O	O
There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
the	O	O
success	Others	Others
rate	Others	Others
at	Others	O
48	Others	O
hours	Others	O
(	O	O
sublingual	O	O
:	O	O
91	O	O
%	O	O
;	O	O
vaginal	O	O
:	O	O
95	O	O
%	O	O
)	O	O
.	O	O

However	O	O
,	O	O
the	O	O
success	Others	Others
rate	Others	Others
at	Others	O
24	Others	O
hours	Others	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
vaginal	O	O
group	O	O
(	O	O
85	O	O
%	O	O
)	O	O
compared	O	O
with	O	O
the	O	O
sublingual	O	O
group	O	O
(	O	O
64	O	O
%	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
median	Others	O
induction-to-abortion	Others	O
interval	Others	O
(	O	O
sublingual	O	O
:	O	O
13.8	O	O
hours	O	O
;	O	O
vaginal	O	O
:	O	O
12.0	O	O
hours	O	O
)	O	O
.	O	O

Significantly	O	O
more	O	O
women	O	O
in	O	O
the	O	O
sublingual	O	O
group	O	O
preferred	O	O
the	O	O
route	O	O
to	O	O
which	O	O
they	O	O
were	O	O
assigned	O	O
when	O	O
compared	O	O
with	O	O
the	O	O
vaginal	O	O
group	O	O
.	O	O

The	Adverseeffect	O
incidence	Adverseeffect	O
of	Adverseeffect	O
fever	Adverseeffect	Physical
was	O	O
also	O	O
less	O	O
in	O	O
the	O	O
sublingual	O	O
group	O	O
.	O	O

CONCLUSION	O	O
The	O	O
use	O	O
of	O	O
vaginal	O	O
misoprostol	O	O
for	O	O
second	O	O
trimester	O	O
medical	O	O
abortion	O	O
resulted	O	O
in	O	O
a	O	O
higher	O	O
success	Others	O
rate	Others	O
than	O	O
sublingual	O	O
misoprostol	O	O
at	O	O
24	O	O
hours	O	O
but	O	O
the	O	O
abortion	Others	O
rate	Others	O
was	O	O
similar	O	O
at	O	O
48	O	O
hours	O	O
.	O	O

Vaginal	O	O
misoprostol	O	O
should	O	O
be	O	O
the	O	O
regimen	O	O
of	O	O
choice	O	O
but	O	O
sublingual	O	O
misoprostol	O	O
is	O	O
also	O	O
an	O	O
effective	O	O
alternative	O	O
.	O	O

The	O	O
influence	O	O
of	O	O
dietary	O	O
fibre	O	O
source	O	O
and	O	O
gender	O	O
on	O	O
the	O	O
postprandial	Physical	Physical
glucose	Physical	Physical
and	O	Physical
lipid	Physical	Physical
response	Physical	Physical
in	O	O
healthy	O	O
subjects	O	O
.	O	O

BACKGROUND	O	O
Consumption	O	O
of	O	O
soluble	O	O
dietary	O	O
fibre	O	O
is	O	O
correlated	O	O
with	O	O
decreased	O	O
postprandial	Physical	Physical
glucose	Physical	Physical
and	O	Physical
insulin	Physical	Physical
responses	Physical	Physical
and	O	O
hence	O	O
has	O	O
beneficial	O	O
effects	O	O
on	O	O
the	O	O
metabolic	O	O
syndrome	O	O
.	O	O

AIM	O	O
OF	O	O
THE	O	O
STUDY	O	O
To	O	O
investigate	O	O
the	O	O
effects	O	O
on	O	O
postprandial	Physical	Physical
glucose	Physical	Physical
,	O	Physical
insulin	Physical	Physical
and	O	Physical
triglyceride	Physical	Physical
concentrations	Physical	Physical
of	O	O
meals	O	O
enriched	O	O
with	O	O
soluble	O	O
dietary	O	O
fibres	O	O
from	O	O
oats	O	O
,	O	O
rye	O	O
bran	O	O
,	O	O
sugar	O	O
beet	O	O
fibre	O	O
or	O	O
a	O	O
mixture	O	O
of	O	O
these	O	O
three	O	O
fibres	O	O
.	O	O

METHODS	O	O
Thirteen	O	O
healthy	O	O
human	O	O
volunteers	O	O
(	O	O
6	O	O
men	O	O
and	O	O
7	O	O
women	O	O
,	O	O
aged	O	O
20-28	O	O
years	O	O
)	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

The	O	O
subjects	O	O
came	O	O
to	O	O
the	O	O
study	O	O
centre	O	O
once	O	O
a	O	O
week	O	O
after	O	O
an	O	O
overnight	O	O
fast	O	O
to	O	O
ingest	O	O
test	O	O
meals	O	O
and	O	O
a	O	O
control	O	O
meal	O	O
in	O	O
random	O	O
order	O	O
.	O	O

The	O	O
meals	O	O
contained	O	O
either	O	O
oat	O	O
powder	O	O
(	O	O
62	O	O
g	O	O
,	O	O
of	O	O
which	O	O
2.7	O	O
soluble	O	O
fibre	O	O
)	O	O
,	O	O
rye	O	O
bran	O	O
(	O	O
31	O	O
g	O	O
,	O	O
of	O	O
which	O	O
1.7	O	O
g	O	O
soluble	O	O
fibre	O	O
)	O	O
,	O	O
sugar	O	Physical
beet	O	Physical
fibre	O	Physical
(	O	O
19	O	O
g	O	O
,	O	O
of	O	O
which	O	O
5	O	O
g	O	O
soluble	O	O
fibre	O	O
)	O	O
,	O	O
a	O	O
mixture	O	O
of	O	O
these	O	O
three	O	O
fibres	O	O
(	O	O
74	O	O
g	O	O
,	O	O
of	O	O
which	O	O
1.7	O	O
g	O	O
soluble	O	O
fibre	O	O
from	O	O
each	O	O
source	O	O
,	O	O
giving	O	O
5	O	O
g	O	O
soluble	O	O
fibre	O	O
)	O	O
or	O	O
no	O	O
added	O	O
fibre	O	O
(	O	O
control	O	O
)	O	O
and	O	O
were	O	O
all	O	O
adjusted	O	O
to	O	O
contain	O	O
the	O	O
same	O	O
total	O	O
amount	O	O
of	O	O
available	O	O
carbohydrates	O	O
.	O	O

Blood	O	O
samples	O	O
were	O	O
drawn	O	O
before	O	O
and	O	O
every	O	O
30	O	O
min	O	O
up	O	O
to	O	O
180	O	O
min	O	O
after	O	O
the	O	O
meals	O	O
.	O	O

RESULTS	O	O
Meals	O	O
with	O	O
rye	O	O
bran	O	O
gave	O	O
a	O	O
lower	O	O
postprandial	Physical	O
glucose	Physical	O
peak	Physical	O
when	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
meal	O	O
,	O	O
and	O	O
this	O	O
effect	O	O
was	O	O
more	O	O
pronounced	O	O
in	O	O
women	O	O
compared	O	O
to	O	O
men	O	O
.	O	O

Oat	O	O
powder	O	O
,	O	O
containing	O	O
a	O	O
low	O	O
amount	O	O
of	O	O
total	O	O
fibre	O	O
and	O	O
a	O	O
high	O	O
amount	O	O
of	O	O
carbohydrates	O	O
in	O	O
liquid	O	O
matrix	O	O
,	O	O
gave	O	O
a	O	O
higher	O	O
incremental	Physical	O
glucose	Physical	O
peak	Physical	O
concentration	Physical	O
compared	O	O
to	O	O
rye	O	O
bran	O	O
and	O	O
sugar	O	O
beet	O	O
fibre	O	O
and	O	O
higher	O	O
insulin	Physical	O
incremental	Physical	O
area	Physical	O
under	Physical	O
curve	Physical	O
compared	O	O
to	O	O
control	O	O
.	O	O

The	O	O
oat	O	O
powder	O	O
also	O	O
influenced	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
mixed	O	O
meal	O	O
,	O	O
diminishing	O	O
the	O	O
glucose-lowering	Physical	O
effects	Physical	O
.	O	O

Postprandial	Physical	Physical
triglyceride	Physical	Physical
levels	Physical	Physical
tended	O	O
to	O	O
be	O	O
higher	O	O
after	O	O
all	O	O
fibre-rich	O	O
meals	O	O
,	O	O
but	O	O
only	O	O
significant	O	O
for	O	O
oat	O	O
powder	O	O
and	O	O
the	O	O
mixed	O	O
meal	O	O
when	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
meal	O	O
.	O	O

CONCLUSIONS	O	O
Postprandial	Physical	O
glucose	Physical	O
,	O	O
insulin	Physical	Physical
and	O	Physical
triglyceride	Physical	Physical
concentrations	Physical	Physical
are	O	O
influenced	O	O
by	O	O
dietary	O	O
fibre-rich	O	O
meals	O	O
,	O	O
depending	O	O
on	O	O
fibre	O	O
source	O	O
,	O	O
dose	O	O
of	O	O
soluble	O	O
and	O	O
total	O	O
fibre	O	O
and	O	O
possibly	O	O
gender	O	O
.	O	O

Small	O	O
but	O	O
important	O	O
errors	O	O
in	O	O
cardiovascular	O	O
risk	O	O
calculation	O	O
by	O	O
practice	O	O
nurses	O	O
:	O	O
a	O	O
cross-sectional	O	O
study	O	O
in	O	O
randomised	O	O
trial	O	O
setting	O	O
.	O	O

BACKGROUND	O	O
Practice	O	O
nurses	O	O
play	O	O
an	O	O
increasingly	O	O
important	O	O
role	O	O
in	O	O
the	O	O
prevention	O	O
of	O	O
cardiovascular	O	O
diseases	O	O
but	O	O
we	O	O
do	O	O
not	O	O
have	O	O
evidence	O	O
about	O	O
the	O	O
accuracy	O	O
of	O	O
their	O	O
cardiovascular	O	O
risk	O	O
assessments	O	O
during	O	O
real	O	O
practice	O	O
consultations	O	O
.	O	O

OBJECTIVES	O	O
To	O	O
examine	O	O
how	O	O
nurses	O	O
perform	O	O
with	O	O
regard	O	O
to	O	O
absolute	O	O
10-year	O	O
cardiovascular	Others	O
risk	Others	O
assessment	Others	O
in	O	O
actual	O	O
practice	O	O
.	O	O

DESIGN	O	O
Cross-sectional	O	O
study	O	O
.	O	O

SETTING	O	O
This	O	O
study	O	O
was	O	O
nested	O	O
in	O	O
the	O	O
IMPALA	O	O
study	O	O
,	O	O
a	O	O
clustered	O	O
randomised	O	O
controlled	O	O
trial	O	O
involving	O	O
24	O	O
general	O	O
practices	O	O
in	O	O
The	O	O
Netherlands	O	O
.	O	O

PARTICIPANTS	O	O
24	O	O
practice	O	O
nurses	O	O
,	O	O
trained	O	O
in	O	O
10-year	O	O
cardiovascular	O	O
risk	O	O
assessment	O	O
,	O	O
calculated	O	O
the	O	O
risk	O	O
of	O	O
a	O	O
total	O	O
of	O	O
421	O	O
patients	O	O
without	O	O
established	O	O
cardiovascular	O	O
diseases	O	O
but	O	O
eligible	O	O
for	O	O
cardiovascular	Others	O
risk	Others	O
assessment	Others	O
.	Others	O

METHODS	O	O
The	O	O
main	O	O
outcome	O	O
measure	O	O
was	O	O
the	O	O
accuracy	Others	Mental
of	Others	Mental
risk	Others	Mental
assessments	Others	Mental
,	O	O
defined	O	O
as	O	O
(	O	O
1	O	O
)	O	O
the	O	O
difference	Others	O
between	Others	O
the	Others	O
10-year	Others	O
cardiovascular	Others	O
risk	Others	O
percentage	Others	O
calculated	Others	O
by	Others	O
nurses	Others	O
and	Others	O
an	Others	O
independent	Others	O
assessor	Others	O
,	O	O
and	O	O
(	O	O
2	O	O
)	O	O
the	O	O
agreement	Others	O
between	Others	O
the	Others	O
treatment	Others	O
categories	Others	O
assigned	Others	O
by	Others	O
the	Others	O
nurses	Others	O
(	Others	O
low	Others	O
,	Others	O
moderate	Others	O
or	Others	O
high	Others	O
risk	Others	O
)	Others	O
and	Others	O
those	Others	O
assigned	Others	O
by	Others	O
the	Others	O
independent	Others	O
assessor	Others	O
.	O	O

RESULTS	O	O
Thirty-one	O	O
(	O	O
7.4	O	O
%	O	O
)	O	O
of	O	O
the	O	O
calculated	O	O
risk	O	O
percentages	O	O
differed	O	O
by	O	O
more	O	O
than	O	O
our	O	O
preset	O	O
limits	O	O
,	O	O
25	O	O
(	O	O
81	O	O
%	O	O
)	O	O
being	O	O
underestimations	O	O
.	O	O

Elderly	O	O
patients	O	O
(	O	O
OR	O	O
1.1	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
1.0-1.1	O	O
)	O	O
,	O	O
male	O	O
patients	O	O
(	O	O
vs.	O	O
female	O	O
OR	O	O
3.1	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
1.2-7.3	O	O
)	O	O
,	O	O
and	O	O
smoking	O	O
patients	O	O
(	O	O
vs.	O	O
non-smoking	O	O
OR	O	O
3.8	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
1.7-8.9	O	O
)	O	O
were	O	O
more	O	O
likely	O	O
to	O	O
have	O	O
their	O	O
cardiovascular	Others	O
risk	Others	O
miscalculated	O	O
.	O	O

Ten	O	O
(	O	O
28	O	O
%	O	O
)	O	O
of	O	O
the	O	O
36	O	O
patients	O	O
who	O	O
should	O	O
be	O	O
assigned	O	O
to	O	O
the	O	O
high-risk	O	O
treatment	O	O
category	O	O
according	O	O
to	O	O
the	O	O
independent	O	O
calculation	O	O
,	O	O
were	O	O
missed	O	O
as	O	O
high-risk	O	O
patients	O	O
by	O	O
the	O	O
practice	O	O
nurses	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
overall	O	O
standard	O	O
of	O	O
accuracy	O	O
of	O	O
cardiovascular	O	O
risk	O	O
assessment	O	O
by	O	O
trained	O	O
practice	O	O
nurses	O	O
in	O	O
actual	O	O
practice	O	O
is	O	O
high	O	O
.	O	O

However	O	O
,	O	O
a	O	O
significant	O	O
number	O	O
of	O	O
high-risk	O	O
patients	O	O
were	O	O
misclassified	O	O
,	O	O
with	O	O
the	O	O
probability	O	O
that	O	O
it	O	O
led	O	O
to	O	O
missed	O	O
opportunities	O	O
for	O	O
risk-reducing	O	O
interventions	O	O
.	O	O

As	O	O
cardiovascular	O	O
risk	O	O
assessments	O	O
are	O	O
frequently	O	O
done	O	O
by	O	O
nurses	O	O
in	O	O
general	O	O
practice	O	O
,	O	O
further	O	O
specific	O	O
training	O	O
should	O	O
be	O	O
considered	O	O
to	O	O
prevent	O	O
undertreatment	O	O
.	O	O

Predictors	O	O
of	O	O
postdischarge	O	O
outcomes	O	O
from	O	O
information	O	O
acquired	O	O
shortly	O	O
after	O	O
admission	O	O
for	O	O
acute	O	O
heart	O	O
failure	O	O
:	O	O
a	O	O
report	O	O
from	O	O
the	O	O
Placebo-Controlled	O	O
Randomized	O	O
Study	O	O
of	O	O
the	O	O
Selective	O	O
A1	O	O
Adenosine	O	O
Receptor	O	O
Antagonist	O	O
Rolofylline	O	O
for	O	O
Patients	O	O
Hospitalized	O	O
With	O	O
Acute	O	O
Decompensated	O	O
Heart	O	O
Failure	O	O
and	O	O
Volume	O	O
Overload	O	O
to	O	O
Assess	O	O
Treatment	O	O
Effect	O	O
on	O	O
Congestion	O	O
and	O	O
Renal	O	O
Function	O	O
(	O	O
PROTECT	O	O
)	O	O
Study	O	O
.	O	O

BACKGROUND	O	O
Acute	O	O
heart	O	O
failure	O	O
is	O	O
a	O	O
common	O	O
reason	O	O
for	O	O
admission	O	O
,	O	O
and	O	O
outcome	O	O
is	O	O
often	O	O
poor	O	O
.	O	O

Improved	O	O
prognostic	O	O
risk	O	O
stratification	O	O
may	O	O
assist	O	O
in	O	O
the	O	O
design	O	O
of	O	O
future	O	O
trials	O	O
and	O	O
in	O	O
patient	O	O
management	O	O
.	O	O

Using	O	O
data	O	O
from	O	O
a	O	O
large	O	O
randomized	O	O
trial	O	O
,	O	O
we	O	O
explored	O	O
the	O	O
prognostic	O	O
value	O	O
of	O	O
clinical	O	O
variables	O	O
,	O	O
measured	O	O
at	O	O
hospital	O	O
admission	O	O
for	O	O
acute	O	O
heart	O	O
failure	O	O
,	O	O
to	O	O
determine	O	O
whether	O	O
a	O	O
few	O	O
selected	O	O
variables	O	O
were	O	O
inferior	O	O
to	O	O
an	O	O
extended	O	O
data	O	O
set	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
The	O	O
prognostic	O	O
model	O	O
included	O	O
37	O	O
clinical	O	O
characteristics	O	O
collected	O	O
at	O	O
baseline	O	O
in	O	O
PROTECT	O	O
,	O	O
a	O	O
study	O	O
comparing	O	O
rolofylline	O	O
and	O	O
placebo	O	O
in	O	O
2033	O	O
patients	O	O
admitted	O	O
with	O	O
acute	O	O
heart	O	O
failure	O	O
.	O	O

Prespecified	O	O
outcomes	O	O
at	O	O
30	O	O
days	O	O
were	O	O
death	Mortality	Mortality
or	Adverseeffect	O
rehospitalization	Mortality	Others
for	Mortality	O
any	Mortality	O
reason	Mortality	O
;	Adverseeffect	O
death	Mortality	Mortality
or	Adverseeffect	O
rehospitalization	Mortality	Physical
for	Mortality	Physical
cardiovascular	Mortality	Physical
or	Mortality	Physical
renal	Mortality	Physical
reasons	Mortality	Physical
;	Adverseeffect	O
and	O	O
,	O	O
at	O	O
both	O	O
30	O	O
and	O	O
180	O	O
days	O	O
,	O	O
all-cause	O	Mortality
mortality	O	Mortality
.	O	O

No	O	O
variable	O	O
had	O	O
a	O	O
c-index	O	O
>	O	O
0.70	O	O
,	O	O
and	O	O
few	O	O
had	O	O
values	O	O
>	O	O
0.60	O	O
;	O	O
c-indices	O	O
were	O	O
lower	O	O
for	O	O
composite	O	O
outcomes	O	O
than	O	O
for	O	O
mortality	O	O
.	O	O

Blood	Physical	O
urea	Physical	O
was	O	O
generally	O	O
the	O	O
strongest	O	O
single	O	O
predictor	O	O
.	O	O

Eighteen	O	O
variables	O	O
contributed	O	O
independent	O	O
prognostic	O	O
information	O	O
,	O	O
but	O	O
a	O	O
reduced	O	O
model	O	O
using	O	O
only	O	O
8	O	O
items	O	O
(	O	O
age	O	O
,	O	O
previous	O	O
heart	O	O
failure	O	O
hospitalization	O	O
,	O	O
peripheral	O	Physical
edema	O	Physical
,	O	O
systolic	O	Physical
blood	O	Physical
pressure	O	Physical
,	O	Physical
serum	O	Physical
sodium	O	Physical
,	O	Physical
urea	O	Physical
,	O	Physical
creatinine	O	Physical
,	O	Physical
and	O	Physical
albumin	O	Physical
)	O	Physical
performed	O	O
similarly	O	O
.	O	O

For	O	O
prediction	O	O
of	O	O
all-cause	Mortality	Mortality
mortality	Mortality	Mortality
at	O	O
180	O	O
days	O	O
,	O	O
the	O	O
model	O	O
c-index	O	O
using	O	O
all	O	O
variables	O	O
was	O	O
0.72	O	O
and	O	O
for	O	O
the	O	O
simplified	O	O
model	O	O
,	O	O
also	O	O
0.72	O	O
.	O	O

CONCLUSIONS	O	O
A	O	O
few	O	O
simple	O	O
clinical	O	O
variables	O	O
measured	O	O
on	O	O
admission	O	O
in	O	O
patients	O	O
with	O	O
acute	O	O
heart	O	O
failure	O	O
predict	O	O
a	O	O
variety	Adverseeffect	O
of	Adverseeffect	O
adverse	Adverseeffect	O
outcomes	Adverseeffect	O
with	O	O
accuracy	Others	O
similar	O	O
to	O	O
more	O	O
complex	O	O
models	O	O
.	O	O

However	O	O
,	O	O
predictive	O	O
models	O	O
were	O	O
of	O	O
only	O	O
moderate	Others	O
accuracy	Others	O
,	O	O
especially	O	O
for	O	O
outcomes	Adverseeffect	O
that	Adverseeffect	O
included	Adverseeffect	O
nonfatal	Adverseeffect	Physical
events	Adverseeffect	Physical
.	O	Physical

Better	O	O
methods	O	O
of	O	O
risk	O	O
stratification	O	O
are	O	O
required	O	O
.	O	O

CLINICAL	O	O
TRIAL	O	O
REGISTRATION	O	O
URL	O	O
:	O	O
http	O	O
:	O	O
//www.clinicaltrials.gov	O	O
.	O	O

Unique	O	O
identifiers	O	O
:	O	O
NCT00328692	O	O
and	O	O
NCT00354458	O	O
.	O	O

Laser	O	O
conization	O	O
versus	O	O
cold	O	O
knife	O	O
conization	O	O
.	O	O

This	O	O
prospective	O	O
,	O	O
randomized	O	O
study	O	O
compares	O	O
,	O	O
for	O	O
the	O	O
first	O	O
time	O	O
,	O	O
measured	O	O
blood	O	Physical
loss	O	Physical
at	O	O
conization	O	O
and	O	O
within	O	O
24	O	O
hours	O	O
after	O	O
using	O	O
either	O	O
the	O	O
cold	O	O
knife	O	O
technique	O	O
or	O	O
the	O	O
carbon	O	O
dioxide	O	O
laser	O	O
scalpel	O	O
.	O	O

One	O	O
hundred	O	O
and	O	O
ten	O	O
consecutive	O	O
patients	O	O
were	O	O
evaluated	O	O
.	O	O

The	O	O
median	Physical	Physical
blood	Physical	Physical
loss	Physical	Physical
in	O	O
the	O	O
laser	O	O
group	O	O
of	O	O
55	O	O
patients	O	O
was	O	O
4.6	O	O
milliliters	O	O
at	O	O
,	O	O
and	O	O
within	O	O
,	O	O
24	O	O
hours	O	O
after	O	O
operation	O	O
compared	O	O
with	O	O
30.1	O	O
milliliters	O	O
in	O	O
the	O	O
cold	O	O
knife	O	O
group	O	O
of	O	O
55	O	O
patients	O	O
.	O	O

More	O	O
important	O	O
,	O	O
however	O	O
,	O	O
is	O	O
that	O	O
the	O	O
corresponding	O	O
figures	O	O
for	O	O
the	O	O
range	Physical	Physical
of	Physical	Physical
bleeding	Physical	Physical
were	O	O
0.4	O	O
to	O	O
155.4	O	O
milliliters	O	O
and	O	O
5.6	O	O
to	O	O
1,570.9	O	O
milliliters	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
incidence	Physical	Physical
rate	Physical	Physical
for	Physical	Physical
bleeding	Physical	Physical
complications	Physical	Physical
requiring	Physical	Physical
surgical	Physical	Physical
intervention	Physical	Physical
was	O	O
1.8	O	O
per	O	O
cet	O	O
for	O	O
the	O	O
laser	O	O
group	O	O
and	O	O
14.6	O	O
per	O	O
cent	O	O
for	O	O
the	O	O
cold	O	O
knife	O	O
group	O	O
.	O	O

This	O	O
difference	O	O
was	O	O
statistically	O	O
significant	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0.015	O	O
--	O	O
Fischer	O	O
's	O	O
exact	O	O
test	O	O
.	O	O

Conization	O	O
for	O	O
treatment	O	O
of	O	O
premalignant	O	O
changes	O	O
of	O	O
the	O	O
cervix	O	O
uteri	O	O
will	O	O
probably	O	O
remain	O	O
the	O	O
treatment	O	O
of	O	O
choice	O	O
for	O	O
some	O	O
time	O	O
to	O	O
come	O	O
.	O	O

It	O	O
is	O	O
our	O	O
opinion	O	O
that	O	O
,	O	O
in	O	O
the	O	O
future	O	O
,	O	O
laser	O	O
conization	O	O
will	O	O
replace	O	O
cold	O	O
knife	O	O
conization	O	O
.	O	O

A	O	O
double-blind	O	O
randomized	O	O
clinical	O	O
evaluation	O	O
of	O	O
enamel	O	O
matrix	O	O
derivative	O	O
proteins	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
proximal	O	O
class-II	O	O
furcation	O	O
involvements	O	O
.	O	O

OBJECTIVE	O	O
The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
randomized	O	O
,	O	O
double-blind	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
clinical	Physical	O
response	Physical	O
of	O	O
proximal	O	O
furcations	O	O
treated	O	O
with	O	O
enamel	O	O
matrix	O	O
derivative	O	O
proteins	O	O
(	O	O
EMD	O	O
)	O	O
.	O	O

MATERIAL	O	O
AND	O	O
METHODS	O	O
Fifteen	O	O
patients	O	O
,	O	O
each	O	O
with	O	O
a	O	O
pair	O	O
of	O	O
contralateral	O	O
class-II	O	O
proximal	O	O
furcation	O	O
involvements	O	O
,	O	O
presenting	O	O
probing	O	O
depths	O	O
(	O	O
PDs	O	O
)	O	O
>	O	O
/=5	O	O
mm	O	O
and	O	O
bleeding	O	O
on	O	O
probing	O	O
(	O	O
BOP	O	O
)	O	O
were	O	O
selected	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
:	O	O
control	O	O
group	O	O
(	O	O
n=15	O	O
)	O	O
-	O	O
open	O	O
flap	O	O
debridement	O	O
(	O	O
OFD	O	O
)	O	O
+24	O	O
%	O	O
ethylenediaminetetraacetic	O	O
acid	O	O
(	O	O
EDTA	O	O
)	O	O
conditioning	O	O
;	O	O
test	O	O
group	O	O
(	O	O
n=15	O	O
)	O	O
-	O	O
OFD+24	O	O
%	O	O
EDTA	O	O
conditioning+EMD	O	O
application	O	O
.	O	O

Plaque	Physical	Physical
index	Physical	Physical
(	Physical	Physical
PI	Physical	Physical
)	Physical	Physical
,	O	Physical
BOP	Physical	Physical
,	O	Physical
PD	Physical	Physical
,	O	O
gingival	Physical	Physical
margin	Physical	Physical
position	Physical	Physical
(	Physical	Physical
GMP	Physical	Physical
)	Physical	Physical
,	O	O
relative	Physical	Physical
vertical	Physical	Physical
and	Physical	Physical
horizontal	Physical	Physical
clinical	Physical	Physical
attachment	Physical	Physical
level	Physical	Physical
(	Physical	O
RVCAL	Physical	O
and	Physical	O
RHCAL	Physical	O
)	Physical	O
,	O	O
vertical	Physical	Physical
and	Physical	Physical
horizontal	Physical	Physical
bone	Physical	Physical
level	Physical	Physical
(	Physical	O
VBL	Physical	O
and	Physical	O
HBL	Physical	O
)	Physical	O
and	O	O
furcation	O	O
closure	O	O
were	O	O
evaluated	O	O
immediately	O	O
before	O	O
and	O	O
2	O	O
,	O	O
4	O	O
and	O	O
6	O	O
months	O	O
after	O	O
the	O	O
surgeries	O	O
.	O	O

RESULTS	O	O
At	O	O
6	O	O
months	O	O
,	O	O
the	O	O
RVCAL	Physical	O
gains	Physical	O
of	O	O
the	O	O
control	O	O
and	O	O
test	O	O
group	O	O
were	O	O
0.39	O	O
+/-	O	O
1.00	O	O
and	O	O
0.54	O	O
+/-	O	O
0.95	O	O
mm	O	O
,	O	O
while	O	O
the	O	O
RHCAL	Physical	O
gains	O	O
were	O	O
1.21	O	O
+/-	O	O
2.28	O	O
and	O	O
1.36	O	O
+/-	O	O
1.26	O	O
mm	O	O
(	O	O
p	O	O
>	O	O
0.05	O	O
)	O	O
.	O	O

The	O	O
VBL	Physical	O
and	Physical	O
HBL	Physical	O
gains	O	O
of	O	O
the	O	O
control	O	O
group	O	O
were	O	O
1.04	O	O
+/-	O	O
1.12	O	O
and	O	O
1.00	O	O
+/-	O	O
1.79	O	O
mm	O	O
,	O	O
and	O	O
0.82	O	O
+/-	O	O
1.82	O	O
and	O	O
1.17	O	O
+/-	O	O
1.38	O	O
mm	O	O
for	O	O
the	O	O
test	O	O
group	O	O
(	O	O
p	O	O
>	O	O
0.05	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
a	O	O
statistical	O	O
difference	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
number	Physical	O
of	Physical	O
the	Physical	O
remaining	Physical	O
class-II	Physical	O
furcations	Physical	O
between	O	O
the	O	O
test	O	O
and	O	O
control	O	O
groups	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
in	O	O
this	O	O
period	O	O
.	O	O

CONCLUSION	O	O
It	O	O
may	O	O
be	O	O
concluded	O	O
that	O	O
the	O	O
use	O	O
of	O	O
EMD	O	O
in	O	O
proximal	O	O
furcations	O	O
did	O	O
not	O	O
promote	O	O
a	O	O
superior	O	O
reduction	O	O
in	O	O
PD	Physical	O
or	O	O
a	O	O
gain	O	O
in	O	O
clinical	Physical	O
and	Physical	O
osseous	Physical	O
attachment	Physical	O
levels	Physical	O
,	O	O
but	O	O
resulted	O	O
in	O	O
a	O	O
higher	O	O
rate	O	O
of	O	O
class-II	Physical	O
to	Physical	O
class-I	Physical	O
furcation	Physical	O
conversion	Physical	O
.	O	O

Chemotherapy	O	O
of	O	O
large	O	O
bowel	O	O
carcinoma	O	O
--	O	O
fluorouracil	O	O
(	O	O
FU	O	O
)	O	O
+	O	O
hydroxyurea	O	O
(	O	O
HU	O	O
)	O	O
vs.	O	O
methyl-CCNU	O	O
,	O	O
oncovin	O	O
,	O	O
fluorouracil	O	O
,	O	O
and	O	O
streptozotocin	O	O
(	O	O
MOF-Strep	O	O
)	O	O
.	O	O

An	O	O
Eastern	O	O
Cooperative	O	O
Oncology	O	O
Group	O	O
study	O	O
.	O	O

In	O	O
this	O	O
prospective	O	O
randomized	O	O
study	O	O
of	O	O
initial	O	O
chemotherapy	O	O
for	O	O
advanced	O	O
measurable	O	O
metastatic	O	O
large	O	O
bowel	O	O
carcinoma	O	O
,	O	O
the	O	O
response	Physical	Physical
rate	Physical	Physical
was	O	O
6/32	O	O
(	O	O
19	O	O
%	O	O
)	O	O
for	O	O
FU	O	O
+	O	O
HU	O	O
and	O	O
5/32	O	O
(	O	O
16	O	O
%	O	O
)	O	O
for	O	O
MOF-Strep	O	O
;	O	O
the	O	O
estimated	O	O
median	Mortality	O
survival	Mortality	O
is	O	O
43	O	O
weeks	O	O
for	O	O
both	O	O
treatments	O	O
.	O	O

Patients	O	O
who	O	O
received	O	O
MOF-Strep	O	O
experienced	O	O
substantially	O	O
greater	O	O
vomiting	Adverseeffect	Physical
and	Adverseeffect	Physical
hematologic	Adverseeffect	Physical
toxicity	Adverseeffect	Physical
than	O	O
patients	O	O
who	O	O
received	O	O
FU	O	O
+	O	O
HU	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
.	O	O

Enhanced	O	O
small	O	O
group	O	O
instruction	O	O
using	O	O
choral	O	O
responding	O	O
and	O	O
student	O	O
interaction	O	O
for	O	O
children	O	O
with	O	O
autism	O	O
and	O	O
developmental	O	O
disabilities	O	O
.	O	O

The	O	O
use	O	O
of	O	O
effective	O	O
instructional	O	O
strategies	O	O
in	O	O
small	O	O
groups	O	O
was	O	O
investigated	O	O
to	O	O
determine	O	O
learning	O	O
effects	O	O
for	O	O
24	O	O
elementary	O	O
age	O	O
students	O	O
with	O	O
autism	O	O
and	O	O
developmental	O	O
disabilities	O	O
.	O	O

Effective	O	O
strategies	O	O
included	O	O
(	O	O
a	O	O
)	O	O
the	O	O
use	O	O
of	O	O
choral	O	O
responding	O	O
;	O	O
(	O	O
b	O	O
)	O	O
the	O	O
use	O	O
of	O	O
student-to-student	O	O
responding	O	O
;	O	O
(	O	O
c	O	O
)	O	O
the	O	O
rotation	O	O
of	O	O
materials	O	O
every	O	O
5	O	O
minutes	O	O
during	O	O
the	O	O
30-minute	O	O
group	O	O
while	O	O
teaching	O	O
2	O	O
to	O	O
3	O	O
concepts	O	O
;	O	O
and	O	O
(	O	O
d	O	O
)	O	O
the	O	O
use	O	O
of	O	O
random	O	O
,	O	O
unpredictable	O	O
trials	O	O
for	O	O
student	O	O
responding	O	O
.	O	O

Thirty-minute	O	O
language	O	O
groups	O	O
were	O	O
targeted	O	O
to	O	O
teach	O	O
receptive	O	O
and	O	O
expressive	O	O
skills	O	O
using	O	O
pictures	O	O
and	O	O
common	O	O
objects	O	O
across	O	O
five	O	O
categories	O	O
(	O	O
e.g.	O	O
,	O	O
household	O	O
items	O	O
,	O	O
foods	O	O
)	O	O
.	O	O

Results	O	O
showed	O	O
increased	O	O
opportunities	Mental	O
to	Mental	O
respond	Mental	O
,	O	O
increased	Mental	O
levels	Mental	O
of	Mental	O
responding	Mental	O
and	Mental	O
academic	Mental	O
engagement	Mental	O
,	O	O
higher	Physical	O
gains	Physical	O
on	Physical	O
weekly	Mental	O
criterion-referenced	Mental	O
pre-	Mental	O
and	Mental	O
posttests	Mental	O
,	O	O
and	O	O
decreased	Physical	O
passive	Mental	O
and	Mental	O
inappropriate	Mental	O
student	Mental	O
behavior	Mental	O
during	O	O
interventions	O	O
.	O	O

White	O	O
coat	O	O
effect	O	O
detected	O	O
using	O	O
self-monitoring	O	O
of	O	O
blood	O	Physical
pressure	O	Physical
at	O	O
home	O	O
:	O	O
comparison	O	O
with	O	O
ambulatory	O	O
blood	O	O
pressure	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
whether	O	O
home	Physical	O
blood	Physical	Physical
pressure	Physical	Physical
(	O	Physical
HBP	O	Physical
)	O	Physical
is	O	O
a	O	O
reliable	O	O
alternative	O	O
to	O	O
ambulatory	O	O
blood	Physical	O
pressure	Physical	O
(	O	O
ABP	O	O
)	O	O
for	O	O
the	O	O
detection	O	O
of	O	O
the	O	O
white	O	O
coat	O	O
effect	O	O
(	O	O
WCE	O	O
)	O	O
.	O	O

Hypertensive	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
measure	O	O
HBP	O	O
for	O	O
2	O	O
weeks	O	O
or	O	O
ABP	O	O
for	O	O
24	O	O
h.	O	O
The	O	O
alternative	O	O
measurement	O	O
was	O	O
then	O	O
performed	O	O
.	O	O

Clinic	Physical	Physical
blood	Physical	Physical
pressure	Physical	Physical
(	Physical	Physical
CBP	Physical	Physical
)	Physical	Physical
was	O	O
measured	O	O
in	O	O
the	O	O
beginning	O	O
and	O	O
end	O	O
of	O	O
the	O	O
study	O	O
.	O	O

Subjects	O	O
with	O	O
a	O	O
difference	O	O
of	O	O
>	O	O
or	O	O
=	O	O
20	O	O
mm	O	O
Hg	O	O
systolic	O	O
or	O	O
>	O	O
or	O	O
=	O	O
10	O	O
mm	O	O
Hg	O	O
diastolic	O	O
BP	O	O
between	O	O
CBP	O	O
and	O	O
awake	O	O
ABP	O	O
or	O	O
CBP	O	O
and	O	O
HBP	O	O
,	O	O
were	O	O
classified	O	O
as	O	O
clinic	O	O
reactors	O	O
.	O	O

A	O	O
total	O	O
of	O	O
189	O	O
patients	O	O
completed	O	O
the	O	O
study	O	O
(	O	O
79	O	O
on	O	O
stable	O	O
antihypertensive	O	O
treatment	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
magnitude	O	O
of	O	O
WCE	Physical	O
assessed	O	O
using	O	O
the	O	O
ABP	Others	O
or	O	O
the	O	O
HBP	Others	O
method	O	O
(	O	O
mean	O	O
discrepancy	O	O
,	O	O
systolic	Physical	Physical
BP	Physical	Physical
:	Physical	O
-1.5	O	O
+/-	O	O
11.7	O	O
mm	O	O
Hg	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
-3.2	O	O
,	O	O
0.2	O	O
;	O	O
diastolic	Physical	Physical
BP	Physical	Physical
:	Physical	O
0.9	O	O
+/-	O	O
7.0	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
-0.1	O	O
,	O	O
1.9	O	O
)	O	O
.	O	O

A	O	O
strong	O	O
association	O	O
existed	O	O
between	O	O
WCE	Physical	O
calculated	O	O
using	O	O
the	O	O
HBP	Others	O
or	O	O
the	O	O
ABP	Others	O
method	O	O
(	O	O
r	O	O
=	O	O
0.64/0.59	O	O
systolic/diastolic	O	O
,	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

The	O	O
proportion	O	O
of	O	O
patients	O	O
classified	O	O
as	O	O
clinic	Physical	O
reactors	Physical	O
was	O	O
identical	O	O
using	O	O
the	O	O
HBP	O	O
or	O	O
the	O	O
ABP	O	O
method	O	O
(	O	O
25.9	O	O
%	O	O
)	O	O
.	O	O

Agreement	O	O
between	O	O
methods	O	O
in	O	O
the	O	O
classification	O	O
of	O	O
clinic	O	O
reactors	O	O
was	O	O
found	O	O
in	O	O
147	O	O
patients	O	O
(	O	O
78	O	O
%	O	O
)	O	O
.	O	O

The	O	O
sensitivity	O	Others
and	O	Others
specificity	O	Others
of	O	O
the	O	O
HBP	O	O
method	O	O
to	O	O
classify	O	Others
correctly	O	Others
clinic	O	Others
reactors	O	Others
(	O	Others
ABP	O	Others
method	O	Others
used	O	O
as	O	O
the	O	O
standard	O	O
)	O	O
were	O	O
57	O	O
%	O	O
and	O	O
85	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
whereas	O	O
its	O	O
positive	O	Others
and	O	Others
negative	O	Others
predictive	O	Others
value	O	Others
were	O	O
57	O	O
%	O	O
and	O	O
85	O	O
%	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
HBP	Others	O
is	O	O
not	O	O
appropriate	O	O
as	O	O
an	O	O
alternative	O	O
to	O	O
ABP	O	O
diagnostic	O	O
testing	O	O
in	O	O
the	O	O
detection	O	O
of	O	O
WCE	O	O
.	O	O

Nevertheless	O	O
,	O	O
HBP	Others	O
appears	O	O
useful	O	O
as	O	O
a	O	O
screening	O	O
test	O	O
for	O	O
the	O	O
detection	O	O
of	O	O
this	O	O
phenomenon	O	O
.	O	O

An	O	O
open	O	O
and	O	O
randomized	O	O
study	O	O
comparing	O	O
the	O	O
efficacy	Others	O
of	O	O
standard	O	O
danazol	O	O
and	O	O
modified	O	O
triptorelin	O	O
regimens	O	O
for	O	O
postoperative	O	O
disease	O	O
management	O	O
of	O	O
moderate	O	O
to	O	O
severe	O	O
endometriosis	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
compare	O	O
the	O	O
efficacy	Others	O
of	O	O
danazol	O	O
and	O	O
triptorelin	O	O
(	O	O
Decapeptyl	O	O
CR	O	O
,	O	O
Ferring	O	O
,	O	O
Kiel	O	O
,	O	O
Germany	O	O
)	O	O
in	O	O
the	O	O
management	O	O
of	O	O
moderate	O	O
and	O	O
severe	O	O
endometriosis	O	O
in	O	O
terms	O	O
of	O	O
symptom	Physical	O
control	Physical	O
and	O	O
revised	O	O
American	Physical	O
Fertility	Physical	O
Society	Physical	O
(	Physical	O
AFS	Physical	O
)	Physical	O
score	Physical	O
reduction	Physical	O
,	O	O
and	O	O
to	O	O
evaluate	O	O
the	O	O
hormonal	Physical	O
profile	Physical	O
of	O	O
patients	O	O
treated	O	O
with	O	O
triptorelin	O	O
every	O	O
6	O	O
weeks	O	O
.	O	O

DESIGN	O	O
Open	O	O
and	O	O
randomized	O	O
trial	O	O
.	O	O

SETTING	O	O
Kwong	O	O
Wah	O	O
Hospital	O	O
,	O	O
a	O	O
large	O	O
public	O	O
hospital	O	O
in	O	O
an	O	O
urban	O	O
location	O	O
(	O	O
Hong	O	O
Kong	O	O
)	O	O
.	O	O

PATIENT	O	O
(	O	O
S	O	O
)	O	O
Forty	O	O
patients	O	O
after	O	O
their	O	O
first	O	O
conservative	O	O
operation	O	O
for	O	O
endometriosis	O	O
,	O	O
with	O	O
surgical	O	O
confirmation	O	O
of	O	O
revised	O	O
AFS	O	O
stage	O	O
III	O	O
or	O	O
IV	O	O
endometriosis	O	O
.	O	O

INTERVENTION	O	O
(	O	O
S	O	O
)	O	O
Postoperative	O	O
6	O	O
months	O	O
'	O	O
therapy	O	O
of	O	O
danazol	O	O
or	O	O
triptorelin	O	O
every	O	O
6	O	O
weeks	O	O
,	O	O
postmedical	O	O
therapy	O	O
second-look	O	O
laparoscopy	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURE	O	O
(	O	O
S	O	O
)	O	O
Symptom	Physical	Physical
control	Physical	Physical
and	O	Physical
patients	Physical	Physical
'	Physical	Physical
tolerance	Physical	Physical
during	O	O
medical	O	O
therapy	O	O
,	O	O
posttherapy	Physical	O
revised	Physical	O
AFS	Physical	O
score	Physical	O
,	O	O
hormonal	Physical	O
profile	Physical	O
during	O	O
triptorelin	O	O
therapy	O	O
.	O	O

RESULT	O	O
(	O	O
S	O	O
)	O	O
Pain	Pain	O
control	Pain	O
was	O	O
similar	O	O
between	O	O
danazol	O	O
and	O	O
triptorelin	O	O
therapy	O	O
.	O	O

There	O	O
was	O	O
less	O	O
breakthrough	Physical	O
bleeding	Physical	O
with	O	O
triptorelin	O	O
.	O	O

More	O	O
patients	O	O
failed	O	O
to	O	O
complete	O	O
the	O	O
whole	O	O
course	O	O
of	O	O
danazol	O	O
because	O	O
of	O	O
its	O	O
side	Adverseeffect	O
effects	Adverseeffect	O
.	Adverseeffect	O

The	O	O
revised	Physical	Others
AFS	Physical	Others
score	Physical	Others
at	O	Others
second-look	O	Others
laparoscopy	O	Others
did	O	O
not	O	O
show	O	O
a	O	O
significant	O	O
difference	O	O
between	O	O
the	O	O
two	O	O
medications	O	O
.	O	O

Adequate	Physical	O
pituitary	Physical	O
suppression	Physical	O
was	O	O
observed	O	O
with	O	O
injection	O	O
of	O	O
triptorelin	O	O
every	O	O
6	O	O
weeks	O	O
.	O	O

CONCLUSION	O	O
(	O	O
S	O	O
)	O	O
Lengthening	O	O
of	O	O
triptorelin	O	O
administration	O	O
intervals	O	O
from	O	O
4	O	O
weeks	O	O
to	O	O
6	O	O
weeks	O	O
is	O	O
effective	O	O
in	O	O
maintaining	O	O
a	O	O
hypoestrogenic	Physical	O
state	Physical	O
.	O	O

Patients	O	O
were	O	O
more	O	O
compliant	O	O
with	O	O
triptorelin	O	O
than	O	O
danazol	O	O
.	O	O

Thus	O	O
,	O	O
triptorelin	O	O
injection	O	O
every	O	O
6	O	O
weeks	O	O
is	O	O
more	O	O
cost-effective	O	Others
than	O	O
conventional	O	O
regimens	O	O
.	O	O

Changes	O	O
in	O	O
H	O	O
reflex	O	O
and	O	O
V	O	O
wave	O	O
following	O	O
short-term	O	O
endurance	O	O
and	O	O
strength	O	O
training	O	O
.	O	O

This	O	O
study	O	O
examined	O	O
the	O	O
effects	O	O
of	O	O
3	O	O
wk	O	O
of	O	O
either	O	O
endurance	O	O
or	O	O
strength	O	O
training	O	O
on	O	O
plasticity	O	O
of	O	O
the	O	O
neural	O	O
mechanisms	O	O
involved	O	O
in	O	O
the	O	O
soleus	O	O
H	O	O
reflex	O	O
and	O	O
V	O	O
wave	O	O
.	O	O

Twenty-five	O	O
sedentary	O	O
healthy	O	O
subjects	O	O
were	O	O
randomized	O	O
into	O	O
an	O	O
endurance	O	O
group	O	O
(	O	O
n	O	O
=	O	O
13	O	O
)	O	O
or	O	O
strength	O	O
group	O	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
.	O	O

Evoked	O	O
V-wave	O	O
,	O	O
H-reflex	O	Physical
,	O	O
and	O	O
M-wave	O	Physical
recruitment	O	Physical
curves	O	Physical
,	O	O
maximal	O	O
voluntary	O	O
contraction	O	O
(	O	O
MVC	O	O
)	O	O
,	O	O
and	O	O
time-to-task-failure	O	O
(	O	O
isometric	O	O
contraction	O	O
at	O	O
40	O	O
%	O	O
MVC	O	O
)	O	O
of	O	O
the	O	O
plantar	O	O
flexors	O	O
were	O	O
recorded	O	O
before	O	O
and	O	O
after	O	O
training	O	O
.	O	O

Following	O	O
strength	O	O
training	O	O
,	O	O
MVC	Physical	Physical
of	Physical	Physical
the	Physical	Physical
plantar	Physical	Physical
flexors	Physical	Physical
increased	O	O
by	O	O
14.4	O	O
?	O	O
5.2	O	O
%	O	O
in	O	O
the	O	O
strength	O	O
group	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
,	O	O
whereas	O	O
time-to-task-failure	O	O
was	O	O
prolonged	O	O
in	O	O
the	O	O
endurance	O	O
group	O	O
(	O	O
22.7	O	O
?	O	O
17.1	O	O
%	O	O
;	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

The	O	O
V	Physical	O
wave-to-maximal	Physical	O
M	Physical	O
wave	Physical	O
(	Physical	O
V/M	Physical	O
(	Physical	O
max	Physical	O
)	Physical	O
)	Physical	O
ratio	Physical	O
increased	O	O
significantly	O	O
(	O	O
55.1	O	O
?	O	O
28.3	O	O
%	O	O
;	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
following	O	O
strength	O	O
training	O	O
,	O	O
but	O	O
the	O	O
maximal	O	O
H	Physical	O
wave-to-maximal	Physical	O
M	Physical	O
wave	Physical	O
(	Physical	O
H	Physical	O
(	Physical	O
max	Physical	O
)	Physical	O
/M	Physical	Physical
(	Physical	Physical
max	Physical	Physical
)	Physical	Physical
)	Physical	Physical
ratio	Physical	Physical
remained	O	O
unchanged	O	O
.	O	O

Conversely	O	O
,	O	O
in	O	O
the	O	O
endurance	O	O
group	O	O
the	O	O
V/M	Physical	Physical
(	Physical	Physical
max	Physical	Physical
)	Physical	Physical
ratio	Physical	Physical
was	O	O
not	O	O
altered	O	O
,	O	O
whereas	O	O
the	O	O
H	Physical	Physical
(	Physical	Physical
max	Physical	Physical
)	Physical	Physical
/M	Physical	Physical
(	Physical	Physical
max	Physical	Physical
)	Physical	Physical
ratio	O	Physical
increased	O	O
by	O	O
30.8	O	O
?	O	O
21.7	O	O
%	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

The	O	O
endurance	O	O
training	O	O
group	O	O
also	O	O
displayed	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
H-reflex	O	Physical
excitability	O	Physical
threshold	O	Physical
while	O	O
the	O	O
H-reflex	O	O
amplitude	O	O
on	O	O
the	O	O
ascending	O	O
limb	O	O
of	O	O
the	O	O
recruitment	O	O
curve	O	O
increased	O	O
.	O	O

Strength	O	O
training	O	O
only	O	O
elicited	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
H-reflex	O	Physical
excitability	O	Physical
threshold	O	Physical
,	O	O
while	O	O
H-reflex	O	O
amplitudes	O	O
over	O	O
the	O	O
ascending	O	O
limb	O	O
remained	O	O
unchanged	O	O
.	O	O

These	O	O
observations	O	O
indicate	O	O
that	O	O
the	O	O
H-reflex	O	O
pathway	O	O
is	O	O
strongly	O	O
involved	O	O
in	O	O
the	O	O
enhanced	O	O
endurance	O	O
resistance	O	O
that	O	O
occurs	O	O
following	O	O
endurance	O	O
training	O	O
.	O	O

On	O	O
the	O	O
contrary	O	O
,	O	O
the	O	O
improvements	O	O
in	O	O
MVC	O	O
following	O	O
strength	O	O
training	O	O
are	O	O
likely	O	O
attributed	O	O
to	O	O
increased	O	O
descending	O	O
drive	O	O
and/or	O	O
modulation	O	O
in	O	O
afferents	O	O
other	O	O
than	O	O
Ia	O	O
afferents	O	O
.	O	O

No	O	O
effect	O	O
of	O	O
acetylsalicylic	O	O
acid	O	O
on	O	O
B-thromboglobulin	Physical	O
and	O	O
platelet	Physical	O
factor	Physical	O
4	Physical	O
plasma	Physical	O
levels	Physical	O
in	O	O
patients	O	O
with	O	O
transient	O	O
ischaemic	O	O
attacks	O	O
.	O	O

We	O	O
studied	O	O
the	O	O
effect	O	O
of	O	O
acetylsalicylic	O	O
acid	O	O
(	O	O
ASA	O	O
)	O	O
versus	O	O
placebo	O	O
on	O	O
B-thromboglobulin	Physical	O
(	Physical	O
B-TG	Physical	O
)	Physical	O
and	O	O
platelet	Physical	O
factor	Physical	O
4	Physical	O
(	Physical	O
PF4	Physical	O
)	Physical	O
plasma	Physical	O
levels	Physical	O
and	O	O
ADP-induced	Physical	O
platelet	Physical	O
aggregation	Physical	O
in	O	O
25	O	O
male	O	O
patients	O	O
with	O	O
transient	O	O
ischaemic	O	O
attacks	O	O
(	O	O
TIA	O	O
)	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
allocated	O	O
randomly	O	O
to	O	O
two	O	O
groups	O	O
:	O	O
14	O	O
patients	O	O
received	O	O
oral	O	O
treatment	O	O
with	O	O
ASA	O	O
500	O	O
mg	O	O
b.i.d	O	O
.	O	O

for	O	O
14	O	O
days	O	O
,	O	O
11	O	O
patients	O	O
placebo	O	O
b.i.d	O	O
.	O	O

for	O	O
the	O	O
same	O	O
period	O	O
.	O	O

B-TG	Physical	O
and	O	O
PF4	Physical	O
plasma	Physical	O
levels	Physical	O
and	O	O
ADP-induced	Physical	O
platelet	Physical	O
aggregation	Physical	O
were	O	O
determined	O	O
in	O	O
basal	O	O
conditions	O	O
,	O	O
and	O	O
two	O	O
hours	O	O
,	O	O
and	O	O
seven	O	O
and	O	O
fourteen	O	O
days	O	O
after	O	O
starting	O	O
with	O	O
ASA	O	O
or	O	O
placebo	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
same	O	O
parameters	O	O
were	O	O
studied	O	O
in	O	O
a	O	O
group	O	O
of	O	O
20	O	O
healthy	O	O
males	O	O
of	O	O
matched	O	O
age	O	O
.	O	O

Basal	Physical	Physical
levels	Physical	Physical
of	Physical	Physical
plasma	Physical	Physical
B-TG	Physical	Physical
and	O	O
PF4	Physical	O
and	O	O
the	O	O
maximal	O	O
amplitude	Physical	O
of	Physical	O
ADP-induced	Physical	O
platelet	Physical	O
aggregation	Physical	O
were	O	O
abnormally	O	O
high	O	O
in	O	O
TIA	O	O
patients	O	O
.	O	O

ASA	O	O
caused	O	O
a	O	O
significant	O	O
reduction	O	O
of	O	O
B-TG	Physical	O
plasma	Physical	O
levels	Physical	O
in	O	O
TIA	O	O
patients	O	O
2	O	O
hours	O	O
after	O	O
the	O	O
first	O	O
administration	O	O
,	O	O
but	O	O
no	O	O
effect	O	O
was	O	O
observed	O	O
at	O	O
the	O	O
7th	O	O
and	O	O
14th	O	O
day	O	O
of	O	O
treatment	O	O
.	O	O

PF4	Physical	Physical
plasma	Physical	Physical
levels	Physical	Physical
were	O	O
unaffected	O	O
by	O	O
ASA	O	O
treatment	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
ASA	O	O
,	O	O
at	O	O
the	O	O
dose	O	O
conventionally	O	O
used	O	O
in	O	O
clinical	O	O
trials	O	O
,	O	O
does	O	O
not	O	O
affect	O	O
the	O	O
release	O	O
of	O	O
two	O	O
alpha-granule	O	O
proteins	O	O
.	O	O

Reactive	O	O
balance	O	O
adjustments	O	O
to	O	O
unexpected	O	O
perturbations	O	O
during	O	O
human	O	O
walking	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
investigation	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
effect	O	O
of	O	O
unexpected	O	O
forward	O	O
perturbations	O	O
(	O	O
FP	O	O
)	O	O
during	O	O
gait	O	O
on	O	O
lower	Physical	O
extremity	Physical	O
joint	Physical	O
mechanics	Physical	O
and	O	O
muscle	Physical	O
Electromyographic	Physical	O
(	Physical	O
EMG	Physical	O
)	Physical	O
patterns	Physical	O
in	O	O
healthy	O	O
adults	O	O
.	O	O

The	O	O
muscles	O	O
surrounding	O	O
the	O	O
hip	O	O
were	O	O
found	O	O
to	O	O
be	O	O
most	O	O
important	O	O
in	O	O
maintaining	Physical	O
control	Physical	O
of	Physical	O
the	Physical	O
trunk	Physical	O
and	O	O
preventing	Physical	O
collapse	Physical	O
in	O	O
response	O	O
to	O	O
the	O	O
FP	O	O
.	O	O

Distinct	Physical	Physical
lower	Physical	Physical
extremity	Physical	Physical
joint	Physical	Physical
moment	Physical	Physical
and	O	Physical
power	Physical	Physical
patterns	Physical	Physical
were	O	O
observed	O	O
in	O	O
response	O	O
to	O	O
the	O	O
FP	O	O
but	O	O
an	O	O
overall	O	O
positive	O	O
moment	Physical	O
of	Physical	O
support	Physical	O
(	O	O
M	O	O
(	O	O
s	O	O
)	O	O
)	O	O
was	O	O
maintained	O	O
.	O	O

Therefore	O	O
,	O	O
reactive	Physical	O
balance	Physical	O
control	Physical	O
was	O	O
a	O	O
synchronized	O	O
effort	O	O
of	O	O
the	O	O
lower	O	O
extremity	O	O
joints	O	O
to	O	O
prevent	O	O
collapse	O	O
during	O	O
the	O	O
FP	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
use	O	O
of	O	O
pyridostigmine	O	O
and	O	O
requirement	O	O
of	O	O
vecuronium	O	O
in	O	O
patients	O	O
with	O	O
myasthenia	O	O
gravis	O	O
.	O	O

CONTEXT	O	O
Patients	O	O
with	O	O
myasthenia	O	O
gravis	O	O
receive	O	O
pyridostigmine	O	O
,	O	O
an	O	O
anticholinesterase	O	O
agent	O	O
,	O	O
as	O	O
a	O	O
part	O	O
of	O	O
therapy	O	O
.	O	O

These	O	O
patients	O	O
demonstrate	O	O
a	O	O
heightened	O	O
sensitivity	O	O
towards	O	O
non-depolarising	O	O
muscle	O	O
relaxants	O	O
.	O	O

Continuing	O	O
pyridostigmine	O	O
till	O	O
the	O	O
day	O	O
of	O	O
the	O	O
surgery	O	O
or	O	O
omitting	O	O
it	O	O
on	O	O
the	O	O
night	O	O
before	O	O
surgery	O	O
could	O	O
provide	O	O
variable	O	O
results	O	O
with	O	O
regards	O	O
to	O	O
the	O	O
effect	O	O
of	O	O
vecuronium	O	O
.	O	O

AIMS	O	O
Myographic	O	O
evaluation	O	O
of	O	O
a	O	O
dose	O	O
of	O	O
vecuronium	O	O
in	O	O
patients	O	O
with	O	O
myasthenia	O	O
gravis	O	O
on	O	O
pyridostigmine	O	O
therapy	O	O
.	O	O

SETTING	O	O
AND	O	O
DESIGN	O	O
A	O	O
randomised	O	O
,	O	O
double-blind	O	O
,	O	O
clinical	O	O
study	O	O
conducted	O	O
in	O	O
a	O	O
teaching	O	O
hospital	O	O
.	O	O

SUBJECTS	O	O
AND	O	O
METHODS	O	O
Medically	O	O
(	O	O
oral	O	O
pyridostigmine	O	O
)	O	O
well-controlled	O	O
adult	O	O
patients	O	O
with	O	O
myasthenia	O	O
gravis	O	O
who	O	O
were	O	O
posted	O	O
for	O	O
thymectomy	O	O
,	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
two	O	O
groups	O	O
.	O	O

Patients	O	O
in	O	O
Group	O	O
1	O	O
received	O	O
their	O	O
last	O	O
dose	O	O
of	O	O
pyridostigmine	O	O
on	O	O
the	O	O
night	O	O
before	O	O
surgery	O	O
while	O	O
those	O	O
in	O	O
Group	O	O
2	O	O
received	O	O
even	O	O
the	O	O
morning	O	O
dose	O	O
of	O	O
the	O	O
drug	O	O
on	O	O
the	O	O
day	O	O
of	O	O
surgery	O	O
.	O	O

Neostigmine	O	O
(	O	O
1-2	O	O
mg	O	O
)	O	O
intravenously	O	O
was	O	O
used	O	O
as	O	O
rescue	O	O
medication	O	O
.	O	O

Vecuronium	O	O
(	O	O
0.01	O	O
mg/kg	O	O
)	O	O
was	O	O
used	O	O
for	O	O
intubation	O	O
and	O	O
muscle	O	O
relaxation	O	O
during	O	O
trans-sternal	O	O
thymectomy	O	O
and	O	O
its	O	O
effect	O	O
was	O	O
reversed	O	O
using	O	O
neostigmine	O	O
and	O	O
atropine	O	O
.	O	O

RESULTS	O	O
Fourteen	O	O
patients	O	O
(	O	O
7	O	O
in	O	O
each	O	O
group	O	O
)	O	O
belonging	O	O
to	O	O
both	O	O
sexes	O	O
were	O	O
enrolled	O	O
in	O	O
the	O	O
study	O	O
.	O	O

The	O	O
intubating	O	O
dose	O	O
of	O	O
vecuronium	O	O
showed	O	O
quicker	O	O
onset	Physical	O
time	Physical	O
(	O	O
155	O	O
sec	O	O
or	O	O
2.7	O	O
min	O	O
approx	O	O
.	O	O

)	O	O
and	O	O
peak	Physical	Others
effect	Physical	Others
(	O	O
99	O	O
%	O	O
T1	O	O
suppression	O	O
)	O	O
in	O	O
patients	O	O
belonging	O	O
to	O	O
Group	O	O
1	O	O
,	O	O
and	O	O
3/7	O	O
(	O	O
43	O	O
%	O	O
)	O	O
complained	O	O
of	O	O
respiratory	O	O
discomfort	O	O
while	O	O
waiting	O	O
for	O	O
surgery	O	O
.	O	O

By	O	O
giving	O	O
the	O	O
morning	O	O
dose	O	O
of	O	O
pyridostigmine	O	O
(	O	O
Group	O	O
2	O	O
)	O	O
,	O	O
an	O	O
identical	O	O
intubating	O	O
dose	O	O
of	O	O
vecuronium	O	O
showed	O	O
relative	Physical	O
resistance	Physical	O
(	O	O
peak	O	O
effect-97	O	O
%	O	O
T1	O	O
suppression	O	O
)	O	O
and	O	O
delayed	Physical	O
onset	Physical	O
time	Physical	O
(	O	O
198	O	O
sec	O	O
approx.	O	O
)	O	O
.	O	O

However	O	O
,	O	O
the	O	O
reversal	O	O
was	O	O
complete	O	O
at	O	O
the	O	O
end	O	O
of	O	O
surgery	O	O
in	O	O
both	O	O
the	O	O
regimens	O	O
.	O	O

CONCLUSIONS	O	O
Omission	O	O
of	O	O
the	O	O
pyridostigmine	O	O
dose	O	O
on	O	O
the	O	O
day	O	O
of	O	O
surgery	O	O
predisposed	O	O
patients	O	O
with	O	O
myasthenia	O	O
gravis	O	O
to	O	O
the	O	O
possibility	O	O
of	O	O
respiratory	O	O
discomfort	O	O
and	O	O
sensitivity	O	O
to	O	O
vecuronium	O	O
.	O	O

Continued	O	O
administration	O	O
significantly	O	O
prolonged	O	O
the	O	O
onset	O	Physical
time	O	Physical
of	O	Physical
vecuronium	O	Physical
and	O	O
the	O	O
patients	O	O
required	O	O
a	O	O
higher	O	O
dose	O	O
of	O	O
vecuronium	O	O
.	O	O

Clinically	O	O
relevant	O	O
improvement	O	O
of	O	O
recurrence-free	Others	Physical
survival	Others	Physical
with	O	Physical
5-aminolevulinic	O	Physical
acid	O	Physical
induced	O	Physical
fluorescence	O	Physical
diagnosis	O	Physical
in	O	O
patients	O	O
with	O	O
superficial	O	O
bladder	O	O
tumors	O	O
.	O	O

PURPOSES	O	O
Fluorescence	O	O
diagnosis	O	O
induced	O	O
by	O	O
5-aminolevulinic	O	O
acid	O	O
enables	O	O
more	O	O
thorough	O	O
transurethral	O	O
resection	O	O
of	O	O
superficial	O	O
bladder	O	O
carcinoma	O	O
compared	O	O
with	O	O
conventional	O	O
white	O	O
light	O	O
.	O	O

We	O	O
performed	O	O
a	O	O
prospective	O	O
,	O	O
single	O	O
institution	O	O
,	O	O
randomized	O	O
trial	O	O
to	O	O
investigate	O	O
whether	O	O
the	O	O
residual	O	O
tumor	O	O
rate	O	O
and	O	O
long-term	O	O
tumor	O	O
recurrence	O	O
can	O	O
be	O	O
decreased	O	O
by	O	O
fluorescence	O	O
diagnosis	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
A	O	O
total	O	O
of	O	O
301	O	O
patients	O	O
underwent	O	O
transurethral	O	O
resection	O	O
of	O	O
bladder	O	O
tumors	O	O
with	O	O
white	O	O
light	O	O
or	O	O
fluorescence	O	O
diagnosis	O	O
.	O	O

Transurethral	O	O
resection	O	O
was	O	O
repeated	O	O
5	O	O
to	O	O
6	O	O
weeks	O	O
later	O	O
to	O	O
evaluate	O	O
the	O	O
residual	O	O
tumor	O	O
rate	O	O
.	O	O

To	O	O
determine	O	O
recurrence-free	Others	O
survival	Others	O
patient	O	O
followup	O	O
was	O	O
performed	O	O
every	O	O
3	O	O
months	O	O
by	O	O
white	O	O
light	O	O
cystoscopy	O	O
and	O	O
urine	O	O
cytology	O	O
.	O	O

Recurrence-free	Others	Mortality
survival	Others	Mortality
was	O	O
analyzed	O	O
via	O	O
Kaplan-Meier	O	O
methods	O	O
and	O	O
multivariable	O	O
Cox	O	O
regression	O	O
analysis	O	O
.	O	O

RESULTS	O	O
A	O	O
total	O	O
of	O	O
191	O	O
patients	O	O
with	O	O
superficial	O	O
bladder	O	O
carcinoma	O	O
were	O	O
available	O	O
for	O	O
efficacy	O	O
analysis	O	O
.	O	O

The	O	O
residual	Physical	O
tumor	Physical	O
rate	Physical	O
was	O	O
25.2	O	O
%	O	O
in	O	O
the	O	O
white	O	O
light	O	O
arm	O	O
versus	O	O
4.5	O	O
%	O	O
in	O	O
the	O	O
fluorescence	O	O
diagnosis	O	O
arm	O	O
(	O	O
p	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

Median	O	O
followup	O	O
in	O	O
the	O	O
white	O	O
light	O	O
arm	O	O
in	O	O
103	O	O
cases	O	O
was	O	O
21.2	O	O
months	O	O
(	O	O
range	O	O
4	O	O
to	O	O
40	O	O
)	O	O
compared	O	O
with	O	O
20.5	O	O
(	O	O
range	O	O
3	O	O
to	O	O
40	O	O
)	O	O
in	O	O
the	O	O
88	O	O
in	O	O
the	O	O
fluorescence	O	O
diagnosis	O	O
arm	O	O
.	O	O

Recurrence-free	Others	Physical
survival	Others	Physical
in	O	O
the	O	O
fluorescence	O	O
diagnosis	O	O
group	O	O
was	O	O
89.6	O	O
%	O	O
after	O	O
12	O	O
and	O	O
24	O	O
months	O	O
compared	O	O
with	O	O
73.8	O	O
%	O	O
and	O	O
65.9	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
the	O	O
white	O	O
light	O	O
group	O	O
(	O	O
p	O	O
=	O	O
0.004	O	O
)	O	O
.	O	O

This	O	O
superiority	O	O
proved	O	O
to	O	O
be	O	O
independent	O	O
of	O	O
risk	O	O
group	O	O
.	O	O

The	O	O
adjusted	O	O
hazard	O	O
ratio	O	O
of	O	O
fluorescence	O	O
diagnosis	O	O
versus	O	O
white	O	O
light	O	O
transurethral	O	O
resection	O	O
was	O	O
0.33	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
0.16	O	O
to	O	O
0.67	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Fluorescence	O	O
diagnosis	O	O
is	O	O
significantly	O	O
superior	O	O
to	O	O
conventional	O	O
white	O	O
light	O	O
transurethral	O	O
resection	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
residual	Physical	O
tumor	Physical	O
rate	Physical	O
and	O	O
recurrence-free	Others	O
survival	Others	O
.	O	O

The	O	O
differences	O	O
in	O	O
recurrence-free	Others	Mortality
survival	Others	Mortality
imply	O	O
that	O	O
fluorescence	O	O
diagnosis	O	O
is	O	O
a	O	O
clinically	O	O
relevant	O	O
procedure	O	O
for	O	O
decreasing	O	O
the	O	O
number	Physical	Others
of	Physical	Others
tumor	Physical	Others
recurrences	Physical	Others
.	Others	O

Shorter	O	O
treatment	O	O
for	O	O
vaginal	O	O
candidosis	O	O
:	O	O
comparison	O	O
between	O	O
single-dose	O	O
oral	O	O
fluconazole	O	O
and	O	O
three-day	O	O
treatment	O	O
with	O	O
local	O	O
miconazole	O	O
.	O	O

Fluconazole	O	O
is	O	O
an	O	O
effective	O	O
,	O	O
simple	O	O
and	O	O
safe	O	O
,	O	O
although	O	O
slightly	O	O
expensive	O	O
,	O	O
agent	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
vaginal	O	O
candidosis	O	O
.	O	O

Single-dose	O	O
fluconazole	O	O
(	O	O
150	O	O
mg	O	O
)	O	O
administered	O	O
orally	O	O
in	O	O
capsule	O	O
form	O	O
was	O	O
compared	O	O
with	O	O
three-day	O	O
local	O	O
treatment	O	O
with	O	O
miconazole	O	O
pessaries	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
vaginal	O	O
candidosis	O	O
in	O	O
a	O	O
randomized	O	O
study	O	O
in	O	O
Finland	O	O
.	O	O

Cure	Physical	Others
rates	Physical	Others
were	O	O
good	O	O
(	O	O
>	O	O
80	O	O
%	O	O
)	O	O
in	O	O
randomized	O	O
patient	O	O
groups	O	O
assessed	O	O
both	O	O
clinically	O	O
and	O	O
by	O	O
the	O	O
results	O	O
of	O	O
yeast	O	O
cultures	O	O
.	O	O

Oral	O	O
administration	O	O
was	O	O
preferred	O	O
to	O	O
local	O	O
therapy	O	O
by	O	O
patients	O	O
in	O	O
both	O	O
the	O	O
miconazole	O	O
and	O	O
fluconazole	O	O
groups	O	O
.	O	O

For	O	O
the	O	O
time	O	O
being	O	O
,	O	O
fluconazole	O	O
is	O	O
not	O	O
recommended	O	O
for	O	O
use	O	O
during	O	O
pregnancy	O	O
or	O	O
lactation	O	O
.	O	O

Long-term	O	O
exposure	O	O
to	O	O
belatacept	O	O
in	O	O
recipients	O	O
of	O	O
extended	O	O
criteria	O	O
donor	O	O
kidneys	O	O
.	O	O

Patients	O	O
in	O	O
the	O	O
BENEFIT-EXT	O	O
study	O	O
received	O	O
extended	O	O
criteria	O	O
donor	O	O
kidneys	O	O
and	O	O
a	O	O
more	O	O
intensive	O	O
(	O	O
MI	O	O
)	O	O
or	O	O
less	O	O
intensive	O	O
(	O	O
LI	O	O
)	O	O
belatacept	O	O
immunosuppression	O	O
regimen	O	O
,	O	O
or	O	O
cyclosporine	O	O
A	O	O
(	O	O
CsA	O	O
)	O	O
.	O	O

Patients	O	O
who	O	O
remained	O	O
on	O	O
assigned	O	O
therapy	O	O
through	O	O
year	O	O
3	O	O
were	O	O
eligible	O	O
to	O	O
enter	O	O
a	O	O
long-term	O	O
extension	O	O
(	O	O
LTE	O	O
)	O	O
study	O	O
.	O	O

Three	O	O
hundred	O	O
four	O	O
patients	O	O
entered	O	O
the	O	O
LTE	O	O
(	O	O
n	O	O
=	O	O
104	O	O
MI	O	O
;	O	O
n	O	O
=	O	O
113	O	O
LI	O	O
;	O	O
n	O	O
=	O	O
87	O	O
CsA	O	O
)	O	O
,	O	O
and	O	O
260	O	O
continued	O	O
treatment	O	O
through	O	O
year	O	O
5	O	O
(	O	O
n	O	O
=	O	O
91	O	O
MI	O	O
;	O	O
n	O	O
=	O	O
100	O	O
LI	O	O
;	O	O
n	O	O
=	O	O
69	O	O
CsA	O	O
)	O	O
.	O	O

Twenty	O	O
patients	O	O
died	Mortality	Mortality
during	O	O
the	O	O
LTE	O	O
(	O	O
n	O	O
=	O	O
5	O	O
MI	O	O
;	O	O
n	O	O
=	O	O
9	O	O
LI	O	O
;	O	O
n	O	O
=	O	O
6	O	O
CsA	O	O
)	O	O
,	O	O
and	O	O
eight	O	O
experienced	O	O
graft	Adverseeffect	Adverseeffect
loss	Adverseeffect	Adverseeffect
(	O	O
n	O	O
=	O	O
2	O	O
MI	O	O
;	O	O
n	O	O
=	O	O
1	O	O
LI	O	O
;	O	O
n	O	O
=	O	O
5	O	O
CsA	O	O
)	O	O
.	O	O

Three	O	O
patients	O	O
experienced	O	O
an	O	O
acute	Adverseeffect	O
rejection	Adverseeffect	O
episode	O	O
(	O	O
n	O	O
=	O	O
2	O	O
MI	O	O
;	O	O
n	O	O
=	O	O
1	O	O
LI	O	O
)	O	O
.	O	O

The	O	O
incidence	O	Adverseeffect
rate	O	Adverseeffect
of	O	Adverseeffect
serious	Adverseeffect	Adverseeffect
adverse	Adverseeffect	Adverseeffect
events	Adverseeffect	Adverseeffect
,	O	Adverseeffect
viral	Adverseeffect	Adverseeffect
infections	O	Adverseeffect
and	O	O
fungal	Adverseeffect	Physical
infections	Adverseeffect	Physical
was	O	O
similar	O	O
across	O	O
groups	O	O
during	O	O
the	O	O
LTE	O	O
.	O	O

There	O	O
were	O	O
four	O	O
cases	O	O
of	O	O
posttransplant	Adverseeffect	O
lymphoproliferative	O	O
disorder	Adverseeffect	O
(	Adverseeffect	O
PTLD	O	O
)	O	O
from	O	O
the	O	O
beginning	O	O
of	O	O
the	O	O
LTE	O	O
to	O	O
year	O	O
5	O	O
(	O	O
n	O	O
=	O	O
3	O	O
LI	O	O
;	O	O
n	O	O
=	O	O
1	O	O
CsA	O	O
)	O	O
;	O	O
two	O	O
of	O	O
three	O	O
PTLD	O	O
cases	O	O
in	O	O
the	O	O
LI	O	O
group	O	O
were	O	O
in	O	O
patients	O	O
who	O	O
were	O	O
seronegative	O	O
for	O	O
Epstein-Barr	O	O
virus	O	O
(	O	O
EBV	O	O
(	O	O
-	O	O
)	O	O
)	O	O
at	O	O
transplantation	O	O
.	O	O

Mean	O	O
?	O	O
SD	O	O
calculated	O	O
GFR	O	O
at	O	O
year	O	O
5	O	O
was	O	O
55.9	O	O
?	O	O
17.5	O	O
(	O	O
MI	O	O
)	O	O
,	O	O
59.0	O	O
?	O	O
29.1	O	O
(	O	O
LI	O	O
)	O	O
and	O	O
44.6	O	O
?	O	O
16.4	O	O
(	O	O
CsA	O	O
)	O	O
mL/min/1.73	O	O
m	O	O
(	O	O
2	O	O
)	O	O
.	O	O

Continued	O	O
treatment	O	O
with	O	O
belatacept	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
consistent	O	O
safety	O	O
profile	O	O
and	O	O
sustained	O	O
improvement	O	O
in	O	O
renal	O	O
function	O	O
versus	O	O
CsA	O	O
over	O	O
time	O	O
.	O	O

Comparative	O	O
drug	O	O
effects	O	O
and	O	O
abuse	O	O
liability	O	O
of	O	O
lorazepam	O	O
,	O	O
buspirone	O	O
,	O	O
and	O	O
secobarbital	O	O
in	O	O
nondependent	O	O
subjects	O	O
.	O	O

The	O	O
pharmacologic	O	O
effects	O	O
of	O	O
lorazepam	O	O
(	O	O
2	O	O
mg	O	O
)	O	O
,	O	O
buspirone	O	O
(	O	O
20	O	O
mg	O	O
,	O	O
10	O	O
mg	O	O
)	O	O
,	O	O
secobarbital	O	O
(	O	O
100	O	O
mg	O	O
)	O	O
,	O	O
and	O	O
placebo	O	O
were	O	O
compared	O	O
in	O	O
15	O	O
male	O	O
,	O	O
experienced	O	O
,	O	O
intermittent	O	O
nontherapeutic	O	O
drug	O	O
users	O	O
.	O	O

All	O	O
drugs	O	O
produced	O	O
a	O	O
drug	O	O
effect	O	O
,	O	O
however	O	O
,	O	O
buspirone	O	O
20	O	O
mg	O	O
was	O	O
significantly	O	O
less	O	O
liked	O	O
than	O	O
were	O	O
lorazepam	O	O
,	O	O
secobarbital	O	O
,	O	O
or	O	O
buspirone	O	O
10	O	O
mg	O	O
(	O	O
p	O	O
less	O	O
than	O	O
.05	O	O
)	O	O
but	O	O
not	O	O
placebo	O	O
.	O	O

Lorazepam	O	O
was	O	O
liked	O	O
better	O	O
than	O	O
were	O	O
other	O	O
drugs	O	O
only	O	O
at	O	O
1	O	O
hour	O	O
and	O	O
only	O	O
compared	O	O
with	O	O
buspirone	O	O
20	O	O
and	O	O
placebo	O	O
.	O	O

Compared	O	O
with	O	O
other	O	O
drugs	O	O
,	O	O
lorazepam	O	O
drug	Others	O
effects	Others	O
were	O	O
greater	O	O
and	O	O
resulted	O	O
in	O	O
more	O	O
prolonged	Physical	O
impairment	Physical	O
of	O	O
a	O	O
motor	Physical	O
tracking	Physical	O
task	Physical	O
,	Physical	O
standing	Physical	O
steadiness	Physical	O
,	Mental	O
and	Mental	O
memory	Mental	O
.	Mental	O

Buspirone	O	O
20	O	O
mg	O	O
significantly	Mental	O
impaired	Mental	O
memory	Mental	O
at	O	O
1	O	O
hour	O	O
compared	O	O
with	O	O
placebo	O	O
.	O	O

Subjects	O	O
were	O	O
more	O	O
likely	O	O
to	O	O
identify	O	O
buspirone	O	O
as	O	O
unfamiliar	O	O
.	O	O

Because	O	O
buspirone	O	O
20	O	O
mg	O	O
was	O	O
less	O	O
liked	O	O
than	O	O
were	O	O
other	O	O
drugs	O	O
,	O	O
dose	O	O
escalation	O	O
as	O	O
part	O	O
of	O	O
drug	Mental	O
abuse	Mental	O
is	O	O
not	O	O
likely	O	O
to	O	O
occur	O	O
.	O	O

Lorazepam	O	O
also	O	O
was	O	O
not	O	O
particularly	O	O
liked	O	O
and	O	O
was	O	O
not	O	O
different	O	O
from	O	O
placebo	O	O
on	O	O
most	O	O
subjective	Others	O
abuse-relevant	Others	O
measures	Others	O
.	O	O

Lack	O	O
of	O	O
effect	Others	O
of	O	O
food	O	O
on	O	O
the	O	O
steady	Others	O
state	Others	O
pharmacokinetics	Others	O
of	Others	O
BMS-181101	Others	O
,	O	O
an	O	O
antidepressant	O	O
,	O	O
in	O	O
healthy	O	O
subjects	O	O
.	O	O

The	O	O
effect	Others	O
of	Others	O
food	Others	O
on	Others	O
the	Others	O
pharmacokinetics	Others	O
of	Others	O
BMS-181101	Others	O
,	O	O
a	O	O
new	O	O
anti-depressant	O	O
under	O	O
development	O	O
,	O	O
was	O	O
investigated	O	O
in	O	O
12	O	O
healthy	O	O
male	O	O
volunteers	O	O
at	O	O
steady	O	O
state	O	O
.	O	O

Each	O	O
subject	O	O
received	O	O
a	O	O
15	O	O
mg	O	O
oral	O	O
dose	O	O
of	O	O
BMS-181101	O	O
twice	O	O
a	O	O
day	O	O
(	O	O
q	O	O
12	O	O
h	O	O
)	O	O
for	O	O
11	O	O
days	O	O
and	O	O
a	O	O
morning	O	O
dose	O	O
of	O	O
BMS-181101	O	O
on	O	O
day	O	O
12	O	O
.	O	O

Six	O	O
subjects	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
BMS-181101	O	O
under	O	O
fasted	O	O
conditions	O	O
from	O	O
days	O	O
1	O	O
to	O	O
6	O	O
and	O	O
then	O	O
crossed	O	O
over	O	O
to	O	O
fed	O	O
conditions	O	O
from	O	O
days	O	O
7	O	O
to	O	O
12	O	O
.	O	O

The	O	O
other	O	O
six	O	O
subjects	O	O
received	O	O
the	O	O
reverse	O	O
conditions	O	O
,	O	O
fed	O	O
for	O	O
days	O	O
1-6	O	O
and	O	O
fasted	O	O
for	O	O
days	O	O
7-12	O	O
.	O	O

Serial	O	O
blood	O	O
samples	O	O
were	O	O
collected	O	O
up	O	O
to	O	O
12	O	O
h	O	O
on	O	O
days	O	O
6	O	O
and	O	O
12	O	O
following	O	O
the	O	O
administration	O	O
of	O	O
the	O	O
morning	O	O
dose	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
trough	O	O
blood	O	O
samples	O	O
were	O	O
collected	O	O
on	O	O
days	O	O
4	O	O
,	O	O
5	O	O
,	O	O
10	O	O
,	O	O
and	O	O
11	O	O
prior	O	O
to	O	O
the	O	O
morning	O	O
dose	O	O
.	O	O

Plasma	O	Physical
samples	O	Physical
were	O	O
analyzed	O	O
for	O	O
intact	Physical	O
BMS-181101	Physical	O
using	O	O
a	O	O
validated	O	O
high-performance	O	O
liquid	O	O
chromatography	O	O
method	O	O
with	O	O
an	O	O
electrochemical	O	O
detector	O	O
.	O	O

BMS-181101	O	O
was	O	O
well	O	O
tolerated	Others	O
both	O	O
with	O	O
and	O	O
without	O	O
ingestion	O	O
of	O	O
food	O	O
.	O	O

The	O	O
statistical	O	O
evaluation	O	O
of	O	O
the	O	O
Cmin	Others	O
values	Others	O
indicated	O	O
that	O	O
steady	Others	O
state	Others	O
of	O	O
BMS-181101	O	O
was	O	O
achieved	O	O
by	O	O
the	O	O
fourth	O	O
day	O	O
of	O	O
dosing	O	O
regardless	O	O
of	O	O
whether	O	O
the	O	O
subject	O	O
was	O	O
fasted	O	O
or	O	O
fed	O	O
.	O	O

When	O	O
BMS-181101	O	O
was	O	O
administered	O	O
with	O	O
food	O	O
,	O	O
Cmax	Others	O
was	Others	O
reduced	Others	O
by	O	O
about	O	O
25	O	O
%	O	O
and	O	O
tmax	Others	O
was	Others	O
prolonged	Others	O
by	O	O
1	O	O
h.	O	O
However	O	O
,	O	O
AUCtau	Others	O
,	Others	O
t1/2	Others	O
,	Others	O
and	Others	O
time	Others	O
to	Others	O
attain	Others	O
steady	Others	O
state	Others	O
of	Others	O
BMS-181101	Others	O
were	O	O
not	O	O
altered	O	O
by	O	O
ingestion	O	O
of	O	O
food	O	O
.	O	O

In	O	O
summary	O	O
,	O	O
BMS-181101	O	O
can	O	O
be	O	O
given	O	O
with	O	O
food	O	O
without	O	O
adversely	O	O
impacting	O	O
the	O	O
safety	Others	O
or	O	O
pharmacokinetic	Others	O
profiles	Others	O
of	O	O
the	O	O
drug	O	O
.	O	O

Warfarin	O	O
for	O	O
atrial	O	O
fibrillation	O	O
.	O	O

The	O	O
patient	O	O
's	O	O
perspective	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
determine	O	O
the	O	O
minimal	Others	O
clinically	Others	O
important	Others	O
difference	Others	O
(	Others	O
MCID	Others	O
)	Others	O
of	O	O
warfarin	O	O
therapy	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
nonvalvular	O	O
atrial	O	O
fibrillation	O	O
from	O	O
the	O	O
perspective	O	O
of	O	O
patients	O	O
using	O	O
2	O	O
different	O	O
elicitation	O	O
methods	O	O
.	O	O

DESIGN	O	O
All	O	O
patients	O	O
completed	O	O
2	O	O
face-to-face	O	O
interviews	O	O
,	O	O
which	O	O
were	O	O
2	O	O
weeks	O	O
apart	O	O
.	O	O

For	O	O
each	O	O
interview	O	O
,	O	O
they	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
1	O	O
of	O	O
2	O	O
elicitation	O	O
methods	O	O
:	O	O
ping-ponging	O	O
or	O	O
starting	O	O
at	O	O
the	O	O
known	O	O
efficacy	O	O
.	O	O

SETTING	O	O
The	O	O
practices	O	O
of	O	O
2	O	O
university-affiliated	O	O
family	O	O
medicine	O	O
centers	O	O
(	O	O
8	O	O
physicians	O	O
each	O	O
)	O	O
,	O	O
14	O	O
community-based	O	O
family	O	O
physicians	O	O
,	O	O
and	O	O
2	O	O
cardiologists	O	O
.	O	O

PATIENTS	O	O
Sixty-four	O	O
patients	O	O
with	O	O
nonvalvular	O	O
atrial	O	O
fibrillation	O	O
who	O	O
were	O	O
initiated	O	O
with	O	O
warfarin	O	O
therapy	O	O
at	O	O
least	O	O
3	O	O
months	O	O
before	O	O
the	O	O
study	O	O
.	O	O

INTERVENTION	O	O
During	O	O
each	O	O
interview	O	O
,	O	O
the	O	O
patients	O	O
'	O	O
MCIDs	O	O
were	O	O
determined	O	O
by	O	O
using	O	O
(	O	O
1	O	O
)	O	O
a	O	O
pictorial	Others	O
flip	Others	O
chart	Others	O
to	Others	O
describe	Others	O
atrial	Physical	O
fibrillation	Physical	O
;	O	O
the	O	O
consequences	Physical	O
of	Physical	O
a	Physical	O
minor	Physical	O
stroke	Physical	O
,	Physical	O
a	Physical	O
major	Physical	O
stroke	Physical	O
,	Physical	O
and	Physical	O
a	Physical	O
major	Physical	O
bleeding	Physical	O
episode	Physical	O
;	O	O
the	O	O
chance	Physical	O
of	Physical	O
stroke	Physical	O
if	Physical	O
not	Physical	O
taking	Physical	O
warfarin	Physical	O
;	O	O
the	O	O
chance	Physical	O
of	Physical	O
a	Physical	O
major	Physical	O
bleeding	Physical	O
episode	Physical	O
if	Physical	O
taking	Physical	O
warfarin	Physical	O
;	O	O
examples	O	Physical
of	O	Physical
the	O	Physical
inconvenience	Others	Physical
,	Others	O
minor	Physical	Adverseeffect
side	Physical	Adverseeffect
effects	Physical	Adverseeffect
,	Others	O
and	Others	O
costs	Others	O
of	Others	O
warfarin	Others	O
therapy	Others	O
;	O	O
and	O	O
then	O	O
(	O	O
2	O	O
)	O	O
1	O	O
of	O	O
the	O	O
2	O	O
elicitation	O	O
methods	O	O
to	O	O
determine	O	O
their	O	O
MCIDs	Others	O
(	Others	O
the	Others	O
smallest	Others	O
reduction	Others	O
in	Others	O
stroke	Others	O
risk	Others	O
at	Others	O
which	Others	O
the	Others	O
patients	Others	O
were	Others	O
willing	Others	O
to	Others	O
take	Others	O
warfarin	Others	O
)	Others	O
.	O	O

Patients	Mental	O
'	Mental	O
knowledge	Mental	O
of	Mental	O
their	Mental	O
stroke	Mental	O
risk	Mental	O
,	O	O
acceptability	Others	O
of	Others	O
the	Others	O
interview	Others	O
process	Others	O
,	O	O
and	O	O
factors	Others	O
determining	Others	O
their	Others	O
preferences	Others	O
were	O	O
also	O	O
assessed	O	O
.	O	O

MAIN	O	O
RESULTS	O	O
Given	O	O
a	O	O
baseline	O	O
risk	O	O
of	O	O
having	O	O
a	O	O
stroke	O	O
in	O	O
the	O	O
next	O	O
2	O	O
years	O	O
,	O	O
if	O	O
not	O	O
taking	O	O
warfarin	O	O
,	O	O
of	O	O
10	O	O
of	O	O
100	O	O
,	O	O
the	O	O
mean	O	O
MCID	Others	O
was	O	O
2.01	O	O
of	O	O
100	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
1.60-2.42	O	O
)	O	O
.	O	O

Fifty-two	O	O
percent	O	O
of	O	O
the	O	O
patients	O	O
would	O	O
take	O	O
warfarin	O	O
for	O	O
an	O	O
absolute	O	O
decrease	O	O
in	O	O
stroke	Physical	O
risk	Physical	O
of	O	O
1	O	O
%	O	O
over	O	O
2	O	O
years	O	O
.	O	O

Before	O	O
eliciting	O	O
their	O	O
MCIDs	O	O
,	O	O
patients	O	O
showed	O	O
poor	O	O
knowledge	Mental	O
of	Mental	O
their	Mental	O
stroke	Mental	O
risk	Mental	O
,	O	O
which	O	O
improved	O	O
afterward	O	O
.	O	O

The	O	O
interview	O	O
process	O	O
was	O	O
well	O	O
accepted	O	O
by	O	O
the	O	O
patients	O	O
.	O	O

The	O	O
MCID	Others	O
using	O	O
the	O	O
ping-ponging	O	O
elicitation	O	O
method	O	O
was	O	O
1.015	O	O
of	O	O
100	O	O
smaller	O	O
compared	O	O
with	O	O
use	O	O
of	O	O
the	O	O
starting	O	O
at	O	O
the	O	O
known	O	O
efficacy	O	O
method	O	O
(	O	O
P	O	O
=	O	O
.01	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
We	O	O
were	O	O
able	O	O
to	O	O
determine	O	O
the	O	O
MCID	Others	O
of	O	O
warfarin	O	O
therapy	O	O
for	O	O
the	O	O
prevention	O	O
of	O	O
stroke	O	O
from	O	O
the	O	O
perspective	O	O
of	O	O
patients	O	O
with	O	O
nonvalvular	O	O
atrial	O	O
fibrillation	O	O
.	O	O

Their	O	O
MCIDs	O	O
were	O	O
much	O	O
smaller	O	O
than	O	O
those	O	O
that	O	O
have	O	O
been	O	O
implied	O	O
by	O	O
some	O	O
experts	O	O
and	O	O
clinicians	O	O
.	O	O

The	O	O
interview	O	O
process	O	O
,	O	O
using	O	O
the	O	O
flip	O	O
chart	O	O
approach	O	O
,	O	O
appeared	O	O
to	O	O
improve	O	O
the	O	O
patients	Mental	O
'	Mental	O
knowledge	Mental	O
of	Mental	O
their	Mental	O
disease	Mental	O
and	Mental	O
its	Mental	O
consequences	Mental	O
and	Mental	O
treatment	Mental	O
.	O	O

The	O	O
method	O	O
used	O	O
to	O	O
elicit	O	O
the	O	O
patients	O	O
'	O	O
MCIDs	Others	O
can	O	O
have	O	O
a	O	O
clinically	O	O
important	O	O
effect	O	O
on	O	O
patient	O	O
responses	O	O
.	O	O

The	O	O
method	O	O
used	O	O
in	O	O
our	O	O
study	O	O
can	O	O
be	O	O
generalized	O	O
to	O	O
other	O	O
conditions	O	O
and	O	O
,	O	O
thus	O	O
,	O	O
could	O	O
be	O	O
helpful	O	O
in	O	O
3	O	O
ways	O	O
:	O	O
(	O	O
1	O	O
)	O	O
from	O	O
a	O	O
clinical	O	O
decision-making	O	O
perspective	O	O
,	O	O
it	O	O
could	O	O
facilitate	O	O
patient-physician	O	O
communication	O	O
;	O	O
(	O	O
2	O	O
)	O	O
it	O	O
could	O	O
clarify	O	O
the	O	O
patient	O	O
perspective	O	O
when	O	O
interpreting	O	O
the	O	O
results	O	O
of	O	O
previously	O	O
completed	O	O
trials	O	O
;	O	O
and	O	O
(	O	O
3	O	O
)	O	O
it	O	O
could	O	O
be	O	O
used	O	O
to	O	O
derive	O	O
more	O	O
clinically	O	O
relevant	O	O
sample	O	O
sizes	O	O
for	O	O
randomized	O	O
treatment	O	O
trials	O	O
.	O	O

Maternal	O	O
breast-milk	O	O
and	O	O
intestinal	O	O
bifidobacteria	O	O
guide	O	O
the	O	O
compositional	O	O
development	O	O
of	O	O
the	O	O
Bifidobacterium	O	O
microbiota	O	O
in	O	O
infants	O	O
at	O	O
risk	O	O
of	O	O
allergic	O	O
disease	O	O
.	O	O

BACKGROUND	O	O
The	O	O
sources	O	O
and	O	O
the	O	O
impact	O	O
of	O	O
maternal	O	O
bacteria	O	O
on	O	O
the	O	O
initial	O	O
inoculum	O	O
of	O	O
the	O	O
intestinal	O	O
microflora	O	O
of	O	O
newborn	O	O
infants	O	O
remain	O	O
elusive	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
assess	O	O
the	O	O
association	O	O
between	O	O
maternal	O	O
breast-milk	O	O
and	O	O
fecal	O	O
bifidobacteria	O	O
and	O	O
infants	O	O
'	O	O
fecal	O	O
bifidobacteria	O	O
.	O	O

METHODS	O	O
Sixty-one	O	O
mother-infant	O	O
pairs	O	O
were	O	O
included	O	O
,	O	O
special	O	O
emphasis	O	O
being	O	O
placed	O	O
on	O	O
the	O	O
maternal	O	O
allergic	O	O
status	O	O
.	O	O

Bifidobacteria	Physical	O
were	O	O
analysed	O	O
by	O	O
a	O	O
direct	O	O
PCR	O	O
method	O	O
in	O	O
fecal	O	O
samples	O	O
from	O	O
mothers	O	O
at	O	O
30-35	O	O
weeks	O	O
of	O	O
gestation	O	O
and	O	O
from	O	O
infants	O	O
at	O	O
1	O	O
month	O	O
of	O	O
age	O	O
and	O	O
from	O	O
breast-milk	O	O
samples	O	O
1	O	O
month	O	O
post-partum	O	O
.	O	O

RESULTS	O	O
Fecal	O	O
Bifidobacterium	O	O
adolescentis	O	O
and	O	O
Bifidobacterium	O	O
bifidum	O	O
colonization	O	O
frequencies	O	O
and	O	O
counts	O	O
among	O	O
mother-infant	O	O
pairs	O	O
correlated	O	O
significantly	O	O
(	O	O
P=0.005	O	O
and	O	O
0.02	O	O
for	O	O
frequencies	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
P=0.002	O	O
and	O	O
0.01	O	O
for	O	O
counts	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Only	O	O
infants	O	O
of	O	O
allergic	O	O
,	O	O
atopic	O	O
mothers	O	O
were	O	O
colonized	O	O
with	O	O
B.	O	O
adolescentis	O	O
.	O	O

Each	O	O
of	O	O
the	O	O
breast-milk	O	O
samples	O	O
contained	O	O
bifidobacteria	O	O
[	O	O
median	O	O
1.4	O	O
x	O	O
10	O	O
(	O	O
3	O	O
)	O	O
bacterial	O	O
cells/mL	O	O
;	O	O
interquartile	O	O
range	O	O
(	O	O
IQR	O	O
)	O	O
48.7-3.8	O	O
x	O	O
10	O	O
(	O	O
3	O	O
)	O	O
]	O	O
.	O	O

Bifidobacterium	Physical	O
longum	Physical	O
was	O	O
the	O	O
most	O	O
frequently	O	O
detected	O	O
species	O	O
in	O	O
breast-milk	O	O
.	O	O

Allergic	O	O
mothers	O	O
had	O	O
significantly	O	O
lower	O	O
amounts	O	O
of	O	O
bifidobacteria	Physical	O
in	O	O
breast-milk	O	O
compared	O	O
with	O	O
non-allergic	O	O
mothers	O	O
[	O	O
median	O	O
1.3	O	O
x	O	O
10	O	O
(	O	O
3	O	O
)	O	O
bacterial	O	O
cells/mL	O	O
(	O	O
IQR	O	O
22.4-3.0	O	O
x	O	O
10	O	O
(	O	O
3	O	O
)	O	O
)	O	O
vs.	O	O
5.6	O	O
x	O	O
10	O	O
(	O	O
3	O	O
)	O	O
bacterial	O	O
cells/mL	O	O
(	O	O
1.8	O	O
x	O	O
10	O	O
(	O	O
3	O	O
)	O	O
-1.8	O	O
x	O	O
10	O	O
(	O	O
4	O	O
)	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
(	O	O
P=0.004	O	O
)	O	O
]	O	O
,	O	O
and	O	O
their	O	O
infants	O	O
had	O	O
concurrently	O	O
lower	O	O
counts	O	O
of	O	O
bifidobacteria	Physical	O
in	O	O
feces	O	O
[	O	O
3.9	O	O
x	O	O
10	O	O
(	O	O
8	O	O
)	O	O
bacterial	O	O
cells/g	O	O
(	O	O
IQR	O	O
6.5	O	O
x	O	O
10	O	O
(	O	O
6	O	O
)	O	O
-1.5	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
)	O	O
in	O	O
infants	O	O
of	O	O
allergic	O	O
mothers	O	O
,	O	O
vs.	O	O
2.5	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
bacterial	O	O
cells/g	O	O
(	O	O
6.5	O	O
x	O	O
10	O	O
(	O	O
8	O	O
)	O	O
-3.2	O	O
x	O	O
10	O	O
(	O	O
10	O	O
)	O	O
)	O	O
in	O	O
infants	O	O
of	O	O
non-allergic	O	O
mothers	O	O
,	O	O
P=0.013	O	O
]	O	O
.	O	O

CONCLUSIONS	O	O
Breast-milk	O	O
contains	O	O
significant	O	O
numbers	O	O
of	O	O
bifidobacteria	O	O
and	O	O
the	O	O
maternal	O	O
allergic	O	O
status	O	O
further	O	O
deranges	O	O
the	O	O
counts	O	O
of	O	O
bifidobacteria	O	O
in	O	O
breast-milk	O	O
.	O	O

Maternal	O	O
fecal	O	O
and	O	O
breast-milk	O	O
bifidobacterial	O	O
counts	O	O
impacted	O	O
on	O	O
the	O	O
infants	O	O
'	O	O
fecal	O	O
Bifidobacterium	O	O
levels	O	O
.	O	O

Breast-milk	O	O
bacteria	O	O
should	O	O
thus	O	O
be	O	O
considered	O	O
an	O	O
important	O	O
source	O	O
of	O	O
bacteria	O	O
in	O	O
the	O	O
establishment	O	O
of	O	O
infantile	O	O
intestinal	O	O
microbiota	O	O
.	O	O

Sex	Mental	O
risk	Mental	O
behavior	Mental	O
among	O	O
adolescent	O	O
and	O	O
young	O	O
adult	O	O
children	O	O
of	O	O
opiate	O	O
addicts	O	O
:	O	O
outcomes	O	O
from	O	O
the	O	O
focus	O	O
on	O	O
families	O	O
prevention	O	O
trial	O	O
and	O	O
an	O	O
examination	O	O
of	O	O
childhood	O	O
and	O	O
concurrent	O	O
predictors	O	O
of	O	O
sex	O	O
risk	O	O
behavior	O	O
.	O	O

This	O	O
study	O	O
reports	O	O
on	O	O
rates	Mental	O
and	Mental	O
predictors	Mental	O
of	Mental	O
sex	Mental	O
risk	Mental	O
behavior	Mental	O
among	O	O
a	O	O
sample	O	O
of	O	O
adolescent	O	O
and	O	O
young	O	O
adult	O	O
children	O	O
of	O	O
parents	O	O
enrolled	O	O
in	O	O
methadone	O	O
treatment	O	O
for	O	O
opiate	O	O
addiction	O	O
.	O	O

Data	O	O
are	O	O
from	O	O
151	O	O
participants	O	O
(	O	O
80	O	O
males	O	O
,	O	O
71	O	O
females	O	O
)	O	O
in	O	O
the	O	O
Focus	O	O
on	O	O
Families	O	O
(	O	O
FOF	O	O
)	O	O
project	O	O
,	O	O
a	O	O
randomized	O	O
trial	O	O
of	O	O
a	O	O
family	O	O
intervention	O	O
and	O	O
a	O	O
study	O	O
of	O	O
the	O	O
development	O	O
of	O	O
at-risk	O	O
children	O	O
.	O	O

The	O	O
study	O	O
participants	O	O
are	O	O
children	O	O
of	O	O
parents	O	O
enrolled	O	O
in	O	O
methadone	O	O
treatment	O	O
between	O	O
1990	O	O
and	O	O
1993	O	O
.	O	O

Participants	O	O
were	O	O
interviewed	O	O
in	O	O
2005	O	O
when	O	O
they	O	O
ranged	O	O
in	O	O
age	O	O
from	O	O
15	O	O
to	O	O
29	O	O
years	O	O
.	O	O

In	O	O
the	O	O
year	O	O
prior	O	O
to	O	O
the	O	O
follow-up	O	O
,	O	O
79	O	O
%	O	O
of	O	O
the	O	O
males	O	O
and	O	O
83	O	O
%	O	O
of	O	O
females	O	O
were	O	O
sexually	O	O
active	O	O
,	O	O
26	O	O
%	O	O
of	O	O
males	O	O
and	O	O
10	O	O
%	O	O
of	O	O
females	O	O
had	O	O
more	O	O
than	O	O
one	O	O
partner	O	O
in	O	O
the	O	O
prior	O	O
year	O	O
,	O	O
and	O	O
34	O	O
%	O	O
of	O	O
males	O	O
and	O	O
24	O	O
%	O	O
of	O	O
females	O	O
reported	O	O
having	O	O
sex	O	O
outside	O	O
of	O	O
a	O	O
committed	O	O
relationship	O	O
.	O	O

Twenty-four	O	O
percent	O	O
of	O	O
males	O	O
and	O	O
17	O	O
%	O	O
of	O	O
females	O	O
met	O	O
criteria	O	O
for	O	O
high-risk	Mental	O
sexual	Mental	O
behavior	Mental	O
,	O	O
reporting	O	O
casual	O	O
or	O	O
multiple	O	O
partners	O	O
in	O	O
the	O	O
prior	O	O
year	O	O
and	O	O
inconsistent	O	O
condom	O	O
use	O	O
.	O	O

Participants	O	O
in	O	O
the	O	O
intervention	O	O
and	O	O
control	O	O
conditions	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
in	O	O
terms	O	O
of	O	O
any	O	O
measure	O	O
of	O	O
sex	Mental	O
risk	Mental	O
behavior	Mental	O
examined	O	O
.	O	O

None	O	O
of	O	O
the	O	O
measures	O	O
of	O	O
parent	O	Mental
behavior	O	Mental
and	O	O
family	O	O
processes	O	O
derived	O	O
from	O	O
data	O	O
at	O	O
baseline	O	O
of	O	O
the	O	O
FOF	O	O
study	O	O
predicted	O	O
whether	O	O
participants	O	O
engaged	O	O
in	O	O
high-risk	Mental	O
sex	Mental	O
.	Mental	O

Among	O	O
measures	O	O
derived	O	O
from	O	O
data	O	O
collected	O	O
at	O	O
long-term	O	O
follow-up	O	O
,	O	O
however	O	O
,	O	O
having	O	O
ever	O	O
met	O	O
criteria	O	O
for	O	O
substance	O	O
abuse	O	O
or	O	O
dependence	O	O
predicted	O	O
greater	O	O
likelihood	O	O
of	O	O
high-risk	Mental	Physical
sexual	Mental	Physical
behavior	Mental	Physical
,	O	O
and	O	O
being	O	O
married	O	O
or	O	O
being	O	O
in	O	O
a	O	O
romantic	O	O
relationship	O	O
was	O	O
associated	O	O
with	O	O
lower	O	O
likelihood	O	O
of	O	O
high-risk	Mental	O
sexual	Mental	O
behavior	Mental	O
.	Mental	O

The	O	O
findings	O	O
point	O	O
to	O	O
the	O	O
important	O	O
role	O	O
of	O	O
committed	O	O
relationships	O	O
in	O	O
regulating	O	Mental
sex	Mental	Mental
risk	Mental	Mental
behavior	Mental	Mental
among	O	O
this	O	O
population	O	O
,	O	O
as	O	O
well	O	O
as	O	O
heightened	O	Mental
levels	O	Mental
of	O	Mental
sex	Mental	Mental
risk	Mental	Mental
behavior	Mental	Mental
associated	O	O
with	O	O
substance	O	O
abuse	O	O
or	O	O
dependence	O	O
.	O	O

LNH-84	O	O
regimen	O	O
:	O	O
a	O	O
multicenter	O	O
study	O	O
of	O	O
intensive	O	O
chemotherapy	O	O
in	O	O
737	O	O
patients	O	O
with	O	O
aggressive	O	O
malignant	O	O
lymphoma	O	O
.	O	O

From	O	O
July	O	O
1984	O	O
to	O	O
September	O	O
1987	O	O
,	O	O
737	O	O
patients	O	O
with	O	O
aggressive	O	O
malignant	O	O
lymphoma	O	O
(	O	O
ML	O	O
)	O	O
were	O	O
treated	O	O
by	O	O
an	O	O
intensive	O	O
regimen	O	O
(	O	O
LNH-84	O	O
)	O	O
comprising	O	O
three	O	O
or	O	O
four	O	O
courses	O	O
of	O	O
doxorubicin	O	O
,	O	O
75	O	O
mg/m2	O	O
;	O	O
cyclophosphamide	O	O
,	O	O
1,200	O	O
mg/m2	O	O
;	O	O
vindesine	O	O
,	O	O
2	O	O
mg/m2	O	O
x	O	O
2	O	O
;	O	O
bleomycin	O	O
,	O	O
10	O	O
mg	O	O
x	O	O
2	O	O
;	O	O
and	O	O
prednisolone	O	O
,	O	O
60	O	O
mg/m2	O	O
x	O	O
5	O	O
(	O	O
ACVB	O	O
)	O	O
,	O	O
consolidation	O	O
with	O	O
high-dose	O	O
methotrexate	O	O
,	O	O
ifosfamide	O	O
,	O	O
etoposide	O	O
,	O	O
asparaginase	O	O
,	O	O
and	O	O
cytarabine	O	O
,	O	O
and	O	O
a	O	O
randomized	O	O
late	O	O
intensification	O	O
with	O	O
two	O	O
courses	O	O
of	O	O
cytarabine	O	O
,	O	O
cyclophosphamide	O	O
,	O	O
teniposide	O	O
,	O	O
bleomycin	O	O
,	O	O
and	O	O
prednisone	O	O
(	O	O
AraCVmB	O	O
)	O	O
.	O	O

Four	O	O
hundred	O	O
forty-two	O	O
patients	O	O
had	O	O
intermediate-grade	O	O
ML	O	O
,	O	O
221	O	O
highgrade	O	O
ML	O	O
,	O	O
and	O	O
74	O	O
unclassified	O	O
ML	O	O
.	O	O

Most	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
advanced	O	O
disease	O	O
:	O	O
stage	O	O
IIE	O	O
(	O	O
23	O	O
%	O	O
)	O	O
,	O	O
III	O	O
(	O	O
13	O	O
%	O	O
)	O	O
,	O	O
or	O	O
IV	O	O
(	O	O
47	O	O
%	O	O
)	O	O
;	O	O
38	O	O
%	O	O
disseminated	O	O
nodes	O	O
;	O	O
38	O	O
%	O	O
two	O	O
or	O	O
more	O	O
extranodal	O	O
sites	O	O
;	O	O
and	O	O
41	O	O
%	O	O
a	O	O
tumoral	O	O
mass	O	O
greater	O	O
than	O	O
10	O	O
cm	O	O
.	O	O

Five	O	O
hundred	O	O
fifty-three	O	O
patients	O	O
(	O	O
75	O	O
%	O	O
)	O	O
went	O	O
into	O	O
complete	Physical	O
remission	Physical	O
(	Physical	O
CR	Physical	O
)	Physical	O
,	O	O
63	O	O
(	O	O
9	O	O
%	O	O
)	O	O
into	O	O
partial	Physical	O
remission	Physical	O
,	O	O
62	O	O
(	O	O
8	O	O
%	O	O
)	O	O
failed	Physical	O
to	Physical	O
respond	Physical	O
,	O	O
and	O	O
59	O	O
(	O	O
8	O	O
%	O	O
)	O	O
died	Mortality	O
during	O	O
ACVB	O	O
courses	O	O
,	O	O
17	O	O
of	O	O
them	O	O
from	O	O
progression	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

With	O	O
a	O	O
median	O	O
follow-up	O	O
of	O	O
23	O	O
months	O	O
,	O	O
the	O	O
estimated	O	Mortality
2-year	O	Mortality
overall	Physical	Mortality
survival	Physical	Mortality
time	Physical	Others
to	Physical	Others
failure	Physical	Others
(	Physical	Others
TTF	Physical	Others
)	Physical	Others
,	O	O
and	O	O
time	Physical	Others
to	Physical	Others
relapse	Physical	Others
(	Physical	Others
TTR	Physical	Others
)	Physical	Others
survival	Physical	O
are	O	O
67	O	O
%	O	O
,	O	O
56	O	O
%	O	O
,	O	O
and	O	O
67	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

Patients	O	O
receiving	O	O
a	O	O
late	O	O
intensification	O	O
had	O	O
the	O	O
same	O	O
relapse	Physical	Physical
rate	Physical	Physical
as	O	O
the	O	O
other	O	O
patients	O	O
.	O	O

A	O	O
persistent	Physical	O
fibronecrotic	Physical	O
mass	Physical	O
was	O	O
found	O	O
in	O	O
150	O	O
patients	O	O
(	O	O
20	O	O
%	O	O
)	O	O
and	O	O
did	O	O
not	O	O
influence	O	O
the	O	O
relapse	Physical	O
rate	Physical	O
.	Others	O

Toxicity	Adverseeffect	Adverseeffect
was	O	Adverseeffect
mainly	O	Adverseeffect
neutropenia	Adverseeffect	Adverseeffect
and	O	O
infection	Physical	O
during	O	O
the	O	O
ACVB	O	O
courses	O	O
,	O	O
with	O	O
40	O	O
patients	O	O
(	O	O
5	O	O
%	O	O
)	O	O
dying	Mortality	O
from	Mortality	O
septic	Mortality	O
complications	Mortality	O
while	O	O
responding	O	O
to	O	O
treatment	O	O
.	O	O

Fifty-three	O	O
percent	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
a	O	O
neutropenia	Adverseeffect	O
less	O	O
than	O	O
0.500	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
/L	O	O
,	O	O
58	O	O
%	O	O
fever	O	O
(	O	O
6	O	O
%	O	O
grade	O	O
4	O	O
)	O	O
,	O	O
and	O	O
49	O	O
%	O	O
a	O	O
documented	Adverseeffect	Physical
infection	Adverseeffect	Physical
(	O	O
8	O	O
%	O	O
grade	O	O
4	O	O
)	O	O
.	O	O

These	O	O
results	O	O
obtained	O	O
with	O	O
the	O	O
LNH-84	O	O
regimen	O	O
demonstrate	O	O
that	O	O
this	O	O
therapeutic	O	O
scheme	O	O
is	O	O
an	O	O
effective	O	O
treatment	O	O
for	O	O
aggressive	O	O
ML	O	O
.	O	O

Coagulation	O	O
factor	O	O
concentrate	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
the	O	O
haemorrhagic	Physical	O
diathesis	Physical	O
of	O	O
fulminant	O	O
hepatic	O	O
failure	O	O
.	O	O

To	O	O
assess	O	O
the	O	O
value	O	O
of	O	O
clotting	O	O
factor	O	O
concentrate	O	O
infusions	O	O
in	O	O
fulminant	O	O
hepatic	Physical	O
failure	Physical	O
,	O	O
a	O	O
controlled	O	O
trial	O	O
was	O	O
performed	O	O
in	O	O
which	O	O
nine	O	O
patients	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
treatment	O	O
with	O	O
either	O	O
concentrate	O	O
alone	O	O
or	O	O
concentrate	O	O
plus	O	O
heparin	O	O
.	O	O

The	O	O
five	O	O
patients	O	O
receiving	O	O
concentrate	O	O
alone	O	O
all	O	O
died	Mortality	Mortality
,	O	O
with	O	O
major	Adverseeffect	O
bleeding	Adverseeffect	O
as	O	O
the	O	O
direct	O	O
cause	O	O
of	O	O
death	O	O
in	O	O
three	O	O
,	O	O
whereas	O	O
in	O	O
the	O	O
four	O	O
receiving	O	O
heparin	O	O
as	O	O
well	O	O
there	O	O
was	O	O
only	O	O
one	O	O
instance	O	O
of	O	O
bleeding	Adverseeffect	O
and	O	O
one	O	O
patient	O	O
survived	Mortality	O
.	Physical	O

Clinical	O	O
evidence	O	O
of	O	O
intravascular	Physical	O
coagulation	Physical	O
appeared	O	O
in	O	O
two	O	O
patients	O	O
treated	O	O
with	O	O
concentrate	O	O
alone	O	O
and	O	O
the	O	O
laboratory	O	O
evidence	O	O
of	O	O
this	O	O
progressed	O	O
during	O	O
the	O	O
period	O	O
of	O	O
infusions	O	O
in	O	O
all	O	O
patients	O	O
in	O	O
both	O	O
treatment	O	O
groups	O	O
,	O	O
although	O	O
to	O	O
a	O	O
lesser	O	O
extent	O	O
in	O	O
those	O	O
receiving	O	O
heparin	O	O
.	O	O

Additional	O	O
evidence	O	O
for	O	O
intravascular	O	O
coagulation	O	O
came	O	O
from	O	O
the	O	O
changes	O	O
observed	O	O
in	O	O
factor	Physical	O
VIII	Physical	O
levels	Physical	O
which	O	O
,	O	O
although	O	O
initially	O	O
high	O	O
in	O	O
all	O	O
patients	O	O
,	O	O
fell	O	O
subsequently	O	O
,	O	O
particularly	O	O
in	O	O
those	O	O
given	O	O
concentrate	O	O
alone	O	O
.	O	O

There	O	O
was	O	O
some	O	O
improvement	O	O
in	O	O
the	O	O
prothrombin	Physical	Physical
ratio	Physical	Physical
in	O	O
both	O	O
groups	O	O
of	O	O
patients	O	O
but	O	O
not	O	O
complete	O	O
correction	O	O
,	O	O
and	O	O
serial	O	O
assays	O	O
of	O	O
clotting	O	O
factors	O	O
showed	O	O
that	O	O
although	O	O
factor	Physical	O
II	Physical	O
rose	O	O
to	O	O
high	O	O
levels	O	O
during	O	O
treatment	O	O
,	O	O
factors	Physical	O
IX	Physical	O
and	Physical	O
X	Physical	O
showed	O	O
little	O	O
response	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
use	O	O
of	O	O
concentrate	O	O
of	O	O
factor	Physical	O
IX	Physical	O
in	O	O
this	O	O
trial	O	O
,	O	O
as	O	O
well	O	O
as	O	O
potentiating	O	O
intravascular	Physical	O
coagulation	Physical	O
,	O	O
was	O	O
inadequate	O	O
as	O	O
replacement	O	O
for	O	O
the	O	O
clotting	O	O
factor	O	O
deficiencies	O	O
.	O	O

Immunologic	Physical	O
response	Physical	O
after	O	O
laparoscopic	O	O
colon	O	O
cancer	O	O
operation	O	O
within	O	O
an	O	O
enhanced	O	O
recovery	O	O
program	O	O
.	O	O

OBJECTIVE	O	O
It	O	O
has	O	O
been	O	O
demonstrated	O	O
that	O	O
colon	O	O
operation	O	O
combined	O	O
with	O	O
fast-track	O	O
(	O	O
FT	O	O
)	O	O
surgery	O	O
and	O	O
laparoscopic	O	O
technique	O	O
can	O	O
shorten	O	O
the	O	O
length	Physical	Others
of	Physical	Others
hospital	Physical	Others
stay	Physical	Others
,	Physical	O
accelerate	Physical	O
recovery	Physical	O
of	Physical	O
intestinal	Physical	O
function	Physical	O
,	O	O
and	O	O
reduce	O	Physical
the	O	Physical
occurrence	Physical	Physical
of	Physical	Physical
post-operative	Physical	Physical
complications	Physical	Physical
.	O	O

However	O	O
,	O	O
there	O	O
are	O	O
no	O	O
reports	O	O
regarding	O	O
the	O	O
combined	O	O
effects	O	O
of	O	O
FT	O	O
colon	O	O
operation	O	O
and	O	O
laparoscopic	O	O
technique	O	O
on	O	O
humoral	Physical	O
inflammatory	Physical	O
cellular	Physical	O
immunity	Physical	O
.	Physical	O

METHODS	O	O
This	O	O
was	O	O
a	O	O
prospective	O	O
,	O	O
controlled	O	O
study	O	O
.	O	O

One	O	O
hundred	O	O
sixty-three	O	O
colon	O	O
cancer	O	O
patients	O	O
underwent	O	O
the	O	O
traditional	O	O
protocol	O	O
and	O	O
open	O	O
operation	O	O
(	O	O
traditional	O	O
open	O	O
group	O	O
,	O	O
n=42	O	O
)	O	O
,	O	O
the	O	O
traditional	O	O
protocol	O	O
and	O	O
laparoscopic	O	O
operation	O	O
(	O	O
traditional	O	O
laparoscopic	O	O
group	O	O
,	O	O
n=40	O	O
)	O	O
,	O	O
the	O	O
FT	O	O
protocol	O	O
and	O	O
open	O	O
operation	O	O
(	O	O
FT	O	O
open	O	O
group	O	O
,	O	O
n=41	O	O
)	O	O
,	O	O
or	O	O
the	O	O
FT	O	O
protocol	O	O
and	O	O
laparoscopic	O	O
operation	O	O
(	O	O
FT	O	O
laparoscopic	O	O
group	O	O
,	O	O
n=40	O	O
)	O	O
.	O	O

Blood	O	O
samples	O	O
were	O	O
taken	O	O
prior	O	O
to	O	O
operation	O	O
as	O	O
well	O	O
as	O	O
on	O	O
days	O	O
1	O	O
,	O	O
3	O	O
,	O	O
and	O	O
5	O	O
after	O	O
operation	O	O
.	O	O

The	O	O
number	Physical	Physical
of	Physical	Physical
lymphocyte	Physical	Physical
subpopulations	Physical	Physical
was	O	O
determined	O	O
by	O	O
flow	O	O
cytometry	O	O
,	O	O
and	O	O
serum	Physical	O
interleukin-6	Physical	O
and	Physical	O
C-reactive	Physical	Physical
protein	Physical	Physical
levels	Physical	Physical
were	O	O
measured	O	O
.	O	O

Post-operative	Others	Physical
hospital	Others	Physical
stay	Others	Physical
,	O	Physical
post-operative	Physical	Physical
morbidity	Physical	Physical
,	O	Physical
readmission	Others	Physical
rate	Others	Physical
,	O	O
and	O	O
in-hospital	Mortality	Mortality
mortality	Mortality	Mortality
were	O	O
recorded	O	O
.	O	O

RESULTS	O	O
Compared	O	O
with	O	O
open	O	O
operation	O	O
,	O	O
laparoscopic	O	O
colon	O	O
operation	O	O
effectively	O	O
inhibited	O	O
the	O	O
release	O	O
of	O	O
post-operative	Physical	O
inflammatory	Physical	O
factors	Physical	O
and	O	O
yielded	O	O
good	O	O
protection	O	O
via	O	O
post-operative	O	O
cell	O	O
immunity	O	O
.	O	O

FT	O	O
surgery	O	O
had	O	O
a	O	O
better	O	O
protective	O	O
role	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
post-operative	O	O
immune	O	O
system	O	O
compared	O	O
with	O	O
traditional	O	O
peri-operative	O	O
care	O	O
.	O	O

Inflammatory	Physical	Physical
reactions	Physical	Physical
,	O	O
based	Physical	O
on	Physical	O
interleukin-6	Physical	O
and	Physical	O
C-reactive	Physical	O
protein	Physical	O
levels	Physical	O
,	O	O
were	O	O
less	O	O
intense	O	O
following	O	O
FT	O	O
laparoscopic	O	O
operation	O	O
compared	O	O
to	O	O
FT	O	O
open	O	O
operation	O	O
;	O	O
however	O	O
,	O	O
there	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
specific	Physical	Physical
immunity	Physical	Physical
(	Physical	Physical
CD3+	Physical	Physical
and	Physical	Physical
CD4+	Physical	Physical
counts	Physical	Physical
,	Physical	Physical
and	Physical	Physical
the	Physical	Physical
CD4+/CD8+	Physical	Physical
ratio	Physical	Physical
)	Physical	Physical
during	O	O
these	O	O
two	O	O
types	O	O
of	O	O
surgical	O	O
procedures	O	O
.	O	O

Post-operative	Adverseeffect	O
hospital	Adverseeffect	O
stay	Adverseeffect	O
in	O	O
patients	O	O
randomized	O	O
to	O	O
the	O	O
FT	O	O
laparoscopic	O	O
group	O	O
was	O	O
significantly	O	O
shorter	O	O
than	O	O
in	O	O
the	O	O
other	O	O
three	O	O
treatment	O	O
groups	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

Post-operative	Adverseeffect	O
complications	Adverseeffect	O
in	O	O
patients	O	O
who	O	O
underwent	O	O
FT	O	O
laparoscopic	O	O
treatment	O	O
were	O	O
less	O	O
than	O	O
in	O	O
the	O	O
other	O	O
three	O	O
treatment	O	O
groups	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
four	O	O
treatment	O	O
groups	O	O
regarding	O	O
readmission	Mortality	Physical
rate	Mortality	Physical
and	O	O
in-hospital	Mortality	Mortality
mortality	Mortality	Mortality
.	O	O

CONCLUSIONS	O	O
The	O	O
laparoscopic	O	O
technique	O	O
and	O	O
FT	O	O
surgery	O	O
rehabilitation	O	O
program	O	O
effectively	O	O
inhibited	O	O
release	O	Physical
of	O	Physical
post-operative	Physical	Physical
inflammatory	Physical	Physical
factors	Physical	Physical
with	Physical	O
a	Physical	O
reduction	Physical	O
in	Physical	O
peri-operative	Physical	O
trauma	Physical	O
and	Physical	O
stress	Physical	O
,	O	O
which	O	O
together	O	O
played	O	O
a	O	O
protective	O	O
role	O	O
on	O	O
the	O	O
post-operative	O	O
immune	O	O
system	O	O
.	O	O

Combining	O	O
two	O	O
treatment	O	O
measures	O	O
during	O	O
colon	O	O
operation	O	O
produced	O	O
better	O	O
protective	Others	O
effects	Others	O
via	Others	O
the	Others	O
immune	Others	O
system	Others	O
.	Physical	O

The	O	O
beneficial	O	O
clinical	O	O
effects	O	O
support	O	O
that	O	O
the	O	O
better-preserved	O	O
post-operative	O	O
immune	O	O
system	O	O
may	O	O
also	O	O
contribute	O	O
to	O	O
the	O	O
improvement	Physical	O
of	Physical	O
post-operative	Physical	O
results	Physical	O
in	O	O
FT	O	O
laparoscopic	O	O
patients	O	O
.	O	O

1999	O	O
WHO/ISH	O	O
Guidelines	O	O
applied	O	O
to	O	O
a	O	O
1999	O	O
MONICA	O	O
sample	O	O
from	O	O
northern	O	O
Sweden	O	O
.	O	O

BACKGROUND	O	O
Treating	O	O
hypertension	O	O
with	O	O
drugs	O	O
is	O	O
so	O	O
far	O	O
the	O	O
most	O	O
cost-effective	O	O
way	O	O
to	O	O
reduce	O	O
this	O	O
important	O	O
risk	O	O
factor	O	O
for	O	O
cardiovascular	O	O
disease	O	O
(	O	O
CVD	O	O
)	O	O
.	O	O

It	O	O
is	O	O
,	O	O
however	O	O
,	O	O
important	O	O
to	O	O
determine	O	O
absolute	O	O
risk	O	O
,	O	O
and	O	O
thereby	O	O
estimate	O	O
indication	O	O
for	O	O
drug	O	O
treatment	O	O
,	O	O
in	O	O
order	O	O
to	O	O
maintain	O	O
a	O	O
cost-effective	O	O
drug	O	O
treatment	O	O
.	O	O

WHO/ISH	O	O
Hypertension	O	O
Guidelines	O	O
from	O	O
1999	O	O
propose	O	O
a	O	O
risk	O	O
stratification	O	O
for	O	O
estimating	O	O
absolute	O	O
risk	O	O
for	O	O
CVD	O	O
based	O	O
on	O	O
blood	O	Physical
pressure	O	Physical
and	O	O
additional	O	O
risk	O	O
factors	O	O
,	O	O
target	O	O
organ	O	O
damage	O	O
(	O	O
TOD	O	O
)	O	O
and	O	O
CVD	O	O
.	O	O

OBJECTIVES	O	O
We	O	O
studied	O	O
the	O	O
consequences	O	O
of	O	O
applying	O	O
the	O	O
recent	O	O
WHO/ISH	O	O
risk	O	O
stratification	O	O
scheme	O	O
to	O	O
a	O	O
MONICA	O	O
sample	O	O
of	O	O
6000	O	O
subjects	O	O
from	O	O
a	O	O
geographically	O	O
defined	O	O
population	O	O
in	O	O
northern	O	O
Sweden	O	O
,	O	O
regarding	O	O
indications	O	O
for	O	O
treatment	O	O
,	O	O
target	O	O
blood	O	O
pressure	O	O
and	O	O
risk	O	O
distribution	O	O
.	O	O

METHODS	O	O
We	O	O
have	O	O
risk-classified	O	O
each	O	O
of	O	O
these	O	O
patients	O	O
using	O	O
a	O	O
computer	O	O
program	O	O
,	O	O
according	O	O
to	O	O
the	O	O
WHO/ISH	O	O
scheme	O	O
.	O	O

Data	O	O
on	O	O
TOD	O	O
were	O	O
not	O	O
available	O	O
.	O	O

RESULTS	O	O
In	O	O
all	O	O
,	O	O
917	O	O
(	O	O
15	O	O
%	O	O
)	O	O
had	O	O
drug-treated	O	O
hypertension	O	O
.	O	O

Three-quarters	O	O
(	O	O
n	O	O
=	O	O
737	O	O
)	O	O
were	O	O
inadequately	O	O
treated	O	O
,	O	O
with	O	O
blood	Physical	O
pressure	Physical	O
levels	Physical	O
at	O	O
or	O	O
above	O	O
140	O	O
or	O	O
90	O	O
mmHg	O	O
.	O	O

1773	O	O
(	O	O
30	O	O
%	O	O
of	O	O
5997	O	O
)	O	O
untreated	O	O
subjects	O	O
had	O	O
a	O	O
blood	O	Physical
pressure	O	Physical
of	O	O
140/90	O	O
or	O	O
above	O	O
;	O	O
16	O	O
%	O	O
in	O	O
the	O	O
low-	O	O
,	O	O
62	O	O
%	O	O
in	O	O
the	O	O
medium-	O	O
,	O	O
8	O	O
%	O	O
in	O	O
the	O	O
high-	O	O
,	O	O
and	O	O
14	O	O
%	O	O
in	O	O
the	O	O
very-high-risk	O	O
group	O	O
.	O	O

The	O	O
corresponding	O	O
risk-group	O	O
pattern	O	O
for	O	O
the	O	O
inadequately	O	O
treated	O	O
hypertensives	O	O
(	O	O
n	O	O
=	O	O
737	O	O
)	O	O
was	O	O
5.5	O	O
,	O	O
48.3	O	O
,	O	O
11.1	O	O
and	O	O
35.2	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

If	O	O
we	O	O
shifted	O	O
the	O	O
target	O	O
blood	O	Physical
pressure	O	Physical
from	O	O
below	O	O
140/90	O	O
to	O	O
below	O	O
130/85	O	O
for	O	O
drug-treated	O	O
subjects	O	O
under	O	O
60	O	O
(	O	O
n	O	O
=	O	O
278	O	O
)	O	O
the	O	O
number	Others	O
of	Others	O
inadequately	Others	O
treated	Others	O
subjects	Others	O
increased	O	O
by	O	O
34	O	O
(	O	O
12.2	O	O
%	O	O
of	O	O
278	O	O
)	O	O
;	O	O
14	O	O
in	O	O
the	O	O
low-risk	O	O
group	O	O
,	O	O
15	O	O
in	O	O
the	O	O
medium-risk	O	O
group	O	O
,	O	O
and	O	O
only	O	O
five	O	O
in	O	O
the	O	O
high-	O	O
or	O	O
very-high-risk	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
Only	O	O
one-fifth	O	O
of	O	O
the	O	O
drug-treated	O	O
hypertensives	O	O
were	O	O
well	O	O
controlled	O	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
newly	Others	O
detected	Others	O
blood	Others	O
pressure	Others	O
elevation	Others	O
was	O	O
high	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
younger	O	O
subjects	O	O
with	O	O
high	O	O
blood	O	O
pressure	O	O
had	O	O
low	O	O
risk	O	O
,	O	O
but	O	O
in	O	O
those	O	O
aged	O	O
45-54	O	O
this	O	O
had	O	O
already	O	O
risen	O	O
to	O	O
a	O	O
medium	O	O
risk	O	O
.	O	O

Changing	O	O
the	O	O
target	O	O
blood	O	O
pressure	O	O
to	O	O
below	O	O
130/85	O	O
,	O	O
for	O	O
subjects	O	O
aged	O	O
below	O	O
60	O	O
,	O	O
as	O	O
recommended	O	O
by	O	O
WHO/ISH	O	O
,	O	O
affects	O	O
predominantly	O	O
low-	O	O
and	O	O
medium-risk	O	O
groups	O	O
.	O	O

Treatment	O	O
with	O	O
metformin	O	O
of	O	O
non-diabetic	O	O
men	O	O
with	O	O
hypertension	O	O
,	O	O
hypertriglyceridaemia	O	O
and	O	O
central	O	O
fat	O	O
distribution	O	O
:	O	O
the	O	O
BIGPRO	O	O
1.2	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
In	O	O
the	O	O
BIGPRO	O	O
1	O	O
trial	O	O
,	O	O
one	O	O
year	O	O
of	O	O
treatment	O	O
with	O	O
metformin	O	O
in	O	O
non-diabetic	O	O
obese	O	O
subjects	O	O
with	O	O
a	O	O
central	O	O
fat	O	O
distribution	O	O
had	O	O
no	O	O
significant	O	O
effect	O	O
on	O	O
fasting	O	Physical
plasma	O	Physical
triglyceride	O	Physical
concentration	O	Physical
or	O	O
on	O	O
blood	O	Physical
pressure	O	Physical
despite	O	O
a	O	O
decrease	O	O
in	O	O
weight	O	Physical
,	O	Physical
fasting	O	Physical
plasma	O	Physical
insulin	O	Physical
and	O	O
glucose	O	O
concentrations	O	O
.	O	O

To	O	O
re-evaluate	O	O
the	O	O
effect	O	O
of	O	O
metformin	O	O
on	O	O
fasting	O	Physical
triglyceride	O	Physical
concentration	O	Physical
and	O	O
on	O	O
blood	O	Physical
pressure	O	Physical
,	O	O
the	O	O
BIGPRO	O	O
1.2	O	O
trial	O	O
included	O	O
non-diabetic	O	O
men	O	O
(	O	O
n=168	O	O
)	O	O
with	O	O
a	O	O
fasting	O	Physical
plasma	O	Physical
triglyceride	O	Physical
concentration	O	Physical
>	O	O
or	O	O
=1.7	O	O
and	O	O
<	O	O
or	O	O
=6.5	O	O
mmol/l	O	O
,	O	O
high	O	Physical
blood	O	Physical
pressure	O	Physical
(	O	O
systolic	O	O
>	O	O
or	O	O
=140	O	O
and	O	O
<	O	O
or	O	O
=180	O	O
and/or	O	O
diastolic	O	O
>	O	O
or	O	O
=90	O	O
and	O	O
<	O	O
or	O	O
=105	O	O
mmHg	O	O
,	O	O
or	O	O
treatment	O	O
for	O	O
hypertension	O	O
)	O	O
and	O	O
a	O	O
waist-to-hip	O	O
ratio	O	O
>	O	O
or	O	O
=0.95	O	O
.	O	O

METHODS	O	O
A	O	O
randomised	O	O
double-blind	O	O
trial	O	O
comparing	O	O
metformin	O	O
treatment	O	O
(	O	O
850	O	O
mg	O	O
bid	O	O
)	O	O
with	O	O
placebo	O	O
.	O	O

RESULTS	O	O
Metformin	O	O
had	O	O
no	O	O
significant	O	O
effect	O	O
either	O	O
on	O	O
blood	Physical	Physical
pressure	Physical	Physical
or	Physical	Physical
plasma	Physical	Physical
triglyceride	Physical	Physical
concentration	Physical	Physical
.	O	O

In	O	O
comparison	O	O
with	O	O
the	O	O
placebo	O	O
group	O	O
,	O	O
fasting	Physical	Physical
plasma	Physical	Physical
insulin	Physical	Physical
(	O	O
p	O	O
<	O	O
0.04	O	O
)	O	O
,	O	O
total	Physical	Physical
cholesterol	Physical	Physical
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
and	O	O
Apo	Physical	O
B	Physical	O
(	O	O
p	O	O
<	O	O
0.008	O	O
)	O	O
concentrations	O	O
decreased	O	O
more	O	O
in	O	O
the	O	O
metformin	O	O
group	O	O
in	O	O
the	O	O
BIGPRO	O	O
1	O	O
.	O	O

2	O	O
trial	O	O
,	O	O
confirming	O	O
most	O	O
of	O	O
the	O	O
previous	O	O
results	O	O
of	O	O
the	O	O
BIGPRO	O	O
1	O	O
trial	O	O
.	O	O

Tissue	Physical	Physical
plasminogen	Physical	Physical
activator	Physical	Physical
antigen	Physical	Physical
concentration	Physical	Physical
decreased	O	O
significantly	O	O
(	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
only	O	O
in	O	O
the	O	O
metformin	O	O
group	O	O
,	O	O
but	O	O
this	O	O
was	O	O
not	O	O
significantly	O	O
different	O	O
from	O	O
the	O	O
placebo	O	O
group	O	O
(	O	O
p	O	O
<	O	O
0.12	O	O
)	O	O
;	O	O
further	O	O
,	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
change	O	O
in	O	O
plasminogen	O	O
activator	O	O
inhibitor	O	O
1	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
consistency	O	O
of	O	O
the	O	O
two	O	O
BIGPRO	O	O
trials	O	O
supports	O	O
the	O	O
conclusion	O	O
that	O	O
metformin	O	O
affects	O	O
several	O	O
cardiovascular	O	O
risk	O	O
factors	O	O
favourably	O	O
in	O	O
non-diabetic	O	O
subjects	O	O
with	O	O
a	O	O
central	O	O
fat	O	O
distribution	O	O
.	O	O

Pegfilgrastim	O	O
for	O	O
peripheral	O	O
CD34+	O	O
mobilization	O	O
in	O	O
patients	O	O
with	O	O
solid	O	O
tumours	O	O
.	O	O

The	O	O
efficacy	Others	O
of	O	O
pegfilgrastim+/-chemotherapy	O	O
for	O	O
mobilizing	O	O
stem	O	O
cells	O	O
in	O	O
patients	O	O
with	O	O
solid	O	O
tumours	O	O
was	O	O
assessed	O	O
.	O	O

In	O	O
cycle	O	O
0	O	O
,	O	O
a	O	O
14-day	O	O
prechemotherapy	O	O
cycle	O	O
,	O	O
patients	O	O
(	O	O
N=61	O	O
)	O	O
were	O	O
randomized	O	O
open-label	O	O
to	O	O
single	O	O
doses	O	O
of	O	O
pegfilgrastim	O	O
(	O	O
6	O	O
,	O	O
12	O	O
or	O	O
18	O	O
mg	O	O
)	O	O
on	O	O
day	O	O
1	O	O
,	O	O
or	O	O
daily	O	O
filgrastim	O	O
(	O	O
10	O	O
microg/kg	O	O
)	O	O
for	O	O
<	O	O
or	O	O
=7	O	O
days	O	O
.	O	O

Mean	O	Physical
peak	O	Physical
peripheral	Physical	Physical
CD34+	Physical	Physical
cell	Physical	Physical
counts	Physical	Physical
increased	O	O
with	O	O
pegfilgrastim	O	O
dose	O	O
,	O	O
but	O	O
were	O	O
significantly	O	O
higher	O	O
than	O	O
filgrastim	O	O
only	O	O
at	O	O
the	O	O
18	O	O
mg	O	O
dose	O	O
(	O	O
10.17	O	O
vs	O	O
4.96	O	O
x	O	O
10	O	O
(	O	O
4	O	O
)	O	O
/ml	O	O
;	O	O
P=0.014	O	O
)	O	O
.	O	O

In	O	O
the	O	O
clinically	O	O
relevant	O	O
period	O	O
of	O	O
days	O	O
3-7	O	O
,	O	O
both	O	O
12	O	O
and	O	O
18	O	O
mg	O	O
pegfilgrastim	O	O
doses	O	O
produced	O	O
significantly	Physical	O
higher	Physical	O
peak	Physical	Physical
CD34+	Physical	Physical
counts	Physical	Physical
(	O	O
8.18	O	O
and	O	O
9.96	O	O
vs	O	O
4.51	O	O
x	O	O
10	O	O
(	O	O
4	O	O
)	O	O
/ml	O	O
for	O	O
filgrastim	O	O
;	O	O
P=0.034	O	O
and	O	O
0.006	O	O
)	O	O
.	O	O

In	O	O
cycle	O	O
1	O	O
,	O	O
patients	O	O
received	O	O
carboplatin/paclitaxel	O	O
on	O	O
day	O	O
1	O	O
,	O	O
followed	O	O
from	O	O
day	O	O
2	O	O
by	O	O
pegfilgrastim	O	O
6-18	O	O
mg	O	O
or	O	O
daily	O	O
filgrastim	O	O
(	O	O
5	O	O
microg/kg/day	O	O
for	O	O
<	O	O
or	O	O
=14	O	O
days	O	O
)	O	O
as	O	O
per	O	O
randomization	O	O
in	O	O
cycle	O	O
0	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
mean	Physical	Physical
peak	Physical	Physical
CD34+	Physical	Physical
count	Physical	Physical
between	O	O
pegfilgrastim	O	O
and	O	O
filgrastim	O	O
,	O	O
but	O	O
there	O	O
was	O	O
an	O	O
advantage	O	O
for	O	O
pegfilgrastim	O	O
18	O	O
mg	O	O
in	O	O
the	O	O
relevant	O	O
period	O	O
of	O	O
days	O	O
7-12	O	O
(	O	O
3.14	O	O
vs	O	O
1.19	O	O
x	O	O
10	O	O
(	O	O
4	O	O
)	O	O
/ml	O	O
;	O	O
P=0.043	O	O
)	O	O
.	O	O

A	O	O
single	O	O
pegfilgrastim	O	O
dose	O	O
(	O	O
>	O	O
or	O	O
=6	O	O
mg	O	O
)	O	O
could	O	O
be	O	O
substituted	O	O
for	O	O
daily	O	O
filgrastim	O	O
in	O	O
cytokine-only	Physical	O
peripheral	Physical	O
CD34+	Physical	O
cell	Physical	O
mobilization	Physical	O
.	Physical	O

Aminocaproic	O	O
acid	O	O
versus	O	O
prednisone	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
traumatic	O	O
hyphema	O	O
.	O	O

A	O	O
randomized	O	O
clinical	O	O
trial	O	O
.	O	O

One	O	O
hundred	O	O
twelve	O	O
patients	O	O
who	O	O
sustained	O	O
hyphema	O	O
after	O	O
blunt	O	O
trauma	O	O
were	O	O
enrolled	O	O
in	O	O
a	O	O
double-blind	O	O
randomized	O	O
clinical	O	O
trial	O	O
to	O	O
determine	O	O
the	O	O
relative	O	O
efficacies	O	O
of	O	O
aminocaproic	O	O
acid	O	O
(	O	O
Amicar	O	O
)	O	O
and	O	O
systemic	O	O
prednisone	O	O
for	O	O
reducing	O	O
the	O	O
rate	Physical	O
of	Physical	O
secondary	Physical	O
hemorrhage	Physical	O
.	O	O

Fifty-six	O	O
patients	O	O
received	O	O
an	O	O
oral	O	O
dosage	O	O
of	O	O
50	O	O
mg/kg	O	O
of	O	O
aminocaproic	O	O
acid	O	O
every	O	O
4	O	O
hours	O	O
for	O	O
5	O	O
days	O	O
,	O	O
up	O	O
to	O	O
a	O	O
maximum	O	O
of	O	O
30	O	O
g	O	O
daily	O	O
,	O	O
and	O	O
56	O	O
patients	O	O
received	O	O
an	O	O
oral	O	O
dosage	O	O
of	O	O
40	O	O
mg	O	O
of	O	O
prednisone	O	O
daily	O	O
(	O	O
adjusted	O	O
for	O	O
weight	O	O
)	O	O
in	O	O
two	O	O
divided	O	O
doses	O	O
.	O	O

Placebo	O	O
pills	O	O
and	O	O
liquids	O	O
were	O	O
given	O	O
to	O	O
each	O	O
patient	O	O
to	O	O
mask	O	O
the	O	O
treatment	O	O
schedules	O	O
.	O	O

There	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
patient	O	O
populations	O	O
for	O	O
any	O	O
demographic	O	O
or	O	O
clinical	O	O
characteristic	O	O
(	O	O
e.g.	O	O
,	O	O
visual	Physical	Physical
acuity	Physical	Physical
,	O	Physical
intraocular	Physical	Physical
pressure	Physical	Physical
[	Physical	Physical
IOP	Physical	Physical
]	Physical	Physical
,	O	O
initial	Physical	O
hyphema	Physical	O
size	Physical	O
)	O	O
measured	O	O
in	O	O
the	O	O
study	O	O
.	O	O

Blacks	O	O
comprised	O	O
53	O	O
%	O	O
of	O	O
the	O	O
study	O	O
population	O	O
,	O	O
and	O	O
the	O	O
mean	O	O
age	O	O
of	O	O
the	O	O
patients	O	O
was	O	O
23.5	O	O
years	O	O
.	O	O

Four	O	O
patients	O	O
in	O	O
each	O	O
of	O	O
the	O	O
treatment	O	O
groups	O	O
experienced	O	O
a	O	O
secondary	Physical	O
hemorrhage	Physical	O
;	O	O
the	O	O
rebleed	Physical	O
rate	Physical	O
was	O	O
7.1	O	O
%	O	O
in	O	O
each	O	O
group	O	O
.	O	O

Teacher	O	O
and	O	O
child	O	O
predictors	O	O
of	O	O
achieving	O	O
IEP	O	O
goals	O	O
of	O	O
children	O	O
with	O	O
autism	O	O
.	O	O

It	O	O
is	O	O
encouraging	O	O
that	O	O
children	O	O
with	O	O
autism	O	O
show	O	O
a	O	O
strong	O	O
response	O	O
to	O	O
early	O	O
intervention	O	O
,	O	O
yet	O	O
more	O	O
research	O	O
is	O	O
needed	O	O
for	O	O
understanding	O	O
the	O	O
variability	O	O
in	O	O
responsiveness	O	O
to	O	O
specialized	O	O
programs	O	O
.	O	O

Treatment	O	O
predictor	O	O
variables	O	O
from	O	O
47	O	O
teachers	O	O
and	O	O
children	O	O
who	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
the	O	O
COMPASS	O	O
intervention	O	O
(	O	O
Ruble	O	O
et	O	O
al	O	O
.	O	O

in	O	O
The	O	O
collaborative	O	O
model	O	O
for	O	O
promoting	O	O
competence	O	O
and	O	O
success	O	O
for	O	O
students	O	O
with	O	O
ASD	O	O
.	O	O

Springer	O	O
,	O	O
New	O	O
York	O	O
,	O	O
2012a	O	O
)	O	O
were	O	O
analyzed	O	O
.	O	O

Predictors	O	O
evaluated	O	O
against	O	O
child	Others	O
IEP	Others	O
goal	Others	O
attainment	Others	O
included	O	O
child	O	O
,	O	O
teacher	O	O
,	O	O
intervention	O	O
practice	O	O
,	O	O
and	O	O
implementation	O	O
practice	O	O
variables	O	O
based	O	O
on	O	O
an	O	O
implementation	O	O
science	O	O
framework	O	O
(	O	O
Dunst	O	O
and	O	O
Trivette	O	O
in	O	O
J	O	O
Soc	O	O
Sci	O	O
8:143-148	O	O
,	O	O
2012	O	O
)	O	O
.	O	O

Findings	O	O
revealed	O	O
one	O	O
child	O	O
(	O	O
engagement	O	O
)	O	O
,	O	O
one	O	O
teacher	O	O
(	O	O
exhaustion	O	O
)	O	O
,	O	O
two	O	O
intervention	O	O
quality	O	O
(	O	O
IEP	O	O
quality	O	O
for	O	O
targeted	O	O
and	O	O
not	O	O
targeted	O	O
elements	O	O
)	O	O
,	O	O
and	O	O
no	O	O
implementation	O	O
quality	O	O
variables	O	O
accounted	O	O
for	O	O
variance	O	O
in	O	O
child	O	O
outcomes	O	O
when	O	O
analyzed	O	O
separately	O	O
.	O	O

When	O	O
the	O	O
four	O	O
significant	O	O
variables	O	O
were	O	O
compared	O	O
against	O	O
each	O	O
other	O	O
in	O	O
a	O	O
single	O	O
regression	O	O
analysis	O	O
,	O	O
IEP	O	O
quality	O	O
accounted	O	O
for	O	O
one	O	O
quarter	O	O
of	O	O
the	O	O
variance	O	O
in	O	O
child	O	O
outcomes	O	O
.	O	O

Double-blind	O	O
comparison	O	O
of	O	O
doxepin	O	O
versus	O	O
bupropion	O	O
in	O	O
outpatients	O	O
with	O	O
a	O	O
major	O	O
depressive	O	O
disorder	O	O
.	O	O

A	O	O
double-blind	O	O
controlled	O	O
study	O	O
comparing	O	O
the	O	O
effects	O	O
of	O	O
bupropion	O	O
to	O	O
doxepin	O	O
in	O	O
outpatients	O	O
with	O	O
primary	O	O
depression	O	O
was	O	O
conducted	O	O
to	O	O
evaluate	O	O
efficacy	Others	Others
and	O	Others
safety	Others	Others
differences	O	Others
between	O	O
the	O	O
two	O	O
drugs	O	O
.	O	O

Following	O	O
a	O	O
7-day	O	O
placebo	O	O
washout	O	O
period	O	O
,	O	O
patients	O	O
could	O	O
be	O	O
treated	O	O
for	O	O
up	O	O
to	O	O
13	O	O
weeks	O	O
on	O	O
either	O	O
treatment	O	O
.	O	O

Antidepressant	Mental	O
response	Mental	O
was	O	O
assessed	O	O
by	O	O
the	O	O
Hamilton	Mental	Mental
Depression	Mental	Mental
and	Mental	Mental
Anxiety	Mental	Mental
Scales	Mental	Mental
,	O	O
Clinical	Mental	Physical
Global	Mental	Physical
Severity	Mental	Physical
and	O	Physical
Improvement	Mental	Physical
Ratings	Mental	Physical
,	O	O
and	O	O
the	O	O
Zung	Mental	Mental
Self-Rating	Mental	Mental
Depression	Mental	Mental
Scale	Mental	Mental
.	O	O

Comparable	O	Others
efficacy	Others	Others
between	O	O
the	O	O
compounds	O	O
was	O	O
found	O	O
across	O	O
the	O	O
13-week	O	O
study	O	O
.	O	O

Doxepin	O	O
differed	O	O
from	O	O
bupropion	O	O
mainly	O	O
on	O	O
the	O	O
sleep	Mental	Mental
factor	Mental	Mental
of	Mental	Mental
the	Mental	Mental
Hamilton	Mental	Mental
Depression	Mental	Mental
Scale	Mental	Mental
,	O	O
with	O	O
doxepin	O	O
improving	O	O
sleep	O	O
to	O	O
a	O	O
greater	O	O
extent	O	O
than	O	O
bupropion	O	O
.	O	O

Doxepin	O	O
produced	O	O
a	O	O
greater	O	O
incidence	O	Adverseeffect
of	O	Adverseeffect
anticholinergic	Adverseeffect	Adverseeffect
side	Adverseeffect	Adverseeffect
effects	Adverseeffect	Adverseeffect
,	O	O
including	O	O
dry	Adverseeffect	O
mouth	Adverseeffect	O
,	O	O
constipation	Adverseeffect	O
,	O	O
sleepiness	Adverseeffect	O
,	O	O
and	O	O
tiredness	Adverseeffect	O
,	O	O
in	O	O
comparison	O	O
to	O	O
bupropion	O	O
.	O	O

Also	O	O
,	O	O
increased	O	O
appetite	Adverseeffect	Physical
and	Adverseeffect	Physical
weight	Adverseeffect	Physical
gain	Adverseeffect	Physical
were	O	O
consistent	O	O
side	O	O
effects	O	O
of	O	O
doxepin	O	O
relative	O	O
to	O	O
bupropion	O	O
.	O	O

Effect	O	O
of	O	O
testosterone	O	O
and	O	O
a	O	O
nutritional	O	O
supplement	O	O
,	O	O
alone	O	O
and	O	O
in	O	O
combination	O	O
,	O	O
on	O	O
hospital	Others	O
admissions	Others	O
in	O	O
undernourished	O	O
older	O	O
men	O	O
and	O	O
women	O	O
.	O	O

BACKGROUND	O	O
In	O	O
older	O	O
people	O	O
,	O	O
undernutrition	O	O
is	O	O
associated	O	O
with	O	O
increased	O	O
hospitalization	Physical	O
rates	Physical	O
and	O	O
mortality	Adverseeffect	O
.	O	O

Because	O	O
weight	O	O
loss	O	O
in	O	O
older	O	O
people	O	O
often	O	O
reflects	O	O
a	O	O
disproportionate	O	O
reduction	O	O
of	O	O
skeletal	O	O
muscle	O	O
,	O	O
anabolic	O	O
treatments	O	O
may	O	O
be	O	O
beneficial	O	O
.	O	O

OBJECTIVE	O	O
Our	O	O
aim	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
hypothesis	O	O
that	O	O
testosterone	O	O
treatment	O	O
and	O	O
a	O	O
nutritional	O	O
supplement	O	O
have	O	O
additive	O	O
benefits	O	O
.	O	O

DESIGN	O	O
Oral	O	O
testosterone	O	O
undecanoate	O	O
(	O	O
40	O	O
mg	O	O
daily	O	O
for	O	O
women	O	O
,	O	O
80	O	O
mg	O	O
twice	O	O
daily	O	O
for	O	O
men	O	O
)	O	O
and	O	O
an	O	O
oral	O	O
nutritional	O	O
supplement	O	O
(	O	O
475	O	O
kcal/d	O	O
)	O	O
were	O	O
administered	O	O
,	O	O
alone	O	O
or	O	O
combined	O	O
,	O	O
for	O	O
1	O	O
y	O	O
to	O	O
49	O	O
community-dwelling	O	O
,	O	O
undernourished	O	O
people	O	O
[	O	O
Mini	O	O
Nutritional	O	O
Assessment	O	O
score	O	O
<	O	O
24	O	O
and	O	O
low	O	Physical
body	O	Physical
weight	O	Physical
(	O	Physical
body	O	Physical
mass	O	Physical
index	O	Physical
,	O	O
in	O	O
kg/m	O	O
(	O	O
2	O	O
)	O	O
:	O	O
<	O	O
22	O	O
)	O	O
or	O	O
recent	O	Physical
weight	O	Physical
loss	O	Physical
(	O	O
>	O	O
7.5	O	O
%	O	O
over	O	O
3	O	O
mo	O	O
)	O	O
]	O	O
aged	O	O
>	O	O
65	O	O
y	O	O
(	O	O
mean	O	O
age	O	O
:	O	O
77	O	O
y	O	O
;	O	O
26	O	O
women	O	O
and	O	O
23	O	O
men	O	O
)	O	O
.	O	O

Hospital	Others	O
admissions	Others	O
and	O	O
other	Others	O
variables	Others	O
were	O	O
assessed	O	O
.	O	O

RESULTS	O	O
In	O	O
subjects	O	O
receiving	O	O
combined	O	O
testosterone	O	O
and	O	O
nutritional	O	O
supplements	O	O
(	O	O
n	O	O
=	O	O
11	O	O
)	O	O
,	O	O
there	O	O
were	O	O
no	O	O
hospital	Others	O
admissions	Others	O
,	O	O
whereas	O	O
there	O	O
were	O	O
9	O	O
admissions	O	O
(	O	O
2	O	O
elective	O	O
)	O	O
in	O	O
13	O	O
subjects	O	O
in	O	O
the	O	O
no-treatment	O	O
group	O	O
,	O	O
4	O	O
in	O	O
the	O	O
testosterone-treated	O	O
group	O	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
,	O	O
and	O	O
5	O	O
in	O	O
the	O	O
supplement-treated	O	O
group	O	O
(	O	O
n	O	O
=	O	O
13	O	O
)	O	O
;	O	O
P	O	O
=	O	O
0.06	O	O
with	O	O
no-treatment	O	O
compared	O	O
with	O	O
combined	O	O
treatment	O	O
.	O	O

When	O	O
compared	O	O
with	O	O
the	O	O
no-treatment	O	O
group	O	O
,	O	O
the	O	O
combined-treatment	O	O
group	O	O
had	O	O
significantly	O	O
fewer	O	O
subjects	Others	O
admitted	Others	O
to	Others	O
hospital	Others	O
(	O	O
0	O	O
compared	O	O
with	O	O
5	O	O
,	O	O
P	O	O
=	O	O
0.03	O	O
)	O	O
,	O	O
fewer	O	O
days	Others	O
in	Others	O
hospital	Others	O
(	O	O
0	O	O
compared	O	O
with	O	O
74	O	O
,	O	O
P	O	O
=	O	O
0.041	O	O
)	O	O
,	O	O
and	O	O
a	O	O
longer	O	O
time	O	O
to	O	O
hospital	O	O
admission	O	O
(	O	O
P	O	O
=	O	O
0.017	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
In	O	O
undernourished	O	O
older	O	O
people	O	O
,	O	O
combined	O	O
treatment	O	O
with	O	O
testosterone	O	O
and	O	O
nutritional	O	Physical
supplementation	O	Physical
reduced	O	O
the	O	O
number	O	O
of	O	O
people	O	O
hospitalized	O	O
and	O	O
the	O	O
duration	O	O
of	O	O
hospital	O	O
admissions	O	O
,	O	O
which	O	O
are	O	O
important	O	O
endpoints	O	O
in	O	O
this	O	O
group	O	O
.	O	O

Larger	O	O
,	O	O
confirmatory	O	O
studies	O	O
are	O	O
now	O	O
needed	O	O
.	O	O

This	O	O
trial	O	O
was	O	O
registered	O	O
before	O	O
commencement	O	O
at	O	O
clinical	O	O
trials.gov	O	O
as	O	O
NCT00117000	O	O
.	O	O

Immunogenicity	Others	Physical
and	O	O
safety	Others	O
of	O	O
a	O	O
plasma-derived	O	O
heat-inactivated	O	O
hepatitis	O	O
B	O	O
vaccine	O	O
(	O	O
CLB	O	O
)	O	O
.	O	O

Studies	O	O
in	O	O
volunteers	O	O
at	O	O
a	O	O
low	O	O
risk	O	O
of	O	O
infection	O	O
with	O	O
hepatitis	O	O
B	O	O
virus	O	O
.	O	O

The	O	O
safety	Others	O
and	O	O
immunogenicity	Others	Physical
of	O	O
a	O	O
plasma-derived	O	O
heat-inactivated	O	O
hepatitis	O	O
B	O	O
vaccine	O	O
(	O	O
CLB	O	O
)	O	O
were	O	O
evaluated	O	O
in	O	O
471	O	O
healthy	O	O
human	O	O
volunteers	O	O
,	O	O
who	O	O
,	O	O
both	O	O
in	O	O
their	O	O
occupations	O	O
and	O	O
in	O	O
their	O	O
private	O	O
lives	O	O
,	O	O
had	O	O
been	O	O
at	O	O
minimal	O	O
risk	O	O
of	O	O
being	O	O
infected	O	O
with	O	O
hepatitis	O	O
B	O	O
virus	O	O
.	O	O

The	O	O
first	O	O
202	O	O
individuals	O	O
received	O	O
three	O	O
3-micrograms	O	O
doses	O	O
of	O	O
heat-inactivated	O	O
hepatitis	O	O
B	O	O
surface	O	O
antigen	O	O
(	O	O
HBsAg	O	O
)	O	O
at	O	O
one-month	O	O
intervals	O	O
(	O	O
trial	O	O
A	O	O
)	O	O
.	O	O

A	O	O
total	O	O
of	O	O
42	O	O
%	O	O
one	O	O
month	O	O
after	O	O
the	O	O
first	O	O
injection	O	O
,	O	O
84	O	O
%	O	O
after	O	O
two	O	O
months	O	O
,	O	O
and	O	O
93	O	O
%	O	O
after	O	O
five	O	O
months	O	O
had	O	O
become	O	O
anti-HBs	O	O
(	O	O
antibody	O	O
to	O	O
hepatitis	O	O
B	O	O
surface	O	O
antigen	O	O
)	O	O
positive	O	O
.	O	O

In	O	O
a	O	O
second	O	O
randomized	O	O
study	O	O
(	O	O
trial	O	O
B	O	O
)	O	O
,	O	O
the	O	O
immunogenicity	Others	O
of	O	O
five	O	O
different	O	O
dosages	O	O
of	O	O
the	O	O
vaccine	O	O
was	O	O
compared	O	O
in	O	O
269	O	O
volunteers	O	O
.	O	O

When	O	O
the	O	O
dose	O	O
of	O	O
HBsAg	O	Physical
was	O	O
diminished	O	O
from	O	O
3	O	O
micrograms	O	O
to	O	O
1.5	O	O
,	O	O
0.6	O	O
,	O	O
and	O	O
0.25	O	O
microgram	O	O
,	O	O
no	O	O
decrease	O	O
of	O	O
the	O	O
anti-HBs	Physical	Physical
response	Physical	Physical
was	O	O
observed	O	O
.	O	O

However	O	O
,	O	O
when	O	O
the	O	O
dose	O	O
was	O	O
diminished	O	O
to	O	O
0.1	O	O
microgram	O	O
of	O	O
HBsAg	O	O
,	O	O
the	O	O
anti-HBs	Physical	O
response	Physical	O
dropped	O	O
significantly	O	O
to	O	O
63	O	O
%	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
.	O	O

In	O	O
the	O	O
recipients	O	O
of	O	O
all	O	O
five	O	O
vaccine	O	O
dosages	O	O
,	O	O
no	O	O
influence	O	O
of	O	O
sex	O	O
and	O	O
age	O	O
was	O	O
found	O	O
on	O	O
the	O	O
anti-HBs	Physical	Physical
conversion	Physical	Physical
rates	Physical	Physical
.	Physical	O

During	O	O
the	O	O
eight-month	O	O
observation	O	O
period	O	O
,	O	O
none	O	O
of	O	O
the	O	O
vaccinees	O	O
became	O	O
HBsAg	Physical	O
and/or	Physical	O
anti-HBc	Physical	O
(	Physical	O
antibody	Physical	O
to	Physical	O
hepatitis	Physical	O
B	Physical	O
core	Physical	O
antigen	Physical	O
)	Physical	O
positive	Physical	O
,	O	O
and	O	O
none	O	O
developed	O	O
antibodies	O	O
associated	O	O
with	O	O
autoimmune	O	O
liver	O	O
disease	O	O
.	O	O

No	O	O
serious	Adverseeffect	Adverseeffect
side	Adverseeffect	Adverseeffect
effects	Adverseeffect	Adverseeffect
were	O	O
observed	O	O
.	O	O

Reduced	O	O
platelet	Physical	O
thromboxane	Physical	O
formation	Physical	O
after	O	O
long-term	O	O
administration	O	O
of	O	O
a	O	O
dihydropyridine	O	O
calcium	O	O
channel	O	O
blocker	O	O
:	O	O
a	O	O
prospective	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
study	O	O
with	O	O
nitrendipine	O	O
in	O	O
borderline	O	O
hypertensive	O	O
patients	O	O
with	O	O
IDDM-type	O	O
diabetes	O	O
mellitus	O	O
.	O	O

Twenty-nine	O	O
IDDM	O	O
patients	O	O
with	O	O
borderline	O	O
hypertension	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
placebo	O	O
or	O	O
nitrendipine	O	O
treatment	O	O
.	O	O

Nitrendipine	O	O
was	O	O
given	O	O
orally	O	O
at	O	O
a	O	O
dosage	O	O
of	O	O
20	O	O
mg	O	O
once	O	O
daily	O	O
over	O	O
4	O	O
weeks	O	O
.	O	O

Stimulated	Physical	O
platelet	Physical	O
thromboxane	Physical	O
formation	Physical	O
at	O	O
rest	O	O
and	O	O
after	O	O
standardized	O	O
,	O	O
non	O	O
exhausting	O	O
exercise	O	O
was	O	O
measured	O	O
by	O	O
standard	O	O
methods	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
plasma	Physical	O
levels	Physical	O
of	Physical	O
platelet	Physical	O
factor	Physical	O
4	Physical	O
and	Physical	O
aggregation	Physical	O
responses	Physical	O
to	Physical	O
collagen	Physical	O
and	Physical	O
ADP	Physical	O
were	O	O
determined	O	O
.	O	O

In	O	O
the	O	O
treatment	O	O
group	O	O
thromboxane	Physical	O
formation	Physical	O
after	O	O
stimulation	O	O
with	O	O
collagen	O	O
(	O	O
0.3	O	O
and	O	O
1.0	O	O
micrograms/ml	O	O
)	O	O
and	O	O
1	O	O
mM	O	O
arachidonic	O	O
acid	O	O
(	O	O
AA	O	O
)	O	O
was	O	O
reduced	O	O
in	O	O
the	O	O
resting	O	O
state	O	O
.	O	O

Exercise	Physical	O
induced	Physical	O
change	Physical	O
of	Physical	O
thromboxane	Physical	O
synthesis	Physical	O
in	O	O
response	O	O
to	O	O
1.0	O	O
micrograms/ml	O	O
collagen	O	O
was	O	O
significantly	O	O
lower	O	O
as	O	O
compared	O	O
to	O	O
placebo	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

In	O	O
parallel	O	O
,	O	O
PF4	Physical	Physical
plasma	Physical	Physical
levels	Physical	Physical
were	O	O
significantly	O	O
lowered	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

Whole	Physical	Physical
blood	Physical	Physical
aggregation	Physical	Physical
after	Physical	O
collagen	Physical	O
stimulation	Physical	O
(	O	O
1.0	O	O
micrograms/ml	O	O
)	O	O
was	O	O
reduced	O	O
after	O	O
4	O	O
weeks	O	O
of	O	O
nitrendipine	O	O
treatment	O	O
,	O	O
but	O	O
ADP	Physical	O
(	Physical	O
5	Physical	O
microM	Physical	O
)	Physical	O
induced	Physical	O
aggregation	Physical	O
was	O	O
not	O	O
.	O	O

These	O	O
effects	O	O
of	O	O
nitrendipine	O	O
were	O	O
not	O	O
seen	O	O
in	O	O
platelet	O	O
rich	O	O
plasma	O	O
.	O	O

In	O	O
conclusion	O	O
long-term	O	O
nitrendipine	O	O
treatment	O	O
may	O	O
inhibit	O	O
collagen	Physical	O
dependent	Physical	O
platelet	Physical	O
activation	Physical	O
in	O	O
the	O	O
blood	O	O
of	O	O
diabetic	O	O
patients	O	O
with	O	O
borderline	O	O
hypertension	O	O
.	O	O

Pedantic	O	O
speaking	O	O
style	O	O
differentiates	O	O
Asperger	O	O
syndrome	O	O
from	O	O
high-functioning	O	O
autism	O	O
.	O	O

Asperger	O	O
syndrome	O	O
(	O	O
AS	O	O
)	O	O
is	O	O
a	O	O
pervasive	O	O
developmental	O	O
disorder	O	O
recently	O	O
introduced	O	O
as	O	O
a	O	O
new	O	O
diagnostic	O	O
category	O	O
in	O	O
the	O	O
ICD-10	O	O
and	O	O
the	O	O
DSM-IV	O	O
.	O	O

Along	O	O
with	O	O
motor	O	O
clumsiness	O	O
,	O	O
pedantic	O	O
speech	O	O
has	O	O
been	O	O
proposed	O	O
as	O	O
a	O	O
clinical	O	O
feature	O	O
of	O	O
AS	O	O
.	O	O

However	O	O
,	O	O
few	O	O
attempts	O	O
have	O	O
been	O	O
made	O	O
to	O	O
define	O	O
and	O	O
measure	O	O
this	O	O
symptom	O	O
.	O	O

We	O	O
studied	O	O
17	O	O
patients	O	O
with	O	O
AS	O	O
(	O	O
ICD-10	O	O
;	O	O
14	O	O
male	O	O
,	O	O
3	O	O
female	O	O
;	O	O
mean	O	O
age	O	O
16.4	O	O
years	O	O
,	O	O
mean	O	O
full-scale	O	O
IQ	O	O
97	O	O
)	O	O
and	O	O
compared	O	O
them	O	O
with	O	O
a	O	O
control	O	O
group	O	O
of	O	O
13	O	O
patients	O	O
with	O	O
normal-intelligence	O	O
autism	O	O
or	O	O
high-functioning	O	O
autism	O	O
(	O	O
HFA	O	O
)	O	O
(	O	O
ICD-10/DSM-III-R	O	O
;	O	O
12	O	O
male	O	O
,	O	O
1	O	O
female	O	O
;	O	O
mean	O	O
age	O	O
15.5	O	O
years	O	O
,	O	O
mean	O	O
full-scale	O	O
IQ	O	O
81.2	O	O
)	O	O
.	O	O

An	O	O
operational	O	O
definition	O	O
of	O	O
pedantic	O	O
speech	O	O
was	O	O
formulated	O	O
and	O	O
a	O	O
rating	O	O
scale	O	O
devised	O	O
.	O	O

13	O	O
(	O	O
76	O	O
%	O	O
)	O	O
of	O	O
the	O	O
AS	O	O
patients	O	O
were	O	O
rated	O	O
as	O	O
pedantic	Others	O
compared	O	O
to	O	O
4	O	O
(	O	O
31	O	O
%	O	O
)	O	O
of	O	O
the	O	O
HFA	O	O
group	O	O
(	O	O
chi	O	O
2	O	O
=	O	O
6.3	O	O
;	O	O
p	O	O
=	O	O
.01	O	O
)	O	O
.	O	O

Results	O	O
suggest	O	O
that	O	O
pedantic	O	O
speech	O	O
is	O	O
common	O	O
in	O	O
AS	O	O
and	O	O
may	O	O
help	O	O
differentiate	O	O
AS	O	O
from	O	O
high-functioning	O	O
autism	O	O
.	O	O

Effect	O	O
of	O	O
patient	O	O
withdrawal	O	O
on	O	O
a	O	O
study	O	O
evaluating	O	O
pharmacist	O	O
management	O	O
of	O	O
hypertension	O	O
.	O	O

STUDY	O	O
OBJECTIVES	O	O
To	O	O
examine	O	O
potential	O	O
threats	O	O
to	O	O
internal	O	O
and	O	O
external	O	O
study	O	O
validity	O	O
caused	O	O
by	O	O
differential	O	O
patient	O	O
withdrawal	O	O
from	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O
evaluating	O	O
pharmacist	O	O
management	O	O
of	O	O
hypertension	O	O
,	O	O
to	O	O
compare	O	O
the	O	O
characteristics	O	O
of	O	O
patients	O	O
who	O	O
withdrew	O	O
with	O	O
those	O	O
of	O	O
patients	O	O
who	O	O
completed	O	O
the	O	O
study	O	O
,	O	O
and	O	O
to	O	O
identify	O	O
characteristics	O	O
that	O	O
predispose	O	O
patients	O	O
to	O	O
withdraw	O	O
from	O	O
hypertension	O	O
management	O	O
.	O	O

DESIGN	O	O
Prospective	O	O
,	O	O
randomized	O	O
,	O	O
comparative	O	O
study	O	O
.	O	O

SETTING	O	O
Network	O	O
of	O	O
primary	O	O
care	O	O
clinics	O	O
.	O	O

PATIENTS	O	O
Four	O	O
hundred	O	O
sixty-three	O	O
patients	O	O
with	O	O
a	O	O
diagnosis	O	O
of	O	O
hypertension	O	O
and	O	O
a	O	O
last	O	O
documented	O	O
systolic	O	O
blood	O	O
pressure	O	O
of	O	O
160	O	O
mm	O	O
Hg	O	O
or	O	O
greater	O	O
and/or	O	O
diastolic	O	Physical
blood	O	Physical
pressure	O	Physical
of	O	O
100	O	O
mm	O	O
Hg	O	O
or	O	O
greater	O	O
.	O	O

INTERVENTION	O	O
Patients	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
the	O	O
pharmacist	O	O
intervention	O	O
or	O	O
usual-care	O	O
(	O	O
control	O	O
)	O	O
group	O	O
.	O	O

Those	O	O
in	O	O
the	O	O
pharmacist	O	O
intervention	O	O
group	O	O
were	O	O
collaboratively	O	O
managed	O	O
by	O	O
a	O	O
primary	O	O
care	O	O
clinical	O	O
pharmacy	O	O
specialist	O	O
and	O	O
their	O	O
primary	O	O
care	O	O
provider	O	O
.	O	O

Patients	O	O
in	O	O
the	O	O
control	O	O
group	O	O
received	O	O
usual	O	O
care	O	O
from	O	O
only	O	O
their	O	O
primary	O	O
care	O	O
provider	O	O
.	O	O

MEASUREMENTS	O	O
AND	O	O
MAIN	O	O
RESULTS	O	O
Of	O	O
the	O	O
463	O	O
patients	O	O
,	O	O
191	O	O
(	O	O
41	O	O
%	O	O
)	O	O
withdrew	O	O
from	O	O
the	O	O
study	O	O
after	O	O
randomization	O	O
and	O	O
272	O	O
(	O	O
59	O	O
%	O	O
)	O	O
completed	O	O
the	O	O
study	O	O
.	O	O

Patients	O	O
who	O	O
withdrew	O	O
from	O	O
the	O	O
pharmacist	O	O
intervention	O	O
group	O	O
were	O	O
similar	O	O
to	O	O
patients	O	O
who	O	O
withdrew	O	O
from	O	O
the	O	O
usual-care	O	O
group	O	O
with	O	O
respect	O	O
to	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
insurance	O	O
status	O	O
,	O	O
and	O	O
chronic	O	O
conditions	O	O
.	O	O

Patients	O	O
who	O	O
smoked	O	O
or	O	O
had	O	O
commercial	O	O
insurance	O	O
were	O	O
more	O	O
likely	O	O
to	O	O
withdraw	Others	O
from	O	O
the	O	O
study	O	O
than	O	O
the	O	O
other	O	O
participants	O	O
.	O	O

However	O	O
,	O	O
multivariate	O	O
analysis	O	O
of	O	O
all	O	O
variables	O	O
,	O	O
when	O	O
adjusted	O	O
for	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
intervention	O	O
,	O	O
revealed	O	O
that	O	O
insurance	Others	O
status	Others	O
was	O	O
the	O	O
only	O	O
variable	O	O
associated	O	O
with	O	O
a	O	O
heightened	O	O
probability	O	O
of	O	O
withdrawal	Others	O
(	O	O
p=0.002	O	O
)	O	O
.	O	O

CONCLUSION	O	O
Although	O	O
this	O	O
study	O	O
had	O	O
a	O	O
high	O	O
withdrawal	O	O
rate	O	O
,	O	O
between-group	O	O
patient	O	O
characteristics	O	O
remained	O	O
balanced	O	O
.	O	O

Therefore	O	O
,	O	O
internal	O	O
validity	O	O
was	O	O
preserved	O	O
,	O	O
and	O	O
outcomes	O	O
from	O	O
the	O	O
study	O	O
groups	O	O
could	O	O
be	O	O
reliably	O	O
compared	O	O
.	O	O

A	O	O
lack	O	O
of	O	O
significant	O	O
differences	O	O
between	O	O
patients	O	O
who	O	O
withdrew	O	O
versus	O	O
those	O	O
who	O	O
completed	O	O
,	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
insurance	O	O
status	O	O
,	O	O
suggests	O	O
that	O	O
external	O	O
validity	O	O
was	O	O
not	O	O
jeopardized	O	O
.	O	O

Effect	O	O
of	O	O
a	O	O
vitamin/mineral	O	O
supplement	O	O
on	O	O
children	O	O
and	O	O
adults	O	O
with	O	O
autism	O	O
.	O	O

BACKGROUND	O	O
Vitamin/mineral	O	O
supplements	O	O
are	O	O
among	O	O
the	O	O
most	O	O
commonly	O	O
used	O	O
treatments	O	O
for	O	O
autism	O	O
,	O	O
but	O	O
the	O	O
research	O	O
on	O	O
their	O	O
use	O	O
for	O	O
treating	O	O
autism	O	O
has	O	O
been	O	O
limited	O	O
.	O	O

METHOD	O	O
This	O	O
study	O	O
is	O	O
a	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
three	O	O
month	O	O
vitamin/mineral	O	O
treatment	O	O
study	O	O
.	O	O

The	O	O
study	O	O
involved	O	O
141	O	O
children	O	O
and	O	O
adults	O	O
with	O	O
autism	O	O
,	O	O
and	O	O
pre	O	O
and	O	O
post	O	O
symptoms	O	O
of	O	O
autism	O	O
were	O	O
assessed	O	O
.	O	O

None	O	O
of	O	O
the	O	O
participants	O	O
had	O	O
taken	O	O
a	O	O
vitamin/mineral	O	O
supplement	O	O
in	O	O
the	O	O
two	O	O
months	O	O
prior	O	O
to	O	O
the	O	O
start	O	O
of	O	O
the	O	O
study	O	O
.	O	O

For	O	O
a	O	O
subset	O	O
of	O	O
the	O	O
participants	O	O
(	O	O
53	O	O
children	O	O
ages	O	O
5-16	O	O
)	O	O
pre	O	O
and	O	O
post	O	O
measurements	O	O
of	O	O
nutritional	O	O
and	O	O
metabolic	O	O
status	O	O
were	O	O
also	O	O
conducted	O	O
.	O	O

RESULTS	O	O
The	O	O
vitamin/mineral	O	O
supplement	O	O
was	O	O
generally	O	O
well-tolerated	Others	Others
,	O	O
and	O	O
individually	O	O
titrated	O	O
to	O	O
optimum	O	O
benefit	O	O
.	O	O

Levels	Physical	O
of	Physical	O
many	Physical	O
vitamins	Physical	O
,	O	O
minerals	Physical	O
,	O	O
and	O	O
biomarkers	Physical	O
improved/increased	O	O
showing	O	O
good	O	O
compliance	Mental	O
and	Physical	O
absorption	Physical	O
.	O	O

Statistically	O	O
significant	O	O
improvements	O	O
in	O	O
metabolic	O	O
status	O	O
were	O	O
many	O	O
including	O	O
:	O	O
total	Physical	O
sulfate	Physical	O
(	O	O
+17	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.001	O	O
)	O	O
,	O	O
S-adenosylmethionine	Physical	O
(	O	O
SAM	O	O
;	O	O
+6	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.003	O	O
)	O	O
,	O	O
reduced	O	O
glutathione	Physical	O
(	O	O
+17	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.0008	O	O
)	O	O
,	O	O
ratio	Physical	O
of	Physical	O
oxidized	Physical	O
glutathione	Physical	O
to	Physical	O
reduced	Physical	O
glutathione	Physical	O
(	O	O
GSSG	O	O
:	O	O
GSH	O	O
;	O	O
-27	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.002	O	O
)	O	O
,	O	O
nitrotyrosine	Physical	O
(	O	O
-29	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.004	O	O
)	O	O
,	O	O
ATP	Physical	O
(	O	O
+25	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.000001	O	O
)	O	O
,	O	O
NADH	Physical	O
(	O	O
+28	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.0002	O	O
)	O	O
,	O	O
and	O	O
NADPH	Physical	O
(	O	O
+30	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.001	O	O
)	O	O
.	O	O

Most	O	O
of	O	O
these	O	O
metabolic	O	O
biomarkers	O	O
improved	O	O
to	O	O
normal	O	O
or	O	O
near-normal	O	O
levels.The	O	O
supplement	O	O
group	O	O
had	O	O
significantly	O	O
greater	O	O
improvements	O	O
than	O	O
the	O	O
placebo	O	O
group	O	O
on	O	O
the	O	O
Parental	Physical	O
Global	Physical	O
Impressions-Revised	Physical	O
(	O	O
PGI-R	O	O
,	O	O
Average	O	O
Change	O	O
,	O	O
p	O	O
=	O	O
0.008	O	O
)	O	O
,	O	O
and	O	O
on	O	O
the	O	O
subscores	O	O
for	O	O
Hyperactivity	Physical	O
(	O	O
p	O	O
=	O	O
0.003	O	O
)	O	O
,	O	O
Tantrumming	Physical	O
(	O	O
p	O	O
=	O	O
0.009	O	O
)	O	O
,	O	O
Overall	Physical	O
(	O	O
p	O	O
=	O	O
0.02	O	O
)	O	O
,	O	O
and	O	O
Receptive	Physical	O
Language	Physical	O
(	O	O
p	O	O
=	O	O
0.03	O	O
)	O	O
.	O	O

For	O	O
the	O	O
other	O	O
three	O	O
assessment	O	O
tools	O	O
the	O	O
difference	O	O
between	O	O
treatment	O	O
group	O	O
and	O	O
placebo	O	O
group	O	O
was	O	O
not	O	O
statistically	O	O
significant.Regression	O	O
analysis	O	O
revealed	O	O
that	O	O
the	O	O
degree	O	O
of	O	O
improvement	O	O
on	O	O
the	O	O
Average	Physical	O
Change	Physical	O
of	Physical	O
the	Physical	O
PGI-R	Physical	O
was	O	O
strongly	O	O
associated	O	O
with	O	O
several	O	O
biomarkers	O	O
(	O	O
adj	O	O
.	O	O

R2	O	O
=	O	O
0.61	O	O
,	O	O
p	O	O
<	O	O
0.0005	O	O
)	O	O
with	O	O
the	O	O
initial	O	O
levels	O	O
of	O	O
biotin	O	Physical
and	O	Physical
vitamin	O	Physical
K	O	Physical
being	O	O
the	O	O
most	O	O
significant	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
;	O	O
both	O	O
biotin	O	O
and	O	O
vitamin	O	O
K	O	O
are	O	O
made	O	O
by	O	O
beneficial	O	O
intestinal	O	O
flora	O	O
.	O	O

CONCLUSIONS	O	O
Oral	O	O
vitamin/mineral	O	O
supplementation	O	O
is	O	O
beneficial	O	O
in	O	O
improving	O	O
the	O	O
nutritional	O	O
and	O	O
metabolic	O	O
status	O	O
of	O	O
children	O	O
with	O	O
autism	O	O
,	O	O
including	O	O
improvements	O	O
in	O	O
methylation	O	O
,	O	O
glutathione	O	O
,	O	O
oxidative	O	O
stress	O	O
,	O	O
sulfation	O	O
,	O	O
ATP	O	O
,	O	O
NADH	O	O
,	O	O
and	O	O
NADPH	O	O
.	O	O

The	O	O
supplement	O	O
group	O	O
had	O	O
significantly	O	O
greater	O	O
improvements	O	O
than	O	O
did	O	O
the	O	O
placebo	O	O
group	O	O
on	O	O
the	O	O
PGI-R	O	O
Average	O	O
Change	O	O
.	O	O

This	O	O
suggests	O	O
that	O	O
a	O	O
vitamin/mineral	O	O
supplement	O	O
is	O	O
a	O	O
reasonable	O	O
adjunct	O	O
therapy	O	O
to	O	O
consider	O	O
for	O	O
most	O	O
children	O	O
and	O	O
adults	O	O
with	O	O
autism	O	O
.	O	O

TRIAL	O	O
REGISTRATION	O	O
CLINICAL	O	O
TRIAL	O	O
REGISTRATION	O	O
NUMBER	O	O
NCT01225198	O	O
.	O	O

Clofarabine	O	O
?	O	O
fludarabine	O	O
with	O	O
once	O	O
daily	O	O
i.v	O	O
.	O	O

busulfan	O	O
as	O	O
pretransplant	O	O
conditioning	O	O
therapy	O	O
for	O	O
advanced	O	O
myeloid	O	O
leukemia	O	O
and	O	O
MDS	O	O
.	O	O

Although	O	O
a	O	O
combination	O	O
of	O	O
i.v	O	O
.	O	O

busulfan	O	O
(	O	O
Bu	O	O
)	O	O
and	O	O
fludarabine	O	O
(	O	O
Flu	O	O
)	O	O
is	O	O
a	O	O
safe	O	O
,	O	O
reduced-toxicity	O	O
conditioning	O	O
program	O	O
for	O	O
acute	O	O
myelogenous	O	O
leukemia/myelodysplastic	O	O
syndromes	O	O
(	O	O
AML/MDS	O	O
)	O	O
,	O	O
recurrent	O	O
leukemia	O	O
posttransplantation	O	O
remains	O	O
a	O	O
problem	O	O
.	O	O

To	O	O
enhance	O	O
the	O	O
conditioning	O	O
regimen	O	O
's	O	O
antileukemic	O	O
effect	O	O
,	O	O
we	O	O
decided	O	O
to	O	O
supplant	O	O
Flu	O	O
with	O	O
clofarabine	O	O
(	O	O
Clo	O	O
)	O	O
,	O	O
and	O	O
assayed	O	O
the	O	O
interactions	O	O
of	O	O
these	O	O
nucleoside	O	O
analogs	O	O
alone	O	O
and	O	O
in	O	O
combination	O	O
with	O	O
Bu	O	O
in	O	O
Bu-resistant	O	O
human	O	O
cell	O	O
lines	O	O
in	O	O
vitro	O	O
.	O	O

We	O	O
found	O	O
pronounced	O	O
synergy	O	O
between	O	O
each	O	O
nucleoside	O	O
and	O	O
the	O	O
alkylator	O	O
but	O	O
even	O	O
more	O	O
enhanced	O	O
cytotoxic	O	O
synergy	O	O
when	O	O
the	O	O
nucleoside	O	O
analogs	O	O
were	O	O
combined	O	O
prior	O	O
to	O	O
exposing	O	O
the	O	O
cells	O	O
to	O	O
Bu	O	O
.	O	O

We	O	O
then	O	O
designed	O	O
a	O	O
4-arm	O	O
clinical	O	O
trial	O	O
in	O	O
patients	O	O
with	O	O
myeloid	O	O
leukemia	O	O
undergoing	O	O
allogeneic	O	O
stem	O	O
cell	O	O
transplantation	O	O
(	O	O
allo-SCT	O	O
)	O	O
.	O	O

Patients	O	O
were	O	O
adaptively	O	O
randomized	O	O
as	O	O
follows	O	O
:	O	O
Arm	O	O
I-Clo	O	O
:	O	O
Flu	O	O
10:30	O	O
mg/m	O	O
(	O	O
2	O	O
)	O	O
,	O	O
Arm	O	O
II-20:20	O	O
mg/m	O	O
(	O	O
2	O	O
)	O	O
,	O	O
Arm	O	O
III-30:10	O	O
mg/m	O	O
(	O	O
2	O	O
)	O	O
,	O	O
and	O	O
Arm	O	O
IV-single-agent	O	O
Clo	O	O
at	O	O
40	O	O
mg/m	O	O
(	O	O
2	O	O
)	O	O
.	O	O

The	O	O
nucleoside	O	O
analog	O	O
(	O	O
s	O	O
)	O	O
were/was	O	O
infused	O	O
over	O	O
1	O	O
hour	O	O
once	O	O
daily	O	O
for	O	O
4	O	O
days	O	O
,	O	O
followed	O	O
on	O	O
each	O	O
day	O	O
by	O	O
Bu	O	O
,	O	O
infused	O	O
over	O	O
3	O	O
hours	O	O
to	O	O
a	O	O
pharmacokinetically	O	O
targeted	O	O
daily	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
(	O	O
AUC	O	O
)	O	O
of	O	O
6000	O	O
?Mol-min	O	O
?	O	O
10	O	O
%	O	O
.	O	O

Fifty-one	O	O
patients	O	O
have	O	O
been	O	O
enrolled	O	O
with	O	O
a	O	O
minimum	O	O
follow-up	O	O
exceeding	O	O
100	O	O
days	O	O
.	O	O

There	O	O
were	O	O
32	O	O
males	O	O
and	O	O
19	O	O
females	O	O
,	O	O
with	O	O
a	O	O
median	O	O
age	O	O
of	O	O
45	O	O
years	O	O
(	O	O
range	O	O
:	O	O
6-59	O	O
)	O	O
.	O	O

Nine	O	O
patients	O	O
had	O	O
chronic	O	O
myeloid	O	O
leukemia	O	O
(	O	O
CML	O	O
)	O	O
(	O	O
BC	O	O
:	O	O
2	O	O
,	O	O
second	O	O
AP	O	O
:	O	O
3	O	O
,	O	O
and	O	O
tyrosine-kinase	O	O
inhibitor	O	O
refractory	O	O
first	O	O
chronic	O	O
phase	O	O
[	O	O
CP	O	O
]	O	O
:	O	O
4	O	O
)	O	O
.	O	O

Forty-two	O	O
patients	O	O
had	O	O
AML	O	O
:	O	O
14	O	O
were	O	O
induction	O	O
failures	O	O
,	O	O
8	O	O
in	O	O
first	O	O
chemotherapy-refractory	O	O
relapse	O	O
,	O	O
7	O	O
in	O	O
untreated	O	O
relapse	O	O
,	O	O
3	O	O
in	O	O
second	O	O
or	O	O
subsequent	O	O
relapse	O	O
,	O	O
4	O	O
were	O	O
in	O	O
second	O	O
complete	O	Physical
remission	O	Physical
(	O	Physical
CR	O	Physical
)	O	Physical
,	O	Physical
and	O	Physical
3	O	Physical
in	O	Physical
second	O	Physical
CR	O	Physical
without	O	Physical
platelet	O	Physical
recovery	O	Physical
(	O	Physical
CRp	O	Physical
)	O	Physical
,	O	O
2	O	O
were	O	O
in	O	O
high-risk	O	O
CR1	O	O
.	O	O

Finally	O	O
,	O	O
1	O	O
patient	O	O
was	O	O
in	O	O
first	O	O
CRp	O	O
.	O	O

Graft-versus-host	O	O
disease	O	O
(	O	O
GVHD	O	O
)	O	O
prophylaxis	O	O
was	O	O
tacrolimus	O	O
and	O	O
mini-methorexate	O	O
(	O	O
MTX	O	O
)	O	O
,	O	O
and	O	O
those	O	O
who	O	O
had	O	O
an	O	O
unrelated	O	O
or	O	O
1	O	O
antigen-mismatched	O	O
donor	O	O
received	O	O
low-dose	O	O
rabbit-ATG	O	O
(	O	O
Thymoglobulin?	O	O
)	O	O
.	O	O

All	O	O
patients	O	O
engrafted	O	O
.	O	O

Forty-one	O	O
patients	O	O
had	O	O
active	O	O
leukemia	O	O
at	O	O
the	O	O
time	O	O
of	O	O
transplant	O	O
,	O	O
and	O	O
35	O	O
achieved	O	O
CR	O	O
(	O	O
85	O	O
%	O	O
)	O	O
.	O	O

Twenty	O	O
of	O	O
the	O	O
42	O	O
AML	O	O
patients	O	O
and	O	O
5	O	O
of	O	O
9	O	O
CML	O	O
patients	O	O
are	O	O
alive	O	O
with	O	O
a	O	O
projected	O	O
median	Mortality	O
overall	Mortality	O
survival	Mortality	O
(	Mortality	O
OS	Mortality	O
)	Mortality	O
of	O	O
23	O	O
months	O	O
.	O	O

Marrow	O	O
and	O	O
blood	O	O
(	O	O
T	O	O
cell	O	O
)	O	O
chimerism	O	O
studies	O	O
at	O	O
day	O	O
+100	O	O
revealed	O	O
that	O	O
both	O	O
in	O	O
the	O	O
lower-dose	O	O
Clo	O	O
groups	O	O
(	O	O
groups	O	O
1+2	O	O
)	O	O
and	O	O
the	O	O
higher-dose	O	O
Clo	O	O
groups	O	O
(	O	O
groups	O	O
3+4	O	O
)	O	O
,	O	O
the	O	O
patients	O	O
had	O	O
a	O	O
median	O	O
of	O	O
100	O	O
%	O	O
donor	O	O
(	O	O
T	O	O
cell	O	O
)	O	O
-derived	O	O
DNA	O	O
.	O	O

There	O	O
has	O	O
been	O	O
no	O	O
secondary	Adverseeffect	O
graft	Adverseeffect	O
failure	Adverseeffect	O
.	O	O

In	O	O
the	O	O
first	O	O
100	O	O
days	O	O
,	O	O
1	O	O
patient	O	O
died	O	Mortality
of	O	Mortality
pneumonia	O	Mortality
,	O	O
and	O	O
1	O	O
of	O	O
liver	O	O
GVHD	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
(	O	O
1	O	O
)	O	O
Clo	O	O
?	O	O
Flu	O	O
with	O	O
i.v	O	O
.	O	O

Bu	O	O
as	O	O
pretransplant	O	O
conditioning	O	O
is	O	O
safe	O	O
in	O	O
high-risk	O	O
myeloid	O	O
leukemia	O	O
patients	O	O
;	O	O
(	O	O
2	O	O
)	O	O
clofarabine	O	O
is	O	O
sufficiently	O	O
immunosuppressive	O	O
to	O	O
support	O	O
allo-SCT	O	O
in	O	O
myeloid	O	O
leukemia	O	O
;	O	O
and	O	O
(	O	O
3	O	O
)	O	O
the	O	O
median	O	Mortality
OS	O	Mortality
of	O	Mortality
23	O	Mortality
months	O	Mortality
in	O	O
this	O	O
high-risk	O	O
patient	O	O
population	O	O
is	O	O
encouraging	O	O
.	O	O

Additional	O	O
studies	O	O
to	O	O
evaluate	O	O
the	O	O
antileukemic	O	O
efficacy	O	O
of	O	O
Clo	O	O
?	O	O
Flu	O	O
with	O	O
i.v	O	O
.	O	O

Bu	O	O
as	O	O
pretransplant	O	O
conditioning	O	O
therapy	O	O
are	O	O
warranted	O	O
.	O	O

Is	O	O
chronic	O	O
sildenafil	O	O
therapy	O	O
safe	O	O
and	O	O
clinically	O	O
beneficial	O	O
in	O	O
patients	O	O
with	O	O
systolic	O	O
heart	O	O
failure	O	O
?	O	O
Sildenafil	O	O
is	O	O
a	O	O
selective	O	O
phosphodiesterase-5	O	O
inhibitor	O	O
and	O	O
causes	O	O
vasodilatation	O	O
,	O	O
particularly	O	O
in	O	O
pulmonary	O	O
circulation	O	O
.	O	O

Since	O	O
left	O	O
heart	O	O
failure	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
pulmonary	O	O
hypertension	O	O
out	O	O
of	O	O
proportion	O	O
to	O	O
left	O	O
heart	O	O
disease	O	O
,	O	O
sildenafil	O	O
may	O	O
have	O	O
beneficial	O	O
effect	O	O
in	O	O
such	O	O
patients	O	O
.	O	O

The	O	O
present	O	O
investigation	O	O
was	O	O
designed	O	O
as	O	O
a	O	O
12-week	O	O
,	O	O
single-center	O	O
,	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
study	O	O
evaluating	O	O
the	O	O
effects	O	O
of	O	O
sildenafil	O	O
on	O	O
mean	Physical	Physical
blood	Physical	Physical
pressure	Physical	Physical
(	O	O
primary	O	O
endpoint	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
left	O	O
systolic	O	O
heart	O	O
failure	O	O
.	O	O

Secondary	O	O
endpoints	O	O
included	O	O
exercise	Physical	Physical
capacity	Physical	Physical
assessed	O	O
by	O	O
6-minute	Physical	O
walk	Physical	O
test	Physical	O
.	O	O

A	O	O
total	O	O
of	O	O
106	O	O
patients	O	O
were	O	O
randomized	O	O
1:1	O	O
to	O	O
sildenafil	O	O
(	O	O
n=53	O	O
)	O	O
or	O	O
placebo	O	O
(	O	O
n=53	O	O
)	O	O
.	O	O

Patients	O	O
received	O	O
sildenafil	O	O
25	O	O
mg	O	O
twice	O	O
a	O	O
day	O	O
or	O	O
matching	O	O
placebo	O	O
for	O	O
the	O	O
first	O	O
2	O	O
weeks	O	O
and	O	O
50	O	O
mg	O	O
3	O	O
times	O	O
a	O	O
week	O	O
for	O	O
the	O	O
remainder	O	O
of	O	O
the	O	O
trial	O	O
.	O	O

The	O	O
placebo-corrected	O	O
effect	O	O
on	O	O
mean	Physical	Physical
blood	Physical	Physical
pressure	Physical	Physical
was	O	O
1.16	O	O
mm	O	O
Hg	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
-1.6	O	O
to	O	O
5.1	O	O
,	O	O
P	O	O
>	O	O
.05	O	O
)	O	O
,	O	O
demonstrating	O	O
that	O	O
sildenafil	O	O
did	O	O
not	O	O
decrease	O	O
mean	Physical	Physical
blood	Physical	Physical
pressure	Physical	Physical
.	O	O

Compared	O	O
with	O	O
placebo	O	O
,	O	O
sildenafil	O	O
increased	O	O
the	O	O
6-minute	Physical	O
walk	Physical	O
test	Physical	O
by	O	O
a	O	O
nonsignificant	O	O
treatment	O	O
effect	O	O
of	O	O
14	O	O
m	O	O
(	O	O
P=.67	O	O
)	O	O
.	O	O

Adverse	Adverseeffect	Adverseeffect
effects	Adverseeffect	Adverseeffect
occurred	O	O
in	O	O
a	O	O
comparable	O	O
proportion	O	O
of	O	O
patients	O	O
taking	O	O
sildenafil	O	O
and	O	O
placebo	O	O
,	O	O
and	O	O
none	O	O
of	O	O
the	O	O
patients	O	O
needed	O	O
to	O	O
discontinue	O	O
therapy	O	O
.	O	O

Sildenafil	O	O
is	O	O
well	O	O
tolerated	Others	O
in	O	O
left	O	O
heart	O	O
failure	O	O
patients	O	O
and	O	O
does	O	O
not	O	O
decrease	O	O
blood	Physical	Physical
pressure	Physical	Physical
.	O	O

It	O	O
can	O	O
be	O	O
safely	O	O
added	O	O
to	O	O
standard	O	O
heart	O	O
failure	O	O
therapy	O	O
.	O	O

Gastric	O	O
ulcer	O	O
treatment	O	O
with	O	O
intravenous	O	O
human	O	O
epidermal	O	O
growth	O	O
factor	O	O
:	O	O
a	O	O
double-blind	O	O
controlled	O	O
clinical	O	O
study	O	O
.	O	O

We	O	O
introduced	O	O
a	O	O
double-blind	O	O
controlled	O	O
clinical	O	O
study	O	O
to	O	O
compare	O	O
intravenous	O	O
human	O	O
epidermal	O	O
growth	O	O
factor	O	O
(	O	O
hEGF	O	O
)	O	O
to	O	O
cetraxate	O	O
hydrochloride	O	O
(	O	O
CH	O	O
)	O	O
,	O	O
an	O	O
antiulcer	O	O
drug	O	O
,	O	O
for	O	O
their	O	O
healing	O	Physical
effect	O	Physical
on	O	Physical
gastric	Physical	Physical
ulcers	Physical	Physical
.	O	O

We	O	O
also	O	O
prospected	O	O
an	O	O
oral	O	O
use	O	O
of	O	O
EGF	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
our	O	O
experimental	O	O
evidence	O	O
.	O	O

In	O	O
the	O	O
clinical	O	O
trial	O	O
,	O	O
the	O	O
rate	Physical	Physical
of	Physical	Physical
ulcer	Physical	Physical
healing	Physical	Physical
within	O	O
8	O	O
weeks	O	O
was	O	O
77.9	O	O
%	O	O
(	O	O
67/86	O	O
)	O	O
in	O	O
patients	O	O
receiving	O	O
6	O	O
micrograms	O	O
EGF	O	O
intravenously	O	O
twice	O	O
a	O	O
week	O	O
,	O	O
being	O	O
significantly	O	O
greater	O	O
than	O	O
51.7	O	O
%	O	O
(	O	O
45/87	O	O
)	O	O
in	O	O
those	O	O
given	O	O
CH	O	O
.	O	O

Taking	O	O
together	O	O
all	O	O
aspects	O	O
assessed	O	O
including	O	O
the	O	O
healing	Physical	Physical
rate	Physical	Physical
,	O	O
pain	Pain	Pain
relief	Pain	Pain
,	Pain	O
blood	Physical	O
examination	Physical	O
and	O	O
adverse	Adverseeffect	Adverseeffect
reactions	Adverseeffect	Adverseeffect
,	O	O
we	O	O
judged	O	O
the	O	O
hEGF	O	O
to	O	O
be	O	O
a	O	O
useful	O	O
and	O	O
safe	O	O
anticuler	O	O
drug	O	O
.	O	O

In	O	O
rats	O	O
,	O	O
50	O	O
micrograms/kg	O	O
mouse	O	O
EGF	O	O
(	O	O
mEGF	O	O
)	O	O
and	O	O
2	O	O
%	O	O
hydroxypropyl	O	O
cellulose	O	O
(	O	O
HPC	O	O
)	O	O
or	O	O
1.0	O	O
g/kg	O	O
sucralfate	O	O
given	O	O
by	O	O
gastric	O	O
intubation	O	O
significantly	O	O
raised	O	O
the	O	O
residual	Physical	O
mEGF	Physical	O
levels	Physical	O
in	O	O
both	O	O
gastric	O	O
luminal	O	O
content	O	O
(	O	O
HPC	O	O
:	O	O
x	O	O
30	O	O
;	O	O
sucralfate	O	O
:	O	O
x	O	O
300	O	O
as	O	O
high	O	O
as	O	O
those	O	O
in	O	O
EGF	O	O
alone	O	O
)	O	O
and	O	O
tissue	O	O
(	O	O
HPC	O	O
:	O	O
x	O	O
60	O	O
;	O	O
sucralfate	O	O
:	O	O
x	O	O
100	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
combined	O	O
treatments	O	O
significantly	O	O
promoted	O	O
healing	Physical	O
of	Physical	O
rat	Physical	O
gastric	Physical	O
ulcers	Physical	O
whereas	O	O
each	O	O
agent	O	O
alone	O	O
had	O	O
no	O	O
significant	O	O
effect	O	O
as	O	O
compared	O	O
with	O	O
control	O	O
(	O	O
saline	O	O
)	O	O
.	O	O

This	O	O
indicated	O	O
the	O	O
beneficial	O	O
effect	O	O
on	O	O
ulcers	O	O
of	O	O
oral	O	O
administration	O	O
of	O	O
EGF	O	O
with	O	O
agents	O	O
allowing	O	O
it	O	O
to	O	O
remain	O	O
at	O	O
high	O	O
levels	O	O
in	O	O
the	O	O
stomach	O	O
,	O	O
whereas	O	O
most	O	O
reports	O	O
suggested	O	O
less	O	O
effect	O	O
of	O	O
oral	O	O
EGF	O	O
on	O	O
healing	O	O
of	O	O
gastroduodenal	O	O
ulcers	O	O
.	O	O

Subsequent	O	O
to	O	O
the	O	O
clinical	O	O
study	O	O
,	O	O
evaluation	O	O
of	O	O
oral	O	O
use	O	O
of	O	O
EGF	O	O
may	O	O
be	O	O
expected	O	O
as	O	O
the	O	O
next	O	O
step	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
ulcers	O	O
.	O	O

The	O	O
experimental	O	O
evidence	O	O
above	O	O
would	O	O
possibly	O	O
be	O	O
a	O	O
guide	O	O
for	O	O
such	O	O
trial	O	O
.	O	O

Psychosocial	O	O
nursing	O	O
therapy	O	O
following	O	O
sudden	O	O
cardiac	O	O
arrest	O	O
:	O	O
impact	O	O
on	O	O
two-year	Mortality	O
survival	Mortality	O
.	O	O

BACKGROUND	O	O
Although	O	O
psychosocial	O	O
therapy	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
reduce	O	O
mortality	Mortality	O
after	O	O
myocardial	O	O
infarction	O	O
,	O	O
it	O	O
is	O	O
unknown	O	O
whether	O	O
the	O	O
benefits	O	O
of	O	O
psychosocial	O	O
therapy	O	O
on	O	O
mortality	O	O
reduction	O	O
extend	O	O
to	O	O
out-of-hospital	O	O
sudden	O	O
cardiac	O	O
arrest	O	O
,	O	O
a	O	O
main	O	O
cause	O	O
of	O	O
cardiovascular	Mortality	O
mortality	Mortality	O
.	O	O

OBJECTIVE	O	O
Describe	O	Others
efficacy	O	Others
of	O	O
psychosocial	O	O
therapy	O	O
on	O	O
two-year	O	O
cardiovascular	Mortality	O
mortality	Mortality	O
in	O	O
sudden	O	O
cardiac	O	O
arrest	O	O
survivors	O	O
.	O	O

METHOD	O	O
Survivors	O	O
of	O	O
out-of-hospital	O	O
ventricular	O	O
fibrillation	O	O
or	O	O
asystole	O	O
(	O	O
N	O	O
=	O	O
129	O	O
)	O	O
,	O	O
documented	O	O
by	O	O
electrocardiograms	O	O
from	O	O
registries	O	O
of	O	O
a	O	O
citywide	O	O
Medic	O	O
One	O	O
unit	O	O
and	O	O
two	O	O
countywide	O	O
emergency	O	O
units	O	O
,	O	O
were	O	O
randomized	O	O
into	O	O
a	O	O
two	O	O
group	O	O
,	O	O
experimental	O	O
,	O	O
longitudinal	O	O
design	O	O
.	O	O

The	O	O
intervention	O	O
consisted	O	O
of	O	O
11	O	O
individual	O	O
sessions	O	O
,	O	O
implementing	O	O
three	O	O
components	O	O
:	O	O
physiologic	O	O
relaxation	O	O
with	O	O
biofeedback	O	O
training	O	O
focused	O	O
on	O	O
altering	O	O
autonomic	O	O
tone	O	O
;	O	O
cognitive	O	O
behavioral	O	O
therapy	O	O
aimed	O	O
at	O	O
self-management	O	O
and	O	O
coping	O	O
strategies	O	O
for	O	O
depression	O	O
,	O	O
anxiety	O	Mental
,	O	O
and	O	O
anger	O	O
;	O	O
and	O	O
cardiovascular	O	Physical
health	O	Physical
education	O	Physical
.	O	O

The	O	O
primary	O	O
outcome	O	O
measure	O	O
was	O	O
cardiovascular	Mortality	O
mortality	Mortality	O
.	O	O

RESULTS	O	O
Risk	Mortality	Mortality
of	Mortality	Mortality
cardiovascular	Mortality	Mortality
death	Mortality	Mortality
was	O	O
significantly	O	O
reduced	O	O
86	O	O
%	O	O
by	O	O
psychosocial	O	O
therapy	O	O
,	O	O
p	O	O
=	O	O
.03	O	O
.	O	O

Six	O	O
of	O	O
the	O	O
seven	O	O
cardiovascular	Mortality	O
deaths	Mortality	O
in	O	O
the	O	O
control	O	O
group	O	O
were	O	O
caused	O	O
by	O	O
ventricular	O	O
arrhythmias	O	O
.	O	O

The	Mortality	O
cardiovascular	Mortality	O
death	Mortality	O
in	O	O
the	O	O
therapy	O	O
group	O	O
was	O	O
due	O	O
to	O	O
stroke	O	O
.	O	O

Controlling	O	O
for	O	O
depression	Physical	O
,	O	O
previous	Physical	O
myocardial	Physical	O
infarction	Physical	O
,	O	O
low	Physical	O
ejection	Physical	O
fraction	Physical	O
,	O	O
decreased	Physical	O
heart	Physical	Physical
rate	Physical	Physical
variability	Physical	Physical
,	O	O
and	O	O
ventricular	Physical	O
ectopic	Physical	O
beats	Physical	O
had	O	O
little	O	O
impact	O	O
on	O	O
estimated	O	O
treatment	O	O
effect	O	O
.	O	O

The	O	O
risk	Mortality	O
of	Mortality	O
all-cause	Mortality	Mortality
mortality	Mortality	Mortality
was	O	O
reduced	O	O
by	O	O
62	O	O
%	O	O
in	O	O
the	O	O
therapy	O	O
group	O	O
,	O	O
p	O	O
=	O	O
.13	O	O
.	O	O

There	O	O
were	O	O
a	O	O
total	O	O
of	O	O
three	O	O
deaths	Mortality	O
in	O	O
the	O	O
therapy	O	O
group	O	O
and	O	O
eight	O	O
deaths	Mortality	Mortality
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

CONCLUSIONS	O	O
Psychosocial	O	O
therapy	O	O
significantly	O	O
reduced	O	O
the	O	O
risk	O	Mortality
of	O	Mortality
cardiovascular	Mortality	Mortality
death	Mortality	Mortality
in	O	O
sudden	O	O
cardiac	O	O
arrest	O	O
survivors	O	O
.	O	O

Pilot	O	O
study	O	O
of	O	O
Panax	O	O
quinquefolius	O	O
(	O	O
American	O	O
ginseng	O	O
)	O	O
to	O	O
improve	O	O
cancer-related	O	Physical
fatigue	O	Physical
:	O	O
a	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
dose-finding	O	O
evaluation	O	O
:	O	O
NCCTG	O	O
trial	O	O
N03CA	O	O
.	O	O

PURPOSE	O	O
This	O	O
pilot	O	O
trial	O	O
sought	O	O
to	O	O
investigate	O	O
whether	O	O
any	O	O
of	O	O
three	O	O
doses	O	O
of	O	O
American	O	O
ginseng	O	O
(	O	O
Panax	O	O
quinquefolius	O	O
)	O	O
might	O	O
help	O	O
cancer-related	O	Physical
fatigue	O	Physical
.	O	O

A	O	O
secondary	O	O
aim	O	O
was	O	O
to	O	O
evaluate	O	O
toxicity	O	O
.	O	O

METHODS	O	O
Eligible	O	O
adults	O	O
with	O	O
cancer	O	O
were	O	O
randomized	O	O
in	O	O
a	O	O
double-blind	O	O
manner	O	O
,	O	O
to	O	O
receive	O	O
American	O	O
ginseng	O	O
in	O	O
doses	O	O
of	O	O
750	O	O
,	O	O
1,000	O	O
,	O	O
or	O	O
2,000	O	O
mg/day	O	O
or	O	O
placebo	O	O
given	O	O
in	O	O
twice	O	O
daily	O	O
dosing	O	O
over	O	O
8	O	O
weeks	O	O
.	O	O

Outcome	O	O
measures	O	O
included	O	O
the	O	O
Brief	Physical	Mental
Fatigue	Physical	Mental
Inventory	Physical	Mental
,	O	Mental
vitality	Physical	Mental
subscale	Physical	Mental
of	Physical	Mental
the	Physical	Mental
Medical	Physical	Mental
Outcome	Physical	Mental
Scale	Physical	Mental
Short	Physical	Mental
Form-36	Physical	Mental
(	Physical	Mental
SF-36	Physical	Mental
)	Physical	Mental
,	O	O
and	O	O
the	O	O
Global	Physical	O
Impression	Physical	O
of	Physical	O
Benefit	Physical	O
Scale	Physical	O
at	O	O
4	O	O
and	O	O
8	O	O
weeks	O	O
.	O	O

RESULTS	O	O
Two	O	O
hundred	O	O
ninety	O	O
patients	O	O
were	O	O
accrued	O	O
to	O	O
this	O	O
trial	O	O
.	O	O

Nonsignificant	O	O
trends	O	O
for	O	O
all	O	O
outcomes	O	O
were	O	O
seen	O	O
in	O	O
favor	O	O
of	O	O
the	O	O
1,000-	O	O
and	O	O
2,000-mg/day	O	O
doses	O	O
of	O	O
American	O	O
ginseng	O	O
.	O	O

Area	O	O
under	O	O
the	O	O
curve	O	O
analysis	O	O
of	O	O
activity	O	Mental
interference	O	Mental
from	O	Mental
the	O	Mental
Brief	Physical	Mental
Fatigue	Physical	Mental
Inventory	Physical	Mental
was	O	O
460-467	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
and	O	O
750	O	O
mg/day	O	O
group	O	O
versus	O	O
480-551	O	O
in	O	O
the	O	O
1,000-	O	O
and	O	O
2,000-mg/day	O	O
arms	O	O
,	O	O
respectively	O	O
.	O	O

Change	O	O
from	O	O
baseline	O	O
in	O	O
the	O	O
vitality	Physical	O
subscale	Physical	O
of	O	O
the	O	O
SF-36	O	Physical
was	O	O
7.3-7.8	O	O
in	O	O
the	O	O
placebo	O	O
and	O	O
the	O	O
750-mg/day	O	O
arm	O	O
,	O	O
versus	O	O
10.5-14.6	O	O
in	O	O
the	O	O
1,000-	O	O
and	O	O
2,000-mg/day	O	O
arms	O	O
.	O	O

Over	O	O
twice	O	O
as	O	O
many	O	O
patients	O	O
on	O	O
ginseng	O	O
perceived	O	O
a	O	O
benefit	O	O
and	O	O
were	O	O
satisfied	Others	O
with	O	O
treatment	O	O
over	O	O
those	O	O
on	O	O
placebo	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
any	O	O
measured	O	O
toxicities	Adverseeffect	O
between	O	O
any	O	O
of	O	O
the	O	O
arms	O	O
.	O	O

CONCLUSION	O	O
There	O	O
appears	O	O
to	O	O
be	O	O
some	O	O
activity	O	O
and	O	O
tolerable	O	Others
toxicity	O	Others
at	O	O
1,000-2,000	O	O
mg/day	O	O
doses	O	O
of	O	O
American	O	O
ginseng	O	O
with	O	O
regard	O	O
to	O	O
cancer-related	O	Physical
fatigue	O	Physical
.	O	O

Thus	O	O
,	O	O
further	O	O
study	O	O
of	O	O
American	O	O
ginseng	O	O
is	O	O
warranted	O	O
.	O	O

Dissociation	O	O
between	O	O
cortical	O	O
activation	O	O
and	O	O
cognitive	O	O
performance	O	O
under	O	O
pharmacological	O	O
blood	O	O
pressure	O	O
elevation	O	O
in	O	O
chronic	O	O
hypotension	O	O
.	O	O

The	O	O
present	O	O
study	O	O
explored	O	O
the	O	O
impact	O	O
of	O	O
pharmacological	O	O
blood	O	O
pressure	O	O
elevation	O	O
on	O	O
cortical	O	Physical
activation	O	Physical
and	O	Physical
reaction	O	Physical
time	O	Physical
in	O	Physical
chronic	O	Physical
hypotension	O	Physical
.	O	O

Effects	O	O
of	O	O
the	O	O
sympathomimetic	O	O
etilefrine	O	O
were	O	O
investigated	O	O
in	O	O
50	O	O
hypotensive	O	O
persons	O	O
based	O	O
on	O	O
a	O	O
randomized	O	O
,	O	O
placebo-controlled	O	O
double	O	O
blind	O	O
design	O	O
.	O	O

As	O	O
an	O	O
indicator	O	O
of	O	O
cortical	O	O
excitability	O	O
,	O	O
the	O	O
contingent	O	O
negative	O	O
variation	O	O
(	O	O
CNV	O	O
)	O	O
,	O	O
induced	O	O
by	O	O
a	O	O
constant	O	O
foreperiod	O	O
reaction	O	O
time	O	O
task	O	O
,	O	O
was	O	O
assessed	O	O
at	O	O
frontal	O	O
(	O	O
F3	O	O
,	O	O
Fz	O	O
,	O	O
F4	O	O
)	O	O
and	O	O
central	O	O
(	O	O
C3	O	O
,	O	O
Cz	O	O
,	O	O
C4	O	O
)	O	O
scalp	O	O
sites	O	O
.	O	O

Etilefrine	O	O
provoked	O	O
a	O	O
decrease	O	O
in	O	O
the	O	O
frontal	Physical	O
and	Physical	O
central	Physical	O
CNV	Physical	O
.	O	O

In	O	O
contrast	O	O
,	O	O
shorter	O	O
reaction	Physical	O
times	Physical	O
were	O	O
observed	O	O
following	O	O
drug	O	O
administration	O	O
.	O	O

The	O	O
degree	O	O
of	O	O
pharmacologically	O	O
induced	Physical	O
blood	Physical	Physical
pressure	Physical	Physical
elevation	Physical	Physical
was	O	O
correlated	O	O
to	O	O
CNV	O	O
attrition	O	O
as	O	O
well	O	O
as	O	O
to	O	O
performance	O	O
enhancement	O	O
.	O	O

Inhibitory	O	O
effects	O	O
of	O	O
baroreceptor	O	O
activation	O	O
on	O	O
cortical	O	O
excitability	O	O
and	O	O
enhanced	O	O
cerebral	O	Physical
blood	O	Physical
flow	O	Physical
are	O	O
considered	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
mediating	O	O
the	O	O
effects	O	O
of	O	O
blood	Physical	Physical
pressure	Physical	Physical
elevation	Physical	O
on	O	O
cerebral	O	Physical
functioning	O	Physical
.	O	O

Implications	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
chronic	O	O
hypotension	O	O
are	O	O
discussed	O	O
.	O	O

The	O	O
ScanBrit	O	O
randomised	O	O
,	O	O
controlled	O	O
,	O	O
single-blind	O	O
study	O	O
of	O	O
a	O	O
gluten-	O	O
and	O	O
casein-free	O	O
dietary	O	O
intervention	O	O
for	O	O
children	O	O
with	O	O
autism	O	O
spectrum	O	O
disorders	O	O
.	O	O

There	O	O
is	O	O
increasing	O	O
interest	O	O
in	O	O
the	O	O
use	O	O
of	O	O
gluten-	O	O
and	O	O
casein-free	O	O
diets	O	O
for	O	O
children	O	O
with	O	O
autism	O	O
spectrum	O	O
disorders	O	O
(	O	O
ASDs	O	O
)	O	O
.	O	O

We	O	O
report	O	O
results	O	O
from	O	O
a	O	O
two-stage	O	O
,	O	O
24-month	O	O
,	O	O
randomised	O	O
,	O	O
controlled	O	O
trial	O	O
incorporating	O	O
an	O	O
adaptive	O	O
'catch-up	O	O
'	O	O
design	O	O
and	O	O
interim	O	O
analysis	O	O
.	O	O

Stage	O	O
1	O	O
of	O	O
the	O	O
trial	O	O
saw	O	O
72	O	O
Danish	O	O
children	O	O
(	O	O
aged	O	O
4	O	O
years	O	O
to	O	O
10	O	O
years	O	O
11	O	O
months	O	O
)	O	O
assigned	O	O
to	O	O
diet	O	O
(	O	O
A	O	O
)	O	O
or	O	O
non-diet	O	O
(	O	O
B	O	O
)	O	O
groups	O	O
by	O	O
stratified	O	O
randomisation	O	O
.	O	O

Autism	Mental	O
Diagnostic	Mental	O
Observation	Mental	O
Schedule	Mental	O
(	Mental	O
ADOS	Mental	O
)	Mental	O
and	O	O
the	O	O
Gilliam	Mental	Others
Autism	Mental	Others
Rating	Mental	Others
Scale	Mental	Others
(	Mental	Others
GARS	Mental	Others
)	Mental	Others
were	O	O
used	O	O
to	O	O
assess	O	O
core	Mental	O
autism	Mental	O
behaviours	Mental	O
,	O	O
Vineland	Mental	O
Adaptive	Mental	O
Behaviour	Mental	O
Scales	Mental	O
(	Mental	O
VABS	Mental	O
)	Mental	O
to	O	O
ascertain	O	O
developmental	O	Mental
level	O	Mental
,	O	Mental
and	O	Mental
Attention-Deficit	Mental	Mental
Hyperactivity	Mental	Mental
Disorder	Mental	Mental
-	Mental	Mental
IV	Mental	Mental
scale	Mental	Mental
(	Mental	Mental
ADHD-IV	Mental	Mental
)	Mental	Mental
to	O	Mental
determine	O	Mental
inattention	O	Mental
and	O	Mental
hyperactivity	O	Mental
.	O	Mental

Participants	O	O
were	O	O
tested	O	O
at	O	O
baseline	O	O
,	O	O
8	O	O
,	O	O
and	O	O
12	O	O
months	O	O
.	O	O

Based	O	O
on	O	O
per	O	O
protocol	O	O
repeated	O	O
measures	O	O
analysis	O	O
,	O	O
data	O	O
for	O	O
26	O	O
diet	O	O
children	O	O
and	O	O
29	O	O
controls	O	O
were	O	O
available	O	O
at	O	O
12	O	O
months	O	O
.	O	O

At	O	O
this	O	O
point	O	O
,	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
improvement	O	O
to	O	O
mean	O	O
diet	O	O
group	O	O
scores	O	O
(	O	O
time*treatment	O	O
interaction	O	O
)	O	O
on	O	O
sub-domains	O	Mental
of	O	Mental
ADOS	Mental	Mental
,	O	Mental
GARS	Mental	Mental
and	O	Mental
ADHD-IV	Mental	Mental
measures	O	Mental
.	O	O

Surpassing	O	O
of	O	O
predefined	O	O
statistical	O	O
thresholds	O	O
as	O	O
evidence	O	O
of	O	O
improvement	O	O
in	O	O
group	O	O
A	O	O
at	O	O
12	O	O
months	O	O
sanctioned	O	O
the	O	O
re-assignment	O	O
of	O	O
group	O	O
B	O	O
participants	O	O
to	O	O
active	O	O
dietary	O	O
treatment	O	O
.	O	O

Stage	O	O
2	O	O
data	O	O
for	O	O
18	O	O
group	O	O
A	O	O
and	O	O
17	O	O
group	O	O
B	O	O
participants	O	O
were	O	O
available	O	O
at	O	O
24	O	O
months	O	O
.	O	O

Multiple	O	O
scenario	O	O
analysis	O	O
based	O	O
on	O	O
inter-	O	O
and	O	O
intra-group	O	O
comparisons	O	O
showed	O	O
some	O	O
evidence	O	O
of	O	O
sustained	O	O
clinical	O	O
group	O	O
improvements	O	O
although	O	O
possibly	O	O
indicative	O	O
of	O	O
a	O	O
plateau	O	O
effect	O	O
for	O	O
intervention	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
dietary	O	O
intervention	O	O
may	O	O
positively	O	O
affect	O	O
developmental	O	Mental
outcome	O	Mental
for	O	O
some	O	O
children	O	O
diagnosed	O	O
with	O	O
ASD	O	O
.	O	O

In	O	O
the	O	O
absence	O	O
of	O	O
a	O	O
placebo	O	O
condition	O	O
to	O	O
the	O	O
current	O	O
investigation	O	O
,	O	O
we	O	O
are	O	O
,	O	O
however	O	O
,	O	O
unable	O	O
to	O	O
disqualify	O	O
potential	O	O
effects	O	O
derived	O	O
from	O	O
intervention	O	O
outside	O	O
of	O	O
dietary	O	O
changes	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
required	O	O
to	O	O
ascertain	O	O
potential	O	O
best-	O	O
and	O	O
non-responders	O	O
to	O	O
intervention	O	O
.	O	O

The	O	O
study	O	O
was	O	O
registered	O	O
with	O	O
ClincialTrials.gov	O	O
,	O	O
number	O	O
NCT00614198	O	O
.	O	O

Study	O	O
of	O	O
the	O	O
therapeutic	O	O
effects	O	O
of	O	O
a	O	O
hippotherapy	O	O
simulator	O	O
in	O	O
children	O	O
with	O	O
cerebral	O	O
palsy	O	O
:	O	O
a	O	O
stratified	O	O
single-blind	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
investigate	O	O
whether	O	O
hippotherapy	O	O
(	O	O
when	O	O
applied	O	O
by	O	O
a	O	O
simulator	O	O
)	O	O
improves	O	O
postural	O	Physical
control	O	Physical
and	O	Physical
balance	O	Physical
in	O	O
children	O	O
with	O	O
cerebral	O	O
palsy	O	O
.	O	O

DESIGN	O	O
Stratified	O	O
single-blind	O	O
randomized	O	O
controlled	O	O
trial	O	O
with	O	O
an	O	O
independent	O	O
assessor	O	O
.	O	O

Stratification	O	O
was	O	O
made	O	O
by	O	O
gross	O	O
motor	O	O
function	O	O
classification	O	O
system	O	O
levels	O	O
,	O	O
and	O	O
allocation	O	O
was	O	O
concealed	O	O
.	O	O

SUBJECTS	O	O
Children	O	O
between	O	O
4	O	O
and	O	O
18	O	O
years	O	O
old	O	O
with	O	O
cerebral	O	O
palsy	O	O
.	O	O

INTERVENTIONS	O	O
Participants	O	O
were	O	O
randomized	O	O
to	O	O
an	O	O
intervention	O	O
(	O	O
simulator	O	O
ON	O	O
)	O	O
or	O	O
control	O	O
(	O	O
simulator	O	O
OFF	O	O
)	O	O
group	O	O
after	O	O
getting	O	O
informed	O	O
consent	O	O
.	O	O

Treatment	O	O
was	O	O
provided	O	O
once	O	O
a	O	O
week	O	O
(	O	O
15	O	O
minutes	O	O
)	O	O
for	O	O
10	O	O
weeks	O	O
.	O	O

MAIN	O	O
MEASURES	O	O
Gross	Physical	Physical
Motor	Physical	Physical
Function	Physical	Physical
Measure	Physical	Physical
(	Physical	O
dimension	Physical	O
B	Physical	O
for	Physical	O
balance	Physical	O
and	Physical	O
the	Physical	O
Total	Physical	Physical
Score	Physical	Physical
)	Physical	Physical
and	O	Physical
Sitting	Physical	Physical
Assessment	Physical	Physical
Scale	Physical	Physical
were	O	O
carried	O	O
out	O	O
at	O	O
baseline	O	O
(	O	O
prior	O	O
to	O	O
randomization	O	O
)	O	O
,	O	O
end	O	O
of	O	O
intervention	O	O
and	O	O
12	O	O
weeks	O	O
after	O	O
completing	O	O
the	O	O
intervention	O	O
.	O	O

RESULTS	O	O
Thirty-eight	O	O
children	O	O
participated	O	O
.	O	O

The	O	O
groups	O	O
were	O	O
balanced	O	O
at	O	O
baseline	O	O
.	O	O

Sitting	Physical	Physical
balance	Physical	Physical
(	O	O
measured	O	O
by	O	O
dimension	O	O
B	O	O
of	O	O
the	O	O
Gross	O	Physical
Motor	O	Physical
Function	O	Physical
Measure	O	Physical
)	O	Physical
improved	O	O
significantly	O	O
in	O	O
the	O	O
treatment	O	O
group	O	O
(	O	O
effect	O	O
size	O	O
=	O	O
0.36	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
0.01-0.71	O	O
)	O	O
and	O	O
the	O	O
effect	Physical	O
size	Physical	O
was	O	O
greater	O	O
in	O	O
the	O	O
severely	O	O
disabled	O	O
group	O	O
(	O	O
effect	O	O
size	O	O
=	O	O
0.80	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
0.13-1.47	O	O
)	O	O
.	O	O

The	O	O
improvements	Physical	O
in	Physical	O
sitting	Physical	Physical
balance	Physical	Physical
were	O	O
not	O	O
maintained	O	O
over	O	O
the	O	O
follow-up	O	O
period	O	O
.	O	O

Changes	O	O
in	O	O
the	O	O
total	Physical	Physical
score	Physical	Physical
of	Physical	Physical
the	Physical	Physical
Gross	Physical	Physical
Motor	Physical	Physical
Function	Physical	Physical
Measure	Physical	Physical
and	O	Physical
the	O	Physical
Sitting	Physical	Physical
Assessment	Physical	Physical
Scale	Physical	Physical
were	O	O
not	O	O
significant	O	O
.	O	O

CONCLUSION	O	O
Hippotherapy	O	O
with	O	O
a	O	O
simulator	O	O
can	O	O
improve	O	O
sitting	Physical	O
balance	Physical	O
in	O	O
cerebral	O	O
palsy	O	O
children	O	O
who	O	O
have	O	O
higher	O	O
levels	O	O
of	O	O
disability	O	O
.	O	O

However	O	O
,	O	O
this	O	O
did	O	O
not	O	O
lead	O	O
to	O	O
a	O	O
change	O	O
in	O	O
the	O	O
overall	O	O
function	O	O
of	O	O
these	O	O
children	O	O
(	O	O
Gross	O	O
Motor	O	O
Function	O	O
Classification	O	O
System	O	O
level	O	O
V	O	O
)	O	O
.	O	O

Short-term	O	O
studies	O	O
on	O	O
the	O	O
use	O	O
of	O	O
glycerol	O	O
as	O	O
an	O	O
osmotic	O	O
agent	O	O
in	O	O
continuous	O	O
ambulatory	O	O
peritoneal	O	O
dialysis	O	O
(	O	O
CAPD	O	O
)	O	O
.	O	O

The	O	O
use	O	O
of	O	O
glycerol	O	O
as	O	O
an	O	O
osmotic	O	O
agent	O	O
in	O	O
two	O	O
different	O	O
concentrations	O	O
(	O	O
92	O	O
mmol/l	O	O
and	O	O
272	O	O
mmol/l	O	O
)	O	O
in	O	O
peritoneal	O	O
dialysis	O	O
fluid	O	O
was	O	O
investigated	O	O
over	O	O
3	O	O
days	O	O
in	O	O
six	O	O
patients	O	O
on	O	O
continuous	O	O
ambulatory	O	O
peritoneal	O	O
dialysis	O	O
and	O	O
compared	O	O
with	O	O
two	O	O
concentrations	O	O
of	O	O
glucose	O	O
(	O	O
76	O	O
mmol/l	O	O
and	O	O
215	O	O
mmol/l	O	O
)	O	O
in	O	O
the	O	O
same	O	O
patients	O	O
.	O	O

The	O	O
calorific	Physical	O
value	Physical	O
of	O	O
the	O	O
absorbed	O	O
osmotic	O	O
agent	O	O
was	O	O
lower	O	O
,	O	O
by	O	O
19	O	O
%	O	O
with	O	O
isotonic	O	O
and	O	O
22	O	O
%	O	O
with	O	O
hypertonic	O	O
solutions	O	O
,	O	O
when	O	O
glycerol	O	O
was	O	O
used	O	O
in	O	O
place	O	O
of	O	O
glucose	O	O
.	O	O

However	O	O
,	O	O
glycerol	O	O
provided	O	O
significantly	O	O
lower	O	O
total	Physical	O
ultrafiltration	Physical	O
than	O	O
glucose	O	O
at	O	O
each	O	O
concentration	O	O
,	O	O
despite	O	O
a	O	O
higher	O	O
initial	O	O
osmotic	O	O
pressure	O	O
of	O	O
the	O	O
glycerol-based	O	O
solutions	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
higher	O	Physical
concentration	O	Physical
of	O	Physical
glycerol	O	Physical
required	O	O
to	O	O
provide	O	O
equal	Physical	O
ultrafiltration	Physical	O
may	O	O
offset	O	O
any	O	O
calorific	O	O
advantage	O	O
.	O	O

Equilibration	Physical	Physical
of	Physical	Physical
creatinine	Physical	Physical
and	Physical	O
urea	Physical	O
was	O	O
slower	O	O
and	O	O
creatinine	Physical	Physical
clearance	Physical	Physical
lower	O	Physical
with	O	O
glycerol	O	O
.	O	O

Solutions	O	O
containing	O	O
glycerol	O	O
were	O	O
initially	O	O
less	O	O
acid	O	O
(	O	O
pH	O	O
6.5	O	O
)	O	O
than	O	O
those	O	O
containing	O	O
glucose	O	O
(	O	O
pH	O	O
5.1	O	O
)	O	O
.	O	O

Blood	Physical	Physical
glycerol	Physical	Physical
levels	Physical	Physical
,	O	O
which	O	O
were	O	O
in	O	O
the	O	O
physiological	O	O
range	O	O
with	O	O
glucose	O	O
as	O	O
the	O	O
osmotic	O	O
agent	O	O
,	O	O
reached	O	O
a	O	O
peak	O	O
80-fold	O	O
greater	O	O
at	O	O
4.3	O	O
+/-	O	O
0.8	O	O
mmol/l	O	O
during	O	O
dialysis	O	O
with	O	O
fluid	O	O
containing	O	O
glycerol	O	O
at	O	O
272	O	O
mmol/l	O	O
and	O	O
eightfold	O	O
higher	O	O
at	O	O
0.42	O	O
+/-	O	O
0.09	O	O
mmol/l	O	O
with	O	O
glycerol	O	O
at	O	O
92	O	O
mmol/l	O	O
.	O	O

There	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
haemolysis	Adverseeffect	O
or	O	O
other	O	O
toxic	Adverseeffect	O
effect	Adverseeffect	O
despite	O	O
these	O	O
levels	O	O
.	O	O

The	O	O
rise	O	Physical
in	O	Physical
blood	O	Physical
glucose	O	Physical
and	O	O
insulin	O	O
noted	O	O
during	O	O
the	O	O
use	O	O
of	O	O
glucose-based	O	O
solutions	O	O
was	O	O
not	O	O
found	O	O
with	O	O
glycerol	O	O
.	O	O

Circulating	Physical	O
levels	Physical	O
of	Physical	O
lactate	Physical	O
,	O	O
pyruvate	Physical	O
,	O	O
alanine	Physical	O
,	O	O
non-esterified	Physical	O
fatty	Physical	O
acids	Physical	O
and	O	O
the	O	O
ketone	O	O
bodies	O	O
were	O	O
similar	O	O
with	O	O
the	O	O
two	O	O
agents	O	O
.	O	O

Although	O	O
these	O	O
short-term	O	O
studies	O	O
have	O	O
shown	O	O
no	O	O
conclusive	O	O
advantage	O	O
of	O	O
glycerol	O	O
over	O	O
glucose	O	O
,	O	O
long-term	O	O
effects	O	O
of	O	O
glycerol	O	O
,	O	O
particularly	O	O
on	O	O
circulating	Physical	O
lipid	Physical	O
levels	Physical	O
,	O	O
will	O	O
determine	O	O
its	O	O
future	O	O
role	O	O
as	O	O
an	O	O
osmotic	O	O
agent	O	O
in	O	O
continuous	O	O
ambulatory	O	O
peritoneal	O	O
dialysis	O	O
.	O	O

Tetracaine	O	O
(	O	O
ametop	O	O
)	O	O
compared	O	O
to	O	O
placebo	O	O
for	O	O
reducing	O	O
pain	O	O
associated	O	O
with	O	O
intramuscular	O	O
injection	O	O
of	O	O
palivizumab	O	O
(	O	O
synagis	O	O
)	O	O
.	O	O

Infants	O	O
receive	O	O
many	O	O
painful	O	O
immunizations	O	O
before	O	O
they	O	O
are	O	O
2	O	O
years	O	O
old	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
if	O	O
topical	O	O
tetracaine	O	O
reduces	O	O
the	O	O
pain	O	Pain
of	O	O
intramuscular	O	O
palivizumab	O	O
compared	O	O
to	O	O
placebo	O	O
.	O	O

There	O	O
were	O	O
two	O	O
study	O	O
injections	O	O
,	O	O
one	O	O
with	O	O
tetracaine	O	O
and	O	O
one	O	O
with	O	O
placebo	O	O
.	O	O

Pain	Pain	Pain
was	O	O
scored	O	O
by	O	O
their	O	O
parents	O	O
and	O	O
a	O	O
pediatric	O	O
nurse	O	O
.	O	O

Topical	O	O
tetracaine	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
pain	Pain	Pain
score	Pain	Pain
,	O	O
although	O	O
it	O	O
did	O	O
lead	O	O
to	O	O
faster	O	O
recovery	Others	O
times	O	O
.	O	O

Additional	O	O
pain-reduction	O	O
strategies	O	O
are	O	O
required	O	O
.	O	O

Hip	O	O
protectors	O	O
improve	O	O
falls	O	Others
self-efficacy	O	Others
.	O	O

OBJECTIVES	O	O
To	O	O
investigate	O	O
the	O	O
effect	O	O
of	O	O
use	O	O
of	O	O
external	O	O
hip	O	O
protectors	O	O
on	O	O
subjects	O	O
'	O	O
fear	O	O
of	O	O
falling	O	O
and	O	O
falls	O	O
self-efficacy	O	O
(	O	O
belief	O	O
in	O	O
their	O	O
own	O	O
ability	O	O
to	O	O
avoid	O	O
falling	O	O
)	O	O
.	O	O

DESIGN	O	O
Randomized	O	O
controlled	O	O
trial	O	O
.	O	O

SETTING	O	O
Aged-care	O	O
health	O	O
services	O	O
in	O	O
Sydney	O	O
,	O	O
Australia	O	O
.	O	O

PARTICIPANTS	O	O
131	O	O
women	O	O
aged	O	O
75	O	O
years	O	O
or	O	O
older	O	O
,	O	O
who	O	O
had	O	O
two	O	O
or	O	O
more	O	O
falls	O	O
or	O	O
one	O	O
fall	O	O
requiring	O	O
hospital	O	O
admission	O	O
in	O	O
the	O	O
previous	O	O
year	O	O
and	O	O
who	O	O
live	O	O
at	O	O
home	O	O
.	O	O

Sixty-one	O	O
subjects	O	O
were	O	O
in	O	O
the	O	O
intervention	O	O
group	O	O
and	O	O
70	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

INTERVENTION	O	O
Use	O	O
of	O	O
external	O	O
hip	O	O
protectors	O	O
and	O	O
encouragement	O	O
to	O	O
use	O	O
the	O	O
protectors	O	O
by	O	O
an	O	O
adherence	O	O
nurse	O	O
.	O	O

MEASUREMENTS	O	O
At	O	O
the	O	O
time	O	O
of	O	O
enrolment	O	O
into	O	O
a	O	O
wider	O	O
study	O	O
examining	O	O
the	O	O
effect	O	O
of	O	O
hip	O	O
protectors	O	O
on	O	O
hip	O	O
fractures	O	O
,	O	O
participants	O	O
recruited	O	O
at	O	O
home	O	O
completed	O	O
an	O	O
assessment	O	Others
of	O	Others
fear	Others	Others
of	Others	Others
falling	Others	Others
and	Others	Others
falls	Others	Others
efficacy	Others	Others
as	O	O
measured	O	O
by	O	O
the	O	O
Falls	Others	Others
Efficacy	Others	Others
Scale	Others	Others
and	Others	Others
the	Others	Others
Modified	Others	Others
Falls	Others	Others
Efficacy	Others	Others
Scale	Others	Others
.	Others	O

At	O	O
4-month	O	O
follow-up	O	O
,	O	O
these	O	O
scales	O	O
were	O	O
readministered	O	O
by	O	O
an	O	O
observer	O	O
who	O	O
was	O	O
not	O	O
aware	O	O
of	O	O
the	O	O
allocation	O	O
of	O	O
the	O	O
participant	O	O
to	O	O
intervention	O	O
or	O	O
control	O	O
groups	O	O
.	O	O

RESULTS	O	O
Fear	Others	Others
of	Others	Others
falling	Others	Others
and	Others	Others
falls	Others	Others
self-efficacy	Others	Others
,	O	O
as	O	O
measured	O	O
by	O	O
the	O	O
Falls	Others	Others
Efficacy	Others	Others
and	Others	Others
Modified	Others	Others
Falls	Others	Others
Efficacy	Others	Others
Scales	Others	Others
,	O	O
were	O	O
similar	O	O
at	O	O
baseline	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Fear	Mental	Physical
of	Mental	Physical
falling	Mental	Physical
was	O	O
present	O	O
at	O	O
follow-up	O	O
in	O	O
43	O	O
%	O	O
of	O	O
subjects	O	O
using	O	O
hip	O	O
protectors	O	O
and	O	O
57	O	O
%	O	O
of	O	O
the	O	O
control	O	O
group	O	O
(	O	O
chi2	O	O
=	O	O
2.58	O	O
,	O	O
P	O	O
=	O	O
0.11	O	O
)	O	O
.	O	O

Hip	O	O
protector	O	O
users	O	O
had	O	O
greater	O	O
improvement	O	O
in	O	O
falls	O	Mental
self-efficacy	Others	Mental
at	O	O
follow-up	O	O
as	O	O
measured	O	O
by	O	O
the	O	O
Falls	Others	O
Efficacy	Others	O
Scale	Others	O
(	O	O
t	O	O
=	O	O
2.44	O	O
,	O	O
P	O	O
=	O	O
0.016	O	O
)	O	O
and	O	O
the	O	O
Modified	Others	O
Falls	Others	O
Efficacy	Others	O
Scale	Others	O
(	O	O
t	O	O
=	O	O
2.08	O	O
,	O	O
P	O	O
=	O	O
0.039	O	O
)	O	O
.	O	O

CONCLUSION	O	O
Hip	O	O
protectors	O	O
improve	O	O
falls	O	O
self-efficacy	O	O
.	O	O

As	O	O
users	O	O
of	O	O
hip	O	O
protectors	O	O
feel	O	O
more	O	O
confident	O	O
that	O	O
they	O	O
can	O	O
complete	O	O
tasks	O	O
safely	O	O
,	O	O
they	O	O
may	O	O
become	O	O
more	O	O
physically	O	O
active	O	O
and	O	O
require	O	O
less	O	O
assistance	O	O
with	O	O
activities	O	O
of	O	O
daily	O	O
living	O	O
.	O	O

Phytase	O	O
and	O	O
1alpha-hydroxycholecalciferol	O	O
supplementation	O	O
of	O	O
broiler	O	O
chickens	O	O
during	O	O
the	O	O
starting	O	O
and	O	O
growing/finishing	O	O
phases	O	O
.	O	O

Supplemental	O	O
1alpha-hydroxycholecalciferol	O	O
(	O	O
1alpha-OHD3	O	O
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
have	O	O
qualitatively	O	O
similar	O	O
and	O	O
quantitatively	O	O
additive	O	O
effects	O	O
to	O	O
exogenous	O	O
phytase	O	O
.	O	O

Two	O	O
experiments	O	O
were	O	O
conducted	O	O
from	O	O
0	O	O
to	O	O
35	O	O
d	O	O
in	O	O
floor	O	O
pens	O	O
to	O	O
determine	O	O
the	O	O
additive	O	O
effect	O	O
of	O	O
phytase	O	O
and	O	O
1alpha-OHD3	O	O
when	O	O
supplemented	O	O
to	O	O
Ca-	O	O
and	O	O
P-deficient	O	O
diets	O	O
.	O	O

In	O	O
both	O	O
experiments	O	O
,	O	O
at	O	O
least	O	O
4	O	O
replicates	O	O
per	O	O
treatment	O	O
(	O	O
50	O	O
chicks	O	O
per	O	O
replicate	O	O
)	O	O
were	O	O
used	O	O
.	O	O

Corn-soybean-meal-and	O	O
soybean-oil-based	O	O
diets	O	O
were	O	O
fed	O	O
and	O	O
birds	O	O
were	O	O
raised	O	O
in	O	O
a	O	O
house	O	O
impervious	O	O
to	O	O
ultraviolet	O	O
light	O	O
.	O	O

During	O	O
the	O	O
starter	O	O
phase	O	O
(	O	O
ST	O	O
)	O	O
,	O	O
from	O	O
0	O	O
to	O	O
18	O	O
d	O	O
,	O	O
chicks	O	O
were	O	O
fed	O	O
a	O	O
23	O	O
%	O	O
CP	O	O
diet	O	O
containing	O	O
0.60	O	O
%	O	O
Ca	O	O
and	O	O
0.47	O	O
%	O	O
total	O	O
P	O	O
(	O	O
tP	O	O
)	O	O
.	O	O

During	O	O
the	O	O
grower/finisher	O	O
phase	O	O
(	O	O
GF	O	O
)	O	O
,	O	O
from	O	O
19	O	O
to	O	O
35	O	O
d	O	O
,	O	O
birds	O	O
were	O	O
fed	O	O
a	O	O
19	O	O
%	O	O
CP	O	O
diet	O	O
containing	O	O
0.30	O	O
%	O	O
Ca	O	O
and	O	O
0.37	O	O
%	O	O
tP	O	O
.	O	O

A	O	O
combination	O	O
of	O	O
1,000	O	O
phytase	O	O
units/kg	O	O
of	O	O
Natuphos	O	O
phytase	O	O
and	O	O
5	O	O
microg/kg	O	O
of	O	O
1alpha-OHD3	O	O
(	O	O
P+1A	O	O
)	O	O
was	O	O
supplemented	O	O
to	O	O
some	O	O
of	O	O
the	O	O
feed	O	O
during	O	O
the	O	O
ST	O	O
and	O	O
GF	O	O
.	O	O

Diets	O	O
containing	O	O
adequate	O	O
Ca	O	O
and	O	O
P	O	O
were	O	O
also	O	O
fed	O	O
during	O	O
the	O	O
ST	O	O
(	O	O
0.90	O	O
%	O	O
Ca	O	O
,	O	O
0.68	O	O
%	O	O
tP	O	O
)	O	O
and	O	O
GF	O	O
(	O	O
0.80	O	O
%	O	O
Ca	O	O
,	O	O
0.67	O	O
%	O	O
tP	O	O
)	O	O
.	O	O

Performance	Physical	O
characteristics	Physical	O
and	O	O
the	O	O
incidence	Physical	O
of	Physical	O
rickets	Physical	O
and	Physical	O
tibial	Physical	O
dyschondroplasia	Physical	O
were	O	O
measured	O	O
at	O	O
18	O	O
and	O	O
35	O	O
d.	O	O
In	O	O
experiment	O	O
1	O	O
,	O	O
unsupplemented	O	O
chicks	O	O
performed	O	O
well	O	O
but	O	O
had	O	O
considerable	O	O
leg	Physical	O
problems	Physical	O
.	O	O

Chicks	O	O
fed	O	O
P+1A	O	O
during	O	O
the	O	O
ST	O	O
or	O	O
GF	O	O
did	O	O
not	O	O
perform	O	O
as	O	O
well	O	O
as	O	O
birds	O	O
fed	O	O
P+1A	O	O
throughout	O	O
.	O	O

Birds	O	O
fed	O	O
P+1A	O	O
throughout	O	O
performed	O	O
as	O	O
well	O	O
birds	O	O
fed	O	O
the	O	O
adequate	O	O
diets	O	O
without	O	O
any	O	O
indication	O	O
of	O	O
leg	O	O
problems	O	O
.	O	O

In	O	O
experiment	O	O
2	O	O
,	O	O
unsupplemented	O	O
birds	O	O
performed	O	O
similarly	O	O
to	O	O
unsupplemented	O	O
birds	O	O
in	O	O
experiment	O	O
1	O	O
.	O	O

However	O	O
,	O	O
chicks	O	O
fed	O	O
the	O	O
supplements	O	O
or	O	O
the	O	O
control	O	O
diets	O	O
did	O	O
not	O	O
perform	O	O
as	O	O
well	O	O
or	O	O
accumulate	Physical	O
as	Physical	O
much	Physical	O
bone	Physical	O
ash	Physical	O
as	O	O
birds	O	O
in	O	O
experiment	O	O
1	O	O
,	O	O
although	O	O
the	O	O
diets	O	O
were	O	O
formulated	O	O
identically	O	O
in	O	O
both	O	O
experiments	O	O
.	O	O

Diets	O	O
with	O	O
as	O	O
little	O	O
as	O	O
0.30	O	O
%	O	O
Ca	O	O
and	O	O
0.37	O	O
%	O	O
tP	O	O
appear	O	O
to	O	O
be	O	O
adequate	O	O
for	O	O
broilers	O	O
older	O	O
than	O	O
18	O	O
d	O	O
if	O	O
supplemented	O	O
with	O	O
the	O	O
correct	O	O
amounts	O	O
of	O	O
phytase	O	O
and	O	O
1alpha-OHD3	O	O
.	O	O

However	O	O
,	O	O
there	O	O
are	O	O
unknown	O	O
variables	O	O
that	O	O
may	O	O
limit	O	O
the	O	O
potential	O	O
of	O	O
broilers	O	O
in	O	O
terms	O	O
of	O	O
bone	Physical	O
mineralization	Physical	O
and	Physical	O
bone	Physical	O
pathology	Physical	O
,	O	O
even	O	O
when	O	O
adequate	O	O
diets	O	O
are	O	O
fed	O	O
.	O	O

Sodium	O	O
bicarbonate	O	O
,	O	O
N-acetylcysteine	O	O
,	O	O
and	O	O
saline	O	O
for	O	O
prevention	O	O
of	O	O
radiocontrast-induced	Adverseeffect	O
nephropathy	Adverseeffect	O
.	O	O

A	O	O
comparison	O	O
of	O	O
3	O	O
regimens	O	O
for	O	O
protecting	O	O
contrast-induced	O	O
nephropathy	O	O
in	O	O
patients	O	O
undergoing	O	O
coronary	O	O
procedures	O	O
.	O	O

A	O	O
single-center	O	O
prospective	O	O
controlled	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
Several	O	O
protective	O	O
therapies	O	O
have	O	O
been	O	O
developed	O	O
to	O	O
prevent	O	O
contrast-induced	Adverseeffect	O
nephropathy	Adverseeffect	O
(	Adverseeffect	O
CIN	Adverseeffect	O
)	Adverseeffect	O
.	Adverseeffect	O

We	O	O
aimed	O	O
to	O	O
investigate	O	O
the	O	O
efficacy	O	O
of	O	O
sodium	O	O
bicarbonate	O	O
by	O	O
comparing	O	O
2	O	O
other	O	O
regimens	O	O
,	O	O
including	O	O
combination	O	O
of	O	O
N-acetylcysteine	O	O
(	O	O
NAC	O	O
)	O	O
plus	O	O
sodium	O	O
chloride	O	O
and	O	O
sodium	O	O
chloride	O	O
alone	O	O
,	O	O
to	O	O
prevent	O	O
CIN	O	O
in	O	O
patients	O	O
undergoing	O	O
cardiovascular	O	O
procedures	O	O
.	O	O

METHODS	O	O
We	O	O
prospectively	O	O
enrolled	O	O
264	O	O
patients	O	O
who	O	O
were	O	O
scheduled	O	O
for	O	O
cardiovascular	O	O
procedures	O	O
and	O	O
had	O	O
a	O	O
baseline	O	O
creatinine	O	O
level	O	O
>	O	O
1.2	O	O
mg/dL	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
assigned	O	O
1	O	O
of	O	O
3	O	O
prophylactic	O	O
regimens	O	O
:	O	O
infusion	O	O
of	O	O
sodium	O	O
bicarbonate	O	O
,	O	O
sodium	O	O
chloride	O	O
,	O	O
sodium	O	O
chloride	O	O
plus	O	O
oral	O	O
NAC	O	O
(	O	O
600	O	O
mg	O	O
bid	O	O
)	O	O
.	O	O

Contrast-induced	Adverseeffect	O
nephropathy	Adverseeffect	O
was	O	O
defined	O	O
as	O	O
an	O	O
increase	Adverseeffect	O
in	Adverseeffect	O
serum	Adverseeffect	Physical
creatinine	Adverseeffect	Physical
level	Adverseeffect	Physical
>	Adverseeffect	O
25	Adverseeffect	O
%	Adverseeffect	O
or	O	O
0.5	O	O
mg/dL	O	O
after	O	O
48	O	O
hours	O	O
.	O	O

RESULTS	O	O
There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
among	O	O
groups	O	O
regarding	O	O
baseline	O	O
demographic	O	O
properties	O	O
and	O	O
nephropathy	O	O
risk	O	O
factors	O	O
.	O	O

The	O	O
change	Adverseeffect	O
in	Adverseeffect	O
creatinine	Adverseeffect	Physical
clearance	Adverseeffect	Physical
was	O	O
significantly	O	O
better	O	O
in	O	O
the	O	O
sodium	O	O
bicarbonate	O	O
group	O	O
than	O	O
other	O	O
2	O	O
groups	O	O
(	O	O
P	O	O
=	O	O
.007	O	O
)	O	O
.	O	O

The	O	O
incidence	Adverseeffect	Physical
of	Adverseeffect	Physical
CIN	Adverseeffect	Physical
was	O	O
significantly	O	O
lower	O	O
in	O	O
the	O	O
sodium	O	O
bicarbonate	O	O
group	O	O
(	O	O
4.5	O	O
%	O	O
)	O	O
compared	O	O
with	O	O
sodium	O	O
chloride	O	O
alone	O	O
(	O	O
13.6	O	O
%	O	O
,	O	O
P	O	O
=	O	O
.036	O	O
)	O	O
and	O	O
tended	O	O
to	O	O
be	O	O
lower	O	O
than	O	O
in	O	O
the	O	O
combination	O	O
group	O	O
(	O	O
12.5	O	O
%	O	O
,	O	O
P	O	O
=	O	O
.059	O	O
)	O	O
.	O	O

After	O	O
adjusting	O	O
the	O	O
Mehran	Adverseeffect	Physical
nephropathy	Adverseeffect	Physical
risk	Adverseeffect	Physical
score	Adverseeffect	Physical
,	O	O
the	O	O
risk	Adverseeffect	O
of	Adverseeffect	O
CIN	Adverseeffect	O
significantly	O	O
reduced	O	O
with	O	O
sodium	O	O
bicarbonate	O	O
compared	O	O
with	O	O
sodium	O	O
chloride	O	O
alone	O	O
(	O	O
adjusted	O	O
risk	O	O
ratio	O	O
0.29	O	O
,	O	O
P	O	O
=	O	O
.043	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Hydration	O	O
with	O	O
sodium	O	O
bicarbonate	O	O
provides	O	O
better	O	O
protection	O	O
against	O	O
CIN	Adverseeffect	O
than	O	O
the	O	O
sodium	O	O
chloride	O	O
infusion	O	O
does	O	O
alone	O	O
.	O	O

Combination	O	O
therapy	O	O
of	O	O
NAC	O	O
plus	O	O
sodium	O	O
chloride	O	O
did	O	O
not	O	O
offer	O	O
additional	O	O
benefit	O	O
over	O	O
hydration	O	O
with	O	O
sodium	O	O
chloride	O	O
alone	O	O
.	O	O

A	O	O
randomized	O	O
trial	O	O
of	O	O
radiation	O	O
therapy	O	O
compared	O	O
to	O	O
split	O	O
course	O	O
radiation	O	O
therapy	O	O
combined	O	O
with	O	O
mitomycin	O	O
C	O	O
and	O	O
5	O	O
fluorouracil	O	O
as	O	O
initial	O	O
treatment	O	O
for	O	O
advanced	O	O
laryngeal	O	O
and	O	O
hypopharyngeal	O	O
squamous	O	O
carcinoma	O	O
.	O	O

Two	O	O
hundred	O	O
and	O	O
twelve	O	O
patients	O	O
with	O	O
previously	O	O
untreated	O	O
advanced	O	O
squamous	O	O
carcinoma	O	O
of	O	O
the	O	O
larynx	O	O
or	O	O
hypopharynx	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
initial	O	O
treatment	O	O
with	O	O
radiotherapy	O	O
,	O	O
50	O	O
Gy	O	O
in	O	O
20	O	O
fractions	O	O
in	O	O
28	O	O
days	O	O
or	O	O
split	O	O
course	O	O
radiotherapy	O	O
and	O	O
concurrent	O	O
chemotherapy	O	O
,	O	O
25	O	O
Gy	O	O
in	O	O
10	O	O
fractions	O	O
in	O	O
14	O	O
days	O	O
followed	O	O
by	O	O
a	O	O
4	O	O
week	O	O
rest	O	O
and	O	O
a	O	O
further	O	O
25	O	O
Gy	O	O
in	O	O
10	O	O
fractions	O	O
in	O	O
14	O	O
days	O	O
starting	O	O
on	O	O
day	O	O
43	O	O
;	O	O
Mitomycin	O	O
C	O	O
was	O	O
given	O	O
on	O	O
day	O	O
1	O	O
and	O	O
day	O	O
43	O	O
and	O	O
5FU	O	O
continuous	O	O
infusions	O	O
on	O	O
days	O	O
1	O	O
--	O	O
4	O	O
and	O	O
days	O	O
43	O	O
--	O	O
46	O	O
.	O	O

Surgery	O	O
was	O	O
reserved	O	O
for	O	O
persistent	O	O
or	O	O
recurrent	O	O
disease	O	O
.	O	O

Two	O	O
hundred	O	O
and	O	O
nine	O	O
of	O	O
the	O	O
212	O	O
patients	O	O
randomized	O	O
were	O	O
included	O	O
in	O	O
the	O	O
analyses	O	O
.	O	O

Outcome	O	O
analyses	O	O
were	O	O
performed	O	O
at	O	O
a	O	O
median	O	O
follow-up	O	O
interval	O	O
of	O	O
4.4	O	O
years	O	O
.	O	O

No	O	O
patients	O	O
were	O	O
lost	O	O
to	O	O
follow-up	O	O
.	O	O

No	O	O
significant	O	O
difference	O	O
was	O	O
found	O	O
between	O	O
the	O	O
two	O	O
arms	O	O
for	O	O
the	O	O
end	O	O
points	O	O
of	O	O
local	Physical	Mortality
relapse-free	Physical	Mortality
rate	Physical	Mortality
(	O	O
p	O	O
=	O	O
0.91	O	O
)	O	O
,	O	O
regional	Physical	O
relapse-free	Physical	O
rate	Physical	O
(	O	O
p	O	O
=	O	O
0.17	O	O
,	O	O
adjusted	O	O
)	O	O
or	O	O
overall	Mortality	Mortality
survival	Mortality	Mortality
(	O	O
p	O	O
=	O	O
0.86	O	O
)	O	O
.	O	O

Eight-eight	O	O
patients	O	O
had	O	O
attempted	O	O
surgical	O	O
resection	O	O
following	O	O
radiotherapy	O	O
failure	O	O
.	O	O

The	O	O
contribution	O	O
of	O	O
salvage	O	O
surgery	O	O
to	O	O
overall	Mortality	Mortality
survival	Mortality	Mortality
was	O	O
similar	O	O
for	O	O
both	O	O
arms	O	O
of	O	O
the	O	O
study	O	O
as	O	O
was	O	O
the	O	O
surgical	Adverseeffect	O
complication	Adverseeffect	O
rate	Adverseeffect	O
.	O	O

Serious	Adverseeffect	O
late	Adverseeffect	O
radiation	Adverseeffect	O
toxicity	Adverseeffect	O
was	O	O
minimal	O	O
(	O	O
3	O	O
%	O	O
in	O	O
the	O	O
RT	O	O
group	O	O
,	O	O
0	O	O
%	O	O
in	O	O
the	O	O
radiation	O	O
therapy	O	O
plus	O	O
chemotherapy	O	O
group	O	O
)	O	O
.	O	O

The	O	O
result	O	O
of	O	O
the	O	O
trial	O	O
shows	O	O
no	O	O
advantage	O	O
in	O	O
terms	O	O
of	O	O
local	O	O
control	O	O
or	O	O
survival	O	O
for	O	O
the	O	O
experimental	O	O
treatment	O	O
arm	O	O
of	O	O
split	O	O
course	O	O
radiotherapy	O	O
and	O	O
concurrent	O	O
chemotherapy	O	O
with	O	O
Mitomycin	O	O
C	O	O
and	O	O
5	O	O
Fluorouracil	O	O
compared	O	O
to	O	O
radiotherapy	O	O
alone	O	O
.	O	O

Study	O	O
of	O	O
the	O	O
vaginal	O	O
tolerance	O	O
to	O	O
Acidform	O	O
,	O	O
an	O	O
acid-buffering	O	O
,	O	O
bioadhesive	O	O
gel	O	O
.	O	O

Vaginal	O	O
tolerance	O	O
tests	O	O
were	O	O
performed	O	O
with	O	O
a	O	O
new	O	O
potential	O	O
microbicidal	O	O
and	O	O
spermicidal	O	O
product	O	O
,	O	O
an	O	O
acid-buffering	O	O
vaginal	O	O
gel	O	O
(	O	O
Acidform	O	O
)	O	O
without	O	O
or	O	O
with	O	O
nonoxynol-9	O	O
(	O	O
N-9	O	O
)	O	O
.	O	O

The	O	O
potential	O	O
advantages	O	O
over	O	O
other	O	O
vaginal	O	O
products	O	O
include	O	O
keeping	O	O
a	O	O
low	O	O
pH	O	O
,	O	O
decrease	O	O
of	O	O
the	O	O
irritating	O	O
effect	O	O
of	O	O
N-9	O	O
on	O	O
the	O	O
cervix	O	O
or	O	O
vaginal	O	O
mucosa	O	O
associated	O	O
with	O	O
greater	O	Physical
retention	O	Physical
of	O	Physical
the	O	Physical
product	O	Physical
after	O	O
application	O	O
,	O	O
and	O	O
decreasing	O	O
messiness	O	O
as	O	O
compared	O	O
to	O	O
other	O	O
vaginal	O	O
products	O	O
.	O	O

Three	O	O
groups	O	O
of	O	O
six	O	O
women	O	O
were	O	O
admitted	O	O
and	O	O
randomly	O	O
assigned	O	O
to	O	O
use	O	O
Acidform	O	O
with	O	O
0	O	O
%	O	O
,	O	O
2.5	O	O
%	O	O
,	O	O
and	O	O
5	O	O
%	O	O
N-9	O	O
.	O	O

Colposcopic	O	O
evaluation	O	O
for	O	O
vulvar	O	O
,	O	O
vaginal	O	O
,	O	O
and	O	O
cervical	O	O
signs	O	O
of	O	O
irritation	O	O
was	O	O
performed	O	O
and	O	O
photographs	O	O
were	O	O
taken	O	O
,	O	O
following	O	O
a	O	O
specific	O	O
World	O	O
Health	O	O
Organization	O	O
protocol	O	O
,	O	O
at	O	O
time	O	O
0	O	O
,	O	O
and	O	O
after	O	O
24	O	O
h	O	O
and	O	O
6	O	O
days	O	O
of	O	O
application	O	O
of	O	O
the	O	O
gel	O	O
.	O	O

No	Physical	O
irritation	Adverseeffect	O
or	Adverseeffect	O
symptom	Adverseeffect	O
was	O	O
reported	O	O
by	O	O
users	O	O
of	O	O
Acidform	O	O
without	O	O
N-9	O	O
.	O	O

A	Physical	O
generalized	Adverseeffect	O
and	Adverseeffect	O
intense	Adverseeffect	Physical
erythema	Adverseeffect	Physical
in	Adverseeffect	Physical
cervix	Adverseeffect	Physical
was	O	O
observed	O	O
in	O	O
10	O	O
of	O	O
12	O	O
Acidform/N-9	O	O
users	O	O
and	O	O
abrasion	O	O
occurred	O	O
in	O	O
nine	O	O
of	O	O
them	O	O
.	O	O

Vulvar	Adverseeffect	O
irritation	Adverseeffect	O
was	O	O
seen	O	O
in	O	O
seven	O	O
of	O	O
these	O	O
10	O	O
volunteers	O	O
.	O	O

N-9	O	O
concentration	O	O
in	O	O
the	O	O
gel	O	O
(	O	O
2.5	O	O
%	O	O
or	O	O
5.0	O	O
%	O	O
)	O	O
was	O	O
not	O	O
related	O	O
to	O	O
the	O	O
findings	O	O
.	O	O

No	Physical	O
ulcer	Adverseeffect	O
,	Adverseeffect	O
exulceration	Adverseeffect	O
,	Adverseeffect	O
or	Adverseeffect	O
de-epithelialization	Adverseeffect	O
was	O	O
observed	O	O
.	O	O

Acidform	O	O
without	O	O
N-9	O	O
was	O	O
well	O	O
tolerated	O	Others
by	O	O
volunteers	O	O
,	O	O
but	O	O
it	O	O
was	O	O
unable	O	O
to	O	O
protect	O	O
the	O	O
cervix	O	O
,	O	O
vagina	O	O
,	O	O
and	O	O
vulva	O	O
from	O	O
the	O	O
N-9	O	O
effects	O	O
.	O	O

A	O	O
randomized	O	O
comparison	O	O
of	O	O
the	O	O
Endeavor	O	O
zotarolimus-eluting	O	O
stent	O	O
versus	O	O
the	O	O
TAXUS	O	O
paclitaxel-eluting	O	O
stent	O	O
in	O	O
de	O	O
novo	O	O
native	O	O
coronary	O	O
lesions	O	O
12-month	O	O
outcomes	O	O
from	O	O
the	O	O
ENDEAVOR	O	O
IV	O	O
trial	O	O
.	O	O

OBJECTIVES	O	O
The	O	O
ENDEAVOR	O	O
IV	O	O
(	O	O
Randomized	O	O
Comparison	O	O
of	O	O
Zotarolimus-Eluting	O	O
and	O	O
Paclitaxel-Eluting	O	O
Stents	O	O
in	O	O
Patients	O	O
with	O	O
Coronary	O	O
Artery	O	O
Disease	O	O
)	O	O
trial	O	O
evaluated	O	O
the	O	O
safety	Others	Others
and	O	Others
efficacy	Others	Others
of	O	O
the	O	O
zotarolimus-eluting	O	O
stent	O	O
(	O	O
ZES	O	O
)	O	O
compared	O	O
with	O	O
the	O	O
paclitaxel-eluting	O	O
stent	O	O
(	O	O
PES	O	O
)	O	O
.	O	O

BACKGROUND	O	O
First-generation	O	O
drug-eluting	O	O
stents	O	O
have	O	O
reduced	O	O
angiographic	O	O
and	O	O
clinical	O	O
restenosis	O	O
,	O	O
but	O	O
long-term	O	O
safety	O	O
remains	O	O
controversial	O	O
.	O	O

A	O	O
second-generation	O	O
drug-eluting	O	O
stent	O	O
,	O	O
which	O	O
delivers	O	O
zotarolimus	O	O
,	O	O
a	O	O
potent	O	O
antiproliferative	O	O
agent	O	O
,	O	O
via	O	O
a	O	O
biocompatible	O	O
phosphorylcholine	O	O
polymer	O	O
on	O	O
a	O	O
cobalt	O	O
alloy	O	O
thin-strut	O	O
stent	O	O
has	O	O
shown	O	O
promising	O	O
experimental	O	O
and	O	O
early	O	O
clinical	O	O
results	O	O
.	O	O

METHODS	O	O
This	O	O
is	O	O
a	O	O
prospective	O	O
,	O	O
randomized	O	O
(	O	O
1:1	O	O
)	O	O
,	O	O
single-blind	O	O
,	O	O
controlled	O	O
trial	O	O
comparing	O	O
outcomes	O	O
of	O	O
patients	O	O
with	O	O
single	O	O
de	O	O
novo	O	O
coronary	O	O
lesions	O	O
treated	O	O
with	O	O
ZES	O	O
or	O	O
PES	O	O
.	O	O

The	O	O
primary	O	O
end	O	O
point	O	O
was	O	O
noninferiority	Physical	O
of	Physical	O
9-month	Physical	O
target	Physical	O
vessel	Physical	O
failure	Physical	O
defined	Physical	O
as	Physical	O
cardiac	Adverseeffect	O
death	Adverseeffect	O
,	Physical	O
myocardial	Physical	O
infarction	Physical	O
,	Physical	O
or	Physical	O
target	Physical	O
vessel	Physical	O
revascularization	Physical	O
.	O	O

RESULTS	O	O
Among	O	O
a	O	O
total	O	O
of	O	O
1,548	O	O
patients	O	O
assigned	O	O
to	O	O
ZES	O	O
(	O	O
n	O	O
=	O	O
773	O	O
)	O	O
or	O	O
PES	O	O
(	O	O
n	O	O
=	O	O
775	O	O
)	O	O
,	O	O
at	O	O
9	O	O
months	O	O
,	O	O
ZES	O	O
was	O	O
noninferior	O	O
to	O	O
PES	O	O
with	O	O
rates	O	O
of	O	O
target	Physical	O
vessel	Physical	O
failure	Physical	O
6.6	O	O
%	O	O
versus	O	O
7.1	O	O
%	O	O
,	O	O
respectively	O	O
(	O	O
p	O	O
(	O	O
noninferiority	O	O
)	O	O
<	O	O
or	O	O
=	O	O
0.001	O	O
)	O	O
.	O	O

There	O	O
were	O	O
fewer	O	O
periprocedural	Physical	O
myocardial	Physical	O
infarctions	Physical	O
with	O	O
ZES	O	O
(	O	O
0.5	O	O
%	O	O
vs.	O	O
2.2	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0.007	O	O
)	O	O
,	O	O
whereas	O	O
at	O	O
12	O	O
months	O	O
,	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
groups	O	O
in	O	O
rates	O	Physical
of	O	Physical
cardiac	Adverseeffect	Physical
death	Adverseeffect	Physical
,	Physical	Physical
myocardial	Physical	Physical
infarction	Physical	Physical
,	Physical	Physical
target	Physical	Physical
vessel	Physical	Physical
revascularization	Physical	Physical
,	Physical	Physical
or	Physical	Physical
stent	Physical	Physical
thrombosis	Physical	Physical
.	O	O

Although	O	O
incidence	O	O
of	O	O
8-month	O	O
binary	Physical	O
angiographic	Physical	O
in-segment	Physical	O
restenosis	Physical	O
was	O	O
higher	O	O
in	O	O
patients	O	O
treated	O	O
with	O	O
ZES	O	O
versus	O	O
PES	O	O
(	O	O
15.3	O	O
%	O	O
vs.	O	O
10.4	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0.284	O	O
)	O	O
,	O	O
rates	O	O
of	O	O
12-month	O	O
target	Physical	O
lesion	Physical	O
revascularization	Physical	O
were	O	O
similar	O	O
(	O	O
4.5	O	O
%	O	O
vs.	O	O
3.2	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0.228	O	O
)	O	O
,	O	O
especially	O	O
in	O	O
patients	O	O
without	O	O
planned	O	O
angiographic	O	O
follow-up	O	O
(	O	O
3.6	O	O
%	O	O
vs.	O	O
3.2	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0.756	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
These	O	O
findings	O	O
demonstrate	O	O
that	O	O
ZES	O	O
has	O	O
similar	O	O
clinical	O	O
safety	O	O
and	O	O
efficacy	O	O
compared	O	O
with	O	O
PES	O	O
in	O	O
simple	O	O
and	O	O
medium	O	O
complexity	O	O
single	O	O
de	O	O
novo	O	O
coronary	O	O
lesions	O	O
.	O	O

(	O	O
ENDEAVOR	O	O
IV	O	O
Clinical	O	O
Trial	O	O
;	O	O
NCT00217269	O	O
)	O	O
.	O	O

Sunbathing	O	O
and	O	O
sunbed	O	O
use	O	O
related	O	O
to	O	O
self-image	O	O
in	O	O
a	O	O
randomized	O	O
sample	O	O
of	O	O
Swedish	O	O
adolescents	O	O
.	O	O

In	O	O
1996	O	O
a	O	O
randomized	O	O
sample	O	O
of	O	O
4,020	O	O
Swedish	O	O
adolescents	O	O
from	O	O
three	O	O
birth	O	O
cohorts	O	O
were	O	O
sent	O	O
a	O	O
questionnaire	O	O
consisting	O	O
of	O	O
50	O	O
items	O	O
concerning	O	O
habitual	O	O
sun-related	O	O
behaviours	O	O
and	O	O
attitudes	O	O
,	O	O
knowledge	O	Mental
about	O	Mental
melanoma	O	Mental
,	O	Mental
risk	O	Mental
perception	O	Mental
and	O	O
self-image	O	O
.	O	O

A	O	O
total	O	O
of	O	O
2,615	O	O
questionnaires	O	O
were	O	O
returned	O	O
.	O	O

Girls	O	O
sunbathed	O	O
and	O	O
used	O	O
sunbeds	O	O
more	O	O
than	O	O
boys	O	O
at	O	O
all	O	O
ages	O	O
.	O	O

Sunbathing	Mental	O
and	O	O
sunbed	Mental	O
use	Mental	O
increased	O	O
with	O	O
age	O	O
.	O	O

Boys	O	O
who	O	O
were	O	O
most	O	O
satisfied	O	O
and	O	O
girls	O	O
least	O	O
satisfied	O	Others
with	O	O
themselves	O	O
sunbathed	Mental	O
most	O	O
.	O	O

Those	O	O
who	O	O
were	O	O
least	O	O
satisfied	O	O
with	O	O
themselves	O	O
used	Mental	O
sunbeds	Mental	O
most	O	O
frequently	O	O
.	O	O

Girls	O	O
reported	O	O
a	O	O
higher	Mental	O
perceived	Mental	Physical
susceptibility	Mental	Physical
to	Mental	Physical
melanoma	Mental	Physical
than	O	O
did	O	O
boys	O	O
.	O	O

The	O	O
perception	Mental	Physical
of	Mental	Physical
susceptibility	Mental	Physical
increased	O	O
with	O	O
age	O	O
.	O	O

Those	O	O
who	O	O
were	O	O
least	O	O
satisfied	O	Others
with	O	O
themselves	O	O
reported	O	O
feeling	O	O
most	Mental	O
susceptible	Mental	O
.	O	O

The	O	O
overall	O	O
main	O	O
reason	Mental	O
for	Mental	O
sunbathing	Mental	O
was	O	O
appearance	O	O
,	O	O
both	O	O
for	O	O
own	O	O
sunbathing	O	O
,	O	O
and	O	O
to	O	O
an	O	O
even	O	O
higher	O	O
degree	O	O
,	O	O
as	O	O
a	O	O
supposed	O	O
reason	O	O
for	O	O
other	O	O
adolescents	O	O
'	O	O
behaviour	O	O
,	O	O
and	O	O
was	O	O
reported	O	O
most	O	O
frequently	O	O
by	O	O
girls	O	O
and	O	O
the	O	O
older	O	O
age	O	O
groups	O	O
.	O	O

The	O	O
second	O	O
most	O	O
'important	O	O
'	O	O
reason	O	O
for	O	O
sunbathing	O	O
was	O	O
'feeling	O	O
warm	O	O
and	O	O
comfortable	O	O
'	O	O
.	O	O

Preventive	O	O
programmes	O	O
aimed	O	O
at	O	O
a	O	O
change	O	O
of	O	O
sun	O	O
related	O	O
behaviours	O	O
among	O	O
Swedish	O	O
adolescents	O	O
have	O	O
to	O	O
be	O	O
tailored	O	O
to	O	O
the	O	O
climate	O	O
and	O	O
cultural	O	O
conditions	O	O
and	O	O
must	O	O
take	O	O
into	O	O
account	O	O
that	O	O
having	O	O
a	O	O
tan	O	O
,	O	O
and	O	O
the	O	O
warmth	O	O
of	O	O
the	O	O
sun	O	O
,	O	O
are	O	O
highly	O	O
valued	O	O
by	O	O
most	O	O
adolescents	O	O
.	O	O

Factors	O	O
predictive	O	O
of	O	O
severe	Physical	O
hypoglycemia	Physical	O
in	O	O
type	O	O
1	O	O
diabetes	O	O
:	O	O
analysis	O	O
from	O	O
the	O	O
Juvenile	O	O
Diabetes	O	O
Research	O	O
Foundation	O	O
continuous	O	O
glucose	O	O
monitoring	O	O
randomized	O	O
control	O	O
trial	O	O
dataset	O	O
.	O	O

OBJECTIVE	O	O
Identify	O	O
factors	O	O
predictive	O	O
of	O	O
severe	Physical	O
hypoglycemia	Physical	O
(	Physical	O
SH	Physical	O
)	Physical	O
and	O	O
assess	O	O
the	O	O
clinical	Others	O
utility	Others	O
of	O	O
continuous	Others	O
glucose	Others	O
monitoring	Others	O
(	Others	O
CGM	Others	O
)	Others	O
to	O	O
warn	O	O
of	O	O
impending	O	O
SH	O	O
.	O	O

RESEARCH	O	O
DESIGN	O	O
AND	O	O
METHODS	O	O
In	O	O
a	O	O
multicenter	O	O
randomized	O	O
clinical	O	O
trial	O	O
,	O	O
436	O	O
children	O	O
and	O	O
adults	O	O
with	O	O
type	O	O
1	O	O
diabetes	O	O
were	O	O
randomized	O	O
to	O	O
a	O	O
treatment	O	O
group	O	O
that	O	O
used	O	O
CGM	O	O
(	O	O
N	O	O
=	O	O
224	O	O
)	O	O
,	O	O
or	O	O
a	O	O
control	O	O
group	O	O
that	O	O
used	O	O
standard	O	O
home	O	O
blood	O	O
glucose	O	O
monitoring	O	O
(	O	O
N	O	O
=	O	O
212	O	O
)	O	O
and	O	O
completed	O	O
12	O	O
months	O	O
of	O	O
follow-up	O	O
.	O	O

After	O	O
6	O	O
months	O	O
,	O	O
the	O	O
original	O	O
control	O	O
group	O	O
initiated	O	O
CGM	O	O
while	O	O
the	O	O
treatment	O	O
group	O	O
continued	O	O
use	O	O
of	O	O
CGM	O	O
for	O	O
6	O	O
months	O	O
.	O	O

Baseline	O	O
risk	O	O
factors	O	O
for	O	O
SH	O	O
were	O	O
evaluated	O	O
over	O	O
12	O	O
months	O	O
of	O	O
follow-up	O	O
using	O	O
proportional	O	O
hazards	O	O
regression	O	O
.	O	O

CGM-derived	Physical	O
indices	Physical	O
of	Physical	O
hypoglycemia	Physical	O
were	O	O
used	O	O
to	O	O
predict	O	O
episodes	O	O
of	O	O
SH	O	O
over	O	O
a	O	O
24-h	O	O
time	O	O
horizon	O	O
.	O	O

RESULTS	O	O
The	O	O
SH	Physical	O
rate	Physical	O
was	O	O
17.9	O	O
per	O	O
100	O	O
person-years	O	O
,	O	O
and	O	O
a	O	O
higher	O	O
rate	O	O
was	O	O
associated	O	O
with	O	O
the	O	O
occurrence	O	O
of	O	O
SH	Physical	O
in	O	O
the	O	O
prior	O	O
6	O	O
months	O	O
and	O	O
female	O	O
sex	O	O
.	O	O

SH	Physical	O
frequency	Physical	O
increased	O	O
eightfold	O	O
when	O	O
30	O	O
%	O	O
of	O	O
CGM	Physical	O
values	Physical	O
were	O	O
?	O	O
70	O	O
mg/dL	O	O
on	O	O
the	O	O
prior	O	O
day	O	O
(	O	O
4.5	O	O
vs.	O	O
0.5	O	O
%	O	O
;	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
,	O	O
but	O	O
the	O	O
positive	O	O
predictive	O	O
value	O	O
(	O	O
PPV	O	O
)	O	O
was	O	O
low	O	O
(	O	O
<	O	O
5	O	O
%	O	O
)	O	O
.	O	O

Results	O	O
were	O	O
similar	O	O
for	O	O
hypoglycemic	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
and	O	O
the	O	O
low	O	Physical
blood	O	Physical
glucose	O	Physical
index	O	Physical
calculated	O	O
by	O	O
CGM	O	O
.	O	O

CONCLUSIONS	O	O
SH	O	O
in	O	O
the	O	O
6	O	O
months	O	O
prior	O	O
to	O	O
the	O	O
study	O	O
was	O	O
the	O	O
strongest	O	O
predictor	O	O
of	O	O
SH	O	O
during	O	O
the	O	O
study	O	O
.	O	O

CGM-measured	O	O
hypoglycemia	O	O
over	O	O
a	O	O
24-h	O	O
span	O	O
is	O	O
highly	O	O
associated	O	O
with	O	O
SH	O	O
the	O	O
following	O	O
day	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
,	O	O
but	O	O
the	O	O
PPV	O	O
is	O	O
low	O	O
.	O	O

Perioperative	Physical	O
fever	O	O
and	O	O
outcome	O	O
in	O	O
surgical	O	O
patients	O	O
with	O	O
aneurysmal	O	O
subarachnoid	O	O
hemorrhage	O	O
.	O	O

OBJECTIVE	O	O
We	O	O
examined	O	O
the	O	O
incidence	O	O
of	O	O
perioperative	O	Physical
fever	O	Physical
and	O	O
its	O	O
relationship	O	O
to	O	O
outcome	O	O
among	O	O
patients	O	O
enrolled	O	O
in	O	O
the	O	O
Intraoperative	O	O
Hypothermia	O	O
for	O	O
Aneurysm	O	O
Surgery	O	O
Trial	O	O
.	O	O

METHODS	O	O
One	O	O
thousand	O	O
patients	O	O
with	O	O
initial	O	O
World	O	O
Federation	O	O
of	O	O
Neurological	O	O
Surgeons	O	O
grades	O	O
of	O	O
I	O	O
to	O	O
III	O	O
undergoing	O	O
clipping	O	O
of	O	O
intracranial	O	O
aneurysms	O	O
after	O	O
subarachnoid	O	O
hemorrhage	O	O
were	O	O
randomized	O	O
to	O	O
intraoperative	O	O
normothermia	O	O
(	O	O
36	O	O
degrees	O	O
C-37	O	O
degrees	O	O
C	O	O
)	O	O
or	O	O
hypothermia	O	O
(	O	O
32.5	O	O
degrees	O	O
C-33.5	O	O
degrees	O	O
C	O	O
)	O	O
.	O	O

Fever	Physical	O
(	O	O
>	O	O
or	O	O
=38.5	O	O
degrees	O	O
C	O	O
)	O	O
and	O	O
other	Physical	Adverseeffect
complications	Adverseeffect	Adverseeffect
(	Adverseeffect	O
including	Adverseeffect	O
infections	Adverseeffect	O
)	Adverseeffect	O
occurring	Physical	O
between	Physical	O
admission	Physical	O
and	Physical	O
discharge	Physical	O
(	Physical	O
or	Physical	O
death	Adverseeffect	O
)	Physical	O
were	O	O
recorded	O	O
.	O	O

Functional	Physical	O
and	Physical	O
neuropsychologic	Mental	O
outcomes	Mental	O
were	O	O
assessed	O	O
3	O	O
months	O	O
postoperatively	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
variable	O	O
for	O	O
the	O	O
trial	O	O
was	O	O
dichotomized	Physical	O
Glasgow	Physical	O
Outcome	Physical	O
Scale	Physical	O
(	Physical	O
good	Physical	O
outcome	Physical	O
versus	Physical	O
all	Physical	O
others	Physical	O
)	Physical	O
.	Physical	O

RESULTS	O	O
Fever	Physical	O
was	O	O
reported	O	O
in	O	O
41	O	O
%	O	O
of	O	O
patients	O	O
.	O	O

In	O	O
97	O	O
%	O	O
of	O	O
these	O	O
,	O	O
fever	Physical	Physical
occurred	O	O
in	O	O
the	O	O
postoperative	O	O
period	O	O
.	O	O

The	O	O
median	Physical	O
time	Physical	O
from	Physical	O
surgery	Physical	O
to	Physical	O
first	Physical	O
fever	Physical	O
was	O	O
3	O	O
days	O	O
.	O	O

All	O	O
measures	O	O
of	O	O
outcome	O	O
were	O	O
worse	O	O
in	O	O
patients	O	O
who	O	O
developed	O	O
fever	O	Physical
,	O	O
even	O	O
in	O	O
those	O	O
without	O	O
infections	Adverseeffect	O
or	O	O
who	O	O
were	O	O
World	O	O
Federation	O	O
of	O	O
Neurological	O	O
Surgeons	O	O
grade	O	O
I.	O	O
Logistic	O	O
regression	O	O
analyses	O	O
were	O	O
performed	O	O
to	O	O
adjust	O	O
for	O	O
differences	O	O
in	O	O
preoperative	O	O
factors	O	O
(	O	O
e.g.	O	O
,	O	O
age	O	O
,	O	O
Fisher	O	O
grade	O	O
,	O	O
initial	O	O
neurological	O	O
status	O	O
)	O	O
.	O	O

This	O	O
demonstrated	O	O
that	O	O
fever	Physical	O
continued	O	O
to	O	O
be	O	O
significantly	O	O
associated	O	O
with	O	O
most	O	O
outcome	O	O
measures	O	O
,	O	O
even	O	O
when	O	O
infection	Adverseeffect	O
was	O	O
added	O	O
to	O	O
the	O	O
model	O	O
.	O	O

An	O	O
alternative	O	O
stepwise	O	O
model	O	O
selection	O	O
process	O	O
including	O	O
all	O	O
fever-related	Physical	O
measures	O	O
from	O	O
the	O	O
preoperative	O	O
and	O	O
intraoperative	O	O
period	O	O
(	O	O
e.g.	O	O
,	O	O
hydrocephalus	O	O
,	O	O
duration	O	O
of	O	O
surgery	O	O
,	O	O
intraoperative	O	O
blood	O	O
loss	O	O
)	O	O
resulted	O	O
in	O	O
the	O	O
loss	O	O
of	O	O
significance	O	O
for	O	O
dichotomized	O	Mental
Glasgow	O	Mental
Outcome	O	Mental
Scale	O	Mental
,	O	O
but	O	O
significant	O	O
associations	O	O
between	O	O
fever	Physical	O
and	O	O
several	O	O
other	O	O
outcome	O	O
measures	O	O
remained	O	O
.	O	O

After	O	O
adding	O	O
postoperative	O	O
delayed	Physical	O
ischemic	Physical	O
neurological	Physical	O
deficits	Physical	O
to	O	O
the	O	O
model	O	O
,	O	O
only	O	O
worsened	O	O
National	Physical	O
Institutes	Physical	O
of	Physical	O
Health	Physical	O
Stroke	Physical	O
Scale	Physical	O
score	Physical	O
,	O	O
Barthel	Physical	Physical
Activities	Physical	Physical
of	Physical	Physical
Daily	Physical	Physical
Living	Physical	Physical
index	Physical	Physical
,	O	Physical
and	O	Physical
discharge	Others	Physical
destination	Others	Physical
(	O	O
home	O	O
versus	O	O
other	O	O
)	O	O
remained	O	O
independently	O	O
associated	O	O
with	O	O
fever	O	O
.	O	O

CONCLUSION	O	O
These	O	O
findings	O	O
suggest	O	O
that	O	O
fever	Physical	O
is	O	O
associated	O	O
with	O	O
worsened	O	O
outcome	O	O
in	O	O
surgical	O	O
subarachnoid	O	O
hemorrhage	O	O
patients	O	O
,	O	O
although	O	O
,	O	O
because	O	O
the	O	O
association	O	O
between	O	O
fever	Physical	O
and	O	O
the	O	O
primary	O	O
outcome	O	O
measure	O	O
for	O	O
the	O	O
trial	O	O
is	O	O
dependent	O	O
on	O	O
the	O	O
covariates	O	O
used	O	O
in	O	O
the	O	O
analysis	O	O
(	O	O
particularly	O	O
operative	O	O
events	O	O
and	O	O
delayed	Physical	O
ischemic	Physical	O
neurological	Physical	O
deficits	Physical	O
)	Physical	O
,	O	O
we	O	O
can	O	O
not	O	O
rule	O	O
out	O	O
the	O	O
possibility	O	O
that	O	O
fever	Physical	O
is	O	O
a	O	O
marker	O	O
for	O	O
other	O	O
events	O	O
.	O	O

Only	O	O
a	O	O
formal	O	O
trial	O	O
of	O	O
fever	Physical	O
treatment	O	O
or	O	O
prevention	O	O
can	O	O
address	O	O
this	O	O
issue	O	O
.	O	O

Observer	O	O
variation	O	O
in	O	O
the	O	O
assessment	Others	O
of	Others	O
outcome	Others	O
in	O	O
traumatic	O	O
brain	O	O
injury	O	O
:	O	O
experience	O	O
from	O	O
a	O	O
multicenter	O	O
,	O	O
international	O	O
randomized	O	O
clinical	O	O
trial	O	O
.	O	O

OBJECTIVE	O	O
Accurate	O	O
and	O	O
consistent	O	O
outcome	Others	O
assessment	Others	O
is	O	O
essential	O	O
to	O	O
randomized	O	O
clinical	O	O
trials	O	O
.	O	O

We	O	O
aimed	O	O
to	O	O
explore	O	O
observer	O	O
variation	O	O
in	O	O
the	O	O
assessment	Others	O
of	Others	O
outcome	Others	O
in	O	O
a	O	O
recently	O	O
completed	O	O
trial	O	O
of	O	O
dexanabinol	O	O
in	O	O
head	O	O
injury	O	O
and	O	O
to	O	O
consider	O	O
steps	O	O
to	O	O
reduce	O	O
such	O	O
variation	O	O
.	O	O

METHODS	O	O
Eight	O	O
hundred	O	O
sixty-one	O	O
patients	O	O
with	O	O
severe	O	O
traumatic	O	O
brain	O	O
injury	O	O
who	O	O
were	O	O
admitted	O	O
to	O	O
86	O	O
centers	O	O
were	O	O
included	O	O
in	O	O
a	O	O
multicenter	O	O
,	O	O
placebo-controlled	O	O
,	O	O
Phase	O	O
III	O	O
trial	O	O
.	O	O

Outcome	O	O
was	O	O
assessed	O	O
at	O	O
3	O	O
and	O	O
6	O	O
months	O	O
postinjury	O	O
using	O	O
the	O	O
extended	Physical	O
Glasgow	Physical	O
Outcome	Physical	O
Scale	Physical	O
;	Others	O
standardized	O	O
assessment	O	O
was	O	O
facilitated	O	O
by	O	O
the	O	O
use	O	O
of	O	O
a	O	O
structured	O	O
interview	O	O
.	O	O

Before	O	O
initiation	O	O
of	O	O
trial	O	O
centers	O	O
,	O	O
outcome	Others	O
ratings	Others	O
were	O	O
obtained	O	O
for	O	O
sample	O	O
cases	O	O
to	O	O
establish	O	O
initial	O	O
levels	O	O
of	O	O
agreement	O	O
.	O	O

Training	O	O
sessions	O	O
in	O	O
outcome	O	O
assessment	O	O
were	O	O
held	O	O
,	O	O
and	O	O
problems	O	O
in	O	O
assigning	O	O
outcome	O	O
were	O	O
investigated	O	O
.	O	O

During	O	O
the	O	O
trial	O	O
,	O	O
a	O	O
process	O	O
of	O	O
central	O	O
review	O	O
was	O	O
established	O	O
to	O	O
monitor	O	O
performance	O	O
.	O	O

Interobserver	O	O
variation	O	O
was	O	O
analyzed	O	O
using	O	O
the	O	O
kappa	O	O
statistic	O	O
.	O	O

RESULTS	O	O
Substantial	Others	O
observer	Others	O
variation	Others	O
was	O	O
found	O	O
in	O	O
the	O	O
rating	O	O
of	O	O
sample	O	O
cases	O	O
(	O	O
weighted	O	O
kappa	O	O
,	O	O
0.72	O	O
;	O	O
confidence	O	O
interval	O	O
,	O	O
0.68-0.75	O	O
)	O	O
and	O	O
in	O	O
assigning	O	O
outcome	Others	O
based	O	O
on	O	O
completed	O	O
structured	O	O
interviews	O	O
(	O	O
weighted	O	O
kappa	O	O
,	O	O
0.61	O	O
;	O	O
confidence	O	O
interval	O	O
,	O	O
0.57-0.64	O	O
)	O	O
.	O	O

In	O	O
the	O	O
early	O	O
stages	O	O
of	O	O
the	O	O
trial	O	O
,	O	O
a	O	O
relatively	O	O
large	O	O
number	O	O
of	O	O
discrepancies	Others	O
(	O	O
29-37	O	O
%	O	O
)	O	O
were	O	O
identified	O	O
on	O	O
central	O	O
review	O	O
.	O	O

This	O	O
number	O	O
declined	O	O
as	O	O
the	O	O
trial	O	O
progressed	O	O
and	O	O
coincided	O	O
with	O	O
investigator	O	O
training	O	O
and	O	O
feedback	O	O
from	O	O
central	O	O
review	O	O
.	O	O

Centers	O	O
with	O	O
higher	O	O
enrollment	O	O
rates	O	O
showed	O	O
better	O	O
performance	O	O
.	O	O

CONCLUSION	O	O
Observer	Others	O
variation	Others	O
in	O	O
outcome	Others	O
assessment	Others	O
is	O	O
a	O	O
significant	O	O
problem	O	O
for	O	O
head	O	O
injury	O	O
trials	O	O
.	O	O

Consistency	Others	O
can	O	O
be	O	O
improved	O	O
by	O	O
standardizing	O	O
procedures	O	O
,	O	O
training	O	O
assessors	O	O
,	O	O
and	O	O
monitoring	O	O
the	O	O
quality	O	O
of	O	O
assessments	O	O
and	O	O
providing	O	O
feedback	O	O
to	O	O
interviewers	O	O
.	O	O

Endometrial	O	O
cytodiagnosis	O	O
using	O	O
a	O	O
new	O	O
softcyte	O	O
versus	O	O
a	O	O
conventional	O	O
endocyte	O	O
.	O	O

A	O	O
new	O	O
endometrial	O	O
cytologic	O	O
sampling	O	O
device	O	O
,	O	O
softcyte	O	O
,	O	O
was	O	O
used	O	O
in	O	O
cytological	O	O
screening	O	O
for	O	O
endometrial	O	O
cancer	O	O
,	O	O
and	O	O
was	O	O
compared	O	O
with	O	O
the	O	O
endocyte	O	O
with	O	O
regard	O	O
to	O	O
manipulability	O	O
,	O	O
adverse	O	O
effects	O	O
(	O	O
including	O	O
pain	O	Pain
and	O	O
hemorrhage	O	O
)	O	O
,	O	O
and	O	O
cellular	O	O
findings	O	O
(	O	O
including	O	O
the	O	O
quantity	O	Physical
of	O	Physical
cells	O	Physical
collected	O	Physical
,	O	O
the	O	O
success	O	Others
rate	O	Others
,	O	O
cell	O	O
freshness	O	O
,	O	O
and	O	O
cellular	O	O
clumping	O	O
)	O	O
.	O	O

A	O	O
total	O	O
of	O	O
315	O	O
women	O	O
(	O	O
premenopause	O	O
251	O	O
,	O	O
postmenopause	O	O
64	O	O
)	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
two	O	O
groups	O	O
who	O	O
underwent	O	O
the	O	O
endometrial	O	O
cytological	O	O
screening	O	O
with	O	O
either	O	O
the	O	O
softcyte	O	O
or	O	O
the	O	O
endocyte	O	O
.	O	O

To	O	O
assess	O	O
the	O	O
value	O	O
of	O	O
the	O	O
softcyte	O	O
we	O	O
compared	O	O
it	O	O
with	O	O
the	O	O
endocyte	O	O
.	O	O

Endometrial	O	O
cytology	O	O
using	O	O
a	O	O
softcyte	O	O
or	O	O
an	O	O
endocyte	O	O
achieved	O	O
high	O	O
correct	Others	O
diagnosis	Others	O
rate	Others	O
for	Others	O
cancer	Others	O
,	O	O
and	O	O
both	O	O
instruments	O	O
are	O	O
valuable	O	O
as	O	O
endometrial	O	O
cytologic	O	O
sample	O	O
devices	O	O
.	O	O

The	O	O
softcyte	O	O
causes	O	O
only	O	O
mild	Pain	O
pain	Pain	O
on	Physical	O
introduction	Physical	O
and	Physical	O
during	Physical	O
collection	Physical	O
,	O	O
and	O	O
a	O	O
large	O	O
quantity	Physical	O
of	Physical	O
cells	Physical	O
could	O	O
be	O	O
harvested	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
softcyte	O	O
is	O	O
a	O	O
useful	O	O
cytologic	O	O
sampling	O	O
device	O	O
in	O	O
screening	O	O
for	O	O
endometrial	O	O
cancer	O	O
.	O	O

A	O	O
comparison	O	O
of	O	O
intermittent	O	O
vaginal	O	O
administration	O	O
of	O	O
misoprostol	O	O
with	O	O
continuous	O	O
dinoprostone	O	O
for	O	O
cervical	Physical	O
ripening	Physical	O
and	Physical	O
labor	Physical	O
induction	Physical	O
.	Physical	O

OBJECTIVE	O	O
Our	O	O
purpose	O	O
was	O	O
to	O	O
compare	O	O
the	O	O
effect	O	O
of	O	O
vaginal	O	O
administration	O	O
of	O	O
misoprostol	O	O
(	O	O
Cytotec	O	O
)	O	O
with	O	O
that	O	O
of	O	O
dinoprostone	O	O
(	O	O
Cervidil	O	O
)	O	O
on	O	O
cervical	Physical	O
ripening	Physical	O
and	Physical	O
labor	Physical	O
induction	Physical	O
.	Physical	O

STUDY	O	O
DESIGN	O	O
Two	O	O
hundred	O	O
patients	O	O
with	O	O
indications	O	O
for	O	O
induction	O	O
of	O	O
labor	O	O
and	O	O
unfavorable	O	O
cervical	O	O
examinations	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
vaginally	O	O
administered	O	O
misoprostol	O	O
(	O	O
prostaglandin	O	O
E1	O	O
)	O	O
or	O	O
the	O	O
dinoprostone	O	O
(	O	O
prostaglandin	O	O
E2	O	O
)	O	O
vaginal	O	O
insert	O	O
.	O	O

Twenty-five	O	O
microgram	O	O
tablets	O	O
of	O	O
misoprostol	O	O
were	O	O
placed	O	O
in	O	O
the	O	O
posterior	O	O
vaginal	O	O
fornix	O	O
every	O	O
4	O	O
hours	O	O
for	O	O
a	O	O
maximum	O	O
of	O	O
six	O	O
doses	O	O
.	O	O

Additional	O	O
misoprostol	O	O
was	O	O
not	O	O
given	O	O
after	O	O
either	O	O
spontaneous	O	O
rupture	O	O
of	O	O
membranes	O	O
,	O	O
adequate	O	O
cervical	O	O
ripening	O	O
(	O	O
Bishop	O	O
score	O	O
of	O	O
>	O	O
or	O	O
=	O	O
8	O	O
or	O	O
cervical	O	O
dilatation	O	O
of	O	O
>	O	O
or	O	O
=	O	O
3	O	O
cm	O	O
)	O	O
,	O	O
or	O	O
beginning	O	O
of	O	O
active	O	O
labor	O	O
.	O	O

The	O	O
vaginal	O	O
insert	O	O
,	O	O
Cervidil	O	O
,	O	O
containing	O	O
10	O	O
mg	O	O
of	O	O
dinoprostone	O	O
in	O	O
a	O	O
timed-release	O	O
preparation	O	O
was	O	O
placed	O	O
in	O	O
the	O	O
posterior	O	O
vaginal	O	O
formix	O	O
for	O	O
a	O	O
maximum	O	O
period	O	O
of	O	O
24	O	O
hours	O	O
.	O	O

The	O	O
vaginal	O	O
insert	O	O
was	O	O
removed	O	O
for	O	O
spontaneous	O	O
rupture	O	O
of	O	O
membranes	O	O
,	O	O
entry	O	O
into	O	O
active	O	O
labor	O	O
,	O	O
adequate	O	O
cervical	O	O
ripening	O	O
,	O	O
or	O	O
abnormality	O	O
of	O	O
uterine	O	O
contractile	O	O
pattern	O	O
or	O	O
fetal	O	O
cardiac	O	O
activity	O	O
.	O	O

RESULTS	O	O
Of	O	O
the	O	O
200	O	O
patients	O	O
enrolled	O	O
,	O	O
99	O	O
were	O	O
randomized	O	O
to	O	O
misoprostol	O	O
and	O	O
101	O	O
to	O	O
dinoprostone	O	O
.	O	O

The	O	O
average	Physical	Physical
interval	Physical	Physical
from	Physical	Physical
start	Physical	Physical
of	Physical	Physical
induction	Physical	Physical
to	Physical	Physical
vaginal	Physical	Physical
delivery	Physical	Physical
was	O	O
1	O	O
hour	O	O
shorter	O	O
in	O	O
the	O	O
misoprostol	O	O
group	O	O
(	O	O
1296.7	O	O
+/-	O	O
722.1	O	O
minutes	O	O
)	O	O
than	O	O
in	O	O
the	O	O
dinoprostone	O	O
group	O	O
(	O	O
1360.0	O	O
+/-	O	O
792.0	O	O
minutes	O	O
)	O	O
,	O	O
but	O	O
this	O	O
difference	O	O
was	O	O
not	O	O
statistically	O	O
significant	O	O
(	O	O
p	O	O
=	O	O
0.97	O	O
)	O	O
.	O	O

Oxytocin	Others	O
augmentation	Others	O
of	Others	O
labor	Others	O
was	O	O
used	O	O
in	O	O
50	O	O
(	O	O
50.5	O	O
%	O	O
)	O	O
misoprostol-treated	O	O
patients	O	O
and	O	O
43	O	O
(	O	O
43.5	O	O
%	O	O
)	O	O
dinoprostone-treated	O	O
patients	O	O
(	O	O
relative	O	O
risk	O	O
1.14	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
0.86	O	O
to	O	O
1.51	O	O
,	O	O
p	O	O
=	O	O
0.35	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
routes	Others	O
of	Others	O
delivery	Others	O
with	O	O
misoprostol	O	O
or	O	O
dinoprostone	O	O
.	O	O

Overall	O	O
,	O	O
38	O	O
patients	O	O
(	O	O
19.3	O	O
%	O	O
)	O	O
had	O	O
cesarean	O	O
deliveries	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significantly	O	O
lower	O	O
prevalence	O	O
of	O	O
tachysystole	Physical	O
(	O	O
six	O	O
or	O	O
more	O	O
uterine	O	O
contractions	O	O
in	O	O
a	O	O
10-minute	O	O
window	O	O
for	O	O
two	O	O
consecutive	O	O
10-minute	O	O
periods	O	O
)	O	O
in	O	O
the	O	O
misoprostol	O	O
group	O	O
(	O	O
7.1	O	O
%	O	O
)	O	O
than	O	O
in	O	O
the	O	O
dinoprostone	O	O
group	O	O
(	O	O
18.4	O	O
%	O	O
)	O	O
(	O	O
relative	O	O
risk	O	O
0.52	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
0.31	O	O
to	O	O
0.89	O	O
,	O	O
p	O	O
=	O	O
0.02	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
frequency	Physical	O
of	Physical	O
uterine	Physical	O
hyperstimulation	Physical	O
or	Physical	O
hypertonus	Physical	O
.	Physical	O

Abnormal	Physical	O
fetal	Physical	O
heart	Physical	O
rate	Physical	O
tracings	Physical	O
were	O	O
found	O	O
in	O	O
23	O	O
(	O	O
23.2	O	O
%	O	O
)	O	O
of	O	O
misoprostol-treated	O	O
patients	O	O
and	O	O
35	O	O
(	O	O
35.7	O	O
%	O	O
)	O	O
of	O	O
dinoprostone-treated	O	O
patients	O	O
(	O	O
relative	O	O
risk	O	O
0.73	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
0.52	O	O
to	O	O
1.01	O	O
,	O	O
p	O	O
=	O	O
0.0546	O	O
)	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
were	O	O
found	O	O
in	O	O
meconium	Physical	O
passage	Physical	O
,	O	O
1-	O	O
or	O	O
5-minute	O	O
Apgar	Physical	O
scores	Physical	O
<	O	O
7	O	O
,	O	O
neonatal	Physical	O
resuscitations	Physical	O
,	Physical	O
or	Physical	O
admissions	Others	O
to	Others	O
the	Others	O
neonatal	Others	O
intensive	Others	O
care	Others	O
unit	Others	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
Vaginally	O	O
administered	O	O
misoprostol	O	O
is	O	O
as	O	O
effective	Others	O
as	O	O
dinoprostone	O	O
for	O	O
cervical	Physical	O
ripening	Physical	O
and	Physical	O
the	Physical	O
induction	Physical	O
of	Physical	O
labor	Physical	O
.	Physical	O

Mean	Others	Others
time	Others	Others
intervals	Others	Others
to	Others	Others
delivery	Others	Others
,	O	O
need	Others	Physical
for	Others	Physical
oxytocin	Others	Physical
augmentation	Others	Physical
,	O	O
and	O	O
routes	Others	O
of	Others	O
delivery	Others	O
were	O	O
similar	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

Incidence	O	O
of	O	O
uterine	Physical	O
tachysystole	Physical	O
with	O	O
misoprostol	O	O
every	O	O
4	O	O
hours	O	O
was	O	O
significantly	O	O
less	O	O
than	O	O
with	O	O
dinoprostone	O	O
.	O	O

Effects	O	O
of	O	O
weight-bearing	O	O
versus	O	O
nonweight-bearing	O	O
exercise	O	O
on	O	O
function	Physical	O
,	O	O
walking	Physical	Mental
speed	Physical	Mental
,	O	O
and	O	O
position	Physical	O
sense	Physical	O
in	O	O
participants	O	O
with	O	O
knee	O	O
osteoarthritis	O	O
:	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
investigate	O	O
whether	O	O
weight-bearing	O	O
(	O	O
WB	O	O
)	O	O
exercise	O	O
enhances	O	O
functional	Physical	O
capacity	Physical	O
to	O	O
a	O	O
greater	O	O
extent	O	O
than	O	O
nonweight-bearing	O	O
(	O	O
NWB	O	O
)	O	O
exercise	O	O
in	O	O
participants	O	O
with	O	O
knee	O	O
osteoarthritis	O	O
.	O	O

DESIGN	O	O
Randomized	O	O
controlled	O	O
trial	O	O
.	O	O

SETTING	O	O
Kinesiology	O	O
laboratory	O	O
.	O	O

PARTICIPANTS	O	O
Participants	O	O
(	O	O
N=106	O	O
)	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
WB	O	O
exercise	O	O
,	O	O
NWB	O	O
exercise	O	O
,	O	O
or	O	O
a	O	O
control	O	O
group	O	O
(	O	O
no	O	O
exercise	O	O
)	O	O
.	O	O

INTERVENTION	O	O
WB	O	O
exercise	O	O
and	O	O
NWB	O	O
exercise	O	O
groups	O	O
underwent	O	O
an	O	O
8-week	O	O
knee	O	O
extension-flexion	O	O
exercise	O	O
program	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
Western	Physical	Physical
Ontario	Physical	Physical
and	Physical	Physical
McMaster	Physical	Physical
Universities	Physical	Physical
Osteoarthritis	Physical	Physical
Index	Physical	Physical
(	Physical	Physical
WOMAC	Physical	Physical
)	Physical	Physical
function	Physical	Physical
scale	Physical	Physical
,	O	Physical
walking	Physical	Physical
speed	Physical	Physical
,	O	Physical
muscle	Physical	Physical
torque	Physical	Physical
,	O	O
and	O	O
knee	Physical	O
reposition	Physical	O
error	Physical	O
were	O	O
assessed	O	O
before	O	O
and	O	O
after	O	O
intervention	O	O
.	O	O

RESULTS	O	O
Equally	O	O
significant	O	O
improvements	O	O
were	O	O
apparent	O	O
for	O	O
all	O	O
outcomes	O	O
after	O	O
WB	O	O
exercise	O	O
and	O	O
NWB	O	O
exercise	O	O
,	O	O
except	O	O
for	O	O
reposition	Physical	O
error	Physical	O
,	O	O
for	O	O
which	O	O
improvement	O	O
was	O	O
greater	O	O
in	O	O
the	O	O
WB	O	O
exercise	O	O
group	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
there	O	O
were	O	O
no	O	O
improvements	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

CONCLUSIONS	O	O
Simple	O	O
knee	O	O
flexion	O	O
and	O	O
extension	O	O
exercises	O	O
(	O	O
WB	O	O
and	O	O
NWB	O	O
)	O	O
performed	O	O
over	O	O
8	O	O
weeks	O	O
resulted	O	O
in	O	O
significant	O	O
improvement	O	O
in	O	O
the	O	O
WOMAC	Physical	Physical
function	Physical	Physical
scale	Physical	Physical
and	O	Physical
knee	O	Physical
strength	O	Physical
compared	O	O
with	O	O
the	O	O
control	O	O
group	O	O
.	O	O

NWB	O	O
exercise	O	O
alone	O	O
may	O	O
be	O	O
sufficient	O	O
enough	O	O
to	O	O
improve	O	O
function	Physical	O
and	O	O
muscle	Physical	O
strength	Physical	O
.	O	O

The	O	O
additional	O	O
benefit	O	O
of	O	O
WB	O	O
exercise	O	O
was	O	O
improved	O	O
position	Physical	O
sense	Physical	O
,	O	O
which	O	O
may	O	O
enhance	O	O
complex	Physical	O
walking	Physical	O
tasks	Physical	O
(	O	O
walking	O	O
on	O	O
figure	O	O
of	O	O
8	O	O
route	O	O
and	O	O
spongy	O	O
surface	O	O
)	O	O
.	O	O

VLDL	Physical	O
,	Physical	O
apolipoproteins	Physical	O
B	Physical	O
,	Physical	O
CIII	Physical	O
,	Physical	O
and	Physical	O
E	Physical	O
,	O	O
and	O	O
risk	O	O
of	O	O
recurrent	Physical	O
coronary	Physical	O
events	Physical	O
in	O	O
the	O	O
Cholesterol	O	O
and	O	O
Recurrent	O	O
Events	O	O
(	O	O
CARE	O	O
)	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
Plasma	O	Physical
triglyceride	O	Physical
concentration	O	Physical
has	O	O
been	O	O
an	O	O
inconsistent	O	O
independent	O	O
risk	O	O
factor	O	O
for	O	O
coronary	O	O
heart	O	O
disease	O	O
,	O	O
perhaps	O	O
because	O	O
of	O	O
the	O	O
metabolic	O	O
heterogeneity	O	O
among	O	O
VLDL	O	O
particles	O	O
,	O	O
the	O	O
main	O	O
carriers	O	O
of	O	O
triglycerides	O	Physical
in	O	Physical
plasma	O	Physical
.	O	Physical

METHODS	O	O
AND	O	O
RESULTS	O	O
We	O	O
conducted	O	O
a	O	O
prospective	O	O
,	O	O
nested	O	O
case-control	O	O
study	O	O
in	O	O
the	O	O
Cholesterol	O	O
and	O	O
Recurrent	O	O
Events	O	O
(	O	O
CARE	O	O
)	O	O
trial	O	O
,	O	O
a	O	O
randomized	O	O
placebo-controlled	O	O
trial	O	O
of	O	O
pravastatin	O	O
in	O	O
4159	O	O
patients	O	O
with	O	O
myocardial	O	O
infarction	O	O
and	O	O
average	O	O
LDL	O	Physical
concentrations	O	Physical
at	O	O
baseline	O	O
(	O	O
115	O	O
to	O	O
174	O	O
mg/dL	O	O
,	O	O
mean	O	O
139	O	O
mg/dL	O	O
)	O	O
.	O	O

Baseline	O	O
concentrations	O	O
of	O	O
VLDL-apolipoprotein	Physical	O
(	O	O
apo	O	O
)	O	O
B	Physical	O
(	Physical	O
the	Physical	O
VLDL	Physical	O
particle	Physical	O
concentration	Physical	O
)	Physical	O
,	Physical	O
VLDL	Physical	O
lipids	Physical	O
,	O	O
and	O	O
apoCIII	Physical	O
and	Physical	O
apoE	Physical	O
in	Physical	O
VLDL+LDL	Physical	O
and	Physical	O
in	Physical	O
HDL	Physical	O
were	O	O
compared	O	O
in	O	O
patients	O	O
who	O	O
had	O	O
either	O	O
a	O	O
myocardial	O	O
infarction	O	O
or	O	O
coronary	O	O
death	O	O
(	O	O
cases	O	O
,	O	O
n=418	O	O
)	O	O
with	O	O
those	O	O
in	O	O
patients	O	O
who	O	O
did	O	O
not	O	O
have	O	O
a	O	O
cardiovascular	O	O
event	O	O
(	O	O
control	O	O
subjects	O	O
,	O	O
n=370	O	O
)	O	O
in	O	O
5	O	O
years	O	O
of	O	O
follow-up	O	O
.	O	O

VLDL-cholesterol	Physical	O
,	O	O
VLDL-triglyceride	Physical	Physical
,	O	O
VLDL-apoB	Physical	O
,	Physical	O
apoCIII	Physical	O
and	O	O
apoE	Physical	O
in	Physical	O
VLDL+LDL	Physical	O
and	O	O
apoE	Physical	Physical
in	Physical	Physical
HDL	Physical	Physical
were	O	O
all	O	O
interrelated	O	O
,	O	O
and	O	O
each	O	O
was	O	O
a	O	O
univariate	O	O
predictor	O	O
of	O	O
subsequent	O	O
coronary	O	O
events	O	O
.	O	O

The	O	O
significant	O	O
independent	O	O
predictors	O	O
were	O	O
VLDL-apoB	Physical	O
(	O	O
relative	O	O
risk	O	O
[	O	O
RR	O	O
]	O	O
3.2	O	O
for	O	O
highest	O	O
to	O	O
lowest	O	O
quintiles	O	O
,	O	O
P	O	O
:	O	O
=0.04	O	O
)	O	O
,	O	O
apoCIII	Physical	O
in	Physical	O
VLDL+LDL	Physical	O
(	O	O
RR	O	O
2.3	O	O
,	O	O
P	O	O
:	O	O
=0.04	O	O
)	O	O
,	O	O
and	O	O
apoE	Physical	Physical
in	Physical	Physical
HDL	Physical	Physical
(	O	O
RR	O	O
1.8	O	O
,	O	O
P	O	O
:	O	O
=0.02	O	O
)	O	O
.	O	O

Plasma	Physical	Physical
triglycerides	Physical	Physical
,	O	O
a	O	O
univariate	O	O
predictor	O	O
of	O	O
coronary	Physical	O
events	Physical	O
(	O	O
RR	O	O
1.6	O	O
,	O	O
P	O	O
:	O	O
=0.03	O	O
)	O	O
,	O	O
was	O	O
not	O	O
related	O	O
to	O	O
coronary	Physical	O
events	Physical	O
(	O	O
RR	O	O
1.3	O	O
,	O	O
P	O	O
:	O	O
=0.6	O	O
)	O	O
when	O	O
apoCIII	Physical	O
in	Physical	O
VLDL+LDL	Physical	O
was	O	O
included	O	O
in	O	O
the	O	O
model	O	O
,	O	O
whereas	O	O
apoCIII	Physical	O
remained	O	O
significant	O	O
.	O	O

Adjustment	O	O
for	O	O
LDL-	Physical	O
and	Physical	O
HDL-cholesterol	Physical	Physical
did	O	O
not	O	O
affect	O	O
these	O	O
results	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
plasma	O	O
concentrations	O	O
of	O	O
VLDL	Physical	O
particles	Physical	O
and	O	O
apoCIII	Physical	O
in	Physical	O
VLDL	Physical	O
and	Physical	O
LDL	Physical	O
are	O	O
more	O	O
specific	O	O
measures	O	O
of	O	O
coronary	O	O
heart	O	O
disease	O	O
risk	O	O
than	O	O
plasma	O	O
triglycerides	O	O
perhaps	O	O
because	O	O
their	O	O
known	O	O
metabolic	O	O
properties	O	O
link	O	O
them	O	O
more	O	O
closely	O	O
to	O	O
atherosclerosis	O	O
.	O	O

Morphological	O	O
onset	O	O
and	O	O
early	O	O
diagnosis	O	O
in	O	O
apical	O	O
hypertrophic	O	O
cardiomyopathy	O	O
:	O	O
a	O	O
long	O	O
term	O	O
analysis	O	O
with	O	O
nuclear	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
.	O	O

OBJECTIVES	O	O
A	O	O
long-term	O	O
follow-up	O	O
study	O	O
with	O	O
nuclear	O	O
magnetic	O	O
resonance	O	O
(	O	O
NMR	O	O
)	O	O
imaging	O	O
was	O	O
undertaken	O	O
to	O	O
detect	O	O
the	O	O
morphological	O	O
onset	O	O
and	O	O
to	O	O
establish	O	O
the	O	O
early	O	O
diagnosis	O	O
in	O	O
apical	O	O
hypertrophic	O	O
cardiomyopathy	O	O
(	O	O
HCM	O	O
)	O	O
.	O	O

BACKGROUND	O	O
A	O	O
spadelike	O	O
configuration	O	O
on	O	O
left	Physical	O
ventriculogram	Physical	O
(	Physical	O
LVG	Physical	O
)	Physical	O
is	O	O
regarded	O	O
as	O	O
a	O	O
diagnostic	O	O
criterion	O	O
for	O	O
the	O	O
classical	O	O
apical	O	O
HCM	O	O
.	O	O

There	O	O
also	O	O
exists	O	O
a	O	O
segmented	O	O
hypertrophy	O	O
at	O	O
the	O	O
apical	O	O
level	O	O
without	O	O
indicating	O	O
the	O	O
spadelike	O	O
features	O	O
(	O	O
a	O	O
nonspade	O	O
configuration	O	O
)	O	O
.	O	O

To	O	O
detect	O	O
the	O	O
hypertrophied	O	O
myocardium	O	O
of	O	O
the	O	O
nonspade	O	O
configuration	O	O
,	O	O
circumferential	O	O
scrutiny	O	O
of	O	O
the	O	O
apex	O	O
is	O	O
required	O	O
.	O	O

Although	O	O
both	O	O
configurations	O	O
can	O	O
be	O	O
underlying	O	O
causes	O	O
of	O	O
giant	O	O
negative	O	O
T	O	O
waves	O	O
,	O	O
etiological	O	O
relationship	O	O
between	O	O
the	O	O
two	O	O
is	O	O
not	O	O
clarified	O	O
.	O	O

METHODS	O	O
The	O	O
criteria	O	O
for	O	O
the	O	O
spadelike	O	O
configuration	O	O
defined	O	O
on	O	O
left	O	O
ventricular	O	O
short-axis	O	O
NMR	O	O
images	O	O
were	O	O
as	O	O
follows	O	O
:	O	O
(	O	O
apical	O	O
maximal	O	O
thickness	O	O
>	O	O
or	O	O
=	O	O
15	O	O
mm	O	O
)	O	O
,	O	O
(	O	O
apical	O	O
anterior	O	O
thickness	O	O
over	O	O
basal	O	O
anterior	O	O
thickness	O	O
>	O	O
or	O	O
=	O	O
1.3	O	O
)	O	O
and	O	O
(	O	O
apical	O	O
posterior	O	O
thickness	O	O
over	O	O
basal	O	O
posterior	O	O
thickness	O	O
>	O	O
or	O	O
=1.3	O	O
)	O	O
.	O	O

Thirteen	O	O
patients	O	O
who	O	O
had	O	O
predominant	O	O
hypertrophy	O	O
(	O	O
>	O	O
or	O	O
=	O	O
15	O	O
mm	O	O
)	O	O
at	O	O
the	O	O
apical	O	O
level	O	O
without	O	O
the	O	O
spadelike	O	O
configuration	O	O
underwent	O	O
NMR	O	O
imaging	O	O
twice	O	O
before	O	O
and	O	O
after	O	O
54+/-10	O	O
months	O	O
'	O	O
follow-up	O	O
.	O	O

RESULTS	O	O
Apical	Physical	O
hypertrophy	Physical	O
that	O	O
had	O	O
been	O	O
confined	O	O
to	O	O
the	O	O
lateral	O	O
wall	O	O
in	O	O
four	O	O
,	O	O
the	O	O
anterior-lateral	O	O
wall	O	O
in	O	O
two	O	O
,	O	O
and	O	O
the	O	O
septal-anterior	O	O
wall	O	O
in	O	O
one	O	O
developed	O	O
to	O	O
become	O	Physical
circumferential	Physical	Physical
hypertrophy	Physical	Physical
that	O	O
fulfilled	O	O
the	O	O
criteria	O	O
for	O	O
the	O	O
spadelike	O	O
configuration	O	O
after	O	O
the	O	O
follow-up	O	O
period	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
spadelike	O	O
configuration	O	O
can	O	O
begin	O	O
with	O	O
the	O	O
nonspade	O	O
configuration	O	O
and	O	O
therefore	O	O
,	O	O
both	O	O
can	O	O
constitute	O	O
a	O	O
single	O	O
disease	O	O
entity	O	O
of	O	O
apical	O	O
HCM	O	O
.	O	O

The	O	O
early	O	O
diagnosis	O	O
of	O	O
apical	Physical	O
HCM	Physical	O
can	O	O
be	O	O
achieved	O	O
by	O	O
identifying	O	O
the	O	O
hypertrophy	Physical	O
frequently	O	O
confined	O	O
to	O	O
the	O	O
lateral	O	O
wall	O	O
at	O	O
the	O	O
apical	O	O
level	O	O
.	O	O

Oral	O	O
health	O	O
impacts	O	O
on	O	O
daily	O	O
living	O	O
related	O	O
to	O	O
four	O	O
different	O	O
treatment	O	O
protocols	O	O
for	O	O
chronic	O	O
periodontitis	O	O
.	O	O

BACKGROUND	O	O
The	O	O
aims	O	O
of	O	O
this	O	O
study	O	O
were	O	O
to	O	O
evaluate	O	O
the	O	O
oral	O	O
health	O	O
impacts	O	O
perceived	O	O
by	O	O
patients	O	O
submitted	O	O
to	O	O
different	O	O
treatments	O	O
of	O	O
chronic	O	O
periodontitis	O	O
and	O	O
their	O	O
association	O	O
with	O	O
clinical	O	O
parameters	O	O
.	O	O

METHODS	O	O
Sixty	O	O
patients	O	O
were	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
the	O	O
following	O	O
therapeutic	O	O
groups	O	O
:	O	O
control	O	O
,	O	O
treated	O	O
with	O	O
full-mouth	O	O
scaling	O	O
and	O	O
root	O	O
planing	O	O
(	O	O
SRP	O	O
)	O	O
;	O	O
test	O	O
1	O	O
,	O	O
treated	O	O
with	O	O
SRP	O	O
and	O	O
400	O	O
mg	O	O
systemically	O	O
administered	O	O
metronidazole	O	O
(	O	O
MET	O	O
)	O	O
three	O	O
times	O	O
per	O	O
day	O	O
for	O	O
10	O	O
days	O	O
;	O	O
test	O	O
2	O	O
,	O	O
treated	O	O
with	O	O
SRP	O	O
and	O	O
professional	O	O
supragingival	O	O
plaque	O	O
removal	O	O
(	O	O
PP	O	O
)	O	O
every	O	O
week	O	O
for	O	O
3	O	O
months	O	O
;	O	O
and	O	O
test	O	O
3	O	O
,	O	O
treated	O	O
with	O	O
SRP	O	O
and	O	O
MET	O	O
plus	O	O
PP	O	O
.	O	O

Clinical	O	O
periodontal	O	O
measurements	O	O
and	O	O
data	O	O
regarding	O	O
patients	O	O
'	O	O
oral	Physical	O
health	Physical	O
impacts	Physical	O
(	Physical	O
perceived	Physical	O
impacts	Physical	O
on	Physical	O
bleeding	Physical	O
gums	Physical	O
,	Physical	O
gingival	Physical	Physical
recession	Physical	Physical
,	Physical	O
sensitivity	Physical	O
to	Physical	O
cold	Physical	O
,	Physical	O
packing	Physical	O
foods	Physical	O
,	Physical	O
aesthetics	Physical	O
,	Physical	O
bad	Physical	O
breath	Physical	O
,	Physical	O
and	Physical	O
tooth	Physical	O
mobility	Physical	O
)	Physical	O
were	O	O
collected	O	O
at	O	O
baseline	O	O
and	O	O
3	O	O
months	O	O
after	O	O
therapy	O	O
.	O	O

RESULTS	O	O
All	O	O
groups	O	O
presented	O	O
significant	O	O
improvement	O	O
in	O	O
oral	Physical	O
health	Physical	O
perceived	Physical	O
impacts	Physical	O
.	Physical	O

There	O	O
was	O	O
no	O	O
statistically	O	O
significant	O	O
difference	O	O
in	O	O
the	O	O
improvement	O	O
of	O	O
oral	Physical	O
health	Physical	O
impacts	Physical	O
among	O	O
groups	O	O
subjected	O	O
to	O	O
different	O	O
treatments	O	O
.	O	O

The	O	O
clinical	O	O
data	O	O
of	O	O
percentage	O	O
of	O	O
deep	Physical	O
probing	Physical	O
depth	Physical	O
,	Physical	O
deep	Physical	Physical
clinical	Physical	Physical
attachment	Physical	Physical
level	Physical	Physical
,	Physical	Physical
and	Physical	Physical
bleeding	Physical	Physical
on	Physical	Physical
probing	Physical	Physical
were	O	O
found	O	O
to	O	O
be	O	O
correlated	O	O
significantly	O	O
with	O	O
oral	O	O
health	O	O
impacts	O	O
.	O	O

CONCLUSIONS	O	O
Periodontal	O	O
treatment	O	O
leads	O	O
to	O	O
a	O	O
significant	O	O
reduction	O	O
of	O	O
self-perceived	Physical	O
impacts	Physical	O
regardless	O	O
of	O	O
the	O	O
non-surgical	O	O
treatment	O	O
protocol	O	O
employed	O	O
.	O	O

Most	O	O
of	O	O
the	O	O
clinical	O	O
data	O	O
were	O	O
associated	O	O
with	O	O
oral	O	O
health	O	O
impacts	O	O
.	O	O

Recombinant	O	O
human	O	O
erythropoietin	O	O
therapy	O	O
for	O	O
anemic	O	O
cancer	O	O
patients	O	O
on	O	O
combination	O	O
chemotherapy	O	O
.	O	O

BACKGROUND	O	O
Patients	O	O
with	O	O
advanced	O	O
cancer	O	O
frequently	O	O
experience	O	O
clinically	Physical	O
significant	Physical	O
anemia	Physical	O
,	O	O
which	O	O
is	O	O
often	O	O
exacerbated	O	O
by	O	O
myelosuppressive	O	O
chemotherapy	O	O
.	O	O

Consistent	O	O
with	O	O
the	O	O
anemia	O	O
of	O	O
chronic	O	O
disease	O	O
,	O	O
studies	O	O
have	O	O
documented	O	O
serum	O	O
erythropoietin	O	O
levels	O	O
that	O	O
are	O	O
inappropriately	O	O
low	O	O
for	O	O
the	O	O
degree	O	O
of	O	O
anemia	O	O
in	O	O
cancer	O	O
patients	O	O
.	O	O

Myelosuppressive	O	O
chemotherapy	O	O
impairs	O	O
erythropoiesis	O	O
,	O	O
which	O	O
may	O	O
not	O	O
fully	O	O
recover	O	O
between	O	O
treatment	O	O
cycles	O	O
.	O	O

Recombinant	O	O
human	O	O
erythropoietin	O	O
(	O	O
rHuEPO	O	O
)	O	O
has	O	O
been	O	O
used	O	O
safely	O	O
and	O	O
effectively	O	O
to	O	O
treat	O	O
anemia	O	O
in	O	O
AIDS	O	O
patients	O	O
receiving	O	O
zidovudine	O	O
(	O	O
AZT	O	O
)	O	O
and	O	O
in	O	O
patients	O	O
with	O	O
chronic	O	O
renal	O	O
failure	O	O
.	O	O

PURPOSE	O	O
This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
evaluate	O	O
the	O	O
clinical	O	O
role	O	O
of	O	O
rHuEPO	O	O
in	O	O
reducing	O	O
symptomatic	Physical	Physical
anemia	Physical	Physical
in	O	O
patients	O	O
with	O	O
advanced	O	O
cancer	O	O
who	O	O
were	O	O
receiving	O	O
myelosuppressive	O	O
chemotherapy	O	O
(	O	O
excluding	O	O
cisplatin	O	O
)	O	O
.	O	O

METHODS	O	O
We	O	O
studied	O	O
153	O	O
anemic	O	O
cancer	O	O
patients	O	O
receiving	O	O
cyclic	O	O
combination	O	O
chemotherapy	O	O
in	O	O
a	O	O
prospective	O	O
multicenter	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
trial	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
either	O	O
rHuEPO	O	O
(	O	O
150	O	O
U/kg	O	O
)	O	O
or	O	O
placebo	O	O
subcutaneously	O	O
three	O	O
times	O	O
a	O	O
week	O	O
for	O	O
a	O	O
maximum	O	O
of	O	O
12	O	O
weeks	O	O
or	O	O
until	O	O
the	O	O
hematocrit	Physical	Physical
level	Physical	Physical
increased	O	O
to	O	O
38	O	O
%	O	O
-40	O	O
%	O	O
.	O	O

If	O	O
the	O	O
hematocrit	Physical	O
reached	O	O
this	O	O
target	O	O
level	O	O
before	O	O
12	O	O
weeks	O	O
,	O	O
the	O	O
rHuEPO	O	O
dose	O	O
could	O	O
be	O	O
reduced	O	O
to	O	O
maintain	O	O
the	O	O
hematocrit	O	O
at	O	O
that	O	O
level	O	O
for	O	O
the	O	O
duration	O	O
of	O	O
the	O	O
study	O	O
.	O	O

Response	O	Physical
to	O	Physical
rHuEPO	O	Physical
therapy	O	Physical
was	O	O
assessed	O	O
by	O	O
measuring	O	O
changes	Physical	Physical
in	Physical	Physical
hematocrit	Physical	Physical
level	Physical	Physical
,	O	Physical
transfusion	Others	Physical
requirements	Others	Physical
,	O	Physical
and	O	Physical
quality	Others	Physical
of	Others	Physical
life	Others	Physical
.	O	O

Quality-of-life	Others	O
assessment	O	O
was	O	O
based	O	O
on	O	O
patients	O	Mental
'	O	Mental
responses	O	Mental
to	O	O
questionnaires	O	O
before	O	O
and	O	O
after	O	O
the	O	O
courses	O	O
of	O	O
therapy	O	O
.	O	O

RESULTS	O	O
The	O	O
increase	O	O
in	O	O
hematocrit	Physical	O
in	O	O
the	O	O
rHuEPO-treated	O	O
group	O	O
compared	O	O
with	O	O
hematocrit	Physical	O
in	O	O
the	O	O
placebo-treated	O	O
group	O	O
was	O	O
statistically	O	O
significant	O	O
(	O	O
P	O	O
=	O	O
.0001	O	O
)	O	O
as	O	O
measured	O	O
by	O	O
percentage	O	O
point	O	O
of	O	O
change	O	O
from	O	O
baseline	O	O
to	O	O
final	O	O
evaluation	O	O
,	O	O
by	O	O
an	O	O
increase	O	O
in	O	O
hematocrit	Physical	Others
level	O	Others
of	O	Others
six	O	Others
percentage	O	Others
points	O	Others
or	O	Others
more	O	Others
unrelated	O	Others
to	O	Others
transfusion	O	Others
,	O	O
and	O	O
by	O	O
a	O	O
rise	O	O
in	O	O
hematocrit	Physical	O
level	Physical	O
to	O	O
38	O	O
%	O	O
or	O	O
more	O	O
unrelated	O	O
to	O	O
transfusion	O	O
.	O	O

There	O	O
was	O	O
a	O	O
trend	O	O
toward	O	O
the	O	O
reduction	O	O
in	O	O
mean	Others	O
units	Others	O
of	Others	O
blood	Others	O
transfused	Others	O
per	Others	O
patient	Others	O
during	O	O
months	O	O
2	O	O
and	O	O
3	O	O
of	O	O
therapy	O	O
combined	O	O
in	O	O
rHuEPO-treated	O	O
patients	O	O
compared	O	O
with	O	O
placebo-treated	O	O
patients	O	O
(	O	O
0.91	O	O
U	O	O
versus	O	O
1.65	O	O
U	O	O
;	O	O
P	O	O
=	O	O
.056	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
rHuEPO-treated	O	O
patients	O	O
experienced	O	O
a	O	O
statistically	O	O
significant	O	O
improvement	O	O
in	O	O
energy	Others	Physical
level	Others	Physical
and	O	O
ability	Others	O
to	Others	O
perform	Others	O
daily	Others	O
activities	Others	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
.05	O	O
)	O	O
.	O	O

The	O	O
two	O	O
treatment	O	O
groups	O	O
showed	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
in	O	O
toxic	Adverseeffect	O
effects	Adverseeffect	O
except	O	O
for	O	O
increased	O	O
incidence	O	O
of	O	O
diaphoresis	Adverseeffect	O
(	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
and	O	O
diarrhea	Adverseeffect	Physical
(	O	O
P	O	O
=	O	O
.05	O	O
)	O	O
in	O	O
the	O	O
rHuEPO-treated	O	O
group	O	O
.	O	O

CONCLUSIONS	O	O
We	O	O
conclude	O	O
that	O	O
rHuEPO	O	O
is	O	O
safe	O	O
and	O	O
effective	O	O
for	O	O
reversing	O	O
anemia	Physical	O
related	O	O
to	O	O
advanced	O	O
cancer	O	O
or	O	O
to	O	O
chemotherapy	O	O
for	O	O
cancer	O	O
.	O	O

Allogeneic	O	O
marrow	O	O
transplantation	O	O
in	O	O
patients	O	O
with	O	O
chronic	O	O
myeloid	O	O
leukemia	O	O
in	O	O
the	O	O
chronic	O	O
phase	O	O
:	O	O
a	O	O
randomized	O	O
trial	O	O
of	O	O
two	O	O
irradiation	O	O
regimens	O	O
.	O	O

A	O	O
randomized	O	O
trial	O	O
was	O	O
performed	O	O
to	O	O
compare	O	O
two	O	O
regimens	O	O
of	O	O
total	O	O
body	O	O
irradiation	O	O
in	O	O
patients	O	O
with	O	O
chronic	O	O
myeloid	O	O
leukemia	O	O
treated	O	O
by	O	O
allogeneic	O	O
marrow	O	O
transplantation	O	O
while	O	O
in	O	O
the	O	O
chronic	O	O
phase	O	O
.	O	O

All	O	O
patients	O	O
received	O	O
cyclophosphamide	O	O
120	O	O
mg/kg	O	O
followed	O	O
by	O	O
total	O	O
body	O	O
irradiation	O	O
and	O	O
marrow	O	O
from	O	O
HLA-identical	O	O
siblings	O	O
.	O	O

Cyclosporine	O	O
and	O	O
methotrexate	O	O
were	O	O
used	O	O
for	O	O
prophylaxis	O	O
against	O	O
acute	O	O
graft-versus-host	O	O
disease	O	O
.	O	O

Fifty-seven	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
2.0	O	O
Gy	O	O
fractions	O	O
of	O	O
irradiation	O	O
daily	O	O
for	O	O
6	O	O
days	O	O
and	O	O
59	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
2.25	O	O
Gy	O	O
fractions	O	O
daily	O	O
for	O	O
7	O	O
days	O	O
.	O	O

The	O	O
probabilities	Physical	O
of	Physical	O
relapse	Physical	O
at	O	O
4	O	O
years	O	O
were	O	O
0.25	O	O
for	O	O
the	O	O
12.0	O	O
Gy	O	O
group	O	O
and	O	O
0.00	O	O
for	O	O
the	O	O
15.75	O	O
Gy	O	O
group	O	O
(	O	O
P	O	O
=	O	O
.008	O	O
)	O	O
.	O	O

The	O	O
actuarial	Mortality	Mortality
probabilities	Mortality	Mortality
of	Mortality	Mortality
survival	Mortality	Mortality
and	O	Mortality
relapse-free	Mortality	Mortality
survival	Mortality	Mortality
at	O	O
4	O	O
years	O	O
were	O	O
0.60	O	O
and	O	O
0.58	O	O
among	O	O
the	O	O
patients	O	O
who	O	O
received	O	O
12.0	O	O
Gy	O	O
compared	O	O
with	O	O
0.66	O	O
and	O	O
0.66	O	O
for	O	O
those	O	O
who	O	O
received	O	O
15.75	O	O
Gy	O	O
.	O	O

The	O	O
4-year	O	O
probabilities	Mortality	O
of	Mortality	O
transplant-related	Mortality	Mortality
mortality	Mortality	Mortality
were	O	O
0.24	O	O
and	O	O
0.34	O	O
respectively	O	O
(	O	O
P	O	O
=	O	O
.13	O	O
)	O	O
while	O	O
the	O	O
probability	Others	O
of	Others	O
moderate	Others	O
to	Others	O
severe	Others	O
acute	Others	O
graft-versus-host	Others	O
disease	Others	O
was	O	O
0.33	O	O
for	O	O
the	O	O
12.0	O	O
Gy	O	O
group	O	O
and	O	O
0.44	O	O
for	O	O
the	O	O
15.75	O	O
Gy	O	O
group	O	O
(	O	O
P	O	O
=	O	O
.15	O	O
)	O	O
.	O	O

The	O	O
lower	O	O
relapse	Physical	O
probability	Physical	O
in	O	O
the	O	O
patients	O	O
receiving	O	O
the	O	O
higher	O	O
dose	O	O
of	O	O
total	O	O
body	O	O
irradiation	O	O
did	O	O
not	O	O
result	O	O
in	O	O
improved	Physical	O
survival	Mortality	Mortality
because	O	Mortality
mortality	O	Mortality
from	O	O
causes	O	O
other	O	O
than	O	O
relapse	O	O
was	O	O
increased	O	O
.	O	O

Effects	O	O
of	O	O
20	O	O
mg	O	O
rosuvastatin	O	O
on	O	O
VLDL1-	O	O
,	O	O
VLDL2-	O	O
,	O	O
IDL-	O	O
and	O	O
LDL-ApoB	O	O
kinetics	O	O
in	O	O
type	O	O
2	O	O
diabetes	O	O
.	O	O

AIMS/HYPOTHESIS	O	O
In	O	O
addition	O	O
to	O	O
its	O	O
efficacy	O	O
in	O	O
reducing	O	O
LDL-cholesterol	Physical	Physical
,	O	O
rosuvastatin	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
significantly	O	O
decrease	O	O
plasma	Physical	O
triacylglycerol	Physical	O
.	O	O

The	O	O
use	O	O
of	O	O
rosuvastatin	O	O
may	O	O
be	O	O
beneficial	O	O
in	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
,	O	O
who	O	O
usually	O	O
have	O	O
increased	O	O
triacylglycerol	Physical	O
levels	Physical	O
.	O	O

However	O	O
,	O	O
its	O	O
effects	O	O
on	O	O
the	O	O
metabolism	O	O
of	O	O
triacylglycerol-rich	O	O
lipoproteins	O	O
in	O	O
type	O	O
2	O	O
diabetic	O	O
patients	O	O
remains	O	O
unknown	O	O
.	O	O

METHODS	O	O
We	O	O
performed	O	O
a	O	O
randomised	O	O
double-blind	O	O
crossover	O	O
trial	O	O
of	O	O
6-week	O	O
treatment	O	O
with	O	O
placebo	O	O
or	O	O
rosuvastatin	O	O
20	O	O
mg	O	O
in	O	O
eight	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
who	O	O
were	O	O
being	O	O
treated	O	O
with	O	O
oral	O	O
glucose-lowering	O	O
agents	O	O
.	O	O

In	O	O
each	O	O
patient	O	O
,	O	O
an	O	O
in	O	O
vivo	O	O
kinetic	O	O
study	O	O
of	O	O
apolipoprotein	O	O
B	O	O
(	O	O
ApoB	O	O
)	O	O
-containing	O	O
lipoproteins	O	O
with	O	O
[	O	O
13C	O	O
]	O	O
leucine	O	O
was	O	O
performed	O	O
at	O	O
the	O	O
end	O	O
of	O	O
each	O	O
treatment	O	O
period	O	O
.	O	O

A	O	O
central	O	O
randomisation	O	O
centre	O	O
used	O	O
computer-generated	O	O
tables	O	O
to	O	O
allocate	O	O
treatments	O	O
.	O	O

Participants	O	O
,	O	O
caregivers	O	O
and	O	O
those	O	O
assessing	O	O
the	O	O
outcomes	O	O
were	O	O
blinded	O	O
to	O	O
group	O	O
assignment	O	O
.	O	O

RESULTS	O	O
Rosuvastatin	O	O
20	O	O
mg	O	O
significantly	O	O
reduced	O	O
plasma	Physical	Physical
LDL-cholesterol	Physical	Physical
,	O	Physical
triacylglycerol	Physical	Physical
and	O	Physical
total	Physical	Physical
ApoB	Physical	Physical
.	O	O

It	O	O
also	O	O
significantly	O	O
reduced	O	O
ApoB	O	O
pool	O	O
sizes	O	O
of	O	O
larger	O	O
triacylglycerol-rich	O	O
VLDL	O	O
particles	O	O
(	O	O
VLDL1	O	O
;	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
,	O	O
smaller	Physical	O
VLDL	Physical	O
particles	Physical	O
(	O	O
VLDL2	O	O
;	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
,	O	O
intermediate	Physical	O
density	Physical	O
lipoprotein	Physical	O
(	O	O
IDL	O	O
;	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
and	O	O
LDL	O	O
(	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
.	O	O

This	O	O
reduction	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
total	Physical	Physical
fractional	Physical	Physical
catabolic	Physical	Physical
rate	Physical	Physical
of	Physical	Physical
VLDL1-ApoB	Physical	Physical
(	O	O
6.70	O	O
+/-	O	O
3.24	O	O
vs	O	O
4.52	O	O
+/-	O	O
2.34	O	O
pool/day	O	O
,	O	O
p	O	O
=	O	O
0.049	O	O
)	O	O
,	O	O
VLDL2-ApoB	O	O
(	O	O
8.72	O	O
+/-	O	O
3.37	O	O
vs	O	O
5.36	O	O
+/-	O	O
2.64	O	O
,	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
,	O	O
IDL-ApoB	O	O
(	O	O
7.06	O	O
+/-	O	O
1.68	O	O
vs	O	O
4.21	O	O
+/-	O	O
1.51	O	O
,	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
and	O	O
LDL-ApoB	O	O
(	O	O
1.02	O	O
+/-	O	O
0.27	O	O
vs	O	O
0.59	O	O
+/-	O	O
0.13	O	O
,	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
.	O	O

Rosuvastatin	O	O
did	O	O
not	O	O
change	O	O
the	O	O
production	Physical	O
rates	Physical	O
of	Physical	O
VLDL2-	Physical	O
,	Physical	O
IDL-	Physical	O
or	Physical	O
LDL-	Physical	O
,	O	O
but	O	O
did	O	O
reduce	O	O
VLDL1-ApoB	Physical	Physical
production	Physical	Physical
rate	Physical	Physical
(	O	O
12.4	O	O
+/-	O	O
4.5	O	O
vs	O	O
19.5	O	O
+/-	O	O
8.4	O	O
mg	O	O
kg	O	O
(	O	O
-1	O	O
)	O	O
day	O	O
(	O	O
-1	O	O
)	O	O
,	O	O
p	O	O
=	O	O
0.035	O	O
)	O	O
.	O	O

No	O	O
side	Adverseeffect	Adverseeffect
effects	Adverseeffect	Adverseeffect
of	O	Adverseeffect
rosuvastatin	O	Adverseeffect
were	O	O
observed	O	O
during	O	O
the	O	O
study	O	O
.	O	O

CONCLUSIONS/INTERPRETATION	O	O
In	O	O
type	O	O
2	O	O
diabetic	O	O
patients	O	O
rosuvastatin	O	O
20	O	O
mg	O	O
not	O	O
only	O	O
induces	O	O
a	O	O
significant	O	O
increase	O	O
of	O	O
LDL-ApoB	Physical	O
catabolism	Physical	O
(	O	O
73	O	O
%	O	O
)	O	O
,	O	O
but	O	O
also	O	O
has	O	O
favourable	O	O
effects	O	O
on	O	O
the	O	O
catabolism	Physical	O
of	Physical	O
triacylglycerol-rich	Physical	O
lipoproteins	Physical	O
,	O	O
e.g	O	O
.	O	O

a	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
catabolism	Physical	O
of	Physical	O
VLDL1-ApoB	Physical	O
(	O	O
48	O	O
%	O	O
)	O	O
,	O	O
VLDL2-ApoB	Physical	O
(	O	O
63	O	O
%	O	O
)	O	O
and	O	O
IDL-ApoB	Physical	O
(	O	O
68	O	O
%	O	O
)	O	O
,	O	O
and	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
production	O	O
rate	O	O
of	O	O
VLDL1-ApoB	Physical	O
(	O	O
-36	O	O
%	O	O
)	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
rosuvastatin	O	O
on	O	O
the	O	O
metabolism	O	O
of	O	O
triacylglycerol-rich	O	O
lipoproteins	O	O
may	O	O
be	O	O
beneficial	O	O
for	O	O
prevention	O	O
of	O	O
atherosclerosis	O	O
in	O	O
type	O	O
2	O	O
diabetic	O	O
patients	O	O
.	O	O

Enhancing	O	O
the	O	O
self-esteem	Mental	O
of	O	O
inpatient	O	O
alcoholics	O	O
.	O	O

This	O	O
study	O	O
examined	O	O
the	O	O
effect	O	O
of	O	O
pairing	O	O
inpatient	O	O
alcoholics	O	O
with	O	O
nursing	O	O
home	O	O
residents	O	O
(	O	O
NHRs	O	O
)	O	O
on	O	O
the	O	O
alcoholics	Mental	O
'	Mental	O
self-esteem	Mental	Mental
.	O	O

In	O	O
this	O	O
PALS	O	O
program	O	O
,	O	O
the	O	O
alcoholic	O	O
inpatients	O	O
assumed	O	O
a	O	O
helping-companion	O	O
relationship	O	O
with	O	O
the	O	O
NHRs	O	O
for	O	O
2	O	O
hr	O	O
per	O	O
day	O	O
during	O	O
their	O	O
last	O	O
2	O	O
weeks	O	O
of	O	O
treatment	O	O
.	O	O

Fifty	O	O
alcoholic	O	O
inpatients	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
the	O	O
PALS	O	O
program	O	O
(	O	O
n	O	O
=	O	O
25	O	O
)	O	O
or	O	O
to	O	O
the	O	O
library	O	O
for	O	O
free	O	O
reading	O	O
time	O	O
(	O	O
n	O	O
=	O	O
25	O	O
)	O	O
.	O	O

The	O	O
Tennessee	Mental	O
Self-Concept	Mental	O
Scale	Mental	O
(	Mental	O
TSCS	Mental	O
)	Mental	O
was	O	O
administered	O	O
to	O	O
all	O	O
subjects	O	O
in	O	O
both	O	O
groups	O	O
before	O	O
and	O	O
after	O	O
the	O	O
interventions	O	O
.	O	O

Of	O	O
the	O	O
nine	O	O
TSCS	Mental	O
scales	Mental	O
,	O	O
the	O	O
improvement	O	O
on	O	O
the	O	O
Moral-Ethical	Mental	Physical
scale	Mental	Physical
was	O	O
significantly	O	O
greater	O	O
in	O	O
the	O	O
PALS	O	O
group	O	O
.	O	O

Because	O	O
the	O	O
alcoholic	O	O
inpatients	O	O
in	O	O
the	O	O
PALS	O	O
group	O	O
engaged	O	O
in	O	O
altruistic	Mental	O
(	Mental	O
moral	Mental	O
)	Mental	O
behavior	Mental	O
,	O	O
this	O	O
study	O	O
provides	O	O
a	O	O
logical	O	O
link	O	O
between	O	O
the	O	O
intervention	O	O
and	O	O
the	O	O
outcome	O	O
,	O	O
which	O	O
has	O	O
been	O	O
a	O	O
prevalent	O	O
weakness	O	O
in	O	O
previous	O	O
studies	O	O
of	O	O
self-esteem	O	O
in	O	O
alcoholics	O	O
.	O	O

Cytokine	Physical	O
levels	Physical	O
and	O	O
systemic	Adverseeffect	O
toxicity	Adverseeffect	O
in	O	O
patients	O	O
undergoing	O	O
isolated	O	O
limb	O	O
perfusion	O	O
with	O	O
high-dose	O	O
tumor	O	O
necrosis	O	O
factor	O	O
,	O	O
interferon	O	O
gamma	O	O
,	O	O
and	O	O
melphalan	O	O
.	O	O

PURPOSE	O	O
Isolated	O	O
limb	O	O
perfusion	O	O
(	O	O
ILP	O	O
)	O	O
with	O	O
tumor	O	O
necrosis	O	O
factor	O	O
(	O	O
TNF	O	O
)	O	O
,	O	O
interferon	O	O
gamma	O	O
,	O	O
and	O	O
melphalan	O	O
(	O	O
M	O	O
)	O	O
has	O	O
been	O	O
reported	O	O
to	O	O
result	O	O
in	O	O
high	O	O
response	Physical	O
rates	Physical	O
for	O	O
extremity	O	O
melanoma	O	O
and	O	O
sarcoma	O	O
.	O	O

We	O	O
have	O	O
evaluated	O	O
the	O	O
relationship	O	O
of	O	O
systemic	O	O
TNF	O	O
exposure	O	O
to	O	O
induction	O	O
of	O	O
several	O	O
secondary	Physical	O
mediators	Physical	O
and	O	O
incidence	O	Adverseeffect
of	O	Adverseeffect
systemic	Adverseeffect	Adverseeffect
toxicity	Adverseeffect	Adverseeffect
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
Nineteen	O	O
patients	O	O
with	O	O
extremity	O	O
melanoma	O	O
(	O	O
n	O	O
=	O	O
16	O	O
)	O	O
or	O	O
sarcoma	O	O
(	O	O
n	O	O
=	O	O
3	O	O
)	O	O
,	O	O
underwent	O	O
90-minute	O	O
ILP	O	O
with	O	O
TNF-alpha	O	O
,	O	O
interferon	O	O
gamma	O	O
(	O	O
0.2	O	O
mg	O	O
)	O	O
,	O	O
and	O	O
M	O	O
(	O	O
10	O	O
to	O	O
13	O	O
mg/L	O	O
of	O	O
limb	O	O
volume	O	O
)	O	O
(	O	O
TNF/IFN/M	O	O
)	O	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
,	O	O
or	O	O
M	O	O
alone	O	O
(	O	O
n	O	O
=	O	O
7	O	O
)	O	O
.	O	O

Continuous	O	O
intraoperative	O	O
monitoring	O	O
(	O	O
CIM	O	O
)	O	O
for	O	O
systemic	O	O
leak	O	O
from	O	O
the	O	O
perfusion	O	O
circuit	O	O
was	O	O
performed	O	O
using	O	O
radioactive	O	O
iodine-131	O	O
albumin	O	O
.	O	O

Cytokine	O	O
levels	O	O
in	O	O
the	O	O
perfusate	O	O
and	O	O
systemic	O	O
circulation	O	O
during	O	O
and	O	O
after	O	O
ILP	O	O
were	O	O
measured	O	O
by	O	O
enzyme-linked	O	O
immunosorbent	O	O
assay	O	O
.	O	O

RESULTS	O	O
Systemic	O	O
leaks	O	O
>	O	O
or	O	O
=	O	O
1	O	O
%	O	O
from	O	O
the	O	O
perfusion	O	O
circuit	O	O
occurred	O	O
in	O	O
six	O	O
patients	O	O
who	O	O
received	O	O
TNF/IFN/M	O	O
and	O	O
in	O	O
four	O	O
who	O	O
received	O	O
M	O	O
alone	O	O
.	O	O

Hypotension	Adverseeffect	Physical
that	Adverseeffect	Physical
required	Adverseeffect	Physical
vasopressor	Adverseeffect	Physical
support	Adverseeffect	Physical
occurred	O	O
in	O	O
six	O	O
of	O	O
six	O	O
patients	O	O
with	O	O
evidence	O	O
of	O	O
a	O	O
leak	O	O
(	O	O
>	O	O
or	O	O
=	O	O
1	O	O
%	O	O
)	O	O
and	O	O
zero	O	O
of	O	O
six	O	O
patients	O	O
without	O	O
a	O	O
leak	O	O
(	O	O
<	O	O
1	O	O
%	O	O
)	O	O
.	O	O

These	O	O
six	O	O
patients	O	O
had	O	O
significantly	O	O
higher	O	O
peak	Physical	Physical
systemic	Physical	Physical
TNF	Physical	Physical
levels	Physical	Physical
during	O	O
and	O	O
after	O	O
perfusion	O	O
than	O	O
patients	O	O
without	O	O
a	O	O
leak	O	O
(	O	O
2.8	O	O
and	O	O
8.2	O	O
ng/mL	O	O
v	O	O
0.7	O	O
and	O	O
2.0	O	O
ng/mL	O	O
,	O	O
respectively	O	O
;	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
.	O	O

All	O	O
patients	O	O
who	O	O
received	O	O
TNF/IFN/M	O	O
had	O	O
significantly	O	O
greater	O	O
increases	O	O
in	O	O
systemic	Physical	Physical
interleukin-6	Physical	Physical
(	Physical	Physical
IL-6	Physical	Physical
)	Physical	Physical
levels	Physical	Physical
than	O	O
in	O	O
patients	O	O
with	O	O
M	O	O
alone	O	O
(	O	O
12,395	O	O
+/-	O	O
10,374	O	O
pg/mL	O	O
v	O	O
79.4	O	O
+/-	O	O
7.2	O	O
pg/mL	O	O
,	O	O
respectively	O	O
;	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

Intracellular	Physical	Physical
adhesion	Physical	Physical
molecule	Physical	Physical
(	Physical	Physical
ICAM	Physical	Physical
)	Physical	Physical
,	Physical	O
IL-8	Physical	O
,	Physical	O
and	Physical	O
TNF-R	Physical	Physical
levels	Physical	Physical
were	O	O
also	O	O
increased	O	O
after	O	O
ILP	O	O
with	O	O
TNF/IFN/M	O	O
.	O	O

CONCLUSION	O	O
ILP	O	O
with	O	O
TNF/IFN/M	O	O
can	O	O
be	O	O
safely	O	O
performed	O	O
,	O	O
as	O	O
I131	O	O
albumin	O	O
provides	O	O
a	O	O
sensitive	O	O
measure	O	O
of	O	O
systemic	O	O
leakage	O	O
from	O	O
the	O	O
perfusion	O	O
circuit	O	O
.	O	O

Patients	O	O
with	O	O
a	O	O
measured	O	O
leak	O	O
of	O	O
>	O	O
or	O	O
=	O	O
1	O	O
%	O	O
develop	O	O
mild	O	Physical
and	O	Physical
transient	O	Physical
postoperative	O	Physical
hypotension	O	Physical
with	O	O
significantly	O	O
higher	O	O
systemic	O	Physical
TNF	O	Physical
levels	O	Physical
and	O	O
lower	O	O
perfusate	O	O
TNF	O	Physical
levels	O	Physical
than	O	O
in	O	O
patients	O	O
without	O	O
leaks	O	O
.	O	O

A	O	O
randomized	O	O
controlled	O	O
study	O	O
of	O	O
parent-assisted	O	O
Children	O	O
's	O	O
Friendship	O	O
Training	O	O
with	O	O
children	O	O
having	O	O
autism	O	O
spectrum	O	O
disorders	O	O
.	O	O

This	O	O
study	O	O
evaluated	O	O
Children	O	O
's	O	O
Friendship	O	O
Training	O	O
(	O	O
CFT	O	O
)	O	O
,	O	O
a	O	O
manualized	O	O
parent-assisted	O	O
intervention	O	O
to	O	O
improve	O	O
social	O	Mental
skills	O	Mental
among	O	O
second	O	O
to	O	O
fifth	O	O
grade	O	O
children	O	O
with	O	O
autism	O	O
spectrum	O	O
disorders	O	O
.	O	O

Comparison	O	O
was	O	O
made	O	O
with	O	O
a	O	O
delayed	O	O
treatment	O	O
control	O	O
group	O	O
(	O	O
DTC	O	O
)	O	O
.	O	O

Targeted	O	O
skills	O	O
included	O	O
conversational	Mental	O
skills	Mental	O
,	O	O
peer	Mental	Others
entry	Mental	Others
skills	Mental	Others
,	O	Others
developing	O	Others
friendship	Mental	Others
networks	O	Others
,	O	O
good	Mental	O
sportsmanship	Mental	O
,	O	O
good	Mental	O
host	Mental	O
behavior	Mental	O
during	Mental	O
play	Mental	O
dates	Mental	O
,	O	O
and	O	O
handling	Mental	O
teasing	Mental	O
.	O	O

At	O	O
post-testing	O	O
,	O	O
the	O	O
CFT	O	O
group	O	O
was	O	O
superior	O	O
to	O	O
the	O	O
DTC	O	O
group	O	O
on	O	O
parent	O	Mental
measures	O	Mental
of	O	Mental
social	Mental	Mental
skill	Mental	Mental
and	O	Mental
play	Mental	Mental
date	Mental	Mental
behavior	Mental	Mental
,	O	O
and	O	O
child	O	Physical
measures	O	Physical
of	O	Physical
popularity	Mental	Physical
and	Mental	Physical
loneliness	Mental	Physical
,	O	O
At	O	O
3-month	O	O
follow-up	O	O
,	O	O
parent	O	O
measures	O	O
showed	O	O
significant	O	O
improvement	O	O
from	O	O
baseline	O	O
.	O	O

Post-hoc	O	O
analysis	O	O
indicated	O	O
more	O	O
than	O	O
87	O	O
%	O	O
of	O	O
children	O	O
receiving	O	O
CFT	O	O
showed	O	O
reliable	O	O
change	O	O
on	O	O
at	O	O
least	O	O
one	O	O
measure	O	O
at	O	O
post-test	O	O
and	O	O
66.7	O	O
%	O	O
after	O	O
3	O	O
months	O	O
follow-up	O	O
.	O	O

Memantine	O	O
add-on	O	O
to	O	O
risperidone	O	O
for	O	O
treatment	O	O
of	O	O
negative	O	Mental
symptoms	O	Mental
in	O	O
patients	O	O
with	O	O
stable	O	O
schizophrenia	O	O
:	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
study	O	O
.	O	O

We	O	O
aimed	O	O
to	O	O
evaluate	O	O
the	O	O
efficacy	O	O
of	O	O
memantine	O	O
add-on	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
primary	O	O
negative	O	O
symptoms	O	O
of	O	O
patients	O	O
with	O	O
stable	O	O
schizophrenia	O	O
.	O	O

In	O	O
a	O	O
double-blind	O	O
placebo-controlled	O	O
clinical	O	O
trial	O	O
,	O	O
40	O	O
patients	O	O
with	O	O
schizophrenia	O	O
(	O	O
Diagnostic	O	O
and	O	O
Statistical	O	O
Manual	O	O
of	O	O
Mental	O	O
Disorders	O	O
,	O	O
Fourth	O	O
Edition	O	O
)	O	O
who	O	O
were	O	O
stabilized	O	O
on	O	O
risperidone	O	O
for	O	O
a	O	O
minimum	O	O
of	O	O
8	O	O
weeks	O	O
were	O	O
randomized	O	O
to	O	O
either	O	O
memantine	O	O
(	O	O
20	O	O
mg	O	O
)	O	O
or	O	O
placebo	O	O
in	O	O
addition	O	O
to	O	O
risperidone	O	O
,	O	O
6	O	O
mg/d	O	O
,	O	O
for	O	O
eight	O	O
weeks	O	O
.	O	O

Assessment	O	O
was	O	O
done	O	O
using	O	O
the	O	O
Positive	Mental	O
and	Mental	O
Negative	Mental	O
Syndrome	Mental	O
Scale	Mental	O
at	O	O
baseline	O	O
,	O	O
week	O	O
4	O	O
,	O	O
and	O	O
week	O	O
8	O	O
.	O	O

The	O	O
Hamilton	Mental	Mental
Depression	Mental	Mental
Rating	Mental	Mental
Scale	Mental	Mental
and	O	O
the	O	O
Extrapyramidal	Mental	Others
Symptom	Mental	Others
Rating	Mental	Others
Scale	Mental	Others
at	O	O
baseline	O	O
and	O	O
week	O	O
8	O	O
were	O	O
used	O	O
to	O	O
assess	O	O
depression	O	O
and	O	O
extrapyramidal	O	O
symptoms	O	O
,	O	O
respectively	O	O
.	O	O

All	O	O
40	O	O
patients	O	O
had	O	O
at	O	O
least	O	O
one	O	O
postbaseline	O	O
measurement	O	O
,	O	O
and	O	O
38	O	O
patients	O	O
completed	O	O
the	O	O
trial	O	O
.	O	O

Patients	O	O
in	O	O
the	O	O
memantine	O	O
group	O	O
showed	O	O
a	O	O
significantly	Mental	O
greater	Mental	O
improvement	Mental	Mental
on	Mental	Mental
negative	Mental	Mental
subscale	Mental	Mental
than	O	O
the	O	O
placebo	O	O
group	O	O
at	O	O
end	O	O
point	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

The	O	O
same	Physical	O
effect	Physical	O
was	O	O
observed	O	O
for	O	O
the	O	O
total	O	O
score	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
and	O	O
the	O	O
general	O	O
psychopathology	O	O
subscale	O	O
score	O	O
(	O	O
P	O	O
=	O	O
0.002	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
reduction	O	Mental
of	O	Mental
positive	O	Mental
symptoms	O	Mental
score	O	Mental
between	O	O
the	O	O
2	O	O
groups	O	O
(	O	O
P	O	O
=	O	O
0.757	O	O
)	O	O
.	O	O

Changes	O	O
in	O	O
the	O	O
Hamilton	O	Mental
Depression	O	Mental
Rating	O	Mental
Scale	O	Mental
and	O	O
the	O	O
Extrapyramidal	O	Physical
Symptom	O	Physical
Rating	O	Physical
Scale	O	Physical
scores	O	Physical
and	O	O
frequency	Adverseeffect	Adverseeffect
of	Adverseeffect	Adverseeffect
adverse	Adverseeffect	Adverseeffect
effects	Adverseeffect	Adverseeffect
did	O	O
not	O	O
differ	O	O
between	O	O
the	O	O
2	O	O
groups	O	O
.	O	O

Our	O	O
study	O	O
showed	O	O
that	O	O
memantine	O	O
is	O	O
a	O	O
tolerable	O	O
and	O	O
efficacious	O	O
add-on	O	O
treatment	O	O
for	O	O
primary	O	O
negative	O	O
symptoms	O	O
of	O	O
schizophrenia	O	O
.	O	O

Effects	O	O
of	O	O
bifidobacterium	O	O
breve	O	O
supplementation	O	O
on	O	O
intestinal	O	O
flora	O	O
of	O	O
low	O	O
birth	O	O
weight	O	O
infants	O	O
.	O	O

BACKGROUND	O	O
It	O	O
is	O	O
known	O	O
that	O	O
the	O	O
bifidobacteria	O	O
flora	O	O
play	O	O
important	O	O
roles	O	O
in	O	O
mucosal	O	O
host	O	O
defense	O	O
and	O	O
can	O	O
prevent	O	O
infectious	O	O
diseases	O	O
.	O	O

Because	O	O
bacterial	O	O
populations	O	O
develop	O	O
during	O	O
the	O	O
first	O	O
day	O	O
of	O	O
life	O	O
,	O	O
the	O	O
authors	O	O
examined	O	O
whether	O	O
the	O	O
early	O	O
administration	O	O
of	O	O
bifidobacteria	O	O
has	O	O
a	O	O
positive	O	O
effect	Physical	O
on	Physical	O
the	Physical	O
health	Physical	O
of	O	O
low	O	O
birth	O	O
weight	O	O
infants	O	O
.	O	O

METHODS	O	O
The	O	O
effects	O	O
of	O	O
oral	O	O
administration	O	O
of	O	O
Bifidobacterium	O	O
breve	O	O
(	O	O
B.	O	O
breve	O	O
)	O	O
supplements	O	O
were	O	O
studied	O	O
in	O	O
a	O	O
controlled	O	O
trial	O	O
with	O	O
low	O	O
birth	O	O
weight	O	O
infants	O	O
(	O	O
average	O	O
birth	O	O
weight	O	O
1489	O	O
g	O	O
)	O	O
.	O	O

The	O	O
infants	O	O
were	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
:	O	O
Group	O	O
A	O	O
and	O	O
B	O	O
received	O	O
a	O	O
dose	O	O
of	O	O
1.6	O	O
x	O	O
10	O	O
(	O	O
8	O	O
)	O	O
cells	O	O
of	O	O
B.	O	O
breve	O	O
supplement	O	O
twice	O	O
a	O	O
day	O	O
,	O	O
commencing	O	O
either	O	O
from	O	O
several	O	O
hours	O	O
after	O	O
birth	O	O
(	O	O
group	O	O
A	O	O
)	O	O
or	O	O
24	O	O
h	O	O
after	O	O
birth	O	O
(	O	O
group	O	O
B	O	O
)	O	O
.	O	O

Group	O	O
C	O	O
,	O	O
the	O	O
control	O	O
group	O	O
,	O	O
received	O	O
no	O	O
supplement	O	O
.	O	O

RESULTS	O	O
There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
birth	Physical	Physical
weight	Physical	Physical
,	O	O
treatment	Physical	O
with	Physical	O
antibiotics	Physical	O
,	O	O
and	O	O
the	O	O
starting	Physical	O
time	Physical	O
of	Physical	O
breast-feeding	Physical	O
among	O	O
the	O	O
three	O	O
groups	O	O
.	O	O

A	O	O
Bifidobacterium-predominant	O	O
flora	O	O
was	O	O
formed	O	O
at	O	O
an	O	O
average	O	O
of	O	O
2	O	O
weeks	O	O
after	O	O
birth	O	O
in	O	O
group	O	O
A	O	O
and	O	O
at	O	O
an	O	O
average	O	O
of	O	O
4	O	O
weeks	O	O
after	O	O
birth	O	O
in	O	O
group	O	O
B	O	O
,	O	O
while	O	O
no	O	O
Bifidobacterium	O	O
was	O	O
isolated	O	O
in	O	O
eight	O	O
out	O	O
of	O	O
10	O	O
infants	O	O
in	O	O
group	O	O
C	O	O
during	O	O
the	O	O
observation	O	O
period	O	O
of	O	O
7	O	O
weeks	O	O
.	O	O

In	O	O
comparison	O	O
between	O	O
group	O	O
A	O	O
and	O	O
B	O	O
,	O	O
Bifidobacterium	O	O
was	O	O
detected	O	O
significantly	O	O
earlier	O	O
in	O	O
group	O	O
A	O	O
,	O	O
and	O	O
the	O	O
number	O	O
of	O	O
Enterobacteriaceae	O	O
present	O	O
in	O	O
the	O	O
infants	O	O
at	O	O
2	O	O
weeks	O	O
after	O	O
birth	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
group	O	O
A	O	O
.	O	O

CONCLUSION	O	O
The	O	O
results	O	O
of	O	O
the	O	O
present	O	O
study	O	O
suggest	O	O
that	O	O
very	O	O
early	O	O
administration	O	O
of	O	O
B.	O	O
breve	O	O
to	O	O
low	O	O
birth	O	O
weight	O	O
infants	O	O
is	O	O
useful	O	O
in	O	O
promoting	O	O
the	O	O
colonization	O	O
of	O	O
the	O	O
Bifidobacterium	O	O
and	O	O
the	O	O
formation	O	O
of	O	O
a	O	O
normal	O	O
intestinal	O	O
flora	O	O
.	O	O

Effect	O	O
of	O	O
four	O	O
intermediate	O	O
layer	O	O
treatments	O	O
on	O	O
microleakage	O	O
of	O	O
Class	O	O
II	O	O
composite	O	O
restorations	O	O
.	O	O

This	O	O
in	O	O
vitro	O	O
study	O	O
examines	O	O
the	O	O
marginal	O	O
sealing	O	O
ability	O	O
of	O	O
four	O	O
different	O	O
intermediate	O	O
materials	O	O
applied	O	O
before	O	O
placement	O	O
of	O	O
a	O	O
condensable	O	O
composite	O	O
.	O	O

Class	O	O
II	O	O
preparations	O	O
were	O	O
made	O	O
with	O	O
gingival	O	O
margins	O	O
placed	O	O
1.0	O	O
mm	O	O
apical	O	O
to	O	O
the	O	O
cementoenamel	O	O
junction	O	O
of	O	O
60	O	O
extracted	O	O
teeth	O	O
,	O	O
randomly	O	O
assigned	O	O
to	O	O
five	O	O
groups	O	O
of	O	O
12	O	O
.	O	O

Following	O	O
restoration	O	O
,	O	O
teeth	O	O
were	O	O
thermocycled	O	O
,	O	O
soaked	O	O
in	O	O
0.5	O	O
%	O	O
basic	O	O
fuchsin	O	O
,	O	O
and	O	O
sectioned	O	O
longitudinally	O	O
.	O	O

The	O	O
resin-modified	O	O
glass	O	O
ionomer	O	O
cement	O	O
demonstrated	O	O
significantly	O	O
less	O	O
microleakage	Physical	Physical
than	O	O
the	O	O
use	O	O
of	O	O
a	O	O
dentin	O	O
bonding	O	O
agent	O	O
alone	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
flowable	O	O
composite	O	O
,	O	O
flowable	O	O
compomer	O	O
,	O	O
or	O	O
autoploymerizing	O	O
composite	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
,	O	O
Dunn	O	O
's	O	O
test	O	O
)	O	O
.	O	O

This	O	O
study	O	O
supports	O	O
the	O	O
use	O	O
of	O	O
the	O	O
glass	O	O
ionomer	O	O
open	O	O
sandwich	O	O
technique	O	O
in	O	O
deep	O	O
Class	O	O
II	O	O
direct	O	O
composite	O	O
restorations	O	O
.	O	O

The	O	O
additional	O	O
value	O	O
of	O	O
a	O	O
night	O	O
splint	O	O
to	O	O
eccentric	O	O
exercises	O	O
in	O	O
chronic	O	O
midportion	O	O
Achilles	O	O
tendinopathy	O	O
:	O	O
a	O	O
randomised	O	O
controlled	O	O
trial	O	O
.	O	O

AIM	O	O
To	O	O
assess	O	O
whether	O	O
the	O	O
use	O	O
of	O	O
a	O	O
night	O	O
splint	O	O
is	O	O
of	O	O
added	O	O
benefit	O	O
on	O	O
functional	O	O
outcome	O	O
in	O	O
treating	O	O
chronic	O	O
midportion	O	O
Achilles	O	O
tendinopathy	O	O
.	O	O

METHODS	O	O
This	O	O
was	O	O
a	O	O
single-blind	O	O
,	O	O
prospective	O	O
,	O	O
single	O	O
centre	O	O
,	O	O
randomised	O	O
controlled	O	O
trial	O	O
set	O	O
in	O	O
the	O	O
Sports	O	O
Medical	O	O
Department	O	O
,	O	O
The	O	O
Hague	O	O
Medical	O	O
Centre	O	O
,	O	O
The	O	O
Netherlands	O	O
.	O	O

Inclusion	O	O
criteria	O	O
were	O	O
:	O	O
age	O	O
18-70	O	O
years	O	O
,	O	O
active	O	O
participation	O	O
in	O	O
sports	O	O
,	O	O
and	O	O
tendon	O	O
pain	O	O
localised	O	O
at	O	O
2-7	O	O
cm	O	O
from	O	O
distal	O	O
insertion	O	O
.	O	O

Exclusion	O	O
criteria	O	O
were	O	O
:	O	O
insertional	O	O
disorders	O	O
,	O	O
partial	O	O
or	O	O
complete	O	O
ruptures	O	O
,	O	O
or	O	O
systemic	O	O
illness	O	O
.	O	O

70	O	O
tendons	O	O
were	O	O
included	O	O
and	O	O
randomised	O	O
into	O	O
one	O	O
of	O	O
two	O	O
treatment	O	O
groups	O	O
:	O	O
eccentric	O	O
exercises	O	O
with	O	O
a	O	O
night	O	O
splint	O	O
(	O	O
night	O	O
splint	O	O
group	O	O
,	O	O
n	O	O
=	O	O
36	O	O
)	O	O
or	O	O
eccentric	O	O
exercises	O	O
only	O	O
(	O	O
eccentric	O	O
group	O	O
,	O	O
n	O	O
=	O	O
34	O	O
)	O	O
.	O	O

INTERVENTIONS	O	O
Both	O	O
groups	O	O
completed	O	O
a	O	O
12-week	O	O
heavy-load	O	O
eccentric	O	O
training	O	O
programme	O	O
.	O	O

One	O	O
group	O	O
received	O	O
a	O	O
night	O	O
splint	O	O
in	O	O
addition	O	O
to	O	O
eccentric	O	O
exercises	O	O
.	O	O

At	O	O
baseline	O	O
and	O	O
follow-up	O	O
at	O	O
12	O	O
weeks	O	O
,	O	O
patient	Others	Others
satisfaction	Others	Others
,	O	O
Victorian	Physical	O
Institute	Physical	O
of	Physical	O
Sport	Physical	O
Assessment-Achilles	Physical	O
questionnaire	Physical	O
(	Physical	O
VISA-A	Physical	O
)	Physical	O
score	Physical	O
and	O	O
reported	Others	O
compliance	Others	O
were	O	O
recorded	O	O
by	O	O
a	O	O
single-blind	O	O
trained	O	O
researcher	O	O
who	O	O
was	O	O
blinded	O	O
to	O	O
the	O	O
treatment	O	O
.	O	O

RESULTS	O	O
After	O	O
12	O	O
weeks	O	O
,	O	O
patient	Others	Others
satisfaction	Others	Others
in	O	O
the	O	O
eccentric	O	O
group	O	O
was	O	O
63	O	O
%	O	O
compared	O	O
with	O	O
48	O	O
%	O	O
in	O	O
the	O	O
night	O	O
splint	O	O
group	O	O
.	O	O

The	O	O
VISA-A	Physical	Mental
score	Physical	Mental
significantly	O	O
improved	O	O
in	O	O
both	O	O
groups	O	O
;	O	O
in	O	O
the	O	O
eccentric	O	O
group	O	O
from	O	O
50.1	O	O
to	O	O
68.8	O	O
(	O	O
p	O	O
=	O	O
0.001	O	O
)	O	O
and	O	O
in	O	O
the	O	O
night	O	O
splint	O	O
group	O	O
from	O	O
49.4	O	O
to	O	O
67.0	O	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
in	O	O
VISA-A	Physical	O
score	Physical	O
(	O	O
p	O	O
=	O	O
0.815	O	O
)	O	O
and	O	O
patient	Others	Others
satisfaction	Others	Others
(	O	O
p	O	O
=	O	O
0.261	O	O
)	O	O
.	O	O

CONCLUSION	O	O
A	O	O
night	O	O
splint	O	O
is	O	O
not	O	O
beneficial	O	O
in	O	O
addition	O	O
to	O	O
eccentric	O	O
exercises	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
chronic	O	O
midportion	O	O
Achilles	O	O
tendinopathy	O	O
.	O	O

Randomized	O	O
trial	O	O
of	O	O
fenretinide	O	O
in	O	O
superficial	O	O
bladder	O	O
cancer	O	O
using	O	O
DNA	O	O
flow	O	O
cytometry	O	O
as	O	O
an	O	O
intermediate	O	O
end	O	O
point	O	O
.	O	O

Retinoids	O	O
have	O	O
shown	O	O
a	O	O
potential	O	O
activity	O	O
in	O	O
preventing	O	O
tumor	O	O
recurrence	O	O
in	O	O
superficial	O	O
bladder	O	O
cancer	O	O
.	O	O

We	O	O
assessed	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
synthetic	O	O
retinoid	O	O
fenretinide	O	O
in	O	O
superficial	O	O
bladder	O	O
cancer	O	O
using	O	O
DNA	O	O
flow	O	O
cytometry	O	O
and	O	O
conventional	O	O
cytology	O	O
as	O	O
surrogate	O	O
biomarkers	O	O
.	O	O

A	O	O
total	O	O
of	O	O
99	O	O
subjects	O	O
with	O	O
resected	O	O
superficial	O	O
bladder	O	O
cancer	O	O
(	O	O
pTa	O	O
,	O	O
pT1	O	O
)	O	O
were	O	O
randomized	O	O
to	O	O
either	O	O
fenretinide	O	O
(	O	O
200	O	O
mg	O	O
day	O	O
p.o	O	O
.	O	O

for	O	O
24	O	O
months	O	O
)	O	O
or	O	O
no	O	O
intervention	O	O
.	O	O

Cystoscopy	O	O
and	O	O
bladder	O	O
washing	O	O
for	O	O
DNA	O	Physical
flow	O	Physical
cytometry	O	Physical
end	O	Physical
points	O	Physical
(	O	O
proportion	O	O
of	O	O
DNA	O	O
aneuploid	O	O
histograms	O	O
,	O	O
hyperdiploid	O	O
fraction	O	O
,	O	O
and	O	O
percentage	O	O
of	O	O
apoptotic	O	O
cells	O	O
)	O	O
and	O	O
proportion	O	O
of	O	O
abnormal	Physical	O
cytological	Physical	O
examinations	Physical	O
were	O	O
repeated	O	O
every	O	O
4	O	O
months	O	O
for	O	O
up	O	O
to	O	O
36	O	O
months	O	O
.	O	O

The	O	O
primary	O	O
study	O	O
end	O	O
point	O	O
was	O	O
the	O	O
proportion	Physical	Physical
of	Physical	Physical
DNA	Physical	Physical
aneuploid	Physical	Physical
histograms	Physical	Physical
after	O	O
12	O	O
months	O	O
.	O	O

This	O	O
figure	O	O
was	O	O
48.9	O	O
%	O	O
in	O	O
the	O	O
fenretinide	O	O
arm	O	O
and	O	O
41.9	O	O
%	O	O
in	O	O
the	O	O
control	O	O
arm	O	O
(	O	O
odds	O	O
ratio	O	O
,	O	O
1.16	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
0.44-3.07	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
any	O	O
other	O	O
response	Physical	O
biomarker	Physical	O
between	O	O
the	O	O
two	O	O
groups	O	O
up	O	O
to	O	O
36	O	O
months	O	O
,	O	O
nor	O	O
was	O	O
any	O	O
biomarker	O	O
able	O	O
to	O	O
predict	O	O
recurrence	O	O
risk	O	O
.	O	O

Recurrence-free	Mortality	Mortality
survival	Mortality	Mortality
was	O	O
comparable	O	O
between	O	O
the	O	O
arms	O	O
(	O	O
27	O	O
events	O	O
in	O	O
the	O	O
fenretinide	O	O
arm	O	O
versus	O	O
21	O	O
in	O	O
the	O	O
control	O	O
arm	O	O
;	O	O
P	O	O
=	O	O
0.36	O	O
)	O	O
.	O	O

Twelve	O	O
subjects	O	O
in	O	O
the	O	O
fenretinide	O	O
arm	O	O
complained	O	O
of	O	O
diminished	O	O
dark	Adverseeffect	O
adaptability	Adverseeffect	O
,	O	O
and	O	O
nine	O	O
subjects	O	O
in	O	O
the	O	O
fenretinide	O	O
arm	O	O
versus	O	O
one	O	O
control	O	O
subject	O	O
had	O	O
mild	Physical	O
dermatological	Physical	O
alterations	Physical	O
.	O	O

We	O	O
conclude	O	O
that	O	O
fenretinide	O	O
showed	O	O
a	O	O
lack	O	O
of	O	O
effect	O	O
on	O	O
the	O	O
DNA	O	O
content	Physical	O
distribution	Physical	O
and	O	O
the	O	O
morphology	Physical	O
of	Physical	O
urothelial	Physical	O
cells	Physical	O
obtained	O	O
in	O	O
serial	O	O
bladder	O	O
washings	O	O
.	O	O

Recurrence-free	Mortality	Mortality
survival	Mortality	Mortality
was	O	O
comparable	O	O
between	O	O
groups	O	O
.	O	O

Because	O	O
our	O	O
data	O	O
are	O	O
hampered	O	O
by	O	O
the	O	O
lack	O	O
of	O	O
predictivity	O	O
of	O	O
the	O	O
selected	O	O
biomarkers	O	O
,	O	O
additional	O	O
studies	O	O
are	O	O
necessary	O	O
to	O	O
assess	O	O
the	O	O
activity	O	O
of	O	O
fenretinide	O	O
in	O	O
preventing	O	O
bladder	O	O
cancer	O	O
.	O	O

Effect	Physical	O
of	O	O
hydrochlorothiazide	O	O
therapy	O	O
on	O	O
cardiac	Physical	O
arrhythmias	Physical	O
in	O	O
African-American	O	O
men	O	O
with	O	O
systemic	O	O
hypertension	O	O
and	O	O
moderate	O	O
to	O	O
severe	O	O
left	O	O
ventricular	O	O
hypertrophy	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
hydrochlorothiazide	O	O
therapy	O	O
on	O	O
ventricular	Physical	O
arrhythmias	Physical	O
was	O	O
studied	O	O
in	O	O
45	O	O
hypertensive	O	O
African-American	O	O
men	O	O
with	O	O
moderate	O	O
to	O	O
severe	O	O
left	O	O
ventricular	O	O
(	O	O
LV	O	O
)	O	O
hypertrophy	O	O
.	O	O

After	O	O
medication	O	O
washout	O	O
,	O	O
patients	O	O
were	O	O
treated	O	O
with	O	O
placebo	O	O
followed	O	O
by	O	O
hydrochlorothiazide	O	O
.	O	O

Clinical	Physical	O
,	O	O
biochemical	Physical	O
,	O	O
and	O	O
48-hour	Physical	O
ambulatory	Physical	O
electrocardiographic	Physical	O
data	Physical	O
was	O	O
collected	O	O
after	O	O
each	O	O
treatment	O	O
phase	O	O
.	O	O

Signal-averaged	Physical	O
electrocardiograms	Physical	O
were	O	O
recorded	O	O
in	O	O
a	O	O
subgroup	O	O
of	O	O
24	O	O
patients	O	O
.	O	O

Average	Physical	Physical
LV	Physical	Physical
posterior	Physical	Physical
wall	Physical	Physical
thickness	Physical	Physical
was	O	O
15	O	O
+/-	O	O
1.1	O	O
mm	O	O
,	O	O
septum	O	O
16	O	O
+/-	O	O
2	O	O
mm	O	O
,	O	O
LV	O	O
mass	O	O
420	O	O
+/-	O	O
90	O	O
g	O	O
,	O	O
and	O	O
LV	O	O
mass	O	O
index	O	O
212	O	O
=	O	O
51	O	O
g/m2	O	O
.	O	O

Systolic	Physical	Physical
blood	Physical	Physical
pressure	Physical	Physical
(	Physical	Physical
BP	Physical	Physical
)	Physical	Physical
was	O	O
168	O	O
+/-	O	O
18	O	O
mm	O	O
Hg	O	O
after	O	O
the	O	O
placebo	O	O
phase	O	O
and	O	O
146	O	O
+/-	O	O
15	O	O
mm	O	O
Hg	O	O
after	O	O
hydrochlorothiazide	O	O
;	O	O
diastolic	O	Physical
BP	O	Physical
was	O	O
103	O	O
+/-	O	O
6	O	O
mm	O	O
Hg	O	O
and	O	O
89	O	O
+/-	O	O
9	O	O
mm	O	O
Hg	O	O
,	O	O
respectively	O	O
.	O	O

Serum	Physical	Physical
potassium	Physical	Physical
decreased	O	O
significantly	O	O
from	O	O
4.2	O	O
+/-	O	O
0.4	O	O
mmol/L	O	O
to	O	O
3.7	O	O
+/-	O	O
0.6	O	O
mmol/L	O	O
after	O	O
hydrochlorothiazide	O	O
therapy	O	O
.	O	O

The	O	O
average	O	O
hourly	O	O
incidence	O	O
of	O	O
ventricular	Physical	O
premature	Physical	O
contractions	Physical	O
was	O	O
22	O	O
with	O	O
placebo	O	O
and	O	O
25	O	O
with	O	O
hydrochlorothiazide	O	O
.	O	O

There	O	O
were	O	O
3	O	O
and	O	O
1	O	O
couplets	O	O
and	O	O
0.2	O	O
and	O	O
0.2	O	O
runs	O	O
of	O	O
ventricular	Physical	Physical
tachycardia	Physical	Physical
per	O	Physical
patient	O	Physical
per	O	Physical
hour	O	Physical
,	O	O
respectively	O	O
.	O	O

Variables	O	O
of	O	O
signal-averaged	Physical	O
electrocardiography	Physical	O
did	O	O
not	O	O
differ	O	O
between	O	O
the	O	O
2	O	O
treatments	O	O
.	O	O

Thus	O	O
,	O	O
in	O	O
hypertensive	O	O
African-American	O	O
men	O	O
with	O	O
moderate	O	O
to	O	O
severe	O	O
LV	O	O
hypertrophy	O	O
,	O	O
hydrochlorothiazide	O	O
does	O	O
not	O	O
worsen	O	O
ventricular	Physical	O
arrhythmias	Physical	O
or	O	O
signal-averaged	Physical	O
electrocardiographic	Physical	O
variables	Physical	O
.	O	O

How	O	O
does	O	O
Cash	O	O
and	O	O
Counseling	O	O
affect	O	O
costs	O	O
?	O	O
OBJECTIVE	O	O
To	O	O
test	O	O
the	O	O
effect	O	O
of	O	O
a	O	O
consumer-directed	O	O
model	O	O
(	O	O
Cash	O	O
and	O	O
Counseling	O	O
)	O	O
of	O	O
Medicaid	O	O
personal	O	O
care	O	O
services	O	O
(	O	O
PCS	O	O
)	O	O
or	O	O
home-	O	O
and	O	O
community-based	O	O
waiver	O	O
services	O	O
(	O	O
HCBS	O	O
)	O	O
on	O	O
the	O	O
cost	O	O
of	O	O
Medicaid	O	O
services	O	O
.	O	O

DATA	O	O
SOURCES/STUDY	O	O
SETTING	O	O
Medicaid	O	O
claims	O	O
data	O	O
were	O	O
collected	O	O
for	O	O
all	O	O
enrollees	O	O
in	O	O
the	O	O
Cash	O	O
and	O	O
Counseling	O	O
demonstration	O	O
.	O	O

Demonstration	O	O
enrollees	O	O
included	O	O
those	O	O
eligible	O	O
for	O	O
PCS	O	O
(	O	O
in	O	O
Arkansas	O	O
)	O	O
,	O	O
those	O	O
assessed	O	O
to	O	O
receive	O	O
such	O	O
services	O	O
(	O	O
in	O	O
New	O	O
Jersey	O	O
)	O	O
,	O	O
and	O	O
recipients	O	O
of	O	O
Medicaid	O	O
HCBS	O	O
(	O	O
in	O	O
Florida	O	O
)	O	O
.	O	O

Enrollment	O	O
occurred	O	O
from	O	O
December	O	O
1998	O	O
through	O	O
April	O	O
2001	O	O
.	O	O

The	O	O
follow-up	O	O
period	O	O
covered	O	O
up	O	O
to	O	O
24	O	O
months	O	O
after	O	O
enrollment	O	O
.	O	O

STUDY	O	O
DESIGN	O	O
Demonstration	O	O
volunteers	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
have	O	O
the	O	O
option	O	O
to	O	O
participate	O	O
in	O	O
Cash	O	O
and	O	O
Counseling	O	O
(	O	O
the	O	O
treatment	O	O
group	O	O
)	O	O
,	O	O
or	O	O
to	O	O
receive	O	O
Medicaid	O	Others
services	O	Others
as	O	O
usual	O	O
from	O	O
an	O	O
agency	O	O
(	O	O
the	O	O
control	O	O
group	O	O
)	O	O
.	O	O

Ordinary	O	O
least	O	O
squares	O	O
regressions	O	O
were	O	O
used	O	O
to	O	O
estimate	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
program	O	O
on	O	O
costs	Others	Others
for	Others	O
Medicaid	Others	O
PCS/waiver	Others	O
services	Others	O
and	O	O
other	O	O
Medicaid	Others	O
services	Others	O
,	O	O
while	O	O
controlling	O	O
for	O	O
consumers	O	O
'	O	O
preenrollment	O	O
characteristics	O	O
and	O	O
preenrollment	O	O
Medicaid	O	O
spending	O	O
.	O	O

Models	O	O
were	O	O
estimated	O	O
separately	O	O
for	O	O
nonelderly	O	O
and	O	O
elderly	O	O
adults	O	O
in	O	O
each	O	O
state	O	O
and	O	O
for	O	O
children	O	O
in	O	O
Florida	O	O
.	O	O

DATA	O	O
EXTRACTION	O	O
METHODS	O	O
Each	O	O
state	O	O
supplied	O	O
claims	O	O
data	O	O
for	O	O
demonstration	O	O
enrollees	O	O
.	O	O

PRINCIPAL	O	O
FINDINGS	O	O
Largely	O	O
because	O	O
the	O	O
program	O	O
increased	O	O
consumers	O	O
'	O	O
ability	O	O
to	O	O
get	O	O
the	O	O
authorized	O	O
amount	O	O
of	O	O
paid	O	O
care	O	O
,	O	O
expenditures	Others	O
for	Others	O
personal	Others	O
care/waiver	Others	O
services	Others	O
were	O	O
higher	O	O
for	O	O
the	O	O
treatment	O	O
group	O	O
than	O	O
for	O	O
the	O	O
control	O	O
group	O	O
in	O	O
each	O	O
state	O	O
and	O	O
age	O	O
group	O	O
,	O	O
except	O	O
among	O	O
the	O	O
elderly	O	O
in	O	O
Florida	O	O
.	O	O

Higher	O	O
costs	Others	Others
for	Others	Others
personal	Others	Others
care/waiver	Others	Others
services	Others	Others
were	O	O
partially	O	O
offset	O	O
by	O	O
savings	O	O
in	O	O
other	O	O
Medicaid	O	O
services	O	O
,	O	O
particularly	O	O
those	O	O
related	O	O
to	O	O
long-term	O	O
care	O	O
.	O	O

During	O	O
year	O	O
1	O	O
,	O	O
total	Others	O
Medicaid	Others	O
costs	Others	O
were	O	O
generally	O	O
higher	O	O
for	O	O
the	O	O
treatment	O	O
group	O	O
than	O	O
for	O	O
the	O	O
control	O	O
group	O	O
,	O	O
with	O	O
treatment-control	O	O
cost	O	O
differences	O	O
ranging	O	O
from	O	O
1	O	O
percent	O	O
(	O	O
and	O	O
statistically	O	O
insignificant	O	O
)	O	O
for	O	O
the	O	O
elderly	O	O
in	O	O
Florida	O	O
to	O	O
17	O	O
percent	O	O
for	O	O
the	O	O
elderly	O	O
in	O	O
Arkansas	O	O
.	O	O

In	O	O
year	O	O
2	O	O
,	O	O
these	O	O
cost	Others	O
differences	Others	O
were	O	O
generally	O	O
greater	O	O
than	O	O
in	O	O
year	O	O
1	O	O
.	O	O

Only	O	O
in	O	O
Arkansas	O	O
did	O	O
the	O	O
treatment-control	O	O
difference	O	O
in	O	O
total	O	O
cost	Others	O
shrink	Others	O
over	Others	O
time-to	Others	O
less	O	O
than	O	O
5	O	O
percent	O	O
(	O	O
and	O	O
statistically	O	O
insignificant	O	O
)	O	O
in	O	O
year	O	O
2	O	O
.	O	O

CONCLUSIONS	O	O
Medicaid	Others	O
costs	Others	O
were	O	O
generally	O	O
higher	O	O
under	O	O
Cash	O	O
and	O	O
Counseling	O	O
because	O	O
those	O	O
in	O	O
the	O	O
traditional	O	O
system	O	O
did	O	O
not	O	O
get	O	O
the	O	O
services	O	O
they	O	O
were	O	O
entitled	O	O
to	O	O
.	O	O

Compared	O	O
with	O	O
the	O	O
treatment	O	O
group	O	O
,	O	O
(	O	O
1	O	O
)	O	O
control	O	O
group	O	O
members	O	O
were	O	O
less	O	O
likely	O	O
to	O	O
receive	Others	O
any	Others	O
services	Others	O
at	O	O
all	O	O
(	O	O
despite	O	O
being	O	O
authorized	O	O
for	O	O
them	O	O
)	O	O
,	O	O
and	O	O
(	O	O
2	O	O
)	O	O
service	O	O
recipients	O	O
received	O	O
a	O	O
lower	Others	O
proportion	Others	Others
of	Others	Others
the	Others	Others
amount	Others	Others
of	Others	Others
care	Others	Others
that	O	O
was	O	O
authorized	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
a	O	O
flaw	O	O
in	O	O
Florida	O	O
's	O	O
reassessment	O	O
procedures	O	O
led	O	O
to	O	O
treatment	O	O
group	O	O
members	O	O
receiving	O	O
more	O	O
generous	O	O
benefit	O	O
amounts	O	O
than	O	O
control	O	O
group	O	O
members	O	O
.	O	O

To	O	O
keep	O	O
total	O	O
Medicaid	O	O
costs	O	O
per	O	O
recipient	O	O
at	O	O
the	O	O
level	O	O
incurred	O	O
under	O	O
the	O	O
traditional	O	O
system	O	O
,	O	O
consumer-directed	O	O
programs	O	O
need	O	O
to	O	O
be	O	O
carefully	O	O
designed	O	O
and	O	O
closely	O	O
monitored	O	O
.	O	O

Migration	O	O
of	O	O
the	O	O
acetabular	O	O
component	O	O
:	O	O
effect	Physical	O
of	Physical	O
cement	Physical	O
pressurization	Physical	O
and	O	O
significance	Physical	O
of	Physical	O
early	Physical	O
radiolucency	Physical	O
:	O	O
a	O	O
randomized	O	O
5-year	O	O
study	O	O
using	O	O
radiostereometry	O	O
.	O	O

BACKGROUND	O	O
Cementing	O	O
technique	O	O
is	O	O
a	O	O
crucial	O	O
factor	O	O
in	O	O
prosthesis	O	O
fixation	O	O
.	O	O

No	O	O
randomized	O	O
studies	O	O
have	O	O
been	O	O
published	O	O
,	O	O
however	O	O
,	O	O
comparing	O	O
the	O	O
outcome	O	O
of	O	O
conventional	O	O
fingerpacking	O	O
with	O	O
the	O	O
outcome	O	O
of	O	O
pressurization	O	O
of	O	O
the	O	O
cement	O	O
prior	O	O
to	O	O
cup	O	O
insertion	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
We	O	O
randomized	O	O
50	O	O
THAs	O	O
to	O	O
either	O	O
fingerpacking	O	O
or	O	O
sequential	O	O
pressurization	O	O
(	O	O
including	O	O
individual	O	O
pressurization	O	O
of	O	O
each	O	O
anchorage	O	O
hole	O	O
)	O	O
and	O	O
followed	O	O
the	O	O
patients	O	O
with	O	O
RSA	O	O
for	O	O
5	O	O
years	O	O
.	O	O

The	O	O
penetration	O	O
of	O	O
cement	O	O
into	O	O
the	O	O
anchorage	O	O
holes	O	O
was	O	O
measured	O	O
on	O	O
digital	O	O
radiographs	O	O
.	O	O

Postoperative	O	O
radiolucent	Physical	O
lines	Physical	O
around	O	O
the	O	O
cup	O	O
were	O	O
correlated	O	O
to	O	O
later	O	O
RSA	O	Physical
results	O	Physical
.	O	O

For	O	O
clinical	O	O
evaluation	O	O
,	O	O
we	O	O
used	O	O
SF-36	O	O
and	O	O
HHS	O	O
.	O	O

RESULTS	O	O
The	O	O
pressurized	O	O
group	O	O
of	O	O
THAs	O	O
was	O	O
more	O	O
stable	O	O
regarding	O	O
changes	O	O
in	O	O
inclination	O	O
.	O	O

We	O	O
found	O	O
no	O	O
other	O	O
difference	O	O
in	O	O
the	O	O
migratory	O	O
behavior	O	O
.	O	O

The	O	O
cement	O	O
penetration	O	O
into	O	O
the	O	O
anchorage	O	O
holes	O	O
was	O	O
deeper	O	O
with	O	O
the	O	O
pressurization	O	O
technique	O	O
than	O	O
with	O	O
fingerpacking	O	O
.	O	O

For	O	O
the	O	O
whole	O	O
group	O	O
taken	O	O
together	O	O
,	O	O
there	O	O
was	O	O
a	O	O
strong	O	O
relation	O	O
between	O	O
the	O	O
presence	O	O
of	O	O
radiolucent	O	O
lines	O	O
as	O	O
measured	O	O
on	O	O
the	O	O
postoperative	O	O
radiograph	O	O
and	O	O
later	O	O
migration	O	O
observed	O	O
by	O	O
RSA	O	O
at	O	O
2	O	O
and	O	O
5	O	O
years	O	O
.	O	O

INTERPRETATION	O	O
Pressurization	O	O
of	O	O
the	O	O
cement	O	O
produced	O	O
better	O	O
cement	O	O
penetration	O	O
and	O	O
increased	O	O
the	O	O
cup	O	O
stability	O	O
in	O	O
terms	O	O
of	O	O
changes	O	O
in	O	O
inclination	O	O
.	O	O

Early	O	O
findings	O	O
of	O	O
radiolucent	O	O
lines	O	O
can	O	O
predict	O	O
later	O	O
unfavorable	O	O
cup	O	O
migration	O	O
.	O	O

[	O	O
Clinical	O	O
observation	O	O
on	O	O
different	O	O
acupuncture	O	O
and	O	O
moxibustion	O	O
therapies	O	O
for	O	O
treatment	O	O
of	O	O
postsurgical	O	O
gastroparesis	O	O
syndrome	O	O
]	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
optimize	O	O
therapy	O	O
of	O	O
acupuncture	O	O
and	O	O
moxibustion	O	O
for	O	O
postsurgical	O	O
gastroparesis	O	O
syndrome	O	O
(	O	O
PGS	O	O
)	O	O
.	O	O

METHODS	O	O
Forty-one	O	O
cases	O	O
of	O	O
PGS	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
3	O	O
groups	O	O
in	O	O
order	O	O
of	O	O
visiting	O	O
.	O	O

Group	O	O
A	O	O
(	O	O
n	O	O
=	O	O
17	O	O
)	O	O
were	O	O
treated	O	O
by	O	O
warming	O	O
needle	O	O
moxibustion	O	O
,	O	O
group	O	O
B	O	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
by	O	O
acupuncture	O	O
plus	O	O
auricular	O	O
point	O	O
sticking	O	O
,	O	O
and	O	O
group	O	O
C	O	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
by	O	O
routine	O	O
acupuncture	O	O
.	O	O

Changes	O	O
of	O	O
gastric	Physical	Physical
drainage	Physical	Physical
volume	Physical	Physical
,	O	O
therapeutic	Physical	Others
times	Physical	Others
and	Physical	Others
cured	Physical	Others
rate	Physical	Others
were	O	O
investigated	O	O
in	O	O
the	O	O
3	O	O
groups	O	O
.	O	O

RESULTS	O	O
All	O	O
the	O	O
3	O	O
therapeutic	O	O
methods	O	O
could	O	O
significantly	O	O
decrease	O	O
gastric	Physical	Physical
drainage	Physical	Physical
volume	Physical	Physical
.	O	O

The	O	O
cured	Physical	Others
rate	Physical	Others
was	O	O
100.0	O	O
%	O	O
and	O	O
the	O	O
therapeutic	Physical	O
times	Physical	O
was	O	O
(	O	O
7.24	O	O
+/-	O	O
3.87	O	O
)	O	O
in	O	O
the	O	O
group	O	O
A	O	O
,	O	O
66.7	O	O
%	O	O
,	O	O
(	O	O
9.83	O	O
+/-	O	O
4.60	O	O
)	O	O
times	O	O
in	O	O
the	O	O
group	O	O
B	O	O
and	O	O
75.0	O	O
%	O	O
,	O	O
(	O	O
15.25	O	O
+/-	O	O
3.81	O	O
)	O	O
times	O	O
in	O	O
the	O	O
group	O	O
C	O	O
,	O	O
with	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
cured	Physical	Physical
rate	Physical	Physical
and	Others	O
the	Others	O
therapeutic	Physical	O
times	Physical	O
among	O	O
the	O	O
3	O	O
groups	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

CONCLUSION	O	O
The	O	O
warming	O	O
needle	O	O
moxibustion	O	O
is	O	O
the	O	O
best	O	O
method	O	O
for	O	O
PGS	O	O
,	O	O
with	O	O
less	O	Others
therapeutic	Physical	Others
times	Physical	Others
,	O	O
high	O	O
cured	Physical	O
rate	Physical	O
and	O	O
rapid	O	O
effect	O	O
.	O	O

Partial	O	O
depletion	Physical	O
of	Physical	O
tissue	Physical	O
factor	Physical	O
pathway	Physical	O
inhibitor	Physical	O
during	O	O
subcutaneous	O	O
administration	O	O
of	O	O
unfractionated	O	O
heparin	O	O
,	O	O
but	O	O
not	O	O
with	O	O
two	O	O
low	O	O
molecular	O	O
weight	O	O
heparins	O	O
.	O	O

Tissue	O	O
factor	O	O
pathway	O	O
inhibitor	O	O
(	O	O
TFPI	O	O
)	O	O
is	O	O
released	O	O
to	O	O
circulating	O	O
blood	O	O
after	O	O
intravenous	O	O
(	O	O
i.v	O	O
.	O	O

)	O	O
and	O	O
subcutaneous	O	O
(	O	O
s.c.	O	O
)	O	O
injections	O	O
of	O	O
heparins	O	O
,	O	O
and	O	O
may	O	O
thus	O	O
contribute	O	O
to	O	O
the	O	O
antithrombotic	O	O
effect	O	O
of	O	O
heparins	O	O
.	O	O

We	O	O
have	O	O
recently	O	O
shown	O	O
that	O	O
total	O	O
TFPI	Physical	O
activity	Physical	O
,	Others	O
plasma	Physical	Physical
free	Physical	Physical
TFPI	Physical	Physical
antigen	Physical	Physical
,	O	O
and	O	O
heparin	Physical	O
releasable	Physical	O
TFPI	Physical	O
were	O	O
partially	O	O
depleted	O	O
during	O	O
repeated	O	O
and	O	O
continuous	O	O
i.v	O	O
.	O	O

infusion	O	O
of	O	O
unfractionated	O	O
heparin	O	O
(	O	O
UFH	O	O
)	O	O
,	O	O
but	O	O
not	O	O
during	O	O
s.c.	O	O
treatment	O	O
with	O	O
a	O	O
low	O	O
molecular	O	O
weight	O	O
heparin	O	O
(	O	O
LMWH	O	O
)	O	O
.	O	O

The	O	O
difference	O	O
may	O	O
be	O	O
attributed	O	O
to	O	O
a	O	O
different	O	O
mode	O	O
of	O	O
action	O	O
or	O	O
the	O	O
different	O	O
mode	O	O
of	O	O
administration	O	O
.	O	O

In	O	O
the	O	O
present	O	O
randomized	O	O
cross-over	O	O
study	O	O
,	O	O
s.c.	O	O
administration	O	O
of	O	O
therapeutic	O	O
doses	O	O
of	O	O
UFH	O	O
was	O	O
compared	O	O
with	O	O
s.c.	O	O
administration	O	O
of	O	O
two	O	O
LMWHs	O	O
.	O	O

12	O	O
healthy	O	O
male	O	O
volunteers	O	O
were	O	O
treated	O	O
for	O	O
3	O	O
d	O	O
with	O	O
UFH	O	O
,	O	O
250	O	O
U/kg	O	O
twice	O	O
daily	O	O
,	O	O
dalteparin	O	O
,	O	O
200	O	O
U/kg	O	O
once	O	O
daily	O	O
,	O	O
and	O	O
enoxaparin	O	O
,	O	O
1.5	O	O
mg/kg	O	O
once	O	O
daily	O	O
.	O	O

Six	O	O
participants	O	O
were	O	O
also	O	O
treated	O	O
with	O	O
UFH	O	O
,	O	O
300	O	O
U/kg	O	O
once	O	O
daily	O	O
.	O	O

On	O	O
day	O	O
5	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
either	O	O
drug	O	O
was	O	O
given	O	O
.	O	O

Peak	Physical	Physical
levels	Physical	Physical
of	Physical	Physical
total	Physical	Physical
TFPI	Physical	Physical
activity	Physical	Physical
and	Others	Physical
free	Physical	Physical
TFPI	Physical	Physical
antigen	Physical	Physical
were	O	O
detected	O	O
1	O	O
h	O	O
after	O	O
injection	O	O
,	O	O
whereas	O	O
maximal	Physical	O
prolongation	Physical	O
of	Physical	O
activated	Physical	O
partial	Physical	O
thromboplastin	Physical	O
time	Physical	O
(	Physical	O
APTT	Physical	O
)	Physical	O
and	Others	O
peak	Physical	O
levels	Physical	O
of	Physical	O
anti-factor	Physical	O
Xa	Physical	O
activity	Physical	O
and	Physical	O
anti-factor	Physical	Physical
IIa	Physical	Physical
activity	Physical	Physical
were	O	O
detected	O	O
after	O	O
4	O	O
h.	O	O
On	O	O
UFH	O	O
administered	O	O
twice	O	O
daily	O	O
,	O	O
free	Physical	Physical
TFPI	Physical	Physical
antigen	Physical	Physical
decreased	O	O
by	O	O
44	O	O
%	O	O
from	O	O
baseline	O	O
level	O	O
before	O	O
the	O	O
first	O	O
injection	O	O
on	O	O
day	O	O
1	O	O
to	O	O
pre-injection	O	O
level	O	O
on	O	O
day	O	O
5	O	O
.	O	O

On	O	O
UFH	O	O
administered	O	O
once	O	O
daily	O	O
,	O	O
basal	Physical	Physical
free	Physical	Physical
TFPI	Physical	Physical
antigen	Physical	Physical
decreased	O	O
by	O	O
50	O	O
%	O	O
,	O	O
56	O	O
%	O	O
and	O	O
27	O	O
%	O	O
on	O	O
day	O	O
2	O	O
,	O	O
3	O	O
and	O	O
5	O	O
respectively	O	O
,	O	O
compared	O	O
with	O	O
day	O	O
1	O	O
.	O	O

Minimal	Physical	O
depletion	Physical	O
of	Physical	O
TFPI	Physical	O
was	O	O
detected	O	O
during	O	O
treatment	O	O
with	O	O
LMWHs	O	O
.	O	O

The	O	O
study	O	O
demonstrates	O	O
the	O	O
different	O	O
modes	O	O
of	O	O
action	O	O
of	O	O
LMWHs	O	O
and	O	O
UFH	O	O
and	O	O
may	O	O
help	O	O
to	O	O
explain	O	O
the	O	O
superior	O	O
antithrombotic	O	O
efficacy	O	O
of	O	O
LMWHs	O	O
.	O	O

Epirubicin	O	O
and	O	O
cyclophosphamide	O	O
versus	O	O
epirubicin	O	O
and	O	O
docetaxel	O	O
as	O	O
first-line	O	O
therapy	O	O
for	O	O
women	O	O
with	O	O
metastatic	O	O
breast	O	O
cancer	O	O
:	O	O
final	O	O
results	O	O
of	O	O
a	O	O
randomised	O	O
phase	O	O
III	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
This	O	O
randomised	O	O
phase	O	O
III	O	O
trial	O	O
was	O	O
carried	O	O
out	O	O
to	O	O
compare	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
epirubicin	O	O
and	O	O
cyclophosphamide	O	O
(	O	O
EC	O	O
)	O	O
with	O	O
epirubicin	O	O
and	O	O
docetaxel	O	O
(	O	O
Taxotere	O	O
)	O	O
(	O	O
ED	O	O
)	O	O
as	O	O
first-line	O	O
chemotherapy	O	O
for	O	O
metastatic	O	O
breast	O	O
cancer	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
Patients	O	O
(	O	O
n	O	O
=	O	O
240	O	O
)	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
either	O	O
ED	O	O
(	O	O
epirubicin	O	O
75	O	O
mg/m	O	O
(	O	O
2	O	O
)	O	O
and	O	O
docetaxel	O	O
75	O	O
mg/m	O	O
(	O	O
2	O	O
)	O	O
)	O	O
or	O	O
EC	O	O
(	O	O
epirubicin	O	O
90	O	O
mg/m	O	O
(	O	O
2	O	O
)	O	O
and	O	O
cyclophosphamide	O	O
600	O	O
mg/m	O	O
(	O	O
2	O	O
)	O	O
)	O	O
.	O	O

The	O	O
primary	O	O
end	O	O
point	O	O
was	O	O
objective	Physical	O
response	Physical	O
rate	Physical	O
(	Physical	O
ORR	Physical	O
)	Physical	O
.	O	O

Secondary	O	O
end	O	O
points	O	O
were	O	O
progression-free	Mortality	Mortality
survival	Mortality	Mortality
(	Mortality	Mortality
PFS	Mortality	Mortality
)	Mortality	Mortality
,	O	Mortality
overall	Mortality	Mortality
survival	Mortality	Mortality
(	Mortality	Mortality
OS	Mortality	Mortality
)	Mortality	Mortality
,	O	Mortality
and	O	Mortality
safety	Mortality	Mortality
.	O	O

RESULTS	O	O
ORR	Physical	O
for	O	O
patients	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
EC	O	O
and	O	O
ED	O	O
were	O	O
42	O	O
%	O	O
and	O	O
47	O	O
%	O	O
,	O	O
respectively	O	O
(	O	O
P	O	O
=	O	O
0.63	O	O
)	O	O
.	O	O

Median	Mortality	Mortality
PFS	Mortality	Mortality
[	O	O
10.1	O	O
versus	O	O
10.3	O	O
months	O	O
;	O	O
hazard	O	O
ratio	O	O
(	O	O
HR	O	O
)	O	O
0.98	O	O
;	O	O
log-rank	O	O
P	O	O
=	O	O
0.38	O	O
]	O	O
and	O	O
OS	Mortality	O
(	O	O
19.9	O	O
versus	O	O
30.0	O	O
months	O	O
;	O	O
HR	O	O
0.663	O	O
;	O	O
log-rank	O	O
P	O	O
=	O	O
0.21	O	O
)	O	O
were	O	O
comparable	O	O
in	O	O
both	O	O
arms	O	O
.	O	O

Although	O	O
grade	Physical	O
3/4	Physical	O
leucopenia	Physical	O
occurred	O	O
more	O	O
frequently	O	O
with	O	O
ED	O	O
(	O	O
81	O	O
%	O	O
versus	O	O
73	O	O
%	O	O
;	O	O
P	O	O
=	O	O
0.01	O	O
)	O	O
,	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
incidence	O	O
of	O	O
febrile	Physical	Physical
neutropenia	Physical	Physical
and	Physical	Physical
grade	Physical	Physical
3/4	Physical	Physical
infections	Physical	Physical
.	O	O

Grade	Adverseeffect	Adverseeffect
3/4	Adverseeffect	Adverseeffect
non-haematologic	Adverseeffect	Adverseeffect
toxicity	Adverseeffect	Adverseeffect
was	O	O
infrequent	O	O
in	O	O
both	O	O
arms	O	O
.	O	O

Congestive	Physical	O
heart	Physical	O
failure	Physical	O
was	O	O
observed	O	O
in	O	O
one	O	O
patient	O	O
in	O	O
each	O	O
arm	O	O
.	O	O

CONCLUSION	O	O
In	O	O
this	O	O
randomised	O	O
trial	O	O
,	O	O
no	O	O
differences	O	O
in	O	O
the	O	O
efficacy	O	O
study	O	O
end	O	O
points	O	O
were	O	O
observed	O	O
between	O	O
the	O	O
two	O	O
treatment	O	O
arms	O	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
in	Others	O
vitro	Others	O
and	Others	O
in	Others	O
vivo	Others	O
release	Others	O
of	Others	O
digoxin	Others	O
from	O	O
four	O	O
different	O	O
soft	O	O
gelatin	O	O
capsule	O	O
formulations	O	O
.	O	O

A	O	O
blinded	O	O
,	O	O
four-treatment	O	O
crossover	O	O
study	O	O
in	O	O
16	O	O
normal	O	O
adult	O	O
male	O	O
volunteers	O	O
compared	O	O
plasma	O	O
concentrations	O	O
and	O	O
urinary	Others	Physical
excretion	Others	Physical
of	Others	Physical
digoxin	Others	Physical
,	O	O
measured	O	O
by	O	O
radioimmunoassay	O	O
,	O	O
after	O	O
oral	O	O
administration	O	O
of	O	O
soft	O	O
gelatin	O	O
capsule	O	O
formulations	O	O
of	O	O
digoxin	O	O
.	O	O

Four	O	O
0.4-mg	O	O
formulations	O	O
with	O	O
different	O	O
in	O	O
vitro	O	O
burst	O	O
times	O	O
and	O	O
dissolution	O	O
rates	O	O
were	O	O
administered	O	O
,	O	O
with	O	O
2-week	O	O
intervals	O	O
between	O	O
treatments	O	O
.	O	O

The	O	O
two	O	O
capsules	O	O
with	O	O
lowest	O	O
in	O	O
vitro	O	O
burst	O	O
times	O	O
(	O	O
2.9	O	O
and	O	O
16	O	O
min	O	O
)	O	O
gave	O	O
comparable	O	O
in	O	O
vivo	O	O
results	O	O
.	O	O

The	O	O
other	O	O
two	O	O
capsules	O	O
,	O	O
with	O	O
in	O	O
vitro	O	O
burst	O	O
times	O	O
of	O	O
62	O	O
and	O	O
229	O	O
min	O	O
,	O	O
produced	O	O
significant	O	O
delays	O	O
in	O	O
digoxin	O	Physical
absorption	O	Physical
.	O	Physical

In	O	O
vitro-in	O	O
vivo	O	O
correlations	O	O
were	O	O
obtained	O	O
by	O	O
comparing	O	O
the	O	O
logarithm	O	O
of	O	O
the	O	O
in	O	O
vitro	O	O
burst	O	O
time	O	O
with	O	O
time	O	O
to	O	O
peak	Others	Physical
plasma	Others	Physical
level	Others	Physical
and	O	O
the	O	O
time	O	O
to	O	O
the	O	O
first	O	O
measurable	O	O
plasma	Others	O
level	Others	O
(	O	O
>	O	O
or	O	O
=	O	O
0	O	O
.	O	O

05	O	O
ng/ml	O	O
)	O	O
.	O	O

Also	O	O
,	O	O
the	O	O
mean	O	Physical
time	O	Physical
to	O	Physical
peak	Others	Physical
plasma	Others	Physical
level	Others	Physical
correlated	O	O
with	O	O
the	O	O
logarithm	O	O
of	O	O
the	O	O
time	O	O
required	O	O
to	O	O
release	O	O
either	O	O
50	O	O
%	O	O
or	O	O
85	O	O
%	O	O
of	O	O
the	O	O
digoxin	O	O
in	O	O
vitro	O	O
.	O	O

No	O	O
significant	O	O
changes	O	O
were	O	O
found	O	O
in	O	O
the	O	O
amount	O	O
of	O	O
digoxin	O	O
absorbed	O	O
from	O	O
each	O	O
capsule	O	O
as	O	O
determined	O	O
by	O	O
urinary	O	O
excretion	O	O
or	O	O
AUC0-infinity	O	O
.	O	O

The	O	O
influence	O	O
of	O	O
breast	O	O
size	O	O
on	O	O
late	O	O
radiation	O	O
effects	O	O
and	O	O
association	O	O
with	O	O
radiotherapy	O	O
dose	O	O
inhomogeneity	O	O
.	O	O

A	O	O
prospective	O	O
assessment	O	O
of	O	O
late	O	O
changes	O	O
in	O	O
breast	O	O
appearance	O	O
in	O	O
559	O	O
patients	O	O
after	O	O
tumour	O	O
excision	O	O
and	O	O
radiotherapy	O	O
for	O	O
early	O	O
breast	O	O
cancer	O	O
noted	O	O
a	O	O
strong	O	O
association	O	O
with	O	O
breast	O	O
size	O	O
.	O	O

Only	O	O
3/48	O	O
(	O	O
6	O	O
%	O	O
)	O	O
patients	O	O
with	O	O
small	O	O
breasts	O	O
developed	O	O
moderate	O	Adverseeffect
or	O	Adverseeffect
severe	O	Adverseeffect
late	O	Adverseeffect
changes	O	Adverseeffect
compared	O	O
with	O	O
94/423	O	O
(	O	O
22	O	O
%	O	O
)	O	O
with	O	O
medium	O	O
sized	O	O
breasts	O	O
and	O	O
34/88	O	O
(	O	O
39	O	O
%	O	O
)	O	O
patients	O	O
with	O	O
large	O	O
breasts	O	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

One	O	O
possibility	O	O
is	O	O
that	O	O
greater	O	O
radiation	O	O
changes	O	O
are	O	O
related	O	O
to	O	O
greater	O	O
dose	O	O
inhomogeneity	O	O
in	O	O
women	O	O
with	O	O
large	O	O
breasts	O	O
.	O	O

To	O	O
explore	O	O
this	O	O
hypothesis	O	O
,	O	O
radiation	O	O
dose	O	O
distributions	O	O
were	O	O
assessed	O	O
in	O	O
a	O	O
separate	O	O
group	O	O
of	O	O
37	O	O
women	O	O
in	O	O
whom	O	O
three-level	O	O
transverse	O	O
computer	O	O
tomographic	O	O
images	O	O
of	O	O
the	O	O
breast	O	O
in	O	O
the	O	O
treatment	O	O
position	O	O
were	O	O
available	O	O
.	O	O

A	O	O
significant	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
breast	O	O
size	O	O
and	O	O
dose	O	O
inhomogeneity	O	O
which	O	O
may	O	O
account	O	O
for	O	O
the	O	O
marked	O	O
changes	O	O
in	O	O
breast	O	O
appearance	O	O
reported	O	O
in	O	O
women	O	O
with	O	O
large	O	O
breasts	O	O
.	O	O

Cyclosporin	O	O
versus	O	O
cyclophosphamide	O	O
for	O	O
patients	O	O
with	O	O
steroid-dependent	O	O
and	O	O
frequently	O	O
relapsing	O	O
idiopathic	O	O
nephrotic	O	O
syndrome	O	O
:	O	O
a	O	O
multicentre	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
compare	O	O
the	O	O
efficacy	Others	O
(	Others	O
maintenance	Others	O
of	Others	O
remission	Others	O
)	Others	O
,	O	O
safety	Others	Others
and	O	Others
tolerability	Others	Others
of	O	Others
cyclosporin	O	Others
(	O	Others
CsA	O	Others
)	O	Others
with	O	O
those	O	O
of	O	O
cyclophosphamide	O	O
in	O	O
patients	O	O
with	O	O
steroid-dependent	O	O
or	O	O
frequently	O	O
relapsing	O	O
nephrotic	O	O
syndrome	O	O
(	O	O
NS	O	O
)	O	O
.	O	O

DESIGN	O	O
Open	O	O
,	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
multicentre	O	O
,	O	O
controlled	O	O
study	O	O
for	O	O
parallel	O	O
groups	O	O
,	O	O
stratified	O	O
for	O	O
adults	O	O
and	O	O
children	O	O
.	O	O

The	O	O
setting	O	O
was	O	O
in	O	O
nephrological	O	O
departments	O	O
in	O	O
Italy	O	O
.	O	O

SUBJECTS	O	O
AND	O	O
INTERVENTIONS	O	O
Seventy-three	O	O
patients	O	O
with	O	O
steroid-sensitive	O	O
idiopathic	O	O
NS	O	O
admitted	O	O
to	O	O
the	O	O
study	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
cyclophosphamide	O	O
(	O	O
2.5	O	O
mg/kg/day	O	O
)	O	O
for	O	O
8	O	O
weeks	O	O
or	O	O
CsA	O	O
(	O	O
5	O	O
mg/kg/day	O	O
in	O	O
adults	O	O
,	O	O
6	O	O
mg/kg/day	O	O
in	O	O
children	O	O
)	O	O
for	O	O
9	O	O
months	O	O
,	O	O
tapered	O	O
off	O	O
by	O	O
25	O	O
%	O	O
every	O	O
month	O	O
until	O	O
complete	O	O
discontinuation	O	O
at	O	O
month	O	O
12	O	O
.	O	O

Seven	O	O
patients	O	O
lost	O	O
to	O	O
follow	O	O
up	O	O
were	O	O
not	O	O
considered	O	O
in	O	O
the	O	O
analysis	O	O
.	O	O

The	O	O
remaining	O	O
66	O	O
patients	O	O
were	O	O
followed	O	O
up	O	O
for	O	O
3-24	O	O
months	O	O
after	O	O
randomization	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
Relapse-free	Mortality	Mortality
survival	Mortality	Mortality
;	O	O
number	Physical	O
of	Physical	O
N.S	Physical	O
.	Physical	O

relapses/patient/year	Physical	O
;	O	O
cumulative	Others	O
dose	Others	O
of	Others	O
prednisone/patient	Others	O
;	O	O
laboratory	Physical	O
investigations	Physical	O
(	Physical	O
kidney	Physical	O
and	Physical	O
liver	Physical	O
functions	Physical	O
,	Physical	O
haematological	Physical	O
parameters	Physical	O
)	Physical	O
;	O	O
incidence	Adverseeffect	Adverseeffect
of	Adverseeffect	Adverseeffect
adverse	Adverseeffect	Adverseeffect
events	Adverseeffect	Adverseeffect
.	O	O

RESULTS	O	O
At	O	O
month	O	O
9	O	O
,	O	O
26	O	O
of	O	O
35	O	O
CsA-treated	O	O
patients	O	O
were	O	O
still	O	O
in	O	O
complete	Physical	O
remission	Physical	O
and	O	O
a	O	O
further	O	O
five	O	O
patients	O	O
were	O	O
in	O	O
partial	Physical	O
remission	Physical	O
;	O	O
18	O	O
of	O	O
28	O	O
cyclophosphamide-treated	O	O
patients	O	O
were	O	O
in	O	O
complete	Physical	O
remission	Physical	O
,	O	O
and	O	O
one	O	O
in	O	O
partial	Physical	Physical
remission	Physical	Physical
(	O	O
P	O	O
=	O	O
NS	O	O
)	O	O
.	O	O

No	O	O
difference	O	O
between	O	O
adults	O	O
and	O	O
children	O	O
was	O	O
seen	O	O
with	O	O
either	O	O
treatment	O	O
.	O	O

The	O	O
risk	Physical	Others
of	Physical	Others
relapse	Physical	Others
was	O	O
similar	O	O
between	O	O
frequent	O	O
relapsers	O	O
(	O	O
19	O	O
of	O	O
22	O	O
)	O	O
and	O	O
steroid-dependent	O	O
patients	O	O
(	O	O
8	O	O
of	O	O
14	O	O
)	O	O
given	O	O
CsA	O	O
,	O	O
and	O	O
those	O	O
given	O	O
cyclophosphamide	O	O
(	O	O
5	O	O
of	O	O
15	O	O
and	O	O
6	O	O
of	O	O
15	O	O
)	O	O
.	O	O

The	O	O
mean	Physical	Others
number	Physical	Others
of	Physical	Others
relapses	Physical	Others
per	Physical	O
year	Physical	O
and	O	O
the	O	O
mean	O	O
dose	Others	O
of	Others	O
prednisone	Others	O
per	Others	O
year	Others	O
were	O	O
significantly	O	O
less	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
in	O	O
both	O	O
groups	O	O
for	O	O
the	O	O
experimental	O	O
year	O	O
than	O	O
for	O	O
the	O	O
year	O	O
before	O	O
randomization	O	O
.	O	O

At	O	O
2	O	O
years	O	O
,	O	O
25	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
given	O	O
CsA	O	O
(	O	O
50	O	O
%	O	O
adults	O	O
and	O	O
20	O	O
%	O	O
children	O	O
)	O	O
and	O	O
63	O	O
%	O	O
of	O	O
those	O	O
given	O	O
cyclophosphamide	O	O
(	O	O
40	O	O
%	O	O
adults	O	O
and	O	O
68	O	O
%	O	O
children	O	O
)	O	O
had	O	O
not	O	O
had	O	O
any	O	O
relapse	Physical	O
of	Physical	O
NS	Physical	O
.	Others	O

Tolerance	Others	O
to	O	O
the	O	O
two	O	O
drugs	O	O
was	O	O
generally	O	O
good	O	O
.	O	O

The	O	O
CsA-related	Adverseeffect	O
side-effects	Adverseeffect	O
were	O	O
mild	O	O
and	O	O
disappeared	O	O
after	O	O
drug	O	O
discontinuation	O	O
.	O	O

CONCLUSIONS	O	O
This	O	O
study	O	O
shows	O	O
that	O	O
both	O	O
treatments	O	O
are	O	O
effective	O	Others
and	O	Others
well	O	Others
tolerated	O	Others
;	O	O
more	O	O
patients	O	O
given	O	O
cyclophosphamide	O	O
had	O	O
stable	Physical	O
remissions	Physical	O
.	Others	O

Failure	O	O
of	O	O
naltrexone	O	O
hydrochloride	O	O
to	O	O
reduce	O	O
self-injurious	O	O
and	O	O
autistic	O	O
behavior	O	O
in	O	O
mentally	O	O
retarded	O	O
adults	O	O
.	O	O

Double-blind	O	O
placebo-controlled	O	O
studies	O	O
.	O	O

BACKGROUND	O	O
It	O	O
is	O	O
hypothesized	O	O
that	O	O
self-injurious	O	O
behavior	O	O
(	O	O
SIB	O	O
)	O	O
and	O	O
symptoms	O	O
of	O	O
autism	O	O
may	O	O
be	O	O
due	O	O
to	O	O
overactivity	O	O
in	O	O
some	O	O
opioid	O	O
systems	O	O
in	O	O
the	O	O
brain	O	O
.	O	O

We	O	O
examined	O	O
the	O	O
efficacy	Others	Others
and	O	Others
safety	Others	Others
of	O	O
naltrexone	O	O
hydrochloride	O	O
,	O	O
an	O	O
opioid	O	O
antagonist	O	O
,	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
SIB	O	O
and	O	O
autism	O	O
in	O	O
mentally	O	O
retarded	O	O
adults	O	O
.	O	O

METHOD	O	O
Thirty-three	O	O
mentally	O	O
retarded	O	O
adults	O	O
with	O	O
autism	O	O
and/or	O	O
SIB	O	O
participated	O	O
in	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
crossover	O	O
studies	O	O
.	O	O

Active	O	O
treatment	O	O
was	O	O
first	O	O
a	O	O
single	O	O
100-mg	O	O
dose	O	O
of	O	O
naltrexone	O	O
hydrochloride	O	O
.	O	O

Subsequently	O	O
,	O	O
19	O	O
subjects	O	O
were	O	O
treated	O	O
with	O	O
50	O	O
mg/d	O	O
and	O	O
14	O	O
with	O	O
150	O	O
mg/d	O	O
of	O	O
naltrexone	O	O
hydrochloride	O	O
for	O	O
4	O	O
weeks	O	O
.	O	O

The	O	O
outcome	O	O
was	O	O
assessed	O	O
by	O	O
means	O	O
of	O	O
direct	O	O
observations	O	O
(	O	O
n	O	O
=	O	O
11	O	O
)	O	O
and	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
scores	O	O
on	O	O
a	O	O
list	Mental	O
of	Mental	O
target	Mental	O
behaviors	Mental	O
,	O	O
the	Mental	O
Aberrant	Mental	Mental
Behavior	Mental	Mental
Checklist	Mental	Mental
,	O	Mental
and	O	Mental
the	O	Mental
Clinical	Mental	Mental
Global	Mental	Mental
Impression	Mental	Mental
Scale	Mental	Mental
.	O	O

RESULTS	O	O
Thirty-two	O	O
subjects	O	O
(	O	O
seven	O	O
with	O	O
autism	O	O
,	O	O
16	O	O
with	O	O
autism	O	O
and	O	O
SIB	O	O
,	O	O
and	O	O
nine	O	O
with	O	O
SIB	O	O
)	O	O
completed	O	O
the	O	O
trial	O	O
.	O	O

Naltrexone	O	O
treatment	O	O
failed	O	O
to	O	O
have	O	O
therapeutic	O	O
effects	O	O
on	O	O
SIB	O	O
and	O	O
autism	O	O
.	O	O

On	O	O
the	O	O
contrary	O	O
,	O	O
naltrexone	O	O
increased	O	O
the	O	O
incidence	Mental	O
of	Mental	O
stereotypic	Mental	O
behavior	Mental	O
on	O	O
the	O	O
Aberrant	Mental	Mental
Behavior	Mental	Mental
Checklist	Mental	Mental
,	O	O
and	O	O
the	O	O
care	O	O
staff	O	O
evaluated	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
50-mg/d	O	O
treatment	O	O
as	O	O
being	O	O
significantly	O	O
worse	O	O
than	O	O
that	O	O
of	O	O
the	O	O
placebo	O	O
treatment	O	O
as	O	O
measured	O	O
by	O	O
the	O	O
Clinical	Mental	Mental
Global	Mental	Mental
Impression	Mental	Mental
Scale	Mental	Mental
.	O	O

CONCLUSION	O	O
Our	O	O
findings	O	O
suggest	O	O
that	O	O
naltrexone	O	O
has	O	O
no	O	O
clinical	O	O
value	O	O
for	O	O
a	O	O
broad	O	O
group	O	O
of	O	O
mentally	O	O
retarded	O	O
subjects	O	O
with	O	O
SIB	O	O
and/or	O	O
autism	O	O
.	O	O

The	O	O
acute	O	Adverseeffect
effects	O	Adverseeffect
of	O	Adverseeffect
fluid	O	Adverseeffect
intake	O	Adverseeffect
on	O	Adverseeffect
urine	O	Adverseeffect
specific	O	Adverseeffect
gravity	O	Adverseeffect
and	O	Adverseeffect
fluid	O	Adverseeffect
retention	O	Adverseeffect
in	O	O
a	O	O
mildly	O	O
dehydrated	O	O
state	O	O
.	O	O

Many	O	O
athletes	O	O
arrive	O	O
at	O	O
training	O	O
sessions	O	O
and	O	O
competitions	O	O
in	O	O
a	O	O
mildly	O	O
hypohydrated	O	O
(	O	O
HYPO	O	O
)	O	O
state	O	O
and	O	O
are	O	O
instructed	O	O
to	O	O
drink	O	O
fluids	O	O
before	O	O
exercise	O	O
to	O	O
reach	O	O
a	O	O
euhydrated	O	O
(	O	O
HYD	O	O
)	O	O
state	O	O
.	O	O

Ten	O	O
recreational	O	O
athletes	O	O
(	O	O
6	O	O
women	O	O
,	O	O
4	O	O
men	O	O
;	O	O
71.9	O	O
?	O	O
4.6	O	O
kg	O	O
,	O	O
25.2	O	O
?	O	O
0.9	O	O
years	O	O
)	O	O
participated	O	O
in	O	O
the	O	O
studies	O	O
to	O	O
examine	O	O
(	O	O
a	O	O
)	O	O
the	O	O
day-to-day	O	Physical
variability	O	Physical
of	O	Physical
morning	O	Physical
urine	O	Physical
specific	O	Physical
gravity	O	Physical
(	O	Physical
USG	O	Physical
)	O	Physical
,	O	O
(	O	O
b	O	O
)	O	O
the	O	O
effects	O	O
of	O	O
consuming	O	O
600	O	O
ml	O	O
of	O	O
water	O	O
on	O	O
the	O	O
hydration	O	O
status	O	O
of	O	O
HYD	O	O
and	O	O
HYPO	O	O
(	O	O
USG	O	O
>	O	O
1.020	O	O
)	O	O
subjects	O	O
,	O	O
and	O	O
(	O	O
c	O	O
)	O	O
the	O	O
effects	O	O
of	O	O
consuming	O	O
water	O	O
(	O	O
W	O	O
)	O	O
,	O	O
salt-water	O	O
(	O	O
SW	O	O
,	O	O
40	O	O
mM	O	O
Na	O	O
)	O	O
,	O	O
a	O	O
carbohydrate-electrolyte	O	O
solution	O	O
with	O	O
3	O	O
%	O	O
or	O	O
light	O	O
carbohydrate	O	O
(	O	O
CES-L	O	O
,	O	O
20	O	O
mM	O	O
Na	O	O
)	O	O
or	O	O
a	O	O
CES	O	O
with	O	O
6	O	O
%	O	O
carbohydrate	O	O
(	O	O
CES	O	O
,	O	O
20	O	O
mM	O	O
Na	O	O
)	O	O
on	O	O
the	O	O
hydration	O	O
status	O	O
of	O	O
HYPO	O	O
subjects	O	O
.	O	O

The	O	O
hydration	O	O
status	O	O
was	O	O
assessed	O	O
with	O	O
USG	O	O
and	O	O
body	O	O
mass	O	O
measures	O	O
and	O	O
urine	O	O
volume	O	O
collections	O	O
.	O	O

The	O	O
day-to-day	O	O
variability	O	O
in	O	O
morning	O	O
USG	O	O
(	O	O
coefficient	O	O
of	O	O
variation	O	O
=	O	O
0.2	O	O
?	O	O
0.1	O	O
%	O	O
)	O	O
was	O	O
low	O	O
and	O	O
the	O	O
responses	O	O
to	O	O
600	O	O
ml	O	O
of	O	O
W	O	O
ingestion	O	O
were	O	O
repeatable	O	O
.	O	O

Pretrial	O	O
USG	O	O
was	O	O
1.022	O	O
?	O	O
0.001	O	O
in	O	O
the	O	O
HYPO	O	O
trial	O	O
and	O	O
decreased	O	O
<	O	O
1.020	O	O
by	O	O
45	O	O
minutes	O	O
(	O	O
1.013	O	O
?	O	O
0.003	O	O
)	O	O
.	O	O

In	O	O
the	O	O
CES	O	O
study	O	O
,	O	O
HYPO	O	O
subjects	O	O
reached	O	O
HYD	O	O
status	O	O
at	O	O
45	O	O
minutes	O	O
in	O	O
all	O	O
conditions	O	O
(	O	O
W	O	O
1.013	O	O
?	O	O
0.003	O	O
,	O	O
SW	O	O
1.013	O	O
?	O	O
0.003	O	O
,	O	O
CES-L	O	O
1.011	O	O
?	O	O
0.003	O	O
,	O	O
CES	O	O
1.017	O	O
?	O	O
0.004	O	O
)	O	O
because	O	O
salt	O	O
or	O	O
CES	O	O
ingestion	O	O
did	O	O
not	O	O
affect	O	O
fluid	Physical	Adverseeffect
retention	Physical	Adverseeffect
(	O	O
W	O	O
68	O	O
%	O	O
,	O	O
SW	O	O
72	O	O
%	O	O
,	O	O
CES-L	O	O
68	O	O
%	O	O
,	O	O
CES	O	O
76	O	O
%	O	O
)	O	O
.	O	O

This	O	O
study	O	O
demonstrated	O	O
that	O	O
mildly	O	O
HYPO	O	O
subjects	O	O
could	O	O
reach	O	O
euhydration	O	O
within	O	O
45	O	O
minutes	O	O
of	O	O
the	O	O
ingestion	O	O
of	O	O
600	O	O
ml	O	O
of	O	O
W	O	O
or	O	O
a	O	O
combination	O	O
of	O	O
salt	O	O
and	O	O
CES	O	O
solutions	O	O
.	O	O

Following	O	O
this	O	O
practice	O	O
will	O	O
minimize	O	O
the	O	O
incidence	O	O
of	O	O
starting	O	O
a	O	O
practice	O	O
or	O	O
competition	O	O
hypohydrated	O	O
.	O	O

Glibenclamide	O	O
vs	O	O
gliclazide	O	O
in	O	O
reducing	O	O
oxidative	Physical	O
stress	Physical	O
in	O	O
patients	O	O
of	O	O
noninsulin	O	O
dependent	O	O
diabetes	O	O
mellitus	O	O
--	O	O
a	O	O
double	O	O
blind	O	O
randomized	O	O
study	O	O
.	O	O

OBJECTIVE	O	O
Parameters	O	O
of	O	O
oxidative	Physical	O
stress	Physical	O
were	O	O
quantitated	O	O
in	O	O
50	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
mellitus	O	O
in	O	O
uncontrolled	O	O
state	O	O
and	O	O
after	O	O
control	O	O
using	O	O
oral	O	O
glibenclamide	O	O
or	O	O
gliclazide	O	O
.	O	O

The	O	O
estimates	O	O
were	O	O
further	O	O
compared	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
irrespective	O	O
of	O	O
drug	O	O
used	O	O
to	O	O
evaluate	O	O
the	O	O
difference	O	O
,	O	O
if	O	O
any	O	O
.	O	O

METHODS	O	O
The	O	O
study	O	O
was	O	O
a	O	O
double	O	O
blind	O	O
,	O	O
uncontrolled	O	O
,	O	O
noncrossover	O	O
and	O	O
randomized	O	O
trial	O	O
.	O	O

Fifty	O	O
patients	O	O
of	O	O
uncontrolled	O	O
type	O	O
2	O	O
diabetes	O	O
were	O	O
divided	O	O
in	O	O
to	O	O
two	O	O
groups	O	O
.	O	O

Group	O	O
I	O	O
(	O	O
25	O	O
patients	O	O
)	O	O
received	O	O
capsule	O	O
A	O	O
(	O	O
glibenclamide	O	O
)	O	O
while	O	O
Group	O	O
II	O	O
(	O	O
25	O	O
patients	O	O
)	O	O
received	O	O
capsule	O	O
B	O	O
(	O	O
gliclazide	O	O
)	O	O
.	O	O

The	O	O
parameters	O	O
studied	O	O
were	O	O
Superoxide	Physical	Physical
dismutase	Physical	Physical
(	Physical	Physical
SOD	Physical	Physical
)	Physical	Physical
,	O	Physical
malonyl-dialdehyde	Physical	Physical
(	Physical	Physical
MDA	Physical	Physical
)	Physical	Physical
and	O	O
reduced	Physical	O
glutathione	Physical	Physical
(	Physical	Physical
GSH	Physical	Physical
)	Physical	Physical
.	O	O

They	O	O
were	O	O
done	O	O
at	O	O
(	O	O
a	O	O
)	O	O
uncontrolled	O	O
stage	O	O
(	O	O
FBS	O	O
--	O	O
165	O	O
+/-	O	O
16.7	O	O
mg/dl	O	O
,	O	O
PP	O	O
--	O	O
240	O	O
+/-	O	O
30.1	O	O
mg/dl	O	O
and	O	O
HbA1	O	O
--	O	O
10.5	O	O
+/-	O	O
0.9	O	O
%	O	O
in	O	O
group	O	O
I	O	O
and	O	O
FBS	O	O
--	O	O
150	O	O
+/-	O	O
15.8	O	O
mg/dl	O	O
,	O	O
PP	O	O
--	O	O
246	O	O
+/-	O	O
29.1	O	O
mg/dl	O	O
HbA1	O	O
10.6	O	O
+/-	O	O
0.8	O	O
%	O	O
in	O	O
group	O	O
II	O	O
)	O	O
and	O	O
during	O	O
controlled	O	O
stage	O	O
at	O	O
12	O	O
weeks	O	O
(	O	O
FBS	O	O
--	O	O
120	O	O
+/-	O	O
18.5	O	O
mg/dl	O	O
,	O	O
PP	O	O
--	O	O
180	O	O
+/-	O	O
19.1	O	O
mg/dl	O	O
and	O	O
HbA1	O	O
--	O	O
8.4	O	O
+/-	O	O
0.29	O	O
%	O	O
in	O	O
group	O	O
I	O	O
and	O	O
FBS	O	O
--	O	O
118	O	O
+/-	O	O
17.6	O	O
mg/dl	O	O
,	O	O
PP	O	O
--	O	O
176	O	O
+/-	O	O
20.1	O	O
mg/dl	O	O
and	O	O
HbA1	O	O
--	O	O
8.5	O	O
+/-	O	O
0.39	O	O
%	O	O
in	O	O
group	O	O
II	O	O
patients	O	O
)	O	O
.	O	O

RESULTS	O	O
The	O	O
significantly	O	O
raised	O	Physical
levels	Physical	Physical
of	Physical	Physical
MDA	Physical	Physical
and	Others	Physical
SOD	Physical	Physical
,	O	Physical
and	O	Physical
decreased	O	Physical
levels	Physical	Physical
of	Physical	Physical
reduced	Physical	Physical
glutathione	Physical	Physical
(	Physical	Physical
GSH	Physical	Physical
)	Physical	Physical
during	O	O
uncontrolled	O	O
stage	O	O
of	O	O
diabetes	O	O
indicated	O	O
free	O	O
radical	O	O
stress	O	O
induced	O	O
lipid	O	O
peroxidation	O	O
.	O	O

The	O	O
significant	O	Physical
fall	Physical	Physical
of	Physical	Physical
MDA	Physical	Physical
and	Physical	Physical
SOD	Physical	Physical
and	O	Physical
increased	Physical	Physical
levels	Physical	Physical
of	Physical	Physical
GSH	Physical	Physical
in	O	Physical
blood	O	Physical
in	O	O
both	O	O
groups	O	O
after	O	O
control	O	O
revealed	O	O
beneficial	O	Physical
effects	O	Physical
of	O	Physical
glycemic	O	Physical
control	O	Physical
on	O	Physical
oxidative	Physical	Physical
stress	Physical	Physical
.	Physical	O

The	O	O
levels	O	O
were	O	O
not	O	O
normalized	O	O
and	O	O
stayed	O	O
higher	O	O
than	O	O
those	O	O
in	O	O
controls	O	O
.	O	O

On	O	O
intergroup	O	O
comparison	O	O
;	O	O
the	O	O
control	O	O
of	O	O
diabetes	O	O
with	O	O
gliclazide	O	O
(	O	O
group	O	O
II	O	O
)	O	O
showed	O	O
improvement	O	O
in	O	O
oxidative	Physical	Physical
stress	Physical	Physical
(	Physical	Physical
MDA	Physical	Physical
,	Physical	Physical
GSH	Physical	Physical
)	Physical	Physical
better	O	Physical
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
than	O	O
glibenclamide	O	O
(	O	O
group	O	O
I	O	O
)	O	O
.	O	O

CONCLUSION	O	O
Oxidative	Physical	O
stress	Physical	O
in	O	O
uncontrolled	O	O
diabetes	O	O
is	O	O
decreased	O	O
with	O	O
glycemic	O	O
control	O	O
.	O	O

The	O	O
control	O	O
of	O	O
diabetes	O	O
with	O	O
gliclazide	O	O
reduced	O	O
oxidative	Physical	O
stress	Physical	O
more	O	O
than	O	O
glibenclamide	O	O
,	O	O
indicating	O	O
higher	O	O
antioxidant	O	O
properties	O	O
of	O	O
gliclazide	O	O
.	O	O

Normalization	O	O
of	O	O
oxidative	Physical	O
stress	Physical	O
was	O	O
not	O	O
achieved	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
required	O	O
to	O	O
see	O	O
long-term	O	O
effect	O	O
of	O	O
drug	O	O
therapy	O	O
in	O	O
combating	O	O
oxidative	Physical	O
stress	Physical	O
after	O	O
achieving	O	O
acceptable	O	O
control	O	O
of	O	O
diabetes	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
body	O	O
positioning	O	O
upon	O	O
maximal	O	O
oxygenation	O	O
of	O	O
patients	O	O
with	O	O
unilateral	O	O
lung	O	O
pathology	O	O
.	O	O

A	O	O
quasi-experimental	O	O
,	O	O
repeated-measures	O	O
cross-over	O	O
design	O	O
study	O	O
on	O	O
the	O	O
effect	O	O
of	O	O
body	O	O
position	O	O
on	O	O
oxygenation	O	Physical
(	O	Physical
SaO2	O	Physical
)	O	Physical
blood	O	Physical
pressure	O	Physical
,	O	O
respiration	O	O
and	O	O
pulse	O	O
in	O	O
patients	O	O
with	O	O
unilateral	O	O
lung	O	O
pathology	O	O
was	O	O
conducted	O	O
.	O	O

Previous	O	O
research	O	O
strongly	O	O
suggests	O	O
that	O	O
positioning	O	O
with	O	O
the	O	O
healthy	O	O
(	O	O
unaffected	O	O
)	O	O
lung	O	O
in	O	O
the	O	O
dependent	O	O
lateral	O	O
(	O	O
down	O	O
)	O	O
position	O	O
is	O	O
related	O	O
to	O	O
improved	O	O
oxygenation	O	O
,	O	O
but	O	O
knowledge	O	O
about	O	O
whether	O	O
this	O	O
effect	O	O
is	O	O
maintained	O	O
over	O	O
time	O	O
is	O	O
lacking	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
investigation	O	O
was	O	O
to	O	O
determine	O	O
:	O	O
(	O	O
1	O	O
)	O	O
Is	O	O
positioning	O	O
with	O	O
the	O	O
unaffected	O	O
lung	O	O
in	O	O
the	O	O
dependent	O	O
lateral	O	O
position	O	O
related	O	O
to	O	O
increased	O	O
arterial	O	Physical
blood	O	Physical
saturation	O	Physical
levels	O	Physical
and	O	O
decreased	O	O
blood	O	Physical
pressure	O	Physical
,	O	O
pulse	O	O
and	O	O
respiration	O	O
?	O	O
(	O	O
2	O	O
)	O	O
What	O	O
is	O	O
the	O	O
relationship	O	O
between	O	O
the	O	O
dependent	O	O
variables	O	O
--	O	O
oxygenation	O	O
saturation	O	O
levels	O	O
,	O	O
blood	O	Physical
pressure	O	Physical
,	O	Physical
pulse	O	Physical
and	O	O
respiration	O	O
--	O	O
and	O	O
the	O	O
independent	O	O
variables	O	O
--	O	O
body	O	O
position	O	O
and	O	O
time	O	O
in	O	O
the	O	O
position	O	O
?	O	O
Thirty-nine	O	O
patients	O	O
with	O	O
unilateral	O	O
lung	O	O
pathology	O	O
were	O	O
positioned	O	O
on	O	O
their	O	O
sides	O	O
with	O	O
the	O	O
unaffected	O	O
lung	O	O
down	O	O
,	O	O
on	O	O
their	O	O
sides	O	O
with	O	O
the	O	O
affected	O	O
lung	O	O
down	O	O
,	O	O
and	O	O
also	O	O
in	O	O
semi-Fowler	O	O
's	O	O
position	O	O
.	O	O

Arterial	Physical	Physical
(	Physical	Physical
SaO2	Physical	Physical
)	Physical	Physical
blood	Physical	Physical
saturation	Physical	Physical
and	Physical	Physical
vital	Physical	Physical
signs	Physical	Physical
were	O	O
measured	O	O
at	O	O
baseline	O	O
0	O	O
,	O	O
15	O	O
and	O	O
30	O	O
minutes	O	O
.	O	O

There	O	O
was	O	O
no	O	O
statistically	O	O
significant	O	O
relationship	O	O
between	O	O
oxygenation	Physical	Physical
level	Physical	Physical
or	Physical	Physical
systolic	Physical	Physical
blood	Physical	Physical
pressure	Physical	Physical
.	Physical	O

Diastolic	Physical	Physical
blood	Physical	Physical
pressure	Physical	Physical
,	Physical	O
respiration	Physical	O
and	Physical	O
pulse	Physical	O
did	O	O
vary	O	O
significantly	O	O
with	O	O
position	O	O
.	O	O

Double-blind	O	O
comparison	O	O
of	O	O
the	O	O
efficacy	Others	O
and	Others	O
safety	Others	O
of	O	O
trandolapril	O	O
2	O	O
mg	O	O
and	O	O
hydrochlorothiazide	O	O
25	O	O
mg	O	O
in	O	O
patients	O	O
with	O	O
mild-to-moderate	O	O
essential	O	O
hypertension	O	O
.	O	O

Investigator	O	O
Study	O	O
Group	O	O
.	O	O

This	O	O
multicenter	O	O
international	O	O
trial	O	O
recruited	O	O
205	O	O
patients	O	O
from	O	O
16	O	O
investigators	O	O
.	O	O

After	O	O
a	O	O
4-week	O	O
,	O	O
single-blind	O	O
placebo	O	O
run-in	O	O
,	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
16	O	O
weeks	O	O
of	O	O
trandolapril	O	O
2	O	O
mg/day	O	O
(	O	O
68	O	O
patients	O	O
)	O	O
,	O	O
hydrochlorothiazide	O	Others
(	O	Others
HCTZ	O	Others
)	O	Others
25	O	Others
mg/day	O	Others
(	O	O
68	O	O
patients	O	O
)	O	O
,	O	O
or	O	O
the	O	O
combination	O	O
(	O	O
69	O	O
patients	O	O
)	O	O
.	O	O

Morning	Physical	O
predosing	Physical	O
supine	Physical	O
diastolic	Physical	O
blood	Physical	O
pressure	Physical	O
(	Physical	O
DBP	Physical	O
)	Physical	O
was	O	O
the	O	O
primary	O	O
efficacy	O	O
measurement	O	O
.	O	O

Intention-to-treat	O	O
analysis	O	O
showed	O	O
significant	O	O
decreases	O	O
in	O	O
all	O	O
three	O	O
groups	O	O
in	O	O
mean	O	Physical
(	O	Physical
+/-	O	Physical
SEM	O	Physical
)	O	Physical
supine	Physical	Physical
DBP	Physical	Physical
throughout	O	O
the	O	O
study	O	O
,	O	O
with	O	O
no	O	O
significant	O	O
differences	O	O
at	O	O
week	O	O
16	O	O
between	O	O
trandolapril	O	O
(	O	O
-10.6	O	O
+/-	O	O
1.3	O	O
mm	O	O
Hg	O	O
)	O	O
and	O	O
HCTZ	O	O
(	O	O
-10.9	O	O
+/-	O	O
1.3	O	O
mm	O	O
Hg	O	O
)	O	O
.	O	O

The	O	O
combination	O	O
gave	O	O
a	O	O
significantly	O	O
greater	O	O
reduction	O	O
than	O	O
either	O	O
drug	O	O
alone	O	O
(	O	O
-15.1	O	O
+/-	O	O
1.13	O	O
mm	O	O
Hg	O	O
)	O	O
.	O	O

Blood	Physical	O
pressure	Physical	O
was	O	O
normalized	O	O
in	O	O
the	O	O
combination	O	O
group	O	O
in	O	O
67	O	O
%	O	O
of	O	O
patients	O	O
,	O	O
a	O	O
significantly	O	O
higher	O	O
proportion	O	O
than	O	O
either	O	O
trandolapril	O	O
(	O	O
63	O	O
%	O	O
)	O	O
or	O	O
HCTZ	O	O
(	O	O
60	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0.04	O	O
)	O	O
.	O	O

Each	O	O
treatment	O	O
was	O	O
well	O	O
tolerated	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
adverse	Adverseeffect	O
events	Adverseeffect	O
was	O	O
similar	O	O
in	O	O
all	O	O
three	O	O
groups	O	O
.	O	O

Trandolapril	O	O
2	O	O
mg	O	O
once	O	O
daily	O	O
is	O	O
an	O	O
effective	O	O
antihypertensive	O	O
agent	O	O
,	O	O
comparable	O	O
to	O	O
HCTZ	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
combination	O	O
of	O	O
the	O	O
two	O	O
drugs	O	O
was	O	O
shown	O	O
to	O	O
enhance	O	O
the	O	O
antihypertensive	Physical	Physical
effect	Physical	Physical
of	O	O
the	O	O
two	O	O
compounds	O	O
alone	O	O
.	O	O

Parents	O	O
'	O	O
state	O	O
and	O	O
trait	O	O
anxiety	O	O
:	O	O
relationships	O	O
with	O	O
anxiety	Mental	O
severity	Mental	O
and	O	O
treatment	O	O
response	O	O
in	O	O
adolescents	O	O
with	O	O
autism	O	O
spectrum	O	O
disorders	O	O
.	O	O

Comorbid	O	O
anxiety	O	O
is	O	O
common	O	O
among	O	O
children	O	O
with	O	O
Autism	O	O
Spectrum	O	O
Disorder	O	O
(	O	O
ASD	O	O
)	O	O
,	O	O
and	O	O
parents	O	O
of	O	O
children	O	O
with	O	O
ASD	O	O
are	O	O
more	O	O
likely	O	O
to	O	O
have	O	O
anxiety	O	O
disorders	O	O
.	O	O

This	O	O
study	O	O
investigated	O	O
the	O	O
relationship	O	O
between	O	O
parents	O	O
'	O	O
state	Mental	Mental
and	O	Mental
trait	Mental	Mental
anxiety	Mental	Mental
and	O	Mental
parent-reported	O	Mental
internalizing	O	Mental
and	O	Mental
externalizing	O	Mental
symptoms	O	Mental
among	O	O
adolescents	O	O
(	O	O
n	O	O
=	O	O
30	O	O
)	O	O
with	O	O
ASD	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
relationship	O	Mental
of	O	Mental
parents	O	Mental
'	O	Mental
anxiety	O	Mental
symptoms	O	Mental
and	O	O
adolescent	O	O
treatment	O	O
response	O	O
in	O	O
the	O	O
context	O	O
of	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

Parental	O	O
state	O	O
anxiety	O	Mental
correlated	O	Mental
with	O	Mental
severity	O	Mental
of	O	Mental
adolescent	O	Mental
anxiety	O	Mental
,	O	O
and	O	O
trait	O	Mental
anxiety	O	Mental
in	O	O
parents	O	O
correlated	O	O
with	O	O
parent-reported	O	O
adolescent	O	O
internalizing	O	O
and	O	O
externalizing	O	O
symptoms	O	O
.	O	O

Also	O	O
,	O	O
parents	O	O
of	O	O
adolescent	O	O
treatment	O	O
responders	O	O
experienced	O	O
a	O	O
decrease	O	O
in	O	O
their	O	O
own	O	O
trait	O	Mental
anxiety	O	Mental
.	O	O

Findings	O	O
highlight	O	O
the	O	O
importance	O	O
of	O	O
considering	O	O
parental	O	O
anxiety	O	O
when	O	O
targeting	O	O
anxiety	O	O
among	O	O
youth	O	O
with	O	O
ASD	O	O
.	O	O

